

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 June 2001 (07.06.2001)

PCT

(10) International Publication Number  
**WO 01/40466 A2**

(51) International Patent Classification <sup>7</sup> : C12N 15/12, C07K 14/47, 14/705, C12N 15/62, C07K 16/18, 16/28, G01N 33/53, A61K 38/17, C12Q 1/68		PCT/US99/30999	20 December 1999 (20.12.1999)	US
		PCT/US99/31243	30 December 1999 (30.12.1999)	US
(21) International Application Number: PCT/US00/32678		PCT/US99/31274	30 December 1999 (30.12.1999)	US
(22) International Filing Date: 1 December 2000 (01.12.2000)		PCT/US00/00219	5 January 2000 (05.01.2000)	US
		PCT/US00/00277	6 January 2000 (06.01.2000)	US
(25) Filing Language: English		PCT/US00/00376	6 January 2000 (06.01.2000)	US
		PCT/US00/03565		
(26) Publication Language: English		PCT/US00/04341	11 February 2000 (11.02.2000)	US
(30) Priority Data:				
PCT/US99/28301		PCT/US00/04342	18 February 2000 (18.02.2000)	US
PCT/US99/28634			18 February 2000 (18.02.2000)	US
PCT/US99/28551		PCT/US00/04414	22 February 2000 (22.02.2000)	US
PCT/US99/28564		PCT/US00/04914	24 February 2000 (24.02.2000)	US
PCT/US99/28565		PCT/US00/05004	24 February 2000 (24.02.2000)	US
60/170,262		PCT/US00/05601	1 March 2000 (01.03.2000)	US
PCT/US99/30095		PCT/US00/05841	2 March 2000 (02.03.2000)	US
PCT/US99/30911		60/187,202	3 March 2000 (03.03.2000)	US
		PCT/US00/06319	10 March 2000 (10.03.2000)	US
		PCT/US00/06884	15 March 2000 (15.03.2000)	US
		PCT/US00/07377	20 March 2000 (20.03.2000)	US
		PCT/US00/07532	21 March 2000 (21.03.2000)	US

[Continued on next page]

(54) Title: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

MSTMFADTLLIVFISVCTALLAEGITWVLVYRTDKYKRLKAEVEKQSKKLEKKKETITESAGR  
QQKKKIERQEEKLKNNNRDLSMVRMKSMAIGFCFTALMGMFNSIFDGRVVAKLPTPLSYIQ  
GLSHRNLLGDDTTDCSFIFLYILCTMSIRQNIQKILGLAPSRAATKQAGGFLGPPPPSGKFS

Important features:

Signal peptide:

amino acids 1-22

N-myristoylation sites.

amino acids 103-109, 163-169

cAMP- and cGMP-dependent protein kinase phosphorylation site.

amino acids 53-57

(57) Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

WO 01/40466 A2



PCT/US00/08439 30 March 2000 (30.03.2000) US  
 PCT/US00/13705 17 May 2000 (17.05.2000) US  
 PCT/US00/14042 22 May 2000 (22.05.2000) US  
 PCT/US00/14941 30 May 2000 (30.05.2000) US  
 PCT/US00/15264 2 June 2000 (02.06.2000) US  
 60/209,832 5 June 2000 (05.06.2000) US  
 PCT/US00/20710 28 July 2000 (28.07.2000) US  
 PCT/US00/22031 11 August 2000 (11.08.2000) US  
 PCT/US00/23522 23 August 2000 (23.08.2000) US  
 PCT/US00/23328 24 August 2000 (24.08.2000) US  
 60/000,000 15 September 2000 (15.09.2000) US  
 PCT/US00/30952 8 November 2000 (08.11.2000) US  
 PCT/US00/30873 10 November 2000 (10.11.2000) US

(71) **Applicant (for all designated States except US): GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants (for US only): BAKER, Kevin, P.** [GB/US]; 14006 Indian Run Drive, Darnestown, MD 20878 (US). **BERESINI, Maureen** [US/US]; 611 Stetson Street, Moss Beach, CA 94038 (US). **DEFORGE, Laura** [US/US]; 1175 Manzanita Drive, Pacifica, CA 94044 (US). **DESNOYERS, Luc** [CA/US]; 2050 Stockton Street, San Francisco, CA 94133 (US). **FILVAROFF, Ellen** [US/US]; 538 18th Avenue, San Francisco, CA 94121 (US). **GAO, Wei-Qiang** [CN/US]; 641 Pilgrim Drive, Foster City, CA 94404 (US). **GERRITSEN, Mary, E.** [CA/US]; 541 Parrott Drive, San Mateo, CA 94402 (US). **GODDARD, Audrey** [CA/US]; 110 Congo Street, San Francisco, CA 94131 (US). **GODOWSKI, Paul, J.** [US/US]; 2627 Easton Drive, Burlingame, CA 94010 (US). **GURNEY, Austin, L.** [US/US]; 1 Debbie Lane, Belmont, CA 94002 (US). **SHERWOOD, Steven** [US/US]; 995 Lundy Lane,

Los Altos, CA 94024 (US). **SMITH, Victoria** [AU/US]; 19 Dwight Road, Burlingame, CA 94010 (US). **STEWART, Timothy, A.** [US/US]; 465 Douglass Street, San Francisco, CA 94114 (US). **TUMAS, Daniel** [US/US]; 3 Rae Avenue, Orinda, CA 94563 (US). **WATANABE, Colin, K.** [US/US]; 128 Corliss Drive, Moraga, CA 94556 (US). **WOOD, William, I.** [US/US]; 35 Southdown Court, Hillsborough, CA 94010 (US). **ZHANG, Zemin** [CN/US]; 876 Taurus Drive, Foster City, CA 94404 (US).

(74) **Agents: KRESNAK, Mark, T. et al.;** Genentech, Inc., MS49, 1 DNA Way, South San Francisco, CA 94080-4990 (US).

(81) **Designated States (national):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

## SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME

### FIELD OF THE INVENTION

5 The present invention relates generally to the identification and isolation of novel DNA and to the recombinant production of novel polypeptides.

### BACKGROUND OF THE INVENTION

10 Extracellular proteins play important roles in, among other things, the formation, differentiation and maintenance of multicellular organisms. The fate of many individual cells, e.g., proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or the immediate environment. This information is often transmitted by secreted polypeptides (for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones) which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins. These secreted polypeptides or signaling molecules normally pass through the cellular secretory pathway to reach their site of  
15 action in the extracellular environment.

Secreted proteins have various industrial applications, including as pharmaceuticals, diagnostics, biosensors and bioreactors. Most protein drugs available at present, such as thrombolytic agents, interferons, interleukins, erythropoietins, colony stimulating factors, and various other cytokines, are secretory proteins. Their receptors, which are membrane proteins, also have potential as therapeutic or diagnostic agents. Efforts  
20 are being undertaken by both industry and academia to identify new, native secreted proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel secreted proteins. Examples of screening methods and techniques are described in the literature [see, for example, Klein et al., *Proc. Natl. Acad. Sci.* 93:7108-7113 (1996); U.S. Patent No. 5,536,637].

Membrane-bound proteins and receptors can play important roles in, among other things, the formation,  
25 differentiation and maintenance of multicellular organisms. The fate of many individual cells, e.g., proliferation, migration, differentiation, or interaction with other cells, is typically governed by information received from other cells and/or the immediate environment. This information is often transmitted by secreted polypeptides (for instance, mitogenic factors, survival factors, cytotoxic factors, differentiation factors, neuropeptides, and hormones) which are, in turn, received and interpreted by diverse cell receptors or membrane-bound proteins.  
30 Such membrane-bound proteins and cell receptors include, but are not limited to, cytokine receptors, receptor kinases, receptor phosphatases, receptors involved in cell-cell interactions, and cellular adhesion molecules like selectins and integrins. For instance, transduction of signals that regulate cell growth and differentiation is regulated in part by phosphorylation of various cellular proteins. Protein tyrosine kinases, enzymes that catalyze that process, can also act as growth factor receptors. Examples include fibroblast growth factor receptor and

nerve growth factor receptor.

Membrane-bound proteins and receptor molecules have various industrial applications, including as pharmaceutical and diagnostic agents. Receptor immunoadhesins, for instance, can be employed as therapeutic agents to block receptor-ligand interactions. The membrane-bound proteins can also be employed for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.

5 Efforts are being undertaken by both industry and academia to identify new, native receptor or membrane-bound proteins. Many efforts are focused on the screening of mammalian recombinant DNA libraries to identify the coding sequences for novel receptor or membrane-bound proteins.

#### SUMMARY OF THE INVENTION

10 In one embodiment, the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence that encodes a PRO polypeptide.

In one aspect, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule encoding a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In other aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94%



nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule comprising the coding sequence of a full-length PRO polypeptide cDNA as disclosed herein, the coding sequence of a PRO polypeptide lacking the signal peptide as disclosed herein, the coding sequence of an extracellular domain of a transmembrane PRO polypeptide, with or without the signal peptide, as disclosed herein or the coding sequence of any other specifically defined fragment of the full-length amino acid sequence as disclosed herein, or (b) the complement of the DNA molecule of (a).

In a further aspect, the invention concerns an isolated nucleic acid molecule comprising a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity to (a) a DNA molecule that encodes the same mature polypeptide encoded by any of the human protein cDNAs deposited with the ATCC as disclosed herein, or (b) the complement of the DNA molecule of (a).

Another aspect the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated, or is complementary to such encoding nucleotide sequence, wherein the transmembrane domain(s) of such polypeptide are disclosed herein. Therefore, soluble extracellular domains of the herein described PRO polypeptides are contemplated.

Another embodiment is directed to fragments of a PRO polypeptide coding sequence, or the complement thereof, that may find use as, for example, hybridization probes, for encoding fragments of a PRO polypeptide that may optionally encode a polypeptide comprising a binding site for an anti-PRO antibody or as antisense oligonucleotide probes. Such nucleic acid fragments are usually at least about 10 nucleotides in length, alternatively at least about 15 nucleotides in length, alternatively at least about 20 nucleotides in length, alternatively at least about 30 nucleotides in length, alternatively at least about 40 nucleotides in length, alternatively at least about 50 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 70 nucleotides in length, alternatively at least about 80 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 100 nucleotides in length, alternatively at least about 110 nucleotides in length, alternatively at least about 120 nucleotides in length,

alternatively at least about 130 nucleotides in length, alternatively at least about 140 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 160 nucleotides in length, alternatively at least about 170 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 190 nucleotides in length, alternatively at least about 200 nucleotides in length, alternatively at least about 250 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 350 nucleotides in length, alternatively at least about 400 nucleotides in length, alternatively at least about 450 nucleotides in length, alternatively at least about 500 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 700 nucleotides in length, alternatively at least about 800 nucleotides in length, alternatively at least about 900 nucleotides in length and alternatively at least about 1000 nucleotides in length, wherein in this context the term "about" means the referenced nucleotide sequence length plus or minus 10% of that referenced length. It is noted that novel fragments of a PRO polypeptide-encoding nucleotide sequence may be determined in a routine manner by aligning the PRO polypeptide-encoding nucleotide sequence with other known nucleotide sequences using any of a number of well known sequence alignment programs and determining which PRO polypeptide-encoding nucleotide sequence fragment(s) are novel. All of such PRO polypeptide-encoding nucleotide sequences are contemplated herein. Also contemplated are the PRO polypeptide fragments encoded by these nucleotide molecule fragments, preferably those PRO polypeptide fragments that comprise a binding site for an anti-PRO antibody.

In another embodiment, the invention provides isolated PRO polypeptide encoded by any of the isolated nucleic acid sequences hereinabove identified.

In a certain aspect, the invention concerns an isolated PRO polypeptide, comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a PRO polypeptide having a full-length amino acid sequence as disclosed herein, an amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane protein, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of the full-length amino acid sequence as disclosed herein.

In a further aspect, the invention concerns an isolated PRO polypeptide comprising an amino acid sequence having at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid

sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to an amino acid sequence encoded by any of the human protein cDNAs deposited with the ATCC as disclosed herein.

In a specific aspect, the invention provides an isolated PRO polypeptide without the N-terminal signal sequence and/or the initiating methionine and is encoded by a nucleotide sequence that encodes such an amino acid sequence as hereinbefore described. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.

Another aspect the invention provides an isolated PRO polypeptide which is either transmembrane domain-deleted or transmembrane domain-inactivated. Processes for producing the same are also herein described, wherein those processes comprise culturing a host cell comprising a vector which comprises the appropriate encoding nucleic acid molecule under conditions suitable for expression of the PRO polypeptide and recovering the PRO polypeptide from the cell culture.

In yet another embodiment, the invention concerns agonists and antagonists of a native PRO polypeptide as defined herein. In a particular embodiment, the agonist or antagonist is an anti-PRO antibody or a small molecule.

In a further embodiment, the invention concerns a method of identifying agonists or antagonists to a PRO polypeptide which comprise contacting the PRO polypeptide with a candidate molecule and monitoring a biological activity mediated by said PRO polypeptide. Preferably, the PRO polypeptide is a native PRO polypeptide.

In a still further embodiment, the invention concerns a composition of matter comprising a PRO polypeptide, or an agonist or antagonist of a PRO polypeptide as herein described, or an anti-PRO antibody, in combination with a carrier. Optionally, the carrier is a pharmaceutically acceptable carrier.

Another embodiment of the present invention is directed to the use of a PRO polypeptide, or an agonist or antagonist thereof as hereinbefore described, or an anti-PRO antibody, for the preparation of a medicament useful in the treatment of a condition which is responsive to the PRO polypeptide, an agonist or antagonist thereof or an anti-PRO antibody.

In other embodiments of the present invention, the invention provides vectors comprising DNA encoding any of the herein described polypeptides. Host cell comprising any such vector are also provided. By way of example, the host cells may be CHO cells, *E. coli*, or yeast. A process for producing any of the herein described polypeptides is further provided and comprises culturing host cells under conditions suitable for expression of the desired polypeptide and recovering the desired polypeptide from the cell culture.

5 In other embodiments, the invention provides chimeric molecules comprising any of the herein described polypeptides fused to a heterologous polypeptide or amino acid sequence. Example of such chimeric molecules comprise any of the herein described polypeptides fused to an epitope tag sequence or a Fc region of an immunoglobulin.

10 In another embodiment, the invention provides an antibody which binds, preferably specifically, to any of the above or below described polypeptides. Optionally, the antibody is a monoclonal antibody, humanized antibody, antibody fragment or single-chain antibody.

In yet other embodiments, the invention provides oligonucleotide probes which may be useful for isolating genomic and cDNA nucleotide sequences, measuring or detecting expression of an associated gene or as antisense probes, wherein those probes may be derived from any of the above or below described nucleotide  
15 sequences. Preferred probe lengths are described above.

In yet other embodiments, the present invention is directed to methods of using the PRO polypeptides of the present invention for a variety of uses based upon the functional biological assay data presented in the Examples below.

#### 20 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a nucleotide sequence (SEQ ID NO:1) of a native sequence PRO177 cDNA, wherein SEQ ID NO:1 is a clone designated herein as "DNA16438-1387".

Figure 2 shows the amino acid sequence (SEQ ID NO:2) derived from the coding sequence of SEQ ID NO:1 shown in Figure 1.

25 Figure 3 shows a nucleotide sequence (SEQ ID NO:3) of a native sequence PRO3574 cDNA, wherein SEQ ID NO:3 is a clone designated herein as "DNA19360-2552".

Figure 4 shows the amino acid sequence (SEQ ID NO:4) derived from the coding sequence of SEQ ID NO:3 shown in Figure 3.

30 Figure 5 shows a nucleotide sequence (SEQ ID NO:5) of a native sequence PRO1280 cDNA, wherein SEQ ID NO:5 is a clone designated herein as "DNA33455-1548".

Figure 6 shows the amino acid sequence (SEQ ID NO:6) derived from the coding sequence of SEQ ID NO:5 shown in Figure 5.

Figure 7 shows a nucleotide sequence (SEQ ID NO:7) of a native sequence PRO4984 cDNA, wherein SEQ ID NO:7 is a clone designated herein as "DNA37155-2651".

35 Figure 8 shows the amino acid sequence (SEQ ID NO:8) derived from the coding sequence of SEQ ID NO:7 shown in Figure 7.

Figure 9 shows a nucleotide sequence (SEQ ID NO:9) of a native sequence PRO4988 cDNA, wherein SEQ ID NO:9 is a clone designated herein as "DNA38269-2654".

Figure 10 shows the amino acid sequence (SEQ ID NO:10) derived from the coding sequence of SEQ ID NO:9 shown in Figure 9.

5 Figure 11 shows a nucleotide sequence (SEQ ID NO:11) of a native sequence PRO305 cDNA, wherein SEQ ID NO:11 is a clone designated herein as "DNA40619-1220".

Figure 12 shows the amino acid sequence (SEQ ID NO:12) derived from the coding sequence of SEQ ID NO:11 shown in Figure 11.

Figure 13 shows a nucleotide sequence (SEQ ID NO:13) of a native sequence PRO1866 cDNA, wherein SEQ ID NO:13 is a clone designated herein as "DNA44174-2513".

10 Figure 14 shows the amino acid sequence (SEQ ID NO:14) derived from the coding sequence of SEQ ID NO:13 shown in Figure 13.

Figure 15 shows a nucleotide sequence (SEQ ID NO:15) of a native sequence PRO4996 cDNA, wherein SEQ ID NO:15 is a clone designated herein as "DNA44675-2662".

15 Figure 16 shows the amino acid sequence (SEQ ID NO:16) derived from the coding sequence of SEQ ID NO:15 shown in Figure 15.

Figure 17 shows a nucleotide sequence (SEQ ID NO:17) of a native sequence PRO4406 cDNA, wherein SEQ ID NO:17 is a clone designated herein as "DNA45408-2615".

Figure 18 shows the amino acid sequence (SEQ ID NO:18) derived from the coding sequence of SEQ ID NO:17 shown in Figure 17.

20 Figure 19 shows a nucleotide sequence (SEQ ID NO:19) of a native sequence PRO1120 cDNA, wherein SEQ ID NO:19 is a clone designated herein as "DNA48606-1479".

Figure 20 shows the amino acid sequence (SEQ ID NO:20) derived from the coding sequence of SEQ ID NO:19 shown in Figure 19.

25 Figure 21 shows a nucleotide sequence (SEQ ID NO:21) of a native sequence PRO4990 cDNA, wherein SEQ ID NO:21 is a clone designated herein as "DNA52753-2656".

Figure 22 shows the amino acid sequence (SEQ ID NO:22) derived from the coding sequence of SEQ ID NO:21 shown in Figure 21.

Figure 23 shows a nucleotide sequence (SEQ ID NO:23) of a native sequence PRO738 cDNA, wherein SEQ ID NO:23 is a clone designated herein as "DNA53915-1258".

30 Figure 24 shows the amino acid sequence (SEQ ID NO:24) derived from the coding sequence of SEQ ID NO:23 shown in Figure 23.

Figure 25 shows a nucleotide sequence (SEQ ID NO:25) of a native sequence PRO3577 cDNA, wherein SEQ ID NO:25 is a clone designated herein as "DNA53991-2553".

35 Figure 26 shows the amino acid sequence (SEQ ID NO:26) derived from the coding sequence of SEQ ID NO:25 shown in Figure 25.

Figure 27 shows a nucleotide sequence (SEQ ID NO:27) of a native sequence PRO1879 cDNA, wherein SEQ ID NO:27 is a clone designated herein as "DNA54009-2517".

Figure 28 shows the amino acid sequence (SEQ ID NO:28) derived from the coding sequence of SEQ ID NO:27 shown in Figure 27.

Figure 29 shows a nucleotide sequence (SEQ ID NO:29) of a native sequence PRO1471 cDNA, wherein SEQ ID NO:29 is a clone designated herein as "DNA56055-1643".

5 Figure 30 shows the amino acid sequence (SEQ ID NO:30) derived from the coding sequence of SEQ ID NO:29 shown in Figure 29.

Figure 31 shows a nucleotide sequence (SEQ ID NO:31) of a native sequence PRO1114 cDNA, wherein SEQ ID NO:31 is a clone designated herein as "DNA57033-1403".

Figure 32 shows the amino acid sequence (SEQ ID NO:32) derived from the coding sequence of SEQ ID NO:31 shown in Figure 31.

10 Figure 33 shows a nucleotide sequence (SEQ ID NO:33) of a native sequence PRO1076 cDNA, wherein SEQ ID NO:33 is a clone designated herein as "DNA57252-1453".

Figure 34 shows the amino acid sequence (SEQ ID NO:34) derived from the coding sequence of SEQ ID NO:33 shown in Figure 33.

15 Figure 35 shows a nucleotide sequence (SEQ ID NO:35) of a native sequence PRO1483 cDNA, wherein SEQ ID NO:35 is a clone designated herein as "DNA58799-1652".

Figure 36 shows the amino acid sequence (SEQ ID NO:36) derived from the coding sequence of SEQ ID NO:35 shown in Figure 35.

Figure 37 shows a nucleotide sequence (SEQ ID NO:37) of a native sequence PRO4985 cDNA, wherein SEQ ID NO:37 is a clone designated herein as "DNA59770-2652".

20 Figure 38 shows the amino acid sequence (SEQ ID NO:38) derived from the coding sequence of SEQ ID NO:37 shown in Figure 37.

Figure 39 shows a nucleotide sequence (SEQ ID NO:39) of a native sequence PRO5000 cDNA, wherein SEQ ID NO:39 is a clone designated herein as "DNA59774-2665".

25 Figure 40 shows the amino acid sequence (SEQ ID NO:40) derived from the coding sequence of SEQ ID NO:39 shown in Figure 39.

Figure 41 shows a nucleotide sequence (SEQ ID NO:41) of a native sequence PRO1881 cDNA, wherein SEQ ID NO:41 is a clone designated herein as "DNA60281-2518".

Figure 42 shows the amino acid sequence (SEQ ID NO:42) derived from the coding sequence of SEQ ID NO:41 shown in Figure 41.

30 Figure 43 shows a nucleotide sequence (SEQ ID NO:43) of a native sequence PRO4314 cDNA, wherein SEQ ID NO:43 is a clone designated herein as "DNA60736-2559".

Figure 44 shows the amino acid sequence (SEQ ID NO:44) derived from the coding sequence of SEQ ID NO:43 shown in Figure 43.

35 Figure 45 shows a nucleotide sequence (SEQ ID NO:45) of a native sequence PRO4987 cDNA, wherein SEQ ID NO:45 is a clone designated herein as "DNA61875-2653".

Figure 46 shows the amino acid sequence (SEQ ID NO:46) derived from the coding sequence of SEQ ID NO:45 shown in Figure 45.

Figure 47 shows a nucleotide sequence (SEQ ID NO:47) of a native sequence PRO4313 cDNA, wherein SEQ ID NO:47 is a clone designated herein as "DNA62312-2558".

Figure 48 shows the amino acid sequence (SEQ ID NO:48) derived from the coding sequence of SEQ ID NO:47 shown in Figure 47.

5 Figure 49 shows a nucleotide sequence (SEQ ID NO:49) of a native sequence PRO4799 cDNA, wherein SEQ ID NO:49 is a clone designated herein as "DNA62849-1604".

Figure 50 shows the amino acid sequence (SEQ ID NO:50) derived from the coding sequence of SEQ ID NO:49 shown in Figure 49.

Figure 51 shows a nucleotide sequence (SEQ ID NO:51) of a native sequence PRO4995 cDNA, wherein SEQ ID NO:51 is a clone designated herein as "DNA66307-2661".

10 Figure 52 shows the amino acid sequence (SEQ ID NO:52) derived from the coding sequence of SEQ ID NO:51 shown in Figure 51.

Figure 53 shows a nucleotide sequence (SEQ ID NO:53) of a native sequence PRO1341 cDNA, wherein SEQ ID NO:53 is a clone designated herein as "DNA66677-2535".

15 Figure 54 shows the amino acid sequence (SEQ ID NO:54) derived from the coding sequence of SEQ ID NO:53 shown in Figure 53.

Figure 55 shows a nucleotide sequence (SEQ ID NO:55) of a native sequence PRO1777 cDNA, wherein SEQ ID NO:55 is a clone designated herein as "DNA71235-1706".

Figure 56 shows the amino acid sequence (SEQ ID NO:56) derived from the coding sequence of SEQ ID NO:55 shown in Figure 55.

20 Figure 57 shows a nucleotide sequence (SEQ ID NO:57) of a native sequence PRO3580 cDNA, wherein SEQ ID NO:57 is a clone designated herein as "DNA71289-2547".

Figure 58 shows the amino acid sequence (SEQ ID NO:58) derived from the coding sequence of SEQ ID NO:57 shown in Figure 57.

25 Figure 59 shows a nucleotide sequence (SEQ ID NO:59) of a native sequence PRO1779 cDNA, wherein SEQ ID NO:59 is a clone designated herein as "DNA73775-1707".

Figure 60 shows the amino acid sequence (SEQ ID NO:60) derived from the coding sequence of SEQ ID NO:59 shown in Figure 59.

Figure 61 shows a nucleotide sequence (SEQ ID NO:61) of a native sequence PRO1754 cDNA, wherein SEQ ID NO:61 is a clone designated herein as "DNA76385-1692".

30 Figure 62 shows the amino acid sequence (SEQ ID NO:62) derived from the coding sequence of SEQ ID NO:61 shown in Figure 61.

Figure 63 shows a nucleotide sequence (SEQ ID NO:63) of a native sequence PRO1906 cDNA, wherein SEQ ID NO:63 is a clone designated herein as "DNA76395-2527".

35 Figure 64 shows the amino acid sequence (SEQ ID NO:64) derived from the coding sequence of SEQ ID NO:63 shown in Figure 63.

Figure 65 shows a nucleotide sequence (SEQ ID NO:65) of a native sequence PRO1870 cDNA, wherein SEQ ID NO:65 is a clone designated herein as "DNA77622-2516".

Figure 66 shows the amino acid sequence (SEQ ID NO:66) derived from the coding sequence of SEQ ID NO:65 shown in Figure 65.

Figure 67 shows a nucleotide sequence (SEQ ID NO:67) of a native sequence PRO4329 cDNA, wherein SEQ ID NO:67 is a clone designated herein as "DNA77629-2573".

5 Figure 68 shows the amino acid sequence (SEQ ID NO:68) derived from the coding sequence of SEQ ID NO:67 shown in Figure 67.

Figure 69 shows a nucleotide sequence (SEQ ID NO:69) of a native sequence PRO4979 cDNA, wherein SEQ ID NO:69 is a clone designated herein as "DNA77645-2648".

Figure 70 shows the amino acid sequence (SEQ ID NO:70) derived from the coding sequence of SEQ ID NO:69 shown in Figure 69.

10 Figure 71 shows a nucleotide sequence (SEQ ID NO:71) of a native sequence PRO1885 cDNA, wherein SEQ ID NO:71 is a clone designated herein as "DNA79302-2521".

Figure 72 shows the amino acid sequence (SEQ ID NO:72) derived from the coding sequence of SEQ ID NO:71 shown in Figure 71.

15 Figure 73 shows a nucleotide sequence (SEQ ID NO:73) of a native sequence PRO1882 cDNA, wherein SEQ ID NO:73 is a clone designated herein as "DNA79865-2519".

Figure 74 shows the amino acid sequence (SEQ ID NO:74) derived from the coding sequence of SEQ ID NO:73 shown in Figure 73.

Figure 75 shows a nucleotide sequence (SEQ ID NO:75) of a native sequence PRO4989 cDNA, wherein SEQ ID NO:75 is a clone designated herein as "DNA80135-2655".

20 Figure 76 shows the amino acid sequence (SEQ ID NO:76) derived from the coding sequence of SEQ ID NO:75 shown in Figure 75.

Figure 77 shows a nucleotide sequence (SEQ ID NO:77) of a native sequence PRO4323 cDNA, wherein SEQ ID NO:77 is a clone designated herein as "DNA80794-2568".

25 Figure 78 shows the amino acid sequence (SEQ ID NO:78) derived from the coding sequence of SEQ ID NO:77 shown in Figure 77.

Figure 79 shows a nucleotide sequence (SEQ ID NO:79) of a native sequence PRO1886 cDNA, wherein SEQ ID NO:79 is a clone designated herein as "DNA80796-2523".

Figure 80 shows the amino acid sequence (SEQ ID NO:80) derived from the coding sequence of SEQ ID NO:79 shown in Figure 79.

30 Figure 81 shows a nucleotide sequence (SEQ ID NO:81) of a native sequence PRO4395 cDNA, wherein SEQ ID NO:81 is a clone designated herein as "DNA80840-2605".

Figure 82 shows the amino acid sequence (SEQ ID NO:82) derived from the coding sequence of SEQ ID NO:81 shown in Figure 81.

35 Figure 83 shows a nucleotide sequence (SEQ ID NO:83) of a native sequence PRO1782 cDNA, wherein SEQ ID NO:83 is a clone designated herein as "DNA80899-2501".

Figure 84 shows the amino acid sequence (SEQ ID NO:84) derived from the coding sequence of SEQ ID NO:83 shown in Figure 83.



Figure 85 shows a nucleotide sequence (SEQ ID NO:85) of a native sequence PRO4338 cDNA, wherein SEQ ID NO:85 is a clone designated herein as "DNA81228-2580".

Figure 86 shows the amino acid sequence (SEQ ID NO:86) derived from the coding sequence of SEQ ID NO:85 shown in Figure 85.

5 Figure 87 shows a nucleotide sequence (SEQ ID NO:87) of a native sequence PRO4341 cDNA, wherein SEQ ID NO:87 is a clone designated herein as "DNA81761-2583".

Figure 88 shows the amino acid sequence (SEQ ID NO:88) derived from the coding sequence of SEQ ID NO:87 shown in Figure 87.

Figure 89 shows a nucleotide sequence (SEQ ID NO:89) of a native sequence PRO5990 cDNA, wherein SEQ ID NO:89 is a clone designated herein as "DNA96042-2682".

10 Figure 90 shows the amino acid sequence (SEQ ID NO:90) derived from the coding sequence of SEQ ID NO:89 shown in Figure 89.

Figure 91 shows a nucleotide sequence (SEQ ID NO:91) of a native sequence PRO3438 cDNA, wherein SEQ ID NO:91 is a clone designated herein as "DNA82364-2538".

15 Figure 92 shows the amino acid sequence (SEQ ID NO:92) derived from the coding sequence of SEQ ID NO:91 shown in Figure 91.

Figure 93 shows a nucleotide sequence (SEQ ID NO:93) of a native sequence PRO4321 cDNA, wherein SEQ ID NO:93 is a clone designated herein as "DNA82424-2566".

Figure 94 shows the amino acid sequence (SEQ ID NO:94) derived from the coding sequence of SEQ ID NO:93 shown in Figure 93.

20 Figure 95 shows a nucleotide sequence (SEQ ID NO:95) of a native sequence PRO4304 cDNA, wherein SEQ ID NO:95 is a clone designated herein as "DNA82430-2557".

Figure 96 shows the amino acid sequence (SEQ ID NO:96) derived from the coding sequence of SEQ ID NO:95 shown in Figure 95.

25 Figure 97 shows a nucleotide sequence (SEQ ID NO:97) of a native sequence PRO1801 cDNA, wherein SEQ ID NO:97 is a clone designated herein as "DNA83500-2506".

Figure 98 shows the amino acid sequence (SEQ ID NO:98) derived from the coding sequence of SEQ ID NO:97 shown in Figure 97.

Figure 99 shows a nucleotide sequence (SEQ ID NO:99) of a native sequence PRO4403 cDNA, wherein SEQ ID NO:99 is a clone designated herein as "DNA83509-2612".

30 Figure 100 shows the amino acid sequence (SEQ ID NO:100) derived from the coding sequence of SEQ ID NO:99 shown in Figure 99.

Figure 101 shows a nucleotide sequence (SEQ ID NO:101) of a native sequence PRO4324 cDNA, wherein SEQ ID NO:101 is a clone designated herein as "DNA83560-2569".

35 Figure 102 shows the amino acid sequence (SEQ ID NO:102) derived from the coding sequence of SEQ ID NO:101 shown in Figure 101.

Figure 103 shows a nucleotide sequence (SEQ ID NO:103) of a native sequence PRO4303 cDNA, wherein SEQ ID NO:103 is a clone designated herein as "DNA84139-2555".

Figure 104 shows the amino acid sequence (SEQ ID NO:104) derived from the coding sequence of SEQ ID NO:103 shown in Figure 103.

Figure 105 shows a nucleotide sequence (SEQ ID NO:105) of a native sequence PRO4305 cDNA, wherein SEQ ID NO:105 is a clone designated herein as "DNA84141-2556".

Figure 106 shows the amino acid sequence (SEQ ID NO:106) derived from the coding sequence of SEQ ID NO:105 shown in Figure 105.

Figure 107 shows a nucleotide sequence (SEQ ID NO:107) of a native sequence PRO4404 cDNA, wherein SEQ ID NO:107 is a clone designated herein as "DNA84142-2613".

Figure 108 shows the amino acid sequence (SEQ ID NO:108) derived from the coding sequence of SEQ ID NO:107 shown in Figure 107.

Figure 109 shows a nucleotide sequence (SEQ ID NO:109) of a native sequence PRO1884 cDNA, wherein SEQ ID NO:109 is a clone designated herein as "DNA84318-2520".

Figure 110 shows the amino acid sequence (SEQ ID NO:110) derived from the coding sequence of SEQ ID NO:109 shown in Figure 109.

Figure 111 shows a nucleotide sequence (SEQ ID NO:111) of a native sequence PRO4349 cDNA, wherein SEQ ID NO:111 is a clone designated herein as "DNA84909-2590".

Figure 112 shows the amino acid sequence (SEQ ID NO:112) derived from the coding sequence of SEQ ID NO:111 shown in Figure 111.

Figure 113 shows a nucleotide sequence (SEQ ID NO:113) of a native sequence PRO4401 cDNA, wherein SEQ ID NO:113 is a clone designated herein as "DNA84912-2610".

Figure 114 shows the amino acid sequence (SEQ ID NO:114) derived from the coding sequence of SEQ ID NO:113 shown in Figure 113.

Figure 115 shows a nucleotide sequence (SEQ ID NO:115) of a native sequence PRO1867 cDNA, wherein SEQ ID NO:115 is a clone designated herein as "DNA84925-2514".

Figure 116 shows the amino acid sequence (SEQ ID NO:116) derived from the coding sequence of SEQ ID NO:115 shown in Figure 115.

Figure 117 shows a nucleotide sequence (SEQ ID NO:117) of a native sequence PRO4319 cDNA, wherein SEQ ID NO:117 is a clone designated herein as "DNA84928-2564".

Figure 118 shows the amino acid sequence (SEQ ID NO:118) derived from the coding sequence of SEQ ID NO:117 shown in Figure 117.

Figure 119 shows a nucleotide sequence (SEQ ID NO:119) of a native sequence PRO4991 cDNA, wherein SEQ ID NO:119 is a clone designated herein as "DNA84932-2657".

Figure 120 shows the amino acid sequence (SEQ ID NO:120) derived from the coding sequence of SEQ ID NO:119 shown in Figure 119.

Figure 121 shows a nucleotide sequence (SEQ ID NO:121) of a native sequence PRO4398 cDNA, wherein SEQ ID NO:121 is a clone designated herein as "DNA86592-2607".

Figure 122 shows the amino acid sequence (SEQ ID NO:122) derived from the coding sequence of SEQ ID NO:121 shown in Figure 121.

Figure 123 shows a nucleotide sequence (SEQ ID NO:123) of a native sequence PRO4346 cDNA, wherein SEQ ID NO:123 is a clone designated herein as "DNA86594-2587".

Figure 124 shows the amino acid sequence (SEQ ID NO:124) derived from the coding sequence of SEQ ID NO:123 shown in Figure 123.

5 Figure 125 shows a nucleotide sequence (SEQ ID NO:125) of a native sequence PRO4350 cDNA, wherein SEQ ID NO:125 is a clone designated herein as "DNA86647-2591".

Figure 126 shows the amino acid sequence (SEQ ID NO:126) derived from the coding sequence of SEQ ID NO:125 shown in Figure 125.

Figure 127 shows a nucleotide sequence (SEQ ID NO:127) of a native sequence PRO4318 cDNA, wherein SEQ ID NO:127 is a clone designated herein as "DNA87185-2563".

10 Figure 128 shows the amino acid sequence (SEQ ID NO:128) derived from the coding sequence of SEQ ID NO:127 shown in Figure 127.

Figure 129 shows a nucleotide sequence (SEQ ID NO:129) of a native sequence PRO4340 cDNA, wherein SEQ ID NO:129 is a clone designated herein as "DNA87656-2582".

15 Figure 130 shows the amino acid sequence (SEQ ID NO:130) derived from the coding sequence of SEQ ID NO:129 shown in Figure 129.

Figure 131 shows a nucleotide sequence (SEQ ID NO:131) of a native sequence PRO4400 cDNA, wherein SEQ ID NO:131 is a clone designated herein as "DNA87974-2609".

Figure 132 shows the amino acid sequence (SEQ ID NO:132) derived from the coding sequence of SEQ ID NO:131 shown in Figure 131.

20 Figure 133 shows a nucleotide sequence (SEQ ID NO:133) of a native sequence PRO4320 cDNA, wherein SEQ ID NO:133 is a clone designated herein as "DNA88001-2565".

Figure 134 shows the amino acid sequence (SEQ ID NO:134) derived from the coding sequence of SEQ ID NO:133 shown in Figure 133.

25 Figure 135 shows a nucleotide sequence (SEQ ID NO:135) of a native sequence PRO4409 cDNA, wherein SEQ ID NO:135 is a clone designated herein as "DNA88004-2575".

Figure 136 shows the amino acid sequence (SEQ ID NO:136) derived from the coding sequence of SEQ ID NO:135 shown in Figure 135.

Figure 137 shows a nucleotide sequence (SEQ ID NO:137) of a native sequence PRO4399 cDNA, wherein SEQ ID NO:137 is a clone designated herein as "DNA89220-2608".

30 Figure 138 shows the amino acid sequence (SEQ ID NO:138) derived from the coding sequence of SEQ ID NO:137 shown in Figure 137.

Figure 139 shows a nucleotide sequence (SEQ ID NO:139) of a native sequence PRO4418 cDNA, wherein SEQ ID NO:139 is a clone designated herein as "DNA89947-2618".

35 Figure 140 shows the amino acid sequence (SEQ ID NO:140) derived from the coding sequence of SEQ ID NO:139 shown in Figure 139.

Figure 141 shows a nucleotide sequence (SEQ ID NO:141) of a native sequence PRO4330 cDNA, wherein SEQ ID NO:141 is a clone designated herein as "DNA90842-2574".

Figure 142 shows the amino acid sequence (SEQ ID NO:142) derived from the coding sequence of SEQ ID NO:141 shown in Figure 141.

Figure 143 shows a nucleotide sequence (SEQ ID NO:143) of a native sequence PRO4339 cDNA, wherein SEQ ID NO:143 is a clone designated herein as "DNA91775-2581".

Figure 144 shows the amino acid sequence (SEQ ID NO:144) derived from the coding sequence of SEQ ID NO:143 shown in Figure 143.

Figure 145 shows a nucleotide sequence (SEQ ID NO:145) of a native sequence PRO4326 cDNA, wherein SEQ ID NO:145 is a clone designated herein as "DNA91779-2571".

Figure 146 shows the amino acid sequence (SEQ ID NO:146) derived from the coding sequence of SEQ ID NO:145 shown in Figure 145.

Figure 147 shows a nucleotide sequence (SEQ ID NO:147) of a native sequence PRO6014 cDNA, wherein SEQ ID NO:147 is a clone designated herein as "DNA92217-2697".

Figure 148 shows the amino acid sequence (SEQ ID NO:148) derived from the coding sequence of SEQ ID NO:147 shown in Figure 147.

Figure 149 shows a nucleotide sequence (SEQ ID NO:149) of a native sequence PRO3446 cDNA, wherein SEQ ID NO:149 is a clone designated herein as "DNA92219-2541".

Figure 150 shows the amino acid sequence (SEQ ID NO:150) derived from the coding sequence of SEQ ID NO:149 shown in Figure 149.

Figure 151 shows a nucleotide sequence (SEQ ID NO:151) of a native sequence PRO4322 cDNA, wherein SEQ ID NO:151 is a clone designated herein as "DNA92223-2567".

Figure 152 shows the amino acid sequence (SEQ ID NO:152) derived from the coding sequence of SEQ ID NO:151 shown in Figure 151.

Figure 153 shows a nucleotide sequence (SEQ ID NO:153) of a native sequence PRO4381 cDNA, wherein SEQ ID NO:153 is a clone designated herein as "DNA92225-2603".

Figure 154 shows the amino acid sequence (SEQ ID NO:154) derived from the coding sequence of SEQ ID NO:153 shown in Figure 153.

Figure 155 shows a nucleotide sequence (SEQ ID NO:155) of a native sequence PRO4348 cDNA, wherein SEQ ID NO:155 is a clone designated herein as "DNA92232-2589".

Figure 156 shows the amino acid sequence (SEQ ID NO:156) derived from the coding sequence of SEQ ID NO:155 shown in Figure 155.

Figure 157 shows a nucleotide sequence (SEQ ID NO:157) of a native sequence PRO4371 cDNA, wherein SEQ ID NO:157 is a clone designated herein as "DNA92233-2599".

Figure 158 shows the amino acid sequence (SEQ ID NO:158) derived from the coding sequence of SEQ ID NO:157 shown in Figure 157.

Figure 159 shows a nucleotide sequence (SEQ ID NO:159) of a native sequence PRO3742 cDNA, wherein SEQ ID NO:159 is a clone designated herein as "DNA92243-2549".

Figure 160 shows the amino acid sequence (SEQ ID NO:160) derived from the coding sequence of SEQ ID NO:159 shown in Figure 159.

Figure 161 shows a nucleotide sequence (SEQ ID NO:161) of a native sequence PRO5773 cDNA, wherein SEQ ID NO:161 is a clone designated herein as "DNA92253-2671".

Figure 162 shows the amino acid sequence (SEQ ID NO:162) derived from the coding sequence of SEQ ID NO:161 shown in Figure 161.

5 Figure 163 shows a nucleotide sequence (SEQ ID NO:163) of a native sequence PRO5774 cDNA, wherein SEQ ID NO:163 is a clone designated herein as "DNA92254-2672".

Figure 164 shows the amino acid sequence (SEQ ID NO:164) derived from the coding sequence of SEQ ID NO:163 shown in Figure 163.

Figure 165 shows a nucleotide sequence (SEQ ID NO:165) of a native sequence PRO4343 cDNA, wherein SEQ ID NO:165 is a clone designated herein as "DNA92255-2584".

10 Figure 166 shows the amino acid sequence (SEQ ID NO:166) derived from the coding sequence of SEQ ID NO:165 shown in Figure 165.

Figure 167 shows a nucleotide sequence (SEQ ID NO:167) of a native sequence PRO4325 cDNA, wherein SEQ ID NO:167 is a clone designated herein as "DNA92269-2570".

15 Figure 168 shows the amino acid sequence (SEQ ID NO:168) derived from the coding sequence of SEQ ID NO:167 shown in Figure 167.

Figure 169 shows a nucleotide sequence (SEQ ID NO:169) of a native sequence PRO4347 cDNA, wherein SEQ ID NO:169 is a clone designated herein as "DNA92288-2588".

Figure 170 shows the amino acid sequence (SEQ ID NO:170) derived from the coding sequence of SEQ ID NO:169 shown in Figure 169.

20 Figure 171 shows a nucleotide sequence (SEQ ID NO:171) of a native sequence PRO3743 cDNA, wherein SEQ ID NO:171 is a clone designated herein as "DNA92290-2550".

Figure 172 shows the amino acid sequence (SEQ ID NO:172) derived from the coding sequence of SEQ ID NO:171 shown in Figure 171.

25 Figure 173 shows a nucleotide sequence (SEQ ID NO:173) of a native sequence PRO4426 cDNA, wherein SEQ ID NO:173 is a clone designated herein as "DNA93012-2622".

Figure 174 shows the amino acid sequence (SEQ ID NO:174) derived from the coding sequence of SEQ ID NO:173 shown in Figure 173.

Figure 175 shows a nucleotide sequence (SEQ ID NO:175) of a native sequence PRO4500 cDNA, wherein SEQ ID NO:175 is a clone designated herein as "DNA93020-2642".

30 Figure 176 shows the amino acid sequence (SEQ ID NO:176) derived from the coding sequence of SEQ ID NO:175 shown in Figure 175.

Figure 177 shows a nucleotide sequence (SEQ ID NO:177) of a native sequence PRO4389 cDNA, wherein SEQ ID NO:177 is a clone designated herein as "DNA94830-2604".

35 Figure 178 shows the amino acid sequence (SEQ ID NO:178) derived from the coding sequence of SEQ ID NO:177 shown in Figure 177.

Figure 179 shows a nucleotide sequence (SEQ ID NO:179) of a native sequence PRO4337 cDNA, wherein SEQ ID NO:179 is a clone designated herein as "DNA94833-2579".

Figure 180 shows the amino acid sequence (SEQ ID NO:180) derived from the coding sequence of SEQ ID NO:179 shown in Figure 179.

Figure 181 shows a nucleotide sequence (SEQ ID NO:181) of a native sequence PRO4992 cDNA, wherein SEQ ID NO:181 is a clone designated herein as "DNA94838-2658".

5 Figure 182 shows the amino acid sequence (SEQ ID NO:182) derived from the coding sequence of SEQ ID NO:181 shown in Figure 181.

Figure 183 shows a nucleotide sequence (SEQ ID NO:183) of a native sequence PRO5996 cDNA, wherein SEQ ID NO:183 is a clone designated herein as "DNA94844-2686".

Figure 184 shows the amino acid sequence (SEQ ID NO:184) derived from the coding sequence of SEQ ID NO:183 shown in Figure 183.

10 Figure 185 shows a nucleotide sequence (SEQ ID NO:185) of a native sequence PRO4345 cDNA, wherein SEQ ID NO:185 is a clone designated herein as "DNA94854-2586".

Figure 186 shows the amino acid sequence (SEQ ID NO:186) derived from the coding sequence of SEQ ID NO:185 shown in Figure 185.

15 Figure 187 shows a nucleotide sequence (SEQ ID NO:187) of a native sequence PRO4978 cDNA, wherein SEQ ID NO:187 is a clone designated herein as "DNA95930".

Figure 188 shows the amino acid sequence (SEQ ID NO:188) derived from the coding sequence of SEQ ID NO:187 shown in Figure 187.

Figure 189 shows a nucleotide sequence (SEQ ID NO:189) of a native sequence PRO5780 cDNA, wherein SEQ ID NO:189 is a clone designated herein as "DNA96868-2677".

20 Figure 190 shows the amino acid sequence (SEQ ID NO:190) derived from the coding sequence of SEQ ID NO:189 shown in Figure 189.

Figure 191 shows a nucleotide sequence (SEQ ID NO:191) of a native sequence PRO5992 cDNA, wherein SEQ ID NO:191 is a clone designated herein as "DNA96871-2683".

25 Figure 192 shows the amino acid sequence (SEQ ID NO:192) derived from the coding sequence of SEQ ID NO:191 shown in Figure 191.

Figure 193 shows a nucleotide sequence (SEQ ID NO:193) of a native sequence PRO4428 cDNA, wherein SEQ ID NO:193 is a clone designated herein as "DNA96880-2624".

Figure 194 shows the amino acid sequence (SEQ ID NO:194) derived from the coding sequence of SEQ ID NO:193 shown in Figure 193.

30 Figure 195 shows a nucleotide sequence (SEQ ID NO:195) of a native sequence PRO4994 cDNA, wherein SEQ ID NO:195 is a clone designated herein as "DNA96986-2660".

Figure 196 shows the amino acid sequence (SEQ ID NO:196) derived from the coding sequence of SEQ ID NO:195 shown in Figure 195.

35 Figure 197 shows a nucleotide sequence (SEQ ID NO:197) of a native sequence PRO5995 cDNA, wherein SEQ ID NO:197 is a clone designated herein as "DNA96988-2685".

Figure 198 shows the amino acid sequence (SEQ ID NO:198) derived from the coding sequence of SEQ ID NO:197 shown in Figure 197.

Figure 199 shows a nucleotide sequence (SEQ ID NO:199) of a native sequence PRO6094 cDNA, wherein SEQ ID NO:199 is a clone designated herein as "DNA96995-2709".

Figure 200 shows the amino acid sequence (SEQ ID NO:200) derived from the coding sequence of SEQ ID NO:199 shown in Figure 199.

5 Figure 201 shows a nucleotide sequence (SEQ ID NO:201) of a native sequence PRO4317 cDNA, wherein SEQ ID NO:201 is a clone designated herein as "DNA97004-2562".

Figure 202 shows the amino acid sequence (SEQ ID NO:202) derived from the coding sequence of SEQ ID NO:201 shown in Figure 201.

Figure 203 shows a nucleotide sequence (SEQ ID NO:203) of a native sequence PRO5997 cDNA, wherein SEQ ID NO:203 is a clone designated herein as "DNA97005-2687".

10 Figure 204 shows the amino acid sequence (SEQ ID NO:204) derived from the coding sequence of SEQ ID NO:203 shown in Figure 203.

Figure 205 shows a nucleotide sequence (SEQ ID NO:205) of a native sequence PRO5005 cDNA, wherein SEQ ID NO:205 is a clone designated herein as "DNA97009-2668".

15 Figure 206 shows the amino acid sequence (SEQ ID NO:206) derived from the coding sequence of SEQ ID NO:205 shown in Figure 205.

Figure 207 shows a nucleotide sequence (SEQ ID NO:207) of a native sequence PRO5004 cDNA, wherein SEQ ID NO:207 is a clone designated herein as "DNA97013-2667".

Figure 208 shows the amino acid sequence (SEQ ID NO:208) derived from the coding sequence of SEQ ID NO:207 shown in Figure 207.

20 Figure 209 shows a nucleotide sequence (SEQ ID NO:209) of a native sequence PRO6001 cDNA, wherein SEQ ID NO:209 is a clone designated herein as "DNA98380-2690".

Figure 210 shows the amino acid sequence (SEQ ID NO:210) derived from the coding sequence of SEQ ID NO:209 shown in Figure 209.

25 Figure 211 shows a nucleotide sequence (SEQ ID NO:211) of a native sequence PRO6013 cDNA, wherein SEQ ID NO:211 is a clone designated herein as "DNA98561-2696".

Figure 212 shows the amino acid sequence (SEQ ID NO:212) derived from the coding sequence of SEQ ID NO:211 shown in Figure 211.

Figure 213 shows a nucleotide sequence (SEQ ID NO:213) of a native sequence PRO4502 cDNA, wherein SEQ ID NO:213 is a clone designated herein as "DNA98575-2644".

30 Figure 214 shows the amino acid sequence (SEQ ID NO:214) derived from the coding sequence of SEQ ID NO:213 shown in Figure 213.

Figure 215 shows a nucleotide sequence (SEQ ID NO:215) of a native sequence PRO6007 cDNA, wherein SEQ ID NO:215 is a clone designated herein as "DNA98593-2694".

35 Figure 216 shows the amino acid sequence (SEQ ID NO:216) derived from the coding sequence of SEQ ID NO:215 shown in Figure 215.

Figure 217 shows a nucleotide sequence (SEQ ID NO:217) of a native sequence PRO6028 cDNA, wherein SEQ ID NO:217 is a clone designated herein as "DNA98600-2703".

Figure 218 shows the amino acid sequence (SEQ ID NO:218) derived from the coding sequence of SEQ ID NO:217 shown in Figure 217.

Figure 219 shows a nucleotide sequence (SEQ ID NO:219) of a native sequence PRO100 cDNA, wherein SEQ ID NO:219 is a clone designated herein as "DNA99333".

Figure 220 shows the amino acid sequence (SEQ ID NO:220) derived from the coding sequence of SEQ ID NO:219 shown in Figure 219.

Figure 221 shows a nucleotide sequence (SEQ ID NO:221) of a native sequence PRO4327 cDNA, wherein SEQ ID NO:221 is a clone designated herein as "DNA99391-2572".

Figure 222 shows the amino acid sequence (SEQ ID NO:222) derived from the coding sequence of SEQ ID NO:221 shown in Figure 221.

Figure 223 shows a nucleotide sequence (SEQ ID NO:223) of a native sequence PRO4315 cDNA, wherein SEQ ID NO:223 is a clone designated herein as "DNA99393-2560".

Figure 224 shows the amino acid sequence (SEQ ID NO:224) derived from the coding sequence of SEQ ID NO:223 shown in Figure 223.

Figure 225 shows a nucleotide sequence (SEQ ID NO:225) of a native sequence PRO5993 cDNA, wherein SEQ ID NO:225 is a clone designated herein as "DNA100276-2684".

Figure 226 shows the amino acid sequence (SEQ ID NO:226) derived from the coding sequence of SEQ ID NO:225 shown in Figure 225.

Figure 227 shows a nucleotide sequence (SEQ ID NO:227) of a native sequence PRO4503 cDNA, wherein SEQ ID NO:227 is a clone designated herein as "DNA100312-2645".

Figure 228 shows the amino acid sequence (SEQ ID NO:228) derived from the coding sequence of SEQ ID NO:227 shown in Figure 227.

Figure 229 shows a nucleotide sequence (SEQ ID NO:229) of a native sequence PRO4976 cDNA, wherein SEQ ID NO:229 is a clone designated herein as "DNA100902-2646".

Figure 230 shows the amino acid sequence (SEQ ID NO:230) derived from the coding sequence of SEQ ID NO:229 shown in Figure 229.

Figure 231 shows a nucleotide sequence (SEQ ID NO:231) of a native sequence PRO5798 cDNA, wherein SEQ ID NO:231 is a clone designated herein as "DNA102899-2679".

Figure 232 shows the amino acid sequence (SEQ ID NO:232) derived from the coding sequence of SEQ ID NO:231 shown in Figure 231.

Figure 233 shows a nucleotide sequence (SEQ ID NO:233) of a native sequence PRO6242 cDNA, wherein SEQ ID NO:233 is a clone designated herein as "DNA104875-2720".

Figure 234 shows the amino acid sequence (SEQ ID NO:234) derived from the coding sequence of SEQ ID NO:233 shown in Figure 233.

Figure 235 shows a nucleotide sequence (SEQ ID NO:235) of a native sequence PRO6095 cDNA, wherein SEQ ID NO:235 is a clone designated herein as "DNA105680-2710".

Figure 236 shows the amino acid sequence (SEQ ID NO:236) derived from the coding sequence of SEQ ID NO:235 shown in Figure 235.



Figure 237 shows a nucleotide sequence (SEQ ID NO:237) of a native sequence PRO6093 cDNA, wherein SEQ ID NO:237 is a clone designated herein as "DNA105779-2708".

Figure 238 shows the amino acid sequence (SEQ ID NO:238) derived from the coding sequence of SEQ ID NO:237 shown in Figure 237.

5 Figure 239 shows a nucleotide sequence (SEQ ID NO:239) of a native sequence PRO6012 cDNA, wherein SEQ ID NO:239 is a clone designated herein as "DNA105794-2695".

Figure 240 shows the amino acid sequence (SEQ ID NO:240) derived from the coding sequence of SEQ ID NO:239 shown in Figure 239.

Figure 241 shows a nucleotide sequence (SEQ ID NO:241) of a native sequence PRO6027 cDNA, wherein SEQ ID NO:241 is a clone designated herein as "DNA105838-2702".

10 Figure 242 shows the amino acid sequence (SEQ ID NO:242) derived from the coding sequence of SEQ ID NO:241 shown in Figure 241.

Figure 243 shows a nucleotide sequence (SEQ ID NO:243) of a native sequence PRO6181 cDNA, wherein SEQ ID NO:243 is a clone designated herein as "DNA107698-2715".

15 Figure 244 shows the amino acid sequence (SEQ ID NO:244) derived from the coding sequence of SEQ ID NO:243 shown in Figure 243.

Figure 245 shows a nucleotide sequence (SEQ ID NO:245) of a native sequence PRO6097 cDNA, wherein SEQ ID NO:245 is a clone designated herein as "DNA107701-2711".

Figure 246 shows the amino acid sequence (SEQ ID NO:246) derived from the coding sequence of SEQ ID NO:245 shown in Figure 245.

20 Figure 247 shows a nucleotide sequence (SEQ ID NO:247) of a native sequence PRO6090 cDNA, wherein SEQ ID NO:247 is a clone designated herein as "DNA107781-2707".

Figure 248 shows the amino acid sequence (SEQ ID NO:248) derived from the coding sequence of SEQ ID NO:247 shown in Figure 247.

25 Figure 249 shows a nucleotide sequence (SEQ ID NO:249) of a native sequence PRO7171 cDNA, wherein SEQ ID NO:249 is a clone designated herein as "DNA108670-2744".

Figure 250 shows the amino acid sequence (SEQ ID NO:250) derived from the coding sequence of SEQ ID NO:249 shown in Figure 249.

Figure 251 shows a nucleotide sequence (SEQ ID NO:251) of a native sequence PRO6258 cDNA, wherein SEQ ID NO:251 is a clone designated herein as "DNA108688-2725".

30 Figure 252 shows the amino acid sequence (SEQ ID NO:252) derived from the coding sequence of SEQ ID NO:251 shown in Figure 251.

Figure 253 shows a nucleotide sequence (SEQ ID NO:253) of a native sequence PRO9820 cDNA, wherein SEQ ID NO:253 is a clone designated herein as "DNA108769-2765".

35 Figure 254 shows the amino acid sequence (SEQ ID NO:254) derived from the coding sequence of SEQ ID NO:253 shown in Figure 253.

Figure 255 shows a nucleotide sequence (SEQ ID NO:255) of a native sequence PRO6243 cDNA, wherein SEQ ID NO:255 is a clone designated herein as "DNA108935-2721".

Figure 256 shows the amino acid sequence (SEQ ID NO:256) derived from the coding sequence of SEQ ID NO:255 shown in Figure 255.

Figure 257 shows a nucleotide sequence (SEQ ID NO:257) of a native sequence PRO6182 cDNA, wherein SEQ ID NO:257 is a clone designated herein as "DNA110700-2716".

5 Figure 258 shows the amino acid sequence (SEQ ID NO:258) derived from the coding sequence of SEQ ID NO:257 shown in Figure 257.

Figure 259 shows a nucleotide sequence (SEQ ID NO:259) of a native sequence PRO6079 cDNA, wherein SEQ ID NO:259 is a clone designated herein as "DNA111750-2706".

Figure 260 shows the amino acid sequence (SEQ ID NO:260) derived from the coding sequence of SEQ ID NO:259 shown in Figure 259.

10 Figure 261 shows a nucleotide sequence (SEQ ID NO:261) of a native sequence PRO7434 cDNA, wherein SEQ ID NO:261 is a clone designated herein as "DNA123430-2755".

Figure 262 shows the amino acid sequence (SEQ ID NO:262) derived from the coding sequence of SEQ ID NO:261 shown in Figure 261.

15 Figure 263 shows a nucleotide sequence (SEQ ID NO:263) of a native sequence PRO9865 cDNA, wherein SEQ ID NO:263 is a clone designated herein as "DNA125154-2785".

Figure 264 shows the amino acid sequence (SEQ ID NO:264) derived from the coding sequence of SEQ ID NO:263 shown in Figure 263.

Figure 265 shows a nucleotide sequence (SEQ ID NO:265) of a native sequence PRO9828 cDNA, wherein SEQ ID NO:265 is a clone designated herein as "DNA142238-2768".

20 Figure 266 shows the amino acid sequence (SEQ ID NO:266) derived from the coding sequence of SEQ ID NO:265 shown in Figure 265.

Figure 267 shows a nucleotide sequence (SEQ ID NO:267) of a native sequence PRO196 cDNA, wherein SEQ ID NO:267 is a clone designated herein as "DNA22779-1130".

25 Figure 268 shows the amino acid sequence (SEQ ID NO:268) derived from the coding sequence of SEQ ID NO:267 shown in Figure 267.

Figure 269 shows a nucleotide sequence (SEQ ID NO:269) of a native sequence PRO197 cDNA, wherein SEQ ID NO:269 is a clone designated herein as "DNA22780-1078".

Figure 270 shows the amino acid sequence (SEQ ID NO:270) derived from the coding sequence of SEQ ID NO:269 shown in Figure 269.

30 Figure 271 shows a nucleotide sequence (SEQ ID NO:271) of a native sequence PRO195 cDNA, wherein SEQ ID NO:271 is a clone designated herein as "DNA26847-1395".

Figure 272 shows the amino acid sequence (SEQ ID NO:272) derived from the coding sequence of SEQ ID NO:271 shown in Figure 271.

35 Figure 273 shows a nucleotide sequence (SEQ ID NO:273) of a native sequence PRO187 cDNA, wherein SEQ ID NO:273 is a clone designated herein as "DNA27864-1155".

Figure 274 shows the amino acid sequence (SEQ ID NO:274) derived from the coding sequence of SEQ ID NO:273 shown in Figure 273.

Figure 275 shows a nucleotide sequence (SEQ ID NO:275) of a native sequence PRO182 cDNA, wherein SEQ ID NO:275 is a clone designated herein as "DNA27865-1091".

Figure 276 shows the amino acid sequence (SEQ ID NO:276) derived from the coding sequence of SEQ ID NO:275 shown in Figure 275.

5 Figure 277 shows a nucleotide sequence (SEQ ID NO:277) of a native sequence PRO188 cDNA, wherein SEQ ID NO:277 is a clone designated herein as "DNA28497-1130".

Figure 278 shows the amino acid sequence (SEQ ID NO:278) derived from the coding sequence of SEQ ID NO:277 shown in Figure 277.

Figure 279 shows a nucleotide sequence (SEQ ID NO:279) of a native sequence PRO183 cDNA, wherein SEQ ID NO:279 is a clone designated herein as "DNA28498".

10 Figure 280 shows the amino acid sequence (SEQ ID NO:280) derived from the coding sequence of SEQ ID NO:279 shown in Figure 279.

Figure 281 shows a nucleotide sequence (SEQ ID NO:281) of a native sequence PRO184 cDNA, wherein SEQ ID NO:281 is a clone designated herein as "DNA28500".

15 Figure 282 shows the amino acid sequence (SEQ ID NO:282) derived from the coding sequence of SEQ ID NO:281 shown in Figure 281.

Figure 283 shows a nucleotide sequence (SEQ ID NO:283) of a native sequence PRO185 cDNA, wherein SEQ ID NO:283 is a clone designated herein as "DNA28503".

Figure 284 shows the amino acid sequence (SEQ ID NO:284) derived from the coding sequence of SEQ ID NO:283 shown in Figure 283.

20 Figure 285 shows a nucleotide sequence (SEQ ID NO:285) of a native sequence PRO200 cDNA, wherein SEQ ID NO:285 is a clone designated herein as "DNA29101-1122".

Figure 286 shows the amino acid sequence (SEQ ID NO:286) derived from the coding sequence of SEQ ID NO:285 shown in Figure 285.

25 Figure 287 shows a nucleotide sequence (SEQ ID NO:287) of a native sequence PRO202 cDNA, wherein SEQ ID NO:287 is a clone designated herein as "DNA30869".

Figure 288 shows the amino acid sequence (SEQ ID NO:288) derived from the coding sequence of SEQ ID NO:287 shown in Figure 287.

Figure 289 shows a nucleotide sequence (SEQ ID NO:289) of a native sequence PRO214 cDNA, wherein SEQ ID NO:289 is a clone designated herein as "DNA32286-1191".

30 Figure 290 shows the amino acid sequence (SEQ ID NO:290) derived from the coding sequence of SEQ ID NO:289 shown in Figure 289.

Figure 291 shows a nucleotide sequence (SEQ ID NO:291) of a native sequence PRO215 cDNA, wherein SEQ ID NO:291 is a clone designated herein as "DNA32288-1132".

35 Figure 292 shows the amino acid sequence (SEQ ID NO:292) derived from the coding sequence of SEQ ID NO:291 shown in Figure 291.

Figure 293 shows a nucleotide sequence (SEQ ID NO:293) of a native sequence PRO219 cDNA, wherein SEQ ID NO:293 is a clone designated herein as "DNA32290-1164".

Figure 294 shows the amino acid sequence (SEQ ID NO:294) derived from the coding sequence of SEQ ID NO:293 shown in Figure 293.

Figure 295 shows a nucleotide sequence (SEQ ID NO:295) of a native sequence PRO211 cDNA, wherein SEQ ID NO:295 is a clone designated herein as "DNA32292-1131".

5 Figure 296 shows the amino acid sequence (SEQ ID NO:296) derived from the coding sequence of SEQ ID NO:295 shown in Figure 295.

Figure 297 shows a nucleotide sequence (SEQ ID NO:297) of a native sequence PRO220 cDNA, wherein SEQ ID NO:297 is a clone designated herein as "DNA32298-1132".

Figure 298 shows the amino acid sequence (SEQ ID NO:298) derived from the coding sequence of SEQ ID NO:297 shown in Figure 297.

10 Figure 299 shows a nucleotide sequence (SEQ ID NO:299) of a native sequence PRO366 cDNA, wherein SEQ ID NO:299 is a clone designated herein as "DNA33085-1110".

Figure 300 shows the amino acid sequence (SEQ ID NO:300) derived from the coding sequence of SEQ ID NO:299 shown in Figure 299.

15 Figure 301 shows a nucleotide sequence (SEQ ID NO:301) of a native sequence PRO216 cDNA, wherein SEQ ID NO:301 is a clone designated herein as "DNA33087-1158".

Figure 302 shows the amino acid sequence (SEQ ID NO:302) derived from the coding sequence of SEQ ID NO:301 shown in Figure 301.

Figure 303 shows a nucleotide sequence (SEQ ID NO:303) of a native sequence PRO221 cDNA, wherein SEQ ID NO:303 is a clone designated herein as "DNA33089-1132".

20 Figure 304 shows the amino acid sequence (SEQ ID NO:304) derived from the coding sequence of SEQ ID NO:303 shown in Figure 303.

Figure 305 shows a nucleotide sequence (SEQ ID NO:305) of a native sequence PRO228 cDNA, wherein SEQ ID NO:305 is a clone designated herein as "DNA33092-1202".

25 Figure 306 shows the amino acid sequence (SEQ ID NO:306) derived from the coding sequence of SEQ ID NO:305 shown in Figure 305.

Figure 307 shows a nucleotide sequence (SEQ ID NO:307) of a native sequence PRO217 cDNA, wherein SEQ ID NO:307 is a clone designated herein as "DNA33094-1131".

Figure 308 shows the amino acid sequence (SEQ ID NO:308) derived from the coding sequence of SEQ ID NO:307 shown in Figure 307.

30 Figure 309 shows a nucleotide sequence (SEQ ID NO:309) of a native sequence PRO222 cDNA, wherein SEQ ID NO:309 is a clone designated herein as "DNA33107-1135".

Figure 310 shows the amino acid sequence (SEQ ID NO:310) derived from the coding sequence of SEQ ID NO:309 shown in Figure 309.

35 Figure 311 shows a nucleotide sequence (SEQ ID NO:311) of a native sequence PRO224 cDNA, wherein SEQ ID NO:311 is a clone designated herein as "DNA33221-1133".

Figure 312 shows the amino acid sequence (SEQ ID NO:312) derived from the coding sequence of SEQ ID NO:311 shown in Figure 311.

Figure 313 shows a nucleotide sequence (SEQ ID NO:313) of a native sequence PRO230 cDNA, wherein SEQ ID NO:313 is a clone designated herein as "DNA33223-1136".

Figure 314 shows the amino acid sequence (SEQ ID NO:314) derived from the coding sequence of SEQ ID NO:313 shown in Figure 313.

5 Figure 315 shows a nucleotide sequence (SEQ ID NO:315) of a native sequence PRO198 cDNA, wherein SEQ ID NO:315 is a clone designated herein as "DNA33457-1078".

Figure 316 shows the amino acid sequence (SEQ ID NO:316) derived from the coding sequence of SEQ ID NO:315 shown in Figure 315.

Figure 317 shows a nucleotide sequence (SEQ ID NO:317) of a native sequence PRO226 cDNA, wherein SEQ ID NO:317 is a clone designated herein as "DNA33460-1166".

10 Figure 318 shows the amino acid sequence (SEQ ID NO:318) derived from the coding sequence of SEQ ID NO:317 shown in Figure 317.

Figure 319 shows a nucleotide sequence (SEQ ID NO:319) of a native sequence PRO261 cDNA, wherein SEQ ID NO:319 is a clone designated herein as "DNA33473-1176".

15 Figure 320 shows the amino acid sequence (SEQ ID NO:320) derived from the coding sequence of SEQ ID NO:319 shown in Figure 319.

Figure 321 shows a nucleotide sequence (SEQ ID NO:321) of a native sequence PRO242 cDNA, wherein SEQ ID NO:321 is a clone designated herein as "DNA33785-1143".

Figure 322 shows the amino acid sequence (SEQ ID NO:322) derived from the coding sequence of SEQ ID NO:321 shown in Figure 321.

20 Figure 323 shows a nucleotide sequence (SEQ ID NO:323) of a native sequence PRO227 cDNA, wherein SEQ ID NO:323 is a clone designated herein as "DNA33786-1132".

Figure 324 shows the amino acid sequence (SEQ ID NO:324) derived from the coding sequence of SEQ ID NO:323 shown in Figure 323.

25 Figure 325 shows a nucleotide sequence (SEQ ID NO:325) of a native sequence PRO237 cDNA, wherein SEQ ID NO:325 is a clone designated herein as "DNA34353-1428".

Figure 326 shows the amino acid sequence (SEQ ID NO:326) derived from the coding sequence of SEQ ID NO:325 shown in Figure 325.

Figure 327 shows a nucleotide sequence (SEQ ID NO:327) of a native sequence PRO241 cDNA, wherein SEQ ID NO:327 is a clone designated herein as "DNA34392-1170".

30 Figure 328 shows the amino acid sequence (SEQ ID NO:328) derived from the coding sequence of SEQ ID NO:327 shown in Figure 327.

Figure 329 shows a nucleotide sequence (SEQ ID NO:329) of a native sequence PRO231 cDNA, wherein SEQ ID NO:329 is a clone designated herein as "DNA34434-1139".

35 Figure 330 shows the amino acid sequence (SEQ ID NO:330) derived from the coding sequence of SEQ ID NO:329 shown in Figure 329.

Figure 331 shows a nucleotide sequence (SEQ ID NO:331) of a native sequence PRO235 cDNA, wherein SEQ ID NO:331 is a clone designated herein as "DNA35558-1167".

Figure 332 shows the amino acid sequence (SEQ ID NO:332) derived from the coding sequence of SEQ ID NO:331 shown in Figure 331.

Figure 333 shows a nucleotide sequence (SEQ ID NO:333) of a native sequence PRO323 cDNA, wherein SEQ ID NO:333 is a clone designated herein as "DNA35595-1228".

5 Figure 334 shows the amino acid sequence (SEQ ID NO:334) derived from the coding sequence of SEQ ID NO:333 shown in Figure 333.

Figure 335 shows a nucleotide sequence (SEQ ID NO:335) of a native sequence PRO245 cDNA, wherein SEQ ID NO:335 is a clone designated herein as "DNA35638-1216".

Figure 336 shows the amino acid sequence (SEQ ID NO:336) derived from the coding sequence of SEQ ID NO:335 shown in Figure 335.

10 Figure 337 shows a nucleotide sequence (SEQ ID NO:337) of a native sequence PRO246 cDNA, wherein SEQ ID NO:337 is a clone designated herein as "DNA35639-1172".

Figure 338 shows the amino acid sequence (SEQ ID NO:338) derived from the coding sequence of SEQ ID NO:337 shown in Figure 337.

15 Figure 339 shows a nucleotide sequence (SEQ ID NO:339) of a native sequence PRO288 cDNA, wherein SEQ ID NO:339 is a clone designated herein as "DNA35663-1129".

Figure 340 shows the amino acid sequence (SEQ ID NO:340) derived from the coding sequence of SEQ ID NO:339 shown in Figure 339.

Figure 341 shows a nucleotide sequence (SEQ ID NO:341) of a native sequence PRO248 cDNA, wherein SEQ ID NO:341 is a clone designated herein as "DNA35674-1142".

20 Figure 342 shows the amino acid sequence (SEQ ID NO:342) derived from the coding sequence of SEQ ID NO:341 shown in Figure 341.

Figure 343 shows a nucleotide sequence (SEQ ID NO:343) of a native sequence PRO257 cDNA, wherein SEQ ID NO:343 is a clone designated herein as "DNA35841-1173".

25 Figure 344 shows the amino acid sequence (SEQ ID NO:344) derived from the coding sequence of SEQ ID NO:343 shown in Figure 343.

Figure 345 shows a nucleotide sequence (SEQ ID NO:345) of a native sequence PRO172 cDNA, wherein SEQ ID NO:345 is a clone designated herein as "DNA35916-1161".

Figure 346 shows the amino acid sequence (SEQ ID NO:346) derived from the coding sequence of SEQ ID NO:345 shown in Figure 345.

30 Figure 347 shows a nucleotide sequence (SEQ ID NO:347) of a native sequence PRO258 cDNA, wherein SEQ ID NO:347 is a clone designated herein as "DNA35918-1174".

Figure 348 shows the amino acid sequence (SEQ ID NO:348) derived from the coding sequence of SEQ ID NO:347 shown in Figure 347.

35 Figure 349 shows a nucleotide sequence (SEQ ID NO:349) of a native sequence PRO265 cDNA, wherein SEQ ID NO:349 is a clone designated herein as "DNA36350-1158".

Figure 350 shows the amino acid sequence (SEQ ID NO:350) derived from the coding sequence of SEQ ID NO:349 shown in Figure 349.

Figure 351 shows a nucleotide sequence (SEQ ID NO:351) of a native sequence PRO326 cDNA, wherein SEQ ID NO:351 is a clone designated herein as "DNA37140-1234".

Figure 352 shows the amino acid sequence (SEQ ID NO:352) derived from the coding sequence of SEQ ID NO:351 shown in Figure 351.

5 Figure 353 shows a nucleotide sequence (SEQ ID NO:353) of a native sequence PRO266 cDNA, wherein SEQ ID NO:353 is a clone designated herein as "DNA37150-1178".

Figure 354 shows the amino acid sequence (SEQ ID NO:354) derived from the coding sequence of SEQ ID NO:353 shown in Figure 353.

Figure 355 shows a nucleotide sequence (SEQ ID NO:355) of a native sequence PRO269 cDNA, wherein SEQ ID NO:355 is a clone designated herein as "DNA38260-1180".

10 Figure 356 shows the amino acid sequence (SEQ ID NO:356) derived from the coding sequence of SEQ ID NO:355 shown in Figure 355.

Figure 357 shows a nucleotide sequence (SEQ ID NO:357) of a native sequence PRO285 cDNA, wherein SEQ ID NO:357 is a clone designated herein as "DNA40021-1154".

15 Figure 358 shows the amino acid sequence (SEQ ID NO:358) derived from the coding sequence of SEQ ID NO:357 shown in Figure 357.

Figure 359 shows a nucleotide sequence (SEQ ID NO:359) of a native sequence PRO328 cDNA, wherein SEQ ID NO:359 is a clone designated herein as "DNA40587-1231".

Figure 360 shows the amino acid sequence (SEQ ID NO:360) derived from the coding sequence of SEQ ID NO:359 shown in Figure 359.

20 Figure 361 shows a nucleotide sequence (SEQ ID NO:361) of a native sequence PRO344 cDNA, wherein SEQ ID NO:361 is a clone designated herein as "DNA40592-1242".

Figure 362 shows the amino acid sequence (SEQ ID NO:362) derived from the coding sequence of SEQ ID NO:361 shown in Figure 361.

25 Figure 363 shows a nucleotide sequence (SEQ ID NO:363) of a native sequence PRO272 cDNA, wherein SEQ ID NO:363 is a clone designated herein as "DNA40620-1183".

Figure 364 shows the amino acid sequence (SEQ ID NO:364) derived from the coding sequence of SEQ ID NO:363 shown in Figure 363.

Figure 365 shows a nucleotide sequence (SEQ ID NO:365) of a native sequence PRO301 cDNA, wherein SEQ ID NO:365 is a clone designated herein as "DNA40628-1216".

30 Figure 366 shows the amino acid sequence (SEQ ID NO:366) derived from the coding sequence of SEQ ID NO:365 shown in Figure 365.

Figure 367 shows a nucleotide sequence (SEQ ID NO:367) of a native sequence PRO331 cDNA, wherein SEQ ID NO:367 is a clone designated herein as "DNA40981-1234".

35 Figure 368 shows the amino acid sequence (SEQ ID NO:368) derived from the coding sequence of SEQ ID NO:367 shown in Figure 367.

Figure 369 shows a nucleotide sequence (SEQ ID NO:369) of a native sequence PRO332 cDNA, wherein SEQ ID NO:369 is a clone designated herein as "DNA40982-1235".

Figure 370 shows the amino acid sequence (SEQ ID NO:370) derived from the coding sequence of SEQ ID NO:369 shown in Figure 369.

Figure 371 shows a nucleotide sequence (SEQ ID NO:371) of a native sequence PRO353 cDNA, wherein SEQ ID NO:371 is a clone designated herein as "DNA41234-1242".

Figure 372 shows the amino acid sequence (SEQ ID NO:372) derived from the coding sequence of SEQ ID NO:371 shown in Figure 371.

Figure 373 shows a nucleotide sequence (SEQ ID NO:373) of a native sequence PRO310 cDNA, wherein SEQ ID NO:373 is a clone designated herein as "DNA43046-1225".

Figure 374 shows the amino acid sequence (SEQ ID NO:374) derived from the coding sequence of SEQ ID NO:373 shown in Figure 373.

Figure 375 shows a nucleotide sequence (SEQ ID NO:375) of a native sequence PRO337 cDNA, wherein SEQ ID NO:375 is a clone designated herein as "DNA43316-1237".

Figure 376 shows the amino acid sequence (SEQ ID NO:376) derived from the coding sequence of SEQ ID NO:375 shown in Figure 375.

Figure 377 shows a nucleotide sequence (SEQ ID NO:377) of a native sequence PRO346 cDNA, wherein SEQ ID NO:377 is a clone designated herein as "DNA44167-1243".

Figure 378 shows the amino acid sequence (SEQ ID NO:378) derived from the coding sequence of SEQ ID NO:377 shown in Figure 377.

Figure 379 shows a nucleotide sequence (SEQ ID NO:379) of a native sequence PRO350 cDNA, wherein SEQ ID NO:379 is a clone designated herein as "DNA44175-1314".

Figure 380 shows the amino acid sequence (SEQ ID NO:380) derived from the coding sequence of SEQ ID NO:379 shown in Figure 379.

Figure 381 shows a nucleotide sequence (SEQ ID NO:381) of a native sequence PRO526 cDNA, wherein SEQ ID NO:381 is a clone designated herein as "DNA44184-1319".

Figure 382 shows the amino acid sequence (SEQ ID NO:382) derived from the coding sequence of SEQ ID NO:381 shown in Figure 381.

Figure 383 shows a nucleotide sequence (SEQ ID NO:383) of a native sequence PRO381 cDNA, wherein SEQ ID NO:383 is a clone designated herein as "DNA44194-1317".

Figure 384 shows the amino acid sequence (SEQ ID NO:384) derived from the coding sequence of SEQ ID NO:383 shown in Figure 383.

Figure 385 shows a nucleotide sequence (SEQ ID NO:385) of a native sequence PRO846 cDNA, wherein SEQ ID NO:385 is a clone designated herein as "DNA44196-1353".

Figure 386 shows the amino acid sequence (SEQ ID NO:386) derived from the coding sequence of SEQ ID NO:385 shown in Figure 385.

Figure 387 shows a nucleotide sequence (SEQ ID NO:387) of a native sequence PRO363 cDNA, wherein SEQ ID NO:387 is a clone designated herein as "DNA45419-1252".

Figure 388 shows the amino acid sequence (SEQ ID NO:388) derived from the coding sequence of SEQ ID NO:387 shown in Figure 387.



Figure 389 shows a nucleotide sequence (SEQ ID NO:389) of a native sequence PRO365 cDNA, wherein SEQ ID NO:389 is a clone designated herein as "DNA46777-1253".

Figure 390 shows the amino acid sequence (SEQ ID NO:390) derived from the coding sequence of SEQ ID NO:389 shown in Figure 389.

5 Figure 391 shows a nucleotide sequence (SEQ ID NO:391) of a native sequence PRO1310 cDNA, wherein SEQ ID NO:391 is a clone designated herein as "DNA47394-1572".

Figure 392 shows the amino acid sequence (SEQ ID NO:392) derived from the coding sequence of SEQ ID NO:391 shown in Figure 391.

Figure 393 shows a nucleotide sequence (SEQ ID NO:393) of a native sequence PRO731 cDNA, wherein SEQ ID NO:393 is a clone designated herein as "DNA48331-1329".

10 Figure 394 shows the amino acid sequence (SEQ ID NO:394) derived from the coding sequence of SEQ ID NO:393 shown in Figure 393.

Figure 395 shows a nucleotide sequence (SEQ ID NO:395) of a native sequence PRO322 cDNA, wherein SEQ ID NO:395 is a clone designated herein as "DNA48336-1309".

15 Figure 396 shows the amino acid sequence (SEQ ID NO:396) derived from the coding sequence of SEQ ID NO:395 shown in Figure 395.

Figure 397 shows a nucleotide sequence (SEQ ID NO:397) of a native sequence PRO536 cDNA, wherein SEQ ID NO:397 is a clone designated herein as "DNA49142-1430".

Figure 398 shows the amino acid sequence (SEQ ID NO:398) derived from the coding sequence of SEQ ID NO:397 shown in Figure 397.

20 Figure 399 shows a nucleotide sequence (SEQ ID NO:399) of a native sequence PRO719 cDNA, wherein SEQ ID NO:399 is a clone designated herein as "DNA49646-1327".

Figure 400 shows the amino acid sequence (SEQ ID NO:400) derived from the coding sequence of SEQ ID NO:399 shown in Figure 399.

25 Figure 401 shows a nucleotide sequence (SEQ ID NO:401) of a native sequence PRO619 cDNA, wherein SEQ ID NO:401 is a clone designated herein as "DNA49821-1562".

Figure 402 shows the amino acid sequence (SEQ ID NO:402) derived from the coding sequence of SEQ ID NO:401 shown in Figure 401.

Figure 403 shows a nucleotide sequence (SEQ ID NO:403) of a native sequence PRO771 cDNA, wherein SEQ ID NO:403 is a clone designated herein as "DNA49829-1346".

30 Figure 404 shows the amino acid sequence (SEQ ID NO:404) derived from the coding sequence of SEQ ID NO:403 shown in Figure 403.

Figure 405 shows a nucleotide sequence (SEQ ID NO:405) of a native sequence PRO1083 cDNA, wherein SEQ ID NO:405 is a clone designated herein as "DNA50921-1458".

35 Figure 406 shows the amino acid sequence (SEQ ID NO:406) derived from the coding sequence of SEQ ID NO:405 shown in Figure 405.

Figure 407 shows a nucleotide sequence (SEQ ID NO:407) of a native sequence PRO862 cDNA, wherein SEQ ID NO:407 is a clone designated herein as "DNA52187-1354".

Figure 408 shows the amino acid sequence (SEQ ID NO:408) derived from the coding sequence of SEQ ID NO:407 shown in Figure 407.

Figure 409 shows a nucleotide sequence (SEQ ID NO:409) of a native sequence PRO733 cDNA, wherein SEQ ID NO:409 is a clone designated herein as "DNA52196-1348".

5 Figure 410 shows the amino acid sequence (SEQ ID NO:410) derived from the coding sequence of SEQ ID NO:409 shown in Figure 409.

Figure 411 shows a nucleotide sequence (SEQ ID NO:411) of a native sequence PRO1188 cDNA, wherein SEQ ID NO:411 is a clone designated herein as "DNA52598-1518".

Figure 412 shows the amino acid sequence (SEQ ID NO:412) derived from the coding sequence of SEQ ID NO:411 shown in Figure 411.

10 Figure 413 shows a nucleotide sequence (SEQ ID NO:413) of a native sequence PRO770 cDNA, wherein SEQ ID NO:413 is a clone designated herein as "DNA54228-1366".

Figure 414 shows the amino acid sequence (SEQ ID NO:414) derived from the coding sequence of SEQ ID NO:413 shown in Figure 413.

15 Figure 415 shows a nucleotide sequence (SEQ ID NO:415) of a native sequence PRO1080 cDNA, wherein SEQ ID NO:415 is a clone designated herein as "DNA56047-1456".

Figure 416 shows the amino acid sequence (SEQ ID NO:416) derived from the coding sequence of SEQ ID NO:415 shown in Figure 415.

Figure 417 shows a nucleotide sequence (SEQ ID NO:417) of a native sequence PRO1017 cDNA, wherein SEQ ID NO:417 is a clone designated herein as "DNA56112-1379".

20 Figure 418 shows the amino acid sequence (SEQ ID NO:418) derived from the coding sequence of SEQ ID NO:417 shown in Figure 417.

Figure 419 shows a nucleotide sequence (SEQ ID NO:419) of a native sequence PRO1016 cDNA, wherein SEQ ID NO:419 is a clone designated herein as "DNA56113-1378".

25 Figure 420 shows the amino acid sequence (SEQ ID NO:420) derived from the coding sequence of SEQ ID NO:419 shown in Figure 419.

Figure 421 shows a nucleotide sequence (SEQ ID NO:421) of a native sequence PRO792 cDNA, wherein SEQ ID NO:421 is a clone designated herein as "DNA56352-1358".

Figure 422 shows the amino acid sequence (SEQ ID NO:422) derived from the coding sequence of SEQ ID NO:421 shown in Figure 421.

30 Figure 423 shows a nucleotide sequence (SEQ ID NO:423) of a native sequence PRO938 cDNA, wherein SEQ ID NO:423 is a clone designated herein as "DNA56433-1406".

Figure 424 shows the amino acid sequence (SEQ ID NO:424) derived from the coding sequence of SEQ ID NO:423 shown in Figure 423.

35 Figure 425 shows a nucleotide sequence (SEQ ID NO:425) of a native sequence PRO1012 cDNA, wherein SEQ ID NO:425 is a clone designated herein as "DNA56439-1376".

Figure 426 shows the amino acid sequence (SEQ ID NO:426) derived from the coding sequence of SEQ ID NO:425 shown in Figure 425.

Figure 427 shows a nucleotide sequence (SEQ ID NO:427) of a native sequence PRO1008 cDNA, wherein SEQ ID NO:427 is a clone designated herein as "DNA57530-1375".

Figure 428 shows the amino acid sequence (SEQ ID NO:428) derived from the coding sequence of SEQ ID NO:427 shown in Figure 427.

5 Figure 429 shows a nucleotide sequence (SEQ ID NO:429) of a native sequence PRO1075 cDNA, wherein SEQ ID NO:429 is a clone designated herein as "DNA57689-1385".

Figure 430 shows the amino acid sequence (SEQ ID NO:430) derived from the coding sequence of SEQ ID NO:429 shown in Figure 429.

Figure 431 shows a nucleotide sequence (SEQ ID NO:431) of a native sequence PRO1007 cDNA, wherein SEQ ID NO:431 is a clone designated herein as "DNA57690-1374".

10 Figure 432 shows the amino acid sequence (SEQ ID NO:432) derived from the coding sequence of SEQ ID NO:431 shown in Figure 431.

Figure 433 shows a nucleotide sequence (SEQ ID NO:433) of a native sequence PRO1056 cDNA, wherein SEQ ID NO:433 is a clone designated herein as "DNA57693-1424".

15 Figure 434 shows the amino acid sequence (SEQ ID NO:434) derived from the coding sequence of SEQ ID NO:433 shown in Figure 433.

Figure 435 shows a nucleotide sequence (SEQ ID NO:435) of a native sequence PRO791 cDNA, wherein SEQ ID NO:435 is a clone designated herein as "DNA57838-1337".

Figure 436 shows the amino acid sequence (SEQ ID NO:436) derived from the coding sequence of SEQ ID NO:435 shown in Figure 435.

20 Figure 437 shows a nucleotide sequence (SEQ ID NO:437) of a native sequence PRO1111 cDNA, wherein SEQ ID NO:437 is a clone designated herein as "DNA58721-1475".

Figure 438 shows the amino acid sequence (SEQ ID NO:438) derived from the coding sequence of SEQ ID NO:437 shown in Figure 437.

25 Figure 439 shows a nucleotide sequence (SEQ ID NO:439) of a native sequence PRO812 cDNA, wherein SEQ ID NO:439 is a clone designated herein as "DNA59205-1421".

Figure 440 shows the amino acid sequence (SEQ ID NO:440) derived from the coding sequence of SEQ ID NO:439 shown in Figure 439.

Figure 441 shows a nucleotide sequence (SEQ ID NO:441) of a native sequence PRO1066 cDNA, wherein SEQ ID NO:441 is a clone designated herein as "DNA59215-1425".

30 Figure 442 shows the amino acid sequence (SEQ ID NO:442) derived from the coding sequence of SEQ ID NO:441 shown in Figure 441.

Figure 443 shows a nucleotide sequence (SEQ ID NO:443) of a native sequence PRO1185 cDNA, wherein SEQ ID NO:443 is a clone designated herein as "DNA59220-1514".

35 Figure 444 shows the amino acid sequence (SEQ ID NO:444) derived from the coding sequence of SEQ ID NO:443 shown in Figure 443.

Figure 445 shows a nucleotide sequence (SEQ ID NO:445) of a native sequence PRO1031 cDNA, wherein SEQ ID NO:445 is a clone designated herein as "DNA59294-1381".

Figure 446 shows the amino acid sequence (SEQ ID NO:446) derived from the coding sequence of SEQ ID NO:445 shown in Figure 445.

Figure 447 shows a nucleotide sequence (SEQ ID NO:447) of a native sequence PRO1360 cDNA, wherein SEQ ID NO:447 is a clone designated herein as "DNA59488-1603".

5 Figure 448 shows the amino acid sequence (SEQ ID NO:448) derived from the coding sequence of SEQ ID NO:447 shown in Figure 447.

Figure 449 shows a nucleotide sequence (SEQ ID NO:449) of a native sequence PRO1309 cDNA, wherein SEQ ID NO:449 is a clone designated herein as "DNA59588-1571".

Figure 450 shows the amino acid sequence (SEQ ID NO:450) derived from the coding sequence of SEQ ID NO:449 shown in Figure 449.

10 Figure 451 shows a nucleotide sequence (SEQ ID NO:451) of a native sequence PRO1107 cDNA, wherein SEQ ID NO:451 is a clone designated herein as "DNA59606-1471".

Figure 452 shows the amino acid sequence (SEQ ID NO:452) derived from the coding sequence of SEQ ID NO:451 shown in Figure 451.

15 Figure 453 shows a nucleotide sequence (SEQ ID NO:453) of a native sequence PRO836 cDNA, wherein SEQ ID NO:453 is a clone designated herein as "DNA59620-1463".

Figure 454 shows the amino acid sequence (SEQ ID NO:454) derived from the coding sequence of SEQ ID NO:453 shown in Figure 453.

Figure 455 shows a nucleotide sequence (SEQ ID NO:455) of a native sequence PRO1132 cDNA, wherein SEQ ID NO:455 is a clone designated herein as "DNA59767-1489".

20 Figure 456 shows the amino acid sequence (SEQ ID NO:456) derived from the coding sequence of SEQ ID NO:455 shown in Figure 455.

Figure 457 shows a nucleotide sequence (SEQ ID NO:457) of a native sequence PRO1131 cDNA, wherein SEQ ID NO:457 is a clone designated herein as "DNA59777-1480".

25 Figure 458 shows the amino acid sequence (SEQ ID NO:458) derived from the coding sequence of SEQ ID NO:457 shown in Figure 457.

Figure 459 shows a nucleotide sequence (SEQ ID NO:459) of a native sequence PRO1130 cDNA, wherein SEQ ID NO:459 is a clone designated herein as "DNA59814-1486".

Figure 460 shows the amino acid sequence (SEQ ID NO:460) derived from the coding sequence of SEQ ID NO:459 shown in Figure 459.

30 Figure 461 shows a nucleotide sequence (SEQ ID NO:461) of a native sequence PRO844 cDNA, wherein SEQ ID NO:461 is a clone designated herein as "DNA59839-1461".

Figure 462 shows the amino acid sequence (SEQ ID NO:462) derived from the coding sequence of SEQ ID NO:461 shown in Figure 461.

35 Figure 463 shows a nucleotide sequence (SEQ ID NO:463) of a native sequence PRO1154 cDNA, wherein SEQ ID NO:463 is a clone designated herein as "DNA59846-1503".

Figure 464 shows the amino acid sequence (SEQ ID NO:464) derived from the coding sequence of SEQ ID NO:463 shown in Figure 463.

Figure 465 shows a nucleotide sequence (SEQ ID NO:465) of a native sequence PRO1181 cDNA, wherein SEQ ID NO:465 is a clone designated herein as "DNA59847-1511".

Figure 466 shows the amino acid sequence (SEQ ID NO:466) derived from the coding sequence of SEQ ID NO:465 shown in Figure 465.

5 Figure 467 shows a nucleotide sequence (SEQ ID NO:467) of a native sequence PRO1126 cDNA, wherein SEQ ID NO:467 is a clone designated herein as "DNA60615-1483".

Figure 468 shows the amino acid sequence (SEQ ID NO:468) derived from the coding sequence of SEQ ID NO:467 shown in Figure 467.

Figure 469 shows a nucleotide sequence (SEQ ID NO:469) of a native sequence PRO1186 cDNA, wherein SEQ ID NO:469 is a clone designated herein as "DNA60621-1516".

10 Figure 470 shows the amino acid sequence (SEQ ID NO:470) derived from the coding sequence of SEQ ID NO:469 shown in Figure 469.

Figure 471 shows a nucleotide sequence (SEQ ID NO:471) of a native sequence PRO1198 cDNA, wherein SEQ ID NO:471 is a clone designated herein as "DNA60622-1525".

15 Figure 472 shows the amino acid sequence (SEQ ID NO:472) derived from the coding sequence of SEQ ID NO:471 shown in Figure 471.

Figure 473 shows a nucleotide sequence (SEQ ID NO:473) of a native sequence PRO1159 cDNA, wherein SEQ ID NO:473 is a clone designated herein as "DNA60627-1508".

Figure 474 shows the amino acid sequence (SEQ ID NO:474) derived from the coding sequence of SEQ ID NO:473 shown in Figure 473.

20 Figure 475 shows a nucleotide sequence (SEQ ID NO:475) of a native sequence PRO1265 cDNA, wherein SEQ ID NO:475 is a clone designated herein as "DNA60764-1533".

Figure 476 shows the amino acid sequence (SEQ ID NO:476) derived from the coding sequence of SEQ ID NO:475 shown in Figure 475.

25 Figure 477 shows a nucleotide sequence (SEQ ID NO:477) of a native sequence PRO1250 cDNA, wherein SEQ ID NO:477 is a clone designated herein as "DNA60775-1532".

Figure 478 shows the amino acid sequence (SEQ ID NO:478) derived from the coding sequence of SEQ ID NO:477 shown in Figure 477.

Figure 479 shows a nucleotide sequence (SEQ ID NO:479) of a native sequence PRO1475 cDNA, wherein SEQ ID NO:479 is a clone designated herein as "DNA61185-1646".

30 Figure 480 shows the amino acid sequence (SEQ ID NO:480) derived from the coding sequence of SEQ ID NO:479 shown in Figure 479.

Figure 481 shows a nucleotide sequence (SEQ ID NO:481) of a native sequence PRO1312 cDNA, wherein SEQ ID NO:481 is a clone designated herein as "DNA61873-1574".

35 Figure 482 shows the amino acid sequence (SEQ ID NO:482) derived from the coding sequence of SEQ ID NO:481 shown in Figure 481.

Figure 483 shows a nucleotide sequence (SEQ ID NO:483) of a native sequence PRO1308 cDNA, wherein SEQ ID NO:483 is a clone designated herein as "DNA62306-1570".

Figure 484 shows the amino acid sequence (SEQ ID NO:484) derived from the coding sequence of SEQ ID NO:483 shown in Figure 483.

Figure 485 shows a nucleotide sequence (SEQ ID NO:485) of a native sequence PRO1326 cDNA, wherein SEQ ID NO:485 is a clone designated herein as "DNA62808-1582".

5 Figure 486 shows the amino acid sequence (SEQ ID NO:486) derived from the coding sequence of SEQ ID NO:485 shown in Figure 485.

Figure 487 shows a nucleotide sequence (SEQ ID NO:487) of a native sequence PRO1192 cDNA, wherein SEQ ID NO:487 is a clone designated herein as "DNA62814-1521".

Figure 488 shows the amino acid sequence (SEQ ID NO:488) derived from the coding sequence of SEQ ID NO:487 shown in Figure 487.

10 Figure 489 shows a nucleotide sequence (SEQ ID NO:489) of a native sequence PRO1246 cDNA, wherein SEQ ID NO:489 is a clone designated herein as "DNA64885-1529".

Figure 490 shows the amino acid sequence (SEQ ID NO:490) derived from the coding sequence of SEQ ID NO:489 shown in Figure 489.

15 Figure 491 shows a nucleotide sequence (SEQ ID NO:491) of a native sequence PRO1356 cDNA, wherein SEQ ID NO:491 is a clone designated herein as "DNA64886-1601".

Figure 492 shows the amino acid sequence (SEQ ID NO:492) derived from the coding sequence of SEQ ID NO:491 shown in Figure 491.

Figure 493 shows a nucleotide sequence (SEQ ID NO:493) of a native sequence PRO1275 cDNA, wherein SEQ ID NO:493 is a clone designated herein as "DNA64888-1542".

20 Figure 494 shows the amino acid sequence (SEQ ID NO:494) derived from the coding sequence of SEQ ID NO:493 shown in Figure 493.

Figure 495 shows a nucleotide sequence (SEQ ID NO:495) of a native sequence PRO1274 cDNA, wherein SEQ ID NO:495 is a clone designated herein as "DNA64889-1541".

25 Figure 496 shows the amino acid sequence (SEQ ID NO:496) derived from the coding sequence of SEQ ID NO:495 shown in Figure 495.

Figure 497 shows a nucleotide sequence (SEQ ID NO:497) of a native sequence PRO1358 cDNA, wherein SEQ ID NO:497 is a clone designated herein as "DNA64890-1612".

Figure 498 shows the amino acid sequence (SEQ ID NO:498) derived from the coding sequence of SEQ ID NO:497 shown in Figure 497.

30 Figure 499 shows a nucleotide sequence (SEQ ID NO:499) of a native sequence PRO1286 cDNA, wherein SEQ ID NO:499 is a clone designated herein as "DNA64903-1553".

Figure 500 shows the amino acid sequence (SEQ ID NO:500) derived from the coding sequence of SEQ ID NO:499 shown in Figure 499.

35 Figure 501 shows a nucleotide sequence (SEQ ID NO:501) of a native sequence PRO1294 cDNA, wherein SEQ ID NO:501 is a clone designated herein as "DNA64905-1558".

Figure 502 shows the amino acid sequence (SEQ ID NO:502) derived from the coding sequence of SEQ ID NO:501 shown in Figure 501.

Figure 503 shows a nucleotide sequence (SEQ ID NO:503) of a native sequence PRO1273 cDNA, wherein SEQ ID NO:503 is a clone designated herein as "DNA65402-1540".

Figure 504 shows the amino acid sequence (SEQ ID NO:504) derived from the coding sequence of SEQ ID NO:503 shown in Figure 503.

5 Figure 505 shows a nucleotide sequence (SEQ ID NO:505) of a native sequence PRO1279 cDNA, wherein SEQ ID NO:505 is a clone designated herein as "DNA65405-1547".

Figure 506 shows the amino acid sequence (SEQ ID NO:506) derived from the coding sequence of SEQ ID NO:505 shown in Figure 505.

Figure 507 shows a nucleotide sequence (SEQ ID NO:507) of a native sequence PRO1195 cDNA, wherein SEQ ID NO:507 is a clone designated herein as "DNA65412-1523".

10 Figure 508 shows the amino acid sequence (SEQ ID NO:508) derived from the coding sequence of SEQ ID NO:507 shown in Figure 507.

Figure 509 shows a nucleotide sequence (SEQ ID NO:509) of a native sequence PRO1271 cDNA, wherein SEQ ID NO:509 is a clone designated herein as "DNA66309-1538".

15 Figure 510 shows the amino acid sequence (SEQ ID NO:510) derived from the coding sequence of SEQ ID NO:509 shown in Figure 509.

Figure 511 shows a nucleotide sequence (SEQ ID NO:511) of a native sequence PRO1338 cDNA, wherein SEQ ID NO:511 is a clone designated herein as "DNA66667-1596".

Figure 512 shows the amino acid sequence (SEQ ID NO:512) derived from the coding sequence of SEQ ID NO:511 shown in Figure 511.

20 Figure 513 shows a nucleotide sequence (SEQ ID NO:513) of a native sequence PRO1343 cDNA, wherein SEQ ID NO:513 is a clone designated herein as "DNA66675-1587".

Figure 514 shows the amino acid sequence (SEQ ID NO:514) derived from the coding sequence of SEQ ID NO:513 shown in Figure 513.

25 Figure 515 shows a nucleotide sequence (SEQ ID NO:515) of a native sequence PRO1434 cDNA, wherein SEQ ID NO:515 is a clone designated herein as "DNA68818-2536".

Figure 516 shows the amino acid sequence (SEQ ID NO:516) derived from the coding sequence of SEQ ID NO:515 shown in Figure 515.

Figure 517 shows a nucleotide sequence (SEQ ID NO:517) of a native sequence PRO1418 cDNA, wherein SEQ ID NO:517 is a clone designated herein as "DNA68864-1629".

30 Figure 518 shows the amino acid sequence (SEQ ID NO:518) derived from the coding sequence of SEQ ID NO:517 shown in Figure 517.

Figure 519 shows a nucleotide sequence (SEQ ID NO:519) of a native sequence PRO1387 cDNA, wherein SEQ ID NO:519 is a clone designated herein as "DNA68872-1620".

35 Figure 520 shows the amino acid sequence (SEQ ID NO:520) derived from the coding sequence of SEQ ID NO:519 shown in Figure 519.

Figure 521 shows a nucleotide sequence (SEQ ID NO:521) of a native sequence PRO1384 cDNA, wherein SEQ ID NO:521 is a clone designated herein as "DNA71159-1617".

Figure 522 shows the amino acid sequence (SEQ ID NO:522) derived from the coding sequence of SEQ ID NO:521 shown in Figure 521.

Figure 523 shows a nucleotide sequence (SEQ ID NO:523) of a native sequence PRO1565 cDNA, wherein SEQ ID NO:523 is a clone designated herein as "DNA73727-1673".

5 Figure 524 shows the amino acid sequence (SEQ ID NO:524) derived from the coding sequence of SEQ ID NO:523 shown in Figure 523.

Figure 525 shows a nucleotide sequence (SEQ ID NO:525) of a native sequence PRO1474 cDNA, wherein SEQ ID NO:525 is a clone designated herein as "DNA73739-1645".

Figure 526 shows the amino acid sequence (SEQ ID NO:526) derived from the coding sequence of SEQ ID NO:525 shown in Figure 525.

10 Figure 527 shows a nucleotide sequence (SEQ ID NO:527) of a native sequence PRO1917 cDNA, wherein SEQ ID NO:527 is a clone designated herein as "DNA76400-2528".

Figure 528 shows the amino acid sequence (SEQ ID NO:528) derived from the coding sequence of SEQ ID NO:527 shown in Figure 527.

15 Figure 529 shows a nucleotide sequence (SEQ ID NO:529) of a native sequence PRO1787 cDNA, wherein SEQ ID NO:529 is a clone designated herein as "DNA76510-2504".

Figure 530 shows the amino acid sequence (SEQ ID NO:530) derived from the coding sequence of SEQ ID NO:529 shown in Figure 529.

Figure 531 shows a nucleotide sequence (SEQ ID NO:531) of a native sequence PRO1556 cDNA, wherein SEQ ID NO:531 is a clone designated herein as "DNA76529-1666".

20 Figure 532 shows the amino acid sequence (SEQ ID NO:532) derived from the coding sequence of SEQ ID NO:531 shown in Figure 531.

Figure 533 shows a nucleotide sequence (SEQ ID NO:533) of a native sequence PRO1561 cDNA, wherein SEQ ID NO:533 is a clone designated herein as "DNA76538-1670".

25 Figure 534 shows the amino acid sequence (SEQ ID NO:534) derived from the coding sequence of SEQ ID NO:533 shown in Figure 533.

Figure 535 shows a nucleotide sequence (SEQ ID NO:535) of a native sequence PRO1693 cDNA, wherein SEQ ID NO:535 is a clone designated herein as "DNA77301-1708".

Figure 536 shows the amino acid sequence (SEQ ID NO:536) derived from the coding sequence of SEQ ID NO:535 shown in Figure 535.

30 Figure 537 shows a nucleotide sequence (SEQ ID NO:537) of a native sequence PRO1868 cDNA, wherein SEQ ID NO:537 is a clone designated herein as "DNA77624-2515".

Figure 538 shows the amino acid sequence (SEQ ID NO:538) derived from the coding sequence of SEQ ID NO:537 shown in Figure 537.

35 Figure 539 shows a nucleotide sequence (SEQ ID NO:539) of a native sequence PRO1890 cDNA, wherein SEQ ID NO:539 is a clone designated herein as "DNA79230-2525".

Figure 540 shows the amino acid sequence (SEQ ID NO:540) derived from the coding sequence of SEQ ID NO:539 shown in Figure 539.



Figure 541 shows a nucleotide sequence (SEQ ID NO:541) of a native sequence PRO1887 cDNA, wherein SEQ ID NO:541 is a clone designated herein as "DNA79862-2522".

Figure 542 shows the amino acid sequence (SEQ ID NO:542) derived from the coding sequence of SEQ ID NO:541 shown in Figure 541.

Figure 543 shows a nucleotide sequence (SEQ ID NO:543) of a native sequence PRO4353 cDNA, wherein SEQ ID NO:543 is a clone designated herein as "DNA80145-2594".

Figure 544 shows the amino acid sequence (SEQ ID NO:544) derived from the coding sequence of SEQ ID NO:543 shown in Figure 543.

Figure 545 shows a nucleotide sequence (SEQ ID NO:545) of a native sequence PRO1801 cDNA, wherein SEQ ID NO:545 is a clone designated herein as "DNA83500-2506".

Figure 546 shows the amino acid sequence (SEQ ID NO:546) derived from the coding sequence of SEQ ID NO:545 shown in Figure 545.

Figure 547 shows a nucleotide sequence (SEQ ID NO:547) of a native sequence PRO4357 cDNA, wherein SEQ ID NO:547 is a clone designated herein as "DNA84917-2597".

Figure 548 shows the amino acid sequence (SEQ ID NO:548) derived from the coding sequence of SEQ ID NO:547 shown in Figure 547.

Figure 549 shows a nucleotide sequence (SEQ ID NO:549) of a native sequence PRO4302 cDNA, wherein SEQ ID NO:549 is a clone designated herein as "DNA92218-2554".

Figure 550 shows the amino acid sequence (SEQ ID NO:550) derived from the coding sequence of SEQ ID NO:549 shown in Figure 549.

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

### I. Definitions

The terms "PRO polypeptide" and "PRO" as used herein and when immediately followed by a numerical designation refer to various polypeptides, wherein the complete designation (i.e., PRO/number) refers to specific polypeptide sequences as described herein. The terms "PRO/number polypeptide" and "PRO/number" wherein the term "number" is provided as an actual numerical designation as used herein encompass native sequence polypeptides and polypeptide variants (which are further defined herein). The PRO polypeptides described herein may be isolated from a variety of sources, such as from human tissue types or from another source, or prepared by recombinant or synthetic methods. The term "PRO polypeptide" refers to each individual PRO/number polypeptide disclosed herein. All disclosures in this specification which refer to the "PRO polypeptide" refer to each of the polypeptides individually as well as jointly. For example, descriptions of the preparation of, purification of, derivation of, formation of antibodies to or against, administration of, compositions containing, treatment of a disease with, etc., pertain to each polypeptide of the invention individually. The term "PRO polypeptide" also includes variants of the PRO/number polypeptides disclosed herein.

A "native sequence PRO polypeptide" comprises a polypeptide having the same amino acid sequence as the corresponding PRO polypeptide derived from nature. Such native sequence PRO polypeptides can be

isolated from nature or can be produced by recombinant or synthetic means. The term "native sequence PRO polypeptide" specifically encompasses naturally-occurring truncated or secreted forms of the specific PRO polypeptide (e.g., an extracellular domain sequence), naturally-occurring variant forms (e.g., alternatively spliced forms) and naturally-occurring allelic variants of the polypeptide. In various embodiments of the invention, the native sequence PRO polypeptides disclosed herein are mature or full-length native sequence polypeptides comprising the full-length amino acids sequences shown in the accompanying figures. Start and stop codons are shown in bold font and underlined in the figures. However, while the PRO polypeptide disclosed in the accompanying figures are shown to begin with methionine residues designated herein as amino acid position 1 in the figures, it is conceivable and possible that other methionine residues located either upstream or downstream from the amino acid position 1 in the figures may be employed as the starting amino acid residue for the PRO polypeptides.

The PRO polypeptide "extracellular domain" or "ECD" refers to a form of the PRO polypeptide which is essentially free of the transmembrane and cytoplasmic domains. Ordinarily, a PRO polypeptide ECD will have less than 1% of such transmembrane and/or cytoplasmic domains and preferably, will have less than 0.5% of such domains. It will be understood that any transmembrane domains identified for the PRO polypeptides of the present invention are identified pursuant to criteria routinely employed in the art for identifying that type of hydrophobic domain. The exact boundaries of a transmembrane domain may vary but most likely by no more than about 5 amino acids at either end of the domain as initially identified herein. Optionally, therefore, an extracellular domain of a PRO polypeptide may contain from about 5 or fewer amino acids on either side of the transmembrane domain/extracellular domain boundary as identified in the Examples or specification and such polypeptides, with or without the associated signal peptide, and nucleic acid encoding them, are contemplated by the present invention.

The approximate location of the "signal peptides" of the various PRO polypeptides disclosed herein are shown in the present specification and/or the accompanying figures. It is noted, however, that the C-terminal boundary of a signal peptide may vary, but most likely by no more than about 5 amino acids on either side of the signal peptide C-terminal boundary as initially identified herein, wherein the C-terminal boundary of the signal peptide may be identified pursuant to criteria routinely employed in the art for identifying that type of amino acid sequence element (e.g., Nielsen et al., Prot. Eng. 10:1-6 (1997) and von Heinje et al., Nucl. Acids. Res. 14:4683-4690 (1986)). Moreover, it is also recognized that, in some cases, cleavage of a signal sequence from a secreted polypeptide is not entirely uniform, resulting in more than one secreted species. These mature polypeptides, where the signal peptide is cleaved within no more than about 5 amino acids on either side of the C-terminal boundary of the signal peptide as identified herein, and the polynucleotides encoding them, are contemplated by the present invention.

"PRO polypeptide variant" means an active PRO polypeptide as defined above or below having at least about 80% amino acid sequence identity with a full-length native sequence PRO polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Such PRO polypeptide variants include, for

instance, PRO polypeptides wherein one or more amino acid residues are added, or deleted, at the N- or C-terminus of the full-length native amino acid sequence. Ordinarily, a PRO polypeptide variant will have at least about 80% amino acid sequence identity, alternatively at least about 81% amino acid sequence identity, alternatively at least about 82% amino acid sequence identity, alternatively at least about 83% amino acid sequence identity, alternatively at least about 84% amino acid sequence identity, alternatively at least about 85% amino acid sequence identity, alternatively at least about 86% amino acid sequence identity, alternatively at least about 87% amino acid sequence identity, alternatively at least about 88% amino acid sequence identity, alternatively at least about 89% amino acid sequence identity, alternatively at least about 90% amino acid sequence identity, alternatively at least about 91% amino acid sequence identity, alternatively at least about 92% amino acid sequence identity, alternatively at least about 93% amino acid sequence identity, alternatively at least about 94% amino acid sequence identity, alternatively at least about 95% amino acid sequence identity, alternatively at least about 96% amino acid sequence identity, alternatively at least about 97% amino acid sequence identity, alternatively at least about 98% amino acid sequence identity and alternatively at least about 99% amino acid sequence identity to a full-length native sequence PRO polypeptide sequence as disclosed herein, a PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other specifically defined fragment of a full-length PRO polypeptide sequence as disclosed herein. Ordinarily, PRO variant polypeptides are at least about 10 amino acids in length, alternatively at least about 20 amino acids in length, alternatively at least about 30 amino acids in length, alternatively at least about 40 amino acids in length, alternatively at least about 50 amino acids in length, alternatively at least about 60 amino acids in length, alternatively at least about 70 amino acids in length, alternatively at least about 80 amino acids in length, alternatively at least about 90 amino acids in length, alternatively at least about 100 amino acids in length, alternatively at least about 150 amino acids in length, alternatively at least about 200 amino acids in length, alternatively at least about 300 amino acids in length, or more.

"Percent (%) amino acid sequence identity" with respect to the PRO polypeptide sequences identified herein is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific PRO polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly

available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. As examples of % amino acid sequence identity calculations using this method, Tables 2 and 3 demonstrate how to calculate the % amino acid sequence identity of the amino acid sequence designated "Comparison Protein" to the amino acid sequence designated "PRO", wherein "PRO" represents the amino acid sequence of a hypothetical PRO polypeptide of interest, "Comparison Protein" represents the amino acid sequence of a polypeptide against which the "PRO" polypeptide of interest is being compared, and "X," "Y" and "Z" each represent different hypothetical amino acid residues.

Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. However, % amino acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 computer program (Altschul et al., Methods in Enzymology 266:460-480 (1996)). Most of the WU-BLAST-2 search parameters are set to the default values. Those not set to default values, i.e., the adjustable parameters, are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11, and scoring matrix = BLOSUM62. When WU-BLAST-2 is employed, a % amino acid sequence identity value is determined by dividing (a) the number of matching identical amino acid residues between the amino acid sequence of the PRO polypeptide of interest having a sequence derived from the native PRO polypeptide and the comparison amino acid sequence of interest (i.e., the sequence against which the PRO polypeptide of interest is being compared which may be a PRO variant polypeptide) as determined by WU-BLAST-2 by (b) the total number of amino acid residues of the PRO polypeptide of interest. For example, in the statement "a polypeptide comprising an the amino acid sequence A which has or having at least 80% amino acid sequence identity to the amino acid sequence B", the amino acid sequence A is the comparison amino acid sequence of interest and the amino acid sequence B is the amino acid sequence of the PRO polypeptide of interest.

Percent amino acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)). The NCBI-BLAST2 sequence

comparison program may be downloaded from <http://www.ncbi.nlm.nih.gov> or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value = 0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.

5 In situations where NCBI-BLAST2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

10 
$$100 \text{ times the fraction } X/Y$$

where X is the number of amino acid residues scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A.

15 "PRO variant polynucleotide" or "PRO variant nucleic acid sequence" means a nucleic acid molecule which encodes an active PRO polypeptide as defined below and which has at least about 80% nucleic acid sequence identity with a nucleotide acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal peptide, as disclosed herein or any other fragment of a full-length PRO polypeptide sequence as disclosed herein. Ordinarily, a PRO variant polynucleotide will have at least about 80% nucleic acid sequence identity, alternatively at least about 81% nucleic acid sequence identity, alternatively at least about 82% nucleic acid sequence identity, alternatively at least about 83% nucleic acid sequence identity, alternatively at least about 84% nucleic acid sequence identity, alternatively at least about 85% nucleic acid sequence identity, alternatively at least about 86% nucleic acid sequence identity, alternatively at least about 87% nucleic acid sequence identity, alternatively at least about 88% nucleic acid sequence identity, alternatively at least about 89% nucleic acid sequence identity, alternatively at least about 90% nucleic acid sequence identity, alternatively at least about 91% nucleic acid sequence identity, alternatively at least about 92% nucleic acid sequence identity, alternatively at least about 93% nucleic acid sequence identity, alternatively at least about 94% nucleic acid sequence identity, alternatively at least about 95% nucleic acid sequence identity, alternatively at least about 96% nucleic acid sequence identity, alternatively at least about 97% nucleic acid sequence identity, alternatively at least about 98% nucleic acid sequence identity and alternatively at least about 99% nucleic acid sequence identity with a nucleic acid sequence encoding a full-length native sequence PRO polypeptide sequence as disclosed herein, a full-length native sequence PRO polypeptide sequence lacking the signal peptide as disclosed herein, an extracellular domain of a PRO polypeptide, with or without the signal sequence, as disclosed herein or any other fragment of a full-

length PRO polypeptide sequence as disclosed herein. Variants do not encompass the native nucleotide sequence.

Ordinarily, PRO variant polynucleotides are at least about 30 nucleotides in length, alternatively at least about 60 nucleotides in length, alternatively at least about 90 nucleotides in length, alternatively at least about 120 nucleotides in length, alternatively at least about 150 nucleotides in length, alternatively at least about 180 nucleotides in length, alternatively at least about 210 nucleotides in length, alternatively at least about 240 nucleotides in length, alternatively at least about 270 nucleotides in length, alternatively at least about 300 nucleotides in length, alternatively at least about 450 nucleotides in length, alternatively at least about 600 nucleotides in length, alternatively at least about 900 nucleotides in length, or more.

"Percent (%) nucleic acid sequence identity" with respect to PRO-encoding nucleic acid sequences identified herein is defined as the percentage of nucleotides in a candidate sequence that are identical with the nucleotides in the PRO nucleic acid sequence of interest, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleic acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. For purposes herein, however, % nucleic acid sequence identity values are generated using the sequence comparison computer program ALIGN-2, wherein the complete source code for the ALIGN-2 program is provided in Table 1 below. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc. and the source code shown in Table 1 below has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available through Genentech, Inc., South San Francisco, California or may be compiled from the source code provided in Table 1 below. The ALIGN-2 program should be compiled for use on a UNIX operating system, preferably digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for nucleic acid sequence comparisons, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:

$$100 \text{ times the fraction } W/Z$$

where W is the number of nucleotides scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to C. As examples of % nucleic acid sequence identity calculations, Tables 4 and 5, demonstrate how to calculate the % nucleic acid sequence identity of the nucleic acid sequence designated "Comparison DNA" to the nucleic acid sequence designated "PRO-DNA", wherein "PRO-DNA" represents a hypothetical PRO-encoding nucleic

acid sequence of interest, "Comparison DNA" represents the nucleotide sequence of a nucleic acid molecule against which the "PRO-DNA" nucleic acid molecule of interest is being compared, and "N", "L" and "V" each represent different hypothetical nucleotides.

Unless specifically stated otherwise, all % nucleic acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. However, %  
5 nucleic acid sequence identity values may also be obtained as described below by using the WU-BLAST-2 computer program (Altschul et al., Methods in Enzymology 266:460-480 (1996)). Most of the WU-BLAST-2 search parameters are set to the default values. Those not set to default values, i.e., the adjustable parameters, are set with the following values: overlap span = 1, overlap fraction = 0.125, word threshold (T) = 11, and scoring matrix = BLOSUM62. When WU-BLAST-2 is employed, a % nucleic acid sequence identity value  
10 is determined by dividing (a) the number of matching identical nucleotides between the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest having a sequence derived from the native sequence PRO polypeptide-encoding nucleic acid and the comparison nucleic acid molecule of interest (i.e., the sequence against which the PRO polypeptide-encoding nucleic acid molecule of interest is being compared which may be a variant PRO polynucleotide) as determined by WU-BLAST-2 by (b) the total number of nucleotides  
15 of the PRO polypeptide-encoding nucleic acid molecule of interest. For example, in the statement "an isolated nucleic acid molecule comprising a nucleic acid sequence A which has or having at least 80% nucleic acid sequence identity to the nucleic acid sequence B", the nucleic acid sequence A is the comparison nucleic acid molecule of interest and the nucleic acid sequence B is the nucleic acid sequence of the PRO polypeptide-encoding nucleic acid molecule of interest.

Percent nucleic acid sequence identity may also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25:3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program may be downloaded from <http://www.ncbi.nlm.nih.gov> or otherwise obtained from the National Institute of Health, Bethesda, MD. NCBI-BLAST2 uses several search parameters, wherein all of those  
20 search parameters are set to default values including, for example, unmask = yes, strand = all, expected occurrences = 10, minimum low complexity length = 15/5, multi-pass e-value = 0.01, constant for multi-pass = 25, dropoff for final gapped alignment = 25 and scoring matrix = BLOSUM62.

In situations where NCBI-BLAST2 is employed for sequence comparisons, the % nucleic acid sequence identity of a given nucleic acid sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given nucleic acid sequence C that has or comprises a certain % nucleic acid  
30 sequence identity to, with, or against a given nucleic acid sequence D) is calculated as follows:

$$100 \text{ times the fraction } W/Z$$

where W is the number of nucleotides scored as identical matches by the sequence alignment program NCBI-BLAST2 in that program's alignment of C and D, and where Z is the total number of nucleotides in D. It will  
35 be appreciated that where the length of nucleic acid sequence C is not equal to the length of nucleic acid sequence D, the % nucleic acid sequence identity of C to D will not equal the % nucleic acid sequence identity of D to

C.

In other embodiments, PRO variant polynucleotides are nucleic acid molecules that encode an active PRO polypeptide and which are capable of hybridizing, preferably under stringent hybridization and wash conditions, to nucleotide sequences encoding a full-length PRO polypeptide as disclosed herein. PRO variant polypeptides may be those that are encoded by a PRO variant polynucleotide.

5 "Isolated," when used to describe the various polypeptides disclosed herein, means polypeptide that has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In preferred embodiments, the polypeptide will be purified (1) to a degree sufficient to obtain at least 10 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain. Isolated polypeptide includes polypeptide *in situ* within recombinant cells, since at least one component of the PRO polypeptide natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by at least one purification step.

15 An "isolated" PRO polypeptide-encoding nucleic acid or other polypeptide-encoding nucleic acid is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the natural source of the polypeptide-encoding nucleic acid. An isolated polypeptide-encoding nucleic acid molecule is other than in the form or setting in which it is found in nature. Isolated polypeptide-encoding nucleic acid molecules therefore are distinguished from the specific polypeptide- 20 encoding nucleic acid molecule as it exists in natural cells. However, an isolated polypeptide-encoding nucleic acid molecule includes polypeptide-encoding nucleic acid molecules contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably 25 linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a 30 polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is 35 accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.



The term "antibody" is used in the broadest sense and specifically covers, for example, single anti-PRO monoclonal antibodies (including agonist, antagonist, and neutralizing antibodies), anti-PRO antibody compositions with polyepitopic specificity, single chain anti-PRO antibodies, and fragments of anti-PRO antibodies (see below). The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts.

"Stringency" of hybridization reactions is readily determinable by one of ordinary skill in the art, and generally is an empirical calculation dependent upon probe length, washing temperature, and salt concentration. In general, longer probes require higher temperatures for proper annealing, while shorter probes need lower temperatures. Hybridization generally depends on the ability of denatured DNA to reanneal when complementary strands are present in an environment below their melting temperature. The higher the degree of desired homology between the probe and hybridizable sequence, the higher the relative temperature which can be used. As a result, it follows that higher relative temperatures would tend to make the reaction conditions more stringent, while lower temperatures less so. For additional details and explanation of stringency of hybridization reactions, see Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).

"Stringent conditions" or "high stringency conditions", as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1 % sodium dodecyl sulfate at 50°C; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1 % Ficoll/0.1 % polyvinylpyrrolidone/50mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at 42°C in 0.2 x SSC (sodium chloride/sodium citrate) and 50% formamide at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC containing EDTA at 55°C.

"Moderately stringent conditions" may be identified as described by Sambrook et al., Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Press, 1989, and include the use of washing solution and hybridization conditions (e.g., temperature, ionic strength and %SDS) less stringent than those described above. An example of moderately stringent conditions is overnight incubation at 37°C in a solution comprising: 20% formamide, 5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed by washing the filters in 1 x SSC at about 37-50°C. The skilled artisan will recognize how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

The term "epitope tagged" when used herein refers to a chimeric polypeptide comprising a PRO polypeptide fused to a "tag polypeptide". The tag polypeptide has enough residues to provide an epitope against which an antibody can be made, yet is short enough such that it does not interfere with activity of the polypeptide to which it is fused. The tag polypeptide preferably also is fairly unique so that the antibody does not

substantially cross-react with other epitopes. Suitable tag polypeptides generally have at least six amino acid residues and usually between about 8 and 50 amino acid residues (preferably, between about 10 and 20 amino acid residues).

As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is "heterologous"), and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.

"Active" or "activity" for the purposes herein refers to form(s) of a PRO polypeptide which retain a biological and/or an immunological activity of native or naturally-occurring PRO, wherein "biological" activity refers to a biological function (either inhibitory or stimulatory) caused by a native or naturally-occurring PRO other than the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring PRO and an "immunological" activity refers to the ability to induce the production of an antibody against an antigenic epitope possessed by a native or naturally-occurring PRO.

The term "antagonist" is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of a native PRO polypeptide disclosed herein. In a similar manner, the term "agonist" is used in the broadest sense and includes any molecule that mimics a biological activity of a native PRO polypeptide disclosed herein. Suitable agonist or antagonist molecules specifically include agonist or antagonist antibodies or antibody fragments, fragments or amino acid sequence variants of native PRO polypeptides, peptides, antisense oligonucleotides, small organic molecules, etc. Methods for identifying agonists or antagonists of a PRO polypeptide may comprise contacting a PRO polypeptide with a candidate agonist or antagonist molecule and measuring a detectable change in one or more biological activities normally associated with the PRO polypeptide.

"Treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathologic condition or disorder. Those in need of treatment include those already with the disorder as well as those prone to have the disorder or those in whom the disorder is to be prevented.

"Chronic" administration refers to administration of the agent(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. "Intermittent" administration is treatment that is not consecutively done without interruption, but rather is cyclic in nature.

"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, cats, cattle, horses, sheep, pigs, goats, rabbits, etc. Preferably, the mammal is human.

Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.

"Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN™, polyethylene glycol (PEG), and PLURONICS™.

"Antibody fragments" comprise a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')<sub>2</sub>, and Fv fragments; diabodies; linear antibodies (Zapata et al., Protein Eng. 8(10): 1057-1062 [1995]); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, a designation reflecting the ability to crystallize readily. Pepsin treatment yields an F(ab')<sub>2</sub> fragment that has two antigen-combining sites and is still capable of cross-linking antigen.

"Fv" is the minimum antibody fragment which contains a complete antigen-recognition and -binding site. This region consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the V<sub>H</sub>-V<sub>L</sub> dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

The Fab fragment also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab fragments differ from Fab' fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')<sub>2</sub> antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

The "light chains" of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains.

Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and

IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2.

"Single-chain Fv" or "sFv" antibody fragments comprise the  $V_H$  and  $V_L$  domains of antibody, wherein these domains are present in a single polypeptide chain. Preferably, the Fv polypeptide further comprises a polypeptide linker between the  $V_H$  and  $V_L$  domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenberg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994).

The term "diabodies" refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain ( $V_H$ ) connected to a light-chain variable domain ( $V_L$ ) in the same polypeptide chain ( $V_H$ - $V_L$ ). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

An "isolated" antibody is one which has been identified and separated and/or recovered from a component of its natural environment. Contaminant components of its natural environment are materials which would interfere with diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or nonproteinaceous solutes. In preferred embodiments, the antibody will be purified (1) to greater than 95% by weight of antibody as determined by the Lowry method, and most preferably more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under reducing or nonreducing conditions using Coomassie blue or, preferably, silver stain. Isolated antibody includes the antibody in situ within recombinant cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, isolated antibody will be prepared by at least one purification step.

An antibody that "specifically binds to" or is "specific for" a particular polypeptide or an epitope on a particular polypeptide is one that binds to that particular polypeptide or epitope on a particular polypeptide without substantially binding to any other polypeptide or polypeptide epitope.

The word "label" when used herein refers to a detectable compound or composition which is conjugated directly or indirectly to the antibody so as to generate a "labeled" antibody. The label may be detectable by itself (e.g. radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.

By "solid phase" is meant a non-aqueous matrix to which the antibody of the present invention can adhere. Examples of solid phases encompassed herein include those formed partially or entirely of glass (e.g., controlled pore glass), polysaccharides (e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol and silicones. In certain embodiments, depending on the context, the solid phase can comprise the well of an assay plate; in others it is a purification column (e.g., an affinity chromatography column). This term also includes a discontinuous solid phase of discrete particles, such as those described in U.S. Patent No. 4,275,149.

A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as a PRO polypeptide or antibody thereto) to a mammal. The

components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.

A "small molecule" is defined herein to have a molecular weight below about 500 Daltons.

An "effective amount" of a polypeptide disclosed herein or an agonist or antagonist thereof is an amount sufficient to carry out a specifically stated purpose. An "effective amount" may be determined empirically and

5 in a routine manner, in relation to the stated purpose.

**Table 1**

```

/*
 *
 * C-C increased from 12 to 15
 * Z is average of EQ
5  * B is average of ND
 * match with stop is _M; stop-stop = 0; J (joker) match = 0
 */
#define _M      -8      /* value of a match with a stop */

10 int  _day[26][26] = {
/*   A B C D E F G H I J K L M N O P Q R S T U V W X Y Z */
/* A */   { 2, 0,-2, 0, 0,-4, 1,-1,-1, 0,-1,-2,-1, 0, _M, 1, 0,-2, 1, 1, 0, 0,-6, 0,-3, 0},
/* B */   { 0, 3,-4, 3, 2,-5, 0, 1,-2, 0, 0,-3,-2, 2, _M,-1, 1, 0, 0, 0, 0,-2,-5, 0,-3, 1},
/* C */   {-2,-4,15,-5,-5,-4,-3,-3,-2, 0,-5,-6,-5,-4, _M,-3,-5,-4, 0,-2, 0,-2,-8, 0, 0,-5},
15 /* D */   { 0, 3,-5, 4, 3,-6, 1, 1,-2, 0, 0,-4,-3, 2, _M,-1, 2,-1, 0, 0, 0,-2,-7, 0,-4, 2},
/* E */   { 0, 2,-5, 3, 4,-5, 0, 1,-2, 0, 0,-3,-2, 1, _M,-1, 2,-1, 0, 0, 0,-2,-7, 0,-4, 3},
/* F */   {-4,-5,-4,-6,-5, 9,-5,-2, 1, 0,-5, 2, 0,-4, _M,-5,-5,-4,-3,-3, 0,-1, 0, 0, 7,-5},
/* G */   { 1, 0,-3, 1, 0,-5, 5,-2,-3, 0,-2,-4,-3, 0, _M,-1,-1,-3, 1, 0, 0,-1,-7, 0,-5, 0},
/* H */   {-1, 1,-3, 1, 1,-2,-2, 6,-2, 0, 0,-2,-2, 2, _M, 0, 3, 2,-1,-1, 0,-2,-3, 0, 0, 2},
20 /* I */   {-1,-2,-2,-2,-2, 1,-3,-2, 5, 0,-2, 2, 2,-2, _M,-2,-2,-2,-1, 0, 0, 4,-5, 0,-1,-2},
/* J */   { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* K */   {-1, 0,-5, 0, 0,-5,-2, 0,-2, 0, 5,-3, 0, 1, _M,-1, 1, 3, 0, 0, 0,-2,-3, 0,-4, 0},
/* L */   {-2,-3,-6,-4,-3, 2,-4,-2, 2, 0,-3, 6, 4,-3, _M,-3,-2,-3,-3,-1, 0, 2,-2, 0,-1,-2},
/* M */   {-1,-2,-5,-3,-2, 0,-3,-2, 2, 0, 0, 4, 6,-2, _M,-2,-1, 0,-2,-1, 0, 2,-4, 0,-2,-1},
25 /* N */   { 0, 2,-4, 2, 1,-4, 0, 2,-2, 0, 1,-3,-2, 2, _M,-1, 1, 0, 1, 0, 0,-2,-4, 0,-2, 1},
/* O */   { _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, _M, 0, _M, _M, _M, _M, _M, _M, _M, _M, _M},
/* P */   { 1,-1,-3,-1,-1,-5,-1, 0,-2, 0,-1,-3,-2,-1, _M, 6, 0, 0, 1, 0, 0,-1,-6, 0,-5, 0},
/* Q */   { 0, 1,-5, 2, 2,-5,-1, 3,-2, 0, 1,-2,-1, 1, _M, 0, 4, 1,-1,-1, 0,-2,-5, 0,-4, 3},
/* R */   {-2, 0,-4,-1,-1,-4,-3, 2,-2, 0, 3,-3, 0, 0, _M, 0, 1, 6, 0,-1, 0,-2, 2, 0,-4, 0},
30 /* S */   { 1, 0, 0, 0, 0,-3, 1,-1,-1, 0, 0,-3,-2, 1, _M, 1,-1, 0, 2, 1, 0,-1,-2, 0,-3, 0},
/* T */   { 1, 0,-2, 0, 0,-3, 0,-1, 0, 0, 0,-1,-1, 0, _M, 0,-1,-1, 1, 3, 0, 0,-5, 0,-3, 0},
/* U */   { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* V */   { 0,-2,-2,-2,-2,-1,-1,-2, 4, 0,-2, 2, 2,-2, _M,-1,-2,-2,-1, 0, 0, 4,-6, 0,-2,-2},
/* W */   {-6,-5,-8,-7,-7, 0,-7,-3,-5, 0,-3,-2,-4,-4, _M,-6,-5, 2,-2,-5, 0,-6,17, 0, 0,-6},
35 /* X */   { 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, _M, 0, 0, 0, 0, 0, 0, 0, 0, 0},
/* Y */   {-3,-3, 0,-4,-4, 7,-5, 0,-1, 0,-4,-1,-2,-2, _M,-5,-4,-4,-3,-3, 0,-2, 0, 0,10,-4},
/* Z */   { 0, 1,-5, 2, 3,-5, 0, 2,-2, 0, 0,-2,-1, 1, _M, 0, 3, 0, 0, 0, 0,-2,-6, 0,-4, 4}
};

40

45

50

55

```

Table 1 (cont')

```

/*
*/
#include <stdio.h>
#include <ctype.h>

5  #define MAXJMP      16      /* max jumps in a diag */
   #define MAXGAP      24      /* don't continue to penalize gaps larger than this */
   #define JMPS        1024    /* max jmps in an path */
10  #define MX          4       /* save if there's at least MX-1 bases since last jmp */

   #define DMAT         3       /* value of matching bases */
   #define DMIS         0       /* penalty for mismatched bases */
   #define DINS0        8       /* penalty for a gap */
   #define DINS1        1       /* penalty per base */
15  #define PINS0        8       /* penalty for a gap */
   #define PINS1        4       /* penalty per residue */

struct jmp {
20     short             n[MAXJMP]; /* size of jmp (neg for dely) */
     unsigned short    x[MAXJMP]; /* base no. of jmp in seq x */
}; /* limits seq to 2^16 - 1 */

struct diag {
25     int               score;      /* score at last jmp */
     long              offset;     /* offset of prev block */
     short             jmp;        /* current jmp index */
     struct jmp         jp;        /* list of jmps */
};

30 struct path {
     int               spc;        /* number of leading spaces */
     short             n[JMPS]; /* size of jmp (gap) */
     int               x[JMPS]; /* loc of jmp (last elem before gap) */
};

35 char               *ofile;      /* output file name */
char               *name[2];      /* seq names: getseqs() */
char               *prog;         /* prog name for err msgs */
char               *seq[2];       /* seqs: getseqs() */
40 int               dmax;         /* best diag: nw() */
int               dmax0;          /* final diag */
int               dna;            /* set if dna: main() */
int               endgaps;        /* set if penalizing end gaps */
int               gapx, gapy;     /* total gaps in seqs */
45 int               len0, len1;   /* seq lens */
int               ngapx, ngapy;   /* total size of gaps */
int               smax;           /* max score: nw() */
int               *xbm;           /* bitmap for matching */
long              offset;        /* current offset in jmp file */
50 struct           diag          *dx; /* holds diagonals */
struct           path          pp[2]; /* holds path for seqs */

char               *calloc(), *malloc(), *index(), *strcpy();
55 char               *getseq(), *g_calloc();

60

```

Table 1 (cont')

```

/* Needleman-Wunsch alignment program
*
* usage: progs file1 file2
* where file1 and file2 are two dna or two protein sequences.
5 * The sequences can be in upper- or lower-case and may contain ambiguity
* Any lines beginning with ';', '>' or '<' are ignored
* Max file length is 65535 (limited by unsigned short x in the jmp struct)
* A sequence with 1/3 or more of its elements ACGTU is assumed to be DNA
10 * Output is in the file "align.out"
*
* The program may create a tmp file in /tmp to hold info about traceback.
* Original version developed under BSD 4.3 on a vax 8650
*/
#include "nw.h"
15 #include "day.h"

static _dbval[26] = {
    1,14,2,13,0,0,4,11,0,0,12,0,3,15,0,0,0,5,6,8,8,7,9,0,10,0
};
20 static _pbval[26] = {
    1, 2|(1<<('D'-'A'))|(1<<('N'-'A')), 4, 8, 16, 32, 64,
    128, 256, 0xFFFFFFFF, 1<<10, 1<<11, 1<<12, 1<<13, 1<<14,
    1<<15, 1<<16, 1<<17, 1<<18, 1<<19, 1<<20, 1<<21, 1<<22,
25 1<<23, 1<<24, 1<<25|(1<<('E'-'A'))|(1<<('Q'-'A'))
};

main(ac, av)                                main
30     int      ac;
     char      *av[];
{
    prog = av[0];
    if (ac != 3) {
35         fprintf(stderr, "usage: %s file1 file2\n", prog);
         fprintf(stderr, "where file1 and file2 are two dna or two protein sequences.\n");
         fprintf(stderr, "The sequences can be in upper- or lower-case\n");
         fprintf(stderr, "Any lines beginning with ';' or '<' are ignored\n");
         fprintf(stderr, "Output is in the file \"align.out\"\n");
         exit(1);
40     }
    namex[0] = av[1];
    namex[1] = av[2];
    seqx[0] = getseq(namex[0], &len0);
    seqx[1] = getseq(namex[1], &len1);
45     xbm = (dna)? _dbval : _pbval;

    endgaps = 0;                                /* 1 to penalize endgaps */
    ofile = "align.out";                        /* output file */

50     nw();                                    /* fill in the matrix, get the possible jumps */
    readjumps();                                /* get the actual jumps */
    print();                                    /* print stats, alignment */

55     cleanup();                                /* unlink any tmp files */
}

```



**Table 1 (cont')**

```

/* do the alignment, return best score: main()
* dna: values in Fitch and Smith, PNAS, 80, 1382-1386, 1983
* pro: PAM 250 values
* When scores are equal, we prefer mismatches to any gap, prefer
5 * a new gap to extending an ongoing gap, and prefer a gap in seqx
* to a gap in seq y.
*/
nw0
{
10     char      *px, *py;          /* seqs and ptrs */
     int      *ndely, *dely;      /* keep track of dely */
     int      ndelx, delx;        /* keep track of delx */
     int      *tmp;              /* for swapping row0, row1 */
     int      mis;               /* score for each type */
15     int      ins0, ins1;        /* insertion penalties */
     register id;                /* diagonal index */
     register ij;                /* jmp index */
     register *col0, *col1;      /* score for curr, last row */
     register xx, yy;            /* index into seqs */

20     dx = (struct diag *)g_calloc("to get diag", len0+len1+1, sizeof(struct diag));

     ndely = (int *)g_calloc("to get ndely", len1+1, sizeof(int));
     dely = (int *)g_calloc("to get dely", len1+1, sizeof(int));
25     col0 = (int *)g_calloc("to get col0", len1+1, sizeof(int));
     col1 = (int *)g_calloc("to get col1", len1+1, sizeof(int));
     ins0 = (dna)? DINS0 : PINS0;
     ins1 = (dna)? DINS1 : PINS1;

30     smax = -10000;
     if (endgaps) {
         for (col0[0] = dely[0] = -ins0, yy = 1; yy <= len1; yy++) {
             col0[yy] = dely[yy] = col0[yy-1] - ins1;
             ndely[yy] = yy;
35         }
         col0[0] = 0;          /* Waterman Bull Math Biol 84 */
     }
     else
40         for (yy = 1; yy <= len1; yy++)
             dely[yy] = -ins0;

     /* fill in match matrix
     */
45     for (px = seqx[0], xx = 1; xx <= len0; px++, xx++) {
         /* initialize first entry in col
         */
         if (endgaps) {
             if (xx == 1)
                 col1[0] = delx = -(ins0+ins1);
50             else
                 col1[0] = delx = col0[0] - ins1;
             ndelx = xx;
         }
         else {
55             col1[0] = 0;
             delx = -ins0;
             ndelx = 0;
         }
     }
60

```

nw

**Table 1 (cont')**

...nw

```

5      for (py = seqx[1], yy = 1; yy <= len1; py++, yy++) {
        mis = col0[yy-1];
        if (dna)
            mis += (xbm[*px-'A']&xbm[*py-'A'])? DMAT : DMIS;
        else
            mis += _day[*px-'A'][*py-'A'];

10      /* update penalty for del in x seq;
        * favor new del over ongoing del
        * ignore MAXGAP if weighting endgaps
        */
        if (endgaps || ndely[yy] < MAXGAP) {
            if (col0[yy] - ins0 >= dely[yy]) {
15                dely[yy] = col0[yy] - (ins0+ins1);
                ndely[yy] = 1;
            } else {
                dely[yy] -= ins1;
                ndely[yy]++;
20            }
        } else {
            if (col0[yy] - (ins0+ins1) >= dely[yy]) {
                dely[yy] = col0[yy] - (ins0+ins1);
                ndely[yy] = 1;
25            } else
                ndely[yy]++;
        }

        /* update penalty for del in y seq;
        * favor new del over ongoing del
        */
        if (endgaps || ndelx < MAXGAP) {
            if (col1[yy-1] - ins0 >= delx) {
30                delx = col1[yy-1] - (ins0+ins1);
                ndelx = 1;
            } else {
                delx -= ins1;
                ndelx++;
35            }
        } else {
            if (col1[yy-1] - (ins0+ins1) >= delx) {
                delx = col1[yy-1] - (ins0+ins1);
                ndelx = 1;
40            } else
                ndelx++;
45        }

        /* pick the maximum score; we're favoring
        * mis over any del and delx over dely
        */
50
55
60

```

**Table 1 (cont')**

...nw

```

id = xx - yy + len1 - 1;
if (mis >= delx && mis >= dely[yy])
    coll[yy] = mis;
5   else if (delx >= dely[yy]) {
        coll[yy] = delx;
        ij = dx[id].ijmp;
        if (dx[id].jp.n[0] && (!dna || (ndelx >= MAXJMP
10      && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
            dx[id].ijmp++;
            if (++ij >= MAXJMP) {
                writejumps(id);
                ij = dx[id].ijmp = 0;
                dx[id].offset = offset;
                offset += sizeof(struct jmp) + sizeof(offset);
            }
        }
        dx[id].jp.n[ij] = ndelx;
        dx[id].jp.x[ij] = xx;
        dx[id].score = delx;
    }
    else {
        coll[yy] = dely[yy];
        ij = dx[id].ijmp;
25      if (dx[id].jp.n[0] && (!dna || (ndely[yy] >= MAXJMP
        && xx > dx[id].jp.x[ij]+MX) || mis > dx[id].score+DINS0)) {
            dx[id].ijmp++;
            if (++ij >= MAXJMP) {
                writejumps(id);
                ij = dx[id].ijmp = 0;
                dx[id].offset = offset;
                offset += sizeof(struct jmp) + sizeof(offset);
            }
        }
        dx[id].jp.n[ij] = -ndely[yy];
        dx[id].jp.x[ij] = xx;
        dx[id].score = dely[yy];
    }
    if (xx == len0 && yy < len1) {
        /* last col
        */
        if (endgaps)
            coll[yy] -= ins0+ins1*(len1-yy);
        if (coll[yy] > smax) {
            smax = coll[yy];
            dmax = id;
        }
    }
}
50   if (endgaps && xx < len0)
        coll[yy-1] -= ins0+ins1*(len0-xx);
    if (coll[yy-1] > smax) {
        smax = coll[yy-1];
        dmax = id;
55   }
    tmp = col0; col0 = coll; coll = tmp;
}
(void) free((char *)ndely);
(void) free((char *)dely);
(void) free((char *)col0);
60   (v id) free((char *)col1);
    }

```

**Table 1 (cont')**

```

/*
 *
 * print() -- only routine visible outside this module
 *
5  * static:
 * getmat() -- trace back best path, count matches: print()
 * pr_align() -- print alignment of described in array p[]: print()
 * dumpblock() -- dump a block of lines with numbers, stars: pr_align()
 * nums() -- put out a number line: dumpblock()
10 * putline() -- put out a line (name, [num], seq, [num]): dumpblock()
 * stars() -- put a line of stars: dumpblock()
 * stripname() -- strip any path and prefix from a seqname
 */

15 #include "nw.h"

#define SPC      3
#define P_LINE  256 /* maximum output line */
#define P_SPC    3 /* space between name or num and seq */

20 extern _day[26][26];
int olen; /* set output line length */
FILE *fx; /* output file */

25 print()
{
    int lx, ly, firstgap, lastgap; /* overlap */

    if ((fx = fopen(ofile, "w")) == 0) {
30         fprintf(stderr, "%s: can't write %s\n", prog, ofile);
        cleanup(1);
    }
    fprintf(fx, "< first sequence: %s (length = %d)\n", namex[0], len0);
    fprintf(fx, "< second sequence: %s (length = %d)\n", namex[1], len1);
35     olen = 60;
    lx = len0;
    ly = len1;
    firstgap = lastgap = 0;
    if (dmax < len1 - 1) { /* leading gap in x */
40         pp[0].spc = firstgap = len1 - dmax - 1;
        ly -= pp[0].spc;
    }
    else if (dmax > len1 - 1) { /* leading gap in y */
45         pp[1].spc = firstgap = dmax - (len1 - 1);
        lx -= pp[1].spc;
    }
    if (dmax0 < len0 - 1) { /* trailing gap in x */
        lastgap = len0 - dmax0 - 1;
        lx -= lastgap;
50     }
    else if (dmax0 > len0 - 1) { /* trailing gap in y */
        lastgap = dmax0 - (len0 - 1);
        ly -= lastgap;
    }
55     getmat(lx, ly, firstgap, lastgap);
    pr_align();
}

60

```

**print**

**Table 1 (cont')**

```

/*
 * trace back the best path, count matches
 */
static
5 getmat(lx, ly, firstgap, lastgap)                                getmat
    int      lx, ly;                                /* "core" (minus endgaps) */
    int      firstgap, lastgap;                      /* leading trailing overlap */
{
    int      nm, i0, i1, siz0, siz1;
10    char     outx[32];
    double   pct;
    register n0, n1;
    register char *p0, *p1;

15    /* get total matches, score
    */
    i0 = i1 = siz0 = siz1 = 0;
    p0 = seqx[0] + pp[1].spc;
    p1 = seqx[1] + pp[0].spc;
20    n0 = pp[1].spc + 1;
    n1 = pp[0].spc + 1;

    nm = 0;
    while ( *p0 && *p1 ) {
25         if (siz0) {
             p1++;
             n1++;
             siz0--;
         }
30         else if (siz1) {
             p0++;
             n0++;
             siz1--;
         }
35         else {
             if (xbm[*p0-'A']&xbm[*p1-'A'])
                 nm++;
             if (n0++ == pp[0].x[i0])
                 siz0 = pp[0].n[i0++];
40             if (n1++ == pp[1].x[i1])
                 siz1 = pp[1].n[i1++];
             p0++;
             p1++;
         }
45     }

    /* pct homology:
    * if penalizing endgaps, base is the shorter seq
    * else, knock off overhangs and take shorter core
    */
50    if (endgaps)
        lx = (len0 < len1)? len0 : len1;
    else
        lx = (lx < ly)? lx : ly;
55    pct = 100.*(double)nm/(double)lx;
    fprintf(fx, "\n");
    fprintf(fx, "< %d match%s in an overlap of %d: %.2f percent similarity\n",
        nm, (nm == 1)? "" : "es", lx, pct);
60

```

Table 1 (cont')

```

fprintf(fx, "< gaps in first sequence: %d", gapx);
if (gapx) {
5      (void) sprintf(outx, " (%d %s%s)",
        ngapx, (dna)? "base":"residue", (ngapx == 1)? "" : "s");
        fprintf(fx, "%s", outx);

    fprintf(fx, ", gaps in second sequence: %d", gapy);
10     if (gapy) {
        (void) sprintf(outx, " (%d %s%s)",
        ngapy, (dna)? "base":"residue", (ngapy == 1)? "" : "s");
        fprintf(fx, "%s", outx);
    }
15     if (dna)
        fprintf(fx,
        "\n< score: %d (match = %d, mismatch = %d, gap penalty = %d + %d per base)\n",
        smax, DMAT, DMIS, DINS0, DINS1);
    else
20     fprintf(fx,
        "\n< score: %d (Dayhoff PAM 250 matrix, gap penalty = %d + %d per residue)\n",
        smax, PINS0, PINS1);
    if (endgaps)
        fprintf(fx,
25     "< endgaps penalized. left endgap: %d %s%s, right endgap: %d %s%s\n",
        firstgap, (dna)? "base" : "residue", (firstgap == 1)? "" : "s",
        lastgap, (dna)? "base" : "residue", (lastgap == 1)? "" : "s");
    else
        fprintf(fx, "< endgaps not penalized\n");
30 }

static      nm;          /* matches in core -- for checking */
static      lmax;        /* lengths of stripped file names */
static      ij[2];       /* jmp index for a path */
static      nc[2];        /* number at start of current line */
35 static      ni[2];       /* current elem number -- for gapping */
static      siz[2];
static char  *ps[2];       /* ptr to current element */
static char  *po[2];       /* ptr to next output char slot */
static char  out[2][P_LINE]; /* output line */
40 static char star[P_LINE]; /* set by stars() */

/*
 * print alignment of described in struct path pp[]
 */
45 static
pr_align()
{
    int      nn;          /* char count */
    int      more;
50     register i;

    for (i = 0, lmax = 0; i < 2; i++) {
        nn = stripname(nameex[i]);
        if (nn > lmax)
55             lmax = nn;

        nc[i] = 1;
        ni[i] = 1;
        siz[i] = ij[i] = 0;
        ps[i] = seqx[i];
60         po[i] = out[i];
    }

```

...getmat

pr\_align

Table 1 (cont')

...pr\_align

```

for (nn = nm = 0, more = 1; more; ) {
    for (i = more = 0; i < 2; i++) {
        /*
5         * do we have more of this sequence?
        */
        if (!*ps[i])
            continue;

10        more++;

        if (pp[i].spc) { /* leading space */
            *po[i]++ = ' ';
            pp[i].spc--;
15        }
        else if (siz[i]) { /* in a gap */
            *po[i]++ = '-';
            siz[i]--;
20        }
        else { /* we're putting a seq element
            */
            *po[i] = *ps[i];
            if (islower(*ps[i]))
                *ps[i] = toupper(*ps[i]);
25            po[i]++;
            ps[i]++;

            /*
            * are we at next gap for this seq?
            */
            if (ni[i] == pp[i].x[ij[i]]) {
                /*
                * we need to merge all gaps
                * at this location
                */
35                siz[i] = pp[i].n[ij[i] + +];
                while (ni[i] == pp[i].x[ij[i]])
                    siz[i] += pp[i].n[ij[i] + +];
            }
            ni[i]++;
40        }
    }
    if (++nn == olen || !more && nn) {
        dumpblock();
45        for (i = 0; i < 2; i++)
            po[i] = out[i];
        nn = 0;
    }
50 }

/*
 * dump a block of lines, including numbers, stars: pr_align()
 */
55 static
dumpblock()
{
    register i;

60    for (i = 0; i < 2; i++)
        *po[i]-- = '\0';

```

dumpblock

**Table 1 (cont')****...dumpblock**

```

5      (void) putc('\n', fx);
      for (i = 0; i < 2; i++) {
          if (*out[i] && (*out[i] != ' ' || *(po[i]) != ' ')) {
              if (i == 0)
                  nums(i);
              if (i == 0 && *out[1])
                  stars();
10         putline(i);
              if (i == 0 && *out[1])
                  fprintf(fx, star);
              if (i == 1)
                  nums(i);
15         }
      }
  }

/*
20  * put out a number line: dumpblock()
  */
  static
  nums(ix)
25  {
      int      ix;      /* index in out[] holding seq line */

      char      nline[P_LINE];
      register  i, j;
      register char *pn, *px, *py;

30      for (pn = nline, i = 0; i < lmax + P_SPC; i++, pn++)
          *pn = ' ';
      for (i = nc[ix], py = out[ix]; *py; py++, pn++) {
          if (*py == ' ' || *py == '-')
              *pn = ' ';
35          else {
              if (i%10 == 0 || (i == 1 && nc[ix] != 1)) {
                  j = (i < 0)? -i : i;
                  for (px = pn; j /= 10, px--)
                      *px = j%10 + '0';
40                  if (i < 0)
                      *px = '-';

                  }
              else
                  *pn = ' ';
45                  i++;
          }
      }
      *pn = '\0';
      nc[ix] = i;
      for (pn = nline; *pn; pn++)
          (void) putc(*pn, fx);
      (void) putc('\n', fx);
  }

55  /*
  * put out a line (name, [num], seq, [num]): dumpblock()
  */
  static
  putline(ix)
60      int      ix;      {

```

**nums****putline**



Table 1 (cont')

...putline

```

5      int          i;
      register char *px;

      for (px = namex[ix], i = 0; *px && *px != ':'; px++, i++)
          (void) putc(*px, fx);
      for (; i < lmax + P_SPC; i++)
          (void) putc(' ', fx);

10     /* these count from 1:
       * ni[] is current element (from 1)
       * nc[] is number at start of current line
       */
15     for (px = out[ix]; *px; px++)
          (void) putc(*px & 0x7F, fx);
      (void) putc('\n', fx);
  }

20  /*
   * put a line of stars (seqs always in out[0], out[1]): dumpblock()
   */
   static
25  stars()
   {
       int          i;
       register char *p0, *p1, cx, *px;

30     if (!*out[0] || (*out[0] == ' ' && *(p0[0]) == ' ') ||
        !*out[1] || (*out[1] == ' ' && *(p0[1]) == ' '))
           return;
       px = star;
35     for (i = lmax + P_SPC; i; i--)
           *px++ = ' ';

       for (p0 = out[0], p1 = out[1]; *p0 && *p1; p0++, p1++) {
           if (isalpha(*p0) && isalpha(*p1)) {
40               if (xbm[*p0-'A'] & xbm[*p1-'A']) {
                   cx = '*';
                   nm++;
               }
           else if (!dna && _day[*p0-'A'][*p1-'A'] > 0)
45               cx = '.';
           else
               cx = ' ';
       }
       else
50         cx = ' ';
       *px++ = cx;
   }
   *px++ = '\n';
   *px = '\0';
55 }

```

stars

60

**Table 1 (cont')**

```
/*  
 * strip path or prefix from pn, return len: pr_align()  
 */
```

```
static
```

5

```
stripname(pn)
```

**stripname**

```
    char    *pn;    /* file name (may be path) */
```

```
{
```

```
    register char    *px, *py;
```

10

```
    py = 0;
```

```
    for (px = pn; *px; px++)
```

```
        if (*px == '/')
```

```
            py = px + 1;
```

15

```
    if (py)
```

```
        (void) strcpy(pn, py);
```

```
    return(strlen(pn));
```

```
}
```

20

25

30

35

40

45

50

55

60

**Table 1 (cont')**

```

/*
 * cleanup() -- cleanup any tmp file
 * getseq() -- read in seq, set dna, len, maxlen
 * g_calloc() -- calloc() with error checkin
5  * readjumps() -- get the good jumps, from tmp file if necessary
 * writejumps() -- write a filled array of jumps to a tmp file: nw()
 */
#include "nw.h"
#include <sys/file.h>

10 char    *jname = "/tmp/homgXXXXXX";          /* tmp file for jumps */
FILE      *fj;

int        cleanup();                          /* cleanup tmp file */
15 long     lseek();

/*
 * remove any tmp file if we blow
 */
20 cleanup(i)
    int     i;
{
    if (fj)
        (void) unlink(jname);
25     exit(i);
}

/*
 * read, return ptr to seq, set dna, len, maxlen
 * skip lines starting with ';', '<', or '>'
 * seq in upper or lower case
 */
30 char    *
getseq(file, len)
35     char    *file;    /* file name */
    int      *len;      /* seq len */
{
    char      line[1024], *pseq;
    register char *px, *py;
    int       natgc, tlen;
    FILE      *fp;

    if ((fp = fopen(file, "r")) == 0) {
        fprintf(stderr, "%s: can't read %s\n", prog, file);
45         exit(1);
    }
    tlen = natgc = 0;
    while (fgets(line, 1024, fp)) {
        if (*line == ';' || *line == '<' || *line == '>')
            continue;
50         for (px = line; *px != '\n'; px++)
            if (isupper(*px) || islower(*px))
                tlen++;
    }
    if ((pseq = malloc((unsigned)(tlen+6))) == 0) {
        fprintf(stderr, "%s: malloc() failed to get %d bytes for %s\n", prog, tlen+6, file);
55         exit(1);
    }
    pseq[0] = pseq[1] = pseq[2] = pseq[3] = '\0';
60

```

cleanup

getseq

Table 1 (cont')

...getseq

```

5      py = pseq + 4;
      *len = tlen;
      rewind(fp);

      while (fgets(line, 1024, fp)) {
          if (*line == ';' || *line == '<' || *line == '>')
              continue;
          for (px = line; *px != '\n'; px++) {
10             if (isupper(*px))
                 *py++ = *px;
             else if (islower(*px))
                 *py++ = toupper(*px);
             if (index("ATGCU",*(py-1)))
                 natgc++;
          }
      }
      *py++ = '\0';
      *py = '\0';
20      (void) fclose(fp);
      dna = natgc > (tlen/3);
      return(pseq+4);
  }

25  char *
  g_alloc(msg, nx, sz)
      char *msg;          /* program, calling routine */
      int nx, sz;          /* number and size of elements */
  {
30      char *px, *calloc();

      if ((px = calloc((unsigned)nx, (unsigned)sz)) == 0) {
          if (*msg) {
35             fprintf(stderr, "%s: g_alloc() failed %s (n=%d, sz=%d)\n", prog, msg, nx, sz);
             exit(1);
          }
      }
      return(px);
  }

40  /*
   * get final jmps from dx[] or tmp file, set pp[], reset dmax: main()
   */
  readjmps()
45  {
      int fd = -1;
      int siz, i0, i1;
      register i, j, xx;

50      if (fj) {
          (void) fclose(fj);
          if ((fd = open(jname, O_RDONLY, 0)) < 0) {
              fprintf(stderr, "%s: can't open() %s\n", prog, jname);
              cleanup(1);
55          }
      }
      for (i = i0 = i1 = 0, dmax0 = dmax, xx = len0; ; i++) {
          while (1) {
60             for (j = dx[dmax].ijmp; j >= 0 && dx[dmax].jp.x[j] >= xx; j--)

```

g\_alloc

readjmps

**Table 1 (cont')****...readjumps**

```

5      if (j < 0 && dx[dmax].offset && fj) {
        (v id) lseek(fd, dx[dmax].offset, 0);
        (void) read(fd, (char *)&dx[dmax].jp, sizeof(struct jmp));
        (void) read(fd, (char *)&dx[dmax].offset, sizeof(dx[dmax].offset));
        dx[dmax].ijmp = MAXJMP-1;
      }
      else
10         break;
    }
    if (i >= JMPS) {
        fprintf(stderr, "%s: too many gaps in alignment\n", prog);
        cleanup(1);
    }
15    if (j >= 0) {
        siz = dx[dmax].jp.n[j];
        xx = dx[dmax].jp.x[j];
        dmax += siz;
        if (siz < 0) { /* gap in second seq */
20            pp[1].n[i1] = -siz;
            xx += siz;
            /* id = xx - yy + len1 - 1
             */
            pp[1].x[i1] = xx - dmax + len1 - 1;
            gapy++;
            ngapy -= siz;
            /* ignore MAXGAP when doing endgaps */
            siz = (-siz < MAXGAP || endgaps)? -siz : MAXGAP;
            i1++;
30        }
        else if (siz > 0) { /* gap in first seq */
            pp[0].n[i0] = siz;
            pp[0].x[i0] = xx;
            gapx++;
            ngapx += siz;
35            /* ignore MAXGAP when doing endgaps */
            siz = (siz < MAXGAP || endgaps)? siz : MAXGAP;
            i0++;
        }
40    }
    else
        break;
}

45    /* reverse the order of jumps
    */
    for (j = 0, i0--; j < i0; j++, i0--) {
        i = pp[0].n[j]; pp[0].n[j] = pp[0].n[i0]; pp[0].n[i0] = i;
        i = pp[0].x[j]; pp[0].x[j] = pp[0].x[i0]; pp[0].x[i0] = i;
50    }
    for (j = 0, i1--; j < i1; j++, i1--) {
        i = pp[1].n[j]; pp[1].n[j] = pp[1].n[i1]; pp[1].n[i1] = i;
        i = pp[1].x[j]; pp[1].x[j] = pp[1].x[i1]; pp[1].x[i1] = i;
55    }
    if (fd >= 0)
        (void) close(fd);
    if (fj) {
        (void) unlink(jname);
        fj = 0;
        offset = 0;
60    }
}

```

Table 1 (cont')**writejumps**

```

/*
 * write a filled jmp struct offset of the prev one (if any): nw()
 */
5  writejumps(ix)
    int    ix;
    {
        char    *mktemp();
10     if (!fj) {
            if (mktemp(jname) < 0) {
                fprintf(stderr, "%s: can't mktemp() %s\n", prog, jname);
                cleanup(1);
            }
15     if ((fj = fopen(jname, "w")) == 0) {
                fprintf(stderr, "%s: can't write %s\n", prog, jname);
                exit(1);
            }
20     }
        (void) fwrite((char *)&dx[ix].jp, sizeof(struct jmp), 1, fj);
        (void) fwrite((char *)&dx[ix].offset, sizeof(dx[ix].offset), 1, fj);
    }
25
30
35
40
45
50
55
60

```

**Table 2**

PRO	XXXXXXXXXXXXXXXXXX	(Length = 15 amino acids)
Comparison Protein	XXXXXXXXYYYYYYY	(Length = 12 amino acids)

5    % amino acid sequence identity =

(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) =

10    5 divided by 15 = 33.3 %

**Table 3**

15    PRO	XXXXXXXXXXX	(Length = 10 amino acids)
Comparison Protein	XXXXXXXXYYYYYYZZYZ	(Length = 15 amino acids)

% amino acid sequence identity =

20    (the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) =

5 divided by 10 = 50%

**Table 4**

PRO-DNA	NNNNNNNNNNNNNNNN	(Length = 14 nucleotides)
Comparison DNA	NNNNNNLLLLLLLLLLLL	(Length = 16 nucleotides)

5     % nucleic acid sequence identity =

(the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) =

10     6 divided by 14 = 42.9%

**Table 5**

15     PRO-DNA	NNNNNNNNNNNNNN	(Length = 12 nucleotides)
Comparison DNA	NNNNLLL	(Length = 9 nucleotides)

% nucleic acid sequence identity =

20     (the number of identically matching nucleotides between the two nucleic acid sequences as determined by ALIGN-2) divided by (the total number of nucleotides of the PRO-DNA nucleic acid sequence) =

4 divided by 12 = 33.3%



## II. Compositions and Methods of the Invention

### A. Full-Length PRO Polypeptides

The present invention provides newly identified and isolated nucleotide sequences encoding polypeptides referred to in the present application as PRO polypeptides. In particular, cDNAs encoding various PRO polypeptides have been identified and isolated, as disclosed in further detail in the Examples below. It is noted that proteins produced in separate expression rounds may be given different PRO numbers but the UNQ number is unique for any given DNA and the encoded protein, and will not be changed. However, for sake of simplicity, in the present specification the protein encoded by the full length native nucleic acid molecules disclosed herein as well as all further native homologues and variants included in the foregoing definition of PRO, will be referred to as "PRO/number", regardless of their origin or mode of preparation.

As disclosed in the Examples below, various cDNA clones have been deposited with the ATCC. The actual nucleotide sequences of those clones can readily be determined by the skilled artisan by sequencing of the deposited clone using routine methods in the art. The predicted amino acid sequence can be determined from the nucleotide sequence using routine skill. For the PRO polypeptides and encoding nucleic acids described herein, Applicants have identified what is believed to be the reading frame best identifiable with the sequence information available at the time.

### B. PRO-Polypeptide Variants

In addition to the full-length native sequence PRO polypeptides described herein, it is contemplated that PRO variants can be prepared. PRO variants can be prepared by introducing appropriate nucleotide changes into the PRO DNA, and/or by synthesis of the desired PRO polypeptide. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the PRO, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.

Variations in the native full-length sequence PRO or in various domains of the PRO described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more codons encoding the PRO that results in a change in the amino acid sequence of the PRO as compared with the native sequence PRO. Optionally the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the PRO. Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the PRO with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.

PRO polypeptide fragments are provided herein. Such fragments may be truncated at the N-terminus or C-terminus, or may lack internal residues, for example, when compared with a full length native protein. Certain fragments lack amino acid residues that are not essential for a desired biological activity of the PRO polypeptide.

PRO fragments may be prepared by any of a number of conventional techniques. Desired peptide fragments may be chemically synthesized. An alternative approach involves generating PRO fragments by enzymatic digestion, e.g., by treating the protein with an enzyme known to cleave proteins at sites defined by particular amino acid residues, or by digesting the DNA with suitable restriction enzymes and isolating the desired fragment. Yet another suitable technique involves isolating and amplifying a DNA fragment encoding a desired polypeptide fragment, by polymerase chain reaction (PCR). Oligonucleotides that define the desired termini of the DNA fragment are employed at the 5' and 3' primers in the PCR. Preferably, PRO polypeptide fragments share at least one biological and/or immunological activity with the native PRO polypeptide disclosed herein.

In particular embodiments, conservative substitutions of interest are shown in Table 6 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 6, or as further described below in reference to amino acid classes, are introduced and the products screened.

Table 6

	<u>Original Residue</u>	<u>Exemplary Substitutions</u>	<u>Preferred Substitutions</u>
20	Ala (A)	val; leu; ile	val
	Arg (R)	lys; gln; asn	lys
25	Asn (N)	gln; his; lys; arg	gln
	Asp (D)	glu	glu
	Cys (C)	ser	ser
	Gln (Q)	asn	asn
	Glu (E)	asp	asp
30	Gly (G)	pro; ala	ala
	His (H)	asn; gln; lys; arg	arg
	Ile (I)	leu; val; met; ala; phe; norleucine	leu
	Leu (L)	norleucine; ile; val; met; ala; phe	ile
35	Lys (K)	arg; gln; asn	arg
	Met (M)	leu; phe; ile	leu
	Phe (F)	leu; val; ile; ala; tyr	leu
	Pro (P)	ala	ala
40	Ser (S)	thr	thr
	Thr (T)	ser	ser
	Trp (W)	tyr; phe	tyr
	Tyr (Y)	trp; phe; thr; ser	phe
	Val (V)	ile; leu; met; phe; ala; norleucine	leu
45			

Substantial modifications in function or immunological identity of the PRO polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.

The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells et al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the PRO variant DNA.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant [Cunningham and Wells, Science, 244: 1081-1085 (1989)]. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.

### C. Modifications of PRO

Covalent modifications of PRO are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a PRO polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C- terminal residues of the PRO. Derivatization with bifunctional agents is useful, for instance, for crosslinking PRO to a water-insoluble support matrix or surface for use in the method for purifying anti-PRO antibodies, and vice-versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-

octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimide.

Other modifications include deamidation of glutamyl and asparaginy residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  $\alpha$ -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the PRO polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence PRO (either by removing the underlying glycosylation site or by deleting the glycosylation by chemical and/or enzymatic means), and/or adding one or more glycosylation sites that are not present in the native sequence PRO. In addition, the phrase includes qualitative changes in the glycosylation of the native proteins, involving a change in the nature and proportions of the various carbohydrate moieties present.

Addition of glycosylation sites to the PRO polypeptide may be accomplished by altering the amino acid sequence. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence PRO (for O-linked glycosylation sites). The PRO amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the PRO polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the PRO polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the PRO polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of PRO comprises linking the PRO polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

The PRO of the present invention may also be modified in a way to form a chimeric molecule comprising PRO fused to another, heterologous polypeptide or amino acid sequence.

In one embodiment, such a chimeric molecule comprises a fusion of the PRO with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl- terminus of the PRO. The presence of such epitope-tagged forms of the PRO can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the PRO to

be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)]; an  $\alpha$ -tubulin epitope peptide [Skinner et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].

In an alternative embodiment, the chimeric molecule may comprise a fusion of the PRO with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule (also referred to as an "immunoadhesin"), such a fusion could be to the Fc region of an IgG molecule. The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of a PRO polypeptide in place of at least one variable region within an Ig molecule. In a particularly preferred embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3 regions of an IgG1 molecule. For the production of immunoglobulin fusions see also US Patent No. 5,428,130 issued June 27, 1995.

#### D. Preparation of PRO

The description below relates primarily to production of PRO by culturing cells transformed or transfected with a vector containing PRO nucleic acid. It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare PRO. For instance, the PRO sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart et al., Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA (1969); Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. *In vitro* protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the PRO may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length PRO.

##### 1. Isolation of DNA Encoding PRO

DNA encoding PRO may be obtained from a cDNA library prepared from tissue believed to possess the PRO mRNA and to express it at a detectable level. Accordingly, human PRO DNA can be conveniently obtained from a cDNA library prepared from human tissue, such as described in the Examples. The PRO-encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis).

Libraries can be screened with probes (such as antibodies to the PRO or oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the gene encoding PRO is to use PCR methodology [Sambrook et al., supra; Dieffenbach et al., PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)].

The Examples below describe techniques for screening a cDNA library. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being screened. Methods of labeling are well known in the art, and include the use of radiolabels like  $^{32}\text{P}$ -labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al., supra.

Sequences identified in such library screening methods can be compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and as described herein.

Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in Sambrook et al., supra, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

## 2. Selection and Transformation of Host Cells

Host cells are transfected or transformed with expression or cloning vectors described herein for PRO production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. The culture conditions, such as media, temperature, pH and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991) and Sambrook et al., supra.

Methods of eukaryotic cell transfection and prokaryotic cell transformation are known to the ordinarily skilled artisan, for example,  $\text{CaCl}_2$ ,  $\text{CaPO}_4$ , liposome-mediated and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes. Infection with *Agrobacterium tumefaciens* is used for transformation of certain plant cells, as described by Shaw et al., Gene, 23:315 (1983) and WO 89/05859 published 29 June 1989. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transfections have been described in U.S. Patent No. 4,399,216. Transformations into yeast are typically carried out according to the

method of Van Solingen et al., J. Bact., 130:946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene, polyornithine, may also be used. For various techniques for transforming mammalian cells, see Keown et al., Methods in Enzymology, 185:527-537 (1990) and Mansour et al., Nature, 336:348-352 (1988).

5           Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells. Suitable prokaryotes include but are not limited to eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as *E. coli*. Various *E. coli* strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31,446); *E. coli* X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325) and K5 772 (ATCC 53,635). Other suitable prokaryotic host cells include  
10 Enterobacteriaceae such as *Escherichia*, e.g., *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, e.g., *Salmonella typhimurium*, *Serratia*, e.g., *Serratia marcescans*, and *Shigella*, as well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41P disclosed in DD 266,710 published 12 April 1989), *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. These examples are illustrative rather than limiting. Strain W3110 is one particularly preferred host or parent host because it is a common host strain for recombinant  
15 DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including *E. coli* W3110 strain 1A2, which has the complete genotype *tonA*; *E. coli* W3110 strain 9E4, which has the complete genotype *tonA ptr3*; *E. coli* W3110 strain 27C7 (ATCC 55,244), which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT kan'*; *E. coli*  
20 W3110 strain 37D6, which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT rbs7 ilvG kan'*; *E. coli* W3110 strain 40B4, which is strain 37D6 with a non-kanamycin resistant *degP* deletion mutation; and an *E. coli* strain having mutant periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7 August 1990. Alternatively, *in vitro* methods of cloning, e.g., PCR or other nucleic acid polymerase reactions, are suitable.

25           In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for PRO-encoding vectors. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism. Others include *Schizosaccharomyces pombe* (Beach and Nurse, Nature, 290: 140 [1981]; EP 139,383 published 2 May 1985); *Kluyveromyces* hosts (U.S. Patent No. 4,943,529; Fleer et al., Bio/Technology, 9:968-975 (1991)) such as, e.g., *K. lactis* (MW98-8C, CBS683, CBS4574; Louvençourt et al., J. Bacteriol., 154(2):737-742 [1983]), *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickerhamii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilum* (ATCC 36,906; Van den Berg et al., Bio/Technology, 8:135 (1990)), *K. thermotolerans*, and *K. marxianus*; *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070; Sreekrishna et al., J. Basic Microbiol., 28:265-278 [1988]); *Candida*; *Trichoderma reesia* (EP 244,234); *Neurospora crassa* (Case et al., Proc. Natl. Acad. Sci. USA, 76:5259-5263 [1979]); *Schwanniomyces*  
35 such as *Schwanniomyces occidentalis* (EP 394,538 published 31 October 1990); and filamentous fungi such as, e.g., *Neurospora*, *Penicillium*, *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance et al., Biochem. Biophys. Res. Commun., 112:284-289 [1983]; Tilburn et al.,

Gene, 26:205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci. USA, 81: 1470-1474 [1984]) and *A. niger* (Kelly and Hynes, EMBO J., 4:475-479 [1985]). Methylotrophic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of *Hansenula*, *Candida*, *Kloeckera*, *Pichia*, *Saccharomyces*, *Torulopsis*, and *Rhodotorula*. A list of specific species that are exemplary of this class of yeasts may be found in C. Anthony, The Biochemistry of Methylotrophs, 269 (1982).

Suitable host cells for the expression of glycosylated PRO are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as *Drosophila* S2 and *Spodoptera* Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol., 36:59 (1977)); Chinese hamster ovary cells/-DHFR (CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); mouse sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art.

### 3. Selection and Use of a Replicable Vector

The nucleic acid (e.g., cDNA or genomic DNA) encoding PRO may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art. Vector components generally include, but are not limited to, one or more of a signal sequence, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques which are known to the skilled artisan.

The PRO may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or polypeptide. In general, the signal sequence may be a component of the vector, or it may be a part of the PRO-encoding DNA that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, lpp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces*  $\alpha$ -factor leaders, the latter described in U.S. Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader (EP 362,179 published 4 April 1990), or the signal described in WO 90/13646 published 15 November 1990. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.



Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2 $\mu$  plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.

5 Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

10 An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the PRO-encoding nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980). A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 [Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene, 7:141 (1979); Tschemper et al., Gene, 10:157 (1980)]. The *trp1* gene  
15 provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, Genetics, 85:12 (1977)].

Expression and cloning vectors usually contain a promoter operably linked to the PRO-encoding nucleic acid sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the  $\beta$ -lactamase and lactose promoter systems  
20 [Chang et al., Nature, 275:615 (1978); Goeddel et al., Nature, 281:544 (1979)], alkaline phosphatase, a tryptophan (*trp*) promoter system [Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776], and hybrid promoters such as the *tac* promoter [deBoer et al., Proc. Natl. Acad. Sci. USA, 80:21-25 (1983)]. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding PRO.

25 Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem., 255:2073 (1980)] or other glycolytic enzymes [Hess et al., J. Adv. Enzyme Reg., 7:149 (1968); Holland, Biochemistry, 17:4900 (1978)], such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose  
30 isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and  
35 promoters for use in yeast expression are further described in EP 73,657.

PRO transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504 published 5 July

1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are compatible with the host cell systems.

Transcription of a DNA encoding the PRO by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the PRO coding sequence, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding PRO.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of PRO in recombinant vertebrate cell culture are described in Gething et al., Nature, 293:620-625 (1981); Mantei et al., Nature, 281:40-46 (1979); EP 117,060; and EP 117,058.

#### 4. Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA analysis), or *in situ* hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence PRO polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to PRO DNA and encoding a specific antibody epitope.

## 5. Purification of Polypeptide

Forms of PRO may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic cleavage. Cells employed in expression of PRO can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

It may be desired to purify PRO from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the PRO. Various methods of protein purification may be employed and such methods are known in the art and described for example in Deutscher, Methods in Enzymology, 182 (1990); Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York (1982). The purification step(s) selected will depend, for example, on the nature of the production process used and the particular PRO produced.

### E. Uses for PRO

Nucleotide sequences (or their complement) encoding PRO have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping and in the generation of anti-sense RNA and DNA. PRO nucleic acid will also be useful for the preparation of PRO polypeptides by the recombinant techniques described herein.

The full-length native sequence PRO gene, or portions thereof, may be used as hybridization probes for a cDNA library to isolate the full-length PRO cDNA or to isolate still other cDNAs (for instance, those encoding naturally-occurring variants of PRO or PRO from other species) which have a desired sequence identity to the native PRO sequence disclosed herein. Optionally, the length of the probes will be about 20 to about 50 bases. The hybridization probes may be derived from at least partially novel regions of the full length native nucleotide sequence wherein those regions may be determined without undue experimentation or from genomic sequences including promoters, enhancer elements and introns of native sequence PRO. By way of example, a screening method will comprise isolating the coding region of the PRO gene using the known DNA sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of the PRO gene of the present invention can be used to screen libraries of human cDNA, genomic DNA or mRNA to determine which members of such libraries the probe hybridizes to. Hybridization techniques are described in further detail in the Examples below.

Any EST sequences disclosed in the present application may similarly be employed as probes, using the methods disclosed herein.

Other useful fragments of the PRO nucleic acids include antisense or sense oligonucleotides comprising a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target PRO mRNA (sense) or PRO DNA (antisense) sequences. Antisense or sense oligonucleotides, according to the present invention, comprise a fragment of the coding region of PRO DNA. Such a fragment generally comprises at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. The ability to derive an antisense or a sense oligonucleotide, based upon a cDNA sequence encoding a given protein is described in, for example, Stein and Cohen (Cancer Res. 48:2659, 1988) and van der Krol et al. (BioTechniques 6:958, 1988).

Binding of antisense or sense oligonucleotides to target nucleic acid sequences results in the formation of duplexes that block transcription or translation of the target sequence by one of several means, including enhanced degradation of the duplexes, premature termination of transcription or translation, or by other means.

The antisense oligonucleotides thus may be used to block expression of PRO proteins. Antisense or sense oligonucleotides further comprise oligonucleotides having modified sugar-phosphodiester backbones (or other sugar linkages, such as those described in WO 91/06629) and wherein such sugar linkages are resistant to endogenous nucleases. Such oligonucleotides with resistant sugar linkages are stable *in vivo* (i.e., capable of resisting enzymatic degradation) but retain sequence specificity to be able to bind to target nucleotide sequences.

Other examples of sense or antisense oligonucleotides include those oligonucleotides which are covalently linked to organic moieties, such as those described in WO 90/10048, and other moieties that increases affinity of the oligonucleotide for a target nucleic acid sequence, such as poly-(L-lysine). Further still, intercalating agents, such as ellipticine, and alkylating agents or metal complexes may be attached to sense or antisense oligonucleotides to modify binding specificities of the antisense or sense oligonucleotide for the target nucleotide sequence.

Antisense or sense oligonucleotides may be introduced into a cell containing the target nucleic acid sequence by any gene transfer method, including, for example,  $\text{CaPO}_4$ -mediated DNA transfection, electroporation, or by using gene transfer vectors such as Epstein-Barr virus. In a preferred procedure, an antisense or sense oligonucleotide is inserted into a suitable retroviral vector. A cell containing the target nucleic acid sequence is contacted with the recombinant retroviral vector, either *in vivo* or *ex vivo*. Suitable retroviral vectors include, but are not limited to, those derived from the murine retrovirus M-MuLV, N2 (a retrovirus derived from M-MuLV), or the double copy vectors designated DCT5A, DCT5B and DCT5C (see WO 90/13641).

Sense or antisense oligonucleotides also may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell.

Alternatively, a sense or an antisense oligonucleotide may be introduced into a cell containing the target nucleic acid sequence by formation of an oligonucleotide-lipid complex, as described in WO 90/10448. The sense or antisense oligonucleotide-lipid complex is preferably dissociated within the cell by an endogenous lipase.

Antisense or sense RNA or DNA molecules are generally at least about 5 bases in length, about 10 bases in length, about 15 bases in length, about 20 bases in length, about 25 bases in length, about 30 bases in length, about 35 bases in length, about 40 bases in length, about 45 bases in length, about 50 bases in length, about 55 bases in length, about 60 bases in length, about 65 bases in length, about 70 bases in length, about 75 bases in length, about 80 bases in length, about 85 bases in length, about 90 bases in length, about 95 bases in length, about 100 bases in length, or more.

The probes may also be employed in PCR techniques to generate a pool of sequences for identification of closely related PRO coding sequences.

Nucleotide sequences encoding a PRO can also be used to construct hybridization probes for mapping the gene which encodes that PRO and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as *in situ* hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries.

When the coding sequences for PRO encode a protein which binds to another protein (example, where the PRO is a receptor), the PRO can be used in assays to identify the other proteins or molecules involved in the binding interaction. By such methods, inhibitors of the receptor/ligand binding interaction can be identified. Proteins involved in such binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. Also, the receptor PRO can be used to isolate correlative ligand(s). Screening assays can be designed to find lead compounds that mimic the biological activity of a native PRO or a receptor for PRO. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates. Small molecules contemplated include synthetic organic or inorganic compounds. The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays and cell based assays, which are well characterized in the art.

Nucleic acids which encode PRO or its modified forms can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops. In one embodiment, cDNA encoding PRO can be used to clone genomic DNA encoding PRO in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express DNA encoding PRO. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009. Typically, particular cells would be targeted for PRO transgene incorporation with tissue-specific enhancers. Transgenic animals that include a copy of a transgene encoding PRO introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of DNA encoding PRO. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this facet of

the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human homologues of PRO can be used to construct a PRO "knock out" animal which has a defective or altered gene encoding PRO as a result of homologous recombination between the endogenous gene encoding PRO and altered genomic DNA encoding PRO introduced into an embryonic stem cell of the animal. For example, cDNA encoding PRO can be used to clone genomic DNA encoding PRO in accordance with established techniques. A portion of the genomic DNA encoding PRO can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas and Capecchi, Cell, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected [see e.g., Li et al., Cell, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras [see e.g., Bradley, in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of the PRO polypeptide.

Nucleic acid encoding the PRO polypeptides may also be used in gene therapy. In gene therapy applications, genes are introduced into cells in order to achieve *in vivo* synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene. "Gene therapy" includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA. Antisense RNAs and DNAs can be used as therapeutic agents for blocking the expression of certain genes *in vivo*. It has already been shown that short antisense oligonucleotides can be imported into cells where they act as inhibitors, despite their low intracellular concentrations caused by their restricted uptake by the cell membrane. (Zamecnik *et al.*, Proc. Natl. Acad. Sci. USA 83:4143-4146 [1986]). The oligonucleotides can be modified to enhance their uptake, e.g. by substituting their negatively charged phosphodiester groups by uncharged groups.

There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells *in vitro*, or *in vivo* in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells *in vitro* include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. The currently preferred *in vivo* gene transfer techniques include transfection with viral

(typically retroviral) vectors and viral coat protein-liposome mediated transfection (Dzau et al., Trends in Biotechnology 11, 205-210 [1993]). In some situations it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are employed, proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half-life. The technique of receptor-mediated endocytosis is described, for example, by Wu et al., J. Biol. Chem. 262, 4429-4432 (1987); and Wagner et al., Proc. Natl. Acad. Sci. USA 87, 3410-3414 (1990). For review of gene marking and gene therapy protocols see Anderson et al., Science 256, 808-813 (1992).

The PRO polypeptides described herein may also be employed as molecular weight markers for protein electrophoresis purposes and the isolated nucleic acid sequences may be used for recombinantly expressing those markers.

The nucleic acid molecules encoding the PRO polypeptides or fragments thereof described herein are useful for chromosome identification. In this regard, there exists an ongoing need to identify new chromosome markers, since relatively few chromosome marking reagents, based upon actual sequence data are presently available. Each PRO nucleic acid molecule of the present invention can be used as a chromosome marker.

The PRO polypeptides and nucleic acid molecules of the present invention may also be used diagnostically for tissue typing, wherein the PRO polypeptides of the present invention may be differentially expressed in one tissue as compared to another, preferably in a diseased tissue as compared to a normal tissue of the same tissue type. PRO nucleic acid molecules will find use for generating probes for PCR, Northern analysis, Southern analysis and Western analysis.

The PRO polypeptides described herein may also be employed as therapeutic agents. The PRO polypeptides of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the PRO product hereof is combined in admixture with a pharmaceutically acceptable carrier vehicle. Therapeutic formulations are prepared for storage by mixing the active ingredient having the desired degree of purity with optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN<sup>TM</sup>, PLURONICS<sup>TM</sup> or PEG.

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution.

Therapeutic compositions herein generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

The route of administration is in accord with known methods, e.g. injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional routes, topical administration, or by sustained release systems.

5 Dosages and desired drug concentrations of pharmaceutical compositions of the present invention may vary depending on the particular use envisioned. The determination of the appropriate dosage or route of administration is well within the skill of an ordinary physician. Animal experiments provide reliable guidance for the determination of effective doses for human therapy. Interspecies scaling of effective doses can be performed following the principles laid down by Mordenti, J. and Chappell, W. "The use of interspecies scaling  
10 in toxicokinetics" In Toxicokinetics and New Drug Development, Yacobi et al., Eds., Pergamon Press, New York 1989, pp. 42-96.

When *in vivo* administration of a PRO polypeptide or agonist or antagonist thereof is employed, normal dosage amounts may vary from about 10 ng/kg to up to 100 mg/kg of mammal body weight or more per day, preferably about 1 µg/kg/day to 10 mg/kg/day, depending upon the route of administration. Guidance as to  
15 particular dosages and methods of delivery is provided in the literature; see, for example, U.S. Pat. Nos. 4,657,760; 5,206,344; or 5,225,212. It is anticipated that different formulations will be effective for different treatment compounds and different disorders, that administration targeting one organ or tissue, for example, may necessitate delivery in a manner different from that to another organ or tissue.

Where sustained-release administration of a PRO polypeptide is desired in a formulation with release  
20 characteristics suitable for the treatment of any disease or disorder requiring administration of the PRO polypeptide, microencapsulation of the PRO polypeptide is contemplated. Microencapsulation of recombinant proteins for sustained release has been successfully performed with human growth hormone (rhGH), interferon- (rhIFN- ), interleukin-2, and MN rgp120. Johnson et al., Nat. Med., 2:795-799 (1996); Yasuda, Biomed. Ther., 27:1221-1223 (1993); Hora et al., Bio/Technology, 8:755-758 (1990); Cleland, "Design and Production of Single Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems," in Vaccine Design: The Subunit and Adjuvant Approach, Powell and Newman, eds, (Plenum Press: New York, 1995), pp. 439-462;  
25 WO 97/03692, WO 96/40072, WO 96/07399; and U.S. Pat. No. 5,654,010.

The sustained-release formulations of these proteins were developed using poly-lactic-coglycolic acid (PLGA) polymer due to its biocompatibility and wide range of biodegradable properties. The degradation  
30 products of PLGA, lactic and glycolic acids, can be cleared quickly within the human body. Moreover, the degradability of this polymer can be adjusted from months to years depending on its molecular weight and composition. Lewis, "Controlled release of bioactive agents from lactide/glycolide polymer," in: M. Chasin and R. Langer (Eds.), Biodegradable Polymers as Drug Delivery Systems (Marcel Dekker: New York, 1990), pp. 1-41.

35 This invention encompasses methods of screening compounds to identify those that mimic the PRO polypeptide (agonists) or prevent the effect of the PRO polypeptide (antagonists). Screening assays for antagonist drug candidates are designed to identify compounds that bind or complex with the PRO polypeptides



encoded by the genes identified herein, or otherwise interfere with the interaction of the encoded polypeptides with other cellular proteins. Such screening assays will include assays amenable to high-throughput screening of chemical libraries, making them particularly suitable for identifying small molecule drug candidates.

The assays can be performed in a variety of formats, including protein-protein binding assays, biochemical screening assays, immunoassays, and cell-based assays, which are well characterized in the art.

5 All assays for antagonists are common in that they call for contacting the drug candidate with a PRO polypeptide encoded by a nucleic acid identified herein under conditions and for a time sufficient to allow these two components to interact.

10 In binding assays, the interaction is binding and the complex formed can be isolated or detected in the reaction mixture. In a particular embodiment, the PRO polypeptide encoded by the gene identified herein or the drug candidate is immobilized on a solid phase, e.g., on a microtiter plate, by covalent or non-covalent attachments. Non-covalent attachment generally is accomplished by coating the solid surface with a solution of the PRO polypeptide and drying. Alternatively, an immobilized antibody, e.g., a monoclonal antibody, specific for the PRO polypeptide to be immobilized can be used to anchor it to a solid surface. The assay is performed by adding the non-immobilized component, which may be labeled by a detectable label, to the immobilized component, e.g., the coated surface containing the anchored component. When the reaction is complete, the non-reacted components are removed, e.g., by washing, and complexes anchored on the solid surface are detected. When the originally non-immobilized component carries a detectable label, the detection of label immobilized on the surface indicates that complexing occurred. Where the originally non-immobilized component does not carry a label, complexing can be detected, for example, by using a labeled antibody specifically binding the immobilized complex.

20 If the candidate compound interacts with but does not bind to a particular PRO polypeptide encoded by a gene identified herein, its interaction with that polypeptide can be assayed by methods well known for detecting protein-protein interactions. Such assays include traditional approaches, such as, e.g., cross-linking, co-immunoprecipitation, and co-purification through gradients or chromatographic columns. In addition, protein-protein interactions can be monitored by using a yeast-based genetic system described by Fields and co-workers (Fields and Song, Nature (London), 340:245-246 (1989); Chien et al., Proc. Natl. Acad. Sci. USA, 88:9578-9582 (1991)) as disclosed by Chevray and Nathans, Proc. Natl. Acad. Sci. USA, 89: 5789-5793 (1991). Many transcriptional activators, such as yeast GAL4, consist of two physically discrete modular domains, one acting as the DNA-binding domain, the other one functioning as the transcription-activation domain. The yeast expression system described in the foregoing publications (generally referred to as the "two-hybrid system") takes advantage of this property, and employs two hybrid proteins, one in which the target protein is fused to the DNA-binding domain of GAL4, and another, in which candidate activating proteins are fused to the activation domain. The expression of a GAL1-*lacZ* reporter gene under control of a GAL4-activated promoter depends on reconstitution of GAL4 activity via protein-protein interaction. Colonies containing interacting polypeptides are detected with a chromogenic substrate for  $\beta$ -galactosidase. A complete kit (MATCHMAKER™) for identifying protein-protein interactions between two specific proteins using the two-hybrid technique is commercially available from Clontech. This system can also be extended to map protein

domains involved in specific protein interactions as well as to pinpoint amino acid residues that are crucial for these interactions.

Compounds that interfere with the interaction of a gene encoding a PRO polypeptide identified herein and other intra- or extracellular components can be tested as follows: usually a reaction mixture is prepared containing the product of the gene and the intra- or extracellular component under conditions and for a time allowing for the interaction and binding of the two products. To test the ability of a candidate compound to inhibit binding, the reaction is run in the absence and in the presence of the test compound. In addition, a placebo may be added to a third reaction mixture, to serve as positive control. The binding (complex formation) between the test compound and the intra- or extracellular component present in the mixture is monitored as described hereinabove. The formation of a complex in the control reaction(s) but not in the reaction mixture containing the test compound indicates that the test compound interferes with the interaction of the test compound and its reaction partner.

To assay for antagonists, the PRO polypeptide may be added to a cell along with the compound to be screened for a particular activity and the ability of the compound to inhibit the activity of interest in the presence of the PRO polypeptide indicates that the compound is an antagonist to the PRO polypeptide. Alternatively, antagonists may be detected by combining the PRO polypeptide and a potential antagonist with membrane-bound PRO polypeptide receptors or recombinant receptors under appropriate conditions for a competitive inhibition assay. The PRO polypeptide can be labeled, such as by radioactivity, such that the number of PRO polypeptide molecules bound to the receptor can be used to determine the effectiveness of the potential antagonist. The gene encoding the receptor can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting. Coligan et al., Current Protocols in Immun., 1(2): Chapter 5 (1991). Preferably, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the PRO polypeptide and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the PRO polypeptide. Transfected cells that are grown on glass slides are exposed to labeled PRO polypeptide. The PRO polypeptide can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase. Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an interactive sub-pooling and re-screening process, eventually yielding a single clone that encodes the putative receptor.

As an alternative approach for receptor identification, labeled PRO polypeptide can be photoaffinity-linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE and exposed to X-ray film. The labeled complex containing the receptor can be excised, resolved into peptide fragments, and subjected to protein micro-sequencing. The amino acid sequence obtained from micro-sequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the gene encoding the putative receptor.

In another assay for antagonists, mammalian cells or a membrane preparation expressing the receptor would be incubated with labeled PRO polypeptide in the presence of the candidate compound. The ability of the compound to enhance or block this interaction could then be measured.

More specific examples of potential antagonists include an oligonucleotide that binds to the fusions of immunoglobulin with PRO polypeptide, and, in particular, antibodies including, without limitation, poly- and monoclonal antibodies and antibody fragments, single-chain antibodies, anti-idiotypic antibodies, and chimeric or humanized versions of such antibodies or fragments, as well as human antibodies and antibody fragments. Alternatively, a potential antagonist may be a closely related protein, for example, a mutated form of the PRO polypeptide that recognizes the receptor but imparts no effect, thereby competitively inhibiting the action of the PRO polypeptide.

Another potential PRO polypeptide antagonist is an antisense RNA or DNA construct prepared using antisense technology, where, e.g., an antisense RNA or DNA molecule acts to block directly the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. Antisense technology can be used to control gene expression through triple-helix formation or antisense DNA or RNA, both of which methods are based on binding of a polynucleotide to DNA or RNA. For example, the 5' coding portion of the polynucleotide sequence, which encodes the mature PRO polypeptides herein, is used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription (triple helix - see Lee et al., Nucl. Acids Res., 6:3073 (1979); Cooney et al., Science, 241: 456 (1988); Dervan et al., Science, 251:1360 (1991)), thereby preventing transcription and the production of the PRO polypeptide. The antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into the PRO polypeptide (antisense - Okano, Neurochem., 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression (CRC Press: Boca Raton, FL, 1988). The oligonucleotides described above can also be delivered to cells such that the antisense RNA or DNA may be expressed *in vivo* to inhibit production of the PRO polypeptide. When antisense DNA is used, oligodeoxyribonucleotides derived from the translation-initiation site, e.g., between about -10 and +10 positions of the target gene nucleotide sequence, are preferred.

Potential antagonists include small molecules that bind to the active site, the receptor binding site, or growth factor or other relevant binding site of the PRO polypeptide, thereby blocking the normal biological activity of the PRO polypeptide. Examples of small molecules include, but are not limited to, small peptides or peptide-like molecules, preferably soluble peptides, and synthetic non-peptidyl organic or inorganic compounds.

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization to the complementary target RNA, followed by endonucleolytic cleavage. Specific ribozyme cleavage sites within a potential RNA target can be identified by known techniques. For further details see, e.g., Rossi, Current Biology, 4:469-471 (1994); and PCT publication No. WO 97/33551 (published September 18, 1997).

Nucleic acid molecules in triple-helix formation used to inhibit transcription should be single-stranded and composed of deoxynucleotides. The base composition of these oligonucleotides is designed such that it promotes triple-helix formation via Hoogsteen base-pairing rules, which generally require sizeable stretches of purines or pyrimidines on one strand of a duplex. For further details see, e.g., PCT publication No. WO 97/33551, *supra*.

These small molecules can be identified by any one or more of the screening assays discussed hereinabove and/or by any other screening techniques well known for those skilled in the art.

Diagnostic and therapeutic uses of the herein disclosed molecules may also be based upon the positive functional assay hits disclosed and described below.

5                                   F.       Anti-PRO Antibodies

The present invention further provides anti-PRO antibodies. Exemplary antibodies include polyclonal, monoclonal, humanized, bispecific, and heteroconjugate antibodies.

1.       Polyclonal Antibodies

10       The anti-PRO antibodies may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the PRO polypeptide or a fusion protein thereof. It may be useful to conjugate  
15       the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

20                                   2.       Monoclonal Antibodies

The anti-PRO antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an  
25       immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

The immunizing agent will typically include the PRO polypeptide or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then  
30       fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or  
35       survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of

HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Manassas, Virginia. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63].

The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against PRO. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980).

After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods [Goding, supra]. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal.

The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences [U.S. Patent No. 4,816,567; Morrison et al., supra] or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.

The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent

heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent crosslinking.

*In vitro* methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.

### 3. Human and Humanized Antibodies

The anti-PRO antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al. and Boerner et al. are also available for the preparation of human monoclonal antibodies (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and

Boerner et al., J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks *et al.*, Bio/Technology 10, 779-783 (1992); Lonberg *et al.*, Nature 368 856-859 (1994); Morrison, Nature 368, 812-13 (1994); Fishwild *et al.*, Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93 (1995).

The antibodies may also be affinity matured using known selection and/or mutagenesis methods as described above. Preferred affinity matured antibodies have an affinity which is five times, more preferably 10 times, even more preferably 20 or 30 times greater than the starting antibody (generally murine, humanized or human) from which the matured antibody is prepared.

#### 4. Bispecific Antibodies

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the PRO, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities [Milstein and Cuello, Nature, 305:537-539 (1983)]. Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).

According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain.

In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.

5 Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g.  $F(ab')_2$  bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan *et al.*, Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate  $F(ab')_2$  fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab' fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab'-TNB derivatives is then reconverted to the Fab'-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab'-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective immobilization of enzymes.

10 Fab' fragments may be directly recovered from *E. coli* and chemically coupled to form bispecific antibodies. Shalaby *et al.*, J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody  $F(ab')_2$  molecule. Each Fab' fragment was separately secreted from *E. coli* and subjected to directed chemical coupling *in vitro* to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.

15 Various technique for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny *et al.*, J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab' portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The "diabody" technology described by Hollinger *et al.*, Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain ( $V_H$ ) connected to a light-chain variable domain ( $V_L$ ) by a linker which is too short to allow pairing between the two domains on the same chain. Accordingly, the  $V_H$  and  $V_L$  domains of one fragment are forced to pair with the complementary  $V_L$  and  $V_H$  domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber *et al.*, J. Immunol. 152:5368 (1994).

25 Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared.

30 Tutt *et al.*, J. Immunol. 147:60 (1991).

Exemplary bispecific antibodies may bind to two different epitopes on a given PRO polypeptide herein. Alternatively, an anti-PRO polypeptide arm may be combined with an arm which binds to a triggering molecule



on a leukocyte such as a T-cell receptor molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular PRO polypeptide. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express a particular PRO polypeptide. These antibodies possess a PRO-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the PRO polypeptide and further binds tissue factor (TF).

#### 5. Heteroconjugate Antibodies

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated that the antibodies may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

#### 6. Effector Function Engineering

It may be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) may be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated may have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron *et al.*, J. Exp Med., **176**: 1191-1195 (1992) and Shopes, J. Immunol., **148**: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity may also be prepared using heterobifunctional cross-linkers as described in Wolff *et al.* Cancer Research, **53**: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fc regions and may thereby have enhanced complement lysis and ADCC capabilities. See Stevenson *et al.*, Anti-Cancer Drug Design, **3**: 219-230 (1989).

#### 7. Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolaca americana* proteins

(PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, croton, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include  $^{212}\text{Bi}$ ,  $^{131}\text{I}$ ,  $^{131}\text{In}$ ,  $^{90}\text{Y}$ , and  $^{186}\text{Re}$ .

Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta *et al.*, Science, **238**: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.

In another embodiment, the antibody may be conjugated to a "receptor" (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a "ligand" (*e.g.*, avidin) that is conjugated to a cytotoxic agent (*e.g.*, a radionucleotide).

#### 8. Immunoliposomes

The antibodies disclosed herein may also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein *et al.*, Proc. Natl. Acad. Sci. USA, **82**: 3688 (1985); Hwang *et al.*, Proc. Natl. Acad. Sci. USA, **77**: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.

Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin *et al.*, J. Biol. Chem., **257**: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon *et al.*, J. National Cancer Inst., **81**(19): 1484 (1989).

#### 9. Pharmaceutical Compositions of Antibodies

Antibodies specifically binding a PRO polypeptide identified herein, as well as other molecules identified by the screening assays disclosed hereinbefore, can be administered for the treatment of various disorders in the form of pharmaceutical compositions.

If the PRO polypeptide is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, lipofections or liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that

specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, *e.g.*, Marasco *et al.*, Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition may comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

The active ingredients may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, *supra*.

The formulations to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, *e.g.*, films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and  $\gamma$  ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT<sup>TM</sup> (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37°C, resulting in a loss of biological activity and possible changes in immunogenicity. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be intermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying sulfhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions.

#### G. Uses for anti-PRO Antibodies

The anti-PRO antibodies of the invention have various utilities. For example, anti-PRO antibodies may be used in diagnostic assays for PRO, *e.g.*, detecting its expression (and in some cases, differential expression) in specific cells, tissues, or serum. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases [Zola, Monoclonal Antibodies: A Manual of Techniques, CRC

Press, Inc. (1987) pp. 147-158]. The antibodies used in the diagnostic assays can be labeled with a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , or  $^{125}\text{I}$ , a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter et al., *Nature*, 144:945 (1962); David et al., *Biochemistry*, 13:1014 (1974); Pain et al., *J. Immunol. Meth.*, 40:219 (1981); and Nygren, *J. Histochem. and Cytochem.*, 30:407 (1982).

Anti-PRO antibodies also are useful for the affinity purification of PRO from recombinant cell culture or natural sources. In this process, the antibodies against PRO are immobilized on a suitable support, such as Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody then is contacted with a sample containing the PRO to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the PRO, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent that will release the PRO from the antibody.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

## EXAMPLES

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Manassas, VA.

### EXAMPLE 1: Extracellular Domain Homology Screening to Identify Novel Polypeptides and cDNA Encoding Therefor

The extracellular domain (ECD) sequences (including the secretion signal sequence, if any) from about 950 known secreted proteins from the Swiss-Prot public database were used to search EST databases. The EST databases included public databases (e.g., Dayhoff, GenBank), and proprietary databases (e.g. LIFESEQ™, Incyte Pharmaceuticals, Palo Alto, CA). The search was performed using the computer program BLAST or BLAST-2 (Altschul et al., *Methods in Enzymology* 266:460-480 (1996)) as a comparison of the ECD protein sequences to a 6 frame translation of the EST sequences. Those comparisons with a BLAST score of 70 (or in some cases 90) or greater that did not encode known proteins were clustered and assembled into consensus DNA sequences with the program "phrap" (Phil Green, University of Washington, Seattle, WA).

Using this extracellular domain homology screen, consensus DNA sequences were assembled relative to the other identified EST sequences using phrap. In addition, the consensus DNA sequences obtained were

often (but not always) extended using repeated cycles of BLAST or BLAST-2 and phrap to extend the consensus sequence as far as possible using the sources of EST sequences discussed above.

Based upon the consensus sequences obtained as described above, oligonucleotides were then synthesized and used to identify by PCR a cDNA library that contained the sequence of interest and for use as probes to isolate a clone of the full-length coding sequence for a PRO polypeptide. Forward and reverse PCR primers generally range from 20 to 30 nucleotides and are often designed to give a PCR product of about 100-1000 bp in length. The probe sequences are typically 40-55 bp in length. In some cases, additional oligonucleotides are synthesized when the consensus sequence is greater than about 1-1.5kbp. In order to screen several libraries for a full-length clone, DNA from the libraries was screened by PCR amplification, as per Ausubel et al., Current Protocols in Molecular Biology, with the PCR primer pair. A positive library was then used to isolate clones encoding the gene of interest using the probe oligonucleotide and one of the primer pairs.

The cDNA libraries used to isolate the cDNA clones were constructed by standard methods using commercially available reagents such as those from Invitrogen, San Diego, CA. The cDNA was primed with oligo dT containing a NotI site, linked with blunt to SalI hemikinased adaptors, cleaved with NotI, sized appropriately by gel electrophoresis, and cloned in a defined orientation into a suitable cloning vector (such as pRKB or pRKD; pRK5B is a precursor of pRK5D that does not contain the SfiI site; see, Holmes et al., Science, 253:1278-1280 (1991)) in the unique XhoI and NotI sites.

#### EXAMPLE 2: Isolation of cDNA clones by Amylase Screening

##### 1. Preparation of oligo dT primed cDNA library

mRNA was isolated from a human tissue of interest using reagents and protocols from Invitrogen, San Diego, CA (Fast Track 2). This RNA was used to generate an oligo dT primed cDNA library in the vector pRK5D using reagents and protocols from Life Technologies, Gaithersburg, MD (Super Script Plasmid System). In this procedure, the double stranded cDNA was sized to greater than 1000 bp and the SalI/NotI linked cDNA was cloned into XhoI/NotI cleaved vector. pRK5D is a cloning vector that has an sp6 transcription initiation site followed by an SfiI restriction enzyme site preceding the XhoI/NotI cDNA cloning sites.

##### 2. Preparation of random primed cDNA library

A secondary cDNA library was generated in order to preferentially represent the 5' ends of the primary cDNA clones. Sp6 RNA was generated from the primary library (described above), and this RNA was used to generate a random primed cDNA library in the vector pSST-AMY.0 using reagents and protocols from Life Technologies (Super Script Plasmid System, referenced above). In this procedure the double stranded cDNA was sized to 500-1000 bp, linked with blunt to NotI adaptors, cleaved with SfiI, and cloned into SfiI/NotI cleaved vector. pSST-AMY.0 is a cloning vector that has a yeast alcohol dehydrogenase promoter preceding the cDNA cloning sites and the mouse amylase sequence (the mature sequence without the secretion signal) followed by the yeast alcohol dehydrogenase terminator, after the cloning sites. Thus, cDNAs cloned into this vector that are fused in frame with amylase sequence will lead to the secretion of amylase from appropriately transfected yeast colonies.

### 3. Transformation and Detection

DNA from the library described in paragraph 2 above was chilled on ice to which was added electrocompetent DH10B bacteria (Life Technologies, 20 ml). The bacteria and vector mixture was then electroporated as recommended by the manufacturer. Subsequently, SOC media (Life Technologies, 1 ml) was added and the mixture was incubated at 37°C for 30 minutes. The transformants were then plated onto 20 standard 150 mm LB plates containing ampicillin and incubated for 16 hours (37°C). Positive colonies were scraped off the plates and the DNA was isolated from the bacterial pellet using standard protocols, e.g. CsCl-gradient. The purified DNA was then carried on to the yeast protocols below.

The yeast methods were divided into three categories: (1) Transformation of yeast with the plasmid/cDNA combined vector; (2) Detection and isolation of yeast clones secreting amylase; and (3) PCR amplification of the insert directly from the yeast colony and purification of the DNA for sequencing and further analysis.

The yeast strain used was HD56-5A (ATCC-90785). This strain has the following genotype: MAT $\alpha$ , ura3-52, leu2-3, leu2-112, his3-11, his3-15, MAL<sup>+</sup>, SUC<sup>+</sup>, GAL<sup>+</sup>. Preferably, yeast mutants can be employed that have deficient post-translational pathways. Such mutants may have translocation deficient alleles in *sec71*, *sec72*, *sec62*, with truncated *sec71* being most preferred. Alternatively, antagonists (including antisense nucleotides and/or ligands) which interfere with the normal operation of these genes, other proteins implicated in this post translation pathway (e.g., SEC61p, SEC72p, SEC62p, SEC63p, TDJ1p or SSA1p-4p) or the complex formation of these proteins may also be preferably employed in combination with the amylase-expressing yeast.

Transformation was performed based on the protocol outlined by Gietz et al., Nucl. Acid. Res., 20:1425 (1992). Transformed cells were then inoculated from agar into YEPD complex media broth (100 ml) and grown overnight at 30°C. The YEPD broth was prepared as described in Kaiser et al., Methods in Yeast Genetics, Cold Spring Harbor Press, Cold Spring Harbor, NY, p. 207 (1994). The overnight culture was then diluted to about  $2 \times 10^6$  cells/ml (approx. OD<sub>600</sub>=0.1) into fresh YEPD broth (500 ml) and regrown to  $1 \times 10^7$  cells/ml (approx. OD<sub>600</sub>=0.4-0.5).

The cells were then harvested and prepared for transformation by transfer into GS3 rotor bottles in a Sorval GS3 rotor at 5,000 rpm for 5 minutes, the supernatant discarded, and then resuspended into sterile water, and centrifuged again in 50 ml falcon tubes at 3,500 rpm in a Beckman GS-6KR centrifuge. The supernatant was discarded and the cells were subsequently washed with LiAc/TE (10 ml, 10 mM Tris-HCl, 1 mM EDTA pH 7.5, 100 mM Li<sub>2</sub>OOCCH<sub>3</sub>), and resuspended into LiAc/TE (2.5 ml).

Transformation took place by mixing the prepared cells (100  $\mu$ l) with freshly denatured single stranded salmon testes DNA (Lofstrand Labs, Gaithersburg, MD) and transforming DNA (1  $\mu$ g, vol. < 10  $\mu$ l) in microfuge tubes. The mixture was mixed briefly by vortexing, then 40% PEG/TE (600  $\mu$ l, 40% polyethylene glycol-4000, 10 mM Tris-HCl, 1 mM EDTA, 100 mM Li<sub>2</sub>OOCCH<sub>3</sub>, pH 7.5) was added. This mixture was gently mixed and incubated at 30°C while agitating for 30 minutes. The cells were then heat shocked at 42°C for 15 minutes, and the reaction vessel centrifuged in a microfuge at 12,000 rpm for 5-10 seconds, decanted and resuspended into TE (500  $\mu$ l, 10 mM Tris-HCl, 1 mM EDTA pH 7.5) followed by recentrifugation. The cells

were then diluted into TE (1 ml) and aliquots (200  $\mu$ l) were spread onto the selective media previously prepared in 150 mm growth plates (VWR).

Alternatively, instead of multiple small reactions, the transformation was performed using a single, large scale reaction, wherein reagent amounts were scaled up accordingly.

The selective media used was a synthetic complete dextrose agar lacking uracil (SCD-Ura) prepared as described in Kaiser et al., Methods in Yeast Genetics, Cold Spring Harbor Press, Cold Spring Harbor, NY, p. 208-210 (1994). Transformants were grown at 30°C for 2-3 days.

The detection of colonies secreting amylase was performed by including red starch in the selective growth media. Starch was coupled to the red dye (Reactive Red-120, Sigma) as per the procedure described by Biely et al., Anal. Biochem., 172:176-179 (1988). The coupled starch was incorporated into the SCD-Ura agar plates at a final concentration of 0.15% (w/v), and was buffered with potassium phosphate to a pH of 7.0 (50-100 mM final concentration).

The positive colonies were picked and streaked across fresh selective media (onto 150 mm plates) in order to obtain well isolated and identifiable single colonies. Well isolated single colonies positive for amylase secretion were detected by direct incorporation of red starch into buffered SCD-Ura agar. Positive colonies were determined by their ability to break down starch resulting in a clear halo around the positive colony visualized directly.

#### 4. Isolation of DNA by PCR Amplification

When a positive colony was isolated, a portion of it was picked by a toothpick and diluted into sterile water (30  $\mu$ l) in a 96 well plate. At this time, the positive colonies were either frozen and stored for subsequent analysis or immediately amplified. An aliquot of cells (5  $\mu$ l) was used as a template for the PCR reaction in a 25  $\mu$ l volume containing: 0.5  $\mu$ l Klentaq (Clontech, Palo Alto, CA); 4.0  $\mu$ l 10 mM dNTP's (Perkin Elmer-Cetus); 2.5  $\mu$ l Kentaq buffer (Clontech); 0.25  $\mu$ l forward oligo 1; 0.25  $\mu$ l reverse oligo 2; 12.5  $\mu$ l distilled water. The sequence of the forward oligonucleotide 1 was:

5'-TGTAACGACGGCCAGTTAAATAGACCTGCAATTATTAATCT-3' (SEQ ID NO:553)

The sequence of reverse oligonucleotide 2 was:

5'-CAGGAAACAGCTATGACCACCTGCACACCTGCAAATCCATT-3' (SEQ ID NO:554)

PCR was then performed as follows:

- |    |               |                  |
|----|---------------|------------------|
| a. | Denature      | 92°C, 5 minutes  |
| b. | 3 cycles of:  |                  |
|    | Denature      | 92°C, 30 seconds |
|    | Anneal        | 59°C, 30 seconds |
|    | Extend        | 72°C, 60 seconds |
| c. | 3 cycles of:  |                  |
|    | Denature      | 92°C, 30 seconds |
|    | Anneal        | 57°C, 30 seconds |
|    | Extend        | 72°C, 60 seconds |
| d. | 25 cycles of: |                  |
|    | Denature      | 92°C, 30 seconds |
|    | Anneal        | 55°C, 30 seconds |
|    | Extend        | 72°C, 60 seconds |

e.

Hold

4°C

The underlined regions of the oligonucleotides annealed to the ADH promoter region and the amylase region, respectively, and amplified a 307 bp region from vector pSST-AMY.0 when no insert was present. Typically, the first 18 nucleotides of the 5' end of these oligonucleotides contained annealing sites for the sequencing primers. Thus, the total product of the PCR reaction from an empty vector was 343 bp. However, signal sequence-fused cDNA resulted in considerably longer nucleotide sequences.

Following the PCR, an aliquot of the reaction (5 µl) was examined by agarose gel electrophoresis in a 1% agarose gel using a Tris-Borate-EDTA (TBE) buffering system as described by Sambrook et al., *supra*. Clones resulting in a single strong PCR product larger than 400 bp were further analyzed by DNA sequencing after purification with a 96 Qiaquick PCR clean-up column (Qiagen Inc., Chatsworth, CA).

### EXAMPLE 3: Isolation of cDNA Clones Using Signal Algorithm Analysis

Various polypeptide-encoding nucleic acid sequences were identified by applying a proprietary signal sequence finding algorithm developed by Genentech, Inc. (South San Francisco, CA) upon ESTs as well as clustered and assembled EST fragments from public (e.g., GenBank) and/or private (LIFESEQ®, Incyte Pharmaceuticals, Inc., Palo Alto, CA) databases. The signal sequence algorithm computes a secretion signal score based on the character of the DNA nucleotides surrounding the first and optionally the second methionine codon(s) (ATG) at the 5'-end of the sequence or sequence fragment under consideration. The nucleotides following the first ATG must code for at least 35 unambiguous amino acids without any stop codons. If the first ATG has the required amino acids, the second is not examined. If neither meets the requirement, the candidate sequence is not scored. In order to determine whether the EST sequence contains an authentic signal sequence, the DNA and corresponding amino acid sequences surrounding the ATG codon are scored using a set of seven sensors (evaluation parameters) known to be associated with secretion signals. Use of this algorithm resulted in the identification of numerous polypeptide-encoding nucleic acid sequences.

### EXAMPLE 4: Isolation of cDNA clones Encoding Human PRO Polypeptides

Using the techniques described in Examples 1 to 3 above, numerous full-length cDNA clones were identified as encoding PRO polypeptides as disclosed herein. These cDNAs were then deposited under the terms of the Budapest Treaty with the American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209, USA (ATCC) as shown in Table 7 below.

Table 7

<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
DNA16438-1387	209771	April 14, 1998
DNA19360-2552	203654	February 9, 1999
DNA33455-1548	PTA-127	May 25, 1999
DNA37155-2651	PTA-429	July 27, 1999
DNA38269-2654	PTA-432	July 27, 1999
DNA40619-1220	209525	December 10, 1997



Table 7 (cont')

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA44174-2513	203577	January 12, 1999
	DNA44675-2662	PTA-430	July 27, 1999
	DNA45408-2615	PTA-203	June 8, 1999
5	DNA48606-1479	203040	July 1, 1998
	DNA52753-2656	PTA-611	August 31, 1999
	DNA53915-1258	209593	January 21, 1998
	DNA53991-2553	203649	February 9, 1999
	DNA54009-2517	203574	January 12, 1999
10	DNA56055-1643	PTA-129	May 25, 1999
	DNA57033-1403	209905	May 27, 1998
	DNA57252-1453	203585	January 12, 1999
	DNA58799-1652	203665	February 9, 1999
	DNA59770-2652	PTA-427	July 27, 1999
15	DNA59774-2665	PTA-615	August 31, 1999
	DNA60281-2518	203582	January 12, 1999
	DNA60736-2559	203838	March 9, 1999
	DNA61875-2653	PTA-428	July 27, 1999
	DNA62312-2558	203836	March 9, 1999
20	DNA62849-1604	PTA-205	June 8, 1999
	DNA66307-2661	PTA-431	July 27, 1999
	DNA66677-2535	203659	February 9, 1999
	DNA71235-1706	203584	January 12, 1999
	DNA71289-2547	PTA-126	May 25, 1999
25	DNA73775-1707	PTA-128	May 25, 1999
	DNA76385-1692	203664	February 9, 1999
	DNA76395-2527	203578	January 12, 1999
	DNA77622-2516	203554	December 22, 1998
	DNA77629-2573	203850	March 16, 1999
30	DNA77645-2648	PTA-45	May 11, 1999
	DNA79302-2521	203545	December 22, 1998
	DNA79865-2519	203544	December 22, 1998
	DNA80135-2655	PTA-234	June 15, 1999
	DNA80794-2568	203848	March 16, 1999
35	DNA80796-2523	203555	December 22, 1998
	DNA80840-2605	203949	April 20, 1999
	DNA80899-2501	203539	December 15, 1998
	DNA81228-2580	203871	March 23, 1999
	DNA81761-2583	203862	March 23, 1999
40	DNA82358-2738	PTA-510	August 10, 1999
	DNA82364-2538	203603	January 20, 1999
	DNA82424-2566	203813	March 2, 1999
	DNA82430-2557	203812	March 2, 1999
	DNA83500-2506	203391	October 29, 1998
45	DNA83509-2612	203965	April 27, 1999
	DNA83560-2569	203816	March 2, 1999
	DNA84139-2555	203814	March 2, 1999
	DNA84141-2556	203810	March 2, 1999
	DNA84142-2613	PTA-22	May 4, 1999
50	DNA84318-2520	203580	January 12, 1999
	DNA84909-2590	203889	March 30, 1999
	DNA84912-2610	203964	April 27, 1999
	DNA84925-2514	203548	December 22, 1998
	DNA84928-2564	203817	March 2, 1999
55	DNA84932-2657	PTA-235	June 15, 1999

Table 7 (cont')

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA86592-2607	203968	April 27, 1999
	DNA86594-2587	203894	March 30, 1999
	DNA86647-2591	203893	March 30, 1999
5	DNA87185-2563	203811	March 2, 1999
	DNA87656-2582	203867	March 23, 1999
	DNA87974-2609	203963	April 27, 1999
	DNA88001-2565	203815	March 2, 1999
	DNA88004-2575	203890	March 30, 1999
10	DNA89220-2608	PTA-130	May 25, 1999
	DNA89947-2618	203970	April 27, 1999
	DNA90842-2574	203845	March 16, 1999
	DNA91775-2581	203861	March 23, 1999
	DNA91779-2571	203844	March 16, 1999
15	DNA92217-2697	PTA-513	August 10, 1999
	DNA92219-2541	203663	February 9, 1999
	DNA92223-2567	203851	March 16, 1999
	DNA92225-2603	203950	April 20, 1999
	DNA92232-2589	203895	March 30, 1999
20	DNA92233-2599	PTA-134	May 25, 1999
	DNA92243-2549	203852	March 16, 1999
	DNA92253-2671	PTA-258	June 22, 1999
	DNA92254-2672	PTA-259	June 22, 1999
	DNA92255-2584	203866	March 23, 1999
25	DNA92269-2570	203853	March 16, 1999
	DNA92288-2588	203892	March 30, 1999
	DNA92290-2550	203847	March 16, 1999
	DNA93012-2622	PTA-21	May 4, 1999
	DNA93020-2642	PTA-121	May 25, 1999
30	DNA94830-2604	203951	April 20, 1999
	DNA94833-2579	203869	March 23, 1999
	DNA94838-2658	PTA-232	June 15, 1999
	DNA94844-2686	PTA-385	July 20, 1999
	DNA94854-2586	203864	March 23, 1999
35	DNA96868-2677	PTA-262	June 22, 1999
	DNA96871-2683	PTA-381	July 20, 1999
	DNA96880-2624	PTA-15	May 4, 1999
	DNA96986-2660	PTA-239	June 15, 1999
	DNA96988-2685	PTA-384	July 20, 1999
40	DNA96995-2709	PTA-475	August 3, 1999
	DNA97004-2562	203854	March 16, 1999
	DNA97005-2687	PTA-378	July 20, 1999
	DNA97009-2668	PTA-257	June 22, 1999
	DNA97013-2667	PTA-231	June 15, 1999
45	DNA98380-2690	PTA-388	July 20, 1999
	DNA98561-2696	PTA-620	August 31, 1999
	DNA98575-2644	PTA-118	May 25, 1999
	DNA98593-2694	PTA-477	August 3, 1999
	DNA98600-2703	PTA-488	August 3, 1999
50	DNA99391-2572	203849	March 16, 1999
	DNA99393-2560	203837	March 9, 1999
	DNA100276-2684	PTA-380	July 20, 1999
	DNA100312-2645	PTA-44	May 11, 1999
	DNA100902-2646	PTA-42	May 11, 1999
55	DNA102899-2679	PTA-123	May 25, 1999

Table 7 (cont')

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA104875-2720	PTA-482	August 3, 1999
	DNA105680-2710	PTA-483	August 3, 1999
	DNA105779-2708	PTA-485	August 3, 1999
5	DNA105794-2695	PTA-480	August 3, 1999
	DNA105838-2702	PTA-476	August 3, 1999
	DNA107698-2715	PTA-472	August 3, 1999
	DNA107701-2711	PTA-487	August 3, 1999
	DNA107781-2707	PTA-484	August 3, 1999
10	DNA108670-2744	PTA-546	August 17, 1999
	DNA108688-2725	PTA-515	August 10, 1999
	DNA108769-2765	PTA-861	October 19, 1999
	DNA108935-2721	PTA-518	August 10, 1999
	DNA110700-2716	PTA-512	August 10, 1999
15	DNA111750-2706	PTA-489	August 3, 1999
	DNA123430-2755	PTA-614	August 31, 1999
	DNA125154-2785	PTA-957	November 16, 1999
	DNA142238-2768	PTA-819	October 5, 1999
	DNA22779-1130	209280	September 18, 1997
20	DNA26847-1395	209772	April 14, 1998
	DNA27864-1155	209375	October 16, 1997
	DNA27865-1091	209296	September 23, 1997
	DNA28497-1130	209279	September 18, 1997
	DNA29101-1122	209653	March 5, 1998
25	DNA32286-1191	209385	October 16, 1997
	DNA32288-1132	209261	September 16, 1997
	DNA32290-1164	209384	October 16, 1997
	DNA32292-1131	209258	September 16, 1997
	DNA32298-1132	209257	September 16, 1997
30	DNA33085-1110	209087	May 30, 1997
	DNA33087-1158	209381	October 16, 1997
	DNA33089-1132	209262	September 16, 1997
	DNA33092-1202	209420	October 28, 1997
	DNA33094-1131	209256	September 16, 1997
35	DNA33107-1135	209251	September 16, 1997
	DNA33221-1133	209263	September 16, 1997
	DNA33223-1136	209264	September 16, 1997
	DNA33460-1166	209376	October 16, 1997
	DNA33473-1176	209391	October 17, 1997
40	DNA33785-1143	209417	October 28, 1997
	DNA33786-1132	209253	September 16, 1997
	DNA34353-1428	209855	May 12, 1998
	DNA34392-1170	209526	December 10, 1997
	DNA34434-1139	209252	September 16, 1997
45	DNA35558-1167	209374	October 16, 1997
	DNA35595-1228	209528	December 10, 1997
	DNA35638-1216	209265	September 16, 1997
	DNA35639-1172	209396	October 17, 1997
	DNA35663-1129	209201	August 18, 1997
50	DNA35674-1142	209416	October 28, 1997
	DNA35841-1173	209403	October 17, 1997
	DNA35916-1161	209419	October 28, 1997
	DNA35918-1174	209402	October 17, 1997
	DNA36350-1158	209378	October 16, 1997
55	DNA37140-1234	209489	November 21, 1997

Table 7 (cont')

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA37150-1178	209401	October 17, 1997
	DNA38260-1180	209397	October 17, 1997
	DNA40021-1154	209389	October 17, 1997
5	DNA40587-1231	209438	November 7, 1997
	DNA40592-1242	209492	November 21, 1997
	DNA40620-1183	209388	October 17, 1997
	DNA40628-1216	209432	November 7, 1997
	DNA40981-1234	209439	November 7, 1997
10	DNA40982-1235	209433	November 7, 1997
	DNA41234-1242	209618	February 5, 1998
	DNA43046-1225	209484	November 21, 1997
	DNA43316-1237	209487	November 21, 1997
	DNA44167-1243	209434	November 7, 1997
15	DNA44184-1319	209704	March 26, 1998
	DNA44194-1317	209808	April 28, 1998
	DNA44196-1353	209847	May 6, 1998
	DNA45419-1252	209616	February 5, 1998
	DNA46777-1253	209619	February 5, 1998
20	DNA47394-1572	203109	August 11, 1998
	DNA48331-1329	209715	March 31, 1998
	DNA48336-1309	209669	March 11, 1998
	DNA49142-1430	203002	June 23, 1998
	DNA49646-1327	209705	March 26, 1998
25	DNA49821-1562	209981	June 16, 1998
	DNA49829-1346	209749	April 7, 1998
	DNA50921-1458	209859	May 12, 1998
	DNA52187-1354	209845	May 6, 1998
	DNA52196-1348	209748	April 7, 1998
30	DNA52598-1518	203107	August 11, 1998
	DNA54228-1366	209801	April 23, 1998
	DNA56047-1456	209948	June 9, 1998
	DNA56112-1379	209883	May 20, 1998
	DNA56113-1378	203049	July 1, 1998
35	DNA56352-1358	209846	May 6, 1998
	DNA56433-1406	209857	May 12, 1998
	DNA56439-1376	209864	May 14, 1998
	DNA57530-1375	209880	May 20, 1998
	DNA57689-1385	209869	May 14, 1998
40	DNA57690-1374	209950	June 9, 1998
	DNA57693-1424	203008	June 23, 1998
	DNA57838-1337	203014	June 23, 1998
	DNA58721-1475	203110	August 11, 1998
	DNA59205-1421	203009	June 23, 1998
45	DNA59215-1425	209961	June 9, 1998
	DNA59220-1514	209962	June 9, 1998
	DNA59294-1381	209866	May 14, 1998
	DNA59488-1603	203157	August 25, 1998
	DNA59588-1571	203106	August 11, 1998
50	DNA59606-1471	209945	June 9, 1998
	DNA59620-1463	209989	June 16, 1998
	DNA59767-1489	203108	August 11, 1998
	DNA59777-1480	203111	August 11, 1998
	DNA59814-1486	203359	October 20, 1998
55	DNA59839-1461	209988	June 16, 1998

Table 7 (cont')

	<u>Material</u>	<u>ATCC Dep. No.</u>	<u>Deposit Date</u>
	DNA59846-1503	209978	June 16, 1998
	DNA59847-1511	203098	August 4, 1998
	DNA60615-1483	209980	June 16, 1998
5	DNA60621-1516	203091	August 4, 1998
	DNA60622-1525	203090	August 4, 1998
	DNA60627-1508	203092	August 4, 1998
	DNA60764-1533	203452	November 10, 1998
	DNA60775-1532	203173	September 1, 1998
10	DNA61185-1646	203464	November 17, 1998
	DNA61873-1574	203132	August 18, 1998
	DNA62306-1570	203254	September 9, 1998
	DNA62808-1582	203358	October 20, 1998
	DNA62814-1521	203093	August 4, 1998
15	DNA64885-1529	203457	November 3, 1998
	DNA64886-1601	203241	September 9, 1998
	DNA64888-1542	203249	September 9, 1998
	DNA64889-1541	203250	September 9, 1998
	DNA64890-1612	203131	August 18, 1998
20	DNA64903-1553	203223	September 15, 1998
	DNA64905-1558	203233	September 15, 1998
	DNA65402-1540	203252	September 9, 1998
	DNA65405-1547	203476	November 17, 1998
	DNA65412-1523	203094	August 4, 1998
25	DNA66309-1538	203235	September 15, 1998
	DNA66667-1596	203267	September 22, 1998
	DNA66675-1587	203282	September 22, 1998
	DNA68818-2536	203657	February 9, 1999
	DNA68864-1629	203276	September 22, 1998
30	DNA68872-1620	203160	August 25, 1998
	DNA71159-1617	203135	August 18, 1998
	DNA73727-1673	203459	November 3, 1998
	DNA73739-1645	203270	September 22, 1998
	DNA76400-2528	203573	January 12, 1999
35	DNA76510-2504	203477	November 17, 1998
	DNA76529-1666	203315	October 6, 1998
	DNA76538-1670	203313	October 6, 1998
	DNA77301-1708	203407	October 27, 1998
	DNA77624-2515	203553	December 22, 1998
40	DNA79230-2525	203549	December 22, 1998
	DNA79862-2522	203550	December 22, 1998
	DNA80145-2594	PTA-204	June 8, 1999
	DNA83500-2506	203391	October 29, 1998
	DNA84917-2597	203863	March 23, 1999
45	DNA92218-2554	203834	March 9, 1999
	DNA96042-2682	PTA-382	July 20, 1999

These deposits were made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations thereunder (Budapest Treaty). This assures maintenance of a viable culture of the deposit for 30 years from the date of deposit. The deposits will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between Genentech, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of

the culture of the deposit to the public upon issuance of the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC § 122 and the Commissioner's rules pursuant thereto (including 37 CFR § 1.14 with particular reference to 886 OG 638).

5           The assignee of the present application has agreed that if a culture of the materials on deposit should die or be lost or destroyed when cultivated under suitable conditions, the materials will be promptly replaced on notification with another of the same. Availability of the deposited material is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

10           EXAMPLE 5: Use of PRO as a hybridization probe

          The following method describes use of a nucleotide sequence encoding PRO as a hybridization probe.

          DNA comprising the coding sequence of full-length or mature PRO as disclosed herein is employed as a probe to screen for homologous DNAs (such as those encoding naturally-occurring variants of PRO) in human  
15       tissue cDNA libraries or human tissue genomic libraries.

          Hybridization and washing of filters containing either library DNAs is performed under the following high stringency conditions. Hybridization of radiolabeled PRO-derived probe to the filters is performed in a solution of 50% formamide, 5x SSC, 0.1% SDS, 0.1% sodium pyrophosphate, 50 mM sodium phosphate, pH 6.8, 2x Denhardt's solution, and 10% dextran sulfate at 42°C for 20 hours. Washing of the filters is performed  
20       in an aqueous solution of 0.1x SSC and 0.1% SDS at 42°C.

          DNAs having a desired sequence identity with the DNA encoding full-length native sequence PRO can then be identified using standard techniques known in the art.

EXAMPLE 6: Expression of PRO in *E. coli*

25           This example illustrates preparation of an unglycosylated form of PRO by recombinant expression in *E. coli*.

          The DNA sequence encoding PRO is initially amplified using selected PCR primers. The primers should contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector. A variety of expression vectors may be employed. An example of a suitable vector is  
30       pBR322 (derived from *E. coli*; see Bolivar et al., Gene, 2:95 (1977)) which contains genes for ampicillin and tetracycline resistance. The vector is digested with restriction enzyme and dephosphorylated. The PCR amplified sequences are then ligated into the vector. The vector will preferably include sequences which encode for an antibiotic resistance gene, a trp promoter, a polyhis leader (including the first six STII codons, polyhis sequence, and enterokinase cleavage site), the PRO coding region, lambda transcriptional terminator, and an  
35       argU gene.

          The ligation mixture is then used to transform a selected *E. coli* strain using the methods described in Sambrook et al., supra. Transformants are identified by their ability to grow on LB plates and antibiotic resistant

colonies are then selected. Plasmid DNA can be isolated and confirmed by restriction analysis and DNA sequencing.

Selected clones can be grown overnight in liquid culture medium such as LB broth supplemented with antibiotics. The overnight culture may subsequently be used to inoculate a larger scale culture. The cells are then grown to a desired optical density, during which the expression promoter is turned on.

5 After culturing the cells for several more hours, the cells can be harvested by centrifugation. The cell pellet obtained by the centrifugation can be solubilized using various agents known in the art, and the solubilized PRO protein can then be purified using a metal chelating column under conditions that allow tight binding of the protein.

10 PRO may be expressed in *E. coli* in a poly-His tagged form, using the following procedure. The DNA encoding PRO is initially amplified using selected PCR primers. The primers will contain restriction enzyme sites which correspond to the restriction enzyme sites on the selected expression vector, and other useful sequences providing for efficient and reliable translation initiation, rapid purification on a metal chelation column, and proteolytic removal with enterokinase. The PCR-amplified, poly-His tagged sequences are then ligated into an expression vector, which is used to transform an *E. coli* host based on strain 52 (W3110  
15 *fuhA(tonA) lon galE rpoHts(htpRts) clpP(lacIq)*. Transformants are first grown in LB containing 50 mg/ml carbenicillin at 30°C with shaking until an O.D.600 of 3-5 is reached. Cultures are then diluted 50-100 fold into CRAP media (prepared by mixing 3.57 g (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.71 g sodium citrate•2H<sub>2</sub>O, 1.07 g KCl, 5.36 g Difco yeast extract, 5.36 g Sheffield hycase SF in 500 mL water, as well as 110 mM MPOS, pH 7.3, 0.55% (w/v) glucose and 7 mM MgSO<sub>4</sub>) and grown for approximately 20-30 hours at 30°C with shaking. Samples are  
20 removed to verify expression by SDS-PAGE analysis, and the bulk culture is centrifuged to pellet the cells. Cell pellets are frozen until purification and refolding.

*E. coli* paste from 0.5 to 1 L fermentations (6-10 g pellets) is resuspended in 10 volumes (w/v) in 7 M guanidine, 20 mM Tris, pH 8 buffer. Solid sodium sulfite and sodium tetrathionate is added to make final concentrations of 0.1M and 0.02 M, respectively, and the solution is stirred overnight at 4°C. This step results  
25 in a denatured protein with all cysteine residues blocked by sulfitolization. The solution is centrifuged at 40,000 rpm in a Beckman Ultracentrifuge for 30 min. The supernatant is diluted with 3-5 volumes of metal chelate column buffer (6 M guanidine, 20 mM Tris, pH 7.4) and filtered through 0.22 micron filters to clarify. The clarified extract is loaded onto a 5 ml Qiagen Ni-NTA metal chelate column equilibrated in the metal chelate column buffer. The column is washed with additional buffer containing 50 mM imidazole (Calbiochem, Utrol grade), pH 7.4. The protein is eluted with buffer containing 250 mM imidazole. Fractions containing the  
30 desired protein are pooled and stored at 4°C. Protein concentration is estimated by its absorbance at 280 nm using the calculated extinction coefficient based on its amino acid sequence.

The proteins are refolded by diluting the sample slowly into freshly prepared refolding buffer consisting of: 20 mM Tris, pH 8.6, 0.3 M NaCl, 2.5 M urea, 5 mM cysteine, 20 mM glycine and 1 mM EDTA.  
35 Refolding volumes are chosen so that the final protein concentration is between 50 to 100 micrograms/ml. The refolding solution is stirred gently at 4°C for 12-36 hours. The refolding reaction is quenched by the addition of TFA to a final concentration of 0.4% (pH of approximately 3). Before further purification of the protein, the

solution is filtered through a 0.22 micron filter and acetonitrile is added to 2-10% final concentration. The refolded protein is chromatographed on a Poros R1/H reversed phase column using a mobile buffer of 0.1% TFA with elution with a gradient of acetonitrile from 10 to 80%. Aliquots of fractions with A280 absorbance are analyzed on SDS polyacrylamide gels and fractions containing homogeneous refolded protein are pooled. Generally, the properly refolded species of most proteins are eluted at the lowest concentrations of acetonitrile since those species are the most compact with their hydrophobic interiors shielded from interaction with the reversed phase resin. Aggregated species are usually eluted at higher acetonitrile concentrations. In addition to resolving misfolded forms of proteins from the desired form, the reversed phase step also removes endotoxin from the samples.

Fractions containing the desired folded PRO polypeptide are pooled and the acetonitrile removed using a gentle stream of nitrogen directed at the solution. Proteins are formulated into 20 mM Hepes, pH 6.8 with 0.14 M sodium chloride and 4% mannitol by dialysis or by gel filtration using G25 Superfine (Pharmacia) resins equilibrated in the formulation buffer and sterile filtered.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

#### EXAMPLE 7: Expression of PRO in mammalian cells

This example illustrates preparation of a potentially glycosylated form of PRO by recombinant expression in mammalian cells.

The vector, pRK5 (see EP 307,247, published March 15, 1989), is employed as the expression vector. Optionally, the PRO DNA is ligated into pRK5 with selected restriction enzymes to allow insertion of the PRO DNA using ligation methods such as described in Sambrook et al., *supra*. The resulting vector is called pRK5-PRO.

In one embodiment, the selected host cells may be 293 cells. Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue culture plates in medium such as DMEM supplemented with fetal calf serum and optionally, nutrient components and/or antibiotics. About 10  $\mu$ g pRK5-PRO DNA is mixed with about 1  $\mu$ g DNA encoding the VA RNA gene [Thimmappaya et al., *Cell*, 31:543 (1982)] and dissolved in 500  $\mu$ l of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M  $\text{CaCl}_2$ . To this mixture is added, dropwise, 500  $\mu$ l of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM  $\text{NaPO}_4$ , and a precipitate is allowed to form for 10 minutes at 25°C. The precipitate is suspended and added to the 293 cells and allowed to settle for about four hours at 37°C. The culture medium is aspirated off and 2 ml of 20% glycerol in PBS is added for 30 seconds. The 293 cells are then washed with serum free medium, fresh medium is added and the cells are incubated for about 5 days.

Approximately 24 hours after the transfections, the culture medium is removed and replaced with culture medium (alone) or culture medium containing 200  $\mu$ Ci/ml  $^{35}\text{S}$ -cysteine and 200  $\mu$ Ci/ml  $^{35}\text{S}$ -methionine. After a 12 hour incubation, the conditioned medium is collected, concentrated on a spin filter, and loaded onto a 15% SDS gel. The processed gel may be dried and exposed to film for a selected period of time to reveal the presence of PRO polypeptide. The cultures containing transfected cells may undergo further incubation (in serum free medium) and the medium is tested in selected bioassays.



In an alternative technique, PRO may be introduced into 293 cells transiently using the dextran sulfate method described by Sompariyac et al., Proc. Natl. Acad. Sci., 12:7575 (1981). 293 cells are grown to maximal density in a spinner flask and 700  $\mu$ g pRK5-PRO DNA is added. The cells are first concentrated from the spinner flask by centrifugation and washed with PBS. The DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with tissue culture medium, and re-introduced into the spinner flask containing tissue culture medium, 5  $\mu$ g/ml bovine insulin and 0.1  $\mu$ g/ml bovine transferrin. After about four days, the conditioned media is centrifuged and filtered to remove cells and debris. The sample containing expressed PRO can then be concentrated and purified by any selected method, such as dialysis and/or column chromatography.

In another embodiment, PRO can be expressed in CHO cells. The pRK5-PRO can be transfected into CHO cells using known reagents such as  $\text{CaPO}_4$  or DEAE-dextran. As described above, the cell cultures can be incubated, and the medium replaced with culture medium (alone) or medium containing a radiolabel such as  $^{35}\text{S}$ -methionine. After determining the presence of PRO polypeptide, the culture medium may be replaced with serum free medium. Preferably, the cultures are incubated for about 6 days, and then the conditioned medium is harvested. The medium containing the expressed PRO can then be concentrated and purified by any selected method.

Epitope-tagged PRO may also be expressed in host CHO cells. The PRO may be subcloned out of the pRK5 vector. The subclone insert can undergo PCR to fuse in frame with a selected epitope tag such as a poly-his tag into a Baculovirus expression vector. The poly-his tagged PRO insert can then be subcloned into a SV40 driven vector containing a selection marker such as DHFR for selection of stable clones. Finally, the CHO cells can be transfected (as described above) with the SV40 driven vector. Labeling may be performed, as described above, to verify expression. The culture medium containing the expressed poly-His tagged PRO can then be concentrated and purified by any selected method, such as by  $\text{Ni}^{2+}$ -chelate affinity chromatography.

PRO may also be expressed in CHO and/or COS cells by a transient expression procedure or in CHO cells by another stable expression procedure.

Stable expression in CHO cells is performed using the following procedure. The proteins are expressed as an IgG construct (immunoadhesin), in which the coding sequences for the soluble forms (e.g. extracellular domains) of the respective proteins are fused to an IgG1 constant region sequence containing the hinge, CH2 and CH2 domains and/or is a poly-His tagged form.

Following PCR amplification, the respective DNAs are subcloned in a CHO expression vector using standard techniques as described in Ausubel et al., Current Protocols of Molecular Biology, Unit 3.16, John Wiley and Sons (1997). CHO expression vectors are constructed to have compatible restriction sites 5' and 3' of the DNA of interest to allow the convenient shuttling of cDNA's. The vector used expression in CHO cells is as described in Lucas et al., Nucl. Acids Res. 24:9 (1774-1779 (1996), and uses the SV40 early promoter/enhancer to drive expression of the cDNA of interest and dihydrofolate reductase (DHFR). DHFR expression permits selection for stable maintenance of the plasmid following transfection.

Twelve micrograms of the desired plasmid DNA is introduced into approximately 10 million CHO cells using commercially available transfection reagents Superfect<sup>®</sup> (Quiagen), Dosper<sup>®</sup> or Fugene<sup>®</sup> (Boehringer

Mannheim). The cells are grown as described in Lucas et al., *supra*. Approximately  $3 \times 10^7$  cells are frozen in an ampule for further growth and production as described below.

The ampules containing the plasmid DNA are thawed by placement into water bath and mixed by vortexing. The contents are pipetted into a centrifuge tube containing 10 mLs of media and centrifuged at 1000 rpm for 5 minutes. The supernatant is aspirated and the cells are resuspended in 10 mL of selective media (0.2  $\mu$ m filtered PS20 with 5% 0.2  $\mu$ m diafiltered fetal bovine serum). The cells are then aliquoted into a 100 mL spinner containing 90 mL of selective media. After 1-2 days, the cells are transferred into a 250 mL spinner filled with 150 mL selective growth medium and incubated at 37°C. After another 2-3 days, 250 mL, 500 mL and 2000 mL spinners are seeded with  $3 \times 10^5$  cells/mL. The cell media is exchanged with fresh media by centrifugation and resuspension in production medium. Although any suitable CHO media may be employed, a production medium described in U.S. Patent No. 5,122,469, issued June 16, 1992 may actually be used. A 3L production spinner is seeded at  $1.2 \times 10^6$  cells/mL. On day 0, the cell number pH is determined. On day 1, the spinner is sampled and sparging with filtered air is commenced. On day 2, the spinner is sampled, the temperature shifted to 33°C, and 30 mL of 500 g/L glucose and 0.6 mL of 10% antifoam (e.g., 35% polydimethylsiloxane emulsion, Dow Corning 365 Medical Grade Emulsion) taken. Throughout the production, the pH is adjusted as necessary to keep it at around 7.2. After 10 days, or until the viability dropped below 70%, the cell culture is harvested by centrifugation and filtering through a 0.22  $\mu$ m filter. The filtrate was either stored at 4°C or immediately loaded onto columns for purification.

For the poly-His tagged constructs, the proteins are purified using a Ni-NTA column (Qiagen). Before purification, imidazole is added to the conditioned media to a concentration of 5 mM. The conditioned media is pumped onto a 6 ml Ni-NTA column equilibrated in 20 mM Hepes, pH 7.4, buffer containing 0.3 M NaCl and 5 mM imidazole at a flow rate of 4-5 ml/min. at 4°C. After loading, the column is washed with additional equilibration buffer and the protein eluted with equilibration buffer containing 0.25 M imidazole. The highly purified protein is subsequently desalted into a storage buffer containing 10 mM Hepes, 0.14 M NaCl and 4% mannitol, pH 6.8, with a 25 ml G25 Superfine (Pharmacia) column and stored at -80°C.

Immunoadhesin (Fc-containing) constructs are purified from the conditioned media as follows. The conditioned medium is pumped onto a 5 ml Protein A column (Pharmacia) which had been equilibrated in 20 mM Na phosphate buffer, pH 6.8. After loading, the column is washed extensively with equilibration buffer before elution with 100 mM citric acid, pH 3.5. The eluted protein is immediately neutralized by collecting 1 ml fractions into tubes containing 275  $\mu$ L of 1 M Tris buffer, pH 9. The highly purified protein is subsequently desalted into storage buffer as described above for the poly-His tagged proteins. The homogeneity is assessed by SDS polyacrylamide gels and by N-terminal amino acid sequencing by Edman degradation.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

#### EXAMPLE 8: Expression of PRO in Yeast

The following method describes recombinant expression of PRO in yeast.

First, yeast expression vectors are constructed for intracellular production or secretion of PRO from the ADH2/GAPDH promoter. DNA encoding PRO and the promoter is inserted into suitable restriction enzyme

sites in the selected plasmid to direct intracellular expression of PRO. For secretion, DNA encoding PRO can be cloned into the selected plasmid, together with DNA encoding the ADH2/GAPDH promoter, a native PRO signal peptide or other mammalian signal peptide, or, for example, a yeast alpha-factor or invertase secretory signal/leader sequence, and linker sequences (if needed) for expression of PRO.

Yeast cells, such as yeast strain AB110, can then be transformed with the expression plasmids described above and cultured in selected fermentation media. The transformed yeast supernatants can be analyzed by precipitation with 10% trichloroacetic acid and separation by SDS-PAGE, followed by staining of the gels with Coomassie Blue stain.

Recombinant PRO can subsequently be isolated and purified by removing the yeast cells from the fermentation medium by centrifugation and then concentrating the medium using selected cartridge filters. The concentrate containing PRO may further be purified using selected column chromatography resins.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

#### EXAMPLE 9: Expression of PRO in Baculovirus-Infected Insect Cells

The following method describes recombinant expression of PRO in Baculovirus-infected insect cells.

The sequence coding for PRO is fused upstream of an epitope tag contained within a baculovirus expression vector. Such epitope tags include poly-his tags and immunoglobulin tags (like Fc regions of IgG). A variety of plasmids may be employed, including plasmids derived from commercially available plasmids such as pVL1393 (Novagen). Briefly, the sequence encoding PRO or the desired portion of the coding sequence of PRO such as the sequence encoding the extracellular domain of a transmembrane protein or the sequence encoding the mature protein if the protein is extracellular is amplified by PCR with primers complementary to the 5' and 3' regions. The 5' primer may incorporate flanking (selected) restriction enzyme sites. The product is then digested with those selected restriction enzymes and subcloned into the expression vector.

Recombinant baculovirus is generated by co-transfecting the above plasmid and BaculoGold™ virus DNA (PharMingen) into *Spodoptera frugiperda* ("Sf9") cells (ATCC CRL 1711) using lipofectin (commercially available from GIBCO-BRL). After 4 - 5 days of incubation at 28°C, the released viruses are harvested and used for further amplifications. Viral infection and protein expression are performed as described by O'Reilley et al., Baculovirus expression vectors: A Laboratory Manual, Oxford: Oxford University Press (1994).

Expressed poly-his tagged PRO can then be purified, for example, by Ni<sup>2+</sup>-chelate affinity chromatography as follows. Extracts are prepared from recombinant virus-infected Sf9 cells as described by Rupert et al., Nature, 362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM MgCl<sub>2</sub>; 0.1 mM EDTA; 10% glycerol; 0.1 % NP-40; 0.4 M KCl), and sonicated twice for 20 seconds on ice. The sonicates are cleared by centrifugation, and the supernatant is diluted 50-fold in loading buffer (50 mM phosphate, 300 mM NaCl, 10% glycerol, pH 7.8) and filtered through a 0.45 μm filter. A Ni<sup>2+</sup>-NTA agarose column (commercially available from Qiagen) is prepared with a bed volume of 5 mL, washed with 25 mL of water and equilibrated with 25 mL of loading buffer. The filtered cell extract is loaded onto the column at 0.5 mL per minute. The column is washed to baseline A<sub>280</sub> with loading buffer, at which point fraction collection is started. Next, the column is washed with a secondary wash buffer (50 mM

phosphate; 300 mM NaCl, 10% glycerol, pH 6.0), which elutes nonspecifically bound protein. After reaching  $A_{280}$  baseline again, the column is developed with a 0 to 500 mM Imidazole gradient in the secondary wash buffer. One mL fractions are collected and analyzed by SDS-PAGE and silver staining or Western blot with  $Ni^{2+}$ -NTA-conjugated to alkaline phosphatase (Qiagen). Fractions containing the eluted His<sub>10</sub>-tagged PRO are pooled and dialyzed against loading buffer.

Alternatively, purification of the IgG tagged (or Fc tagged) PRO can be performed using known chromatography techniques, including for instance, Protein A or protein G column chromatography.

Many of the PRO polypeptides disclosed herein were successfully expressed as described above.

#### EXAMPLE 10: Preparation of Antibodies that Bind PRO

This example illustrates preparation of monoclonal antibodies which can specifically bind PRO.

Techniques for producing the monoclonal antibodies are known in the art and are described, for instance, in Goding, *supra*. Immunogens that may be employed include purified PRO, fusion proteins containing PRO, and cells expressing recombinant PRO on the cell surface. Selection of the immunogen can be made by the skilled artisan without undue experimentation.

Mice, such as Balb/c, are immunized with the PRO immunogen emulsified in complete Freund's adjuvant and injected subcutaneously or intraperitoneally in an amount from 1-100 micrograms. Alternatively, the immunogen is emulsified in MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, MT) and injected into the animal's hind foot pads. The immunized mice are then boosted 10 to 12 days later with additional immunogen emulsified in the selected adjuvant. Thereafter, for several weeks, the mice may also be boosted with additional immunization injections. Serum samples may be periodically obtained from the mice by retro-orbital bleeding for testing in ELISA assays to detect anti-PRO antibodies.

After a suitable antibody titer has been detected, the animals "positive" for antibodies can be injected with a final intravenous injection of PRO. Three to four days later, the mice are sacrificed and the spleen cells are harvested. The spleen cells are then fused (using 35% polyethylene glycol) to a selected murine myeloma cell line such as P3X63AgU.1, available from ATCC, No. CRL 1597. The fusions generate hybridoma cells which can then be plated in 96 well tissue culture plates containing HAT (hypoxanthine, aminopterin, and thymidine) medium to inhibit proliferation of non-fused cells, myeloma hybrids, and spleen cell hybrids.

The hybridoma cells will be screened in an ELISA for reactivity against PRO. Determination of "positive" hybridoma cells secreting the desired monoclonal antibodies against PRO is within the skill in the art.

The positive hybridoma cells can be injected intraperitoneally into syngeneic Balb/c mice to produce ascites containing the anti-PRO monoclonal antibodies. Alternatively, the hybridoma cells can be grown in tissue culture flasks or roller bottles. Purification of the monoclonal antibodies produced in the ascites can be accomplished using ammonium sulfate precipitation, followed by gel exclusion chromatography. Alternatively, affinity chromatography based upon binding of antibody to protein A or protein G can be employed.

**EXAMPLE 11: Purification of PRO Polypeptides Using Specific Antibodies**

Native or recombinant PRO polypeptides may be purified by a variety of standard techniques in the art of protein purification. For example, pro-PRO polypeptide, mature PRO polypeptide, or pre-PRO polypeptide is purified by immunoaffinity chromatography using antibodies specific for the PRO polypeptide of interest. In general, an immunoaffinity column is constructed by covalently coupling the anti-PRO polypeptide antibody to an activated chromatographic resin.

Polyclonal immunoglobulins are prepared from immune sera either by precipitation with ammonium sulfate or by purification on immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway, N.J.). Likewise, monoclonal antibodies are prepared from mouse ascites fluid by ammonium sulfate precipitation or chromatography on immobilized Protein A. Partially purified immunoglobulin is covalently attached to a chromatographic resin such as CnBr-activated SEPHAROSE™ (Pharmacia LKB Biotechnology). The antibody is coupled to the resin, the resin is blocked, and the derivative resin is washed according to the manufacturer's instructions.

Such an immunoaffinity column is utilized in the purification of PRO polypeptide by preparing a fraction from cells containing PRO polypeptide in a soluble form. This preparation is derived by solubilization of the whole cell or of a subcellular fraction obtained via differential centrifugation by the addition of detergent or by other methods well known in the art. Alternatively, soluble PRO polypeptide containing a signal sequence may be secreted in useful quantity into the medium in which the cells are grown.

A soluble PRO polypeptide-containing preparation is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of PRO polypeptide (*e.g.*, high ionic strength buffers in the presence of detergent). Then, the column is eluted under conditions that disrupt antibody/PRO polypeptide binding (*e.g.*, a low pH buffer such as approximately pH 2-3, or a high concentration of a chaotrope such as urea or thiocyanate ion), and PRO polypeptide is collected.

**EXAMPLE 12: Drug Screening**

This invention is particularly useful for screening compounds by using PRO polypeptides or binding fragment thereof in any of a variety of drug screening techniques. The PRO polypeptide or fragment employed in such a test may either be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the PRO polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. Such cells, either in viable or fixed form, can be used for standard binding assays. One may measure, for example, the formation of complexes between PRO polypeptide or a fragment and the agent being tested. Alternatively, one can examine the diminution in complex formation between the PRO polypeptide and its target cell or target receptors caused by the agent being tested.

Thus, the present invention provides methods of screening for drugs or any other agents which can affect a PRO polypeptide-associated disease or disorder. These methods comprise contacting such an agent with an PRO polypeptide or fragment thereof and assaying (i) for the presence of a complex between the agent and the PRO polypeptide or fragment, or (ii) for the presence of a complex between the PRO polypeptide or fragment

and the cell, by methods well known in the art. In such competitive binding assays, the PRO polypeptide or fragment is typically labeled. After suitable incubation, free PRO polypeptide or fragment is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of the particular agent to bind to PRO polypeptide or to interfere with the PRO polypeptide/cell complex.

Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to a polypeptide and is described in detail in WO 84/03564, published on September 13, 1984. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. As applied to a PRO polypeptide, the peptide test compounds are reacted with PRO polypeptide and washed. Bound PRO polypeptide is detected by methods well known in the art. Purified PRO polypeptide can also be coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies can be used to capture the peptide and immobilize it on the solid support.

This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding PRO polypeptide specifically compete with a test compound for binding to PRO polypeptide or fragments thereof. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PRO polypeptide.

#### EXAMPLE 13: Rational Drug Design

The goal of rational drug design is to produce structural analogs of biologically active polypeptide of interest (*i.e.*, a PRO polypeptide) or of small molecules with which they interact, *e.g.*, agonists, antagonists, or inhibitors. Any of these examples can be used to fashion drugs which are more active or stable forms of the PRO polypeptide or which enhance or interfere with the function of the PRO polypeptide *in vivo* (*c.f.*, Hodgson, Bio/Technology, 9: 19-21 (1991)).

In one approach, the three-dimensional structure of the PRO polypeptide, or of an PRO polypeptide-inhibitor complex, is determined by x-ray crystallography, by computer modeling or, most typically, by a combination of the two approaches. Both the shape and charges of the PRO polypeptide must be ascertained to elucidate the structure and to determine active site(s) of the molecule. Less often, useful information regarding the structure of the PRO polypeptide may be gained by modeling based on the structure of homologous proteins. In both cases, relevant structural information is used to design analogous PRO polypeptide-like molecules or to identify efficient inhibitors. Useful examples of rational drug design may include molecules which have improved activity or stability as shown by Braxton and Wells, Biochemistry, 31:7796-7801 (1992) or which act as inhibitors, agonists, or antagonists of native peptides as shown by Athauda *et al.*, J. Biochem., 113:742-746 (1993).

It is also possible to isolate a target-specific antibody, selected by functional assay, as described above, and then to solve its crystal structure. This approach, in principle, yields a pharmacore upon which subsequent drug design can be based. It is possible to bypass protein crystallography altogether by generating anti-idiotypic antibodies (anti-ids) to a functional, pharmacologically active antibody. As a mirror image of a mirror image, the binding site of the anti-ids would be expected to be an analog of the original receptor. The anti-id could then

be used to identify and isolate peptides from banks of chemically or biologically produced peptides. The isolated peptides would then act as the pharmacore.

By virtue of the present invention, sufficient amounts of the PRO polypeptide may be made available to perform such analytical studies as X-ray crystallography. In addition, knowledge of the PRO polypeptide amino acid sequence provided herein will provide guidance to those employing computer modeling techniques in place of or in addition to x-ray crystallography.

**EXAMPLE 14: Identification of PRO Polypeptides That Stimulate TNF- $\alpha$  Release In Human Blood (Assay 128)**

This assay shows that certain PRO polypeptides of the present invention act to stimulate the release of TNF- $\alpha$  in human blood. PRO polypeptides testing positive in this assay are useful for, among other things, research purposes where stimulation of the release of TNF- $\alpha$  would be desired and for the therapeutic treatment of conditions wherein enhanced TNF- $\alpha$  release would be beneficial. Specifically, 200  $\mu$ l of human blood supplemented with 50mM Hepes buffer (pH 7.2) is aliquoted per well in a 96 well test plate. To each well is then added 300 $\mu$ l of either the test PRO polypeptide in 50 mM Hepes buffer (at various concentrations) or 50 mM Hepes buffer alone (negative control) and the plates are incubated at 37°C for 6 hours. The samples are then centrifuged and 50 $\mu$ l of plasma is collected from each well and tested for the presence of TNF- $\alpha$  by ELISA assay. A positive in the assay is a higher amount of TNF- $\alpha$  in the PRO polypeptide treated samples as compared to the negative control samples.

The following PRO polypeptides tested positive in this assay: PRO195, PRO202, PRO215, PRO221, PRO217, PRO222, PRO198, PRO245, PRO172, PRO265, PRO266, PRO344, PRO337, PRO322, PRO1286, PRO1279, PRO1338 and PRO1343.

**EXAMPLE 15: Detection of Polypeptides That Affect Glucose or FFA Uptake in Skeletal Muscle (Assay 106)**

This assay is designed to determine whether PRO polypeptides show the ability to affect glucose or FFA uptake by skeletal muscle cells. PRO polypeptides testing positive in this assay would be expected to be useful for the therapeutic treatment of disorders where either the stimulation or inhibition of glucose uptake by skeletal muscle would be beneficial including, for example, diabetes or hyper- or hypo-insulinemia.

In a 96 well format, PRO polypeptides to be assayed are added to primary rat differentiated skeletal muscle, and allowed to incubate overnight. Then fresh media with the PRO polypeptide and +/- insulin are added to the wells. The sample media is then monitored to determine glucose and FFA uptake by the skeletal muscle cells. The insulin will stimulate glucose and FFA uptake by the skeletal muscle, and insulin in media without the PRO polypeptide is used as a positive control, and a limit for scoring. As the PRO polypeptide being tested may either stimulate or inhibit glucose and FFA uptake, results are scored as positive in the assay if greater than 1.5 times or less than 0.5 times the insulin control.

The following PRO polypeptides tested positive as being capable of affecting glucose and/or FFA uptake by skeletal muscle in this assay: PRO182, PRO366, PRO198, PRO172 and PRO719.

**EXAMPLE 16: Chondrocyte Re-differentiation Assay (Assay 110)**

This assay shows that certain polypeptides of the invention act to induce redifferentiation of chondrocytes, therefore, are expected to be useful for the treatment of various bone and/or cartilage disorders such as, for example, sports injuries and arthritis. The assay is performed as follows. Porcine chondrocytes are isolated by overnight collagenase digestion of articular cartilage of metacarpophalangeal joints of 4-6 month old female pigs. The isolated cells are then seeded at 25,000 cells/cm<sup>2</sup> in Ham F-12 containing 10% FBS and 4 µg/ml gentamycin. The culture media is changed every third day and the cells are then seeded in 96 well plates at 5,000 cells/well in 100µl of the same media without serum and 100 µl of the test PRO polypeptide, 5 nM staurosporin (positive control) or medium alone (negative control) is added to give a final volume of 200 µl/well. After 5 days of incubation at 37°C, a picture of each well is taken and the differentiation state of the chondrocytes is determined. A positive result in the assay occurs when the redifferentiation of the chondrocytes is determined to be more similar to the positive control than the negative control.

The following polypeptide tested positive in this assay: PRO182, PRO366, PRO198 and PRO1868.

**EXAMPLE 17: Chondrocyte Proliferation Assay (Assay 111)**

This assay is designed to determine whether PRO polypeptides of the present invention show the ability to induce the proliferation and/or redifferentiation of chondrocytes in culture. PRO polypeptides testing positive in this assay would be expected to be useful for the therapeutic treatment of various bone and/or cartilage disorders such as, for example, sports injuries and arthritis.

Porcine chondrocytes are isolated by overnight collagenase digestion of articular cartilage of the metacarpophalangeal joint of 4-6 month old female pigs. The isolated cells are then seeded at 25,000 cells/cm<sup>2</sup> in Ham F-12 containing 10% FBS and 4 µg/ml gentamycin. The culture media is changed every third day and the cells are reseeded to 25,000 cells/cm<sup>2</sup> every five days. On day 12, the cells are seeded in 96 well plates at 5,000 cells/well in 100µl of the same media without serum and 100 µl of either serum-free medium (negative control), staurosporin (final concentration of 5 nM; positive control) or the test PRO polypeptide are added to give a final volume of 200 µl/well. After 5 days at 37°C, 20 µl of Alamar blue is added to each well and the plates are incubated for an additional 3 hours at 37°C. The fluorescence is then measured in each well (Ex:530 nm; Em: 590 nm). The fluorescence of a plate containing 200 µl of the serum-free medium is measured to obtain the background. A positive result in the assay is obtained when the fluorescence of the PRO polypeptide treated sample is more like that of the positive control than the negative control.

The following PRO polypeptides tested positive in this assay: PRO202, PRO224, PRO172 and PRO1312.

**EXAMPLE 18: Detection of PRO Polypeptides That Affect Glucose or FFA Uptake by Primary Rat Adipocytes (Assay 94)**

This assay is designed to determine whether PRO polypeptides show the ability to affect glucose or FFA uptake by adipocyte cells. PRO polypeptides testing positive in this assay would be expected to be useful for the therapeutic treatment of disorders where either the stimulation or inhibition of glucose uptake by adipocytes



would be beneficial including, for example, obesity, diabetes or hyper- or hypo-insulinemia.

In a 96 well format, PRO polypeptides to be assayed are added to primary rat adipocytes, and allowed to incubate overnight. Samples are taken at 4 and 16 hours and assayed for glycerol, glucose and FFA uptake. After the 16 hour incubation, insulin is added to the media and allowed to incubate for 4 hours. At this time, a sample is taken and glycerol, glucose and FFA uptake is measured. Media containing insulin without the PRO polypeptide is used as a positive reference control. As the PRO polypeptide being tested may either stimulate or inhibit glucose and FFA uptake, results are scored as positive in the assay if greater than 1.5 times or less than 0.5 times the insulin control.

The following PRO polypeptides tested positive as being capable of affecting glucose and/or FFA uptake in this assay: PRO202, PRO211, PRO344 and PRO1338.

#### EXAMPLE 19: Gene Expression in Bovine Pericytes (Assay 105)

This assay is designed to identify PRO polypeptides which activate gene expression in pericytes. Such polypeptides would be expected to be useful as growth factors and/or for situations where the activation of gene expression is desired or beneficial. Bovine pericytes are plated on 60mm culture dishes in growth media for 1 week. On day 1, various PRO polypeptides are diluted (1%) and incubated with the pericytes for 1, 4 and 24 hr. timepoints. The cells are harvested and the RNA isolated using TRI-Reagent following the included instructions. The RNA is then quantified by reading the 260/280 OD using a spectrophotometer. The gene expression analysis is done by TaqMan reactions using Perkin Elmer reagents and specially designed bovine probes and primers. Expression of the following genes is analyzed: GAPDH, beta-integrin, connective tissue growth factor (CTGF), ICAM-1, monocyte chemoattractant protein-1 (MCP-1), osteopontin, transforming growth factor-beta (TGF-beta), TGF-beta receptor, tissue inhibitor of metalloproteinase (TIMP), tissue factor (TF), VEGF- $\alpha$ , thrombospondin, VEGF- $\beta$ , angiopoietin-2, and collagenase. Replicates are then averaged and the SD determined. The gene expression levels are then normalized to GAPDH. These are then normalized to the expression levels obtained with a protein (PIN32) which does not significantly induce gene expression in bovine pericytes when compared to untreated controls. Any PRO polypeptide that gives a gene expression level 2-fold or higher over the PIN32 control is considered a positive hit.

The following PRO polypeptides tested positive in this assay: PRO366.

#### EXAMPLE 20: Identification of PRO Polypeptides That Activate Pericytes (Assay 125)

This assay shows that certain polypeptides of the invention act to activate proliferation of pericyte cells and, therefore, are useful not only as diagnostic markers for particular types of pericyte-associated tumors but also for giving rise to antagonists which would be expected to be useful for the therapeutic treatment of pericyte-associated tumors. Such PRO polypeptides also would be expected to be useful as growth factors and/or for situations where the induction of cell proliferation is desired or beneficial. Activation of pericyte proliferation also correlates with the induction of angiogenesis and, as such, PRO polypeptides capable of inducing pericyte proliferation would be expected to be useful for the treatment of conditions where induced angiogenesis would be beneficial including, for example, wound healing, and the like. Specifically, on day 1, pericytes are received

from VEC Technologies, and all but 5 ml media is removed from the flask. On day 2, the pericytes are trypsinized, washed, spun and plated on 96 well plates. On day 7, the media is removed and the pericytes are treated with 100  $\mu$ l of either the specific PRO polypeptide or control treatments (positive control = DME+5% +/- PDGF @ 500ng/ $\mu$ l; negative control=PIN32, a polypeptide determined to have no significant effect on pericyte proliferation). C-fos and GAPDH gene expression levels are then determined and the replicates are averaged and the SD is determined. The c-fos values are normalized to GAPDH and the results are expressed as fold increase over PIN32. Anything providing at least a 2-fold or higher response as compared to the negative control is considered positive for the assay.

The following polypeptides tested positive in this assay: PRO366.

**EXAMPLE 21: Ability of PRO Polypeptides to Stimulate the Release of Proteoglycans from Cartilage (Assay 97)**

The ability of various PRO polypeptides to stimulate the release of proteoglycans from cartilage tissue was tested as follows.

The metacarpophalangeal joint of 4-6 month old pigs was aseptically dissected, and articular cartilage was removed by free hand slicing being careful to avoid the underlying bone. The cartilage was minced and cultured in bulk for 24 hours in a humidified atmosphere of 95% air, 5% CO<sub>2</sub> in serum free (SF) media (DME/F12 1:1) with 0.1% BSA and 100U/ml penicillin and 100 $\mu$ g/ml streptomycin. After washing three times, approximately 100 mg of articular cartilage was aliquoted into micronics tubes and incubated for an additional 24 hours in the above SF media. PRO polypeptides were then added at 1% either alone or in combination with 18 ng/ml interleukin-1 $\alpha$ , a known stimulator of proteoglycan release from cartilage tissue. The supernatant was then harvested and assayed for the amount of proteoglycans using the 1,9-dimethyl-methylene blue (DMB) colorimetric assay (Farndale and Buttle, *Biochem. Biophys. Acta* 883:173-177 (1985)). A positive result in this assay indicates that the test polypeptide will find use, for example, in the treatment of sports-related joint problems, articular cartilage defects, osteoarthritis or rheumatoid arthritis.

When various PRO polypeptides were tested in the above assay, the polypeptides demonstrated a marked ability to stimulate release of proteoglycans from cartilage tissue both basally and after stimulation with interleukin-1 $\alpha$  and at 24 and 72 hours after treatment, thereby indicating that these PRO polypeptides are useful for stimulating proteoglycan release from cartilage tissue. As such, these PRO polypeptides are useful for the treatment of sports-related joint problems, articular cartilage defects, osteoarthritis or rheumatoid arthritis. The polypeptides testing positive in this assay are : PRO216.

**EXAMPLE 22: Proliferation of Rat Utricular Supporting Cells (Assay 54)**

This assay shows that certain polypeptides of the invention act as potent mitogens for inner ear supporting cells which are auditory hair cell progenitors and, therefore, are useful for inducing the regeneration of auditory hair cells and treating hearing loss in mammals. The assay is performed as follows. Rat UEC-4 utricular epithelial cells are aliquoted into 96 well plates with a density of 3000 cells/well in 200  $\mu$ l of serum-containing medium at 33°C. The cells are cultured overnight and are then switched to serum-free medium at

37°C. Various dilutions of PRO polypeptides (or nothing for a control) are then added to the cultures and the cells are incubated for 24 hours. After the 24 hour incubation, <sup>3</sup>H-thymidine (1 µCi/well) is added and the cells are then cultured for an additional 24 hours. The cultures are then washed to remove unincorporated radiolabel, the cells harvested and Cpm per well determined. Cpm of at least 30% or greater in the PRO polypeptide treated cultures as compared to the control cultures is considered a positive in the assay.

5           The following polypeptides tested positive in this assay: PRO172.

EXAMPLE 23: Stimulatory Activity in Mixed Lymphocyte Reaction (MLR) Assay (Assay 24)

10           This example shows that certain polypeptides of the invention are active as a stimulator of the proliferation of stimulated T-lymphocytes. Compounds which stimulate proliferation of lymphocytes are useful therapeutically where enhancement of an immune response is beneficial. A therapeutic agent may take the form of antagonists of the polypeptide of the invention, for example, murine-human chimeric, humanized or human antibodies against the polypeptide.

15           The basic protocol for this assay is described in Current Protocols in Immunology, unit 3.12; edited by J E Coligan, A M Kruisbeek, D H Marglies, E M Shevach, W Strober, National Institutes of Health, Published by John Wiley & Sons, Inc.

20           More specifically, in one assay variant, peripheral blood mononuclear cells (PBMC) are isolated from mammalian individuals, for example a human volunteer, by leukopheresis (one donor will supply stimulator PBMCs, the other donor will supply responder PBMCs). If desired, the cells are frozen in fetal bovine serum and DMSO after isolation. Frozen cells may be thawed overnight in assay media (37°C, 5% CO<sub>2</sub>) and then washed and resuspended to 3x10<sup>6</sup> cells/ml of assay media (RPMI; 10% fetal bovine serum, 1% penicillin/streptomycin, 1% glutamine, 1% HEPES, 1% non-essential amino acids, 1% pyruvate). The stimulator PBMCs are prepared by irradiating the cells (about 3000 Rads).

          The assay is prepared by plating in triplicate wells a mixture of:

25           100:1 of test sample diluted to 1% or to 0.1%,  
          50 :1 of irradiated stimulator cells, and  
          50 :1 of responder PBMC cells.

100 microliters of cell culture media or 100 microliter of CD4-IgG is used as the control. The wells are then incubated at 37°C, 5% CO<sub>2</sub> for 4 days. On day 5, each well is pulsed with tritiated thymidine (1.0 mCi/well; Amersham). After 6 hours the cells are washed 3 times and then the uptake of the label is evaluated.

30           In another variant of this assay, PBMCs are isolated from the spleens of Balb/c mice and C57B6 mice. The cells are teased from freshly harvested spleens in assay media (RPMI; 10% fetal bovine serum, 1% penicillin/streptomycin, 1% glutamine, 1% HEPES, 1% non-essential amino acids, 1% pyruvate) and the PBMCs are isolated by overlaying these cells over Lympholyte M (Organon Teknika), centrifuging at 2000 rpm for 20 minutes, collecting and washing the mononuclear cell layer in assay media and resuspending the cells to 1x10<sup>7</sup> cells/ml of assay media. The assay is then conducted as described above.

35           Positive increases over control are considered positive with increases of greater than or equal to 180% being preferred. However, any value greater than control indicates a stimulatory effect for the test protein.

The following PRO polypeptides tested positive in this assay: PRO344.

**EXAMPLE 24: Pericyte c-Fos Induction (Assay 93)**

This assay shows that certain polypeptides of the invention act to induce the expression of c-fos in pericyte cells and, therefore, are useful not only as diagnostic markers for particular types of pericyte-associated tumors but also for giving rise to antagonists which would be expected to be useful for the therapeutic treatment of pericyte-associated tumors. Induction of c-fos expression in pericytes is also indicative of the induction of angiogenesis and, as such, PRO polypeptides capable of inducing the expression of c-fos would be expected to be useful for the treatment of conditions where induced angiogenesis would be beneficial including, for example, wound healing, and the like. Specifically, on day 1, pericytes are received from VEC Technologies and all but 5 ml of media is removed from flask. On day 2, the pericytes are trypsinized, washed, spun and then plated onto 96 well plates. On day 7, the media is removed and the pericytes are treated with 100  $\mu$ l of PRO polypeptide test samples and controls (positive control = DME+5% serum +/- PDGF at 500 ng/ml; negative control = protein 32). Replicates are averaged and SD/CV are determined. Fold increase over Protein 32 (buffer control) value indicated by chemiluminescence units (RLU) luminometer reading verses frequency is plotted on a histogram. Two-fold above Protein 32 value is considered positive for the assay. ASY Matrix: Growth media = low glucose DMEM = 20% FBS + 1X pen strep + 1X fungizone. Assay Media = low glucose DMEM +5% FBS.

The following polypeptides tested positive in this assay: PRO301, PRO619, PRO1066 and PRO1265.

**EXAMPLE 25: Cytokine Release Assay (Assay 120)**

This assay is designed to determine whether PRO polypeptides of the present invention are capable of inducing the release of cytokines from peripheral blood mononuclear cells (PBMCs). PRO polypeptides capable of inducing the release of cytokines from PBMCs are useful from the treatment of conditions which would benefit from enhanced cytokine release and will be readily evident to those of ordinary skill in the art. Specifically,  $1 \times 10^6$  cells/ml of peripheral blood mononuclear cells (PBMC) are cultured with 1% of a PRO polypeptide for 3 days in complete RPMI media. The supernatant is then harvested and tested for increased concentrations of various cytokines by ELISA as compared to a human IgG treated control. A positive in the assay is a 10-fold or greater increase in cytokine concentration in the PRO polypeptide treated sample as compared to the human IgG treated control.

The following polypeptides tested positive in this assay: PRO526 and PRO1343.

**EXAMPLE 26: Inhibition of A-Peptide Binding to Factor VIIA (Assay 118)**

This assay is designed to identify PRO polypeptides which are capable of inhibiting the binding of A-peptide to factor VIIA, thereby affecting the blood coagulation cascade. PRO polypeptides testing positive in this assay are expected to be useful for the treatment of conditions where alteration of the blood coagulation cascade would be beneficial including, for example, stroke, heart attack and various coagulation disorders. These PRO polypeptides are also useful for the identification of agonist and antagonist molecules which would

also be useful for treatment of those conditions.

Specifically, 384 well plates are coated with soluble factor VIIA and are incubated overnight at 4°C. The wells are then decanted and are blocked by the addition of 0.5% BSA for 1 hour. The wells are then washed and 20µl of biotinylated A-peptide and either various concentration of the PRO polypeptide (test) or nothing (negative control) are added to each well. The plates are then incubated for 1 hour at room temperature. The wells are again washed and then 40µl of streptavidin-europium is added to each well. The plates are then incubated for 30 minutes at room temperature and then washed. 40µl of a fluorescence enhancement solution is then added to each well, the plates incubated for 5 minutes at room temperature and each well is then read on Wallac Victor reader under europium delayed fluorescence settings. Percent inhibition of binding of the A-peptide to the factor VIIA is then determined (as compared to the negative control), wherein a positive in the assay is a percent inhibition of 30% or greater.

The following PRO polypeptides tested positive in this assay: PRO182.

**EXAMPLE 27: Inhibition of Adipocyte Differentiation Assay (Assay 66)**

This assay is designed to identify PRO polypeptides which are capable of inhibiting insulin-induced differentiation of adipocytes. PRO polypeptides testing positive in this assay would be expected to be useful for the treatment of conditions associated with obesity, diabetes, etc.

Specifically, 3T3-L1 cells are seeded into the wells of 96 well plates at  $6 \times 10^4$  cells/well and allowed to grow to confluency for 7 days. At day 7, the cells are treated with various concentrations of the PRO polypeptide (or nothing for the negative control) in the presence of 1µg/ml insulin,  $0.25 \times 10^{-6}$  M dexamethasone and 0.5mM IBMX. The samples are then incubated at 37°C in 7% CO<sub>2</sub> for 2 days. After the incubation, the media is removed by aspiration and the cells are washed with PBS and re-exposed to the PRO polypeptide (or nothing for the negative control) and 1µg/ml insulin. After 5 days, the media is removed and replaced with fresh PRO polypeptide (or nothing for the negative control) and insulin. After 5 days, the cells are lysed and the cell lysate is assayed using Sigma's Triglyceride [INT] kit (Sigma procedure #336). A positive in the assay is 20% greater inhibition of adipocyte differentiation in the PRO polypeptide treated samples as compared to the negative control.

The following PRO polypeptides tested positive in this assay: PRO185 and PRO198.

**EXAMPLE 28: HUVEC Stimulation by PRO Polypeptides (Assay 131)**

This assay is designed to identify PRO polypeptides which are capable of stimulating the proliferation of HUVEC cells. PRO polypeptides testing positive in this assay would be expected to be useful for inducing angiogenesis for the treatment of conditions where angiogenesis would be beneficial including, for example, wound healing, and the like. Antagonists of these PRO polypeptides would be expected to be useful for inhibiting angiogenesis for the treatment of, for example, tumors, and the like.

Specifically, COSTAR® flat bottom black plates are treated with fibronectin for 20 minutes and then washed twice with PBS. HUVEC cells are then plated at 2000 cells/well in an appropriate growth medium. The plates are then incubated overnight and then the PRO polypeptide (1% final concentration), nothing (negative

control) or IL1 $\beta$  (3.3 ng/ml final concentration; positive control) is added. The plates are again incubated overnight, stained with ICAM1-Cy5 and read on FMAT. A positive in the assay is a 2-fold or greater increase in fluorescence as compared to the positive control.

The following PRO polypeptides tested positive in this assay: PRO222.

5 **EXAMPLE 29: Promotion of Chondrocyte Redifferentiation (Assay 129)**

This assay is designed to determine whether PRO polypeptides of the present invention show the ability to induce the proliferation and/or redifferentiation of chondrocytes in culture. PRO polypeptides testing positive in this assay would be expected to be useful for the therapeutic treatment of various bone and/or cartilage disorders such as, for example, sports injuries and arthritis.

10 Porcine chondrocytes are isolated by overnight collagenase digestion of articular cartilage of the metacarpophalangeal joint of 4-6 month old female pigs. The isolated cells are then seeded at 25,000 cells/cm<sup>2</sup> in Ham F-12 containing 10% FBS and 4  $\mu$ g/ml gentamycin. The culture media is changed every third day. On day 12, the cells are seeded in 96 well plates at 5,000 cells/well in 100  $\mu$ l of the same media without serum and 100  $\mu$ l of either serum-free medium (negative control), staurosporin (final concentration of 5 nM; positive control) or the test PRO polypeptide are added to give a final volume of 200  $\mu$ l/well. After 5 days at 37°C, 22  $\mu$ l of media containing 100  $\mu$ g/ml Hoechst 33342 and 50  $\mu$ g/ml 5-CFDA is added to each well and incubated for an additional 10 minutes at 37°C. A picture of the green fluorescence is taken for each well and the differentiation state of the chondrocytes is calculated by morphometric analysis. A positive result in the assay is obtained when the > 50% of the PRO polypeptide treated cells are differentiated (compared to the background obtained by the negative control).

20 The following PRO polypeptides tested positive in this assay: PRO301.

**EXAMPLE 30: Microarray Analysis to Detect Overexpression of PRO Polypeptides in Cancerous Tumors**

25 Nucleic acid microarrays, often containing thousands of gene sequences, are useful for identifying differentially expressed genes in diseased tissues as compared to their normal counterparts. Using nucleic acid microarrays, test and control mRNA samples from test and control tissue samples are reverse transcribed and labeled to generate cDNA probes. The cDNA probes are then hybridized to an array of nucleic acids immobilized on a solid support. The array is configured such that the sequence and position of each member of the array is known. For example, a selection of genes known to be expressed in certain disease states may be arrayed on a solid support. Hybridization of a labeled probe with a particular array member indicates that the sample from which the probe was derived expresses that gene. If the hybridization signal of a probe from a test (disease tissue) sample is greater than hybridization signal of a probe from a control (normal tissue) sample, the gene or genes overexpressed in the disease tissue are identified. The implication of this result is that an overexpressed protein in a diseased tissue is useful not only as a diagnostic marker for the presence of the disease condition, but also as a therapeutic target for treatment of the disease condition.

35 The methodology of hybridization of nucleic acids and microarray technology is well known in the art. In the present example, the specific preparation of nucleic acids for hybridization and probes, slides, and

hybridization conditions are all detailed in U.S. Provisional Patent Application Serial No. 60/193,767, filed on March 31, 2000 and which is herein incorporated by reference.

In the present example, cancerous tumors derived from various human tissues were studied for PRO polypeptide-encoding gene expression relative to non-cancerous human tissue in an attempt to identify those PRO polypeptides which are overexpressed in cancerous tumors. Two sets of experimental data were generated. In one set, cancerous human colon tumor tissue and matched non-cancerous human colon tumor tissue from the same patient ("matched colon control") were obtained and analyzed for PRO polypeptide expression using the above described microarray technology. In the second set of data, cancerous human tumor tissue from any of a variety of different human tumors was obtained and compared to a "universal" epithelial control sample which was prepared by pooling non-cancerous human tissues of epithelial origin, including liver, kidney, and lung. mRNA isolated from the pooled tissues represents a mixture of expressed gene products from these different tissues. Microarray hybridization experiments using the pooled control samples generated a linear plot in a 2-color analysis. The slope of the line generated in a 2-color analysis was then used to normalize the ratios of (test:control detection) within each experiment. The normalized ratios from various experiments were then compared and used to identify clustering of gene expression. Thus, the pooled "universal control" sample not only allowed effective relative gene expression determinations in a simple 2-sample comparison, it also allowed multi-sample comparisons across several experiments.

In the present experiments, nucleic acid probes derived from the herein described PRO polypeptide-encoding nucleic acid sequences were used in the creation of the microarray and RNA from the tumor tissues listed above were used for the hybridization thereto. A value based upon the normalized ratio:experimental ratio was designated as a "cutoff ratio". Only values that were above this cutoff ratio were determined to be significant. Table 8 below shows the results of these experiments, demonstrating that various PRO polypeptides of the preent invention are significantly overexpressed in various human tumor tissues as compared to a non-cancerous human tissue control. As described above, these data demonstrate that the PRO polypeptides of the present invention are useful not only as diagnostic markers for the presence of one or more cancerous tumors, but also serve as therapeutic targets for the treatment of those tumors.

Table 8

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO177	breast tumor	universal normal control
30	PRO177	liver tumor	universal normal control
	PRO177	lung tumor	universal normal control
	PRO3574	breast tumor	universal normal control
	PRO3574	colon tumor	matched normal colon control
	PRO1280	breast tumor	universal normal control
35	PRO1280	lung tumor	universal normal control
	PRO4984	lung tumor	universal normal control
	PRO4988	colon tumor	universal normal control
	PRO4988	lung tumor	universal normal control
	PRO305	lung tumor	universal normal control
40	PRO305	colon tumor	universal normal control
	PRO1866	prostate tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO1866	lung tumor	universal normal control
	PRO1866	colon tumor	universal normal control
	PRO4996	breast tumor	universal normal control
5	PRO4996	lung tumor	universal normal control
	PRO4406	lung tumor	universal normal control
	PRO4406	colon tumor	universal normal control
	PRO1120	colon tumor	universal normal control
	PRO1120	breast tumor	universal normal control
10	PRO1120	rectal tumor	universal normal control
	PRO4990	lung tumor	universal normal control
	PRO738	cervical tumor	universal normal control
	PRO738	lung tumor	universal normal control
	PRO738	breast tumor	universal normal control
15	PRO3577	lung tumor	universal normal control
	PRO1879	breast tumor	universal normal control
	PRO1879	lung tumor	universal normal control
	PRO1879	colon tumor	universal normal control
	PRO1471	lung tumor	universal normal control
20	PRO1076	prostate tumor	universal normal control
	PRO1483	lung tumor	universal normal control
	PRO4985	rectal tumor	universal normal control
	PRO4985	colon tumor	universal normal control
	PRO4985	breast tumor	universal normal control
25	PRO4985	lung tumor	universal normal control
	PRO5000	lung tumor	universal normal control
	PRO1881	liver tumor	universal normal control
	PRO1881	lung tumor	universal normal control
	PRO1881	breast tumor	universal normal control
30	PRO4314	lung tumor	universal normal control
	PRO4314	breast tumor	universal normal control
	PRO4987	lung tumor	universal normal control
	PRO4313	lung tumor	universal normal control
	PRO4313	breast tumor	universal normal control
35	PRO4799	colon tumor	universal normal control
	PRO4995	liver tumor	universal normal control
	PRO4995	colon tumor	universal normal control
	PRO4995	colon tumor	matched normal colon control
	PRO1341	prostate tumor	universal normal control
40	PRO1341	lung tumor	universal normal control
	PRO1341	colon tumor	universal normal control
	PRO1341	colon tumor	matched normal colon control
	PRO1777	lung tumor	universal normal control
	PRO1777	colon tumor	matched normal colon control
45	PRO3580	lung tumor	universal normal control
	PRO3580	prostate tumor	universal normal control
	PRO1779	lung tumor	universal normal control
	PRO1779	colon tumor	universal normal control
	PRO1779	cervical tumor	universal normal control
50	PRO1754	breast tumor	universal normal control
	PRO1754	lung tumor	universal normal control
	PRO1906	breast tumor	universal normal control
	PRO1906	colon tumor	universal normal control
	PRO1906	prostate tumor	universal normal control
55	PRO1870	breast tumor	universal normal control



Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO4329	lung tumor	universal normal control
	PRO4979	colon tumor	universal normal control
	PRO1885	rectal tumor	universal normal control
5	PRO1885	colon tumor	universal normal control
	PRO1885	colon tumor	matched normal colon control
	PRO1882	prostate tumor	universal normal control
	PRO1882	lung tumor	universal normal control
	PRO1882	colon tumor	universal normal control
10	PRO1882	breast tumor	universal normal control
	PRO1882	cervical tumor	universal normal control
	PRO4989	rectal tumor	universal normal control
	PRO4989	breast tumor	universal normal control
	PRO4989	colon tumor	matched normal colon control
15	PRO4989	colon tumor	universal normal control
	PRO4323	lung tumor	universal normal control
	PRO4323	liver tumor	universal normal control
	PRO1886	breast tumor	universal normal control
	PRO1886	lung tumor	universal normal control
20	PRO1886	rectal tumor	universal normal control
	PRO4395	colon tumor	universal normal control
	PRO4395	prostate tumor	universal normal control
	PRO4395	lung tumor	universal normal control
	PRO4395	cervical tumor	universal normal control
25	PRO1782	colon tumor	universal normal control
	PRO1782	lung tumor	universal normal control
	PRO4388	lung tumor	universal normal control
	PRO4341	breast tumor	universal normal control
	PRO4341	lung tumor	universal normal control
30	PRO3438	lung tumor	universal normal control
	PRO4321	breast tumor	universal normal control
	PRO4321	lung tumor	universal normal control
	PRO4321	colon tumor	universal normal control
	PRO4304	breast tumor	universal normal control
35	PRO4304	lung tumor	universal normal control
	PRO4403	colon tumor	universal normal control
	PRO4403	breast tumor	universal normal control
	PRO4403	lung tumor	universal normal control
	PRO4324	lung tumor	universal normal control
40	PRO4324	breast tumor	universal normal control
	PRO4303	cervical tumor	universal normal control
	PRO4303	lung tumor	universal normal control
	PRO4303	breast tumor	universal normal control
	PRO4303	colon tumor	universal normal control
45	PRO4303	prostate tumor	universal normal control
	PRO4305	breast tumor	universal normal control
	PRO4305	lung tumor	universal normal control
	PRO4305	colon tumor	universal normal control
	PRO4305	liver tumor	universal normal control
50	PRO4404	lung tumor	universal normal control
	PRO4404	breast tumor	universal normal control
	PRO4404	rectal tumor	universal normal control
	PRO1884	lung tumor	universal normal control
	PRO4349	colon tumor	universal normal control
55	PRO4349	lung tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO4401	colon tumor	universal normal control
	PRO4401	lung tumor	universal normal control
	PRO1867	lung tumor	universal normal control
5	PRO1867	liver tumor	universal normal control
	PRO4319	breast tumor	universal normal control
	PRO4319	lung tumor	universal normal control
	PRO4991	lung tumor	universal normal control
	PRO4991	colon tumor	universal normal control
10	PRO4398	lung tumor	universal normal control
	PRO4346	lung tumor	universal normal control
	PRO4350	colon tumor	universal normal control
	PRO4350	prostate tumor	universal normal control
	PRO4350	lung tumor	universal normal control
15	PRO4318	prostate tumor	universal normal control
	PRO4318	lung tumor	universal normal control
	PRO4340	breast tumor	universal normal control
	PRO4340	lung tumor	universal normal control
	PRO4400	breast tumor	universal normal control
20	PRO4400	lung tumor	universal normal control
	PRO4320	lung tumor	universal normal control
	PRO4409	lung tumor	universal normal control
	PRO4409	cervical tumor	universal normal control
	PRO4409	colon tumor	universal normal control
25	PRO4399	lung tumor	universal normal control
	PRO4399	breast tumor	universal normal control
	PRO4418	lung tumor	universal normal control
	PRO4418	breast tumor	universal normal control
	PRO4330	cervical tumor	universal normal control
30	PRO4330	colon tumor	matched normal colon control
	PRO4339	breast tumor	universal normal control
	PRO4339	colon tumor	universal normal control
	PRO4326	lung tumor	universal normal control
	PRO4326	colon tumor	universal normal control
35	PRO6014	breast tumor	universal normal control
	PRO3446	colon tumor	universal normal control
	PRO3446	lung tumor	universal normal control
	PRO4322	lung tumor	universal normal control
	PRO4322	rectal tumor	universal normal control
40	PRO4322	colon tumor	matched normal colon control
	PRO4381	breast tumor	universal normal control
	PRO4381	lung tumor	universal normal control
	PRO4381	colon tumor	universal normal control
	PRO4348	lung tumor	universal normal control
45	PRO4348	prostate tumor	universal normal control
	PRO4371	breast tumor	universal normal control
	PRO3742	colon tumor	universal normal control
	PRO3742	lung tumor	universal normal control
	PRO5773	lung tumor	universal normal control
50	PRO5773	colon tumor	universal normal control
	PRO5773	prostate tumor	universal normal control
	PRO5774	colon tumor	universal normal control
	PRO4343	colon tumor	universal normal control
	PRO4325	lung tumor	universal normal control
55	PRO4347	lung tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO4347	colon tumor	universal normal control
	PRO4347	rectal tumor	universal normal control
	PRO3743	colon tumor	universal normal control
5	PRO3743	lung tumor	universal normal control
	PRO3743	prostate tumor	universal normal control
	PRO4426	colon tumor	universal normal control
	PRO4500	colon tumor	universal normal control
	PRO4389	breast tumor	universal normal control
10	PRO4389	lung tumor	universal normal control
	PRO4337	colon tumor	universal normal control
	PRO4337	breast tumor	universal normal control
	PRO4337	lung tumor	universal normal control
	PRO4992	lung tumor	universal normal control
15	PRO5996	lung tumor	universal normal control
	PRO4345	lung tumor	universal normal control
	PRO4345	colon tumor	universal normal control
	PRO5780	lung tumor	universal normal control
	PRO5780	breast tumor	universal normal control
20	PRO5992	lung tumor	universal normal control
	PRO5992	colon tumor	universal normal control
	PRO5992	breast tumor	universal normal control
	PRO4428	prostate tumor	universal normal control
	PRO4994	lung tumor	universal normal control
25	PRO5995	lung tumor	universal normal control
	PRO5995	colon tumor	universal normal control
	PRO6094	lung tumor	universal normal control
	PRO6094	colon tumor	universal normal control
	PRO4317	lung tumor	universal normal control
30	PRO4317	colon tumor	universal normal control
	PRO4317	liver tumor	universal normal control
	PRO4317	colon tumor	matched normal colon control
	PRO5997	colon tumor	universal normal control
	PRO5997	lung tumor	universal normal control
35	PRO5005	lung tumor	universal normal control
	PRO5005	colon tumor	universal normal control
	PRO5004	colon tumor	universal normal control
	PRO6001	breast tumor	universal normal control
	PRO6013	colon tumor	universal normal control
40	PRO4502	lung tumor	universal normal control
	PRO4502	colon tumor	universal normal control
	PRO6007	breast tumor	universal normal control
	PRO6028	breast tumor	universal normal control
	PRO6028	colon tumor	universal normal control
45	PRO4327	prostate tumor	universal normal control
	PRO4315	colon tumor	universal normal control
	PRO5993	lung tumor	universal normal control
	PRO5993	colon tumor	universal normal control
	PRO4503	colon tumor	universal normal control
50	PRO4976	lung tumor	universal normal control
	PRO5798	lung tumor	universal normal control
	PRO5798	colon tumor	universal normal control
	PRO6242	colon tumor	universal normal control
	PRO6242	colon tumor	matched normal colon control
55	PRO6242	breast tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO6242	liver tumor	universal normal control
	PRO6242	rectal tumor	universal normal control
	PRO6095	breast tumor	universal normal control
5	PRO6095	lung tumor	universal normal control
	PRO6093	colon tumor	universal normal control
	PRO6093	breast tumor	universal normal control
	PRO6093	lung tumor	universal normal control
	PRO6093	colon tumor	matched normal colon control
10	PRO6012	colon tumor	universal normal control
	PRO6027	lung tumor	universal normal control
	PRO6027	colon tumor	universal normal control
	PRO6027	rectal tumor	universal normal control
	PRO6181	prostate tumor	universal normal control
15	PRO6181	lung tumor	universal normal control
	PRO6181	colon tumor	universal normal control
	PRO6097	colon tumor	universal normal control
	PRO6097	lung tumor	universal normal control
	PRO6090	lung tumor	universal normal control
20	PRO7171	lung tumor	universal normal control
	PRO7171	colon tumor	universal normal control
	PRO7171	breast tumor	universal normal control
	PRO6258	prostate tumor	universal normal control
	PRO6258	breast tumor	universal normal control
25	PRO6258	cervical tumor	universal normal control
	PRO6258	liver tumor	universal normal control
	PRO6258	colon tumor	universal normal control
	PRO9820	prostate tumor	universal normal control
	PRO6243	lung tumor	universal normal control
30	PRO6182	lung tumor	universal normal control
	PRO6079	lung tumor	universal normal control
	PRO6079	colon tumor	universal normal control
	PRO6079	breast tumor	universal normal control
	PRO6079	prostate tumor	universal normal control
35	PRO7434	lung tumor	universal normal control
	PRO9865	colon tumor	universal normal control
	PRO9828	colon tumor	universal normal control
	PRO196	colon tumor	universal normal control
	PRO196	lung tumor	universal normal control
40	PRO196	breast tumor	universal normal control
	PRO197	colon tumor	universal normal control
	PRO197	lung tumor	universal normal control
	PRO197	breast tumor	universal normal control
	PRO195	colon tumor	universal normal control
45	PRO195	lung tumor	universal normal control
	PRO195	breast tumor	universal normal control
	PRO187	lung tumor	universal normal control
	PRO187	liver tumor	universal normal control
	PRO182	colon tumor	universal normal control
50	PRO182	lung tumor	universal normal control
	PRO182	breast tumor	universal normal control
	PRO188	rectal tumor	universal normal control
	PRO183	colon tumor	universal normal control
	PRO183	lung tumor	universal normal control
55	PRO183	breast tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO183	rectal tumor	universal normal control
	PRO184	lung tumor	universal normal control
	PRO184	breast tumor	universal normal control
5	PRO185	lung tumor	universal normal control
	PRO200	colon tumor	universal normal control
	PRO200	lung tumor	universal normal control
	PRO200	breast tumor	universal normal control
	PRO200	rectal tumor	universal normal control
10	PRO202	colon tumor	universal normal control
	PRO202	lung tumor	universal normal control
	PRO202	breast tumor	universal normal control
	PRO202	rectal tumor	universal normal control
	PRO202	liver tumor	universal normal control
15	PRO214	colon tumor	universal normal control
	PRO214	lung tumor	universal normal control
	PRO215	colon tumor	universal normal control
	PRO215	lung tumor	universal normal control
	PRO215	breast tumor	universal normal control
20	PRO219	colon tumor	universal normal control
	PRO219	lung tumor	universal normal control
	PRO219	breast tumor	universal normal control
	PRO219	liver tumor	universal normal control
	PRO211	lung tumor	universal normal control
25	PRO211	breast tumor	universal normal control
	PRO220	colon tumor	universal normal control
	PRO220	lung tumor	universal normal control
	PRO220	breast tumor	universal normal control
30	PRO366	colon tumor	universal normal control
	PRO366	lung tumor	universal normal control
	PRO366	breast tumor	universal normal control
	PRO216	lung tumor	universal normal control
	PRO221	colon tumor	universal normal control
	PRO221	lung tumor	universal normal control
35	PRO221	breast tumor	universal normal control
	PRO228	lung tumor	universal normal control
	PRO228	breast tumor	universal normal control
	PRO217	lung tumor	universal normal control
	PRO217	breast tumor	universal normal control
40	PRO222	colon tumor	universal normal control
	PRO222	lung tumor	universal normal control
	PRO222	breast tumor	universal normal control
	PRO224	colon tumor	universal normal control
	PRO224	lung tumor	universal normal control
45	PRO224	breast tumor	universal normal control
	PRO224	prostate tumor	universal normal control
	PRO224	rectal tumor	universal normal control
	PRO230	colon tumor	universal normal control
	PRO230	lung tumor	universal normal control
50	PRO230	breast tumor	universal normal control
	PRO230	prostate tumor	universal normal control
	PRO198	colon tumor	universal normal control
	PRO198	lung tumor	universal normal control
	PRO198	breast tumor	universal normal control
55	PRO198	liver tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO226	lung tumor	universal normal control
	PRO226	breast tumor	universal normal control
	PRO261	lung tumor	universal normal control
5	PRO242	colon tumor	universal normal control
	PRO242	lung tumor	universal normal control
	PRO242	breast tumor	universal normal control
	PRO227	colon tumor	universal normal control
	PRO227	lung tumor	universal normal control
10	PRO237	colon tumor	universal normal control
	PRO237	lung tumor	universal normal control
	PRO237	breast tumor	universal normal control
	PRO237	prostate tumor	universal normal control
	PRO241	colon tumor	universal normal control
15	PRO241	lung tumor	universal normal control
	PRO241	breast tumor	universal normal control
	PRO231	colon tumor	universal normal control
	PRO231	lung tumor	universal normal control
	PRO231	breast tumor	universal normal control
20	PRO231	rectal tumor	universal normal control
	PRO235	colon tumor	universal normal control
	PRO235	lung tumor	universal normal control
	PRO235	breast tumor	universal normal control
	PRO235	liver tumor	universal normal control
25	PRO323	lung tumor	universal normal control
	PRO323	breast tumor	universal normal control
	PRO323	rectal tumor	universal normal control
	PRO245	colon tumor	universal normal control
	PRO245	lung tumor	universal normal control
30	PRO245	breast tumor	universal normal control
	PRO245	cervical tumor	universal normal control
	PRO245	liver tumor	universal normal control
	PRO246	colon tumor	universal normal control
	PRO246	lung tumor	universal normal control
35	PRO246	breast tumor	universal normal control
	PRO288	lung tumor	universal normal control
	PRO288	breast tumor	universal normal control
	PRO248	lung tumor	universal normal control
	PRO248	rectal tumor	universal normal control
40	PRO257	colon tumor	universal normal control
	PRO257	lung tumor	universal normal control
	PRO257	prostate tumor	universal normal control
	PRO172	colon tumor	universal normal control
	PRO172	lung tumor	universal normal control
45	PRO172	breast tumor	universal normal control
	PRO258	colon tumor	universal normal control
	PRO258	lung tumor	universal normal control
	PRO258	breast tumor	universal normal control
	PRO265	lung tumor	universal normal control
50	PRO265	breast tumor	universal normal control
	PRO265	rectal tumor	universal normal control
	PRO326	colon tumor	universal normal control
	PRO326	lung tumor	universal normal control
	PRO326	breast tumor	universal normal control
55	PRO326	liver tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO266	colon tumor	universal normal control
	PRO266	lung tumor	universal normal control
	PRO266	breast tumor	universal normal control
5	PRO269	lung tumor	universal normal control
	PRO269	rectal tumor	universal normal control
	PRO285	colon tumor	universal normal control
	PRO285	lung tumor	universal normal control
	PRO285	breast tumor	universal normal control
10	PRO328	colon tumor	universal normal control
	PRO328	lung tumor	universal normal control
	PRO328	breast tumor	universal normal control
	PRO344	breast tumor	universal normal control
	PRO272	lung tumor	universal normal control
15	PRO301	colon tumor	universal normal control
	PRO301	lung tumor	universal normal control
	PRO301	breast tumor	universal normal control
	PRO331	colon tumor	universal normal control
	PRO331	lung tumor	universal normal control
20	PRO331	breast tumor	universal normal control
	PRO332	colon tumor	universal normal control
	PRO332	lung tumor	universal normal control
	PRO332	breast tumor	universal normal control
	PRO353	colon tumor	universal normal control
25	PRO353	lung tumor	universal normal control
	PRO353	breast tumor	universal normal control
	PRO310	colon tumor	universal normal control
	PRO310	lung tumor	universal normal control
	PRO310	breast tumor	universal normal control
30	PRO310	rectal tumor	universal normal control
	PRO337	colon tumor	universal normal control
	PRO337	lung tumor	universal normal control
	PRO337	breast tumor	universal normal control
	PRO346	lung tumor	universal normal control
35	PRO350	lung tumor	universal normal control
	PRO350	breast tumor	universal normal control
	PRO526	colon tumor	universal normal control
	PRO526	lung tumor	universal normal control
	PRO526	breast tumor	universal normal control
40	PRO381	colon tumor	universal normal control
	PRO381	lung tumor	universal normal control
	PRO381	breast tumor	universal normal control
	PRO381	prostate tumor	universal normal control
	PRO846	colon tumor	universal normal control
45	PRO846	lung tumor	universal normal control
	PRO363	colon tumor	universal normal control
	PRO363	lung tumor	universal normal control
	PRO365	lung tumor	universal normal control
	PRO365	breast tumor	universal normal control
50	PRO1310	breast tumor	universal normal control
	PRO731	colon tumor	universal normal control
	PRO731	lung tumor	universal normal control
	PRO731	breast tumor	universal normal control
	PRO322	colon tumor	universal normal control
55	PRO322	lung tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO322	breast tumor	universal normal control
	PRO322	rectal tumor	universal normal control
	PRO322	liver tumor	universal normal control
5	PRO536	lung tumor	universal normal control
	PRO536	breast tumor	universal normal control
	PRO536	liver tumor	universal normal control
	PRO719	colon tumor	universal normal control
	PRO719	lung tumor	universal normal control
10	PRO719	breast tumor	universal normal control
	PRO619	colon tumor	universal normal control
	PRO619	lung tumor	universal normal control
	PRO619	breast tumor	universal normal control
	PRO771	colon tumor	universal normal control
15	PRO771	lung tumor	universal normal control
	PRO771	breast tumor	universal normal control
	PRO1083	colon tumor	universal normal control
	PRO1083	lung tumor	universal normal control
	PRO1083	breast tumor	universal normal control
20	PRO1083	prostate tumor	universal normal control
	PRO862	colon tumor	universal normal control
	PRO862	lung tumor	universal normal control
	PRO862	breast tumor	universal normal control
	PRO733	colon tumor	universal normal control
25	PRO733	lung tumor	universal normal control
	PRO733	breast tumor	universal normal control
	PRO733	liver tumor	universal normal control
	PRO1188	lung tumor	universal normal control
	PRO1188	breast tumor	universal normal control
30	PRO1188	rectal tumor	universal normal control
	PRO770	lung tumor	universal normal control
	PRO770	breast tumor	universal normal control
	PRO1080	colon tumor	universal normal control
	PRO1080	lung tumor	universal normal control
35	PRO1080	breast tumor	universal normal control
	PRO1017	colon tumor	universal normal control
	PRO1017	lung tumor	universal normal control
	PRO1017	breast tumor	universal normal control
	PRO1016	colon tumor	universal normal control
40	PRO1016	lung tumor	universal normal control
	PRO1016	breast tumor	universal normal control
	PRO1016	rectal tumor	universal normal control
	PRO792	lung tumor	universal normal control
	PRO938	colon tumor	universal normal control
45	PRO938	lung tumor	universal normal control
	PRO938	breast tumor	universal normal control
	PRO1012	colon tumor	universal normal control
	PRO1012	lung tumor	universal normal control
	PRO1012	rectal tumor	universal normal control
50	PRO1012	liver tumor	universal normal control
	PRO1008	lung tumor	universal normal control
	PRO1075	colon tumor	universal normal control
	PRO1075	lung tumor	universal normal control
	PRO1007	colon tumor	universal normal control
55	PRO1007	lung tumor	universal normal control



Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO1007	breast tumor	universal normal control
	PRO1007	rectal tumor	universal normal control
	PRO1056	colon tumor	universal normal control
5	PRO1056	lung tumor	universal normal control
	PRO1056	breast tumor	universal normal control
	PRO791	colon tumor	universal normal control
	PRO791	lung tumor	universal normal control
	PRO791	breast tumor	universal normal control
10	PRO791	rectal tumor	universal normal control
	PRO1111	colon tumor	universal normal control
	PRO1111	lung tumor	universal normal control
	PRO1111	breast tumor	universal normal control
	PRO812	lung tumor	universal normal control
15	PRO812	breast tumor	universal normal control
	PRO812	rectal tumor	universal normal control
	PRO1066	lung tumor	universal normal control
	PRO1185	colon tumor	universal normal control
	PRO1185	lung tumor	universal normal control
20	PRO1185	breast tumor	universal normal control
	PRO1031	lung tumor	universal normal control
	PRO1360	lung tumor	universal normal control
	PRO1360	breast tumor	universal normal control
	PRO1309	lung tumor	universal normal control
25	PRO1309	breast tumor	universal normal control
	PRO1107	lung tumor	universal normal control
	PRO1107	breast tumor	universal normal control
	PRO836	colon tumor	universal normal control
	PRO836	lung tumor	universal normal control
30	PRO1132	lung tumor	universal normal control
	PRO1132	breast tumor	universal normal control
	PRO1131	colon tumor	universal normal control
	PRO1131	lung tumor	universal normal control
	PRO1131	breast tumor	universal normal control
35	PRO1131	liver tumor	universal normal control
	PRO1130	colon tumor	universal normal control
	PRO1130	lung tumor	universal normal control
	PRO1130	breast tumor	universal normal control
	PRO844	colon tumor	universal normal control
40	PRO844	lung tumor	universal normal control
	PRO844	breast tumor	universal normal control
	PRO844	rectal tumor	universal normal control
	PRO1154	colon tumor	universal normal control
	PRO1154	lung tumor	universal normal control
45	PRO1154	rectal tumor	universal normal control
	PRO1154	liver tumor	universal normal control
	PRO1181	lung tumor	universal normal control
	PRO1181	breast tumor	universal normal control
	PRO1126	colon tumor	universal normal control
50	PRO1126	lung tumor	universal normal control
	PRO1126	breast tumor	universal normal control
	PRO1126	adrenal tumor	universal normal control
	PRO1186	colon tumor	universal normal control
	PRO1186	lung tumor	universal normal control
55	PRO1186	breast tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO1186	liver tumor	universal normal control
	PRO1198	colon tumor	universal normal control
	PRO1198	lung tumor	universal normal control
5	PRO1159	lung tumor	universal normal control
	PRO1159	breast tumor	universal normal control
	PRO1159	liver tumor	universal normal control
	PRO1265	colon tumor	universal normal control
	PRO1265	breast tumor	universal normal control
10	PRO1250	colon tumor	universal normal control
	PRO1250	lung tumor	universal normal control
	PRO1250	breast tumor	universal normal control
	PRO1475	colon tumor	universal normal control
	PRO1475	breast tumor	universal normal control
15	PRO1312	colon tumor	universal normal control
	PRO1312	lung tumor	universal normal control
	PRO1312	breast tumor	universal normal control
	PRO1308	colon tumor	universal normal control
	PRO1308	lung tumor	universal normal control
20	PRO1308	liver tumor	universal normal control
	PRO1326	colon tumor	universal normal control
	PRO1325	lung tumor	universal normal control
	PRO1326	breast tumor	universal normal control
	PRO1192	colon tumor	universal normal control
25	PRO1192	lung tumor	universal normal control
	PRO1192	breast tumor	universal normal control
	PRO1246	colon tumor	universal normal control
	PRO1246	lung tumor	universal normal control
	PRO1246	breast tumor	universal normal control
30	PRO1246	prostate tumor	universal normal control
	PRO1356	colon tumor	universal normal control
	PRO1356	lung tumor	universal normal control
	PRO1356	breast tumor	universal normal control
	PRO1275	lung tumor	universal normal control
35	PRO1275	breast tumor	universal normal control
	PRO1274	lung tumor	universal normal control
	PRO1358	colon tumor	universal normal control
	PRO1358	lung tumor	universal normal control
	PRO1358	prostate tumor	universal normal control
40	PRO1286	colon tumor	universal normal control
	PRO1286	lung tumor	universal normal control
	PRO1286	prostate tumor	universal normal control
	PRO1286	rectal tumor	universal normal control
	PRO1294	colon tumor	universal normal control
45	PRO1294	lung tumor	universal normal control
	PRO1294	breast tumor	universal normal control
	PRO1294	rectal tumor	universal normal control
	PRO1273	lung tumor	universal normal control
	PRO1273	rectal tumor	universal normal control
50	PRO1279	colon tumor	universal normal control
	PRO1279	lung tumor	universal normal control
	PRO1195	lung tumor	universal normal control
	PRO1195	breast tumor	universal normal control
	PRO1271	lung tumor	universal normal control
55	PRO1271	breast tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO1271	liver tumor	universal normal control
	PRO1338	colon tumor	universal normal control
	PRO1338	lung tumor	universal normal control
5	PRO1338	breast tumor	universal normal control
	PRO1343	colon tumor	universal normal control
	PRO1343	lung tumor	universal normal control
	PRO1343	breast tumor	universal normal control
	PRO1343	rectal tumor	universal normal control
10	PRO1434	lung tumor	universal normal control
	PRO1418	lung tumor	universal normal control
	PRO1418	liver tumor	universal normal control
	PRO1387	colon tumor	universal normal control
	PRO1387	lung tumor	universal normal control
15	PRO1387	prostate tumor	universal normal control
	PRO1387	rectal tumor	universal normal control
	PRO1384	colon tumor	universal normal control
	PRO1384	lung tumor	universal normal control
	PRO1565	colon tumor	universal normal control
20	PRO1565	lung tumor	universal normal control
	PRO1565	prostate tumor	universal normal control
	PRO1474	colon tumor	universal normal control
	PRO1474	lung tumor	universal normal control
	PRO1474	breast tumor	universal normal control
25	PRO1474	rectal tumor	universal normal control
	PRO1917	colon tumor	universal normal control
	PRO1917	lung tumor	universal normal control
	PRO1917	breast tumor	universal normal control
	PRO1787	colon tumor	universal normal control
30	PRO1787	lung tumor	universal normal control
	PRO1787	breast tumor	universal normal control
	PRO1556	lung tumor	universal normal control
	PRO1556	breast tumor	universal normal control
	PRO1561	colon tumor	universal normal control
35	PRO1561	lung tumor	universal normal control
	PRO1561	rectal tumor	universal normal control
	PRO1693	colon tumor	universal normal control
	PRO1693	lung tumor	universal normal control
	PRO1693	breast tumor	universal normal control
40	PRO1868	lung tumor	universal normal control
	PRO1868	breast tumor	universal normal control
	PRO1890	colon tumor	universal normal control
	PRO1890	lung tumor	universal normal control
	PRO1890	breast tumor	universal normal control
45	PRO1890	prostate tumor	universal normal control
	PRO1887	colon tumor	universal normal control
	PRO1887	breast tumor	universal normal control
	PRO4353	lung tumor	universal normal control
	PRO4353	breast tumor	universal normal control
50	PRO1801	colon tumor	universal normal control
	PRO1801	lung tumor	universal normal control
	PRO4357	lung tumor	universal normal control
	PRO4357	breast tumor	universal normal control
	PRO4302	colon tumor	universal normal control
55	PRO4302	lung tumor	universal normal control

Table 8 (cont')

	<u>Molecule</u>	<u>is overexpressed in:</u>	<u>as compared to:</u>
	PRO4302	breast tumor	universal normal control
	PRO4302	prostate tumor	universal normal control
	PRO5990	colon tumor	universal normal control
5	PRO5990	lung tumor	universal normal control
	PRO5990	breast tumor	universal normal control

**EXAMPLE 31: Identification of Receptor/Ligand Interactions**

In this assay, various PRO polypeptides are tested for ability to bind to a panel of potential receptor or ligand molecules for the purpose of identifying receptor/ligand interactions. The identification of a ligand for a known receptor, a receptor for a known ligand or a novel receptor/ligand pair is useful for a variety of indications including, for example, targeting bioactive molecules (linked to the ligand or receptor) to a cell known to express the receptor or ligand, use of the receptor or ligand as a reagent to detect the presence of the ligand or receptor in a composition suspected of containing the same, wherein the composition may comprise cells suspected of expressing the ligand or receptor, modulating the growth of or another biological or immunological activity of a cell known to express or respond to the receptor or ligand, modulating the immune response of cells or toward cells that express the receptor or ligand, allowing the preparation of agonists, antagonists and/or antibodies directed against the receptor or ligand which will modulate the growth of or a biological or immunological activity of a cell expressing the receptor or ligand, and various other indications which will be readily apparent to the ordinarily skilled artisan.

The assay is performed as follows. A PRO polypeptide of the present invention suspected of being a ligand for a receptor is expressed as a fusion protein containing the Fc domain of human IgG (an immunoadhesin). Receptor-ligand binding is detected by allowing interaction of the immunoadhesin polypeptide with cells (e.g. Cos cells) expressing candidate PRO polypeptide receptors and visualization of bound immunoadhesin with fluorescent reagents directed toward the Fc fusion domain and examination by microscope. Cells expressing candidate receptors are produced by transient transfection, in parallel, of defined subsets of a library of cDNA expression vectors encoding PRO polypeptides that may function as receptor molecules. Cells are then incubated for 1 hour in the presence of the PRO polypeptide immunoadhesin being tested for possible receptor binding. The cells are then washed and fixed with paraformaldehyde. The cells are then incubated with fluorescent conjugated antibody directed against the Fc portion of the PRO polypeptide immunoadhesin (e.g. FITC conjugated goat anti-human-Fc antibody). The cells are then washed again and examined by microscope. A positive interaction is judged by the presence of fluorescent labeling of cells transfected with cDNA encoding a particular PRO polypeptide receptor or pool of receptors and an absence of similar fluorescent labeling of similarly prepared cells that have been transfected with other cDNA or pools of cDNA. If a defined pool of cDNA expression vectors is judged to be positive for interaction with a PRO polypeptide immunoadhesin, the individual cDNA species that comprise the pool are tested individually (the pool is "broken down") to determine the specific cDNA that encodes a receptor able to interact with the PRO polypeptide immunoadhesin.

In another embodiment of this assay, an epitope-tagged potential ligand PRO polypeptide (e.g. 8 histidine "His" tag) is allowed to interact with a panel of potential receptor PRO polypeptide molecules that have

been expressed as fusions with the Fc domain of human IgG (immunoadhesins). Following a 1 hour co-incubation with the epitope tagged PRO polypeptide, the candidate receptors are each immunoprecipitated with protein A beads and the beads are washed. Potential ligand interaction is determined by western blot analysis of the immunoprecipitated complexes with antibody directed towards the epitope tag. An interaction is judged to occur if a band of the anticipated molecular weight of the epitope tagged protein is observed in the western blot analysis with a candidate receptor, but is not observed to occur with the other members of the panel of potential receptors.

Using these assays, the following receptor/ligand interactions have been herein identified:

- (1) PRO1801 binds to PRO1114 and PRO4978.
- (2) PRO100 binds to PRO1114.

The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by the construct deposited, since the deposited embodiment is intended as a single illustration of certain aspects of the invention and any constructs that are functionally equivalent are within the scope of this invention. The deposit of material herein does not constitute an admission that the written description herein contained is inadequate to enable the practice of any aspect of the invention, including the best mode thereof, nor is it to be construed as limiting the scope of the claims to the specific illustrations that it represents. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims.

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

0-1	Form - PCT/RO/134 (EASY) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared using	PCT-EASY Version 2.91 (updated 10.10.2000)
0-2	International Application No.	
0-3	Applicant's or agent's file reference	P3330R1
1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
1-1	page	98
1-2	line	34
1-3	Identification of Deposit	
1-3-1	Name of depositary institution	American Type Culture Collection
1-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
1-3-3	Date of deposit	14 April 1998 (14.04.1998)
1-3-4	Accession Number	ATCC 209771
1-4	Additional Indications	NONE
1-5	Designated States for Which Indications are Made	all designated States
1-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
2	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
2-1	page	98
2-2	line	35
2-3	Identification of Deposit	
2-3-1	Name of depositary institution	American Type Culture Collection
2-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
2-3-3	Date of deposit	09 February 1999 (09.02.1999)
2-3-4	Accession Number	ATCC 203654
2-4	Additional Indications	NONE
2-5	Designated States for Which Indications are Made	all designated States
2-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
3	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
3-1	page	98
3-2	line	36

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

3-3	Identification of Deposit	
3-3-1	Name of depositary institution	American Type Culture Collection
3-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
3-3-3	Date of deposit	25 May 1999 (25.05.1999)
3-3-4	Accession Number	ATCC PTA-127
3-4	Additional Indications	NONE
3-5	Designated States for Which Indications are Made	all designated States
3-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
4	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
4-1	page	98
4-2	line	37
4-3	Identification of Deposit	
4-3-1	Name of depositary institution	American Type Culture Collection
4-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
4-3-3	Date of deposit	27 July 1999 (27.07.1999)
4-3-4	Accession Number	ATCC PTA-429
4-4	Additional Indications	NONE
4-5	Designated States for Which Indications are Made	all designated States
4-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
5	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
5-1	page	98
5-2	line	38
5-3	Identification of Deposit	
5-3-1	Name of depositary institution	American Type Culture Collection
5-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
5-3-3	Date of deposit	27 July 1999 (27.07.1999)
5-3-4	Accession Number	ATCC PTA-432
5-4	Additional Indications	NONE
5-5	Designated States for Which Indications are Made	all designated States
5-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

<b>6</b>	<b>The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:</b>	
6-1	page	98
6-2	line	39
<b>6-3</b>	<b>Identification of Deposit</b>	
6-3-1	Name of depositary institution	American Type Culture Collection
6-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
6-3-3	Date of deposit	10 December 1997 (10.12.1997)
6-3-4	Accession Number	ATCC 209525
<b>6-4</b>	<b>Additional Indications</b>	
		NONE
<b>6-5</b>	<b>Designated States for Which Indications are Made</b>	
		all designated States
<b>6-6</b>	<b>Separate Furnishing of Indications</b>	
	These indications will be submitted to the International Bureau later	NONE
<b>7</b>	<b>The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:</b>	
7-1	page	99
7-2	line	2
<b>7-3</b>	<b>Identification of Deposit</b>	
7-3-1	Name of depositary institution	American Type Culture Collection
7-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
7-3-3	Date of deposit	12 January 1999 (12.01.1999)
7-3-4	Accession Number	ATCC 203577
<b>7-4</b>	<b>Additional Indications</b>	
		NONE
<b>7-5</b>	<b>Designated States for Which Indications are Made</b>	
		all designated States
<b>7-6</b>	<b>Separate Furnishing of Indications</b>	
	These indications will be submitted to the International Bureau later	NONE
<b>8</b>	<b>The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:</b>	
8-1	page	99
8-2	line	3
<b>8-3</b>	<b>Identification of Deposit</b>	
8-3-1	Name of depositary institution	American Type Culture Collection
8-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
8-3-3	Date of deposit	27 July 1999 (27.07.1999)
8-3-4	Accession Number	ATCC PTA-430
<b>8-4</b>	<b>Additional Indications</b>	
		NONE
<b>8-5</b>	<b>Designated States for Which Indications are Made</b>	
		all designated States



PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

8-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
9	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
9-1	page	99
9-2	line	4
9-3	Identification of Deposit	
9-3-1	Name of depositary institution	American Type Culture Collection
9-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
9-3-3	Date of deposit	08 June 1999 (08.06.1999)
9-3-4	Accession Number	ATCC PTA-203
9-4	Additional Indications	NONE
9-5	Designated States for Which Indications are Made	all designated States
9-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
10	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
10-1	page	99
10-2	line	5
10-3	Identification of Deposit	
10-3-1	Name of depositary institution	American Type Culture Collection
10-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
10-3-3	Date of deposit	01 July 1998 (01.07.1998)
10-3-4	Accession Number	ATCC 203040
10-4	Additional Indications	NONE
10-5	Designated States for Which Indications are Made	all designated States
10-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
11	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
11-1	page	99
11-2	line	6
11-3	Identification of Deposit	
11-3-1	Name of depositary institution	American Type Culture Collection
11-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
11-3-3	Date of deposit	31 August 1999 (31.08.1999)
11-3-4	Accession Number	ATCC PTA-611

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

11-4	Additional Indications	NONE
11-5	Designated States for Which Indications are Made	all designated States
11-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
12	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
12-1	page	99
12-2	line	7
12-3	Identification of Deposit	
12-3-1	Name of depositary institution	American Type Culture Collection
12-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
12-3-3	Date of deposit	21 January 1998 (21.01.1998)
12-3-4	Accession Number	ATCC 209593
12-4	Additional Indications	NONE
12-5	Designated States for Which Indications are Made	all designated States
12-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
13	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
13-1	page	99
13-2	line	8
13-3	Identification of Deposit	
13-3-1	Name of depositary institution	American Type Culture Collection
13-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
13-3-3	Date of deposit	09 February 1999 (09.02.1999)
13-3-4	Accession Number	ATCC 203649
13-4	Additional Indications	NONE
13-5	Designated States for Which Indications are Made	all designated States
13-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
14	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
14-1	page	99
14-2	line	9

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

14-3	Identification of Deposit	
14-3-1	Name of depositary institution	American Type Culture Collection
14-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
14-3-3	Date of deposit	12 January 1999 (12.01.1999)
14-3-4	Accession Number	ATCC 203574
14-4	Additional Indications	NONE
14-5	Designated States for Which Indications are Made	all designated States
14-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
15	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
15-1	page	99
15-2	line	10
15-3	Identification of Deposit	
15-3-1	Name of depositary institution	American Type Culture Collection
15-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
15-3-3	Date of deposit	25 May 1999 (25.05.1999)
15-3-4	Accession Number	ATCC PTA-129
15-4	Additional Indications	NONE
15-5	Designated States for Which Indications are Made	all designated States
15-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
16	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
16-1	page	99
16-2	line	11
16-3	Identification of Deposit	
16-3-1	Name of depositary institution	American Type Culture Collection
16-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
16-3-3	Date of deposit	27 May 1998 (27.05.1998)
16-3-4	Accession Number	ATCC 209905
16-4	Additional Indications	NONE
16-5	Designated States for Which Indications are Made	all designated States
16-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

17	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
17-1	page	99
17-2	line	12
17-3	Identification of Deposit	
17-3-1	Name of depositary institution	American Type Culture Collection
17-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
17-3-3	Date of deposit	12 January 1999 (12.01.1999)
17-3-4	Accession Number	ATCC 203585
17-4	Additional Indications	NONE
17-5	Designated States for Which Indications are Made	all designated States
17-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
18	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
18-1	page	99
18-2	line	13
18-3	Identification of Deposit	
18-3-1	Name of depositary institution	American Type Culture Collection
18-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
18-3-3	Date of deposit	09 February 1999 (09.02.1999)
18-3-4	Accession Number	ATCC 203665
18-4	Additional Indications	NONE
18-5	Designated States for Which Indications are Made	all designated States
18-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
19	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
19-1	page	99
19-2	line	14
19-3	Identification of Deposit	
19-3-1	Name of depositary institution	American Type Culture Collection
19-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
19-3-3	Date of deposit	27 July 1999 (27.07.1999)
19-3-4	Accession Number	ATCC PTA-427
19-4	Additional Indications	NONE
19-5	Designated States for Which Indications are Made	all designated States

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

19-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
20	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
20-1	page	99
20-2	line	15
20-3	Identification of Deposit	
20-3-1	Name of depositary institution	American Type Culture Collection
20-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
20-3-3	Date of deposit	31 August 1999 (31.08.1999)
20-3-4	Accession Number	ATCC PTA-615
20-4	Additional Indications	NONE
20-5	Designated States for Which Indications are Made	all designated States
20-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
21	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
21-1	page	99
21-2	line	16
21-3	Identification of Deposit	
21-3-1	Name of depositary institution	American Type Culture Collection
21-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
21-3-3	Date of deposit	12 January 1999 (12.01.1999)
21-3-4	Accession Number	ATCC 203582
21-4	Additional Indications	NONE
21-5	Designated States for Which Indications are Made	all designated States
21-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
22	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
22-1	page	99
22-2	line	17
22-3	Identification of Deposit	
22-3-1	Name of depositary institution	American Type Culture Collection
22-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
22-3-3	Date of deposit	09 March 1999 (09.03.1999)
22-3-4	Accession Number	ATCC 203838

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

22-4	Additional Indications	NONE
22-5	Designated States for Which Indications are Made	all designated States
22-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
23	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
23-1	page	99
23-2	line	18
23-3	Identification of Deposit	
23-3-1	Name of depositary institution	American Type Culture Collection
23-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
23-3-3	Date of deposit	27 July 1999 (27.07.1999)
23-3-4	Accession Number	ATCC PTA-428
23-4	Additional Indications	NONE
23-5	Designated States for Which Indications are Made	all designated States
23-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
24	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
24-1	page	99
24-2	line	19
24-3	Identification of Deposit	
24-3-1	Name of depositary institution	American Type Culture Collection
24-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
24-3-3	Date of deposit	09 March 1999 (09.03.1999)
24-3-4	Accession Number	ATCC 203836
24-4	Additional Indications	NONE
24-5	Designated States for Which Indications are Made	all designated States
24-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
25	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
25-1	page	99
25-2	line	20

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

25-3	Identification of Deposit	
25-3-1	Name of depositary institution	American Type Culture Collection
25-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
25-3-3	Date of deposit	08 June 1999 (08.06.1999)
25-3-4	Accession Number	ATCC PTA-205
25-4	Additional Indications	NONE
25-5	Designated States for Which Indications are Made	all designated States
25-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
26	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
26-1	page	99
26-2	line	21
26-3	Identification of Deposit	
26-3-1	Name of depositary institution	American Type Culture Collection
26-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
26-3-3	Date of deposit	27 July 1999 (27.07.1999)
26-3-4	Accession Number	ATCC PTA-431
26-4	Additional Indications	NONE
26-5	Designated States for Which Indications are Made	all designated States
26-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
27	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
27-1	page	99
27-2	line	22
27-3	Identification of Deposit	
27-3-1	Name of depositary institution	American Type Culture Collection
27-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
27-3-3	Date of deposit	09 February 1999 (09.02.1999)
27-3-4	Accession Number	ATCC 203659
27-4	Additional Indications	NONE
27-5	Designated States for Which Indications are Made	all designated States
27-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

28	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
28-1	page	99
28-2	line	23
28-3	Identification of Deposit	
28-3-1	Name of depositary institution	American Type Culture Collection
28-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
28-3-3	Date of deposit	12 January 1999 (12.01.1999)
28-3-4	Accession Number	ATCC 203584
28-4	Additional Indications	NONE
28-5	Designated States for Which Indications are Made	all designated States
28-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
29	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
29-1	page	99
29-2	line	24
29-3	Identification of Deposit	
29-3-1	Name of depositary institution	American Type Culture Collection
29-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
29-3-3	Date of deposit	25 May 1999 (25.05.1999)
29-3-4	Accession Number	ATCC PTA-126
29-4	Additional Indications	NONE
29-5	Designated States for Which Indications are Made	all designated States
29-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
30	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
30-1	page	99
30-2	line	25
30-3	Identification of Deposit	
30-3-1	Name of depositary institution	American Type Culture Collection
30-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
30-3-3	Date of deposit	25 May 1999 (25.05.1999)
30-3-4	Accession Number	ATCC PTA-128
30-4	Additional Indications	NONE
30-5	Designated States for Which Indications are Made	all designated States



PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

30-6	Separat Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
31	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
31-1	page	99
31-2	line	26
31-3	Identification of Deposit	
31-3-1	Name of depositary institution	American Type Culture Collection
31-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
31-3-3	Date of deposit	09 February 1999 (09.02.1999)
31-3-4	Accession Number	ATCC 203664
31-4	Additional Indications	NONE
31-5	Designated States for Which Indications are Made	all designated States
31-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
32	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
32-1	page	99
32-2	line	27
32-3	Identification of Deposit	
32-3-1	Name of depositary institution	American Type Culture Collection
32-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
32-3-3	Date of deposit	12 January 1999 (12.01.1999)
32-3-4	Accession Number	ATCC 203578
32-4	Additional Indications	NONE
32-5	Designated States for Which Indications are Made	all designated States
32-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
33	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
33-1	page	99
33-2	line	28
33-3	Identification of Deposit	
33-3-1	Name of depositary institution	American Type Culture Collection
33-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
33-3-3	Date of deposit	22 December 1998 (22.12.1998)
33-3-4	Accession Number	ATCC 203554

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

33-4	Additional Indications	NONE
33-5	Designated States for Which Indications are Made	all designated States
33-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
34	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
34-1	page	99
34-2	line	29
34-3	Identification of Deposit	
34-3-1	Name of depositary institution	American Type Culture Collection
34-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
34-3-3	Date of deposit	16 March 1999 (16.03.1999)
34-3-4	Accession Number	ATCC 203850
34-4	Additional Indications	NONE
34-5	Designated States for Which Indications are Made	all designated States
34-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
35	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
35-1	page	99
35-2	line	30
35-3	Identification of Deposit	
35-3-1	Name of depositary institution	American Type Culture Collection
35-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
35-3-3	Date of deposit	11 May 1999 (11.05.1999)
35-3-4	Accession Number	ATCC PTA-45
35-4	Additional Indications	NONE
35-5	Designated States for Which Indications are Made	all designated States
35-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
36	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
36-1	page	99
36-2	line	31

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

36-3	Identification of Deposit	
36-3-1	Name of depositary institution	American Type Culture Collection
36-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
36-3-3	Date of deposit	22 December 1998 (22.12.1998)
36-3-4	Accession Number	ATCC 203545
36-4	Additional Indications	NONE
36-5	Designated States for Which Indications are Made	all designated States
36-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
37	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
37-1	page	99
37-2	line	32
37-3	Identification of Deposit	
37-3-1	Name of depositary institution	American Type Culture Collection
37-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
37-3-3	Date of deposit	22 December 1998 (22.12.1998)
37-3-4	Accession Number	ATCC 203544
37-4	Additional Indications	NONE
37-5	Designated States for Which Indications are Made	all designated States
37-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
38	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
38-1	page	99
38-2	line	33
38-3	Identification of Deposit	
38-3-1	Name of depositary institution	American Type Culture Collection
38-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
38-3-3	Date of deposit	15 June 1999 (15.06.1999)
38-3-4	Accession Number	ATCC PTA-234
38-4	Additional Indications	NONE
38-5	Designated States for Which Indications are Made	all designated States
38-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

39	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
39-1	page	99
39-2	line	34
39-3	Identification of Deposit	
39-3-1	Name of depositary institution	American Type Culture Collection
39-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
39-3-3	Date of deposit	16 March 1999 (16.03.1999)
39-3-4	Accession Number	ATCC 203848
39-4	Additional Indications	NONE
39-5	Designated States for Which Indications are Made	all designated States
39-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
40	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
40-1	page	99
40-2	line	35
40-3	Identification of Deposit	
40-3-1	Name of depositary institution	American Type Culture Collection
40-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
40-3-3	Date of deposit	22 December 1998 (22.12.1998)
40-3-4	Accession Number	ATCC 203555
40-4	Additional Indications	NONE
40-5	Designated States for Which Indications are Made	all designated States
40-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
41	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
41-1	page	99
41-2	line	36
41-3	Identification of Deposit	
41-3-1	Name of depositary institution	American Type Culture Collection
41-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
41-3-3	Date of deposit	20 April 1999 (20.04.1999)
41-3-4	Accession Number	ATCC 203949
41-4	Additional Indications	NONE
41-5	Designated States for Which Indications are Made	all designated States

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

41-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
42	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
42-1	page	99
42-2	line	37
42-3	Identification of Deposit	
42-3-1	Name of depositary institution	American Type Culture Collection
42-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
42-3-3	Date of deposit	15 December 1998 (15.12.1998)
42-3-4	Accession Number	ATCC 203539
42-4	Additional Indications	NONE
42-5	Designated States for Which Indications are Made	all designated States
42-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
43	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
43-1	page	99
43-2	line	38
43-3	Identification of Deposit	
43-3-1	Name of depositary institution	American Type Culture Collection
43-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
43-3-3	Date of deposit	23 March 1999 (23.03.1999)
43-3-4	Accession Number	ATCC 203871
43-4	Additional Indications	NONE
43-5	Designated States for Which Indications are Made	all designated States
43-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
44	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
44-1	page	99
44-2	line	39
44-3	Identification of Deposit	
44-3-1	Name of depositary institution	American Type Culture Collection
44-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
44-3-3	Date of deposit	23 March 1999 (23.03.1999)
44-3-4	Accession Number	ATCC 203862

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

44-4	Additional Indications	NONE
44-5	Designated States for Which Indications are Made	all designated States
44-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
45	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
45-1	page	99
45-2	line	40
45-3	Identification of Deposit	
45-3-1	Name of depositary institution	American Type Culture Collection
45-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
45-3-3	Date of deposit	10 August 1999 (10.08.1999)
45-3-4	Accession Number	ATCC PTA-510
45-4	Additional Indications	NONE
45-5	Designated States for Which Indications are Made	all designated States
45-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
46	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
46-1	page	99
46-2	line	41
46-3	Identification of Deposit	
46-3-1	Name of depositary institution	American Type Culture Collection
46-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
46-3-3	Date of deposit	20 January 1999 (20.01.1999)
46-3-4	Accession Number	ATCC 203603
46-4	Additional Indications	NONE
46-5	Designated States for Which Indications are Made	all designated States
46-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
47	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
47-1	page	99
47-2	line	42

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

47-3	Identification of Deposit	
47-3-1	Name of depositary institution	American Type Culture Collection
47-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
47-3-3	Date of deposit	02 March 1999 (02.03.1999)
47-3-4	Accession Number	ATCC 203813
47-4	Additional Indications	NONE
47-5	Designated States for Which Indications are Made	all designated States
47-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
48	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
48-1	page	99
48-2	line	43
48-3	Identification of Deposit	
48-3-1	Name of depositary institution	American Type Culture Collection
48-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
48-3-3	Date of deposit	02 March 1999 (02.03.1999)
48-3-4	Accession Number	ATCC 203812
48-4	Additional Indications	NONE
48-5	Designated States for Which Indications are Made	all designated States
48-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
49	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
49-1	page	99
49-2	line	44
49-3	Identification of Deposit	
49-3-1	Name of depositary institution	American Type Culture Collection
49-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
49-3-3	Date of deposit	29 October 1998 (29.10.1998)
49-3-4	Accession Number	ATCC 203391
49-4	Additional Indications	NONE
49-5	Designated States for Which Indications are Made	all designated States
49-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

50	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
50-1	page	99
50-2	line	45
50-3	Identification of Deposit	
50-3-1	Name of depositary institution	American Type Culture Collection
50-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
50-3-3	Date of deposit	27 April 1999 (27.04.1999)
50-3-4	Accession Number	ATCC 203965
50-4	Additional Indications	NONE
50-5	Designated States for Which Indications are Made	all designated States
50-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
51	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
51-1	page	99
51-2	line	46
51-3	Identification of Deposit	
51-3-1	Name of depositary institution	American Type Culture Collection
51-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
51-3-3	Date of deposit	02 March 1999 (02.03.1999)
51-3-4	Accession Number	ATCC 203816
51-4	Additional Indications	NONE
51-5	Designated States for Which Indications are Made	all designated States
51-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
52	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
52-1	page	99
52-2	line	47
52-3	Identification of Deposit	
52-3-1	Name of depositary institution	American Type Culture Collection
52-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
52-3-3	Date of deposit	02 March 1999 (02.03.1999)
52-3-4	Accession Number	ATCC 203814
52-4	Additional Indications	NONE
52-5	Designated States for Which Indications are Made	all designated States



PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

52-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
53	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
53-1	page	99
53-2	line	48
53-3	Identification of Deposit	
53-3-1	Name of depositary institution	American Type Culture Collection
53-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
53-3-3	Date of deposit	02 March 1999 (02.03.1999)
53-3-4	Accession Number	ATCC 203810
53-4	Additional Indications	NONE
53-5	Designated States for Which Indications are Made	all designated States
53-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
54	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
54-1	page	99
54-2	line	49
54-3	Identification of Deposit	
54-3-1	Name of depositary institution	American Type Culture Collection
54-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
54-3-3	Date of deposit	04 May 1999 (04.05.1999)
54-3-4	Accession Number	ATCC PTA-22
54-4	Additional Indications	NONE
54-5	Designated States for Which Indications are Made	all designated States
54-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
55	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
55-1	page	99
55-2	line	50
55-3	Identification of Deposit	
55-3-1	Name of depositary institution	American Type Culture Collection
55-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
55-3-3	Date of deposit	12 January 1999 (12.01.1999)
55-3-4	Accession Number	ATCC 203580

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

55-4	Additional Indications	NONE
55-5	Designated States for Which Indications are Made	all designated States
55-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
56	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
56-1	page	99
56-2	line	51
56-3	Identification of Deposit	
56-3-1	Name of depositary institution	American Type Culture Collection
56-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
56-3-3	Date of deposit	30 March 1999 (30.03.1999)
56-3-4	Accession Number	ATCC 203889
56-4	Additional Indications	NONE
56-5	Designated States for Which Indications are Made	all designated States
56-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
57	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
57-1	page	99
57-2	line	52
57-3	Identification of Deposit	
57-3-1	Name of depositary institution	American Type Culture Collection
57-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
57-3-3	Date of deposit	27 April 1999 (27.04.1999)
57-3-4	Accession Number	ATCC 203964
57-4	Additional Indications	NONE
57-5	Designated States for Which Indications are Made	all designated States
57-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
58	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
58-1	page	99
58-2	line	53

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

58-3	Identification of Dep sit	
58-3-1	Name of depositary institution	American Type Culture Collection
58-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
58-3-3	Date of deposit	22 December 1998 (22.12.1998)
58-3-4	Accession Number	ATCC 203548
58-4	Additional Indications	NONE
58-5	Designated States for Which Indications are Made	all designated States
58-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
59	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
59-1	page	99
59-2	line	54
59-3	Identification of Deposit	
59-3-1	Name of depositary institution	American Type Culture Collection
59-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
59-3-3	Date of deposit	02 March 1999 (02.03.1999)
59-3-4	Accession Number	ATCC 203817
59-4	Additional Indications	NONE
59-5	Designated States for Which Indications are Made	all designated States
59-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
60	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
60-1	page	99
60-2	line	55
60-3	Identification of Deposit	
60-3-1	Name of depositary institution	American Type Culture Collection
60-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
60-3-3	Date of deposit	15 June 1999 (15.06.1999)
60-3-4	Accession Number	ATCC PTA-235
60-4	Additional Indications	NONE
60-5	Designated States for Which Indications are Made	all designated States
60-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

61	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
61-1	page	100
61-2	line	2
61-3	Identification of Deposit	
61-3-1	Name of depositary institution	American Type Culture Collection
61-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
61-3-3	Date of deposit	27 April 1999 (27.04.1999)
61-3-4	Accession Number	ATCC 203968
61-4	Additional Indications	NONE
61-5	Designated States for Which Indications are Made	all designated States
61-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
62	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
62-1	page	100
62-2	line	3
62-3	Identification of Deposit	
62-3-1	Name of depositary institution	American Type Culture Collection
62-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
62-3-3	Date of deposit	30 March 1999 (30.03.1999)
62-3-4	Accession Number	ATCC 203894
62-4	Additional Indications	NONE
62-5	Designated States for Which Indications are Made	all designated States
62-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
63	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
63-1	page	100
63-2	line	4
63-3	Identification of Deposit	
63-3-1	Name of depositary institution	American Type Culture Collection
63-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
63-3-3	Date of deposit	30 March 1999 (30.03.1999)
63-3-4	Accession Number	ATCC 203893
63-4	Additional Indications	NONE
63-5	Designated States for Which Indications are Made	all designated States

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

63-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
64	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
64-1	page	100
64-2	line	5
64-3	Identification of Deposit	
64-3-1	Name of depositary institution	American Type Culture Collection
64-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
64-3-3	Date of deposit	02 March 1999 (02.03.1999)
64-3-4	Accession Number	ATCC 203811
64-4	Additional Indications	NONE
64-5	Designated States for Which Indications are Made	all designated States
64-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
65	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
65-1	page	100
65-2	line	6
65-3	Identification of Deposit	
65-3-1	Name of depositary institution	American Type Culture Collection
65-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
65-3-3	Date of deposit	23 March 1999 (23.03.1999)
65-3-4	Accession Number	ATCC 203867
65-4	Additional Indications	NONE
65-5	Designated States for Which Indications are Made	all designated States
65-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
66	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
66-1	page	100
66-2	line	7
66-3	Identification of Deposit	
66-3-1	Name of depositary institution	American Type Culture Collection
66-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
66-3-3	Date of deposit	27 April 1999 (27.04.1999)
66-3-4	Accession Number	ATCC 203963

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

66-4	Additional Indications	NONE
66-5	Designated States for Which Indications are Made	all designated States
66-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
67	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
67-1	page	100
67-2	line	8
67-3	Identification of Deposit	
67-3-1	Name of depositary institution	American Type Culture Collection
67-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
67-3-3	Date of deposit	02 March 1999 (02.03.1999)
67-3-4	Accession Number	ATCC 203815
67-4	Additional Indications	NONE
67-5	Designated States for Which Indications are Made	all designated States
67-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
68	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
68-1	page	100
68-2	line	9
68-3	Identification of Deposit	
68-3-1	Name of depositary institution	American Type Culture Collection
68-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
68-3-3	Date of deposit	30 March 1999 (30.03.1999)
68-3-4	Accession Number	ATCC 203890
68-4	Additional Indications	NONE
68-5	Designated States for Which Indications are Made	all designated States
68-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
69	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
69-1	page	100
69-2	line	10

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

69-3	Identification of Deposit	
69-3-1	Name of depositary institution	American Type Culture Collection
69-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
69-3-3	Date of deposit	25 May 1999 (25.05.1999)
69-3-4	Accession Number	ATCC PTA-130
69-4	Additional Indications	NONE
69-5	Designated States for Which Indications are Made	all designated States
69-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
70	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
70-1	page	100
70-2	line	11
70-3	Identification of Deposit	
70-3-1	Name of depositary institution	American Type Culture Collection
70-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
70-3-3	Date of deposit	27 April 1999 (27.04.1999)
70-3-4	Accession Number	ATCC 203970
70-4	Additional Indications	NONE
70-5	Designated States for Which Indications are Made	all designated States
70-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
71	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
71-1	page	100
71-2	line	12
71-3	Identification of Deposit	
71-3-1	Name of depositary institution	American Type Culture Collection
71-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
71-3-3	Date of deposit	16 March 1999 (16.03.1999)
71-3-4	Accession Number	ATCC 203845
71-4	Additional Indications	NONE
71-5	Designated States for Which Indications are Made	all designated States
71-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

72	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
72-1	page	100
72-2	line	13
72-3	Identification of Deposit	
72-3-1	Name of depositary institution	American Type Culture Collection
72-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
72-3-3	Date of deposit	23 March 1999 (23.03.1999)
72-3-4	Accession Number	ATCC 203861
72-4	Additional Indications	NONE
72-5	Designated States for Which Indications are Made	all designated States
72-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
73	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
73-1	page	100
73-2	line	14
73-3	Identification of Deposit	
73-3-1	Name of depositary institution	American Type Culture Collection
73-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
73-3-3	Date of deposit	16 March 1999 (16.03.1999)
73-3-4	Accession Number	ATCC 203844
73-4	Additional Indications	NONE
73-5	Designated States for Which Indications are Made	all designated States
73-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
74	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
74-1	page	100
74-2	line	15
74-3	Identification of Deposit	
74-3-1	Name of depositary institution	American Type Culture Collection
74-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
74-3-3	Date of deposit	10 August 1999 (10.08.1999)
74-3-4	Accession Number	ATCC PTA-513
74-4	Additional Indications	NONE
74-5	Designated States for Which Indications are Made	all designated States



PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

74-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
75	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
75-1	page	100
75-2	line	16
75-3	Identification of Deposit	
75-3-1	Name of depositary institution	American Type Culture Collection
75-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
75-3-3	Date of deposit	09 February 1999 (09.02.1999)
75-3-4	Accession Number	ATCC 203663
75-4	Additional Indications	NONE
75-5	Designated States for Which Indications are Made	all designated States
75-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
76	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
76-1	page	100
76-2	line	17
76-3	Identification of Deposit	
76-3-1	Name of depositary institution	American Type Culture Collection
76-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
76-3-3	Date of deposit	16 March 1999 (16.03.1999)
76-3-4	Accession Number	ATCC 203851
76-4	Additional Indications	NONE
76-5	Designated States for Which Indications are Made	all designated States
76-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
77	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
77-1	page	100
77-2	line	18
77-3	Identification of Deposit	
77-3-1	Name of depositary institution	American Type Culture Collection
77-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
77-3-3	Date of deposit	20 April 1999 (20.04.1999)
77-3-4	Accession Number	ATCC 203950

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

77-4	Additional Indications	NONE
77-5	Designated States for Which Indications are Made	all designated States
77-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
78	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
78-1	page	100
78-2	line	19
78-3	Identification of Deposit	
78-3-1	Name of depositary institution	American Type Culture Collection
78-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
78-3-3	Date of deposit	30 March 1999 (30.03.1999)
78-3-4	Accession Number	ATCC 203895
78-4	Additional Indications	NONE
78-5	Designated States for Which Indications are Made	all designated States
78-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
79	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
79-1	page	100
79-2	line	20
79-3	Identification of Deposit	
79-3-1	Name of depositary institution	American Type Culture Collection
79-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
79-3-3	Date of deposit	25 May 1999 (25.05.1999)
79-3-4	Accession Number	ATCC PTA-134
79-4	Additional Indications	NONE
79-5	Designated States for Which Indications are Made	all designated States
79-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
80	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
80-1	page	100
80-2	line	21

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

80-3	Identification of Deposit	
80-3-1	Name of depositary institution	American Type Culture Collection
80-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
80-3-3	Date of deposit	16 March 1999 (16.03.1999)
80-3-4	Accession Number	ATCC 203852
80-4	Additional Indications	NONE
80-5	Designated States for Which Indications are Made	all designated States
80-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
81	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
81-1	page	100
81-2	line	22
81-3	Identification of Deposit	
81-3-1	Name of depositary institution	American Type Culture Collection
81-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
81-3-3	Date of deposit	22 June 1999 (22.06.1999)
81-3-4	Accession Number	ATCC PTA-258
81-4	Additional Indications	NONE
81-5	Designated States for Which Indications are Made	all designated States
81-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
82	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
82-1	page	100
82-2	line	23
82-3	Identification of Deposit	
82-3-1	Name of depositary institution	American Type Culture Collection
82-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
82-3-3	Date of deposit	22 June 1999 (22.06.1999)
82-3-4	Accession Number	ATCC PTA-259
82-4	Additional Indications	NONE
82-5	Designated States for Which Indications are Made	all designated States
82-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

83	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
83-1	page	100
83-2	line	24
83-3	Identification of Deposit	
83-3-1	Name of depositary institution	American Type Culture Collection
83-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
83-3-3	Date of deposit	23 March 1999 (23.03.1999)
83-3-4	Accession Number	ATCC 203866
83-4	Additional Indications	NONE
83-5	Designated States for Which Indications are Made	all designated States
83-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
84	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
84-1	page	100
84-2	line	25
84-3	Identification of Deposit	
84-3-1	Name of depositary institution	American Type Culture Collection
84-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
84-3-3	Date of deposit	16 March 1999 (16.03.1999)
84-3-4	Accession Number	ATCC 203853
84-4	Additional Indications	NONE
84-5	Designated States for Which Indications are Made	all designated States
84-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
85	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
85-1	page	100
85-2	line	26
85-3	Identification of Deposit	
85-3-1	Name of depositary institution	American Type Culture Collection
85-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
85-3-3	Date of deposit	30 March 1999 (30.03.1999)
85-3-4	Accession Number	ATCC 203892
85-4	Additional Indications	NONE
85-5	Designated States for Which Indications are Made	all designated States

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

85-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
86	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
86-1	page	100
86-2	line	27
86-3	Identification of Deposit	
86-3-1	Name of depositary institution	American Type Culture Collection
86-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
86-3-3	Date of deposit	16 March 1999 (16.03.1999)
86-3-4	Accession Number	ATCC 203847
86-4	Additional Indications	NONE
86-5	Designated States for Which Indications are Made	all designated States
86-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
87	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
87-1	page	100
87-2	line	28
87-3	Identification of Deposit	
87-3-1	Name of depositary institution	American Type Culture Collection
87-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
87-3-3	Date of deposit	04 May 1999 (04.05.1999)
87-3-4	Accession Number	ATCC PTA-21
87-4	Additional Indications	NONE
87-5	Designated States for Which Indications are Made	all designated States
87-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
88	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
88-1	page	100
88-2	line	29
88-3	Identification of Deposit	
88-3-1	Name of depositary institution	American Type Culture Collection
88-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
88-3-3	Date of deposit	25 May 1999 (25.05.1999)
88-3-4	Accession Number	ATCC PTA-121

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

88-4	Additional Indications	NONE
88-5	Designated States for Which Indications are Made	all designated States
88-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
89	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
89-1	page	100
89-2	line	30
89-3	Identification of Deposit	
89-3-1	Name of depositary institution	American Type Culture Collection
89-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
89-3-3	Date of deposit	20 April 1999 (20.04.1999)
89-3-4	Accession Number	ATCC 203951
89-4	Additional Indications	NONE
89-5	Designated States for Which Indications are Made	all designated States
89-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
90	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
90-1	page	100
90-2	line	31
90-3	Identification of Deposit	
90-3-1	Name of depositary institution	American Type Culture Collection
90-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
90-3-3	Date of deposit	23 March 1999 (23.03.1999)
90-3-4	Accession Number	ATCC 203869
90-4	Additional Indications	NONE
90-5	Designated States for Which Indications are Made	all designated States
90-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
91	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
91-1	page	100
91-2	line	32

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

91-3	Identification of Deposit	
91-3-1	Name of depositary institution	American Type Culture Collection
91-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
91-3-3	Date of deposit	15 June 1999 (15.06.1999)
91-3-4	Accession Number	ATCC PTA-232
91-4	Additional Indications	NONE
91-5	Designated States for Which Indications are Made	all designated States
91-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
92	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
92-1	page	100
92-2	line	33
92-3	Identification of Deposit	
92-3-1	Name of depositary institution	American Type Culture Collection
92-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
92-3-3	Date of deposit	20 July 1999 (20.07.1999)
92-3-4	Accession Number	ATCC PTA-385
92-4	Additional Indications	NONE
92-5	Designated States for Which Indications are Made	all designated States
92-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
93	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
93-1	page	100
93-2	line	34
93-3	Identification of Deposit	
93-3-1	Name of depositary institution	American Type Culture Collection
93-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
93-3-3	Date of deposit	23 March 1999 (23.03.1999)
93-3-4	Accession Number	ATCC 203864
93-4	Additional Indications	NONE
93-5	Designated States for Which Indications are Made	all designated States
93-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

94	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
94-1	page	100
94-2	line	35
94-3	Identification of Deposit	
94-3-1	Name of depositary institution	American Type Culture Collection
94-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
94-3-3	Date of deposit	22 June 1999 (22.06.1999)
94-3-4	Accession Number	ATCC PTA-262
94-4	Additional Indications	NONE
94-5	Designated States for Which Indications are Made	all designated States
94-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
95	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
95-1	page	100
95-2	line	36
95-3	Identification of Deposit	
95-3-1	Name of depositary institution	American Type Culture Collection
95-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
95-3-3	Date of deposit	20 July 1999 (20.07.1999)
95-3-4	Accession Number	ATCC PTA-381
95-4	Additional Indications	NONE
95-5	Designated States for Which Indications are Made	all designated States
95-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
96	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
96-1	page	100
96-2	line	37
96-3	Identification of Deposit	
96-3-1	Name of depositary institution	American Type Culture Collection
96-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
96-3-3	Date of deposit	04 May 1999 (04.05.1999)
96-3-4	Accession Number	ATCC PTA-15
96-4	Additional Indications	NONE
96-5	Designated States for Which Indications are Made	all designated States



PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

96-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
97	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
97-1	page	100
97-2	line	38
97-3	Identification of Deposit	
97-3-1	Name of depositary institution	American Type Culture Collection
97-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
97-3-3	Date of deposit	15 June 1999 (15.06.1999)
97-3-4	Accession Number	ATCC PTA-239
97-4	Additional Indications	NONE
97-5	Designated States for Which Indications are Made	all designated States
97-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
98	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
98-1	page	100
98-2	line	39
98-3	Identification of Deposit	
98-3-1	Name of depositary institution	American Type Culture Collection
98-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
98-3-3	Date of deposit	20 July 1999 (20.07.1999)
98-3-4	Accession Number	ATCC PTA-384
98-4	Additional Indications	NONE
98-5	Designated States for Which Indications are Made	all designated States
98-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
99	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
99-1	page	100
99-2	line	40
99-3	Identification of Deposit	
99-3-1	Name of depositary institution	American Type Culture Collection
99-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
99-3-3	Date of deposit	03 August 1999 (03.08.1999)
99-3-4	Accession Number	ATCC PTA-475

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

99-4	Additional Indications	NONE
99-5	Designated States for Which Indications are Made	all designated States
99-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
100	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
100-1	page	100
100-2	line	41
100-3	Identification of Deposit	
100-3-1	Name of depositary institution	American Type Culture Collection
100-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
100-3-3	Date of deposit	16 March 1999 (16.03.1999)
100-3-4	Accession Number	ATCC 203854
100-4	Additional Indications	NONE
100-5	Designated States for Which Indications are Made	all designated States
100-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
101	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
101-1	page	100
101-2	line	42
101-3	Identification of Deposit	
101-3-1	Name of depositary institution	American Type Culture Collection
101-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
101-3-3	Date of deposit	20 July 1999 (20.07.1999)
101-3-4	Accession Number	ATCC PTA-378
101-4	Additional Indications	NONE
101-5	Designated States for Which Indications are Made	all designated States
101-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
102	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
102-1	page	100
102-2	line	43

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

102-3	Identification of Deposit	
102-3-1	Name of depositary institution	American Type Culture Collection
102-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
102-3-3	Date of deposit	22 June 1999 (22.06.1999)
102-3-4	Accession Number	ATCC PTA-257
102-4	Additional Indications	NONE
102-5	Designated States for Which Indications are Made	all designated States
102-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
103	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
103-1	page	100
103-2	line	44
103-3	Identification of Deposit	
103-3-1	Name of depositary institution	American Type Culture Collection
103-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
103-3-3	Date of deposit	15 June 1999 (15.06.1999)
103-3-4	Accession Number	ATCC PTA-231
103-4	Additional Indications	NONE
103-5	Designated States for Which Indications are Made	all designated States
103-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
104	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
104-1	page	100
104-2	line	45
104-3	Identification of Deposit	
104-3-1	Name of depositary institution	American Type Culture Collection
104-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
104-3-3	Date of deposit	20 July 1999 (20.07.1999)
104-3-4	Accession Number	ATCC PTA-388
104-4	Additional Indications	NONE
104-5	Designated States for Which Indications are Made	all designated States
104-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

105	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
105-1	page	100
105-2	line	46
105-3	Identification of Deposit	
105-3-1	Name of depositary institution	American Type Culture Collection
105-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
105-3-3	Date of deposit	31 August 1999 (31.08.1999)
105-3-4	Accession Number	ATCC PTA-620
105-4	Additional Indications	NONE
105-5	Designated States for Which Indications are Made	all designated States
105-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
106	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
106-1	page	100
106-2	line	47
106-3	Identification of Deposit	
106-3-1	Name of depositary institution	American Type Culture Collection
106-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
106-3-3	Date of deposit	25 May 1999 (25.05.1999)
106-3-4	Accession Number	ATCC PTA-118
106-4	Additional Indications	NONE
106-5	Designated States for Which Indications are Made	all designated States
106-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
107	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
107-1	page	100
107-2	line	48
107-3	Identification of Deposit	
107-3-1	Name of depositary institution	American Type Culture Collection
107-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
107-3-3	Date of deposit	03 August 1999 (03.08.1999)
107-3-4	Accession Number	ATCC PTA-477
107-4	Additional Indications	NONE
107-5	Designated States for Which Indications are Made	all designated States

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

107-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
108	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
108-1	page	100
108-2	line	49
108-3	Identification of Deposit	
108-3-1	Name of depositary institution	American Type Culture Collection
108-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
108-3-3	Date of deposit	03 August 1999 (03.08.1999)
108-3-4	Accession Number	ATCC PTA-488
108-4	Additional Indications	NONE
108-5	Designated States for Which Indications are Made	all designated States
108-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
109	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
109-1	page	100
109-2	line	50
109-3	Identification of Deposit	
109-3-1	Name of depositary institution	American Type Culture Collection
109-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
109-3-3	Date of deposit	16 March 1999 (16.03.1999)
109-3-4	Accession Number	ATCC 203849
109-4	Additional Indications	NONE
109-5	Designated States for Which Indications are Made	all designated States
109-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
110	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
110-1	page	100
110-2	line	51
110-3	Identification of Deposit	
110-3-1	Name of depositary institution	American Type Culture Collection
110-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
110-3-3	Date of deposit	09 March 1999 (09.03.1999)
110-3-4	Accession Number	ATCC 203837

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

110-4	Additional Indications	NONE
110-5	Designated States for Which Indications are Made	all designated States
110-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
111	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
111-1	page	100
111-2	line	52
111-3	Identification of Deposit	
111-3-1	Name of depositary institution	American Type Culture Collection
111-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
111-3-3	Date of deposit	20 July 1999 (20.07.1999)
111-3-4	Accession Number	ATCC PTA-380
111-4	Additional Indications	NONE
111-5	Designated States for Which Indications are Made	all designated States
111-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
112	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
112-1	page	100
112-2	line	53
112-3	Identification of Deposit	
112-3-1	Name of depositary institution	American Type Culture Collection
112-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
112-3-3	Date of deposit	11 May 1999 (11.05.1999)
112-3-4	Accession Number	ATCC PTA-44
112-4	Additional Indications	NONE
112-5	Designated States for Which Indications are Made	all designated States
112-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
113	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
113-1	page	100
113-2	line	54

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

113-3	Identification of Deposit	
113-3-1	Name of depositary institution	American Type Culture Collection
113-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
113-3-3	Date of deposit	11 May 1999 (11.05.1999)
113-3-4	Accession Number	ATCC PTA-42
113-4	Additional Indications	NONE
113-5	Designated States for Which Indications are Made	all designated States
113-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
114	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
114-1	page	100
114-2	line	55
114-3	Identification of Deposit	
114-3-1	Name of depositary institution	American Type Culture Collection
114-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
114-3-3	Date of deposit	25 May 1999 (25.05.1999)
114-3-4	Accession Number	ATCC PTA-123
114-4	Additional Indications	NONE
114-5	Designated States for Which Indications are Made	all designated States
114-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
115	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
115-1	page	101
115-2	line	2
115-3	Identification of Deposit	
115-3-1	Name of depositary institution	American Type Culture Collection
115-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
115-3-3	Date of deposit	03 August 1999 (03.08.1999)
115-3-4	Accession Number	ATCC PTA-482
115-4	Additional Indications	NONE
115-5	Designated States for Which Indications are Made	all designated States
115-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

116	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
116-1	page	101
116-2	line	3
116-3	Identification of Deposit	
116-3-1	Name of depositary institution	American Type Culture Collection
116-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
116-3-3	Date of deposit	03 August 1999 (03.08.1999)
116-3-4	Accession Number	ATCC PTA-483
116-4	Additional Indications	NONE
116-5	Designated States for Which Indications are Made	all designated States
116-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
117	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
117-1	page	101
117-2	line	4
117-3	Identification of Deposit	
117-3-1	Name of depositary institution	American Type Culture Collection
117-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
117-3-3	Date of deposit	03 August 1999 (03.08.1999)
117-3-4	Accession Number	ATCC PTA-485
117-4	Additional Indications	NONE
117-5	Designated States for Which Indications are Made	all designated States
117-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
118	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
118-1	page	101
118-2	line	5
118-3	Identification of Deposit	
118-3-1	Name of depositary institution	American Type Culture Collection
118-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
118-3-3	Date of deposit	03 August 1999 (03.08.1999)
118-3-4	Accession Number	ATCC PTA-480
118-4	Additional Indications	NONE
118-5	Designated States for Which Indications are Made	all designated States



PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

118-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
119	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
119-1	page	101
119-2	line	6
119-3	Identification of Deposit	
119-3-1	Name of depositary institution	American Type Culture Collection
119-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
119-3-3	Date of deposit	03 August 1999 (03.08.1999)
119-3-4	Accession Number	ATCC PTA-476
119-4	Additional Indications	NONE
119-5	Designated States for Which Indications are Made	all designated States
119-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
120	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
120-1	page	101
120-2	line	7
120-3	Identification of Deposit	
120-3-1	Name of depositary institution	American Type Culture Collection
120-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
120-3-3	Date of deposit	03 August 1999 (03.08.1999)
120-3-4	Accession Number	ATCC PTA-472
120-4	Additional Indications	NONE
120-5	Designated States for Which Indications are Made	all designated States
120-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
121	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
121-1	page	101
121-2	line	8
121-3	Identification of Deposit	
121-3-1	Name of depositary institution	American Type Culture Collection
121-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
121-3-3	Date of deposit	03 August 1999 (03.08.1999)
121-3-4	Accession Number	ATCC PTA-487

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

121-4	Additional Indications	NONE
121-5	Designated States for Which Indications are Made	all designated States
121-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
122	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
122-1	page	101
122-2	line	9
122-3	Identification of Deposit	
122-3-1	Name of depositary institution	American Type Culture Collection
122-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
122-3-3	Date of deposit	03 August 1999 (03.08.1999)
122-3-4	Accession Number	ATCC PTA-484
122-4	Additional Indications	NONE
122-5	Designated States for Which Indications are Made	all designated States
122-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
123	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
123-1	page	101
123-2	line	10
123-3	Identification of Deposit	
123-3-1	Name of depositary institution	American Type Culture Collection
123-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
123-3-3	Date of deposit	17 August 1999 (17.08.1999)
123-3-4	Accession Number	ATCC PTA-546
123-4	Additional Indications	NONE
123-5	Designated States for Which Indications are Made	all-designated States
123-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
124	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
124-1	page	101
124-2	line	11

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

124-3	Identification of Deposit	
124-3-1	Name of depositary institution	American Type Culture Collection
124-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
124-3-3	Date of deposit	10 August 1999 (10.08.1999)
124-3-4	Accession Number	ATCC PTA-515
124-4	Additional Indications	NONE
124-5	Designated States for Which Indications are Made	all designated States
124-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
125	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
125-1	page	101
125-2	line	12
125-3	Identification of Deposit	
125-3-1	Name of depositary institution	American Type Culture Collection
125-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
125-3-3	Date of deposit	19 October 1999 (19.10.1999)
125-3-4	Accession Number	ATCC PTA-861
125-4	Additional Indications	NONE
125-5	Designated States for Which Indications are Made	all designated States
125-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
126	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
126-1	page	101
126-2	line	13
126-3	Identification of Deposit	
126-3-1	Name of depositary institution	American Type Culture Collection
126-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
126-3-3	Date of deposit	10 August 1999 (10.08.1999)
126-3-4	Accession Number	ATCC PTA-518
126-4	Additional Indications	NONE
126-5	Designated States for Which Indications are Made	all designated States
126-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

127	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
127-1	page	101
127-2	line	14
127-3	Identification of Deposit	
127-3-1	Name of depositary institution	American Type Culture Collection
127-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
127-3-3	Date of deposit	10 August 1999 (10.08.1999)
127-3-4	Accession Number	ATCC PTA-512
127-4	Additional Indications	NONE
127-5	Designated States for Which Indications are Made	all designated States
127-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
128	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
128-1	page	101
128-2	line	15
128-3	Identification of Deposit	
128-3-1	Name of depositary institution	American Type Culture Collection
128-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
128-3-3	Date of deposit	03 August 1999 (03.08.1999)
128-3-4	Accession Number	ATCC PTA-489
128-4	Additional Indications	NONE
128-5	Designated States for Which Indications are Made	all designated States
128-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
129	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
129-1	page	101
129-2	line	16
129-3	Identification of Deposit	
129-3-1	Name of depositary institution	American Type Culture Collection
129-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
129-3-3	Date of deposit	31 August 1999 (31.08.1999)
129-3-4	Accession Number	ATCC PTA-614
129-4	Additional Indications	NONE
129-5	Designated States for Which Indications are Made	all designated States

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

129-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
130	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
130-1	page	101
130-2	line	17
130-3	Identification of Deposit	
130-3-1	Name of depositary institution	American Type Culture Collection
130-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
130-3-3	Date of deposit	16 November 1999 (16.11.1999)
130-3-4	Accession Number	ATCC PTA-957
130-4	Additional Indications	NONE
130-5	Designated States for Which Indications are Made	all designated States
130-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
131	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
131-1	page	101
131-2	line	18
131-3	Identification of Deposit	
131-3-1	Name of depositary institution	American Type Culture Collection
131-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
131-3-3	Date of deposit	05 October 1999 (05.10.1999)
131-3-4	Accession Number	ATCC PTA-819
131-4	Additional Indications	NONE
131-5	Designated States for Which Indications are Made	all designated States
131-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
132	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
132-1	page	101
132-2	line	19
132-3	Identification of Deposit	
132-3-1	Name of depositary institution	American Type Culture Collection
132-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
132-3-3	Date of deposit	18 September 1997 (18.09.1997)
132-3-4	Accession Number	ATCC 209280

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

132-4	Additional Indications	NONE
132-5	Designated States for Which Indications are Made	all designated States
132-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
133	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
133-1	page	101
133-2	line	20
133-3	Identification of Deposit	
133-3-1	Name of depositary institution	American Type Culture Collection
133-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
133-3-3	Date of deposit	14 April 1998 (14.04.1998)
133-3-4	Accession Number	ATCC 209772
133-4	Additional Indications	NONE
133-5	Designated States for Which Indications are Made	all designated States
133-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
134	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
134-1	page	101
134-2	line	21
134-3	Identification of Deposit	
134-3-1	Name of depositary institution	American Type Culture Collection
134-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
134-3-3	Date of deposit	16 October 1997 (16.10.1997)
134-3-4	Accession Number	ATCC 209375
134-4	Additional Indications	NONE
134-5	Designated States for Which Indications are Made	all designated States
134-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
135	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
135-1	page	101
135-2	line	22

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

135-3	Identification of Deposit	
135-3-1	Name of depositary institution	American Type Culture Collection
135-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
135-3-3	Date of deposit	23 September 1997 (23.09.1997)
135-3-4	Accession Number	ATCC 209296
135-4	Additional Indications	NONE
135-5	Designated States for Which Indications are Made	all designated States
135-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
136	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
136-1	page	101
136-2	line	23
136-3	Identification of Deposit	
136-3-1	Name of depositary institution	American Type Culture Collection
136-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
136-3-3	Date of deposit	18 September 1997 (18.09.1997)
136-3-4	Accession Number	ATCC 209279
136-4	Additional Indications	NONE
136-5	Designated States for Which Indications are Made	all designated States
136-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
137	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
137-1	page	101
137-2	line	24
137-3	Identification of Deposit	
137-3-1	Name of depositary institution	American Type Culture Collection
137-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
137-3-3	Date of deposit	05 March 1998 (05.03.1998)
137-3-4	Accession Number	ATCC 209653
137-4	Additional Indications	NONE
137-5	Designated States for Which Indications are Made	all designated States
137-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

138	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
138-1	page	101
138-2	line	25
138-3	Identification of Deposit	
138-3-1	Name of depositary institution	American Type Culture Collection
138-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
138-3-3	Date of deposit	16 October 1997 (16.10.1997)
138-3-4	Accession Number	ATCC 209385
138-4	Additional Indications	NONE
138-5	Designated States for Which Indications are Made	all designated States
138-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
139	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
139-1	page	101
139-2	line	26
139-3	Identification of Deposit	
139-3-1	Name of depositary institution	American Type Culture Collection
139-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
139-3-3	Date of deposit	16 September 1997 (16.09.1997)
139-3-4	Accession Number	ATCC 209261
139-4	Additional Indications	NONE
139-5	Designated States for Which Indications are Made	all designated States
139-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
140	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
140-1	page	101
140-2	line	27
140-3	Identification of Deposit	
140-3-1	Name of depositary institution	American Type Culture Collection
140-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
140-3-3	Date of deposit	16 October 1997 (16.10.1997)
140-3-4	Accession Number	ATCC 209384
140-4	Additional Indications	NONE
140-5	Designated States for Which Indications are Made	all designated States



PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

140-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
141	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
141-1	page	101
141-2	line	28
141-3	Identification of Deposit	
141-3-1	Name of depositary institution	American Type Culture Collection
141-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
141-3-3	Date of deposit	16 September 1997 (16.09.1997)
141-3-4	Accession Number	ATCC 209258
141-4	Additional Indications	NONE
141-5	Designated States for Which Indications are Made	all designated States
141-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
142	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
142-1	page	101
142-2	line	29
142-3	Identification of Deposit	
142-3-1	Name of depositary institution	American Type Culture Collection
142-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
142-3-3	Date of deposit	16 September 1997 (16.09.1997)
142-3-4	Accession Number	ATCC 209257
142-4	Additional Indications	NONE
142-5	Designated States for Which Indications are Made	all designated States
142-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
143	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
143-1	page	101
143-2	line	30
143-3	Identification of Deposit	
143-3-1	Name of depositary institution	American Type Culture Collection
143-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
143-3-3	Date of deposit	30 May 1997 (30.05.1997)
143-3-4	Accession Number	ATCC 209087

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

143-4	Additional Indications	NONE
143-5	Designated States for Which Indications are Made	all designated States
143-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
144	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
144-1	page	101
144-2	line	31
144-3	Identification of Deposit	
144-3-1	Name of depositary institution	American Type Culture Collection
144-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
144-3-3	Date of deposit	16 October 1997 (16.10.1997)
144-3-4	Accession Number	ATCC 209381
144-4	Additional Indications	NONE
144-5	Designated States for Which Indications are Made	all designated States
144-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
145	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
145-1	page	101
145-2	line	32
145-3	Identification of Deposit	
145-3-1	Name of depositary institution	American Type Culture Collection
145-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
145-3-3	Date of deposit	16 September 1997 (16.09.1997)
145-3-4	Accession Number	ATCC 209262
145-4	Additional Indications	NONE
145-5	Designated States for Which Indications are Made	all designated States
145-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
146	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
146-1	page	101
146-2	line	33

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

146-3	Identification of Deposit	
146-3-1	Name of depositary institution	American Type Culture Collection
146-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
146-3-3	Date of deposit	28 October 1997 (28.10.1997)
146-3-4	Accession Number	ATCC 209420
146-4	Additional Indications	NONE
146-5	Designated States for Which Indications are Made	all designated States
146-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
147	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
147-1	page	101
147-2	line	34
147-3	Identification of Deposit	
147-3-1	Name of depositary institution	American Type Culture Collection
147-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
147-3-3	Date of deposit	16 September 1997 (16.09.1997)
147-3-4	Accession Number	ATCC 209256
147-4	Additional Indications	NONE
147-5	Designated States for Which Indications are Made	all designated States
147-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
148	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
148-1	page	101
148-2	line	35
148-3	Identification of Deposit	
148-3-1	Name of depositary institution	American Type Culture Collection
148-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
148-3-3	Date of deposit	16 September 1997 (16.09.1997)
148-3-4	Accession Number	ATCC 209251
148-4	Additional Indications	NONE
148-5	Designated States for Which Indications are Made	all designated States
148-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

149	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
149-1	page	101
149-2	line	36
149-3	Identification of Deposit	
149-3-1	Name of depositary institution	American Type Culture Collection
149-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
149-3-3	Date of deposit	16 September 1997 (16.09.1997)
149-3-4	Accession Number	ATCC 209263
149-4	Additional Indications	NONE
149-5	Designated States for Which Indications are Made	all designated States
149-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
150	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
150-1	page	101
150-2	line	37
150-3	Identification of Deposit	
150-3-1	Name of depositary institution	American Type Culture Collection
150-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
150-3-3	Date of deposit	16 September 1997 (16.09.1997)
150-3-4	Accession Number	ATCC 209264
150-4	Additional Indications	NONE
150-5	Designated States for Which Indications are Made	all designated States
150-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
151	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
151-1	page	101
151-2	line	38
151-3	Identification of Deposit	
151-3-1	Name of depositary institution	American Type Culture Collection
151-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
151-3-3	Date of deposit	16 October 1997 (16.10.1997)
151-3-4	Accession Number	ATCC 209376
151-4	Additional Indications	NONE
151-5	Designated States for Which Indications are Made	all designated States

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

151-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
152	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
152-1	page	101
152-2	line	39
152-3	Identification of Deposit	
152-3-1	Name of depositary institution	American Type Culture Collection
152-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
152-3-3	Date of deposit	17 October 1997 (17.10.1997)
152-3-4	Accession Number	ATCC 209391
152-4	Additional Indications	NONE
152-5	Designated States for Which Indications are Made	all designated States
152-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
153	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
153-1	page	101
153-2	line	40
153-3	Identification of Deposit	
153-3-1	Name of depositary institution	American Type Culture Collection
153-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
153-3-3	Date of deposit	28 October 1997 (28.10.1997)
153-3-4	Accession Number	ATCC 209417
153-4	Additional Indications	NONE
153-5	Designated States for Which Indications are Made	all designated States
153-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
154	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
154-1	page	101
154-2	line	41
154-3	Identification of Deposit	
154-3-1	Name of depositary institution	American Type Culture Collection
154-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
154-3-3	Date of deposit	16 September 1997 (16.09.1997)
154-3-4	Accession Number	ATCC 209253

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

154-4	Additional Indications	NONE
154-5	Designated States for Which Indications are Made	all designated States
154-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
155	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
155-1	page	101
155-2	line	42
155-3	Identification of Deposit	
155-3-1	Name of depositary institution	American Type Culture Collection
155-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
155-3-3	Date of deposit	12 May 1998 (12.05.1998)
155-3-4	Accession Number	ATCC 209855
155-4	Additional Indications	NONE
155-5	Designated States for Which Indications are Made	all designated States
155-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
156	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
156-1	page	101
156-2	line	43
156-3	Identification of Deposit	
156-3-1	Name of depositary institution	American Type Culture Collection
156-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
156-3-3	Date of deposit	10 December 1997 (10.12.1997)
156-3-4	Accession Number	ATCC 209526
156-4	Additional Indications	NONE
156-5	Designated States for Which Indications are Made	all designated States
156-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
157	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
157-1	page	101
157-2	line	44

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

157-3	Identification of Deposit	
157-3-1	Name of depositary institution	American Type Culture Collection
157-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
157-3-3	Date of deposit	16 September 1997 (16.09.1997)
157-3-4	Accession Number	ATCC 209252
157-4	Additional Indications	NONE
157-5	Designated States for Which Indications are Made	all designated States
157-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
158	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
158-1	page	101
158-2	line	45
158-3	Identification of Deposit	
158-3-1	Name of depositary institution	American Type Culture Collection
158-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
158-3-3	Date of deposit	16 October 1997 (16.10.1997)
158-3-4	Accession Number	ATCC 209374
158-4	Additional Indications	NONE
158-5	Designated States for Which Indications are Made	all designated States
158-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
159	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
159-1	page	101
159-2	line	46
159-3	Identification of Deposit	
159-3-1	Name of depositary institution	American Type Culture Collection
159-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
159-3-3	Date of deposit	10 December 1997 (10.12.1997)
159-3-4	Accession Number	ATCC 209528
159-4	Additional Indications	NONE
159-5	Designated States for Which Indications are Made	all designated States
159-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

160	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
160-1	page	101
160-2	line	47
160-3	Identification of Deposit	
160-3-1	Name of depositary institution	American Type Culture Collection
160-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
160-3-3	Date of deposit	16 September 1997 (16.09.1997)
160-3-4	Accession Number	ATCC 209265
160-4	Additional Indications	NONE
160-5	Designated States for Which Indications are Made	all designated States
160-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
161	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
161-1	page	101
161-2	line	48
161-3	Identification of Deposit	
161-3-1	Name of depositary institution	American Type Culture Collection
161-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
161-3-3	Date of deposit	17 October 1997 (17.10.1997)
161-3-4	Accession Number	ATCC 209396
161-4	Additional Indications	NONE
161-5	Designated States for Which Indications are Made	all designated States
161-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
162	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
162-1	page	101
162-2	line	49
162-3	Identification of Deposit	
162-3-1	Name of depositary institution	American Type Culture Collection
162-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
162-3-3	Date of deposit	18 August 1997 (18.08.1997)
162-3-4	Accession Number	ATCC 209201
162-4	Additional Indications	NONE
162-5	Designated States for Which Indications are Made	all designated States



PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

162-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
163	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
163-1	page	101
163-2	line	50
163-3	Identification of Deposit	
163-3-1	Name of depositary institution	American Type Culture Collection
163-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
163-3-3	Date of deposit	28 October 1997 (28.10.1997)
163-3-4	Accession Number	ATCC 209416
163-4	Additional Indications	NONE
163-5	Designated States for Which Indications are Made	all designated States
163-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
164	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
164-1	page	101
164-2	line	51
164-3	Identification of Deposit	
164-3-1	Name of depositary institution	American Type Culture Collection
164-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
164-3-3	Date of deposit	17 October 1997 (17.10.1997)
164-3-4	Accession Number	ATCC 209403
164-4	Additional Indications	NONE
164-5	Designated States for Which Indications are Made	all designated States
164-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
165	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
165-1	page	101
165-2	line	52
165-3	Identification of Deposit	
165-3-1	Name of depositary institution	American Type Culture Collection
165-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
165-3-3	Date of deposit	28 October 1997 (28.10.1997)
165-3-4	Accession Number	ATCC 209419

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

165-4	Additional Indications	NONE
165-5	Designated States for Which Indications are Made	all designated States
165-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
166	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
166-1	page	101
166-2	line	53
166-3	Identification of Deposit	
166-3-1	Name of depositary institution	American Type Culture Collection
166-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
166-3-3	Date of deposit	17 October 1997 (17.10.1997)
166-3-4	Accession Number	ATCC 209402
166-4	Additional Indications	NONE
166-5	Designated States for Which Indications are Made	all designated States
166-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
167	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
167-1	page	101
167-2	line	54
167-3	Identification of Deposit	
167-3-1	Name of depositary institution	American Type Culture Collection
167-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
167-3-3	Date of deposit	16 October 1997 (16.10.1997)
167-3-4	Accession Number	ATCC 209378
167-4	Additional Indications	NONE
167-5	Designated States for Which Indications are Made	all designated States
167-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
168	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
168-1	page	101
168-2	line	55

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

168-3	Identification of Deposit	
168-3-1	Name of depositary institution	American Type Culture Collection
168-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
168-3-3	Date of deposit	21 November 1997 (21.11.1997)
168-3-4	Accession Number	ATCC 209489
168-4	Additional Indications	NONE
168-5	Designated States for Which Indications are Made	all designated States
168-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
169	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
169-1	page	102
169-2	line	2
169-3	Identification of Deposit	
169-3-1	Name of depositary institution	American Type Culture Collection
169-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
169-3-3	Date of deposit	17 October 1997 (17.10.1997)
169-3-4	Accession Number	ATCC 209401
169-4	Additional Indications	NONE
169-5	Designated States for Which Indications are Made	all designated States
169-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
170	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
170-1	page	102
170-2	line	3
170-3	Identification of Deposit	
170-3-1	Name of depositary institution	American Type Culture Collection
170-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
170-3-3	Date of deposit	17 October 1997 (17.10.1997)
170-3-4	Accession Number	ATCC 209397
170-4	Additional Indications	NONE
170-5	Designated States for Which Indications are Made	all designated States
170-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

171	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
171-1	page	102
171-2	line	4
171-3	Identification of Deposit	
171-3-1	Name of depositary institution	American Type Culture Collection
171-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
171-3-3	Date of deposit	17 October 1997 (17.10.1997)
171-3-4	Accession Number	ATCC 209389
171-4	Additional Indications	NONE
171-5	Designated States for Which Indications are Made	all designated States
171-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
172	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
172-1	page	102
172-2	line	5
172-3	Identification of Deposit	
172-3-1	Name of depositary institution	American Type Culture Collection
172-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
172-3-3	Date of deposit	07 November 1997 (07.11.1997)
172-3-4	Accession Number	ATCC 209438
172-4	Additional Indications	NONE
172-5	Designated States for Which Indications are Made	all designated States
172-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
173	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
173-1	page	102
173-2	line	6
173-3	Identification of Deposit	
173-3-1	Name of depositary institution	American Type Culture Collection
173-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
173-3-3	Date of deposit	21 November 1997 (21.11.1997)
173-3-4	Accession Number	ATCC 209492
173-4	Additional Indications	NONE
173-5	Designated States for Which Indications are Made	all designated States

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

173-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
174	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
174-1	page	102
174-2	line	7
174-3	Identification of Deposit	
174-3-1	Name of depositary institution	American Type Culture Collection
174-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
174-3-3	Date of deposit	17 October 1997 (17.10.1997)
174-3-4	Accession Number	ATCC 209388
174-4	Additional Indications	NONE
174-5	Designated States for Which Indications are Made	all designated States
174-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
175	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
175-1	page	102
175-2	line	8
175-3	Identification of Deposit	
175-3-1	Name of depositary institution	American Type Culture Collection
175-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
175-3-3	Date of deposit	07 November 1997 (07.11.1997)
175-3-4	Accession Number	ATCC 209432
175-4	Additional Indications	NONE
175-5	Designated States for Which Indications are Made	all designated States
175-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
176	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
176-1	page	102
176-2	line	9
176-3	Identification of Deposit	
176-3-1	Name of depositary institution	American Type Culture Collection
176-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
176-3-3	Date of deposit	07 November 1997 (07.11.1997)
176-3-4	Accession Number	ATCC 209439

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

176-4	Additional Indications	NONE
176-5	Designated States for Which Indications are Made	all designated States
176-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
177	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
177-1	page	102
177-2	line	10
177-3	Identification of Deposit	
177-3-1	Name of depositary institution	American Type Culture Collection
177-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
177-3-3	Date of deposit	07 November 1997 (07.11.1997)
177-3-4	Accession Number	ATCC 209433
177-4	Additional Indications	NONE
177-5	Designated States for Which Indications are Made	all designated States
177-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
178	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
178-1	page	102
178-2	line	11
178-3	Identification of Deposit	
178-3-1	Name of depositary institution	American Type Culture Collection
178-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
178-3-3	Date of deposit	05 February 1998 (05.02.1998)
178-3-4	Accession Number	ATCC 209618
178-4	Additional Indications	NONE
178-5	Designated States for Which Indications are Made	all designated States
178-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
179	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
179-1	page	102
179-2	line	12

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

179-3	Identification of Deposit	
179-3-1	Name of depositary institution	American Type Culture Collection
179-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
179-3-3	Date of deposit	21 November 1997 (21.11.1997)
179-3-4	Accession Number	ATCC 209484
179-4	Additional Indications	NONE
179-5	Designated States for Which Indications are Made	all designated States
179-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
180	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
180-1	page	102
180-2	line	13
180-3	Identification of Deposit	
180-3-1	Name of depositary institution	American Type Culture Collection
180-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
180-3-3	Date of deposit	21 November 1997 (21.11.1997)
180-3-4	Accession Number	ATCC 209487
180-4	Additional Indications	NONE
180-5	Designated States for Which Indications are Made	all designated States
180-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
181	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
181-1	page	102
181-2	line	14
181-3	Identification of Deposit	
181-3-1	Name of depositary institution	American Type Culture Collection
181-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
181-3-3	Date of deposit	07 November 1997 (07.11.1997)
181-3-4	Accession Number	ATCC 209434
181-4	Additional Indications	NONE
181-5	Designated States for Which Indications are Made	all designated States
181-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

182	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
182-1	page	102
182-2	line	15
182-3	Identification of Deposit	
182-3-1	Name of depositary institution	American Type Culture Collection
182-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
182-3-3	Date of deposit	26 March 1998 (26.03.1998)
182-3-4	Accession Number	ATCC 209704
182-4	Additional Indications	NONE
182-5	Designated States for Which Indications are Made	all designated States
182-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
183	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
183-1	page	102
183-2	line	16
183-3	Identification of Deposit	
183-3-1	Name of depositary institution	American Type Culture Collection
183-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
183-3-3	Date of deposit	28 April 1998 (28.04.1998)
183-3-4	Accession Number	ATCC 209808
183-4	Additional Indications	NONE
183-5	Designated States for Which Indications are Made	all designated States
183-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
184	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
184-1	page	102
184-2	line	17
184-3	Identification of Deposit	
184-3-1	Name of depositary institution	American Type Culture Collection
184-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
184-3-3	Date of deposit	06 May 1998 (06.05.1998)
184-3-4	Accession Number	ATCC 209847
184-4	Additional Indications	NONE
184-5	Designated States for Which Indications are Made	all designated States



PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

184-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
185	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
185-1	page	102
185-2	line	18
185-3	Identification of Deposit	
185-3-1	Name of depositary institution	American Type Culture Collection
185-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
185-3-3	Date of deposit	05 February 1998 (05.02.1998)
185-3-4	Accession Number	ATCC 209616
185-4	Additional Indications	NONE
185-5	Designated States for Which Indications are Made	all designated States
185-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
186	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
186-1	page	102
186-2	line	19
186-3	Identification of Deposit	
186-3-1	Name of depositary institution	American Type Culture Collection
186-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
186-3-3	Date of deposit	05 February 1998 (05.02.1998)
186-3-4	Accession Number	ATCC 209619
186-4	Additional Indications	NONE
186-5	Designated States for Which Indications are Made	all designated States
186-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
187	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
187-1	page	102
187-2	line	20
187-3	Identification of Deposit	
187-3-1	Name of depositary institution	American Type Culture Collection
187-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
187-3-3	Date of deposit	11 August 1998 (11.08.1998)
187-3-4	Accession Number	ATCC 203109

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

187-4	Additional Indications	NONE
187-5	Designated States for Which Indications are Made	all designated States
187-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
188	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
188-1	page	102
188-2	line	21
188-3	Identification of Deposit	
188-3-1	Name of depositary institution	American Type Culture Collection
188-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
188-3-3	Date of deposit	31 March 1998 (31.03.1998)
188-3-4	Accession Number	ATCC 209715
188-4	Additional Indications	NONE
188-5	Designated States for Which Indications are Made	all designated States
188-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
189	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
189-1	page	102
189-2	line	22
189-3	Identification of Deposit	
189-3-1	Name of depositary institution	American Type Culture Collection
189-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
189-3-3	Date of deposit	11 March 1998 (11.03.1998)
189-3-4	Accession Number	ATCC 209669
189-4	Additional Indications	NONE
189-5	Designated States for Which Indications are Made	all designated States
189-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
190	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
190-1	page	102
190-2	line	23

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

190-3	Identification of Deposit	
190-3-1	Name of depositary institution	American Type Culture Collection
190-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
190-3-3	Date of deposit	23 June 1998 (23.06.1998)
190-3-4	Accession Number	ATCC 203002
190-4	Additional Indications	NONE
190-5	Designated States for Which Indications are Made	all designated States
190-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
191	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
191-1	page	102
191-2	line	24
191-3	Identification of Deposit	
191-3-1	Name of depositary institution	American Type Culture Collection
191-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
191-3-3	Date of deposit	26 March 1998 (26.03.1998)
191-3-4	Accession Number	ATCC 209705
191-4	Additional Indications	NONE
191-5	Designated States for Which Indications are Made	all designated States
191-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
192	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
192-1	page	102
192-2	line	25
192-3	Identification of Deposit	
192-3-1	Name of depositary institution	American Type Culture Collection
192-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
192-3-3	Date of deposit	16 June 1998 (16.06.1998)
192-3-4	Accession Number	ATCC 209981
192-4	Additional Indications	NONE
192-5	Designated States for Which Indications are Made	all designated States
192-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

193	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
193-1	page	102
193-2	line	26
193-3	Identification of Deposit	
193-3-1	Name of depositary institution	American Type Culture Collection
193-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
193-3-3	Date of deposit	07 April 1998 (07.04.1998)
193-3-4	Accession Number	ATCC 209749
193-4	Additional Indications	NONE
193-5	Designated States for Which Indications are Made	all designated States
193-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
194	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
194-1	page	102
194-2	line	27
194-3	Identification of Deposit	
194-3-1	Name of depositary institution	American Type Culture Collection
194-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
194-3-3	Date of deposit	12 May 1998 (12.05.1998)
194-3-4	Accession Number	ATCC 209859
194-4	Additional Indications	NONE
194-5	Designated States for Which Indications are Made	all designated States
194-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
195	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
195-1	page	102
195-2	line	28
195-3	Identification of Deposit	
195-3-1	Name of depositary institution	American Type Culture Collection
195-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
195-3-3	Date of deposit	06 May 1998 (06.05.1998)
195-3-4	Accession Number	ATCC 209845
195-4	Additional Indications	NONE
195-5	Designated States for Which Indications are Made	all designated States

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

195-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
196	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
196-1	page	102
196-2	line	29
196-3	Identification of Deposit	
196-3-1	Name of depositary institution	American Type Culture Collection
196-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
196-3-3	Date of deposit	07 April 1998 (07.04.1998)
196-3-4	Accession Number	ATCC 209748
196-4	Additional Indications	NONE
196-5	Designated States for Which Indications are Made	all designated States
196-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
197	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
197-1	page	102
197-2	line	30
197-3	Identification of Deposit	
197-3-1	Name of depositary institution	American Type Culture Collection
197-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
197-3-3	Date of deposit	11 August 1998 (11.08.1998)
197-3-4	Accession Number	ATCC 203107
197-4	Additional Indications	NONE
197-5	Designated States for Which Indications are Made	all designated States
197-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
198	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
198-1	page	102
198-2	line	31
198-3	Identification of Deposit	
198-3-1	Name of depositary institution	American Type Culture Collection
198-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
198-3-3	Date of deposit	23 April 1998 (23.04.1998)
198-3-4	Accession Number	ATCC 209801

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

198-4	Additional Indications	NONE
198-5	Designated States for Which Indications are Made	all designated States
198-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
199	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
199-1	page	102
199-2	line	32
199-3	Identification of Deposit	
199-3-1	Name of depositary institution	American Type Culture Collection
199-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
199-3-3	Date of deposit	09 June 1998 (09.06.1998)
199-3-4	Accession Number	ATCC 209948
199-4	Additional Indications	NONE
199-5	Designated States for Which Indications are Made	all designated States
199-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
200	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
200-1	page	102
200-2	line	33
200-3	Identification of Deposit	
200-3-1	Name of depositary institution	American Type Culture Collection
200-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
200-3-3	Date of deposit	20 May 1998 (20.05.1998)
200-3-4	Accession Number	ATCC 209883
200-4	Additional Indications	NONE
200-5	Designated States for Which Indications are Made	all designated States
200-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
201	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
201-1	page	102
201-2	line	34

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

201-3	Identification of Deposit	
201-3-1	Name of depositary institution	American Type Culture Collection
201-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
201-3-3	Date of deposit	01 July 1998 (01.07.1998)
201-3-4	Accession Number	ATCC 203049
201-4	Additional Indications	NONE
201-5	Designated States for Which Indications are Made	all designated States
201-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
202	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
202-1	page	102
202-2	line	35
202-3	Identification of Deposit	
202-3-1	Name of depositary institution	American Type Culture Collection
202-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
202-3-3	Date of deposit	06 May 1998 (06.05.1998)
202-3-4	Accession Number	ATCC 209846
202-4	Additional Indications	NONE
202-5	Designated States for Which Indications are Made	all designated States
202-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
203	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
203-1	page	102
203-2	line	36
203-3	Identification of Deposit	
203-3-1	Name of depositary institution	American Type Culture Collection
203-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
203-3-3	Date of deposit	12 May 1998 (12.05.1998)
203-3-4	Accession Number	ATCC 209857
203-4	Additional Indications	NONE
203-5	Designated States for Which Indications are Made	all designated States
203-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

204	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
204-1	page	102
204-2	line	37
204-3	Identification of Deposit	
204-3-1	Name of depositary institution	American Type Culture Collection
204-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
204-3-3	Date of deposit	14 May 1998 (14.05.1998)
204-3-4	Accession Number	ATCC 209864
204-4	Additional Indications	NONE
204-5	Designated States for Which Indications are Made	all designated States
204-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
205	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
205-1	page	102
205-2	line	38
205-3	Identification of Deposit	
205-3-1	Name of depositary institution	American Type Culture Collection
205-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
205-3-3	Date of deposit	20 May 1998 (20.05.1998)
205-3-4	Accession Number	ATCC 209880
205-4	Additional Indications	NONE
205-5	Designated States for Which Indications are Made	all designated States
205-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
206	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
206-1	page	102
206-2	line	39
206-3	Identification of Deposit	
206-3-1	Name of depositary institution	American Type Culture Collection
206-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
206-3-3	Date of deposit	14 May 1998 (14.05.1998)
206-3-4	Accession Number	ATCC 209869
206-4	Additional Indications	NONE
206-5	Designated States for Which Indications are Made	all designated States



PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

206-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
207	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
207-1	page	102
207-2	line	40
207-3	Identification of Deposit	
207-3-1	Name of depositary institution	American Type Culture Collection
207-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
207-3-3	Date of deposit	09 June 1998 (09.06.1998)
207-3-4	Accession Number	ATCC 209950
207-4	Additional Indications	NONE
207-5	Designated States for Which Indications are Made	all designated States
207-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
208	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
208-1	page	102
208-2	line	41
208-3	Identification of Deposit	
208-3-1	Name of depositary institution	American Type Culture Collection
208-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
208-3-3	Date of deposit	23 June 1998 (23.06.1998)
208-3-4	Accession Number	ATCC 203008
208-4	Additional Indications	NONE
208-5	Designated States for Which Indications are Made	all designated States
208-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
209	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
209-1	page	102
209-2	line	42
209-3	Identification of Deposit	
209-3-1	Name of depositary institution	American Type Culture Collection
209-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
209-3-3	Date of deposit	23 June 1998 (23.06.1998)
209-3-4	Accession Number	ATCC 203014

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

209-4	Additional Indications	NONE
209-5	Designated States for Which Indications are Made	all designated States
209-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
210	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
210-1	page	102
210-2	line	43
210-3	Identification of Deposit	
210-3-1	Name of depositary institution	American Type Culture Collection
210-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
210-3-3	Date of deposit	11 August 1998 (11.08.1998)
210-3-4	Accession Number	ATCC 203110
210-4	Additional Indications	NONE
210-5	Designated States for Which Indications are Made	all designated States
210-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
211	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
211-1	page	102
211-2	line	44
211-3	Identification of Deposit	
211-3-1	Name of depositary institution	American Type Culture Collection
211-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
211-3-3	Date of deposit	23 June 1998 (23.06.1998)
211-3-4	Accession Number	ATCC 203009
211-4	Additional Indications	NONE
211-5	Designated States for Which Indications are Made	all designated States
211-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
212	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
212-1	page	102
212-2	line	45

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

212-3	Identification of Deposit	
212-3-1	Name of depositary institution	American Type Culture Collection
212-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
212-3-3	Date of deposit	09 June 1998 (09.06.1998)
212-3-4	Accession Number	ATCC 209961
212-4	Additional Indications	NONE
212-5	Designated States for Which Indications are Made	all designated States
212-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
213	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
213-1	page	102
213-2	line	46
213-3	Identification of Deposit	
213-3-1	Name of depositary institution	American Type Culture Collection
213-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
213-3-3	Date of deposit	09 June 1998 (09.06.1998)
213-3-4	Accession Number	ATCC 209962
213-4	Additional Indications	NONE
213-5	Designated States for Which Indications are Made	all designated States
213-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
214	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
214-1	page	102
214-2	line	47
214-3	Identification of Deposit	
214-3-1	Name of depositary institution	American Type Culture Collection
214-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
214-3-3	Date of deposit	14 May 1998 (14.05.1998)
214-3-4	Accession Number	ATCC 209866
214-4	Additional Indications	NONE
214-5	Designated States for Which Indications are Made	all designated States
214-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

215	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
215-1	page	102
215-2	line	48
215-3	Identification of Deposit	
215-3-1	Name of depositary institution	American Type Culture Collection
215-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
215-3-3	Date of deposit	25 August 1998 (25.08.1998)
215-3-4	Accession Number	ATCC 203157
215-4	Additional Indications	NONE
215-5	Designated States for Which Indications are Made	all designated States
215-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
216	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
216-1	page	102
216-2	line	49
216-3	Identification of Deposit	
216-3-1	Name of depositary institution	American Type Culture Collection
216-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
216-3-3	Date of deposit	11 August 1998 (11.08.1998)
216-3-4	Accession Number	ATCC 203106
216-4	Additional Indications	NONE
216-5	Designated States for Which Indications are Made	all designated States
216-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
217	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
217-1	page	102
217-2	line	50
217-3	Identification of Deposit	
217-3-1	Name of depositary institution	American Type Culture Collection
217-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
217-3-3	Date of deposit	09 June 1998 (09.06.1998)
217-3-4	Accession Number	ATCC 209945
217-4	Additional Indications	NONE
217-5	Designated States for Which Indications are Made	all designated States

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

217-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
218	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
218-1	page	102
218-2	line	51
218-3	Identification of Deposit	
218-3-1	Name of depositary institution	American Type Culture Collection
218-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
218-3-3	Date of deposit	16 June 1998 (16.06.1998)
218-3-4	Accession Number	ATCC 209989
218-4	Additional Indications	NONE
218-5	Designated States for Which Indications are Made	all designated States
218-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
219	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
219-1	page	102
219-2	line	52
219-3	Identification of Deposit	
219-3-1	Name of depositary institution	American Type Culture Collection
219-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
219-3-3	Date of deposit	11 August 1998 (11.08.1998)
219-3-4	Accession Number	ATCC 203108
219-4	Additional Indications	NONE
219-5	Designated States for Which Indications are Made	all designated States
219-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
220	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
220-1	page	102
220-2	line	53
220-3	Identification of Deposit	
220-3-1	Name of depositary institution	American Type Culture Collection
220-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
220-3-3	Date of deposit	11 August 1998 (11.08.1998)
220-3-4	Accession Number	ATCC 203111

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

220-4	Additional Indications	NONE
220-5	Designated States for Which Indications are Made	all designated States
220-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
221	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
221-1	page	102
221-2	line	54
221-3	Identification of Deposit	
221-3-1	Name of depositary institution	American Type Culture Collection
221-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
221-3-3	Date of deposit	20 October 1998 (20.10.1998)
221-3-4	Accession Number	ATCC 203359
221-4	Additional Indications	NONE
221-5	Designated States for Which Indications are Made	all designated States
221-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
222	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
222-1	page	102
222-2	line	55
222-3	Identification of Deposit	
222-3-1	Name of depositary institution	American Type Culture Collection
222-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
222-3-3	Date of deposit	16 June 1998 (16.06.1998)
222-3-4	Accession Number	ATCC 209988
222-4	Additional Indications	NONE
222-5	Designated States for Which Indications are Made	all designated States
222-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
223	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
223-1	page	103
223-2	line	2

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

223-3	Identification of Deposit	
223-3-1	Name of depositary institution	American Type Culture Collection
223-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
223-3-3	Date of deposit	16 June 1998 (16.06.1998)
223-3-4	Accession Number	ATCC 209978
223-4	Additional Indications	NONE
223-5	Designated States for Which Indications are Made	all designated States
223-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
224	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
224-1	page	103
224-2	line	3
224-3	Identification of Deposit	
224-3-1	Name of depositary institution	American Type Culture Collection
224-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
224-3-3	Date of deposit	04 August 1998 (04.08.1998)
224-3-4	Accession Number	ATCC 203098
224-4	Additional Indications	NONE
224-5	Designated States for Which Indications are Made	all designated States
224-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
225	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
225-1	page	103
225-2	line	4
225-3	Identification of Deposit	
225-3-1	Name of depositary institution	American Type Culture Collection
225-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
225-3-3	Date of deposit	16 June 1998 (16.06.1998)
225-3-4	Accession Number	ATCC 209980
225-4	Additional Indications	NONE
225-5	Designated States for Which Indications are Made	all designated States
225-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

226	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
226-1	page	103
226-2	line	5
226-3	Identification of Deposit	
226-3-1	Name of depositary institution	American Type Culture Collection
226-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
226-3-3	Date of deposit	04 August 1998 (04.08.1998)
226-3-4	Accession Number	ATCC 203091
226-4	Additional Indications	NONE
226-5	Designated States for Which Indications are Made	all designated States
226-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
227	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
227-1	page	103
227-2	line	6
227-3	Identification of Deposit	
227-3-1	Name of depositary institution	American Type Culture Collection
227-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
227-3-3	Date of deposit	04 August 1998 (04.08.1998)
227-3-4	Accession Number	ATCC 203090
227-4	Additional Indications	NONE
227-5	Designated States for Which Indications are Made	all designated States
227-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
228	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
228-1	page	103
228-2	line	7
228-3	Identification of Deposit	
228-3-1	Name of depositary institution	American Type Culture Collection
228-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
228-3-3	Date of deposit	04 August 1998 (04.08.1998)
228-3-4	Accession Number	ATCC 203092
228-4	Additional Indications	NONE
228-5	Designated States for Which Indications are Made	all designated States



PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

228-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
229	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
229-1	page	103
229-2	line	8
229-3	Identification of Deposit	
229-3-1	Name of depositary institution	American Type Culture Collection
229-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
229-3-3	Date of deposit	10 November 1998 (10.11.1998)
229-3-4	Accession Number	ATCC 203452
229-4	Additional Indications	NONE
229-5	Designated States for Which Indications are Made	all designated States
229-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
230	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
230-1	page	103
230-2	line	9
230-3	Identification of Deposit	
230-3-1	Name of depositary institution	American Type Culture Collection
230-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
230-3-3	Date of deposit	01 September 1998 (01.09.1998)
230-3-4	Accession Number	ATCC 203173
230-4	Additional Indications	NONE
230-5	Designated States for Which Indications are Made	all designated States
230-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
231	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
231-1	page	103
231-2	line	10
231-3	Identification of Deposit	
231-3-1	Name of depositary institution	American Type Culture Collection
231-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
231-3-3	Date of deposit	17 November 1998 (17.11.1998)
231-3-4	Accession Number	ATCC 203464

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

231-4	Additional Indications	NONE
231-5	Designated States for Which Indications are Made	all designated States
231-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
232	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
232-1	page	103
232-2	line	11
232-3	Identification of Deposit	
232-3-1	Name of depositary institution	American Type Culture Collection
232-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
232-3-3	Date of deposit	18 August 1998 (18.08.1998)
232-3-4	Accession Number	ATCC 203132
232-4	Additional Indications	NONE
232-5	Designated States for Which Indications are Made	all designated States
232-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
233	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
233-1	page	103
233-2	line	12
233-3	Identification of Deposit	
233-3-1	Name of depositary institution	American Type Culture Collection
233-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
233-3-3	Date of deposit	09 September 1998 (09.09.1998)
233-3-4	Accession Number	ATCC 203254
233-4	Additional Indications	NONE
233-5	Designated States for Which Indications are Made	all designated States
233-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
234	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
234-1	page	103
234-2	line	13

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

234-3	Identification of Deposit	
234-3-1	Name of depositary institution	American Type Culture Collection
234-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
234-3-3	Date of deposit	20 October 1998 (20.10.1998)
234-3-4	Accession Number	ATCC 203358
234-4	Additional Indications	NONE
234-5	Designated States for Which Indications are Made	all designated States
234-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
235	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
235-1	page	103
235-2	line	14
235-3	Identification of Deposit	
235-3-1	Name of depositary institution	American Type Culture Collection
235-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
235-3-3	Date of deposit	04 August 1998 (04.08.1998)
235-3-4	Accession Number	ATCC 203093
235-4	Additional Indications	NONE
235-5	Designated States for Which Indications are Made	all designated States
235-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
236	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
236-1	page	103
236-2	line	15
236-3	Identification of Deposit	
236-3-1	Name of depositary institution	American Type Culture Collection
236-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
236-3-3	Date of deposit	03 November 1998 (03.11.1998)
236-3-4	Accession Number	ATCC 203457
236-4	Additional Indications	NONE
236-5	Designated States for Which Indications are Made	all designated States
236-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

237	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
237-1	page	103
237-2	line	16
237-3	Identification of Deposit	
237-3-1	Name of depositary institution	American Type Culture Collection
237-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
237-3-3	Date of deposit	09 September 1998 (09.09.1998)
237-3-4	Accession Number	ATCC 203241
237-4	Additional Indications	NONE
237-5	Designated States for Which Indications are Made	all designated States
237-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
238	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
238-1	page	103
238-2	line	17
238-3	Identification of Deposit	
238-3-1	Name of depositary institution	American Type Culture Collection
238-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
238-3-3	Date of deposit	09 September 1998 (09.09.1998)
238-3-4	Accession Number	ATCC 203249
238-4	Additional Indications	NONE
238-5	Designated States for Which Indications are Made	all designated States
238-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
239	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
239-1	page	103
239-2	line	18
239-3	Identification of Deposit	
239-3-1	Name of depositary institution	American Type Culture Collection
239-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
239-3-3	Date of deposit	09 September 1998 (09.09.1998)
239-3-4	Accession Number	ATCC 203250
239-4	Additional Indications	NONE
239-5	Designated States for Which Indications are Made	all designated States

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

239-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
240	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
240-1	page	103
240-2	line	19
240-3	Identification of Deposit	
240-3-1	Name of depositary institution	American Type Culture Collection
240-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
240-3-3	Date of deposit	18 August 1998 (18.08.1998)
240-3-4	Accession Number	ATCC 203131
240-4	Additional Indications	NONE
240-5	Designated States for Which Indications are Made	all designated States
240-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
241	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
241-1	page	103
241-2	line	20
241-3	Identification of Deposit	
241-3-1	Name of depositary institution	American Type Culture Collection
241-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
241-3-3	Date of deposit	15 September 1998 (15.09.1998)
241-3-4	Accession Number	ATCC 203223
241-4	Additional Indications	NONE
241-5	Designated States for Which Indications are Made	all designated States
241-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
242	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
242-1	page	103
242-2	line	21
242-3	Identification of Deposit	
242-3-1	Name of depositary institution	American Type Culture Collection
242-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
242-3-3	Date of deposit	15 September 1998 (15.09.1998)
242-3-4	Accession Number	ATCC 203233

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

242-4	Additional Indications	NONE
242-5	Designated States for Which Indications are Made	all designated States
242-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
243	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
243-1	page	103
243-2	line	22
243-3	Identification of Deposit	
243-3-1	Name of depositary institution	American Type Culture Collection
243-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
243-3-3	Date of deposit	09 September 1998 (09.09.1998)
243-3-4	Accession Number	ATCC 203252
243-4	Additional Indications	NONE
243-5	Designated States for Which Indications are Made	all designated States
243-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
244	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
244-1	page	103
244-2	line	23
244-3	Identification of Deposit	
244-3-1	Name of depositary institution	American Type Culture Collection
244-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
244-3-3	Date of deposit	17 November 1998 (17.11.1998)
244-3-4	Accession Number	ATCC 203476
244-4	Additional Indications	NONE
244-5	Designated States for Which Indications are Made	all designated States
244-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
245	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
245-1	page	103
245-2	line	24

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

245-3	Identification of Deposit	
245-3-1	Name of depositary institution	American Type Culture Collection
245-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
245-3-3	Date of deposit	04 August 1998 (04.08.1998)
245-3-4	Accession Number	ATCC 203094
245-4	Additional Indications	NONE
245-5	Designated States for Which Indications are Made	all designated States
245-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
246	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
246-1	page	103
246-2	line	25
246-3	Identification of Deposit	
246-3-1	Name of depositary institution	American Type Culture Collection
246-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
246-3-3	Date of deposit	15 September 1998 (15.09.1998)
246-3-4	Accession Number	ATCC 203235
246-4	Additional Indications	NONE
246-5	Designated States for Which Indications are Made	all designated States
246-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
247	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
247-1	page	103
247-2	line	26
247-3	Identification of Deposit	
247-3-1	Name of depositary institution	American Type Culture Collection
247-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209United States of America
247-3-3	Date of deposit	22 September 1998 (22.09.1998)
247-3-4	Accession Number	ATCC 203267
247-4	Additional Indications	NONE
247-5	Designated States for Which Indications are Made	all designated States
247-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

248	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
248-1	page	103
248-2	line	27
248-3	Identification of Deposit	
248-3-1	Name of depositary institution	American Type Culture Collection
248-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
248-3-3	Date of deposit	22 September 1998 (22.09.1998)
248-3-4	Accession Number	ATCC 203282
248-4	Additional Indications	NONE
248-5	Designated States for Which Indications are Made	all designated States
248-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
249	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
249-1	page	103
249-2	line	28
249-3	Identification of Deposit	
249-3-1	Name of depositary institution	American Type Culture Collection
249-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
249-3-3	Date of deposit	09 February 1999 (09.02.1999)
249-3-4	Accession Number	ATCC 203657
249-4	Additional Indications	NONE
249-5	Designated States for Which Indications are Made	all designated States
249-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
250	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
250-1	page	103
250-2	line	29
250-3	Identification of Deposit	
250-3-1	Name of depositary institution	American Type Culture Collection
250-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
250-3-3	Date of deposit	22 September 1998 (22.09.1998)
250-3-4	Accession Number	ATCC 203276
250-4	Additional Indications	NONE
250-5	Designated States for Which Indications are Made	all designated States



PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

250-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
251	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
251-1	page	103
251-2	line	30
251-3	Identification of Deposit	
251-3-1	Name of depositary institution	American Type Culture Collection
251-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
251-3-3	Date of deposit	25 August 1998 (25.08.1998)
251-3-4	Accession Number	ATCC 203160
251-4	Additional Indications	NONE
251-5	Designated States for Which Indications are Made	all designated States
251-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
252	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
252-1	page	103
252-2	line	31
252-3	Identification of Deposit	
252-3-1	Name of depositary institution	American Type Culture Collection
252-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
252-3-3	Date of deposit	18 August 1998 (18.08.1998)
252-3-4	Accession Number	ATCC 203135
252-4	Additional Indications	NONE
252-5	Designated States for Which Indications are Made	all designated States
252-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
253	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
253-1	page	103
253-2	line	32
253-3	Identification of Deposit	
253-3-1	Name of depositary institution	American Type Culture Collection
253-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
253-3-3	Date of deposit	03 November 1998 (03.11.1998)
253-3-4	Accession Number	ATCC 203459

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

253-4	Additional Indications	NONE
253-5	Designated States for Which Indications are Made	all designated States
253-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
254	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
254-1	page	103
254-2	line	33
254-3	Identification of Deposit	
254-3-1	Name of depositary institution	American Type Culture Collection
254-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
254-3-3	Date of deposit	22 September 1998 (22.09.1998)
254-3-4	Accession Number	ATCC 203270
254-4	Additional Indications	NONE
254-5	Designated States for Which Indications are Made	all designated States
254-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
255	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
255-1	page	103
255-2	line	34
255-3	Identification of Deposit	
255-3-1	Name of depositary institution	American Type Culture Collection
255-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
255-3-3	Date of deposit	12 January 1999 (12.01.1999)
255-3-4	Accession Number	ATCC 203573
255-4	Additional Indications	NONE
255-5	Designated States for Which Indications are Made	all designated States
255-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
256	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
256-1	page	103
256-2	line	35

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

256-3	Identification of Deposit	
256-3-1	Name of depositary institution	American Type Culture Collection
256-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
256-3-3	Date of deposit	17 November 1998 (17.11.1998)
256-3-4	Accession Number	ATCC 203477
256-4	Additional Indications	NONE
256-5	Designated States for Which Indications are Made	all designated States
256-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
257	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
257-1	page	103
257-2	line	36
257-3	Identification of Deposit	
257-3-1	Name of depositary institution	American Type Culture Collection
257-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
257-3-3	Date of deposit	06 October 1998 (06.10.1998)
257-3-4	Accession Number	ATCC 203315
257-4	Additional Indications	NONE
257-5	Designated States for Which Indications are Made	all designated States
257-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
258	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
258-1	page	103
258-2	line	37
258-3	Identification of Deposit	
258-3-1	Name of depositary institution	American Type Culture Collection
258-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
258-3-3	Date of deposit	06 October 1998 (06.10.1998)
258-3-4	Accession Number	ATCC 203313
258-4	Additional Indications	NONE
258-5	Designated States for Which Indications are Made	all designated States
258-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

259	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
259-1	page	103
259-2	line	38
259-3	Identification of Deposit	
259-3-1	Name of depositary institution	American Type Culture Collection
259-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
259-3-3	Date of deposit	27 October 1998 (27.10.1998)
259-3-4	Accession Number	ATCC 203407
259-4	Additional Indications	NONE
259-5	Designated States for Which Indications are Made	all designated States
259-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
260	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
260-1	page	103
260-2	line	39
260-3	Identification of Deposit	
260-3-1	Name of depositary institution	American Type Culture Collection
260-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
260-3-3	Date of deposit	22 December 1998 (22.12.1998)
260-3-4	Accession Number	ATCC 203553
260-4	Additional Indications	NONE
260-5	Designated States for Which Indications are Made	all designated States
260-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
261	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
261-1	page	103
261-2	line	40
261-3	Identification of Deposit	
261-3-1	Name of depositary institution	American Type Culture Collection
261-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
261-3-3	Date of deposit	22 December 1998 (22.12.1998)
261-3-4	Accession Number	ATCC 203549
261-4	Additional Indications	NONE
261-5	Designated States for Which Indications are Made	all designated States

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

261-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
262	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
262-1	page	103
262-2	line	41
262-3	Identification of Deposit	
262-3-1	Name of depositary institution	American Type Culture Collection
262-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
262-3-3	Date of deposit	22 December 1998 (22.12.1998)
262-3-4	Accession Number	ATCC 203550
262-4	Additional Indications	NONE
262-5	Designated States for Which Indications are Made	all designated States
262-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
263	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
263-1	page	103
263-2	line	42
263-3	Identification of Deposit	
263-3-1	Name of depositary institution	American Type Culture Collection
263-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
263-3-3	Date of deposit	08 June 1999 (08.06.1999)
263-3-4	Accession Number	ATCC PTA-204
263-4	Additional Indications	NONE
263-5	Designated States for Which Indications are Made	all designated States
263-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
264	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
264-1	page	103
264-2	line	43
264-3	Identification of Deposit	
264-3-1	Name of depositary institution	American Type Culture Collection
264-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
264-3-3	Date of deposit	29 October 1998 (29.10.1998)
264-3-4	Accession Number	ATCC 203391

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

264-4	Additional Indications	NONE
264-5	Designated States for Which Indications are Made	all designated States
264-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
265	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
265-1	page	103
265-2	line	44
265-3	Identification of Deposit	
265-3-1	Name of depositary institution	American Type Culture Collection
265-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
265-3-3	Date of deposit	23 March 1999 (23.03.1999)
265-3-4	Accession Number	ATCC 203863
265-4	Additional Indications	NONE
265-5	Designated States for Which Indications are Made	all designated States
265-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
266	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
266-1	page	103
266-2	line	45
266-3	Identification of Deposit	
266-3-1	Name of depositary institution	American Type Culture Collection
266-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
266-3-3	Date of deposit	09 March 1999 (09.03.1999)
266-3-4	Accession Number	ATCC 203834
266-4	Additional Indications	NONE
266-5	Designated States for Which Indications are Made	all designated States
266-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
267	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
267-1	page	103
267-2	line	46

PCT

P3330R1

Original (for SUBMISSION) - printed on 01.12.2000 02:57:35 PM

267-3	Identification of Deposit	
267-3-1	Name of depositary institution	American Type Culture Collection
267-3-2	Address of depositary institution	10801 University Blvd., Manassas, Virginia 20110-2209 United States of America
267-3-3	Date of deposit	20 July 1999 (20.07.1999)
267-3-4	Accession Number	ATCC PTA-382
267-4	Additional Indications	NONE
267-5	Designated States for Which Indications are Made	all designated States
267-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

## FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the international application: (yes or no)	
0-4-1	Authorized officer	

## FOR INTERNATIONAL BUREAU USE ONLY

0-5	This form was received by the international Bureau on:	
0-5-1	Authorized officer	

**WHAT IS CLAIMED IS:**

1. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254).



NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure 374 (SEQ ID NO:374), Figure 376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID NO:380), Figure 382 (SEQ ID NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure 388 (SEQ ID NO:388), Figure 390 (SEQ ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID NO:394), Figure 396 (SEQ ID NO:396), Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure 402 (SEQ ID NO:402), Figure 404 (SEQ ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID NO:408), Figure 410 (SEQ ID NO:410), Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure 416 (SEQ ID NO:416), Figure 418 (SEQ ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID NO:422), Figure 424 (SEQ ID NO:424), Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure 430 (SEQ ID NO:430), Figure 432 (SEQ ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID NO:436), Figure 438 (SEQ ID NO:438), Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure 444 (SEQ ID NO:444), Figure 446 (SEQ ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID NO:450), Figure 452 (SEQ ID NO:452), Figure 454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure 458 (SEQ ID NO:458), Figure 460 (SEQ ID NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID NO:464), Figure 466 (SEQ ID NO:466), Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure 472 (SEQ ID NO:472), Figure 474 (SEQ ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID NO:478), Figure 480 (SEQ ID NO:480), Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure 486 (SEQ ID NO:486), Figure 488 (SEQ ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID NO:492), Figure 494 (SEQ ID NO:494), Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure 500 (SEQ ID NO:500), Figure 502 (SEQ ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID NO:506), Figure 508 (SEQ ID NO:508), Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure 514 (SEQ ID NO:514), Figure 516 (SEQ ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID

NO:520), Figure 522 (SEQ ID NO:522), Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure 536 (SEQ ID NO:536), Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548) and Figure 550 (SEQ ID NO:550).

5

2. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39), Figure 41 (SEQ ID NO:41), Figure 43 (SEQ ID NO:43), Figure 45 (SEQ ID NO:45), Figure 47 (SEQ ID NO:47), Figure 49 (SEQ ID NO:49), Figure 51 (SEQ ID NO:51), Figure 53 (SEQ ID NO:53), Figure 55 (SEQ ID NO:55), Figure 57 (SEQ ID NO:57), Figure 59 (SEQ ID NO:59), Figure 61 (SEQ ID NO:61), Figure 63 (SEQ ID NO:63), Figure 65 (SEQ ID NO:65), Figure 67 (SEQ ID NO:67), Figure 69 (SEQ ID NO:69), Figure 71 (SEQ ID NO:71), Figure 73 (SEQ ID NO:73), Figure 75 (SEQ ID NO:75), Figure 77 (SEQ ID NO:77), Figure 79 (SEQ ID NO:79), Figure 81 (SEQ ID NO:81), Figure 83 (SEQ ID NO:83), Figure 85 (SEQ ID NO:85), Figure 87 (SEQ ID NO:87), Figure 89 (SEQ ID NO:89), Figure 91 (SEQ ID NO:91), Figure 93 (SEQ ID NO:93), Figure 95 (SEQ ID NO:95), Figure 97 (SEQ ID NO:97), Figure 99 (SEQ ID NO:99), Figure 101 (SEQ ID NO:101), Figure 103 (SEQ ID NO:103), Figure 105 (SEQ ID NO:105), Figure 107 (SEQ ID NO:107), Figure 109 (SEQ ID NO:109), Figure 111 (SEQ ID NO:111), Figure 113 (SEQ ID NO:113), Figure 115 (SEQ ID NO:115), Figure 117 (SEQ ID NO:117), Figure 119 (SEQ ID NO:119), Figure 121 (SEQ ID NO:121), Figure 123 (SEQ ID NO:123), Figure 125 (SEQ ID NO:125), Figure 127 (SEQ ID NO:127), Figure 129 (SEQ ID NO:129), Figure 131 (SEQ ID NO:131), Figure 133 (SEQ ID NO:133), Figure 135 (SEQ ID NO:135), Figure 137 (SEQ ID NO:137), Figure 139 (SEQ ID NO:139), Figure 141 (SEQ ID NO:141), Figure 143 (SEQ ID NO:143), Figure 145 (SEQ ID NO:145), Figure 147 (SEQ ID NO:147), Figure 149 (SEQ ID NO:149), Figure 151 (SEQ ID NO:151), Figure 153 (SEQ ID NO:153), Figure 155 (SEQ ID NO:155), Figure 157 (SEQ ID NO:157), Figure 159 (SEQ ID NO:159), Figure 161 (SEQ ID NO:161), Figure 163 (SEQ ID NO:163), Figure 165 (SEQ ID NO:165), Figure 167 (SEQ ID NO:167), Figure 169 (SEQ ID NO:169), Figure 171 (SEQ ID NO:171), Figure 173 (SEQ ID NO:173), Figure 175 (SEQ ID NO:175), Figure 177 (SEQ ID NO:177), Figure 179 (SEQ ID NO:179), Figure 181 (SEQ ID NO:181), Figure 183 (SEQ ID NO:183), Figure 185 (SEQ ID NO:185), Figure 187 (SEQ ID NO:187), Figure 189 (SEQ ID NO:189), Figure 191 (SEQ ID NO:191), Figure 193 (SEQ ID NO:193), Figure 195 (SEQ ID NO:195), Figure 197 (SEQ ID NO:197), Figure 199 (SEQ ID NO:199), Figure 201 (SEQ ID NO:201), Figure 203 (SEQ ID NO:203), Figure 205 (SEQ ID NO:205), Figure 207 (SEQ ID NO:207), Figure 209 (SEQ ID NO:209), Figure 211 (SEQ ID NO:211), Figure 213 (SEQ ID NO:213), Figure 215 (SEQ ID NO:215), Figure 217 (SEQ ID NO:217), Figure 219 (SEQ ID NO:219), Figure 221 (SEQ ID

NO:221), Figure 223 (SEQ ID NO:223), Figure 225 (SEQ ID NO:225), Figure 227 (SEQ ID NO:227), Figure 229 (SEQ ID NO:229), Figure 231 (SEQ ID NO:231), Figure 233 (SEQ ID NO:233), Figure 235 (SEQ ID NO:235), Figure 237 (SEQ ID NO:237), Figure 239 (SEQ ID NO:239), Figure 241 (SEQ ID NO:241), Figure 243 (SEQ ID NO:243), Figure 245 (SEQ ID NO:245), Figure 247 (SEQ ID NO:247), Figure 249 (SEQ ID NO:249), Figure 251 (SEQ ID NO:251), Figure 253 (SEQ ID NO:253), Figure 255 (SEQ ID NO:255), Figure 257 (SEQ ID NO:257), Figure 259 (SEQ ID NO:259), Figure 261 (SEQ ID NO:261), Figure 263 (SEQ ID NO:263), Figure 265 (SEQ ID NO:265), Figure 267 (SEQ ID NO:267), Figure 269 (SEQ ID NO:269), Figure 271 (SEQ ID NO:271), Figure 273 (SEQ ID NO:273), Figure 275 (SEQ ID NO:275), Figure 277 (SEQ ID NO:277), Figure 279 (SEQ ID NO:279), Figure 281 (SEQ ID NO:281), Figure 283 (SEQ ID NO:283), Figure 285 (SEQ ID NO:285), Figure 287 (SEQ ID NO:287), Figure 289 (SEQ ID NO:289), Figure 291 (SEQ ID NO:291), Figure 293 (SEQ ID NO:293), Figure 295 (SEQ ID NO:295), Figure 297 (SEQ ID NO:297), Figure 299 (SEQ ID NO:299), Figure 301 (SEQ ID NO:301), Figure 303 (SEQ ID NO:303), Figure 305 (SEQ ID NO:305), Figure 307 (SEQ ID NO:307), Figure 309 (SEQ ID NO:309), Figure 311 (SEQ ID NO:311), Figure 313 (SEQ ID NO:313), Figure 315 (SEQ ID NO:315), Figure 317 (SEQ ID NO:317), Figure 319 (SEQ ID NO:319), Figure 321 (SEQ ID NO:321), Figure 323 (SEQ ID NO:323), Figure 325 (SEQ ID NO:325), Figure 327 (SEQ ID NO:327), Figure 329 (SEQ ID NO:329), Figure 331 (SEQ ID NO:331), Figure 333 (SEQ ID NO:333), Figure 335 (SEQ ID NO:335), Figure 337 (SEQ ID NO:337), Figure 339 (SEQ ID NO:339), Figure 341 (SEQ ID NO:341), Figure 343 (SEQ ID NO:343), Figure 345 (SEQ ID NO:345), Figure 347 (SEQ ID NO:347), Figure 349 (SEQ ID NO:349), Figure 351 (SEQ ID NO:351), Figure 353 (SEQ ID NO:353), Figure 355 (SEQ ID NO:355), Figure 357 (SEQ ID NO:357), Figure 359 (SEQ ID NO:359), Figure 361 (SEQ ID NO:361), Figure 363 (SEQ ID NO:363), Figure 365 (SEQ ID NO:365), Figure 367 (SEQ ID NO:367), Figure 369 (SEQ ID NO:369), Figure 371 (SEQ ID NO:371), Figure 373 (SEQ ID NO:373), Figure 375 (SEQ ID NO:375), Figure 377 (SEQ ID NO:377), Figure 379 (SEQ ID NO:379), Figure 381 (SEQ ID NO:381), Figure 383 (SEQ ID NO:383), Figure 385 (SEQ ID NO:385), Figure 387 (SEQ ID NO:387), Figure 389 (SEQ ID NO:389), Figure 391 (SEQ ID NO:391), Figure 393 (SEQ ID NO:393), Figure 395 (SEQ ID NO:395), Figure 397 (SEQ ID NO:397), Figure 399 (SEQ ID NO:399), Figure 401 (SEQ ID NO:401), Figure 403 (SEQ ID NO:403), Figure 405 (SEQ ID NO:405), Figure 407 (SEQ ID NO:407), Figure 409 (SEQ ID NO:409), Figure 411 (SEQ ID NO:411), Figure 413 (SEQ ID NO:413), Figure 415 (SEQ ID NO:415), Figure 417 (SEQ ID NO:417), Figure 419 (SEQ ID NO:419), Figure 421 (SEQ ID NO:421), Figure 423 (SEQ ID NO:423), Figure 425 (SEQ ID NO:425), Figure 427 (SEQ ID NO:427), Figure 429 (SEQ ID NO:429), Figure 431 (SEQ ID NO:431), Figure 433 (SEQ ID NO:433), Figure 435 (SEQ ID NO:435), Figure 437 (SEQ ID NO:437), Figure 439 (SEQ ID NO:439), Figure 441 (SEQ ID NO:441), Figure 443 (SEQ ID NO:443), Figure 445 (SEQ ID NO:445), Figure 447 (SEQ ID NO:447), Figure 449 (SEQ ID NO:449), Figure 451 (SEQ ID NO:451), Figure 453 (SEQ ID NO:453), Figure 455 (SEQ ID NO:455), Figure 457 (SEQ ID NO:457), Figure 459 (SEQ ID NO:459), Figure 461 (SEQ ID NO:461), Figure 463 (SEQ ID NO:463), Figure 465 (SEQ ID NO:465), Figure 467 (SEQ ID NO:467), Figure 469 (SEQ ID NO:469), Figure 471 (SEQ ID NO:471), Figure 473 (SEQ ID NO:473), Figure 475 (SEQ ID NO:475), Figure 477 (SEQ ID NO:477), Figure 479 (SEQ ID NO:479), Figure 481 (SEQ ID NO:481), Figure 483 (SEQ ID NO:483), Figure 485 (SEQ ID NO:485), Figure 487 (SEQ ID

NO:487), Figure 489 (SEQ ID NO:489), Figure 491 (SEQ ID NO:491), Figure 493 (SEQ ID NO:493), Figure 495 (SEQ ID NO:495), Figure 497 (SEQ ID NO:497), Figure 499 (SEQ ID NO:499), Figure 501 (SEQ ID NO:501), Figure 503 (SEQ ID NO:503), Figure 505 (SEQ ID NO:505), Figure 507 (SEQ ID NO:507), Figure 509 (SEQ ID NO:509), Figure 511 (SEQ ID NO:511), Figure 513 (SEQ ID NO:513), Figure 515 (SEQ ID NO:515), Figure 517 (SEQ ID NO:517), Figure 519 (SEQ ID NO:519), Figure 521 (SEQ ID NO:521), Figure 523 (SEQ ID NO:523), Figure 525 (SEQ ID NO:525), Figure 527 (SEQ ID NO:527), Figure 529 (SEQ ID NO:529), Figure 531 (SEQ ID NO:531), Figure 533 (SEQ ID NO:533), Figure 535 (SEQ ID NO:535), Figure 537 (SEQ ID NO:537), Figure 539 (SEQ ID NO:539), Figure 541 (SEQ ID NO:541), Figure 543 (SEQ ID NO:543), Figure 545 (SEQ ID NO:545), Figure 547 (SEQ ID NO:547) and Figure 549 (SEQ ID NO:549).

3. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:1), Figure 3 (SEQ ID NO:3), Figure 5 (SEQ ID NO:5), Figure 7 (SEQ ID NO:7), Figure 9 (SEQ ID NO:9), Figure 11 (SEQ ID NO:11), Figure 13 (SEQ ID NO:13), Figure 15 (SEQ ID NO:15), Figure 17 (SEQ ID NO:17), Figure 19 (SEQ ID NO:19), Figure 21 (SEQ ID NO:21), Figure 23 (SEQ ID NO:23), Figure 25 (SEQ ID NO:25), Figure 27 (SEQ ID NO:27), Figure 29 (SEQ ID NO:29), Figure 31 (SEQ ID NO:31), Figure 33 (SEQ ID NO:33), Figure 35 (SEQ ID NO:35), Figure 37 (SEQ ID NO:37), Figure 39 (SEQ ID NO:39), Figure 41 (SEQ ID NO:41), Figure 43 (SEQ ID NO:43), Figure 45 (SEQ ID NO:45), Figure 47 (SEQ ID NO:47), Figure 49 (SEQ ID NO:49), Figure 51 (SEQ ID NO:51), Figure 53 (SEQ ID NO:53), Figure 55 (SEQ ID NO:55), Figure 57 (SEQ ID NO:57), Figure 59 (SEQ ID NO:59), Figure 61 (SEQ ID NO:61), Figure 63 (SEQ ID NO:63), Figure 65 (SEQ ID NO:65), Figure 67 (SEQ ID NO:67), Figure 69 (SEQ ID NO:69), Figure 71 (SEQ ID NO:71), Figure 73 (SEQ ID NO:73), Figure 75 (SEQ ID NO:75), Figure 77 (SEQ ID NO:77), Figure 79 (SEQ ID NO:79), Figure 81 (SEQ ID NO:81), Figure 83 (SEQ ID NO:83), Figure 85 (SEQ ID NO:85), Figure 87 (SEQ ID NO:87), Figure 89 (SEQ ID NO:89), Figure 91 (SEQ ID NO:91), Figure 93 (SEQ ID NO:93), Figure 95 (SEQ ID NO:95), Figure 97 (SEQ ID NO:97), Figure 99 (SEQ ID NO:99), Figure 101 (SEQ ID NO:101), Figure 103 (SEQ ID NO:103), Figure 105 (SEQ ID NO:105), Figure 107 (SEQ ID NO:107), Figure 109 (SEQ ID NO:109), Figure 111 (SEQ ID NO:111), Figure 113 (SEQ ID NO:113), Figure 115 (SEQ ID NO:115), Figure 117 (SEQ ID NO:117), Figure 119 (SEQ ID NO:119), Figure 121 (SEQ ID NO:121), Figure 123 (SEQ ID NO:123), Figure 125 (SEQ ID NO:125), Figure 127 (SEQ ID NO:127), Figure 129 (SEQ ID NO:129), Figure 131 (SEQ ID NO:131), Figure 133 (SEQ ID NO:133), Figure 135 (SEQ ID NO:135), Figure 137 (SEQ ID NO:137), Figure 139 (SEQ ID NO:1390), Figure 141 (SEQ ID NO:141), Figure 143 (SEQ ID NO:143), Figure 145 (SEQ ID NO:145), Figure 147 (SEQ ID NO:147), Figure 149 (SEQ ID NO:149), Figure 151 (SEQ ID NO:151), Figure 153 (SEQ ID NO:153), Figure 155 (SEQ ID NO:155), Figure 157 (SEQ ID NO:157), Figure 159 (SEQ ID NO:159), Figure 161 (SEQ ID NO:161), Figure 163 (SEQ ID NO:163), Figure 165 (SEQ ID NO:165), Figure 167 (SEQ ID NO:167), Figure 169 (SEQ ID NO:169), Figure 171 (SEQ ID NO:171), Figure 173 (SEQ ID NO:173), Figure 175 (SEQ ID NO:175), Figure 177 (SEQ ID NO:177), Figure 179 (SEQ ID NO:179), Figure 181 (SEQ ID NO:181), Figure 183 (SEQ ID NO:183), Figure 185 (SEQ ID NO:185), Figure 187 (SEQ ID NO:187), Figure 189 (SEQ ID NO:189), Figure 191 (SEQ

ID NO:191), Figure 193 (SEQ ID NO:193), Figure 195 (SEQ ID NO:195), Figure 197 (SEQ ID NO:197),  
Figure 199 (SEQ ID NO:199), Figure 201 (SEQ ID NO:201), Figure 203 (SEQ ID NO:203), Figure 205 (SEQ  
ID NO:205), Figure 207 (SEQ ID NO:207), Figure 209 (SEQ ID NO:209), Figure 211 (SEQ ID NO:211),  
Figure 213 (SEQ ID NO:213), Figure 215 (SEQ ID NO:215), Figure 217 (SEQ ID NO:217), Figure 219 (SEQ  
ID NO:219), Figure 221 (SEQ ID NO:221), Figure 223 (SEQ ID NO:223), Figure 225 (SEQ ID NO:225),  
5 Figure 227 (SEQ ID NO:227), Figure 229 (SEQ ID NO:229), Figure 231 (SEQ ID NO:231), Figure 233 (SEQ  
ID NO:233), Figure 235 (SEQ ID NO:235), Figure 237 (SEQ ID NO:237), Figure 239 (SEQ ID NO:239),  
Figure 241 (SEQ ID NO:241), Figure 243 (SEQ ID NO:243), Figure 245 (SEQ ID NO:245), Figure 247 (SEQ  
ID NO:247), Figure 249 (SEQ ID NO:249), Figure 251 (SEQ ID NO:251), Figure 253 (SEQ ID NO:253),  
Figure 255 (SEQ ID NO:255), Figure 257 (SEQ ID NO:257), Figure 259 (SEQ ID NO:259), Figure 261 (SEQ  
10 ID NO:261), Figure 263 (SEQ ID NO:263), Figure 265 (SEQ ID NO:265), Figure 267 (SEQ ID NO:267),  
Figure 269 (SEQ ID NO:269), Figure 271 (SEQ ID NO:271), Figure 273 (SEQ ID NO:273), Figure 275 (SEQ  
ID NO:275), Figure 277 (SEQ ID NO:277), Figure 279 (SEQ ID NO:279), Figure 281 (SEQ ID NO:281),  
Figure 283 (SEQ ID NO:283), Figure 285 (SEQ ID NO:285), Figure 287 (SEQ ID NO:287), Figure 289 (SEQ  
ID NO:289), Figure 291 (SEQ ID NO:291), Figure 293 (SEQ ID NO:293), Figure 295 (SEQ ID NO:295),  
15 Figure 297 (SEQ ID NO:297), Figure 299 (SEQ ID NO:299), Figure 301 (SEQ ID NO:301), Figure 303 (SEQ  
ID NO:303), Figure 305 (SEQ ID NO:305), Figure 307 (SEQ ID NO:307), Figure 309 (SEQ ID NO:309),  
Figure 311 (SEQ ID NO:311), Figure 313 (SEQ ID NO:313), Figure 315 (SEQ ID NO:315), Figure 317 (SEQ  
ID NO:317), Figure 319 (SEQ ID NO:319), Figure 321 (SEQ ID NO:321), Figure 323 (SEQ ID NO:323),  
Figure 325 (SEQ ID NO:325), Figure 327 (SEQ ID NO:327), Figure 329 (SEQ ID NO:329), Figure 331 (SEQ  
20 ID NO:331), Figure 333 (SEQ ID NO:333), Figure 335 (SEQ ID NO:335), Figure 337 (SEQ ID NO:337),  
Figure 339 (SEQ ID NO:339), Figure 341 (SEQ ID NO:341), Figure 343 (SEQ ID NO:343), Figure 345 (SEQ  
ID NO:345), Figure 347 (SEQ ID NO:347), Figure 349 (SEQ ID NO:349), Figure 351 (SEQ ID NO:351),  
Figure 353 (SEQ ID NO:353), Figure 355 (SEQ ID NO:355), Figure 357 (SEQ ID NO:357), Figure 359 (SEQ  
ID NO:359), Figure 361 (SEQ ID NO:361), Figure 363 (SEQ ID NO:363), Figure 365 (SEQ ID NO:365),  
25 Figure 367 (SEQ ID NO:367), Figure 369 (SEQ ID NO:369), Figure 371 (SEQ ID NO:371), Figure 373 (SEQ  
ID NO:373), Figure 375 (SEQ ID NO:375), Figure 377 (SEQ ID NO:377), Figure 379 (SEQ ID NO:379),  
Figure 381 (SEQ ID NO:381), Figure 383 (SEQ ID NO:383), Figure 385 (SEQ ID NO:385), Figure 387 (SEQ  
ID NO:387), Figure 389 (SEQ ID NO:389), Figure 391 (SEQ ID NO:391), Figure 393 (SEQ ID NO:393),  
Figure 395 (SEQ ID NO:395), Figure 397 (SEQ ID NO:397), Figure 399 (SEQ ID NO:399), Figure 401 (SEQ  
30 ID NO:401), Figure 403 (SEQ ID NO:403), Figure 405 (SEQ ID NO:405), Figure 407 (SEQ ID NO:407),  
Figure 409 (SEQ ID NO:409), Figure 411 (SEQ ID NO:411), Figure 413 (SEQ ID NO:413), Figure 415 (SEQ  
ID NO:415), Figure 417 (SEQ ID NO:417), Figure 419 (SEQ ID NO:419), Figure 421 (SEQ ID NO:421),  
Figure 423 (SEQ ID NO:423), Figure 425 (SEQ ID NO:425), Figure 427 (SEQ ID NO:427), Figure 429 (SEQ  
ID NO:429), Figure 431 (SEQ ID NO:431), Figure 433 (SEQ ID NO:433), Figure 435 (SEQ ID NO:435),  
35 Figure 437 (SEQ ID NO:437), Figure 439 (SEQ ID NO:439), Figure 441 (SEQ ID NO:441), Figure 443 (SEQ  
ID NO:443), Figure 445 (SEQ ID NO:445), Figure 447 (SEQ ID NO:447), Figure 449 (SEQ ID NO:449),  
Figure 451 (SEQ ID NO:451), Figure 453 (SEQ ID NO:453), Figure 455 (SEQ ID NO:455), Figure 457 (SEQ

ID NO:457), Figure 459 (SEQ ID NO:459), Figure 461 (SEQ ID NO:461), Figure 463 (SEQ ID NO:463), Figure 465 (SEQ ID NO:465), Figure 467 (SEQ ID NO:467), Figure 469 (SEQ ID NO:469), Figure 471 (SEQ ID NO:471), Figure 473 (SEQ ID NO:473), Figure 475 (SEQ ID NO:475), Figure 477 (SEQ ID NO:477), Figure 479 (SEQ ID NO:479), Figure 481 (SEQ ID NO:481), Figure 483 (SEQ ID NO:483), Figure 485 (SEQ ID NO:485), Figure 487 (SEQ ID NO:487), Figure 489 (SEQ ID NO:489), Figure 491 (SEQ ID NO:491), Figure 493 (SEQ ID NO:493), Figure 495 (SEQ ID NO:495), Figure 497 (SEQ ID NO:497), Figure 499 (SEQ ID NO:499), Figure 501 (SEQ ID NO:501), Figure 503 (SEQ ID NO:503), Figure 505 (SEQ ID NO:505), Figure 507 (SEQ ID NO:507), Figure 509 (SEQ ID NO:509), Figure 511 (SEQ ID NO:511), Figure 513 (SEQ ID NO:513), Figure 515 (SEQ ID NO:515), Figure 517 (SEQ ID NO:517), Figure 519 (SEQ ID NO:519), Figure 521 (SEQ ID NO:521), Figure 523 (SEQ ID NO:523), Figure 525 (SEQ ID NO:525), Figure 527 (SEQ ID NO:527), Figure 529 (SEQ ID NO:529), Figure 531 (SEQ ID NO:531), Figure 533 (SEQ ID NO:533), Figure 535 (SEQ ID NO:535), Figure 537 (SEQ ID NO:537), Figure 539 (SEQ ID NO:539), Figure 541 (SEQ ID NO:541), Figure 543 (SEQ ID NO:543), Figure 545 (SEQ ID NO:545), Figure 547 (SEQ ID NO:547) and Figure 549 (SEQ ID NO:549).

4. Isolated nucleic acid having at least 80% nucleic acid sequence identity to the full-length coding sequence of the DNA deposited under any ATCC accession number shown in Table 7.

5. A vector comprising the nucleic acid of Claim 1.

6. The vector of Claim 5 operably linked to control sequences recognized by a host cell transformed with the vector.

7. A host cell comprising the vector of Claim 5.

8. The host cell of Claim 7, wherein said cell is a CHO cell.

9. The host cell of Claim 7, wherein said cell is an *E. coli*.

10. The host cell of Claim 7, wherein said cell is a yeast cell.

11. A process for producing a PRO polypeptides comprising culturing the host cell of Claim 7 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.

12. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10),

Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48),  
5 Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86),  
10 Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure

284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure 374 (SEQ ID NO:374), Figure 376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID NO:380), Figure 382 (SEQ ID NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure 388 (SEQ ID NO:388), Figure 390 (SEQ ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID NO:394), Figure 396 (SEQ ID NO:396), Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure 402 (SEQ ID NO:402), Figure 404 (SEQ ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID NO:408), Figure 410 (SEQ ID NO:410), Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure 416 (SEQ ID NO:416), Figure 418 (SEQ ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID NO:422), Figure 424 (SEQ ID NO:424), Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure 430 (SEQ ID NO:430), Figure 432 (SEQ ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID NO:436), Figure 438 (SEQ ID NO:438), Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure 444 (SEQ ID NO:444), Figure 446 (SEQ ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID NO:450), Figure 452 (SEQ ID NO:452), Figure 454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure 458 (SEQ ID NO:458), Figure 460 (SEQ ID NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID NO:464), Figure 466 (SEQ ID NO:466), Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure 472 (SEQ ID NO:472), Figure 474 (SEQ ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID NO:478), Figure 480 (SEQ ID NO:480), Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure 486 (SEQ ID NO:486), Figure 488 (SEQ ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID NO:492), Figure 494 (SEQ ID NO:494), Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure 500 (SEQ ID NO:500), Figure 502 (SEQ ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID NO:506), Figure 508 (SEQ ID NO:508), Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure 514 (SEQ ID NO:514), Figure 516 (SEQ ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID NO:520), Figure 522 (SEQ ID NO:522), Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure 536 (SEQ ID NO:536), Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548) and



Figure 550 (SEQ ID NO:550).

13. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence encoded by the full-length coding sequence of the DNA deposited under any ATCC accession number shown in Table 7.

14. A chimeric molecule comprising a polypeptide according to Claim 12 fused to a heterologous amino acid sequence.

15. The chimeric molecule of Claim 14, wherein said heterologous amino acid sequence is an epitope tag sequence.

16. The chimeric molecule of Claim 14, wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.

17. An antibody which specifically binds to a polypeptide according to Claim 12.

18. The antibody of Claim 17, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.

19. Isolated nucleic acid having at least 80% nucleic acid sequence identity to:

(a) a nucleotide sequence encoding the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ

ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158),  
5 Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228),  
15 Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298),  
25 Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368),  
35 Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure 374 (SEQ ID NO:374), Figure 376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID NO:380), Figure 382 (SEQ ID NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure 388 (SEQ ID NO:388), Figure 390 (SEQ

ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID NO:394), Figure 396 (SEQ ID NO:396),  
 Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure 402 (SEQ ID NO:402), Figure 404 (SEQ  
 ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID NO:408), Figure 410 (SEQ ID NO:410),  
 Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure 416 (SEQ ID NO:416), Figure 418 (SEQ  
 ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID NO:422), Figure 424 (SEQ ID NO:424),  
 5 Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure 430 (SEQ ID NO:430), Figure 432 (SEQ  
 ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID NO:436), Figure 438 (SEQ ID NO:438),  
 Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure 444 (SEQ ID NO:444), Figure 446 (SEQ  
 ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID NO:450), Figure 452 (SEQ ID NO:452),  
 Figure 454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure 458 (SEQ ID NO:458), Figure 460 (SEQ  
 10 ID NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID NO:464), Figure 466 (SEQ ID NO:466),  
 Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure 472 (SEQ ID NO:472), Figure 474 (SEQ  
 ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID NO:478), Figure 480 (SEQ ID NO:480),  
 Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure 486 (SEQ ID NO:486), Figure 488 (SEQ  
 ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID NO:492), Figure 494 (SEQ ID NO:494),  
 15 Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure 500 (SEQ ID NO:500), Figure 502 (SEQ  
 ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID NO:506), Figure 508 (SEQ ID NO:508),  
 Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure 514 (SEQ ID NO:514), Figure 516 (SEQ  
 ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID NO:520), Figure 522 (SEQ ID NO:522),  
 Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ  
 20 ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure 536 (SEQ ID NO:536),  
 Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ  
 ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548) or Figure 550 (SEQ ID NO:550),  
 lacking its associated signal peptide;

(b) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2  
 25 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ  
 ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18  
 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure  
 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32),  
 Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID  
 30 NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ  
 ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56  
 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure  
 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70),  
 Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID  
 35 NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ  
 ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94  
 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100),

Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366),

Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure 374 (SEQ ID NO:374), Figure 376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID NO:380), Figure 382 (SEQ ID NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure 388 (SEQ ID NO:388), Figure 390 (SEQ ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID NO:394), Figure 396 (SEQ ID NO:396), Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure 402 (SEQ ID NO:402), Figure 404 (SEQ ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID NO:408), Figure 410 (SEQ ID NO:410), Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure 416 (SEQ ID NO:416), Figure 418 (SEQ ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID NO:422), Figure 424 (SEQ ID NO:424), Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure 430 (SEQ ID NO:430), Figure 432 (SEQ ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID NO:436), Figure 438 (SEQ ID NO:438), Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure 444 (SEQ ID NO:444), Figure 446 (SEQ ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID NO:450), Figure 452 (SEQ ID NO:452), Figure 454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure 458 (SEQ ID NO:458), Figure 460 (SEQ ID NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID NO:464), Figure 466 (SEQ ID NO:466), Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure 472 (SEQ ID NO:472), Figure 474 (SEQ ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID NO:478), Figure 480 (SEQ ID NO:480), Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure 486 (SEQ ID NO:486), Figure 488 (SEQ ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID NO:492), Figure 494 (SEQ ID NO:494), Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure 500 (SEQ ID NO:500), Figure 502 (SEQ ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID NO:506), Figure 508 (SEQ ID NO:508), Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure 514 (SEQ ID NO:514), Figure 516 (SEQ ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID NO:520), Figure 522 (SEQ ID NO:522), Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure 536 (SEQ ID NO:536), Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548) or Figure 550 (SEQ ID NO:550), with its associated signal peptide; or

(c) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID

NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114),  
5 Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184),  
15 Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254),  
25 Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324),  
35 Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ

ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure 374 (SEQ ID NO:374), Figure 376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID NO:380), Figure 382 (SEQ ID NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure 388 (SEQ ID NO:388), Figure 390 (SEQ ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID NO:394), Figure 396 (SEQ ID NO:396), Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure 402 (SEQ ID NO:402), Figure 404 (SEQ ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID NO:408), Figure 410 (SEQ ID NO:410), Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure 416 (SEQ ID NO:416), Figure 418 (SEQ ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID NO:422), Figure 424 (SEQ ID NO:424), Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure 430 (SEQ ID NO:430), Figure 432 (SEQ ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID NO:436), Figure 438 (SEQ ID NO:438), Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure 444 (SEQ ID NO:444), Figure 446 (SEQ ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID NO:450), Figure 452 (SEQ ID NO:452), Figure 454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure 458 (SEQ ID NO:458), Figure 460 (SEQ ID NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID NO:464), Figure 466 (SEQ ID NO:466), Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure 472 (SEQ ID NO:472), Figure 474 (SEQ ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID NO:478), Figure 480 (SEQ ID NO:480), Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure 486 (SEQ ID NO:486), Figure 488 (SEQ ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID NO:492), Figure 494 (SEQ ID NO:494), Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure 500 (SEQ ID NO:500), Figure 502 (SEQ ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID NO:506), Figure 508 (SEQ ID NO:508), Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure 514 (SEQ ID NO:514), Figure 516 (SEQ ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID NO:520), Figure 522 (SEQ ID NO:522), Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure 536 (SEQ ID NO:536), Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548) or Figure 550 (SEQ ID NO:550), lacking its associated signal peptide.

20. An isolated polypeptide having at least 80% amino acid sequence identity to:

(a) an amino acid sequence of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID

NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312),



Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure 374 (SEQ ID NO:374), Figure 376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID NO:380), Figure 382 (SEQ ID NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure 388 (SEQ ID NO:388), Figure 390 (SEQ ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID NO:394), Figure 396 (SEQ ID NO:396), Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure 402 (SEQ ID NO:402), Figure 404 (SEQ ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID NO:408), Figure 410 (SEQ ID NO:410), Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure 416 (SEQ ID NO:416), Figure 418 (SEQ ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID NO:422), Figure 424 (SEQ ID NO:424), Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure 430 (SEQ ID NO:430), Figure 432 (SEQ ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID NO:436), Figure 438 (SEQ ID NO:438), Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure 444 (SEQ ID NO:444), Figure 446 (SEQ ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID NO:450), Figure 452 (SEQ ID NO:452), Figure 454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure 458 (SEQ ID NO:458), Figure 460 (SEQ ID NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID NO:464), Figure 466 (SEQ ID NO:466), Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure 472 (SEQ ID NO:472), Figure 474 (SEQ ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID NO:478), Figure 480 (SEQ ID NO:480), Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure 486 (SEQ ID NO:486), Figure 488 (SEQ ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID NO:492), Figure 494 (SEQ ID NO:494), Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure 500 (SEQ ID NO:500), Figure 502 (SEQ ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID NO:506), Figure 508 (SEQ ID NO:508), Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure 514 (SEQ ID NO:514), Figure 516 (SEQ ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID NO:520), Figure 522 (SEQ ID NO:522), Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure 536 (SEQ ID NO:536), Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548) or Figure 550 (SEQ ID NO:550), lacking its associated signal peptide;

(b) an amino acid sequence of an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ

5 ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure 270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID

NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure 374 (SEQ ID NO:374), Figure 376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID NO:380), Figure 382 (SEQ ID NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure 388 (SEQ ID NO:388), Figure 390 (SEQ ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID NO:394), Figure 396 (SEQ ID NO:396), Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure 402 (SEQ ID NO:402), Figure 404 (SEQ ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID NO:408), Figure 410 (SEQ ID NO:410), Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure 416 (SEQ ID NO:416), Figure 418 (SEQ ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID NO:422), Figure 424 (SEQ ID NO:424), Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure 430 (SEQ ID NO:430), Figure 432 (SEQ ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID NO:436), Figure 438 (SEQ ID NO:438), Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure 444 (SEQ ID NO:444), Figure 446 (SEQ ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID NO:450), Figure 452 (SEQ ID NO:452), Figure 454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure 458 (SEQ ID NO:458), Figure 460 (SEQ ID NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID NO:464), Figure 466 (SEQ ID NO:466), Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure 472 (SEQ ID NO:472), Figure 474 (SEQ ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID NO:478), Figure 480 (SEQ ID NO:480), Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure 486 (SEQ ID NO:486), Figure 488 (SEQ ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID NO:492), Figure 494 (SEQ ID NO:494), Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure 500 (SEQ ID NO:500), Figure 502 (SEQ ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID NO:506), Figure 508 (SEQ ID NO:508), Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure 514 (SEQ ID NO:514), Figure 516 (SEQ ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID NO:520), Figure 522 (SEQ ID NO:522), Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure 536 (SEQ ID NO:536), Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548) or Figure 550 (SEQ ID NO:550), with its associated signal peptide; or

(c) an amino acid sequence of an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:2), Figure 4 (SEQ ID NO:4), Figure 6 (SEQ ID NO:6), Figure 8 (SEQ ID NO:8), Figure 10 (SEQ ID NO:10), Figure 12 (SEQ ID NO:12), Figure 14 (SEQ ID NO:14), Figure 16 (SEQ ID NO:16), Figure 18 (SEQ ID NO:18), Figure 20 (SEQ ID NO:20), Figure 22 (SEQ ID NO:22), Figure 24 (SEQ ID NO:24), Figure 26 (SEQ ID NO:26), Figure 28 (SEQ ID NO:28), Figure 30 (SEQ ID NO:30), Figure 32 (SEQ ID NO:32), Figure 34 (SEQ ID NO:34), Figure 36 (SEQ ID NO:36), Figure 38 (SEQ ID NO:38), Figure 40 (SEQ ID NO:40), Figure 42 (SEQ ID NO:42), Figure 44 (SEQ ID NO:44), Figure 46 (SEQ ID NO:46), Figure 48 (SEQ ID NO:48), Figure 50 (SEQ ID NO:50), Figure 52 (SEQ ID NO:52), Figure 54 (SEQ ID NO:54), Figure 56 (SEQ ID NO:56), Figure 58 (SEQ ID NO:58), Figure 60 (SEQ ID NO:60), Figure 62 (SEQ ID NO:62), Figure 64 (SEQ ID NO:64), Figure 66 (SEQ ID NO:66), Figure 68 (SEQ ID NO:68), Figure 70 (SEQ ID NO:70), Figure 72 (SEQ ID NO:72), Figure 74 (SEQ ID NO:74), Figure 76 (SEQ ID NO:76), Figure 78 (SEQ ID NO:78), Figure 80 (SEQ ID NO:80), Figure 82 (SEQ ID NO:82), Figure 84 (SEQ ID NO:84), Figure 86 (SEQ ID NO:86), Figure 88 (SEQ ID NO:88), Figure 90 (SEQ ID NO:90), Figure 92 (SEQ ID NO:92), Figure 94 (SEQ ID NO:94), Figure 96 (SEQ ID NO:96), Figure 98 (SEQ ID NO:98), Figure 100 (SEQ ID NO:100), Figure 102 (SEQ ID NO:102), Figure 104 (SEQ ID NO:104), Figure 106 (SEQ ID NO:106), Figure 108 (SEQ ID NO:108), Figure 110 (SEQ ID NO:110), Figure 112 (SEQ ID NO:112), Figure 114 (SEQ ID NO:114), Figure 116 (SEQ ID NO:116), Figure 118 (SEQ ID NO:118), Figure 120 (SEQ ID NO:120), Figure 122 (SEQ ID NO:122), Figure 124 (SEQ ID NO:124), Figure 126 (SEQ ID NO:126), Figure 128 (SEQ ID NO:128), Figure 130 (SEQ ID NO:130), Figure 132 (SEQ ID NO:132), Figure 134 (SEQ ID NO:134), Figure 136 (SEQ ID NO:136), Figure 138 (SEQ ID NO:138), Figure 140 (SEQ ID NO:140), Figure 142 (SEQ ID NO:142), Figure 144 (SEQ ID NO:144), Figure 146 (SEQ ID NO:146), Figure 148 (SEQ ID NO:148), Figure 150 (SEQ ID NO:150), Figure 152 (SEQ ID NO:152), Figure 154 (SEQ ID NO:154), Figure 156 (SEQ ID NO:156), Figure 158 (SEQ ID NO:158), Figure 160 (SEQ ID NO:160), Figure 162 (SEQ ID NO:162), Figure 164 (SEQ ID NO:164), Figure 166 (SEQ ID NO:166), Figure 168 (SEQ ID NO:168), Figure 170 (SEQ ID NO:170), Figure 172 (SEQ ID NO:172), Figure 174 (SEQ ID NO:174), Figure 176 (SEQ ID NO:176), Figure 178 (SEQ ID NO:178), Figure 180 (SEQ ID NO:180), Figure 182 (SEQ ID NO:182), Figure 184 (SEQ ID NO:184), Figure 186 (SEQ ID NO:186), Figure 188 (SEQ ID NO:188), Figure 190 (SEQ ID NO:190), Figure 192 (SEQ ID NO:192), Figure 194 (SEQ ID NO:194), Figure 196 (SEQ ID NO:196), Figure 198 (SEQ ID NO:198), Figure 200 (SEQ ID NO:200), Figure 202 (SEQ ID NO:202), Figure 204 (SEQ ID NO:204), Figure 206 (SEQ ID NO:206), Figure 208 (SEQ ID NO:208), Figure 210 (SEQ ID NO:210), Figure 212 (SEQ ID NO:212), Figure 214 (SEQ ID NO:214), Figure 216 (SEQ ID NO:216), Figure 218 (SEQ ID NO:218), Figure 220 (SEQ ID NO:220), Figure 222 (SEQ ID NO:222), Figure 224 (SEQ ID NO:224), Figure 226 (SEQ ID NO:226), Figure 228 (SEQ ID NO:228), Figure 230 (SEQ ID NO:230), Figure 232 (SEQ ID NO:232), Figure 234 (SEQ ID NO:234), Figure 236 (SEQ ID NO:236), Figure 238 (SEQ ID NO:238), Figure 240 (SEQ ID NO:240), Figure 242 (SEQ ID NO:242), Figure 244 (SEQ ID NO:244), Figure 246 (SEQ ID NO:246), Figure 248 (SEQ ID NO:248), Figure 250 (SEQ ID NO:250), Figure 252 (SEQ ID NO:252), Figure 254 (SEQ ID NO:254), Figure 256 (SEQ ID NO:256), Figure 258 (SEQ ID NO:258), Figure 260 (SEQ ID NO:260), Figure 262 (SEQ ID NO:262), Figure 264 (SEQ ID NO:264), Figure 266 (SEQ ID NO:266), Figure 268 (SEQ ID NO:268), Figure

270 (SEQ ID NO:270), Figure 272 (SEQ ID NO:272), Figure 274 (SEQ ID NO:274), Figure 276 (SEQ ID NO:276), Figure 278 (SEQ ID NO:278), Figure 280 (SEQ ID NO:280), Figure 282 (SEQ ID NO:282), Figure 284 (SEQ ID NO:284), Figure 286 (SEQ ID NO:286), Figure 288 (SEQ ID NO:288), Figure 290 (SEQ ID NO:290), Figure 292 (SEQ ID NO:292), Figure 294 (SEQ ID NO:294), Figure 296 (SEQ ID NO:296), Figure 298 (SEQ ID NO:298), Figure 300 (SEQ ID NO:300), Figure 302 (SEQ ID NO:302), Figure 304 (SEQ ID NO:304), Figure 306 (SEQ ID NO:306), Figure 308 (SEQ ID NO:308), Figure 310 (SEQ ID NO:310), Figure 312 (SEQ ID NO:312), Figure 314 (SEQ ID NO:314), Figure 316 (SEQ ID NO:316), Figure 318 (SEQ ID NO:318), Figure 320 (SEQ ID NO:320), Figure 322 (SEQ ID NO:322), Figure 324 (SEQ ID NO:324), Figure 326 (SEQ ID NO:326), Figure 328 (SEQ ID NO:328), Figure 330 (SEQ ID NO:330), Figure 332 (SEQ ID NO:332), Figure 334 (SEQ ID NO:334), Figure 336 (SEQ ID NO:336), Figure 338 (SEQ ID NO:338), Figure 340 (SEQ ID NO:340), Figure 342 (SEQ ID NO:342), Figure 344 (SEQ ID NO:344), Figure 346 (SEQ ID NO:346), Figure 348 (SEQ ID NO:348), Figure 350 (SEQ ID NO:350), Figure 352 (SEQ ID NO:352), Figure 354 (SEQ ID NO:354), Figure 356 (SEQ ID NO:356), Figure 358 (SEQ ID NO:358), Figure 360 (SEQ ID NO:360), Figure 362 (SEQ ID NO:362), Figure 364 (SEQ ID NO:364), Figure 366 (SEQ ID NO:366), Figure 368 (SEQ ID NO:368), Figure 370 (SEQ ID NO:370), Figure 372 (SEQ ID NO:372), Figure 374 (SEQ ID NO:374), Figure 376 (SEQ ID NO:376), Figure 378 (SEQ ID NO:378), Figure 380 (SEQ ID NO:380), Figure 382 (SEQ ID NO:382), Figure 384 (SEQ ID NO:384), Figure 386 (SEQ ID NO:386), Figure 388 (SEQ ID NO:388), Figure 390 (SEQ ID NO:390), Figure 392 (SEQ ID NO:392), Figure 394 (SEQ ID NO:394), Figure 396 (SEQ ID NO:396), Figure 398 (SEQ ID NO:398), Figure 400 (SEQ ID NO:400), Figure 402 (SEQ ID NO:402), Figure 404 (SEQ ID NO:404), Figure 406 (SEQ ID NO:406), Figure 408 (SEQ ID NO:408), Figure 410 (SEQ ID NO:410), Figure 412 (SEQ ID NO:412), Figure 414 (SEQ ID NO:414), Figure 416 (SEQ ID NO:416), Figure 418 (SEQ ID NO:418), Figure 420 (SEQ ID NO:420), Figure 422 (SEQ ID NO:422), Figure 424 (SEQ ID NO:424), Figure 426 (SEQ ID NO:426), Figure 428 (SEQ ID NO:428), Figure 430 (SEQ ID NO:430), Figure 432 (SEQ ID NO:432), Figure 434 (SEQ ID NO:434), Figure 436 (SEQ ID NO:436), Figure 438 (SEQ ID NO:438), Figure 440 (SEQ ID NO:440), Figure 442 (SEQ ID NO:442), Figure 444 (SEQ ID NO:444), Figure 446 (SEQ ID NO:446), Figure 448 (SEQ ID NO:448), Figure 450 (SEQ ID NO:450), Figure 452 (SEQ ID NO:452), Figure 454 (SEQ ID NO:454), Figure 456 (SEQ ID NO:456), Figure 458 (SEQ ID NO:458), Figure 460 (SEQ ID NO:460), Figure 462 (SEQ ID NO:462), Figure 464 (SEQ ID NO:464), Figure 466 (SEQ ID NO:466), Figure 468 (SEQ ID NO:468), Figure 470 (SEQ ID NO:470), Figure 472 (SEQ ID NO:472), Figure 474 (SEQ ID NO:474), Figure 476 (SEQ ID NO:476), Figure 478 (SEQ ID NO:478), Figure 480 (SEQ ID NO:480), Figure 482 (SEQ ID NO:482), Figure 484 (SEQ ID NO:484), Figure 486 (SEQ ID NO:486), Figure 488 (SEQ ID NO:488), Figure 490 (SEQ ID NO:490), Figure 492 (SEQ ID NO:492), Figure 494 (SEQ ID NO:494), Figure 496 (SEQ ID NO:496), Figure 498 (SEQ ID NO:498), Figure 500 (SEQ ID NO:500), Figure 502 (SEQ ID NO:502), Figure 504 (SEQ ID NO:504), Figure 506 (SEQ ID NO:506), Figure 508 (SEQ ID NO:508), Figure 510 (SEQ ID NO:510), Figure 512 (SEQ ID NO:512), Figure 514 (SEQ ID NO:514), Figure 516 (SEQ ID NO:516), Figure 518 (SEQ ID NO:518), Figure 520 (SEQ ID NO:520), Figure 522 (SEQ ID NO:522), Figure 524 (SEQ ID NO:524), Figure 526 (SEQ ID NO:526), Figure 528 (SEQ ID NO:528), Figure 530 (SEQ ID NO:530), Figure 532 (SEQ ID NO:532), Figure 534 (SEQ ID NO:534), Figure

536 (SEQ ID NO:536), Figure 538 (SEQ ID NO:538), Figure 540 (SEQ ID NO:540), Figure 542 (SEQ ID NO:542), Figure 544 (SEQ ID NO:544), Figure 546 (SEQ ID NO:546), Figure 548 (SEQ ID NO:548) or Figure 550 (SEQ ID NO:550), lacking its associated signal peptide.

21. A method of detecting a PRO1801 polypeptide in a sample suspected of containing a PRO1801 polypeptide, said method comprising contacting said sample with a PRO1114 or PRO4978 polypeptide and determining the formation of a PRO1801/PRO1114 or PRO1801/PRO4978 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO1801 polypeptide in said sample.

22. The method according to Claim 21, wherein said sample comprises cells suspected of expressing said PRO1801 polypeptide.

23. The method according to Claim 21, wherein said PRO1114 or PRO4978 polypeptide is labeled with a detectable label.

24. The method according to Claim 21, wherein said PRO1114 or PRO4978 polypeptide is attached to a solid support.

25. A method of detecting a PRO1114 or PRO4978 polypeptide in a sample suspected of containing a PRO1114 or PRO4978 polypeptide, said method comprising contacting said sample with a PRO1801 polypeptide and determining the formation of a PRO1801/PRO1114 or PRO1801/PRO4978 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO1114 or PRO4978 polypeptide in said sample.

26. The method according to Claim 25, wherein said sample comprises cells suspected of expressing said PRO1114 or PRO4978 polypeptide.

27. The method according to Claim 25, wherein said PRO1801 polypeptide is labeled with a detectable label.

28. The method according to Claim 25, wherein said PRO1801 polypeptide is attached to a solid support.

29. A method of linking a bioactive molecule to a cell expressing a PRO1801 polypeptide, said method comprising contacting said cell with a PRO1114 or PRO4978 polypeptide that is bound to said bioactive molecule and allowing said PRO1801 and said PRO1114 or PRO4978 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

30. The method according to Claim 29, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

31. The method according to Claim 29, wherein said bioactive molecule causes the death of said cell.

32. A method of linking a bioactive molecule to a cell expressing a PRO1114 or PRO4978 polypeptide, said method comprising contacting said cell with a PRO1801 polypeptide that is bound to said bioactive molecule and allowing said PRO1801 and said PRO1114 or PRO4978 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

33. The method according to Claim 32, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

34. The method according to Claim 32, wherein said bioactive molecule causes the death of said cell.

35. A method of modulating at least one biological activity of a cell expressing a PRO1801 polypeptide, said method comprising contacting said cell with a PRO1114 or PRO4978 polypeptide or an anti-PRO1801 polypeptide antibody, whereby said PRO1114 or PRO4978 polypeptide or anti-PRO1801 polypeptide antibody binds to said PRO1801 polypeptide, thereby modulating at least one biological activity of said cell.

36. The method according to Claim 35, wherein said cell is killed.

37. A method of modulating at least one biological activity of a cell expressing a PRO1114 or PRO4978 polypeptide, said method comprising contacting said cell with a PRO1801 polypeptide or an anti-PRO1114 or anti-PRO4978 polypeptide antibody, whereby said PRO1801 polypeptide or anti-PRO1114 or anti-PRO4978 polypeptide antibody binds to said PRO1114 or PRO4978 polypeptide, thereby modulating at least one biological activity of said cell.

38. The method according to Claim 37, wherein said cell is killed.

39. A method of detecting a PRO1114 polypeptide in a sample suspected of containing a PRO1114 polypeptide, said method comprising contacting said sample with a PRO100 polypeptide and determining the formation of a PRO100/PRO1114 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO1114 polypeptide in said sample.

40. The method according to Claim 39, wherein said sample comprises cells suspected of expressing said PRO1114 polypeptide.

41. The method according to Claim 39, wherein said PRO100 polypeptide is labeled with a detectable label.

42. The method according to Claim 39, wherein said PRO100 polypeptide is attached to a solid support.

43. A method of detecting a PRO100 polypeptide in a sample suspected of containing a PRO100 polypeptide, said method comprising contacting said sample with a PRO1114 polypeptide and determining the formation of a PRO100/PRO1114 polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a PRO100 polypeptide in said sample.

44. The method according to Claim 43, wherein said sample comprises cells suspected of expressing said PRO100 polypeptide.

45. The method according to Claim 43, wherein said PRO1114 polypeptide is labeled with a detectable label.

46. The method according to Claim 43, wherein said PRO1114 polypeptide is attached to a solid support.

47. A method of linking a bioactive molecule to a cell expressing a PRO100 polypeptide, said method comprising contacting said cell with a PRO1114 polypeptide that is bound to said bioactive molecule and allowing said PRO100 and said PRO1114 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.

48. The method according to Claim 47, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

49. The method according to Claim 47, wherein said bioactive molecule causes the death of said cell.

50. A method of linking a bioactive molecule to a cell expressing a PRO1114 polypeptide, said method comprising contacting said cell with a PRO100 polypeptide that is bound to said bioactive molecule and allowing said PRO100 and said PRO1114 polypeptides to bind to one another, thereby linking said bioactive molecules to said cell.



51. The method according to Claim 50, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.

52. The method according to Claim 50, wherein said bioactive molecule causes the death of said cell.

53. A method of modulating at least one biological activity of a cell expressing a PRO100 polypeptide, said method comprising contacting said cell with a PRO1114 polypeptide or an anti-PRO100 polypeptide antibody, whereby said PRO1114 polypeptide or anti-PRO100 polypeptide antibody binds to said PRO100 polypeptide, thereby modulating at least one biological activity of said cell.

54. The method according to Claim 53, wherein said cell is killed.

55. A method of modulating at least one biological activity of a cell expressing a PRO1114 polypeptide, said method comprising contacting said cell with a PRO100 polypeptide or an anti-PRO1114 polypeptide antibody, whereby said PRO100 polypeptide or anti-PRO1114 polypeptide antibody binds to said PRO1114 polypeptide, thereby modulating at least one biological activity of said cell.

56. The method according to Claim 55, wherein said cell is killed.

57. A method for stimulating the release of TNF- $\alpha$  from human blood, said method comprising contacting said blood with a PRO195, PRO202, PRO215, PRO221, PRO217, PRO222, PRO198, PRO245, PRO172, PRO265, PRO266, PRO344, PRO337, PRO322, PRO1286, PRO1279, PRO1338 or PRO1343 polypeptide, wherein the release of TNF- $\alpha$  from said blood is stimulated.

58. A method for modulating the uptake of glucose or FFA by skeletal muscle cells, said method comprising contacting said cells with a PRO182, PRO366, PRO198, PRO172 or PRO719 polypeptide, wherein the uptake of glucose or FFA by said cells is modulated.

59. A method for stimulating the proliferation or differentiation of chondrocyte cells, said method comprising contacting said cells with a PRO182, PRO366, PRO198, PRO1868, PRO202, PRO224, PRO172, PRO301 or PRO1312 polypeptide, wherein the proliferation or differentiation of said cells is stimulated.

60. A method for modulating the uptake of glucose or FFA by adipocyte cells, said method comprising contacting said cells with a PRO202, PRO211, PRO344 or PRO1338 polypeptide, wherein the uptake of glucose or FFA by said cells is modulated.

61. A method for stimulating the proliferation of or gene expression in pericyte cells, said method comprising contacting said cells with a PRO366 polypeptide, wherein the proliferation of or gene expression in said cells is stimulated.

5 62. A method for stimulating the release of proteoglycans from cartilage, said method comprising contacting said cartilage with a PRO216 polypeptide, wherein the release of proteoglycans from said cartilage is stimulated.

63. A method for stimulating the proliferation of inner ear utricular supporting cells, said method comprising contacting said cells with a PRO172 polypeptide, wherein the proliferation of said cells is stimulated.

10 64. A method for stimulating the proliferation of T-lymphocyte cells, said method comprising contacting said cells with a PRO344 polypeptide, wherein the proliferation of said cells is stimulated.

15 65. A method for stimulating the release of a cytokine from PBMC cells, said method comprising contacting said cells with a PRO526 or PRO1343 polypeptide, wherein the release of a cytokine from said cells is stimulated.

20 66. A method for inhibiting the binding of A-peptide to factor VIIA, said method comprising contacting a composition comprising said A-peptide and said factor VIIA with a PRO182 polypeptide, wherein the binding of said A-peptide to said factor VIIA is inhibited.

67. A method for inhibiting the differentiation of adipocyte cells, said method comprising contacting said cells with a PRO185 or PRO198 polypeptide, wherein the differentiation of said cells is inhibited.

25 68. A method for stimulating the proliferation of endothelial cells, said method comprising contacting said cells with a PRO222 polypeptide, wherein the proliferation of said cells is inhibited.

30 69. A method for detecting the presence of tumor in an mammal, said method comprising comparing the level of expression of any PRO polypeptide shown in Table 8 in (a) a test sample of cells taken from said mammal and (b) a control sample of normal cells of the same cell type, wherein a higher level of expression of said PRO polypeptide in the test sample as compared to the control sample is indicative of the presence of tumor in said mammal.

35 70. The method of Claim 69, wherein said tumor is lung tumor, colon tumor, breast tumor, prostate tumor, rectal tumor, cervical tumor or liver tumor.

71. . . . . An oligonucleotide probe derived from any of the nucleotide sequences shown in the accompanying figures.

1/550

**FIGURE 1**

GTTACTCGGTGGTGGCGGAGTCTACGGAAGCCGTTTTTCGCTTCACTTTTCCTGGCTGTAGAGC  
GCTTTCCCCCTGGCGGGTGAGAGTGCAGAGACGAAGGTGCGAGATGAGCACTATGTTTCGCGGA  
CACTCTCCTCATCGTTTTTATCTCTGTGTGCACGGCTCTGCTCGCAGAGGGCATAACCTGGGT  
CCTGGTTTACAGGACAGACAAGTACAAGAGACTGAAGGCAGAAGTGGAACAGAGTAAAAA  
ATTGGAAGAAGAAGGAACAATAACAGAGTCAGCTGGTCGACAACAGAAAAAGAAAATAGA  
GAGACAAGAAGAGAACTGAAGAATAACAACAGAGATCTATCAATGGTTCGAATGAAATCCAT  
GTTTGCTATTGGCTTTTGTTTTACTGCCCTAATGGGAATGTTCAATTCCATATTTGATGGTAG  
AGTGGTGGCAAAGCTTCCTTTTACCCCTCTTTCTTACATCCAAGGACTGTCTCATCGAAATCT  
GCTGGGAGATGACACCACAGACTGTTCTTCATTTTCCTGTATATTCTCTGTACTATGTCGAT  
TCGACAGAACATTCAGAAGATTCTCGGCCTTGCCCCTTCACGAGCCGCCACCAAGCAGGCAGG  
TGGATTTCTTGGCCCACCACCTCCTTCTGGGAAGTTCTCTTGAACTCAAGAACTCTTTATTTT  
CTATCATTTCTTTCTAGACACACACATCAGACTGGCAACTGTTTTGTAGCAAGAGCCATAGG  
TAGCCTTACTACTTGGGCCTCTTTCTAGTTTTTGAATTATTTCTAAGCCTTTTGGGTATGATTA  
GAGTGAAAATGGCAGCCAGCAAACTTGATAGTGCTTTTGGTCCTAGATGATTTTTATCAAATA  
AGTGGATTGATTAGTTAAGTTCAGGTAATGTTTATGTAATGAAAAACAAATAGCATCCTTCTT  
GTTTCATTTACATAAGTATTTTCTGTGGGACCGACTCTCAAGGCACTGTGTATGCCCTGCAAG  
TTGGCTGTCTATGAGCATTTAGAGATTTAGAAGAAAAATTTAGTTTGTTTAACCCTTGTAAGT  
GTTTGTTTTGTTGTTGTTTTTTTTTCAAGCCAAATACATGACATAAGATCAATAAAGAGGCCA  
AATTTTTAGCTGTTTTATGTACAAGGAGAGATCTGTTTCATTTTGTTTTGCCGTATTTCTAGA  
TATAAGTTTTAGCATGGGCCAGGAAGGACTAAAATAAAAGTTTTTAAGGTACAAAAAAAAAAAA  
AAAA

2/550

**FIGURE 2**

MSTMFADTLLIVFISVCTALLAEGITWVLVYRTDKYKRLKAEVEKQSKKLEKKKETITESAGR  
QQKKKIERQEEKLKNNNRDLSMVRMKSMFAIGFCFTALMGMFNSIFDGRVVAKLPFTPLSYIQ  
GLSHRNLLGDDTTDCSFIFLYIILCTMSIRQNIQKILGLAPSRAATKQAGGFLGPPPPSGKFS

**Important features:****Signal peptide:**

amino acids 1-22

**N-myristoylation sites.**

amino acids 103-109, 163-169

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 53-57

3/550

**FIGURE 3**

AGCCGGGGGCGGGTTTGAAGACGCGTCGTTGGGTTTTGGAGGCCGTGAAACAGCCGTTTGAGT  
TTGGCTGCGGGTGGAGAACGTTTGTCAAGGGGCCCCGGCCAAGAAGGAGGCCCGCCTGTTACGAT  
GGTGTCCATGAGTTTCAAGCGGAACCGCAGTGACCGGTTCTACAGCACCCGGTGCTGCGGCTG  
TTGCCATGTCCGCACCGGGACGATCATCCTGGGGACCTGGTACATGGTAGTAAACCTATTGAT  
GGCAATTTTGCTGACTGTGGAAGTGACTCATCCAACTCCATGCCAGCTGTCAACATTCAGTA  
TGAAGTCATCGGTAATTACTATTCGTCTGAGAGAATGGCTGATAATGCCTGTGTTCTTTTTGC  
CGTCTCTGTTCTTATGTTTATAATCAGTTCAATGCTGGTTTATGGAGCAATTTCTTATCAAGT  
GGGTTGGCTGATTCCATTCTTCTGTTACCGACTTTTTGACTTCGTCCTCAGTTGCCTGGTTGC  
TATTAGTTCTCTCACCTATTTGCCAAGAATCAAAGAATATCTGGATCAACTACCTGATTTTCC  
CTACAAAGATGACCTCCTGGCCTTGGACTCCAGCTGCCTCCTGTTTCATTGTTCTTGTGTTCTT  
TGCCTTATTCATCATTTTTTAAGGCTTATCTAATTAAGTGTGTTTGGAACTGCTATAAATACAT  
CAACAACCGAAACGTGCCGGAGATTGCTGTGTACCCTGCCTTTGAAAGCACCTCCTCAGTACG  
TTTTGCCAACCTATGAAATGGCCGTGAAAATGCCTGAAAAAGAACCACCACCTCCTTACTTAC  
CTGCCTGAAGAAATTCTGCCTTTGACAATAAATCCTATAACCAGCTTTTTGTTTGTGTTATGTTA  
CAGAATGCTGCAATTCAGGGCTCTTCAAACCTGTTTGATATAAAATATGTTGTCTTTTGTGTTA  
AGCATTTATTTTCAAACACTAAGGAGCTTTTTGACATCTGTTAAACGTCTTTTTGTTTTTTT  
TTAAGTCTTTTACATTTTAATAGTTTTTGAAGACAATCTAGGTTAAGCAAGAGCAAAGTGCCA  
TTGTTTGCCTTTAATTGGGGGGTGGGAAGGGAAAGAGGGTACTTGCCACATAGTTTCCTTTTT  
AACTGCACTTTCTTTATATAATCGTTTGCATTTTGTACTTGCTACCCTGAGTACTTTCAGGA  
AGACTGACTTAAATATTCGGGGTGAGTAAGTAGTTGGGTATAAGATCTGAACTTTTCATCTGC  
AGAGGCAAGAAAAATATTTGACATTGTGACTTGACTGTGGAAGATGATGGTTGCATGTTTCTA  
GTTTGTATATGTTTCCATCTTTGTGATAAGATGATTTAATAAATCTCTTTAAATACTAAAAA  
AAAAA

4/550

**FIGURE 4**

MVSMSEFKRNRSDRFYSTRCCGCCHVRTGTIILGTWYMVVNLLMAILLTVEVTHPNSMPAVNIQ  
YEVIIGNYYSSERMADNACVLFAVSVMFIISSMLVYGAIYQVGWLIPFFCYRLFDFVLSCLV  
AISSLTYLPRIKEYLDQLPDFPYKDDLLALDSSCLLFIVLVFFALFIIFKAYLINCWNCYKY  
INNRRNVPEIAVYPAFESTSSVRFANL

**Important features of the protein:**

**Transmembrane domain (Possible type II transmembrane protein):**

amino acids 30-49, 81-100, 111-131, 158-175

**N-glycosylation site.**

amino acids 9-13

**Tyrosine kinase phosphorylation sites.**

amino acids 8-16, 193-202

**N-myristoylation site.**

amino acids 68-74

5/550

**FIGURE 5**

CCCGCTGGCCCGTCAGTGCTCTCCCCGTCGTTTGCCCTCTCCAGTTCCCCCAGTGCCTGCCCT  
ACGCACCCCCGATGGCGGAGCTGCGGCCTAGCGGCGCCCCCGGCCCCACCGCGCCCCCGGCCCC  
TGGCCCGACTGCCCCCCCCGGCCTTCGCTTCGCTCTTCCCCCGGGACTGCACGCCATCTACGG  
AGAGTGCCGCGCCTTTACCCTGACCAGCCGAACCCGCTCCAGGTTACCGCTATCGTCAAGTA  
CTGGTTGGGTGGCCCAGACCCCTTGGAATATGTTAGCATGTACAGGAATGTGGGGAGCCCTTC  
TGCTAACATCCCCGAGCACTGGCACTACATCAGCTTCGGCCTGAGTGATCTCTATGGTGACAA  
CAGAGTCCATGAGTTTACAGGAACAGATGGACCTAGTGTTTGGCTTTGAGTTGACCTTTTCG  
TCTGAAGAGAGAACTGGGGAGTCTGCCCCACCAACATGGCCCGCAGAGTTAATGCAGGGCTT  
GGCACGATACGTGTTCCAGTCAGAGAACACCTTCTGCAGTGGGGACCATGTGTCTTGGCACAG  
CCCTTTGGATAACAGTGAGTCAAGAATTCAGCACATGCTGCTGACAGAGGACCCACAGATGCA  
GCCCGTGACAGACACCCTTTGGGGTAGTTACCTTCCTCCAGATCGTTGGTGTCTGCACTGAAGA  
GCTACACTCAGCCCAGCAGTGGAACGGGCAGGGCATCCTGGAGCTGCTGCGGACAGTGCCTAT  
TGCTGGCGGCCCTGGCTGATAACTGACATGCGGAGGGGAGAGACCATATTTGAGATCGATCC  
ACACCTGCAAGAGAGAGTTGACAAAGGCATCGAGACAGATGGCTCCAACCTGAGTGGTGTCTAG  
TGCCAAGTGTGCTTGGGATGACCTGAGCCGGCCCCCGAGGATGACGAGGACAGCCGGAGCAT  
CTGCATCGGCACACAGCCCCGGCGACTCTCTGGCAAAGACACAGAGCAGATCCGGGAGACCCT  
GAGGAGAGGACTCGAGATCAACAGCAAACCTGTCCTTCCACCAATCAACCCTCAGCGGCAGAA  
TGGCCTCGCCCACGACCGGGCCCCGAGCCGCAAAGACAGCCTGGAAAGTGACAGCTCCACGGC  
CATCATTCCCCATGAGCTGATTCGCACGCGGCAGCTTGAGAGCGTACATCTGAAATTCAACCA  
GGAGTCCGGAGCCCTCATTCCTCTCTGCCTAAGGGGAGGCTCCTGCATGGACGGCACTTTAC  
ATATAAAAGTATCACAGGTGACATGGCCATCACGTTTGTCTCCACGGGAGTGGAAGGCGCCTT  
TGCCACTGAGGAGCATCCTTACGCGGCTCATGGACCCTGGTTACAACCTCTGAACCTATCCTCG  
GAGCTCTGCCCTCCCGTCTTGGAAACGTCTTCTGCCCTGAGGAGAGGGTAGTCAGCATCTCCA  
ATTTTCAGCAGCTCAAGAACCTTGGCCCCACAGGACTTCGCAGATGTCACATTGCCCTCAG  
TCCCCTGAATGCCCTTCGGACCCAACCCCAATTCCCAAGCCCCTGACCCCTAGCTGCCGGG  
GTTCCCACTCCCAGTGCCACAACCCCTCACCTCCCCTGGCAGCCCCTCAGCGAGCCTGAGGC  
CCAGCACCCGCTGGCTCCCCAGCACATGGTCCCCTCCCATGGGCTGTTGCCAGGGAACCGGG  
GCGCGGTGGGAACGAGCTGCTGGCCTCGGCATGTTTCAATAAAGTTGCTGTGCTGGGAG



6/550

**FIGURE 6**

MAELRPSGAPGPTAPPAPGPTAPPAFASLFPPGLHAIYGECRRLYPDQPNPLQVTAIVKYWLG  
GPDPLDYVSMYRNVGSPSANIPEHWHYISFGLSDLYGDNRVHEFTGTDGPGSGFGFELTFRLKR  
ETGESAPPTWPAELMQGLARYVFQSENTFCSGDHVSWHSPLDNSESRIQHMLLTEDPQMOPVQ  
TPFGVVTFLQIVGVCTEELHSAQQWNGQGILELLRTVPIAGGPWLITDMRRGETIFEIDPHLQ  
ERVDKGIETDGSNLSGVSAKCAWDDLSRPPEDDEDSRSICIGTQPRRLSGKDTEQIRETLRRG  
LEINSKPVLPPINPQRQNGLAHDRAPSRKDSLESDSSTAIIPHELIRTRQLESVHLKFNQESG  
ALIPLCLRGRLLHGRHFTYKSITGDMAITFVSTGVEGAFATEEHPYAAHGPWLQL

**Important features:****N-glycosylation site.**

amino acids 265-268

7/550

**FIGURE 7**

CGCGAATGAAGTTTGCATTTTCCTCTGTTCTTGAGCCCAGCTTCTTCTCGTCTCCCACCCAG  
CTTCCCGGCATTGGAAGAAGGGACCGTCCTCTTCCTTGTCTTGGCCACCCAAATCCTGGTATC  
GAAAGGGTTGAACGGACCGGAAGTGTGCAGCAGCGACGGGTCCCCAGCTAATCGACGCCGGAA  
GTAGCAATTACTAGACAAGCATTCCGCCGCCGGCTTCGCT**ATG**GCGGCAATCCCCCAGATTC  
CTGGCAGCCACCCAACGTTTACTTGGAGACCAGCATGGGAATCATTGTGCTGGAGCTGTACTG  
GAAGCATGCTCCAAAGACCTGTAAGAACTTTGCTGAGTTGGCTCGTCGAGGTTACTACAATGG  
CACAAAATTCCACAGAATTATCAAAGACTTCATGATCCAAGGAGGTGACCCAACAGGGACAGG  
TCGAGGTGGTGCATCTATCTATGGCAAACAATTTGAAGATGAACTTCATCCAGACTTGAAATT  
CACGGGGGGCTGGAATTCTCGCAATGGCCAATGCGGGGGCCAGATACCAATGGCAGCCAGTTCTT  
TGTGACCCTCGCCCCCAGTGGCTTGACGGCAAACACACCATTTTTGGCCGAGTGTGTCA  
GGGCATAGGAATGGTGAATCGCGTGGGAATGGTAGAAACAACTCCCAGGACCGCCCTGTGGA  
CGACGTGAAGATCATTAAGGCATACCCTTCTGGG**TAG**ACTTGCTACCCTCTTGAGCAGCTCTT  
CTGAGATGGCCCCAGTGAACCAGCTTCTAGATGACATAGAATGACATGTAATGCTAAATTTCA  
TTTTGGCTTTGCAAGTCATGAAGCTTAGGAGGCCTGGCATCTTGGGTGAGTTAGAGATGGAAG  
TACATTTTAAATAGGATGCTTCTTTTCTCTTCCCCAGTGCCTAGGTTGCCAGAGCATTTCAC  
AAATGCCCCCTGTTTATCAATAGGTGACTACTTACTACACATGAACCATAATGCTGCTTCTTGT  
GCATGTCTGCTCTGATATACGTCGAACAATGTAGCAGCCACTGTCATTTCTCAGTGGTTTTGC  
CTAACCAAACCTTCTTCCTAAGGAGATTTATATTCTGGCCTACACAGCAGTCCTTGATGGCTGA  
CAGCCACAGAATTCCAAACCAAGTAGTGTCTGTCAGCCCTCTTAACCTCTGTGCACGCCCTATT  
TCAGTCTTTTACATTTGTTCTTCTAGGGAATGTATGCATCTCTATATATATTTTCCCTCTCAA  
AACCAGAACATCAACAGTGCTGTTTCTGACACTTCAGACATCCCACGCAAAGCCACATTGAAT  
TTTTGCCAAATGAAAAACACATCCAACAATCAAGTTTCTAAGAAGGTGTCAAGTGGGGAATAA  
TAATAATGTATAATAATCAAGAAATTAGTTTATTAAAAGGAAGCAGAAGCATTGACCATTTTT  
TCCCAGAGAAGAGGAGAAATCTGTAGTGAGCAAAGGACAGACCATGAATCCTCCTTGAGAAGT  
AGTACTCTCAGAAAGGAGAAGCGCCACTCAAGTTCTTTTAACCCAAGACTTTAGAGAAATTAG  
GTCCAAGATTTTTATATGTTTCAGTTGTTTATGTATAAAAAATACTTTCTGGATTTTGTGGGGA  
GGAGCAGGAGAGGAAGGAAGTTAATACCTATGTAATACATAGAACTTCCACAATAAAATGCC  
ATTGATGGTTAAAAAAAAAAAAAAAAAAAAA

8/550

**FIGURE 8**

MAAIPPSWQPPNVYLETSMGIIVLELYWKHAPKTCKNFAELARRGYNGTKFHRIIKDFMIQ  
GGDPTGTGRGGASIYGKQFEDELHPDLKFTGAGILAMANAGPDTNGSQFFVTLAPTQWLDGKH  
TIFGRVCQGIGMVNRVGMVETNSQDRPVDDVKI IKAYPSG

**Important features:****N-glycosylation sites:**

amino acids 49-52, 108-111

**N-myristoylation sites:**

amino acids 64-69, 69-74, 143-148

**Cyclophilin-type peptidyl-prolyl cis-trans isomerase signature:**

amino acids 48-65

9/550

FIGURE 9

CGGACGCGTGGGCGCGCGGAGCGCAGCGGTGGGAGGCGGCGACCAGCCGGTTGAGGCCCCAG  
GCTTGGCCTCACCACAATGTGGCACGAGGCTCGGAAGCATGAGCGGAAGCTTCGAGGCATGAT  
GGTCGACTACAAGAAGAGGGCGGAGCGGAGACGGGAGTATTATGAAAAGATCAAGAAGGACCC  
AGCCCAGTTCTGCAGGTACATGGCCGAGCTTGCAAGGTGCACCTGGATTCTGCAGTCGCCCT  
GGCCGCTGAGAGCCCTGTTAATATGATGCCCTGGCAGGGGGACACCAACAACATGATTGACCG  
ATTCGATGTCCGTGCCCACCTGGACCACATCCCCGACTACACCCCCCTCTGCTCACCACCAT  
CTCCCCAGAACAGGAGTTCGGACGAACGGAAGTGTAACCTACGAGCGCTACAGAGGCCTGGTGCA  
GAACGACTTTGCCGGCATCTCAGAGGAGCAGTGCCTGTACCAGATCTACATTGATGAGTTGTA  
CGGAGGCCTCCAGAGACCCAGCGAAGATGAGAAGAAGAAGCTGGCAGAGAAGAAGGCTTCCAT  
CGGTTATACCTACGAGGACAGCACGGTGGCCGAGGTAGAGAAGGCGGCAGAAAAGCCAGAGGA  
GGAGGAGTCAGCGGCCGAGGAGGAGAGCAACTCGGACGAAGATGAGGTCATCCCCGACATCGA  
CGTGGAGGTGGACGTGGATGAATTGAACCAGGAGCAGGTGGCAGATCTCAACAAACAGGCCAC  
GACTTATGGCATGGCCGACGGTGAATTTCGTGAGGATGCTCCGGAAGACAAGGAGGAGGCAGA  
GGCCATCAAGCATGCCAAGGCTCTTGAGGAGGAGAAGGCCATGTACTCGGGACGCCGCTCTCG  
ACGCCAGCGGAGAGAGTTTCGGGAGAAGCGGCTGAGGGGTGCAAGATCAGCCCACCCAGCTA  
TGCCCGCCGAGACAGCCCCACCTATGACCCCTATAAGCGGTCAACCTCGGAGTCCAGCTCAGA  
GTCCCGCTCCCGCTCCCGCTCCCGGACCCCGGGCCGCGAGGAGAAGATCACGTTTATCACCAG  
TTTTGGGGGCAGCGATGAGGAGGCAGCCGAGCCGCTGCTGCCGCAGCAGCATCAGGAGTCAC  
CACAGGGAAGCCCCCGCACCTCCCCAGCCTGGCGGGCCCCGCCCCGGGACGTAATGCCAGCGC  
CCGCCGCCGCTCCTCCTCCTCCTCCTCCTCCTCCTCCTGCTCGAGGACCTCCAGCTCCCGCTC  
CAGCTCTCGCTCCAGCTCCCGCTCTCGCCGTGGTGGGGGCTACTACCGTTCCGGCCGCCACGC  
CCGCTCCCGGTCCCGCTCCTGGTCCCGCTCCCGCTCCCGCTCCCGGCGCTATTCCCGGTCCCG  
TAGCCGTGGCCGGCGGCACTCAGGTGGGGGCTCCCGAGACGGACACCGGTACTCCCGCTCGCC  
CGCCCGCGGTGGTGGTTACGGGCCCCGGCGCAGAAGCAGGAGCCGCTCCCACTCAGGGGACCG  
CTACAGGCGGGGCGGCCGGGGCCTCAGGCACCACAGCAGTAGCCGCAGCCGCAGCAGCTGGTC  
CCTCAGCCCGTCCCGCAGTCGCAGCCTGACTCGCAGCCGCAGCCATAGCCCCAGCCCCAGCCA  
GAGCCGCAGCCGCAGCCGCAGCCGCAGCCAGAGCCCCTCGCCATCACCCGCAAGAGAGAAGCT  
GACCAGGCCGGCCGCGTCCCCTGCTGTGGGCGAGAAGCTGAAAAAGACCGAACCTGCCGCTGG  
TAAAGAGACAGGAGCTGCCAAAGTCACCCAAGCTGACGCCTCAGGAGAAGCTGAAACTGAGGA  
TGCAGAAGGCGCTGAACAGGCAGTTCAAGGCGGATTAAGAAGGCGGCACAAGAAAAGATGATCC  
AGCAGGAGCATGAGCGGCAGGAGCGGGAAGACGAGCTTCGAGCCATGGCCCGCAAGATCCGCA  
TGAAGGAGCGGGAACGCCGAGAGAAGGAGAGAGAAGAGTGGGAACGCCAGTACAGCCGGCAGA  
GCCGCTCACCTCCCCCGATACAGTCGAGAATACAGCTCTTCTCGAAGGCGCTCAAGGTCCC  
GATCCCGAAGCCCCCATTACCGACATTAGGCAGAAGAGTGGGGGGTGGGGAGGACAAGGGGGT  
GGGTAAGGGGCTCAAGCTGTGATGCTGCTGGTTTTATCTCTAGTGAAATAAAGTCAAAAGTTA  
TTTAATTCCCGTCAA  
AAAAAAA

10/550

FIGURE 10

MWHEARKHERKLRGMMVDYKKRAERRREYYEKIKKDPAQFLQVHGRACKVHLD SAVALAAESP  
VNMPWQGD TNNMIDRFDVRAHL DHI PDYTPPLLTTISPEQESDERKCNYERYRGLVQND FAG  
ISEEQCLYQIYIDELYGGLQRPSEDEKKKLAEEKKASIGYTYEDSTVAEVEKAAEKPEEEESAA  
EEESNSDEDEVIPDIDVEVDVDELNQE QVADLNKQATTYGMADGDFVRMLRKDK EEAEAIKHA  
KALEEEKAMYSGRRSRRQRREFREKRLRGRKISPPSYARRDSPTYDPYKRSPSESSSESRSRS  
RSPTPGREEKITFITSFGGSDEEAAAAAAAAAASGVTTGKPPAPPQPGGPAPGRNASARRRSS  
SSSSSSSASRTSSSRSSSRSSSRSSRRGGGYRSGRHARSRSRSWSRSRSRSRRYSRSRSRGRR  
HSGGGSRDGHRYSRSPARRGGYGPRRRSRSRSHSGDRYRRGGRGLRHHSSSRSSRSSLSPSR  
RSLTRSRSHSPSPSQSRSRSRSRSPSPSPSPAREKLTRPAASPAVGEKLKKTEPAAGKETGA  
AKVTQADASGEAETEDAEGAEQAVQGG

**Important features:****N-glycosylation site:**

amino acids 370-373

**Glycosaminoglycan attachment site:**

amino acids 443-446

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**amino acids 159-162, 282-285, 291-294, 374-377, 375-378, 430-433,  
440-443, 466-469**Casein kinase II phosphorylation site:**amino acids 149-152, 166-169, 171-174, 187-190, 193-196, 195-198,  
303-306, 307-310, 335-338, 571-574**N-myristoylation sites:**

amino acids 118-123, 229-234, 350-355, 446-451, 586-591

**Amidation sites:**

amino acids 263-266, 280-283, 438-441

11/550

**FIGURE 11**

GGTAGGCGCGCCCAGACCTGAGACGGGTTGGGACTGGGCTGCGTCACGCGCGGGCTCTAAGCG  
CCCGGGGCCCCGCCAGTGGCCGGCACAGCCAATCGCAGCGCGGGAAGGCGGTGGGGGCGGGG  
AAGGCCGCCTGGAAACTTAAATCCCGAGGCGGGCGAACCTGCACCAGACCGCGGACGTCTGTA  
ATCTCAGAGGCTTGTTTGCTGAGGGTGCCTGCGCAGCTGCGACGGCTGCTGGTTTTGAAACAT  
GAATCTTTCGCTCGTCCTGGCTGCCTTTTGCTTGGGAATAGCCTCCGCTGTTCCAAAATTTGA  
CCAAAATTTGGATACAAAGTGGTACCAGTGAAGGCAACACACAGAAGATTATATGGCGCGAA  
TGAAGAAGGATGGAGGAGAGCAGTGTGGGAAAAGAATATGAAAATGATTGAACTGCACAATGG  
GGAATACAGCCAAGGGAAACATGGCTTCACAATGGCCATGAATGCTTTTGGTGACATGACCAA  
TGAAGAATTCAGGCAGATGATGGGTGCTTTGCAAACCAGAAATTCAGGAAGGGGAAAGTGTT  
CCGTGAGCCTCTGTTTCTTGATCTTCCCAAATCTGTGGATTGGAGAAAGAAAGGCTACGTGAC  
GCCAGTGAAGAATCAGAAACAGTGTGGTTCTTGTTGGGCTTTTAGTGCGACTGGTGCTCTTGA  
AGGACAGATGTTCCGGAAACTGGGAACTTGTCTCACTGAGCGAGCAGAATCTGGTGGACTG  
TTCGCGTCCTCAAGGCAATCAGGGCTGCAATGGTGGCTTCATGGCTAGGGCCTTCCAGTATGT  
CAAGGAGAACGGAGGCCTGGACTCTGAGGAATCCTATCCATATGTAGCAGTGGATGAAATCTG  
TAAGTACAGACCTGAGAATTCTGTTGCTAATGACACTGGCTTCACAGTGGTCGCACCTGGAAA  
GGAGAAGGCCCTGATGAAAGCAGTCGCAACTGTGGGGCCCATCTCCGTTGCTATGGATGCAGG  
CCATTCGTCTTCCAGTTCTACAAATCAGGCATTTATTTTGAACCAGACTGCAGCAGCAAAAA  
CCTGGATCATGGTGTTCTGGTGGTTGGCTACGGCTTTGAAGGAGCAAATTCGAATAACAGCAA  
GTATTGGCTCGTCAAAAACAGCTGGGGTCCAGAATGGGGCTCGAATGGCTATGTAAAAATAGC  
CAAAGACAAGAACAACCACTGTGGAATCGCCACAGCAGCCAGCTACCCCAATGTGTGAGCTGA  
TGGATGGTGAGGAGGAAGGACTTAAGGACAGCATGTCTGGGGAAATTTTATCTTGAAACTGAC  
CAAACGCTTATTGTGTAAGATAAACCAGTTGAATCATGGAGGATCCAAGTTGAGATTTTAATT  
CTGTGACATTTTTTACAAGGGTAAAATGTTACCACTACTTTAATTATTGTTATACACAGCTTTA  
TGATATCAAAGACTCATTGCTTAATTCTAAGACTTTTGAATTTTCATTTTTTAAAAAGATGTA  
CAAAACAGTTTGAAATAAATTTTAATTCGTATATA

12/550

**FIGURE 12**

MNLSLVLA AFCLGIASAVPKFDQNLDTKWYQWKATHRRLYGANEEGWRRRAVWEKNMKMIELHN  
GEYSQKGHGFTMAMNAFGDMTNEEFRQMMGCFRNQKFRKGKVFREPLFLDLPKSVDWRKKG YV  
TPVKNQKQCGSCWAFSATGALEGQMFRKTGKLVSLSEQNLVDCSRPQGNQGCNGGF MARAFQY  
VKENGGLDSEESYPYVAVDEICKYRPENSVANDTGFTVVAPGKEKALMKAVATVGPISVAMDA  
GHSSFQFYKSGIYFEPDCSSKNLDHGVLVVGYGFEGANSNSKYWLVKNSWGP EWGSNGYVKI  
AKDKNNHCGIATAASYPNV

**Important features:****Signal sequence**

amino acids 1-17

**N-glycosylation sites.**

amino acids 2-6, 221-225, 292-296

**N-myristoylation sites.**amino acids 13-19, 93-99, 136-142, 145-151, 174-180, 177-183,  
180-186, 194-200, 288-294, 324-330**Eukaryotic thiol (cysteine) proteases cysteine active site.**

amino acids 132-144

**Eukaryotic thiol (cysteine) proteases histidine active site.**

amino acids 275-286

13/550

**FIGURE 13**

GGCGGCGTCATGTGATCCGCTTCCCTGCTCCTTTAAGCGTCCACAGGCGGCGGAGCGGCCACA  
ATCACAGCTCCGGGCATTGGGGGAACCCGAGCCGGCTGCGCCGGGGGAATCCGTGCGGGCGCC  
TTCCGTCCCGGTCCCATCCTCGCCGCGCTCCAGCACCTCTGAAGTTTTGACGCGCCAGAAAG  
GAGGCGAGGAAGGAGGGAGTGTGTGAGAGGAGGGAGCAAAAAGCTCACCTAAAACATTTATT  
TCAAGGAGAAAAGAAAAAGGGGGGGCGCAAAAATGGCTGGGGCAATTATAGAAAACATGAGCA  
CCAAGAAGCTGTGCATTGTTGGTGGGATTCTGCTCGTGTTCCAAATCATCGCCTTTCTGGTGG  
GAGGCTTGATTGCTCCAGGGCCCCACAACGGCAGTGTCTACATGTGCGTGAAATGTGTGGATG  
CCCGTAAGAACCATCACAAGACAAAATGGTTTCGTGCCTTGGGGACCCAATCATTGTGACAAGA  
TCCGAGACATTGAAGAGGCAATTCCAAGGGAAATTGAAGCCAATGACATCGTGTTCCTGTTTC  
ACATTCCCCTCCCCACATGGAGATGAGTCCTTGGTTCCAATTCATGCTGTTTATCCTGCAGC  
TGGACATTGCCTTCAAGCTAAACAACCAAATCAGAGAAAATGCAGAAGTCTCCATGGACGTTT  
CCCTGGCTTACCGTGATGACGCATTTGCTGAGTGGACTGAAATGGCCCATGAAAGAGTACCAC  
GGAAACTCAAATGCACCTTCACATCTCCAAGACTCCAGAGCATGAGGGCCGTTACTATGAAT  
GTGATGTCCTTCCTTTTCATGGAAATTGGGTCTGTGGCCCATAGTTTACCTTTTAAACATCC  
GGCTGCCTGTGAATGAGAAGAAGAAAATCAATGTGGGAATTGGGGAGATAAAGGATATCCGGT  
TGGTGGGGATCCACCAAAATGGAGGCTTCACCAAGGTGTGGTTTGCCATGAAGACCTTCCTTA  
CGCCCAGCATCTTCATCATTATGGTGTGGTATTGGAGGAGGATCACCATGATGTCCCGACCCC  
CAGTGCTTCTGGAAAAAGTCATCTTTGCCCTTGGGATTTCCATGACCTTTATCAATATCCCAG  
TGGAATGGTTTTCCATCGGGTTTGACTGGACCTGGATGCTGCTGTTTGGTGACATCCGACAGG  
GCATCTTCTATGCGATGCTTCTGTCCTTCTGGATCATCTTCTGTGGCGAGCACATGATGGATC  
AGCACGAGCGGAACCACATCGCAGGGTATTGGAAGCAAGTCGGACCCATTGCCGTTGGCTCCT  
TCTGCCTCTTCATATTTGACATGTGTGAGAGAGGGGTACAACCTCACGAATCCCTTCTACAGTA  
TCTGGACTACAGACATTGGAACAGAGCTGGCCATGGCCTTCATCATCGTGGCTGGAATCTGCC  
TCTGCCTCTACTTCCTGTTTCTATGCTTCATGGTATTTTCAGGTGTTTCGGAACATCAGTGGGA  
AGCAGTCCAGCCTGCCAGCTATGAGCAAAGTCCGGCGGCTACACTATGAGGGGCTAATTTTTTA  
GGTTCAAGTTCCTCATGCTTATCACCTTGGCCTGCGCTGCCATGACTGTCATCTTCTTCATCG  
TTAGTCAGGTAACGGAAGGCCATTGGAAATGGGGCGGCGTCACAGTCCAAGTGAACAGTGCCT  
TTTTACAGGCATCTATGGGATGTGGAATCTGTATGTCTTTGCTCTGATGTTCTTGATGCAC  
CATCCCATAAAACTATGGAGAAGACCAGTCCAATGGCGATCTGGGTGTCCATAGTGGGGAAG  
AACTCCAGCTCACCACCCTATCACCCATGTGGACGGACCCACTGAGATCTACAAGTTGACCC  
GCAAGGAGGCCAGGAGTAGGAGGCTGCAGCGCCCGGCTGGGACGGTCTCTCCATACCCAGC  
CCCTCTAAGTAGAGTGGGGAGCATGCCAGAGAGAGCTCAATGTACAAATGAATGCCTCATGGC  
TCTTAGCTGTGGTTTCTTGGACCAGCGGCATGGACATTTGTCAGTTTGCCTTCTGACGGTAGC  
TTTTGGAGGAAGATTCTTGCAGCCACTAATGCATTGTGTATGATAACAAAACTCTGGTATGA  
CACATTTTCTGTGATCATTGTTAATTAGTGACATAGTAACATCTGTAGCAGCTGGTTAGTAAA  
CCTCATGTGGGGGTGGGGTGGGGGTGTATTCTTGGGGGATGGTTTGGGCCGAATGGGGAGTG  
GAATATTTGACATTTTTCCTGTTTTAAATTCTAGGATAGATTTTAAACATCCTTTGCGGTCCCA  
GTCCAAGGTAGGCTGGTGTCTAGTCTTCTCACTCCTAATCCATGACCACTGTTTTTTTCTTA  
TTATATCACCAGGTAGCCTACTGAGTTAATATTTAAGTTGTCAATAGATAAGTGTCCCTGTT  
TTGTGGCATAATAAATACTGAATTTTCATGAGAAGATTTATCCACCAGGGGTATTTAGCTTTG  
AAACCAAATCTGTGTATCTAATACTAACCAATCTGTTGGATGTGGATTTTAAAAAATGTTTGC  
TAAACTACCCAAGTAAGATTTACTGTATTAAATGGCCTTCGGGTCTGAAAAGCTTTTTTAAACC  
TCTTGCTTAAATGCGTTTTATTTTGATAAGATACTTCAAATAGCCTCCAAAAGTGTAGATCC  
AATCACTTAAATAAACCTGTATGTATATGCAAAAAAAAAAAAAAAAAAAAAA



14/550

**FIGURE 14**

MAGAI IENMSTKKLCIVGGILLVFQIIAFLVGGLIAPGPTTAVSYMSVKCVDARKNHHKTKWF  
VPWGPNHCDKIRDIEEAIPREIEANDIVFSVHIPLPHMEMSPWFQFMLFILQLDIAFKLNNQI  
RENAEVSM DVSLAYRDDAFAEWTEMAHERVPRKLKCTFTSPKTPEHEGRYYECDVLPFMEIGS  
VAHKFYLLNIRLPVNEKKKINVGIGEIKDIRLVGIHQNGGFTKVWFAMKTFLTPSIFIIMVWY  
WRRITMMSRPPVLLEKVIFALGISMTFINIPVEWFSIGFDWTWMLLFGDIRQGI FYAMLLSFW  
IIFCGEHMMDQHERNHIAGYWKQVGPIAVGSFCLFIFDMCERGVQLTNPFIYSIWTTDIGTELA  
MAFIIIVAGICLCLYFLFLCFMVFQVFRNISGKQSSLPAMSKVRRLLHYEGLIFRKF LMLITLA  
CAAMTVIFFIVSQVTEGHWKWGGVTVQVNSAFFTGIYGMWNLYVFALMFLYAPSHKNYGEDQS  
NGDLGVHSGEELQLTTTITHVDGPTEIYKLTRKEAQE

**Important features of the protein:****Signal peptide:**

amino acids 1-42

**Transmembrane domains:**amino acids 239-253, 269-284, 302-318, 338-352, 377-399, 434-452,  
471-488**N-glycosylation sites.**

amino acids 8-12, 406-410

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 254-258

**N-myristoylation sites.**amino acids 223-229, 274-280, 305-311, 358-364, 374-380, 386-392,  
509-515

15/550

**FIGURE 15**

GTGAGGGGAACAGCTGATCCGTCTGTTGGGAGGACAGATATCTCAAGGCCAGGATGGAAGAAT  
CACCCTAAGCCGGGCACCATCCCGTGGTGGAGTCAACTTTCTCAATGTAGCCCGGACCTACA  
TCCCCAACACCAAGGTGGAATGTCACCTACACCCTTCCCCCAGGCACCATGCCCAGTGCCAGTG  
ACTGGATTGGCATCTTCAAGGTGGAGGCTGCCTGTGTTCCGGGATTACCACACATTTGTGTGGT  
CTTCCGTGCCTGAAAGTACAAGTATGATGGTTCCCCCATTCACACCAGTGTCCAGTTCCAAGCCA  
GCTACCTGCCCCAACACAGGAGCTCAGCTCTACCAGTTCCGATATGTGAACCGCCAGGGCCAGG  
TGTGTGGGCAGAGCCCCCTTTCCAGTTCCGAGAGCCAAGGCCCATGGATGAACTGGTGACCC  
TGGAGGAGGCTGATGGGGGCTCTGACATCCTGCTGGTTGTCCCCAAGGCAACTGTGTTACAGA  
ACCAGCTCGATGAGAGCCAGCAAGAACGGAATGACCTGATGCAGCTGAAGCTACAGCTGGAGG  
GACAGGTGACAGAGCTGAGGAGCCGAGTGCAGGAGCTCGAGAGGGCTCTGGCAACTGCCAGGC  
AGGAGCACACGGAGCTGATGGAACAGTACAAGGGGATTTCCCGGTCCCATGGGGAGATCACAG  
AAGAGAGGGACATCCTGAGCCGGCAACAGGGAGACCATGTGGCACGCATCCTGGAGCTAGAGG  
ATGACATCCAGACCATCAGTGAGAAAGTGTGACGAAGGAAGTGGAGCTGGACAGGCTTAGAG  
ACACAGTGAAGGCCCTGACTCGGGAACAAGAGAAGCTCCTTGGGCAACTGAAAGAAGTACAAG  
CAGACAAGGAGCAAAGTGAGGCTGAGCTCCAAGTGGCACAACAGGAGAACCATCACTTAAATT  
TGGACCTGAAGGAGGCGAAGAGCTGGCAAGAGGAGCAGAGTGTCTAGGCTCAGCGACTGAAAG  
ACAAGGTGGCCAGATGAAGGACACCCTAGGCCAGGCCAGCAGCGGGTGGCCGAGCTGGAGC  
CCTTGAAGGAGCAGCTTCGAGGGGGCCAGGAGCTTGCAGCCTCAAGCCAGCAGAAAGCCACCC  
TTCTTGGGGAGGAGTTGGCCAGTGCAGCAGCAGCCAGGGACCGCACCATAGCCGAACCTACACC  
GCAGCCGCCTGGAAGTGGCTGAAGTTAACGGCAGGCTGGCTGAGCTCGGTTTGCAGTTGAAGG  
AAGAAAAATGCCAATGGAGCAAGGAGCGGGCAGGGCTGCTGCAGAGTGTGGAGGCAGAGAAGG  
ACAAGATCCTGAAGCTGAGTGCAGAGATACTTCGATTGGAGAAGGCAGTTCAGGAGGAGAGGA  
CCCAAAACCAAGTGTTCAAGACTGAGCTGGCCCCGGGAGAAGGATTCTAGCCTGGTACAGTTGT  
CAGAAAGTAAGCGGGAGCTGACAGAGCTGCGGTGAGCCCTGCGTGTGCTCCAGAAGGAAAAGG  
AGCAGTTACAGGAGGAGAAACAGGAATTGCTAGAGTACATGAGAAAGCTAGAGGCCCGCCTGG  
AGAAGGTGGCAGATGAGAAGTGAATGAGGATGCCACCACAGAGGATGAGGAGGCCGCTGTGG  
GGCTGAGCTGCCCCGGCAGCTCTGACAGACTCAGAGGACGAGTCCCCAGAAGACATGAGGCTCC  
CACCCTATGGCCTTTGTGAGCGTGGAGACCCAGGCTCCTCTCCTGCTGGGCCTCGAGAGGCTT  
CTCCCCCTTGTGTGTCATCAGCCAGCCGGCTCCCATTTCTCCTCACCTCTCTGGGCCAGCTGAGG  
ACAGTAGCTCTGACTCGGAGGCTGAAGATGAGAAGTCAGTCCTGATGGCAGCTGTGCAGAGTG  
GGGGTGAGGAGGCCAACTTACTGCTTCTTGAAGTGGGCAGTGCCTTCTATGACATGGCCAGTG  
GCTTTACAGTGGGTACCTGTGAGAAACCAGCACTGGGGGCCCTGCCACCCCCACATGGAAGG  
AGTGTCTATCTGTAAGGAGCGCTTTCCTGCTGAGAGTGACAAGGATGCCCTGGAGGACCACA  
TGGATGGACACTTCTTTTTTCAGCACCCAGGACCCCTTCACCTTTGAGTGAATCTTACTCCCTCG  
TACATGCACAAATACACACTCATGCACACACACACTCACACACATGCATACACTTAGGTTTCA  
TGCCCATTTTCTATCACACTGGGCTCCATGATATTCTGTTCCCTAAGAACTGCTTCTGTGTGC  
CCTGTTTTTCATCCCAAGATTTCTCACTTCATCCTCTCCTACCTGGCTCTTTTGTCCCAGGGAG  
GGGTCTGTTTCGGAAGCAGTGGCTGAATTTATCCCTGAAAGTGGTTTTTGGAGGAACCGGGAT  
GGAGGAGGCCCTTCCCCTGTGGGAATAGAATCGTCCACTCCTAGCCCTGGTTGCTTCTGATACA  
CAGCCACTGCACACACACACTCACACTCACACTCCCTTGTCTGATGCCCCAAAGCCAATTCTCT  
GGGGCACCCCTACCCTCTCTTATTTGGAGTTTCCGTTGGTTTACCTGAGTTTTCTCTGGGGTCT  
GCACAGAGGCAGCAGCATGGACATCATGGCCTCTCAGGTCCCTTTTGGTTCTCAGTTTCATTG  
GTTCTCTTTCTGTTCCCCCATTTGACTTCTGTGCCCCACCCTAGCCTTTTCCATAACCTTAGG  
TATTCAGTTTGGAGGGGTTTTTTGTATTTTTTGAGGATTCCTGTATTCTGTATCCTCTCCTCGC  
ATCTCCTCACATGGAAAGAAATAATGTATTTGTGCTTCTGTGAGGAATGGGGGGAACAAGTG  
GTCCCAGGTATCCCCATTTCCAAGGCCCCCTCCCTCTCCAGGTCCCCCACAGCAATAAAAG  
CTTCCCCCTGATATCCATCCCTTTGTAGTTTGAACAAATATATTTATATGATATGTAA

16/550

**FIGURE 16**

MEESPLSRAPSRGGVNFLNVARTYIPNTKVECHYTLPPGTMPASDWIGIFKVEAACVRDYHT  
FVWSSVPESTTDGSPIHSTSVQFQASYLPKPGAQLYQFRYVNRQGQVCGQSPPFQFREPRPMDE  
LVTLEEADGGSDILLVVPKATVLQNLQDESQQERNLDMQLKLQLEGQVTELRSRVQELERALA  
TARQEHTELMEQYKGISRSHGEITEERDILSRQQGDHVARILELEDDIQTISEKVLTKVELD  
RLRDTVKALTREQEKLKGQLKEVQADKEQSEAEQVAQQENHHLNLDLKEAKSWQEEQSAQAQ  
RLKDKVAQMKDTLGQAQQRVAELEPLKEQLRGAQELAASSQQKATLLGEELASAAAARDRTIA  
ELHRSRLEVAEVNGLRLAELGLHLKEEKQWSKERAGLLQSVEAEKDKILKLSAEILRLEKAVQ  
EERTQNQVFKTELAREKDSSLVQLSESKRELTELRSALRVLQKEKEQLQEEKQELLEMYMRKLE  
ARLEKVADEKWNEDATTEDEEAAGVGLSCPAALTDSEDESPEDMRLPPYGLCERGDGSSPAGP  
REASPLVVISQPAPISPHLSGPAEDSSSDSEAEDKSVLMAAVQSGGEEANLLLPELGSAFYD  
MASGFTVGTLSSETSTGGPATPTWKECPICKERFPAESDKDALEDHMDGHHFFSTQDPFTFE

**Important features:****Casein kinase II phosphorylation sites:**

amino acids 28-31, 43-46, 68-71, 72-75, 129-132, 156-159, 208-  
211, 239-242, 282-285, 305-308, 376-379, 383-383, 468-471, 520-  
523, 521-524, 537-540, 539-542, 543-546, 593-596, 595-598, 597-  
600, 612-615, 639-642, 652-655, 667-670, 683-686

**N-myristoylation sites:**

amino acids 39-44, 107-112, 204-209, 414-419, 561-566, 613-618

**Cell attachment sequence:**

amino acids 557-559

**Leucine zipper pattern sequence:**

amino acids 163-184, 475-496, 482-503

17/550

**FIGURE 17**

GCAAGTTGGGAATTTTAGACTGTCACTGCACATGGACCTCTGGGAAGACGTCTGGCGAGAGCT  
AGGCCCACTGGCCCTACAGACGGATCTTGCTGGCTCACCTGTCCCTGTGGAGGTTCCCCTGGG  
AAGGCAAGATGCCCAACAACAGCACTGCTCTGTCAATTGGCCAATGTTACCTACATCACCATGG  
AAATTTTCATTGGACTCTGCGCCATAGTGGGCAACGTGCTGGTCATCTGCGTGGTCAAGCTGA  
ACCCAGCCTGCAGACCACCACCTTCTATTTCAATTGTCTCTCTAGCCCTGGCTGACATTGCTG  
TTGGGGTGCTGGTCATGCCTTTGGCCATTGTTGTCAGCCTGGGCATCACAATCCACTTCTACA  
GCTGCCTTTTTATGACTTGCCTACTGCTTATCTTTACCCACGCCTCCATCATGTCCCTTGCTGG  
CCATCGCTGTGGACCGATACTTGCGGGTCAAGCTTACCGTCAGATTCAGAATTCCTGGGCTCC  
CTGGGTGCATTCTATCATTCCAGTTGAAAGTTTGCTTCCTTCCAGTCATGTGGCTCTTCATTC  
TACTCTCCTTGGCTCTCATTTTCAAGATGCCATGGTCATGGATGAAAAGGTCAAGAGAAGCTTTG  
TGCTGGACACGGCTTCTGCCATCTGCAACTACAATGCCCACTACAAGAATCACCCCAAATACT  
GGTGCCGAGGCTATTTCCGTGACTACTGCAACATCATCGCCTTCTCCCCTAACAGCACCAATC  
ATGTGGCCCTGAGGGACACAGGGAACCAGCTCATTGTCACTATGTCTGCTGACCAAAGAGG  
ACACGGGCTGGTACTGGTGTGGCATCCAGCGGGACTTTGCCAGGGATGACATGGATTTTACAG  
AGCTGATTGTAAGTACGACAAAGGAACCCTGGCCAATGACTTTTGGTCTGGGAAAGACCTAT  
CAGGCAACAAAACCAGAAGCTGCAAGGCTCCCAAAGTTGTCCGCAAGGCTGACCGCTCCAGGA  
CGTCCATTCTCATCATTTGCATACTGATCACGGGTTTGGGAATCATCTCTGTAATCAGTCATT  
TGACCAAAAGGAGGAGAAGTCAAAGGAATAGAAGGGTAGGCAACACTTTGAAGCCCTTCTCGC  
GTGTCTGACTCCAAAGGAAATGGCTCCTACTGAACAGATGTGACTGAAGATTTTTTTAATTT  
AGTTCATAAAGTGATGCTACAACAGAATAATCACCATGACAACTGGCCACACCTCAGAGACT  
GATTCTGATCTCCCAGGAATTCTGAAGGACCCTCTATCCTTGACAACAATCATTTGCAGCCAG  
GTAGCAACGGCGGTAGTCAGAGGAGCTATGATAGACCACACCCAAGCAAGGCTGCCCTCAAAT  
AACATCTCAAGATCTTAGTTCTTATGCATTCCATCAGTCAGAAGTGAAGAAGAGGTGGAGAAT  
CTGGATTGGGGACCAGGAAATCACTTGTATTTTGTAGCCAATAAATTCCTAGCCAGTGTTGA  
ATGAAAAAAAAAAAAA

18/550

**FIGURE 18**

MPNNSTALSLANVTYITMEIFIGLCAIVGNVLVICVVKLNPSLQTTTFYFIVSLALADIAVGV  
LVMPLAIVVSLGITIHFYSCLEFMTCLLLIFTHASIMSLLAIAVDRLRVKLTVRFRIPGLPGC  
ILSFQLKVCFLPVMWLFILLSLALISDAMVMDEKVKRSFVLDTASAICNYNHYKNHPKYWCR  
GYFRDYCNIIAFSPNSTNHVALRDTGNQLIVTMSCLTKEDTGWYWCGIQRDFARDDMDFTTELI  
VTDDKGTLANDFWSGKDLGNGKTRSCAPKVVVRKADRSRTSILIICILITGLGIISVISHLTK  
RRRSQRNRRVGNTLKPFSRVLTPKEMAPTEQM

**Important features of the protein:****Transmembrane domains:**

amino acids 16-35, 62-80, 89-101, 134-152, 292-311

**N-glycosylation sites.**

amino acids 3-7, 4-8, 12-16, 204-208, 273-277

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 316-320

**N-myristoylation sites.**

amino acids 122-128, 125-131, 258-264

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 214-225

**G-protein coupled receptors proteins.**

amino acids 29-59, 76-116

19/550

**FIGURE 19**

CTCGGGCGCGCACAGGCAGCTCGGTTTGCCCTGCGATTGAGCTGCGGGTTCGCGGCCGGCGCCGGCCCTCTCCAATG  
GCAATGTGTGTGGCTGGAGGCGAGCGCAGGCTTTTCGGCAAAGGCAGTCGAGTGTTCGAGACCGGGGCGAGTC  
CTGTGAAAGCAGATAAAAGAAAACATTTATTAACGTGTCATTACGAGGGGAGCGCCCGCCGGGCTGTCGCACT  
CCCCGCGGAACATTTGGCTCCCTCCAGCTCCGAGAGAGGAGAAGAAGAAAGCGGAAAAGAGGCAGATTACGTCG  
TTTCCAGCCAAGTGGACCTGATCGATGGCCCTCCTGAATTTATCACGATATTTGATTTATTAGCGATGCCCCCTG  
GTTTGTGTGTTACGCACACACACGTGCACACAAGGCTCTGGCTCGCTTCCCTCCCTCGTTTCCAGCTCCTGGGCG  
AATCCCACATCTGTTTCAACTCTCCGCCGAGGGCGAGCAGGAGCGAGAGTGTGTGCAATCTGCGAGTGAAGAGGG  
ACGAGGGAAAAGAAACAAAGCCACAGACGCAACTTGAGACTCCCGCATCCCAAAAGAACACCAGATCAGCAAAA  
AAAGAAGATGGGGCCCCCGAGCCTCGTGTGCTGTGCTGTCCGCAACTGTGTTCTCCCTGCTGGGTGGAAGCTC  
GGCCTTCCCTGTGCGACCACCGCCTGAAAGGCAGGTTTCAGAGGGACCGCAGGAACATCCGCCCCAACATCATCCT  
GGTGTGACGGACGACCAGGATGTGGAGCTGGGTTCCATGCAGGTGATGAACAAGACCGGCGCATCATGGAGCA  
GGGCGGGGCGCACTTCATCAACGCCTTCGTGACCACACCCATGTGCTGCCCTCACGCTCCTCCATCCTCACTGG  
CAAGTACGTCCACAACCAACACCTACACCAACAATGAGAAGTGTCTCTCGCCCTCCTGGCAGGCACAGCACGA  
GAGCGCACCTTTGCCGTGTACCTCAATAGCACTGGCTACCGGACAGCTTTCTTCGGGAAGTATCTTAATGAATA  
CAACGGCTCCTACGTGCCACCCCGGCTGGAAGGAGTGGGTCCGACTCCTTAAAAACTCCGCTTTTATPACTACAC  
GCTGTGTGCGAACGGGGTGAAAGAGAAGCACGGCTCCGACTACTCCAAGGATTACCTCACAGACCTCATCACAA  
TGACAGCGTGAGCTTCTTCCGCACGTCCAAGAAGATGTACCCGCACAGGCCAGTCTCATGGTCATCAGCCATGC  
AGCCCCCACGGCCCTGAGGATTCAGCCCCACAATATTCACGCCTCTTCCCAAACGCATCTCAGCACATCAGCC  
GAGCTACAACCTACGCGCCCCAACCCGGACAACACTGGATCATGCGCTACACGGGGCCCATGAAGCCCATCCACAT  
GGAATTCACCAACATGCTCCAGCGGAAGCGCTTGACAGCCCTCATGTGCGTGGACGACTCCATGGAGACGATTTA  
CAACATGCTGGTTGAGACGGGCGAGCTGGACAACACGTACATCGTATACACCGCCGACCACGGTTACCACATCGG  
CCAGTTTGGCCTGGTGAAAGGGAATCCATGCCATATGAGTTTGACATCAGGGTCCCGTTTCTACGTGAGGGGCC  
CAACGTGGAAGCCGGCTGTCTGAATCCCCACATCGTCTCAACATTGACCTGGCCCCACCATCCTGGACATTGC  
AGGCCTGGACATACCTGCGGATATGGACGGGAATCCATCCTCAAGCTGCTGGACACGGAGCGGCCGGTGAAATCG  
GTTTCACTTGAAAAAGAAGATGAGGGTCTGGCGGGACTCCTTCTTGGTGGAGAGAGGCAAGCTGCTACACAAGAG  
AGACAATGACAAGGTGGACGCCCAGGAGGAGAAGTCTTGCCCAAGTACCAGCGTGTGAAGGACCTGTGTACAGCG  
TGCTGAGTACCAGACGGCGTGTGAGCAGCTGGGACAGAAGTGGCAGTGTGTGGAGGACGCCACGGGGAAGCTGAA  
GCTGCATAAGTGCAAGGGCCCCATGCGGCTGGGCGGCAGCAGAGCCCTCTCCAACCTCGTGCCCAAGTACTACGG  
GCAGGGCAGCGAGGCCTGCACCTGTGACAGCGGGGACTACAAGCTCAGCCTGGCCGGACGCCGGAACCACTCTT  
CAAGAAGAAGTACAAGGCCAGCTATGTCCGCAAGTCTGCTCCATCCGCTCAGTGGCCATCGAGGTGGACGCGAGGGT  
GTACCACGTAGGCCTGGGTGATGCCGCCAGCCCCGAAACCTCACCAAGCGGCACTGGCCAGGGGGCCCTGAGGA  
CCAAGATGACAAGGATGGTGGGACTTCACTGGCACTGGAGGCTTCCCGACTACTCAGCCGCCAACCCCATTA  
AGTGACACATCGGTGCTACATCCTAGAGAACGACACAGTCCAGTGTGACCTGGACCTGTACAAGTCCCTGCAGGC  
CTGGAAAGACCACAAGCTGCACATCGACCACGAGATTGAAACCTGCAGAACAAAATTAAGAACCTGAGGGAAAGT  
CCGAGGTACCTGAAGAAAAAGCGGCCAGAAGAATGTGACTGTACAAAATCAGCTACCACACCCAGCACAAAGG  
CCGCCTCAAGCACAGAGGCTCCAGTCTGCATCCTTTTCAGGAAGGGCCTGCAAGAGAAGGACAAGGTGTGGCTGTT  
GCGGGAGCAGAAGCGCAAGAAGAACTCCGCAAGCTGCTCAAGCGCCTGCAGAACACGACACGTGCAGCATGCC  
AGGCCTCACGTGCTTACCCACGACAACCAGCACTGGCAGACGGCGCCTTTCTGGACACTGGGGCCTTTCTGTGC  
CTGCACCAGCGCCAACAATAACACGTACTGGTGCATGAGGACCATCAATGAGACTCACAATTTCTCTTCTGTGA  
ATTTGCAACTGGCTTCTAGAGTACTTTGATCTCAACACAGACCCCTACCAGCTGATGAATGCAGTGAACACACT  
GGACAGGGATGTCTCAACCAGCTACACGTACAGCTCATGGAGCTGAGGAGCTGCAAGGGTTACAAGCAGTGTAA  
CCCCCGGACTCGAAACATGGACCTGGATGGAGGAAGCTATGAGCAATACAGGCAGTTTCAGCGTCGAAGTGGCC  
AGAAATGAAGAGACCTTCTTCCAAATCACTGGGACAACCTGTGGGAAGGCTGGGAAGGTTAAGAAACAACAGAGGT  
GGACCTCCAAAAACATAGAGGCATCACCTGACTGCACAGGCAATGAAAAACCATGTGGGTGATTTCCAGCAGACC  
TGTGCTATTGGCCAGGAGGCTGAGAAAGCAAGCAGCACTCTCAGTCAACATGACAGATTCTGGAGGATAACCA  
GCAGGAGCAGAGATAACTTCAGGAAGTCCATTTTGGCCCTGCTTTTGGATTATACCTCACCAGCTGCAC  
AAAATGCATTTTTTTCGTATCAAAAAGTCACCACTAACCTCCCCAGAGCTCACAAAGGAAAACGGAGAGAGCG  
AGCGAGAGAGATTTCTTGGAAATTTCTCCCAAGGGCGAAAGTCATTGGAAATTTTTAAATCATAGGGGAAAAGCA  
GTCCTGTTCTAAATCCTCTTATTCTTTTGGTTTGTACAAAGAAGGAACTAAGAAGCAGGACAGAGGCAACGTGG  
AGAGGTGAAAACAGTGCAGAGACGTTTGACAATGAGTACAGTACACAAAAGAGATGACATTTACCTAGCACTAT  
AAACCTGGTTGCCTCTGAAGAACTGCCTTATTGTATATATGTGACTATTTACATGTAATCAACATGGGAACCT  
TTTAGGGGAACCTAATAAGAAATCCCAATTTTCAGGAGTGGTGGTGTCAATAAACGCTCTGTGGCCAGTGTAAAA  
GAAAAA

20/550

**FIGURE 20**

MGPPSLVLCLLSATVFSLLGGSSAFLSHHRLKGRFQRDRRNIRPNIILVLTDDQDVELGSMQV  
MNKTRRIMEQGGAHFINAFVTTMCCPSRSSILTGKYVHNHNTYTNNECSPSWQAQHEST  
FAVYLNSTGYRTAFFGKYLNEYNGSYVPPGWKEWVGLLKNSRFYNYTLCRNGVKEKHGSDYSK  
DYLTDLITNDSVSFFRTSKKMYPHRPVLMVISHAAPHGPEDSAPQYSRLFPNASQHITPSYNY  
APNPDKHWIMRYTGPMKPIHMEFTNMLQRKRLQTLMSVDDSMETIYNMLVETGELDNTYIVYT  
ADHGYHIGQFGLVKGKSMPYEFDIRVPFYVRGPNVEAGCLNPHIVLNIDLAPTILDIAGLDIP  
ADM DGKSILKLLDTERP VNRFLK KKM RVWRDSFLVERGKLLHKRDNDKVDAQEENFLPKYQR  
VKDLCQRAEYQTACEQLGQKWQCVEDATGKLLKHKCKGPMRLGGSRALSNLVPKYYGQGSEAC  
TCDSGDYKLSLAGRRKKLFKKKYKASYVRSRSIRSAIEVDGRVYHVGLGDAAQPRNLTKRHW  
PGAPEDQDDKDGGDFSGTGGLPDYSAANPIKVTHRCYILENDTVQCDLDLYKSLQAWKDHKLH  
IDHEIETLQNKIKNLREVRGHLKKKRPEECDCHKISYHTQHKGRLLKHRGSSLHPFRKGLQEKD  
KVWLLREQKRKKLRKLLKRLQNNDTCMPGLTCFTHDNQHWQTAPFWTLGPFCACTSANNNT  
YWC MRTINETHNFLFCEFATGFLEYFDLNTDPYQLMNAVNTLDRDVLNQLHVQLMELRSCKGY  
KQCNPRTRNMDLDGGSYEQYRQFQRRKWPEMKRPSSKSLGQLWEGWEG

**Important features:****Signal peptide:**

amino acids 1-17

**Sulfatases signature 1.**

amino acids 86-99

**Homologous region to sulfatase:**

amino acids 87-106, 133-146, 216-229, 291-320, 365-375

**N-glycosylation sites.**amino acids 65-69, 112-116, 132-136, 149-153, 171-175, 198-202,  
241-245, 561-565, 608-612, 717-721, 754-758, 764-768

21/550

**FIGURE 21**

GGGCGCGCGAGAGCTGCTAGGGCGGTTTCTCTGCCTCGGGCCTGTTGGGCAGGGCCGGCT  
AAGGTGCGCGTGCTCGCTGGTTCTAACCCTTCTGTTGGGCGTTTCTGCTGAGAGGCGGGA  
GGCGCTGAGAGTCTGTGCGGAGGTCCGTGGACAGACTGCTTTGCTCGTTGTTGCTCTTCG  
GAGGCGGCGATCCCCGAAGGCGAGCTGAAATACGGCTGCAGGCTACAATTTGCAGCCGAC  
GATTATGGAAGACGGAAGCGGGAGAGGTGGCCACCCCTC**ATG**GAGCGCTTGTGCTCGGAT  
GGCTTCGCATTTCCCCAATACCCCATTAACCGTATCATCTGAAGAGGATCCACAGAGCT  
GTCTTACATGGTAATCTAGAGAACTGAAGTACCTTCTGCTCACGTATTATGACGCCAAT  
AAGAGAGACAGGAAGGAAAGGACCGCCCTACATTTGGCCTGTGCCACTGGCCAACCGGAA  
ATGGTACATCTCCTGGTGTCCAGAAGATGTGAGCTTAACCTCTGCGACCGTGAAGACAGG  
ACACCTCTGATCAAGGCTGTACAACTGAGGCAGGAGGCTTGTGCAACTCTTCTGCTGCAA  
AATGGCGCCAATCCAAATATTACGGATTTCTTTGGAAGGACTGCTCTGCACTACGCTGTG  
TATAATGAAGATACATCCATGATAGAAAACTTCTTTCACATGGTACAAATATTGAAGAA  
TGCAGCAAGGTAT**TAG**GTCAACCAATGTTATTTTCAAACCTATCTGAAATGAATTTATTTTA  
ACATTGACACATGTAAGGGTCAATTTTTCATATTTGGAAGCTCAAACATTCCTTGAATGA  
AAATATTTTGAAATGCCTTAACTGTCTAAGATTTTACTTTAAATATTGGAACTTTAAAG  
AAGCATTATAGGGAACAGCCTTTTTTTCATGCACCTTATGGTAAATAACTATAAAAACAAAT  
GAATTACAATAAATTTATAATTCATGACAACTGAATTTGGGAAAGGTAATAGTTAAGTGT  
TTTTCCACTAAATTACTTTTT



22/550

## **FIGURE 22**

MERLCSDGFAFPQYPIKPYHLKRIHRAVLHGNLEKLKYLLLTYYDANKRDRKERTALHLACAT  
GQPEMVHLLVSRRCENLDCDREDRTPLIKAVQLRQEACATLLLQNGANPNITDFFGRTALHYA  
VYNEDTSMIEKLLSHGTNIEECSKV

### **Important features of the protein:**

#### **N-glycosylation site.**

amino acids 113-117

#### **N-myristoylation site.**

amino acids 109-115

#### **Microbodies C-terminal targeting signal.**

amino acids 149-153

23/550

**FIGURE 23**

GAGGCAGAAAGGCAGAAAGGAGAAAATTCAGGATAACTCTCCTGAGGGGTGAGCCAAGCCCTG  
CCATGTAGTGCACGCAGGACATCAACAAACACAGATAACAGGAAATGATCCATTCCCTGTGGT  
CACTTATTCTAAAGGCCCAACCTTCAAAGTTCAAGTAGTGAT**ATG**GATGACTCCACAGAAAG  
GGAGCAGTCACGCCTTACTTCTTGCCTTAAGAAAAGAGAAGAAATGAAACTGAAGGAGTGTGT  
TTCCATCCTCCCACGGAAGGAAAGCCCCTCTGTCCGATCCTCCAAAGACGGAAAGCTGCTGGC  
TGCAACCTTGCTGCTGGCACTGCTGTCTTGCTGCCTCACGGTGGTGTCTTTCTACCAGGTGGC  
CGCCCTGCAAGGGGACCTGGCCAGCCTCCGGGCAGAGCTGCAGGGCCACCACGCGGAGAAGCT  
GCCAGCAGGAGCAGGAGCCCCCAAGGCCGGCCTGGAGGAAGCTCCAGCTGTCACCGCGGGACT  
GAAAATCTTTGAACCACCAGCTCCAGGAGAAGGCAACTCCAGTCAGAACAGCAGAAATAAGCG  
TGCCGTTCAAGGTCCAGAAGAAACAGTCACTCAAGACTGCTTGCAACTGATTGCAGACAGTGA  
AACACCAACTATACAAAAGGATCTTACACATTTGTTCCATGGCTTCTCAGCTTTAAAAGGGG  
AAGTGCCCTAGAAGAAAAAGAGAATAAAATATTGGTCAAAGAACTGGTTACTTTTTTATATA  
TGGTCAGGTTTTATATACTGATAAGACCTACGCCATGGGACATCTAATTCAGAGGAAGAAGGT  
CCATGTCTTTGGGGATGAATTGAGTCTGGTGACTTTGTTTCGATGTATTCAAATATGCCTGA  
AACACTACCCAATAATTCCTGCTATTGAGCTGGCATTGCAAACTGGAAGAAGGAGATGAACT  
CCAATTGCAATACCAAGAGAAAATGCACAAATATCACTGGATGGAGATGTCACATTTTTTGG  
TGCATTGAAACTGCTG**TGA**CCTACTTACACCATGTCTGTAGCTATTTTCCTCCCTTTCTCTGT  
ACCTCTAAGAAGAAAGAATCTAACTGAAAATACCAAAAAAAAAAAAAAAAAA

24/550

**FIGURE 24**

MDDSTEREQSRLTSCCLKKREEMKLKECVSILPRKESPSVRSSKDGKLLAATLLLALLSCCLTV  
VSFYQVAALQGD LASLRAELQGHHA EKLPAGAGAPKAGLEEAPAVTAGLKIFEP PAPGEGNSS  
QNSRNKRAVQGPEETVTQDCLQLIADSETPTIQKGSYTFVPWLLSFKRGSALEEKENKILVKE  
TGYFFIYGQVLYTDKTYAMGH LIQRKKVHVFGDELSLVTLFR CIQNMPETLPNNSCYSAGIAK  
LEEGDELQLAIPRENAQISLDGDVTFFGALKLL

**Transmembrane domain:**

amino acids 47-72

**N-glycosylation site.**

amino acids 124-127, 242-245

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 33-36, 173-176

**N-myristoylation site.**

amino acids 96-101

**TNF family proteins.**

amino acids 172-206

25/550

**FIGURE 25**

CTGCTTGGATACCTCCAGTCCCCAACTGTGTTCCAGGAGTTTTCTTGGCCGAAGCTGCCCGA  
TGTTTGAGCCTTTTCTTCCCAGAGAAGAAGATGGACTGAAAGCTGCCAGTTGGGGACTTTTTG  
TGATCACGGCGTTGCAGCGTTTTAAAGGAGGTGATGGGGCTTGCGCTGGCTTGTCTTCCCACC  
CAAGTGAAGAGTTGATGTTCACTGGTTATGCTTAGACAATGTGCAGTTTGTGTTAATTTAAAA  
TTTTGGGTGGGATAGGGGCATAGGCTTGTGAAGGGCAGTCCGGATCCGGAGGAACCTCGTCTTT  
GTCCCTGGTAGGAGAGACACCCCACTATCCTCGATGCCGTCAGCCTTGGCCATCTTCACT  
TGCCGCCCCGAACTCGCACCCGTTTCAGGAGCGTCATGTCTACCTGGACGAGCCCATCAAATC  
GGCCGCTCAGTGGCCCCGCTGTGACCAAGCGCAGAATAATGCCACTTTTGATTGCAAAGTGCTA  
TCAAGGAACCACGCTCTCGTCTGGTTTGATCACAAGACGGGCAAGTTTTATCTTCAAGACACT  
AAAAGTAGTAATGGTACTTTTATAAATAGCCAGAGATTGAGTCGAGGCTCTGAAGAAAGTCCA  
CCATGTGAAATTCTTTCCGGTGACATTATCCAGTTTGGAGTAGACGTGACAGAGAATACACGG  
AAAGTTACCCATGGGTGTATTGTTTCCACAATAAAACTTTTTCTACCAGATGGT**ATG**GGAAGCC  
CGGCTCCGCTCAGATGTCATCCATGCACCATTACCAAGTCCTGTTGACAAAGTTGCTGCTAAC  
ACTCCAAGTATGTACTCTCAGGAACATTCCAGCTTTCTCAGTATCTACAGGAGGCCTTACAT  
CGGGAACAAATGTTGGAACAGAAGTTAGCCACGCTTCAGCGGCTACTAGCCATCACCCAAGAG  
GCTTCAGATACCAGTTGGCAGGCTTTAATAGATGAAGATAGACTCTTATCACGGTTAGAAGTT  
ATGGGAAACCAATTACAGGCATGCTCCAAAAATCAAACAGAAGATAGTTTACGAAAGGAACTT  
ATAGCATTACAAGAGGATAAACATAACTATGAGACAACAGCCAAAGAGTCCCTGAGGCGGGTT  
CTTCAGGAGAAAATTGAAGTGGTTAGAAAACCTTTCAGAAGTTGAGCGAAGTCTGAGTAATACT  
GAAGATGAATGTACCCATCTGAAAGAAATGAATGAAAGGACTCAGGAAGAATTAAGAGAATTA  
GCCAACAAATATAATGGAGCAGTTAATGAGATTAAAGATTTATCTGATAAATTAAGGTAGCA  
GAGGGAAAACAAGAGGAAATCCAACAGAAGGGACAGGCTGAGAAAAAAGAATTACAACATAAA  
ATAGATGAAATGGAAGAAAAAGAACAGGAGCTCCAGGCCAAAAATAGAAGCTTTGCAAGCTGAT  
AATGATTTACCAATGAAAGGCTAACAGCTTTACAAGTACGGTTAGAACATCTTCAGGAGAAA  
ACTCTTAAAGAATGCAGCAGCTTGGCTGATCGTCGAAGGGCATCTAACCAAAGCGGTAGAAGA  
AACAAAGCTTTCAAAAGGTTTGTCTTCTGTTTTCTATGTTTTTTGACAGTTCTTTTGGAT**TAA**  
TGAAGGTTAGTGTATATTTTCAAGGTTATAGTATTTTAACCATCAGTTTACTTCTTATAGCTC  
ACAAAATAGCAAGCCAGTAACAGTATCAGATAATATATAAAATAATCAGACTTCTGTTTTAAG  
AAGGGTATCGTAACTGGAATGTGTCTTTTTAAGTGGATGTATATTTATGGTTTTTTGAATGTT  
AGTACTTGATATAGGTTTCTTTAGGTATTAAAGATTTGTTGCAATCTCTGTCATTCCCAGCAT  
TAATTTTCACTTTGATCTCAAATTTTAATCAAACACAATGTAAGTCGTTTGTGATACAACCTA  
AGTGAAACATGCTTGCACTTCTATTTTGGGGGTTACAGTACCTTTAAAATCTCTTATGATGTT  
TAATATTTTCTTAAATTTTGGCATCTCAGTTTGATTTAAACAAAATTAATGACTTTTGTGAAT  
GTAGAATCTTCTTATATTTTATGAGTAGTCCAGTAATTGCCCAAAGTAGTTTATTGTGTTAAT  
TCTGTTACAGTTGTCAGAGAAGAAAAGTGAGTTTTAAAGCACCATATTGTCAAGTCACTTTTA  
TACATAGGGAAATTAGGCAAATAAATTTGGTGGCATGTGTTTATCATAGTAGAACCTTTCATTA  
GACTATACCAGTATAAAATTTAAACTAGATTACAGTCCTTTTGGCCAATTAACATTGAG  
TTACAAAAGTTTGAGATACTTAATTTTAGTACATTCTATTTTATTAAAGTAACTGGATTCACT  
TGACTTTTTTAAACCATGTAAGAGGATGGTGTTATTTCAAATATCTCGTGGTTTCCATTCTGAA  
TTTTGTGCACGGCAGATGCCATATTTGGGGAAAAAATGCATAGAATATGCATCATTAATATTG  
TTTTGGCAAACAGGCATTGAGTTTCAAGACAGTGAACATTTTTTAGTACATATGGCAATTTTT  
TTCACCTTATTAAAGTGAGATGAGAACAGACCTTAAATAGCTTTTACCTCACCATCCAAATA  
CCTATTCAGATTAGTTGGTTGAATAGCCAGCACTTTGAAGTAGAGCCTTAGG

26/550

**FIGURE 26**

MEARLRSDVIHAPLPSPVDKVAANTPSMYSQELFQLSQYLQEALHREQMLEQKLATLQRLAI  
TQEASDTSWQALIDEDRLLSRLEVVMGNQLQACSKNQTEDSLRKELIALQEDKHNYETTAKESL  
RRVLQEKIEVVRKLSEVERSLSNTEDECTHLKEMNERTQEELRELANKYNGAVNEIKDLSDKL  
KVAEGKQEEIQQKGQAEKKELQHKIDEMEEKEQELQAKIEALQADNDFTNERLTALQVRLEHL  
QEKTLKECSSLADRRRASNQSGRRNKAFKRFVFCFSMFFDSSFG

**Important features of the protein:****N-glycosylation sites.**

amino acids 98-102, 271-275

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 138-142, 267-271

**Amidation site.**

amino acids 273-277

**Tropomyosins proteins.**

amino acids 169-217

27/550

FIGURE 27

GAACCTGGCGCCGCCGGAACCTGATCGCGGCCTAGTCCCGACGCGTGTGTGCTAGTGAGCCGGA  
GCCGGCGACGGCGGCAGTGGCGGCCCGGCCTGCAGGAGCCCGACGGGGTCTCTGCCATGGGGG  
AGTGACGCGCCTGCACCCGCTGTTCCGCGGCAGCGGCGAGACATGAGGAGACCCCGCGACAGG  
GGCAGCGGCGGCGGCTCGTGAGCCCCGGGATGAGGAGAGAAATACGGCGGGGACGTGCTGGCCG  
GCCCCGGCGGCGGCGGCGGCCTTGGGCCGGTGGACGTACCCAGCGCTCGATTAAACAAAATATA  
TTGTGTTACTATGTTTCACTAAATTTTTGAAGGCTGTGGGACTTTTCGAATCATATGATCTCC  
TAAAAGCTGTTACATTGTTTCAGTTTCATTTTTATATTAAACTTGGGACTGCATTTTTTATGG  
TTTTGTTTCAAAGCCATTTTCTTCTGGGAAAACATTACCAAACACCAGTGGATCAAATAT  
TTAAACATGCAGTTGCTGGGTGTATTATTTCACTCTTGTGGTTTTTTGGCCTCACTCTTTGTG  
GACCACTAAGGACTTTGCTGCTATTTGAGCACAGTGATATTGTTGTCATTTCACTACTCAGTG  
TTTTGTTTACCAGTTCTGGAGGAGGACCAGCAAAGACAAGGGGAGCTGCTTTTTTTCATTATTG  
CTGTGATCTGTTTATTGCTTTTTGACAATGATGATCTCATGGCTAAAATGGCTGAACACCCTG  
AAGGACATCATGACAGTGCTCTAACTCATATGCTTTACACAGCCATTGCCTTCTTAGGTGTGG  
CAGATCACAAGGGTGGAGTATTATTGCTAGTACTGGCTTTGTGTTGTAAAGTTGGTTTTTCATA  
CAGCTTCCAGAAAGCTCTCTGTGCGACGTTGGTGGAGCTAAACGTCTTCAAGCTTTATCTCATC  
TTGTTTTCTGTGCTTCTCTTGTGCCCATGGGTGCTTGTCTTTCTGTGACAAGTAAAG  
TGGAGTCTTGGTTTTCTCTCATTATGCCTTTTGAACGGTTATCTTTTTTGTGATGATCCTGG  
ATTTCTACGTGGATTCCATTTGTTTCAGTCAAATGGAAGTTTCCAAATGTGCTCGTTATGGAT  
CCTTTCCCATTTTTATTAGTGCTCTCCTTTTTTGAAATTTTTGGACACATCCAATAACAGACC  
AGCTTCGGGCTATGAACAAAGCAGCACACCAGGAGAGCACTGAACACGTCCTGTCTGGAGGAG  
TGGTAGTGAGTGCTATATTCTTCATTTTTGTCTGCCAATATCTTATCATCTCCCTCTAAGAGAG  
GACAAAAAGGTACCCTTATTGGATATTCTCCTGAAGGAACACCTCTTTATAACTTCATGGGTG  
ATGCTTTTTCAGCATAGCTCTCAATCGATCCCTAGGTTTATTAAGGAATCACTAAAACAAATTC  
TTGAGGAGAGTGAAGTCTAGGCAGATCTTTTACTTCTTGTGCTTGAATCTGCTTTTTTACCTTTG  
TGGAATTATTCTATGGCGTGCTGACCAATAGTCTGGGCCTGATCTCGGATGGATTCCACATGC  
TTTTTGACTGCTCTGCTTTAGTCATGGGACTTTTTGCTGCCCTGATGAGTAGGTGGAAAGCCA  
CTCGGATTTTTCTCCTATGGGTACGGCCGAATAGAAATTCGTCTGGATTTATTAATGGACTTT  
TTCTAATAGTAATAGCGTTTTTTGTGTTTATGGAGTCAGTGGCTAGATTGATTGATCCTCCAG  
AATTAGACACTCACATGTTAACACCAGTCTCAGTTGGAGGGCTGATAGTAAACCTTATTGGTA  
TCTGTGCCTTTTAGCCATGCCCATAGCCATGCCCATGGAGCTTCTCAAGGAAGCTGTCACCTCAT  
CTGATCACAGCCATTACACCATATGCATGGACACAGTGACCATGGGCATGGTCACAGCCACG  
GATCTGCGGGTGGAGGCATGAATGCTAACATGAGGGGTGTATTTCTACATGTTTTGGCAGATA  
CACTTGGCAGCATTGGTGTGATCGTATCCACAGTTCTTATAGAGCAGTTTGGATGGTTTCATCG  
CTGACCCACTCTGTTCTCTTTCTACTGCTATATTAATATTTCTCAGTGTTGTTCCACTGATTA  
AAGATGCCTGCCAGGTTCTACTCCTGAGATTGCCACCAGAATATGAAAAAGAACTACATATTG  
CTTTAGAAAAGATACAGAAAATTGAAGGATTAATATCATACCGAGACCCTCATTTTTTGGCGTC  
ATTCTGCTAGTATTGTGGCAGGAACAATTCATATACAGGTGACATCTGATGTGCTAGAACAAA  
GAATAGTACAGCAGGTTACAGGAATACTTAAAGATGCTGGAGTAAACAATTTAACAATTCAG  
TGGAAAAGGAGGCATACTTTCAACATATGTCTGGCCTAAGTACTGGATTTTCATGATGTTCTGG  
CTATGACAAAACAAATGGAATCCATGAAATACTGCAAAGATGGTACTTACATCATGTGAGATA  
ACTCAAGAATTACCCCTGGAGAATAACAATGAAGATTAAATGACTCAGTATTTGTAATATTG  
CCAGAAGGATAAAAATTACACATTAAGTGTACAGAAACAGAGTCCCTACTACTGGATCAAGG  
AATCTTTCTTGAAGGAAATTTAAATACAGAATGAAACATTAATGGTAAAAAAA

28/550

**FIGURE 28**

MEEKYGGDVLAGPGGGGGLGPVDVPSARLTKYIVLLCFTKFLKAVGLFESYDLLKAVHIVQFI  
FILKLGTAFPMVLFQKPFSSGKTITKHQWIKIFKHAVAGCIISLLWFFGLTLCGPLRTLTLLE  
HSDIVVISLSSVLFTSSGGGPAKTRGAFFIIAIVICLLLFNDNDLMAKMAEHPEGHDSALTH  
MLYTAIAFLGVADHKGGVLLLVLALCCKVGFHTASRKLSVDVGGAKRLQALSHLVSVLLCPW  
VIVLSVTTESKVESWFSLIMPFATVIFVFMILDFYVDSICSVKMEVSKCARYGSFPIFISALL  
FGNFWTHPITDQLRAMNKAHQESTEHLVSGGVVSAIFFILSANILSSPSKRGQKGTIGYS  
PEGTPLYNFMGDAFQHSQSIPRFIKESLKQILEESDSRQIFYFLCLNLLFTFVELFYGVLTN  
SLGLISDGFHMLFDCSALVMGLFAALMSRWKATRIFSYGYGRIEILSGFINGLEFLIVIAFFVF  
MESVARLIDPPELDTHMLTPVSVGGLIVNLIGICAFSHAHSHAHGASQGSCHSSDHS SHHMH  
GHSDHGHGSHSGSAGGGMNANMRGVFLHVLADTLGSIGVIVSTVLIEQFGWFIADPLCSLSTA  
ILIFLSVVPLIKDACQVLLLRLPPEYEKELHIALEKIQKIEGLISYRDPHFWRHSASIVAGTI  
HIQVTSVDLEQRIVQQVTGILKDAGVNNLTIQVEKEAYFQHMSGLSTGFHDVLAMTKQMESMK  
YCKDGTIIM

**Important features of the protein:****Signal peptide:**

amino acids 1-46

**Transmembrane domains:**amino acids 59-77, 101-119, 150-167, 205-223, 239-258, 267-284,  
305-324, 343-360, 421-440, 452-469, 486-505, 522-539, 592-612,  
621-641**N-glycosylation site.**

amino acids 721-725

**Glycosaminoglycan attachment site.**

amino acids 143-147

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 225-229

**Tyrosine kinase phosphorylation sites.**

amino acids 750-758, 756-764

**N-myristoylation sites.**amino acids 14-20, 46-52, 102-108, 112-118, 144-150, 317-323,  
347-353, 369-375, 372-378, 437-443, 462-468, 529-535, 549-555,  
553-559, 579-585, 582-588, 583-589, 584-590, 605-611, 737-743**Multicopper oxidases protein:**

amino acids 561-569

29/550

**FIGURE 29**

GGCACGAGGGCAGGATATTAGAAATGGCTACTCCCCAGTCAATTTTCATCTTTGCAATCTGCA  
TTTTAATGATAACAGAATTAATTCTGGCCTCAAAAAGCTACTATGATATCTTAGGTGTGCCAA  
AATCGGCATCAGAGCGCCAAATCAAGAAGGCCTTTCACAAGTTGGCCATGAAGTACCACCCTG  
ACAAAATAAGAGCCCGGATGCTGAAGCAAAATTCAGAGAGATTGCAGAAGCATATGAAACAC  
TCTCAGATGCTAATAGACGAAAAGAGTATGATACACTTGGACACAGTGCTTTTACTAGTGGTA  
AAGGACAAAGAGGTAGTGGAAGTTCTTTTGAGCAGTCATTTAACTTCAATTTTGATGACTTAT  
TTAAAGACTTTGGCTTTTTTGGTCAAAACCAAAACACTGGATCCAAGAAGCGTTTTGAAAATC  
ATTTCCAGACACGCCAGGATGGTGGTTCCAGTAGACAAAGGCATCATTTCCAAGAATTTTCTT  
TTGGAGGTGGATTATTTGATGACATGTTTGAAGATATGGAGAAAATGTTTTCTTTTAGTGGTT  
TTGACTCTACCAATCAGCATACAGTACAGACTGAAAATAGATTTTCATGGATCTAGCAAGCACT  
GCAGGACTGTCACTCAACGAAGAGGAAATATGGTTACTACATACTGACTGTTTCAGGACAGT  
AGTTCTTATTCTATTCTCACTAAATCCAACCTGGTTGACTCTTCCTCATTATCTTTGATGCTAA  
ACAATTTTCTGTGAACTATTTTGACAAGTGCATGATTTCACTTTAAACAATTTGATATAGCTA  
TTAAATATATTTAAGGGTTTTTTTTTTTGACAAATTCAACATTCAACGAGTAGACAAAATGCT  
AATTATTTCCCTGATTAGGAAAGTTTCTTTAAAAAACACGTAATTTTGCCTAGTGCTTTTTCT  
CTACCTGCCCTTGGGCTCACTAATATCACCAGTATTATTACCAAGAAAATATTGAGTTTACCT  
GATTAAACTTTAAAAGTTAATTGTAGATTTAAATTGTGTGAACCTAATGATTTTTGCAGTGAA  
ACCTTTACTAATTCAAAGTTGCATGTTCTATGACATCTGTGACTTGCGTTGCAGAGTGACAT  
GAAACTGTATAATTGAGTCATTCAAGTAAAGGAGAACAGTATCTTGGTTAATTGCTACTGAAAG  
GTTGAGAAAGGAATGGTTTGATATTTACCACAGCGCTGTGCCTTTCTACAGTAGAACTGGGGT  
AAAGGAAATGGTTTTATTGCCCATAGTCATTTAGGCTGGAAAAAAGTTGAAAACCTTAACGAAA  
TATTGCCAAGAGATTGTTATGTGTTTGGTTCCAGCCTAAAAATGATTTTGTAGTGTTGAAATC  
ATAGCTACTTACATAGCTTTTTTCATATTTCTTTCTTAGTTGTTGGCACTCTTAGGTCTTAGTA  
TGGATTTATGTGTTTGTGTGTGTGTAGTTTATCCTCTCTCTCATCTTTATCTAGAGATTGACT  
GATACCTCATTCTGTTTGTAACCAGCCAGTAATTTCTGTGCAACCTTACTATGTGCAATAT  
TTTTAAATCCTGAGAAATGTGTGCTTTTGTTCGGATAGACTTATTTCTTTAGTTCTGCACT  
TTTCCACATTATACTCCATATGAGTATTAATCCTATGGATACATATTAACAAGTGCTCAT



30/550

**FIGURE 30**

MATPQSIFIFAICILMITELILASKSYDILGVPKSASERQIKKAFHKLAMKYHPDKNKSPDA  
EAKFREIAEAYETLS DANRRKEYDTLGHSAFTSGKGQRGSGSSFEQSFNFNFDDLFKDFGFFG  
QNQNTGSKKRFEHFQTRQDGGSSRQRHHFQEFSGGGLFDDMFEDMEKMFSFSGFDSTNQHT  
VQTENRFHGSSKHCRTVTQRRGNMVTITYTDCSGQ

**Important features of the protein:****Signal peptide:**

amino acids 1-23

**Nt-dnaJ domain signature.**

amino acids 27-59, 66-90

**Glycosaminoglycan attachment site.**

amino acids 96-100

**N-myristoylation sites.**

amino acids 32-38, 99-105, 102-108, 126-132, 211-217

31/550

**FIGURE 31**

AAAGTTACATTTTCTCTGGAACCTCTCCTAGGCCACTCCCTGCTGATGCAACATCTGGGTTTGG  
GCAGAAAGGAGGGTGCTTCGGAGCCCGCCCTTTCTGAGCTTCCTGGGCCGGCTCTAGAACAAT  
TCAGGCTTCGCTGCGACTCAGACCTCAGCTCCAACATATGCATTCTGAAGAAAGATGGCTGAG  
ATGGACAGAATGCTTTATTTTGGAAAGAAACAATGTTCTAGGTCAAACCTGAGTCTACCAAATG  
CAGACTTTCACAATGGTTCTAGAAGAAATCTGGACAAGTCTTTTCATGTGGTTTTTCTACGCA  
TTGATTCCATGTTTGCTCACAGATGAAGTGGCCATTCTGCCTGCCCTCAGAACCTCTCTGTA  
CTCTCAACCAACATGAAGCATCTCTTGATGTGGAGCCCAGTGATCGCGCCTGGAGAAACAGTG  
TACTATTCTGTGGAATACCAGGGGGAGTACGAGAGCCTGTACACGAGCCACATCTGGATCCCC  
AGCAGCTGGTGCTCACTCACTGAAGGTCCTGAGTGTGATGTCACTGATGACATCACGGCCACT  
GTGCCATACAACCTTCGTGTGAGGGCCACATTGGGCTCACAGACCTCAGCCTGGAGCATCCTG  
AAGCATCCCTTTAATAGAAACTCAACCATCCTTACCCGACCTGGGATGGAGATCACCAAAGAT  
GGCTTCCACCTGGTTATTGAGCTGGAGGACCTGGGGCCCCAGTTTGAGTTCCTTGTGGCCTAC  
TGGAGGAGGGAGCCTGGTGCCGAGGAACATGTCAAAATGGTGAGGAGTGGGGGTATTCCAGTG  
CACCTAGAAACCATGGAGCCAGGGGCTGCATACTGTGTGAAGGCCCAGACATTCGTGAAGGCC  
ATTGGGAGGTACAGCGCCTTCAGCCAGACAGAATGTGTGGAGGTGCAAGGAGAGGCCATTCCC  
CTGGTACTGGCCCTGTTTGCCTTTGTTGGCTTCATGCTGATCCTTGTGGTTCGTGCCACTGTTT  
GTCTGGAAAATGGGCCGGCTGCTCCAGTACTCCTGTTGCCCCGTGGTGGTTCCTCCCAGACACC  
TTGAAAATAACCAATTCACCCCAGAAGTTAATCAGCTGCAGAAGGGAGGAGGTGGATGCCTGT  
GCCACGGCTGTGATGTCTCCTGAGGAACTCCTCAGGGCCTGGATCTCATAGGTTTGCGBAAGG  
GCCCAGGTGAAGCCGAGAACCTGGTCTGCATGACATGGAACCATGAGGGGACAAGTTGTGTT  
TCTGTTTTCCGCCACGGACAAGGGATGAGAGAAGTAGGAAGAGCCTGTTGTCTACAAGTCTAG  
AAGCAACCATCAGAGGCAGGGTGGTTTGTCTAACAGAACTGACTGAGGCTTAGGGGATGTG  
ACCTCTAGACTGGGGGCTGCCACTTGCTGGCTGAGCAACCCTGGGAAAAGTGACTTCATCCCT  
TCGGTCCTAAGTTTTTCTCATCTGTAATGGGGGAATTACCTACACACCTGCTAAACACACACAC  
ACAGAGTCTCTCTCTATATATACACACGTACACATAAATACACCCAGCACTTGCAAGGCTAGA  
GGGAACTGGTGACACTCTACAGTCTGACTGATTGAGTGTCTGGAGAGCAGGACATAAATG  
TATGATGAGAATGATCAAGGACTCTACACACTGGGTGGCTTGAGAGGCCACTTTCCAGAAT  
AATCCTTGAGAGAAAAGGAATCATGGGAGCAATGGTGTGAGTTCACTTCAAGCCCAATGCCG  
GTGCAGAGGGGAATGGCTTAGCGAGCTCTACAGTAGGTGACCTGGAGGAAGGTCACAGCCACA  
CTGAAAATGGGATGTGCATGAACACGGAGGATCCATGAACTACTGTAAAGTGTGACAGTGTG  
TGCACACTGCAGACAGCAGGTGAAATGTATGTGTGCAATGCGACGAGAATGCAGAAGTCAGTA  
ACATGTGCATGTTTGTGTGCTCCTTTTTTCTGTTGGTAAAGTACAGAATTCAGCAAATAAAA  
AGGGCCACCCTGGCCAAAAGCGGTAAAAA

32/550

**FIGURE 32**

MQTFTMVLEEIWTSLEFMWFFYALIPCLLTDEVAILPAPQNLSVLSTNMKHLMLWSPVIA PGET  
VYYSVEYQGEYESLYTSHIWIPSSWCSLTEGPECDVTDDITATVPYNLRVRATLGSQTSAWSI  
LKHPFNRNSTILTRPGMEITKDGFHLVIELEDLGPQFEFLVAYWRREPGAEEHVKMVRSGGIP  
VHLETMEPGAAYCVKAQTFVKAIGRYSAFSQTECVEVQGEAIPLVLALFAFVGFM LILVVVPL  
FVWKMGRLLQYSCCPVVVLPDTLKITNSPQKLISCRREEVDACATAVMSPEELLRAWIS

**Important features:****Signal peptide:**

amino acids 1-29

**Transmembrane domain:**

amino acids 230-255

**N-glycosylation sites.**

amino acids 40-44, 134-138

**Tissue factor proteins.**

amino acids 92-120

**Integrins alpha chain proteins.**

amino acids 232-263

33/550

FIGURE 33

GAGACACGCGAGCGGGGAGACCTCCAAGGCAGCGAGGCATCGGACATGTGTGTCAGCACATCTGG  
GGCGCACATCCGTCGAGCCCGAGGGGAGATTTGCCGGAACAATTCAAACCTGCGATATTGATCT  
TGGGGGTGACTGTCCCTGGCCGGCTGTCTGGGTGGGAGTGCAGTGTGCACTCGCTCGGAAGTG  
TGTGCGAGTGTGTATGTGTGTGTGCCGTGTCTGGGCTCCCCCTTCCCCCGTTTTCCCGTCGA  
GTGATGCACTTGAATGAGAATCAGAGGATGAAATAGTCTGGGAGGTGCTTTTTCTTCTTCA  
AGCCAATTTTCATCGTCTGCATATCAGCTCAACAGAATTCACCAAAAATCCATGAAGGCTGGTG  
GGCATAACAAGGAGGTGGTCCAGGGAAGCTTTGTTCCAGTTCCTTCTTTCTGGGGATTGGTGAA  
CTCAGCTTGGAATCTTTGCTCTGTGGGGAAACGGCAGTCGCCAGTCAACATAGAGACCAGTCA  
CATGATCTTCGACCCCTTTCTGACACCTCTTCGCATCAACACGGGGGGCAGGAAGGTCAGTGG  
GACCATGTACAACACTGGAAGACACGTATCCCTTCGCCTGGACAAGGAGCACTTGGTCAACAT  
ATCTGGAGGGCCCATGACATACAGCCACCGGCTGGAGGAGATCCGACTACACTTTGGGAGTGA  
GGACAGCCAAGGGTCGGAGCACCTCCTCAATGGACAGGCCTTCTCTGGGGAGGTGCAGCTCAT  
CCACTATAACCATGAGCTATATACGAATGTACAGAAGCTGCAAAGAGTCCAAATGGATTGGT  
GGTAGTTTCTATATTTATAAAAGTTTCTGATTTCATCAAACCCATTTCTTAATCGAATGCTCAA  
CAGAGATACTATCACAAGAATAACATATAAAAATGATGCATATTTACTACAGGGGCTTAATAT  
AGAGGAACCTATATCCAGAGACCTCTAGTTTCATCACTTACGATGGGTGATGACTATCCCACC  
CTGCTATGAGACAGCAAGTTGGATCATAATGAACAAACCTGTCTATATAACCAGGATGCAGAT  
GCATTCCTTGCGCCTGCTCAGCCAGAACCAGCCATCTCAGATCTTTCTGAGCATGAGTGACAA  
CTTCAGGCCTGTCCAGCCACTCAACAACCGCTGCATCCGCACCAATATCAACTTCAGTTTACA  
GGGGAAGGACTGTCCAAACAACCGAGCCCAGAAGCTTCAGTATAGAGTAAATGAATGGCTCCT  
CAAGTAGGGAACAAGCCAAGAAGAATCCCACCTCAGTGAAATGCTACAACCTGTGAATTGACG  
TAACCTAGAATGTCCCCCTTCTTGCTTCTCTCTCCTTCTTTCCCCCAAGCCTCATTCACTTCT  
GGGATTGGCCCTTTCTTCATGAAAAGTGTCTGCGAAACCATGGCAGAGGAATACATCTCTCAC  
ACATACTCACAACACACACACAAGCACTTGCACATACATACAAACACATGCAAACATACCTA  
CACACACACACTCTCTTACAACCTCCATCATGGGAAGTCAAGTTTCAGAAACAAAAGTCTCAT  
TCATAAGAGGTCTTAGAAGAAAATAACCAGTTAACCTGATTTCAATTTTGATACCGTTTTCT  
GAACTAATAAATCTACCCAATGAGACTTTTCAGCCTTTGTACATACAAAATCTTCCAAAAGA  
GAGAGGAGAAAATACAGCTCTGATGGCATCAAACGGACTTTGCATCAAGTAATTTAGATAGT  
GTCCTAGGATCCTTTGAGGGTGCTGGTAGCAGGTGAGCAGGACAAAGTTGACCAAGGACACTT  
ATTTCTAGATTATGATTCTTCTGTTTACTCAACAATTTACAAAGAAAAAAGGACAGACATTG  
AAGAGCTACACATTGTATATATATACACACAGACTATAAGGAAATGGAATTATTTCCCTCTTT  
GTCACATATCTGTAGTAGGATTTGCCAAGATCAGAAATGATCCATTTGCTGTTTCTTGTTTTC  
CAAAGGTCATACATTGTGTTTGGTTATTGTTACCAGCTCAATAAATGTGTTTAACGAGTTAAT  
TTCATTTTTCTGGCTTTGGTCTGTTCTCCTTACAGGCTAAGCCCTGGCTCCATGCAACT  
GCATTCCTTTGATTTCACTTGTTCTTCATCTACATGTTTTGTTTCAATTTGCAGCCAGTTTTTAC  
TGAGTTTGTGGCAATCAGGAATGCATTTGCTAAGCAAGTATGACTTTAATTCACCTCCATGGC  
TCAATCATTCACATGAGGTGAGCTTCAGCCTGAGATAGCAGGCGACAGACTTCTTGCGTTTCA  
AACTGCCATGCCCCCTGTGATGCTCCCGTGAAGGAATGCACTTTGCCTTGTAAGTTCCTGG  
GAAAGGGGTATGTTTTCTCTCCAGGTGCAGCCAGATCTCACAAAGTACAAAACGAATGCCTTT  
CTTTTCTTGTTTATAATGGTCACTCACTGTGTTTGGTTACTGTCAAGAAATCAATAAATGTGT  
TTAACAAGTTA

34/550

**FIGURE 34**

MEIVWEVLFLLLQANFIVCISAQQNSPKIHEGWWAYKEVVQGSFVPVPSFWGLVNSAWNLC SVG  
KRQSPVNIETSHMIFDPFLTPLRINTGGRKVSGTMYNTGRHVSLRLDKEHLVNISSGGPMTYSH  
RLEEIRLHFGSEDSQGSHELLNGQAFSGEVQLIHYNHELYTNVTEAAKSPNGLVVVSIFIKVS  
DSSNPFLNRMLNRDTITRITYKNDAYLLQGLNIEELYPETSSFITYDGSMTIPPCYETASWII  
MNKPVIYITRMQMHSRLRLLSQNQPSQIFLSMSDNFRPVQPLNNRCIRTNINFSLQKDCPNRA  
QKLQYRVNEWLLK

**Important features:****Signal peptide:**

amino acids 1-20

**Eukaryotic-type carbonic anhydrases proteins.**

amino acids 126-162, 220-269, 43-91

**N-glycosylation sites.**

amino acids 116-119, 168-171, 302-305

35/550

FIGURE 35

GTCGGAACCCCTCAGGCCACCCTCGGGAGTCCTGGGGTCCAGAGGGGTGTCCCTGTACCCCTTGAC  
ACAGGACCCTCACTCTGCAGGGATAAGCCAGCTGCGCCTGCAGCCTAGGGTGCCAAGGAGGCTGCTGA  
TTGTGGCCACAGCCTCATCTGAACGCCAGGAGACCAGGATACCGAGGCACCGGATCCCCCTCTCTGTG  
CCCTGGGGAGCCCCAGTGCTGCCCAGTCACCCCAGGGCTGAGGTCTGCGTCCCTAGTGGTGCAAGGCC  
TGGTAGGACCACGGGGCAGGGAATGTGAGCGCCATCCGAGCTCACGGTGTCTGAGTCGCGGCTTCGT  
GACTTTGGCAGGGGGCCTCCGGACCAGTGACCCCAAGTCAAACCCAGAGGGTCTTGGGCGGCAGCGACA  
AGGAGGTATTGAGGCTCCAGGCCAGGTGGGGCCGGACGCCCCCAGCCATCCACCATGGTGGTGGCACA  
CCCCACCGCCACTGCCACCACCACGCCACTGCCACTGTACGGCCACCGTTGTGATGACCACGGCCA  
CCATGGACCTGCGGGACTGGCTGTTCCCTGCTGCTACGGGCTCATCGCCTTCCTGACGGAGGTCATCGAC  
AGCACCACTGCCCCCTCGGTGTGCCGCTGCGACAACGGCTTCATCTACTGCAACGACCGGGGACTCAC  
ATCCATCCCCGCAGATATCCCTGATGACGCCACCACCCTCTACCTGCAGAACAACAGATCAACAACG  
CCGGCATCCCCCAGGACCTCAAGACCAAGGTCAACGTGCAGGTCTATCTACCTATACGAGAATGACCTG  
GATGAGTTCCCCATCAACCTGCCCCGCTCCCTCCGGGAGCTGCACCTGCAGGACAACAATGTGCGCAC  
CATTGCCAGGGACTCGCTGGCCCGCATCCCGCTGCTGGAGAAGCTGCACCTGGATGACAACCTCCGTGT  
CCACCGTCAGCATTGAGGAGGACGCCTTCGCCGACAGCAAACAGCTCAAGCTGCTCTTCCTGAGCCGG  
AACCACCTGAGCAGCATCCCCCTCGGGGCTGCCGCACACGCTGGAGGAGCTGCGGCTGGATGACAACCG  
CATCTCCACCATCCCGCTGCATGCCTTCAAGGGCCTCAACAGCCTGCGGCGCCTGGTGTGGACGGTA  
ACCTGCTGGCCAACCAGCGCATCGCCGACGACACCTTCAGCCGCCTACAGAACCTCACAGAGCTCTCG  
CTGGTGCGCAATTGCTGGCCGCGCCACCCCTCAACCTGCCAGCGCCACCTGCAGAAGCTCTACCT  
GCAGGACAATGCCATCAGCCACATCCCTTACAACACGCTGGCCAAGATGCGTGAGCTGGAGCGGCTGG  
ACCTGTGTCAGGAACAACCTGACCACGCTGCCCGCGGCTGTTTCGACGACCTGGGGAACCTGGCCAG  
CTGCTGCTCAGGAACAACCCCTTGTTTTGTGGTGCACACCTCATGTGGCTGCGGGACTGGGTGAAGGC  
ACGGGCGGCGCTGGTCAACGTGCGGGGCTCATGTGCCAGGGCCCTGAGAAGGTCCGGGGCATGGCCA  
TCAAGGACATTACCAGCGAGATGGACGAGTGTGTTGAGACGGGGCCGAGGGCGGCGTGGCCAATGCG  
GCTGCCAAGACCACGGCCAGCAACCACGCCTTGCCACCACGCCCCAGGGTTCCCTGTTTTACCCCTCAA  
GGCCAAAAGGCCAGGGCTGCGCCTCCCCGACTCCAACATTGACTACCCCATGGCCACGGGTGATGGCG  
CCAAGACCCTGGCCATCCACGTGAAGGCCCTGACGGCAGACTCCATCCGCATCACGTGGAAGGCCACG  
CTCCCCGCCTCCTCTTTCCGGCTCAGTTGGCTGCGCCTGGGCCACAGCCCAGCCGTGGGCTCCATCAC  
GGAGACCTTGGTGCAGGGGGACAAGACAGAGTACCTGCTGACAGCCCTGGAGCCCCAAGTCCACCTACA  
TCATCTGCATGGTCACCATGGAGACCAGCAATGCCTATGTAGCTGATGAGACACCCGTGTGTGCCAAG  
GCAGAGACAGCCGACAGCTATGGCCCTACCACCACACTCAACCAGGAGCAGAACGCTGGCCCCATGGC  
GAGCCTGCCCCCTGGCGGGCATCATCGGCGGGGAGTGGCTCTGGTCTTCTCTTCTTGGTCTTGGGG  
CCATCTGCTGGTACGTGCACCAGGCTGGCGAGCTGCTGACCCGGGAGAGGGCCTACAACCGGGGACG  
AGGAAAAAGGATGACTATATGGAGTCAGGACCAAGAAGGATAACTCCATCCTGGAAATCCGCGGCC  
TGGGCTGCAGATGCTGCCCATCAACCCGTACCGCGCCAAAGAGGAGTACGTGGTCCACACTATCTTCC  
CCTCCAACGGCAGCAGCCTCTGCAAGGCCACACACACCATTTGGCTACGGCACCAACGCGGGGCTACCGG  
GACGGCGGCATCCCCGACATAGACTACTCCTACACATTGATGCCCCGCCACCCGGGCTGCCCCGCCTCA  
GCCCCAGCTGCCCTGGCGTGGCCATGTGGCTTTGCCAGCCTGCTGCAATCCAAGAGAGCAAGGAAGA  
GAAATTCCATGGGTGACTTTCCCTCCGCAGAAAGCAAAGTTTGGGGAGGGCTGACGATTTTGTAGAACA  
CAACAGTGACAATTTTTTTTTTAAAGAATAGAAGGCAGGAGGGGAATTTCGACATTGTTGAAGACATAA  
TTTATACCAAGTTATGCCAGTTGGGGAGGGAAGGACTAAAAATAATATTGCAGGCAGGGCTGGGTTGG  
GTTTTTTTTTTTTCCCCCTGAACTGGAAGGATACTACCTGTACAACATCTGTGGACACCTCATGCTCT  
GTTCAAGGCCATCACAAAGGAACCGCCAGGGAGAAGCAGCCGGCTCTCAAAGCTCCCACGCAGCTCTC  
CCGCCACTGGCCACTCGCTGGCGACCCGATGGAAGGTTTTAGGCTCCTCACAAAGGAGAGAGGGAAG  
AAAAGATCTTTTGGCCTGGAGATATGGTCCTGAAATCTCTCCCCTGGCTTATTCCATACCATTTCCT  
TGCAGATTTGCAGAAACATGGCATCTTTCACTGCATTCTTTGAACAATCATGTAGTCGATTAAAAAAA  
AAAACAAACTTTTTTTTCCTAGGCTGAAGCCCTCTTCAGTTCCATGCACCACGCTCCGTAGAAGCCCC  
GGCGGAAGCCGTAGCTTTCCCTGCCACCTGGAGGTGCATCTGTCTGCCTGTCTATCCCTGTGCGGGTG  
TCTCTAAGTACAGATGGGTAGATAGAGCCACATGCACGGTCTTACCCTTCTTCTGGGTGAGTTCTT  
ACCATTTCTGAACAATAGAATTGTGAAAGTGTAAAAA

36/550

**FIGURE 36**

MVVAHPTATATTTPTATVTATVVMTTATMDLRDWLFLCYGLIAFLTEVIDSTTCPSVCRCNDG  
FIYCNDRGLTSIPADIPDDATTLYLQNNQINNAGIPQDLKTKVNVQVIYLYENDLDEFFPINLP  
RSLRELHLQDNNVRTIARDSLARIPLLEKLHLDNNSVSTVSIEEDAFADSKQLKLLFLSRNHL  
SSIPSGLPHTLEELRLDDNRISTIPLHAFKGLNSLRRLVLDGNLLANQRIADDTFSRLQNLTE  
LSLVRNSLAAPPLNLPSAHLQKLYLQDNAISHIPYNTLAKMRELERLDLSNNNLTTLPRLFD  
DLGNLAQLLLRNNPWFCGCNLMWLRDWVKARAAVVNVRLMCQGPEKVRGMAIKDITSEMDEC  
FETGPQGGVANAAAKTTASNHASATTPQGSFLTAKAKRPGRLPDSNIDYPMATGDGAKTLAI  
HVKALTADSIRITWKATLPASSFRLSWRLRGHSPAVGSITETLVQGDKEYLLTALEPKSTYI  
ICMVTMETSNAAYVADETPVCAKAETADSYGPTTTLNQEQNAGPMASLPLAGIIGGAVALVFLF  
LVLGAICWYVHQAGELLTRERAYNRGSRKKDDYMESGTTKDNSILEIRGPGLOMLPINPYRAK  
EEYVVHTIFPSNGSSLCKATHTIGYGTTRGYRDGGIPDIDYSYT

**Important features of the protein:****Transmembrane domain:**

amino acids 552-573

**N-glycosylation sites.**

amino acids 249-252, 305-308, 642-645

**Leucine zipper pattern.**

amino acids 182-203, 299-320

**Phospholipase A2 aspartic acid active site.**

amino acids 57-67

37/550

**FIGURE 37**

GGTGA CTGAAGCGAGCCTGGCCTCTTG CATCCTCCGCTGTGTACCTCCCTCCCTTTTTTTCCGCCT  
TCTGCCAGCAGAAGCAGCAGCCGAGCACCTGAGCCGCTACTGCCGCTCACTCAGGACAACGCT**ATGG**  
CTGAGCCTGGGCACAGCCACCATCTCTCCGCCAGAGTCAGGAGAAGAACTGAGAGGCGCATACCCCGG  
CTGTGGCGGCTGCTGCTCTGGGCTGGGACCGCTTCCAGGTGACCCAGGGAACGGGACCGGAGCTTCA  
TGCCTGCAAAGAGTCTGAGTACCACTATGAGTACACGGCGTGTGACAGCACGGGTTCAGGTGGAGGG  
TCGCCGTGCCGCATACCCCGGGCCTGTGCACAGCCTGTCTGACCCCGTCAAGGGCACCGAGTGCTCC  
TTCTCCTGCAACGCCCGGGAGTTTCTGGATATGAAGGACCAGTCATGTAAGCCATGCGCTGAGGGCCG  
CTACTCCCTCGGCACAGGCATTTCGGTTTGATGAGTGGGATGAGCTGCCCCATGGCTTTGCCAGCCTCT  
CAGCCAACATGGAGCTGGATGACAGTGCTGCTGAGTCCACCGGGAACGTACTTCGTCCAAGTGGGTT  
CCCCGGGGCGACTACATCGCCTCCAACACGGACGAATGCACAGCCACACTGATGTACGCCGTCAACCT  
GAAGCAATCTGGCACCGTTAACTTCGAATACTACTATCCAGACTCCAGCATCATCTTTGAGTTTTTCG  
TTCAGAATGACCAGTGCCAGCCCAATGCAGATGACTCCAGGTGGATGAAGACCACAGAGAAAGGATGG  
GAATTCCACAGTGTGGAGCTAAATCGAGGCAATAATGTCTCTATTGGAGAACCACAGCCTTCTCAGT  
ATGGACCAAAGTACCCAAGCCTGTGCTGGTGAGAAACATTGCCATAACAGGGGTGGCCTACACTTCAG  
AATGCTTCCCCTGCAAACCTGGCACGTATGCAGACAAGCAGGGCTCCTCTTTCTGCAAACCTTTGCCCA  
GCCAACTCTTATTCAAATAAAGGAGAACTTCTTGCCACCAGTGTGACCCTGACAAATACTCAGAGAA  
AGGATCTTCTTCTGTAACTGCGCCAGCTTGACAGACAAAGATTATTTCTACACACACACGGCCT  
GCGATGCCAACGGAGAGACACAACTCATGTACAAATGGGCCAAGCCGAAAATCTGTAGCGAGGACCTT  
GAGGGGGCAGTGAAGCTGCCTGCCTCTGGTGTGAAGACCCACTGCCACCCCTGCAACCCAGGCTTCTT  
CAAAACCAACACAGCACCTGCCAGCCCTGCCCATATGGTTCCCTACTCCAATGGCTCAGACTGTACCC  
GCTGCCCTGCAGGGACTGAACCTGCTGTGGGATTTGAATACAAATGGTGGAACACGCTGCCACAAAC  
ATGGAACGACCGTTCTCAGTGGGATCAACTTCGAGTACAAGGGCATGACAGGCTGGGAGGTGGCTGG  
TGATCACATTTACACAGCTGCTGGAGCCTCAGACAATGACTTCATGATTCTCACTCTGGTTGTGCCAG  
GATTTAGACCTCCGCAGTCGGTGATGGCAGACACAGAGAATAAAGAGGTGGCCAGAATCACATTTGTC  
TTTGAGACCCTCTGTTCTGTGAACGTGTGAGCTCTACTTCATGGTGGGTGTGAATTCTAGGACCAACAC  
TCCTGTGGAGACGTGGAAAGGTTCCAAAGGCAAACAGTCTTATACCTACATCATTGAGGAGAACACTA  
CCACGAGCTTCACCTGGGCCTTCCAGAGGACCACTTTTCATGAGGCAAGCAGGAAGTACACCAATGAC  
GTTGCCAAGATCTACTCCATCAATGTCACCAATGTTATGAATGGCGTGGCCTCCTACTGCCGTCCCTG  
TGCCCTAGAAGCCTCTGATGTGGGCTCCTCCTGCACCTCTTGTCTGCTGGTTACTATATTGACCGAG  
ATTCAGGAACCTGCCACTCCTGCCCCCTAACACAATTCTGAAAGCCCACCAGCCTTATGGTGTCCAG  
GCCTGTGTGCCCTGTGGTCCAGGGACCAAGAACACAAGATCCACTCTCTGTGCTACAATGATTGCAC  
CTTCTCAGCAACACTCCAACAGGACTTTCAACTACAACCTTCTCCGCTTTGGCAAACACCGTCACTC  
TTGCTGGAGGGCCAAGCTTCACTTCCAAAGGGTTGAAATACTTCCATCACTTTACCTCAGTCTCTGT  
GGAAACCAGGGTAGGAAAATGTCTGTGTGCACCTGACAATGTCACTGACCTCCGGATTCTGAGGGTGA  
GTCAGGGTTCTCCAAATCTATCACAGCCTACGTCTGCCAGGCAGTCATCATCCCCCAGAGGTGACAG  
GCTACAAGGCCGGGGTTTCTCACAGCCTGTGACCTTGCTGATCGACTTATTGGGGTGACAACAGAT  
ATGACTCTGGATGGAATCACCTCCCCAGCTGAACTTTTCCACCTGGAGTCTTGGGAATACCGGACGT  
GATCTTCTTTTATAGGTCCAATGATGTGACCCAGTCTGTCAGTTCTGGGAGATCAACCACCATCCGCG  
TCAGGTGCAGTCCACAGAAAAGTGTCCCTGGAAGTTTGCTGCTGCCAGGAACGTGCTCAGATGGGACC  
TGTGATGGCTGCAACTTCCACTTCCCTGTGGGAGAGCGCGGCTGCTTGCCCCGCTCTGCTCAGTGGCTGA  
CTACCATGCTATCGTCAGCAGCTGTGTGGCTGGGATCCAGANGACTACTTACGTGTGNCGAGAACCCA  
AGCTATGCTCTGGTGGCATTTCTCTGCCTGAGCAGAGAGTCACCATCTGCAAACCATAGATTTCTGG  
CTGAAAGTGGGCATCTCTGCAGGCACCTGTACTGCCATCCTGCTCACCCTCTTGACCTGCTACTTTTG  
GAAAAAGAAATCAAAAAGTAGAGTACAAGTACTCCAAGCTGGTGTGATGAATGCTACTCTCAAGGACTGTG  
ACCTGCCAGCAGCTGACAGCTGCGCCATCATGGAAGGCGAGGATGTAGAGGACGACCTCATCTTTACC  
AGCAAGAAGTCACTTTTGGGAAGATCAAATCAATTTACCTCCAAGAGGACTCCTGATGGATTGACTC  
AGTGCCGCTGAAGACATCCTCAGGAGGCCAGACATGGACCT**GTGAG**AGGACAGTGCCTGCCTCACCTG  
CCTCCTCACCTTG CATAGCACCTTTGCAAGCCTGCGGCGATTTGGGTGCCAGCATCCTGCAACACCCA  
CTGCTGGAAATCTCTTCATTGTGGCCTTATCAGATGTTTGAATTTT CAGATCTTTTTTTTATAGAGTACC  
CAAACCTCCTTTCTGCTTGCTC AAACCTGCCAAATATACCCACATTTTTTTTTTAAAAAAAAAAAAAA  
AA  
AAA



38/550

**FIGURE 38**

MAEPGHSHHLSARVRRRTERRIPRLWRLLLLWAGTAFQVTQGTGPELHACKESEYHYEYTACDS  
TGSRRWRVAVPHTPGLCTSLSDPVKGTECSFSCNAGEFLDMKDQSCKPCAEGRYSLGTGIRFDE  
WDELPHGFASLSANMELDDSAESTGNCTSSKWVPRGDYIASNTDECTATLMYAVNLKQSGTV  
NFEYYPDSSIIIEFFVQNDQCQPNADDSRWMKTTEKGWEFHSVELNRGNVLYWRTTAFSVW  
TKVPKPVLVRNIAITGVAYTSECFCKPGTYADKQSSFCCKLCPANSYSNKGETSCHQCDPK  
YSEKSSSSCNVRPACTDKDYFYHTACDANGETQLMYKWAKPKICSEDLEGAVKLPASGVKTH  
CPPCNPFGFFKTNNSTCQPCPYGSYSNGSDCTRCPAGTEPAVGFEYKWWNTLPTNMETTVLSGI  
NFEYKGMTGWEVAGDHIYTAAGASDNDFMILTLVVPGRPPQSVMADTENKEVARITFVFETL  
CSVNCELYFMVGVNSRTNTPVETWKGSKGKQSYTYIIIEENTTTSTFWAFQRTTFHEASRKYTN  
DVAKIYSINVTNVMNGVASYCRPCALEASDVSSCTSCPAGYYIDRDSGTCHSCPPNTILKAH  
QPYGVQACVPCPGPGTKNNKIHSCLYNDCTFSRNTPTRTFNYNFSALANTVTLAGGPSFTSKGL  
KYFHHFTLSLCGNQGRKMSVCTDNVTDLRIPEGESGFSKSITAYVCQAVIIPPEVTGYKAGVS  
SQPVSLADRLIGVTTDMTLDGITSAPALFHLES LGIPDVIFFYRSNDVTQSCSSGRSTTIRVR  
CSPQKTVPGSLLLPGTCS DGTCDGCNFHFLWESAAACPLCSVADYHAI VSSCVAGIQXTTYVX  
REPKLCSGGISLPEQRTICKTIDFWLKVGISAGTCTAILLTVLTCTCYFWKKNQKLEYKYSKLV  
MNATLKDCDLPAADSCAIMEGEDVEDDLIFTSKKS LFGKIKSFTSKRTPDGFD SVPLKTSSGG  
PMDML

**Important features of the protein:****N-glycosylation sites:**

amino acids 153-156, 390-393, 391-394, 404-407, 544-547, 576-579,  
672-675, 717-720, 947-950

**cAMP- and cGMP-dependent protein kinase phosphorylation sites:**

amino acids 15-18, 563-566, 709-712

**Casein kinase II phosphorylation sites:**

amino acids 42-45, 59-62, 81-84, 146-149, 168-171, 282-285, 331-  
334, 340-343, 431-434, 449-452, 465-468, 523-526, 557-560, 761-  
764, 780-783, 835-838, 860-863, 893-896, 949-952

**Tyrosine kinase phosphorylation sites:**

amino acids 50-56, 109-116

**N-myristoylation sites:**

amino acids 77-82, 88-93, 152-157, 268-273, 288-293, 320-325,  
400-405, 405-410, 414-419, 463-468, 599-604, 616-621, 634-639,  
644-649, 839-844, 874-879, 912-917, 916-921

**Amidation site:**

amino acids 707-710

**Cell attachment sequence:**

amino acids 162-164

39/550

**FIGURE 39**

GGGAAGGGGTTCTGGGCTGCCGCAGGCACACAGGCCAGAGCTTCGTGGATACCTGCAGGGCCC  
AAAGGTCCCTCCCTGTTTTGAAGAGTGAGTGATGGCTATGAGGTAGCGGCCAGGCTGATCACC  
CCTGCGTTGGCTGGAGGCAGAATTCTGTAAATCCTCGCCAAGTCTTTCTCCAGGCCACTGGTT  
AGCTCATCTCAGCCTCCTCTGGGAGCATCAACACCAACATGGCACAGGGGACTGCAGTGGTGT  
GCTTTGGACCTGTGTACCCACCCAAGGCTAAAGGCAGAGCCAGGTGACTTTGCGGGGGTCTCT  
TCTCTAGGATTATCTGTACTTCCCCTCTGTCTCTTTTACTACGGGAGATCGAGCTAGCTATA  
ACCCACCTTCTTTCATGAGAACCACACTAAATTGCAAAAATTATCCCAGTGCTGGAGGAGGGC  
AGCAGGTTGAGATTATGTTGGCAGGAAGAATGTTGGCATTGATTGGCACGCAGGGGACGAGAG  
CTGCTTTGTGCTTTAAAGGAGCCAAGTTACACCCTGTTTAACCCTGCCTTCAAAGGGACGACT  
CTGTAAGATTCTCTGCTACTTATTCAAGTTGACACGATGCCCTTCACACTCCACCTGAGGTCC  
CGCCTTCCCTCTGCCATAAGGAGTTTGATTCTACAAAAGAAACCAACATCAGAAATACATCC  
AGCATGGCTGGAGAGCTCCGACCAGCCAGCCTGGTGGTCTGCCCAGGTCCCTTGCTCCAGCT  
TTTGAAAGATTCTGCCAGGTCAACACTGGTCTCTACCCCTGCTGGGCCAGAGTGAGCCAGAA  
AAGTGGATGCTGCCCCCTCAAGGTGCTATCTCAGAGACCAGGATGGGCCATCCCCAGTTCTGG  
AAATACGAGTTCGGTGCCTGCACCGGTAGCCTGGCTTCGCTGGAGCAGTACTCGGAGCAGCTG  
AAGGACATGGTGGCCTTCTTCTGGGCTGCAGCTTCTCCCTGGAGGAGGCCTTGAGAAAGCG  
GGGCTCCCCAGAAGAGACCCAGCAGGTACAGCCAGGCGGGTGCATACAAGACAACAGTGCCT  
TGTGTTACCCATGCTGGCTTCTGCTGCCCTCTGGTGGTCACGATGAGGCCCATTTCCAAGGAC  
AAGCTGGAAGGGCTGGTGCGGGCTGCTGCTCCCTCGGAGGTGAGCAGGGGCAACCTGTTTAC  
ATGGGCGACCCAGAACTGTTGGGAATCAAAGAGCTTTCCAAACCTGCCTACGGGGATGCCATG  
GTGTGTCCCCCAGGGGAGGTTCCAGTGTTCTGGCCTTCTCCGCTGACCAGTCTCGGAGCTGTC  
AGCAGCTGTGAGACCCCACTGGCTTTTGCCAGCATCCCAGGCTGCACAGTTATGACTGACCTG  
AAGGATGCAAAGGCTCCACCTGGTTGTCTACCCCAGAGAGAATTCCAGAGGTCCATCACATT  
TCCAAGATCCTCTGCACTACAGCATCGCGTCAGTCTCTGCTTCTCAGAAGATCAGAGAACTA  
GAGTCTATGATCGGCATAGACCCAGGGAACCGGGGGATTGGGCACCTGCTCTGTAAAGATGAG  
CTGCTGAAGGCCTCTCTCTCGCTGTCCCATGCCCGCTCAGTGCTCATCACCCTGGGTTCCCC  
ACACATTTCAATCATGAGCCTCCAGAAGAGACAGATGGCCCAACAGGAGCTGTTGCTCTGGTT  
GCCTTCCCTGCAGGCCTTGAGAAAGGAGGTGCGCCATAATCGTTGACCAGAGAGCCTGGAACCTG  
CACCAGAAGATTGTTGAAGATGCTGTTGAGCAAGGTGTTCTGAAGACGCAGATCCCGATATTA  
ACTTACCAAGGTGGATCAGTGGAAGCTGCTCAGGCATTCCCTGTGCAAAAATGGGGACCCGCAG  
ACACCTAGATTTGACCACCTGGTGGCCATAGAGCGTGCCGGAAGAGCTGCTGATGGCAATTAC  
TACAATGCAAGGAAGATGAACATCAAGCACTTGTTGACCCCATTTGACGATCTTTTTTCTTGCT  
GCGAAGAAGATTCCCTGGAATCTCATCAACTGGAGTCGGTGATGGAGGCAACGAGCTTGGGATG  
GGTAAAGTCAAGGAGGCTGTGAGGAGGCACATACGGCACGGGGATGTCATCGCCTGCGACGTG  
GAGGCTGACTTTGCCGTCAATTGCTGGTGTCTTAAGTGGGGAGGCTATGCCCTGGCCTGCGCA  
CTCTACATCCTGTACTCATGTGCTGTCCACAGTCAGTACCTGAGGAAAGCAGTCGGACCCCTCC  
AGGGCACCTGGAGATCAGGCCTGGACTCAGGCCCTCCCGTCGGTCATTAAGGAAGAAAAAATG  
CTGGGCATCTTGGTGCAGCACAAAGTCCGGAGTGGCGTCTCGGGCATCGTGGGCATGGAGGTG  
GATGGGCTGCCCTTCCACAACACCCACGCCGAGATGATCCAGAAGCTGGTGGACGTCAACACG  
GCACAGGTGTAACCGTCCATGTTCCGTGTGAGCAGAGTCCCTACCAACGGGCAGGTCTGCATC  
CGGGGAGAATGCAGCTGCTTCTGGCGACAATCCTGCTAGTAAACACTGGTCTTCGGTGAGCAA  
CGAACACTCGCCTGGCCTGGGAAACTGCATGCCCACTTTCTGGGAGGGGTTAGTGCAGGTGCC  
GTGGACAAAGGACAACATTTCTCTGGGGCTTTTTAACTTTTATTCTTAAGACTCTAAAGGCGT  
TGATTTCAACCCTCCTTCACTCTGGCTTCTTCAGGCAACCCACGTGGTCTCCTATGAGAATCT  
TCTCGACAGTTACTTATGGGGACACTTGTGAACAATTAAGTCCAGGGGCAGAGCATGAGAAC  
AACATTCCCAGGCCATGTAGGATAGGATACTCCAGACTCCAGTCATCCTCCCCCATCCATGGT  
TTCTGTTACTCATGGTTTTCAGTTACTCATAGCCAAGTGCAGACCGAAATACTAAATGAAAAA  
TTTCAGAAATAAACAACTCTTAAGTTTTAAAAA

40/550

**FIGURE 40**

MPFTLHLRSRLPSAIRSLILQKKPNIRNTSSMAGELRPASLVVLPRSLAPAFERFCQVNTGPL  
PLLGQSEPEKWMPLPPQGAISETRMGHPQFWKYEFGACTGSLASLEQYSEQLKDMVAFFLGCSF  
SLEEAL EKAGLPRRDPAGHSQAGAYKTTVPCVTHAGFCCPLVVTMRPIPKDKLEGLVRACCSL  
GGEQGPVHMGDPPELLGIKELSKPAYGDAMVCPPEVVPVFWPSPLTSLGAVSSCETPLAFASI  
PGCTVMTDLKDAKAPPGCLTPERIPEVHHISQDPLHYSIASVSASQKIRELESMIGIDPGNRG  
IGHLLCKDELLKASLSLSHARSVLITTFPPTHFNHEPPEETDGPPGAVALVAFLQALEKEVAI  
IVDQRAWNLHQKIVEDAVEQGVLTQIPILTYQGGSV EAAQAF LCKNGDPQTPRFDHLVAIER  
AGRAADGNYYNARKMNIHLVDPIDDLFLAAKKIPGISSTGVGDGGNELGMGKVKEAVRRHIR  
HGDVIACDVEADFAVIAGVSNWGGYALACALYILYSCAVHSQYLRKAVGPSRAPGDQAWTQAL  
PSVIKEEKMLGILVQHKVRSVSGIVGMEVDGLPFHNTHAEMIQLVDVTTAQV

**Signal peptide:**

amino acids 1-17

**Transmembrane domain:**

amino acids 358-378, 517-539

**N-glycosylation site.**

amino acids 28-32

**Tyrosine kinase phosphorylation site.**

amino acids 444-452

**N-myristoylation site.**

amino acids 98-104, 102-108, 123-129, 149-155, 181-187, 190-196,  
238-244, 308-314, 399-405, 413-419, 448-454, 477-483, 482-488,  
487-493

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 233-244, 531-542

41/550

**FIGURE 41**

CTTTCCTGTTTTATCCGCAGCCCTTTTCTTCTTTGAGTTAGTAAAGATTTATTCTGTAACCTG  
ACACTCATCTGGCCCTTTGCAGTTTGCCAGCCATATTCCCATGTGATTTCCCCTGGATCCAG  
GCCCCATCCGGCTGGCAGGAGGGGGCTCTGACGTACAGGTTGGAAATCAGAAGTCTGTGAGA  
GCGCGGGAGTGATGGCAGCTCTGGGTCCCAGACCTGGCCCGACCCCTCTGCTTCACCTECAG  
CTCTGCTGCTCCTCTACTCTTGGGTGAGATCCCTTTGGAGCCACAGCGAGGAACCCTGTGGT  
CCTCAGGCAGGTGTACCTTGAGTCAGCCAGGAGCCCTCTTTTCCTGTGTCAAAGCCTGCCCTC  
GGGCTCTGCTCACCTCTGGTGACCCTCCAAGATGCCCCTGCCCTCAGTTTCCCCTCATGATCT  
GGCCTCTGCCCCCTTCTCTAGCCACAGCCTCTAGTACACTTTAGCAATACCACCAGACTAGTT  
AGAGTTCCCCACTCACCAAGCAAGACATGCAGTTTCATGCCTCTGTGCCTTCGCTCATGCTGT  
TTCTTCCGACTGGAATGCCTTCCCCTGCTCCTCCTGCCTTGTCTGCCTGGCAAGTTCATCTCT  
CACGATCCCCTCAAAGGCCCCCTCCTCCAGGAAGGCAACCCCTGTGCCCCCTCCCCTCCAGGCT  
ACCTCTGCACTTTGTCAATGCTTCTCTTGTGGCACTTATCACACTGTATTTTACTTGTTTACA  
TGTTTGTCTCCCCTTCTAGACTGTGAATCCTTAAGGGCATGGACTGTATCTTATGCATCTCTG  
TATTTCTGCGCCTAGCACGGTGCCTAGCACACAGTAGGCGCTCAATAAATGTTGAATGAATGA  
ATGATTT

42/550

## **FIGURE 42**

MQFHASVPSLMLFLPTGMPSPAPPALSAWQVHLSPQRPPPPGRQPLCPSPPGYLCTLSMLL  
LWHLSHCILLVYMFVSPSRL

**Important features of the protein:**

**Signal peptide:**

amino acids 1-22

**Microbodies C-terminal targeting signal.**

amino acids 81-83

43/550

**FIGURE 43**

GTTTCCAACAAGGATGATATGAAGACTTCCCTGAAGAAAGTTGTGAAGGGACCTCCTACGAGA  
**TG**ATGATGCAGTGTGTGTCCCGCATGTTGGCCCACCCCCTGCATGTCATCTCAATGCGCTGCA  
TGGTCCAGTTTGTGGGACGGGAGGCCAAGTACAGTGGTGTGCTGAGCTCCATTGGGAAGATTT  
TCAAAGAGGAAGGGCTGCTGGGATTCTTCGTTGGATTAATCCCTCACCTCCTGGGCGATGTGG  
TTTTCTTGTGGGGCTGTAACCTGCTGGCCCACTTCATCAATGCCTACCTGGTGGATGACAGCT  
TCAGCCAGGCCCTGGCCATCCGGAGCTATACCAAGTTCGTGATGGGGATTGCAGTGAGCATGC  
TGACCTACCCCTTCCCTGCTAGTTGGCGACCTCATGGCTGTGAACAACCTGCGGGCTGCAAGCTG  
GGCTCCCCCCTTACTCCCCAGTGTTCAAATCCTGGATTCACTGCTGGAAGTACCTGAGTGTGC  
AGGGCCAGCTCTTCCGAGGCTCCAGCCTGCTTTTCCGCCGGGTGTCATCAGGATCATGCTTTG  
CCCTGGAG**TAA**CCTGAATCATCTAAAAACACGGTCTCAACCTGGCCACTGTGGGTGAGGCCT  
GACCACCTTGGGACACCTGCAAGACGACTCCAACCCAACAACAACCAGATGTGCTCCAGCCCA  
GCCGGGCTTCAGTTCCATATTTGCCATGTGTCTGTCCAGATGTGGGGTTGAGCGGGGGTGGGG  
CTGCACCCAGTGGATTGGGTCACCCGGCAGACCTAGGGAAGGTGAGGCGAGGTGGGGAGTTGG  
CAGAATCCCCATACCTCGCAGATTTGCTGAGTCTGTCTTGTGCAGAGGGCCAGAGAATGGCTT  
ATGGGGGCCCAGGTTGGATGGGGAAAGGCTAATGGGGTCAGACCCACCCCGTCTACCCCTCC  
AGTCAGCCCAGCGCCCATCCTGCAGCTCAGCTGGGAGCATCATTCTCCTGCTTTGTACATAGG  
GTGTGGTCCCCTGGCACGTGGCCACCATCATGTCTAGGCCTATGCTAGGAGGCAAATGGCCAG  
GCTCTGCCTGTGTTTTTCTCAACACTACTTTTCTGATATGAGGGCAGCACCTGCCTCTGAATG  
GGAAATCATGCAACTACTCAGAATGTGTCCTCCTCATCTAATGCTCATCTGTTTAATGGTGAT  
GCCTCGCGTACAGGATCTGGTTACCTGTGCAGTTGTGAATACCCAGAGGTTGGGCAGATCAGT  
GTCTCTAGTCCTACCCAGTTTTTAAAGTTCATGGTAAGATTTGACCTCATCTCCCGCAAATAAA  
TGTATTGGTGATTTGGAAAAAAAAAAAAAAAAAAAA

44/550

**FIGURE 44**

MMMQCVSRMLAHPLHVISMRCMVQFVGREAKYSGVLSSIGKIFKEEGLLGFFVGLIPHLLGDV  
VFLWGCNLLAHFINAYLVDDSFQALAIRSYTKFVMGIAVSMLTYPFLLVGDLMAVNNCGLQA  
GLPPYSPVFKSWIHCWKYLSVQGQLFRGSSLLFRRVSSGSCFALE

**Important features of the protein:****Signal peptide:**

amino acids 1-18

**Transmembrane domains:**

amino acids 51-72, 97-114

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 160-163

**N-myristoylation sites.**

amino acids 34-39, 100-105, 123-128, 165-170

45/550

FIGURE 45

GCTCACTCTTTGGGTCCACACTGCCTTTATGAGCTGTAACACTCACTGGGAATGTCTGCAGCT  
TCACTCCTGAAGCCAGCGAGACCACGAACCCACCAGGAGGAACAAACAACTCCAGACGCGCAG  
CCTTAAGAGCTGTAACACTCACCGCGAAGGTCTGCAGCTTCACTCCTGAGCCAGCCAGACCAC  
GAACCCACCAGAAGGAAGAACTCCAAACACATCCGAACATCAGAAGGAGCAAACCTCGTGACA  
CGCCACCTTTAAGAACCGTGACACTCAACGCTAGGGTCCGCGGCTTCATTCTTGAAGTCAGTG  
AGACCAAGAACCCACCAATTCCGGACACGGCAAAGTAACATCCTAGACATGGCTTTAGAGATC  
CACATGTCAGACCCCATGTGCCTCATCGAGAACTTTAATGAGCAGCTGAAGGTTAATCAGGAA  
GCTTTGGAGATCCTGTCTGCCATTACGCAACCTGTAGTTGTGGTAGCGATTGTGGGCCTCTAT  
CGCACTGGCAAATCCTACCTGATGAACAAGCTGGCTGGGAAGAACAAGGGCTTCTCTGTTGCA  
TCTACGGTGCAGTCTCACACCAAGGGAATTTGGATATGGTGTGTGCCTCATCCCAACTGGCCA  
AATCACACATTAGTTCTGCTTGACACCGAGGGCCTGGGAGATGTAGAGAAGGCTGACAACAAG  
AATGATATCCAGATCTTTGCACTGGCACTCTTACTGAGCAGCACCTTTGTGTACAATACTGTG  
AACAAAATTGATCAGGGTGCTATCGACCTACTGCACAATGTGACAGAAGTACAGATCTGCTC  
AAGGCAAGAACTCACCTGACCTTGACAGGGTTGAAGATCCTGCTGACTCTGCGAGCTTCTTC  
CCAGACTTAGTGTGGACTCTGAGAGATTTCTGCTTAGGCCTGGAAATAGATGGGCAACTTGTC  
ACACCAGATGAATACCTGGAGAATTCCTAAGGCCAAAGCAAGGTAGTGATCAAAGAGTTCAA  
AATTTCAATTTGCCCCGTCTGTGTATACAGAAGTTCTTTCCAAAAAAGAAATGCTTTATCTTT  
GACTTACCTGCTCACCAAAAAAAGCTTGCCCAACTTGAAACACTGCCTGATGATGAGCTAGAG  
CCTGAATTTGTGCAACAAGTGACAGAATTCTGTTCTTACATCTTTAGCCATTCTATGACCAAG  
ACTCTTCCAGGTGGCATCATGGTCAATGGATCTCGTCTAAAGAACCTGGTGCTGACCTATGTC  
AATGCCATCAGCAGTGGGGATCTGCCTTGATAGAGAATGCAGTCCTGGCCTTGGCTCAGAGA  
GAGAACTCAGCTGCAGTGCAAAAGGCCATTGCCCACTATGACCAGCAAATGGGCCAGAAAGTG  
CAGCTGCCCATGGAAACCCTCCAGGAGCTGCTGGACCTGCACAGGACCAGTGAGAGGGAGGCC  
ATTGAAGTCTTCATGAAAACTCTTTCAAGGATGTAGACCAAAGTTTCCAGAAAGAATTGGAG  
ACTCTACTAGATGCAAAACAGAATGACATTTGTAAACGGAACCTGGAAGCATCCTCGGATTAT  
TGCTCGGCTTTACTTAAGGATATTTTTGGTCCTCTAGAAGAAGCAGTGAAGCAGGGAATTTAT  
TCTAAGCCAGGAGGCCATAATCTCTTCATTCAGAAAACAGAAGAACTGAAGGCAAAGTACTAT  
CGGGAGCCTCGGAAAGGAATACAGGCTGAAGAAGTTCTGCAGAAATATTTAAAGTCCAAGGAG  
TCTGTGAGTCATGCAATATTACAGACTGACCAGGCTCTCACAGAGACGGAAAAAAGAAGAAA  
GAGGCACAAGTGAAAGCAGAAGCTGAAAAGGCTGAAGCGCAAAGGTTGGCGGCGATTCAAAGG  
CAGAACGAGCAAATGATGCAGGAGAGGGAGAGACTCCATCAGGAACAAGTGAGACAAATGGAG  
ATAGCCAAACAAAATTGGCTGGCAGAGCAACAGAAAATGCAGGAACAACAGATGCAGGAACAG  
GCTGCACAGCTCAGCACAACATTCCAAGCTCAAAATAGAAGCCTTCTCAGTGAGCTCCAGCAC  
GCCAGAGGGCTGTTAATAACGATGATCCATGTGTTTTACTCTAAAGTGCTAAATATGGGAGT  
TTCCTTTTTTTTACTCTTTGTCACTGATGACACAACAGAAAAGAACTGTAGACCTTGGGACAA  
TCAACATTTAAATAAACTTTATAATTATTTAA



46/550

**FIGURE 46**

MALEIHMSDPMCLIENFNEQLKVNQEALEILSAITQPVVVVAIVGLYRTGKSYLMNKLAKGNK  
GFSVASTVQSHTKGIWIWCVPHPNWPNHTLVLLDTEGLGDVEKADNKNDIQIFALALLSSTF  
VYNTVKNIDQGAIDLLHNVTELTDLLKARNSPDLDRVEDPADSASFFPDLVWTLRDFCLGLEI  
DGQLVTPDEYLENSLRPKQGSQDQVQNFNLPRLCIQKFFPKKKCFIFDLPAHQKKLAQLETLP  
DDELEPEFVQQVTEFCSYIFSHSMTKTLPGGIMVNGSRLKKNLVLTYVNAISSGDLPCIENAVL  
ALAQRENSAAVQKAIHYDQQMGQKVQLPMETLQELLDLHRTSERAIEVFMKNSFKDVDQSF  
QKELETLLDAKQNDICKRNLEASSDYCSALLKDIFGPLEEAVKQGIYSKPGGHNLFIQKTEEL  
KAKYYREPRKGIQAEVLQKYLKSKESVSHAILQTDQALTETETEKKKKEAQVKAEAEKAEQRL  
AAIQRQNEQMMQERERLHQEQVRQMEIAKQNWLAEQQKMQEQQMQEQAAQLSTTFQAQNRSL  
SELQHAQRAVNNDPCVLL

**Important features of the protein:****Transmembrane domains:**

amino acids 31-49, 114-131

**N-glycosylation sites.**

amino acids 90-94, 144-148, 287-291, 563-567

**N-myristoylation sites.**

amino acids 45-51, 283-289

**Prenyl group binding site.**

amino acids 583-588

**ATP/GTP-binding site motif A (P-loop).**

amino acids 45-53

47/550

**FIGURE 47**

CACTCATTTCATTCCAAAGGGTCTCTCAAGGCAATGGTAATGTGCAAGGAGGTGATACCTAAAT  
GAATGACCAAAAGAACATGCTTCTGCTTTTGTGTGTCTCCTACATTTTAGACATTTGTTTGT  
TCTCTTGGTAGCCTTTAAATTCCCTTGAAGCCCAGGACCATGTCTCACTTACCTTTGTGTTTCC  
ACTAACTAGTCTACCTCCTGGAATTGGCAGATACTCAGTGAAAGCCTGTGAAATAAGTGATGT  
CTATTTCTAGCATATTATTCTGAGATTTAATGATAGATTTAGTGATTGAATGAGATTTCCATT  
TTCAAATACAGCAAAAGCATAACTATTTTCATTTCATTTCATATTTCATTCAACTTCATTCTCAA  
ATTAGGTCCTGAGTTAACTAATAATTACCTTTGAAATGTGTGGGTTATTTGAGGCAATCAGGT  
GGTGACATTGAGCTCTCAGCCAGAGTTTGTCTTCTGGAATTGATTCAGTTCATTGCATTGATT  
TTTGTCTCAGAAGCCAAGGTTTCCCATGAAAAATCATTCCCACTTGAATTGGGCTGTGATTC  
TTGCTGCGTTTAAAGTAAAGGAAGCCTCTTGGTTCTAGTTCTGCAAACTTACACACTGAACTGG  
GACAAGTTTTTGTTTAGAGTAATGGCTGGGAAAAGAGGAACCTTTCATTTTATTGAGAAGTCA  
AAAACAAAGGCCTCCCAGCCACCTGGAGATGTTTTGTTGCAGACACCAGCCTGGCTCTGTCTT  
TATGCCTAACAATTGAGCATCCAGTCTTCTTTGTGCTGGGACCATTGCTCAGCTCTGCAAGGG  
GAAAAGAGGGAGAAAGCCAGAGCTGCCAGGCTTCTTGCACTGGGGCCGGGGGAGGGTTCCTGG  
GAAGCAGGTGCTCTCTGGCTTCTTGGTACGTGAGGCTCTCGGAGCTGCCTCTCCTCTGACCCT  
CAGGTCCTCACCGAGTTTGCTCCAGGAGTATATTGAAAACATACCCAGTGCTCTCTCAAGCAC  
CCACTGCTTAGAGGGCCCAGATTTCTTTTCCTTCTTTCCCTTGCAAGAGCTGGAGACTGCATCG  
GGCATCTGGTGTTTAACTAAACAGGAAACTGACTAAAGGTCCACAGTGCTCATTGTGTAGA  
CTAGCTGCCCTCCGATGGGTGCTCTGATTATCAGTGTTCCAGTGCAGGGCCTGTCACTAAAC  
AGGCCTCACTTCCTCCTTGGGGGCTTTCCCATGGGAGGTGTGGCTTTTTACTCTACATGGAAA  
TGACTCTCTGCAGCCACAGAACACAGTCATTTTCTGAATTATCCCAGTCTCTCATGCGCCCTG  
GATTCCTCCAGATGCCTTATATCTCTTGTGCAAAGTTGTCTAAAATTTGGTTCCCAGCTTCCA  
AGCCTTGCCTTTTGGCCTTCCTGGAAGTATTTTTGTTGATGAGTCGTCTGTCATTATTCTCTA  
AAATGATTTGCTTTTTGTTTCTTTTCATTTCCTATTTCCACCCACATATACACACATGCTTCTT  
AACTTAGGGGATTACATGCCAATAAATCTATTGTTGAAAATGCACTAATACTATCGCAAAGAC  
GAAAATTCACAGGCTGAACCGTTGTAAGTCCATATGCTCCTCAACTTACATGTGTGATGGAGT  
TATGCCCAAATAAGTCCATCGTCAAGTTGAAAAATCAAAATCAAGCCATCTTAGGTTGAGGAC  
CATTTGTTTGTACCTCCAAAGATGTCATATCTTTAAACATACTCCCTAGCTTTTCTTTTACT  
TTTTATTTTGAAGTAATTATAGAATCACAGAAAGTTGCAAAAAA

48/550

## **FIGURE 48**

MGALIISGSSAGPVTKQASLPPWGLSHGRCGFLLYMENTLCSHRTQSFSELSQSLMRPGFLQM  
PYISCAKLSKIWFPAKPCLLAFLEVFLMSRLSLFSKMICFLFLSFLFPPHIYTHAS

**Important features of the protein:**

**Signal peptide:**

amino acids 1-41

**Transmembrane domain:**

amino acids 88-107

**Casein kinase II phosphorylation site.**

amino acids 47-50

**N-myristoylation site.**

amino acids 24-29

49/550

**FIGURE 49**

GGCTTCTACAGTCCACAACACCCACCAGCCCCAGGCCAGCAGAATGAGCCCAGTGAGTGCCGGGGCTCCCAGTT  
TGGCTGTTGCTATGACAACGTGGCCACTGCAGCCGGTCTCTTGGGGAAGGCTGTGTGGGCCAGCCCAGCCATGC  
CTACCCCGTGGGTGCTGCTGCCCAGTGCCCATGGCTCTTGTGCAGACTGGGCTGCCCGCTGGTACTTCGTTGC  
CTCTGTGGGCAATGTAACCGCTTCTGGTATGGCGGCTGCCATGGCAATGCCAATAACTTTGCCTCGGAGCAAGA  
GTGCATGAGCAGCTGCCAGGGATCTCTCCATGGGCCCCGTCTGCCAGCCTGGGGCTTCTGGAAGGAGCACCCA  
CACGGATGGTGGCGGCAGCAGTCTGCAGGCGAGCAGGAACCCAGCCAGCACAGGACAGGGGCCGCGGTGCAGAG  
AAAGCCCTGGCCTTCTGGTGGTCTCTGGCGGCAAGACCAACAGCCTGGGCCAGGGGAGGCCCCCACACCCAGGC  
CTTTGGAGAATGGCCATGGGGGCAGGAGCTTGGGTCCAGGGCCCCCTGGACTGGGTGGAGATGCCGGATCACCAGC  
GCCACCCTTCCACAGCTCCTCTACAGATCTCACTTCCACCTCTCCAGGATTAGCTTGGCAGGTGTGGAGCCCT  
CGTTGGTGCAGGCAGCCCTGGGGCAGTTGGTGGCGCTCTCTGTCTCAGACGACACTGCCCGGAATCCCAGGCTG  
CCTGGCAGAAAGATGGCCAGCCCATCTCCTCTGACAGGCACAGGCTGCAGTTCCGACGGATCCCTGATCATCCACC  
CCCTGCAGGCAGAGGACGCGGGCACCTACAGCTGTGGCAGCACCCGGCCAGGCCGCGACTCCCAGAAGATCCAAC  
TCCGCATTATAGGGGGTGACATGGCCGTGCTGTCTGAGGCTGAGCTGAGCCGCTTCCCTCAGCCCAGGGACCCAG  
CTCAGGACTTTGGCCAAGCGGGGGCTGCTGGGCCCCCTGGGGGCCATCCCCTCTTACACCCACAGCCTGCAACA  
GGCTGCGTTTGGACCAGAACCAGCCCCGGGTGGTGGATGCCAGTCCAGGCCAGCGGATCCGGATGACCTGCCGTG  
CCGAAGGCTTCCCGCCCCAGCCATCGAGTGGCAGAGAGATGGGCAGCCTGTCTCTTCTCCAGACACAGCTGC  
AGCCTGATGGCTCCCTGGTCATTAGCCGAGTGGCTGTAGAAGATGGCGGCTTCTACACCTGTGTGCTTCAATG  
GGCAGGACCGAGACCAGCGATGGGTCCAGCTCAGAGTTCTGGGGGAGCTGACAATCTCAGGACTGCCCCCTACTG  
TGACAGTGCCAGAGGGTGATACGGCCAGGCTATTGTGTGTGGTAGCAGGAGAAAGTGTGAACATCAGGTGGTCCA  
GGAACGGGTACCTGTGCAGGCTGATGGCCACCGTGTCCACCAGTCCCCAGATGGCAGCTGCTCATTATCAACT  
TGCGGGCCAGGGATGAGGGCTCCTACATGTGCAGTGCCTACCAGGGGAGCCAGGCAGTCAGCCGCAGCACCCGAGG  
TGAAGGTGGTCTCACCAGCACCCACCGCCCCAGGCCAGGGAGCTCGCTCGACCAGCCAGAGCTGG  
CCAAGTGTGATTTGATCCTGCAGGCCAGCTTTGTGGCAATGAGTATTACTCCAGCTTCTGCTGTGCCAGCTGTT  
CACGTTTCCAGCCTCACGCTCAGCCCATCTGGCAGTAGGGATGAAGGCTAGTTCAGCCCCAGTCCAAAATAGTT  
CATAGGGCTAGGGAGAAAGGAAGATGGACTCTTGGCTTCTCTCTCTGGCTGGCAAAGGGAGTTATCTTCTGGAA  
TACATTAGCTCTTTCAAAACCCACCCAGTGTTTAGCCTCAACGGCAGCCAGTTACCAGCTTCTCTCTGTAGCCT  
TCAGCAGTGTTGCATCTCTGACATAACCACAGGCTGCTGTTTTCAAGAAGAGCAATCTGTTTGGATAAGAAAAA  
CCTTTACTTTACAGCTTCCCTTTATAATTTGTTTACACAGGAATAGTTAAATGCATTGTTTGTGTTTTTGGAG  
ACGGAGTTTCACTCTTGTGCCCAGGCTGGAGGGCAATGGCGCGATCTCAGCTCACTGCAACCTCCGCTCTCCTGG  
GTTCTTGATTCTCCTGTGTACGCTTCTGAGTAGCTGGGATTACAGATGCCTATCACCATGCCTGGGTAATTTTT  
GTATTTTTAGTTGAGATGGGGTTTCGCCATGTTGGCCAGGCTGGTCTCGAATTCTGACCTCAGATGATCTGCCC  
GCCTCAGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACCACGCCCAGCCATCAATGCATTTTTTTTTATTTT  
TTTTTTGAGACAGAGTTTCGCACTTCTTGGCCAGGCTGGAGTACAATGGTGCGATCTTGGCTCACTGCAACCTCC  
ACCTCCTGGGTTCAAGCGCTTCTCCAGCCTCAGCCTCCTGAGTAGCTGGGATTACAGGTATGTGCCACCATGCCT  
GGCTAATTTTGTATTTTGGTGGAGACGGGGTTTCTCCATGTTGGTTCAGACTGGTCTTGAAGCCTCCGACCTCAGG  
TAATCCGCCCCGCTCCGCTCCCAAATGCTGGGATTAGAGGTGTGAGCCACTGTGCCAGCCCATCAATGTGTT  
TTAAAGCTAGCTGTGAGGTTCCACTTAATTTAAAGCTGGGCAGGGAGATGTGTAATGATTTCAAAGTTAACACC  
TGTTTGTGTTTCTAAAGGGCATGCCAAGTCTGCTGTATCAGGGAAGTATTCTGTGCTAAAATCAGCGATGGTTCA  
TTGCTCTAGTCTCTCTACCCCTTCTAGGCAGTGCATCAGTCAGCTCTAAATCTGGTGCAGAGGGTTAACAGCATA  
ACCCTTGTGTTGGCAAAATGGAATAGATGTTAAGACCTCAAATAGGGATTGGGATGAAACAGCTCCGTTCTCCTGG  
GTTATCTGAGCATGAAAGAACTGGAACGCTCCTTACGTCAGATGTTGGACCTTGAAGCCCTCCTGAGGCCAAC  
ATGCAATCTGGCTGTGACGGTTCATCTGACACCTGTGTAAGCTGACCAGCCTGCTCTGTACAGTGACAATGAG  
GAGCCCCCTCTCTTCTTAAGTAGGAATCTGTGAAGCAAAATGTTTGGCTGCCAAAGACAAATCAGACTGTGAGTCA  
TTAAAAACAGCATTAGCAGGATGAGGATAGCAATGGGGAAGGGTTGTGGGCAATGCAGTAACAGGGAAATGGCTT  
CAGAAATGGTTTGGAGTTGGAAGACAACATTCTTCTCAGGACTTCTAATTCCTTGATGCTAAAAGAAGAGG  
CATGGATTCTATGAGCTTCCAAGTCCCTTTCCACTTTAAACCTTCTACAAATCTTTCAGAGGACTGCCTAGTAGCA  
AAGGTTATTCTGGACACAGGAAAGACGGGCATTACAGGGACCAAAGCTCTGAAAGGTGACTTTTTATTACCAACA  
CACTGGCTGGAAGGGACAAACCACATCACGGGTGAGTGATACTTCTCAGTCTTCTCTACTCATTCAACAAAGG  
AAATGTGGGCTGGGGCAGAGGTCTTTTTTCAATTAATACTGGAATAATATTGAAGAGCATCCATGTTCACTTATG  
GCTGGTTTTGCTATAGAAATTGGAATAAAGGCCACTTTTTTG

50/550

**FIGURE 50**

MGPVVPSLGLLEGAPTRMVAAAVLQASRNPASTGQGPRCRES PGLLVVSGGKTNSLGQGRPPT  
PRPLENGHGG RSLGPGPLDWVEMPDHQRHPSTAPPTDLTSHLSRISLAGVEPSLVQAALGQLV  
RLSCSDDTAPESQAAWQKDGQPISSDRHRLQFDGSLIIHPLQAEDAGTYSCGSTRPGRDSQKI  
QLRIIGGDMAVLSEAELSRFPQPRDPAQDFGQAGAAGPLGAI PSSHPQPANRLRLDQNQPRV  
DASPGQRIRMT CRAEGFPPPAIEWQRDQGPVSSPRHQLQPDGSLVISRVAVEDGGFYTCVAFN  
GQDRDQRWVQLRVLGELTISGLPPTVTVP EGD TARLLCVVAGESVNIRWSRNL PVQADGHRV  
HQSPDGTLLIYNLRARDEGSYMCSAYQGSQAVSRSTE VKVVS PAPT AQPRDPGRDCVDQPELA  
NCDLILQAQLCGNEYYS SFCCASCSRFQPHAQPIWQ

**Important features of the protein:****Signal peptide:**

amino acids 1-16

**Tyrosine kinase phosphorylation site.**

amino acids 392-400

**N-myristoylation sites.**amino acids 9-15, 50-56, 112-118, 146-152, 173-179, 195-201,  
220-226, 229-235, 280-286, 306-312, 336-342, 397-403**Myelin P0 protein.**

amino acids 153-182

51/550

**FIGURE 51**

CAGGCAGAAGCGAACAAAGACCCAGCAAGAGAAGGCAGAGGCTAAGACCCATCCCGTATCTGC  
TCTCCTGAAATAATTCTGGAGTCA**ATG**CCTGAAATGCCAGAGGACATGGAGCAGGAGGAAGTTA  
ACATCCCTAATAGGAGGGTTCTGGTTACTGGTGCCACTGGGCTTCTTGGCAGAGCTGTACACA  
AAGAATTTTCAGCAGAATAATTGGCATGCAGTTGGCTGTGGTTTCAGAAGAGCAAGACCAAAAT  
TTGAACAGGTTAATCTGTTGGATTCTAATGCAGTTCATCACATCATTCATGATTTTTCAGCCCC  
ATGTTATAGTACATTGTGCAGCAGAGAGAAGACCAGATGTTGTAGAAAATCAGCCAGATGCTG  
CCTCTCAACTTAATGTGGATGCTTCTGGGAATTTAGCAAAGGAAGCAGCTGCTGTTGGAGCAT  
TTCTCATCTACATTAGCTCAGATTATGTATTTGATGGAACAAATCCACCTTACAGAGAGGAAG  
ACATACCAGCTCCCCTAAATTTGTATGGCAAACAAAATTAGATGGAGAAAAGGCTGTCCTGG  
AGAACAATCTAGGAGCTGCTGTTTTGAGGATTCCTATTCTGTATGGGGAAGTTGAAAAGCTCG  
AAGAAAGTGCTGTGACTGTTATGTTTGATAAAGTGCAGTTCAGCAACAAGTCAGCAAACATGG  
ATCACTGGCAGCAGAGGTTCCCCACACATGTCAAAGATGTGGCCACTGTGTGCCGGCAGCTAG  
CAGAGAAGAGAATGCTGGATCCATCAATTAAGGGAACCTTTCCTGCTGCTGGCAATGAACAGA  
TGACTAAGTATGAAATGGCATGTGCAATTGCAGATGCCTTCAACCTCCCCAGCAGTCACTTAA  
GACCTATTACTGACAGCCCTGTCCTAGGAGCACACGTCAGGAGAAATGCTCAGCTTGACTGCT  
CCAAATTGGAGACCTTGGGCATTGGCCAACGAACACCATTTTGAATTGGAATCAAAGAATCAC  
TTTGGCCTTTCCTCATTGACAAGAGATGGAGACAAACGGTCTTTCAT**TAG**TTTTATTTGTGTTG  
GGTTCTTTTTTTTTTTTAAATGAAAAGTATAGTATGTGGCACTTTTTTAAAGAACAAAGGAAATA  
GTTTTGTATGAGTACTTTAATTGTGACTCTTAGGATCTTTCAGGTAAATGATGCTCTTGCACT  
AGTGAAATTGTCTAAAGAACTAAAGGGCAGTCATGCCCTGTTTGCAGTAATTTTTCTTTTTTA  
TCATTTTGTTTGTCTGGCTAAACTTGGAGTTGAGTATAGTAAATTATGATCCTTAAATATT  
TGAGAGTCAGGATGAAGCAGATCTGCTGTAGACTTTTCAGATGAAATTGTTCAATTCTCGTAAC  
CTCCATATTTTCAGGATTTTTGAAGCTGTTGACCTTTTCATGTTGATTATTTTAAATTGTGTG  
AAATAGTATAAAAATCATTGGTGTTCAATTATTTGCTTTGCCTGAGCTCAGATCAAAATGTTTG  
AAGAAAGGAACCTTTATTTTTGCAAGTTACGTACAGTTTTTATGCTTGAGATATTTCAACATGT  
TATGTATATTGGAACCTTCTACAGCTTGATGCCTCCTGCTTTTATAGCAGTTTATGGGGAGCAC  
TTGAAAGAGCGTGTGTACATGTATTTTTTTTCTAGGCAAACATTGAATGCAAACGTGTATTTT  
TTTAATATAAATATATAACTGTCCTTTTCATCCCATGTTGCCGCTAAGTGATATTTTCATATGT  
GTGGTTATACTCATAATAATGGGCCTTGTAAGTCTTTTCACCATTCATGAATAATAATAATA  
TGTAAGTCTGGCATGTAATGCTTAGTTTTCTTGATTTTACTTCTTTTTTTTAAATGTAAGGACC  
AACTTCTAACTAATTGTTCTTTTGTGCTTTAATTTTTTAAATTAACATTCTTCTGATGTA  
ACATGTGATACATACAAAAGAATATAGTTTAATATGTATTGAAATAAAACACAATAAAATT

52/550

**FIGURE 52**

MPEMPEDMEQEEVNI PNRRVLVTGATGLLGRAVHKEFQQNNWHAVGCGFRRARPKFEQVNLLD  
SNAVHHIIHDFQPHVIVHCAAERRPDVVENQPDAASQLNVDASGNLAKEAAAVGAFLIYISSD  
YVFDGTNPPYREEDI PAPLNLYGKTKLDGEKAVLENNLGAAVLRIPILYGEVEKLEESAVTVM  
FDKVQFSNKSANMDHWQQRFP THVKDVATVCRQLAEKRMLDPSIKGTFHWSGNEQMTKYEMAC  
AIADAFNLPSSHLRPITDSPVLGAQRPRNAQLDCSKLET LGIGQRTPF RIGIKESLWPFLIDK  
RWRQTVFH

**Signal peptide:**

amino acids 1-30

**Transmembrane domain:**

amino acids 105-127

**N-glycosylation site.**

amino acids 197-201

**N-myristoylation site.**

amino acids 303-309

**Short-chain dehydrogenases/reductases family proteins.**

amino acids 18-30

53/550

**FIGURE 53**

TGGGCTCCCTCCAGCACTGCTGTTGCCTGCTGCCTAAGATGGGTGACACTTGGGCCAGCTTCCCTGGCCTGGGC  
CACCCACCCAGCAATGCTGCTGATCTCCCTCCTCTTGGCAGCCGGGTTGATGCACTCGGATGCCGGCACCAGCT  
GCCCCGTCTTTGCACATGCCGTAACCAGGTGGTGGATTGTAGCAGCCAGCGGCTATTCTCCGTGCCCCCAGACC  
TGCCAAATGGACACCCGAAACCTCAGCCTGGCCCAACCCGATCACAGCAGTGCCGCTGGCTACCTCACATGCT  
ACATGGAGCTCCAGGTGCTGGATTGACACAACAACCTCCTTAATGGAGCTGCCCCGGGGCCTCTTCCCTCCATGCCA  
AGCGCTTGGCACACTTGGACCTGAGCTACAACAATTCAGCCATGTGCCAGCCGACATGTTCCAGGAGGCCCATG  
GGCTAGTCCACATCGACCTGAGCCACAACCCCTGGCTGCGGAGGGTGCATCCCCAGGCCCTTTCAGGGCCTCATGC  
AGCTCCGAGACCTGGACCTCAGTTATGGGGGCTGGCCTTCCTCAGCCTGGAGGCTCTTGAGGGCCTACCGGGGC  
TGGTGACCTGACAGATCGGTGGCAATCCCTGGGTGTGTGGCTGCACCATGGAACCCCTGCTGAAGTGGCTGCGAA  
ACCGGATCCAGCGCTGTACAGCAGATTCTCAGCTGAGTGCCTGGGCGGGCCCTCTGAAGTCGAGGGCGCCCCGC  
TCTTCTCACTCACTGAGGAGAGCTTCAAGGCTGCCACCTGACCCTGACCCTGGATGATTACCTATTTCATTGCGT  
TCGTGGGCTTCGTGGTCTCCATTGCTTCTGTGGCCACCAACTTCCTCCTGGGCATCACTGCCAACTGCTGCCACC  
GCTGGAGCAAGGCCAGTGAAGAGGAAGAGATCTGACATGCCTGCCTCTCATCCCTCCATGCTGCTGACCGCCACA  
GCTGCTGGCCACCAGACGCCCTCCCTGATTGCTCACTCTGGTTCATGGTGACCTGGCTGCCCTCAGTCATGGTTC  
AAGCAAGGTGGGGACACTCATTTTGTATGAGCATCTGCTTGGGGCCAGGCGGCACGCTAGGAATTGGGAACATCA  
GATGAATGACTCAGTCCCTGCCCTCAAGCAGCTCCCTCTGCTCAAGGAGAGAGATCCAAAACTATTCCCTTT  
AAGCATATATGTAGGACTCTGAGCAGCTCATTATGGAGGCCAGAGGAGGAGCCATCATCTGTATCTAGCAATG  
TCCATGAGAATTATAAGATTAGAGTGATTTGTGAAGTGGGTGCATCAGGAAATATCTACTTTGTCAGGTAGGCAAA  
GAAGGTGTCTGCACATGGCAGAGGCCAGAATATGCATAGTGTGCTGTGTTGAGAAGAGTGAACAGTTCCCTGGTC  
ACTTACTTGTATAGAGGGGGTGTGGCACAGAACTCAAACCTACCCCTCACCTCCTGACACCAAACTGTCAGCTC  
TCAGCAATGCCAGCCACTGCCTACAGGGAGTAAGAACACCTCTATGACAGCCCCCTGGCCTCCTTCCACCAGCAGC  
TACCAGGTGAGACACCTCCAGACTGCCCTGACTGCCCTCATGACCAAAATGTCACCAAGTTGGTGAGGTCCCAGGCAGCA  
GGCTGAGGATGGACACTTTCAATGCCCTTGCTCCCTGCCTCTCACTCAAGTTTTGCTTCAGAAGAGAGAGGCAGGA  
GGCCCAGCAACTGGGGCAGCAAGAGTCTGGCACCTTGGGATCCTAATCATGTGACTGTTCTTGCCACAGTGCTC  
ATGCCACAGGGTCTCACCAGGAAAGTGCCTGTGGGCCACAGACCCACAGCCTGGCAGCACCCAGAGCTAAAAGG  
GGACAAAAGGCAGCACAGTTATGACCATATGAGGCTTTGCATTTTCTTCTAAGCAACTTACCCACGTTAAGCATGA  
GGGTGAGAGAGCTATTAATACTAAGCCCTTGCCAGTGTGAGTACTTTGAAAAGCTCTCTGCACAAACCATTTCC  
CTTTGACACACACACACAAATCTTTTGGGTGAGTGAACGCTGTGTTTCCATTTTACGGATGAGGCAACTAAGGCT  
CAGAGAGGTTAAAGTACATGCCACTATGAGCAAGATAAAGTCTGTGCTCTTTCTACTGCCCATCCAGTTGGG  
GAACATCACCATTCCCTCTAGAGTTATATAAATTCAAATTCAGTACAGCTGACAAAGTTCCCTCATAAGGTCCAG  
GCACTCCTCTGGGCACTTTTATATCTATTGACTCACTTCTTTCAATTCTCACAGCAACACTGCCTGGTGGTTTTT  
ATTATCCCCATTTGACAGATGAATTAATCGTAGAGAGTTGAGTGACTTACCCAAGGTTGTCTGGATAAGCCCTAG  
AAGGAAGGCGGTAGGCAGCTCCATTGAGGAACTGCATCTAATCAGTCAGTCAAAAATCAAGTAACCTTTACGAG  
CAAAGCACAAATTATCATCATCGTGGTCTTCTTCACTCAGTTTCGTCAGCAGCATCATTTATCTCCCTCTATTGTT  
CAGCACCGGATAGTTTATGAGTATTTTGCATCATTCTCCTTGACTTTTACATCCCTGTGCGAGGATTAATCA  
AACATCAGTAATCCTGTTTTACAGATGGGGAAAAAGTCTCAAGGTTGGATATGACTTGCTATGTGGCAAGGTTG  
GGGCTCAACCTTAACACAGTTCTCTTTCCAGTGCTTTCTCAAGTGCTTGGGGAAGAGAATGCCCTCAGAAGGCTGG  
GTAGTGGGGCCCTGGAATTCAGCATCCATGAATGTGCTAGTGGATAAGCTAAATAGAAGGCAGCCAAACCCATCT  
CTGTACAGATTGAACATATGCTCACGGTAGGGCAAAATGCAGGCTCTGAAACAGAGACTACACAGGTAACACCTG  
AATAGGACACTCTGCTTTACAATGTGTAGATAAAAACATCAGCAATGGTGGCCATGGTGAGTGTGAAAG  
TAAGATCTTTGGGAATCAAGAAAGGAAGCTGTGTTAACCCTCCTGCTCAAGCCCTGCTGCGTGTGTTGCAAGAG  
ATACTAAGAGAGCAAGAAAGCTATAGGTGAGAACCTCTGCAGTTTAGGAGAAGAATCAAGGCACAGTCCAACA  
TGCTGATAAGTCTGGCCAGGAGGAGAATTAACACAGGGGCTTTCCACACCTCCCTTGCCCCAAGCTCCAGCGGTA  
TTCTATCAGCCCATCCTCCTGGAAAGCCTGAAAGGAATGAAGGAGGCTAATAAGTCATCTTCCAGGAAGGCATCC  
CTCACTCGTCTCCCTGAGCTAGTCAACCAAAAGAGTCTTCAAGAACTTTGCTAGACCTGAAGTACTTGAACCT  
GTGTCCCCTGAATCTTTCTTACAACATCTGGGACAAATCCCTGGTCCCTGTGACATCCGAAGCAGAACTGTGCCCT  
GCTCTCTCCTTCTGTGATGACCAAGGATGGTGAAGTCAAGTTGTCTCTACAAGCCAGGCCAGCAACCTAAATAC  
TTGGAGAGGAACTTTTAGAACTATAATCCTGACAAAATAGAAAAGTTTCCCATAGGGGCATACCATAATACTAT  
AATAACCTCCCAGGAATATTGTTTGCCAAAATGTAGTTAATATATTTTAAGATATATGCTTTTTTGATAGGAC  
TAGAACCCAGAAAAGACACCAATGCCCCCTTGACATCAATGTCCTTTCTAGTGGGACAATTTGGTCTCCATTAAT  
GCCAAACCTTCTGAACAGGATACATGGCTTTTAAAGGACAGATGTTTCTCCTGCTGTAAGTCTCCTCAGTTT  
ACTAGGACACAATGAGGAAAGTATTCAACCTCCTCATGCCAAAGGAATTCCTGCTCTCCCCACGCCCATCAT  
CTTGTCCAAGCTATCAGAAGCAACCTTCTAGAGATAATCTAACAATCCTGATTAGAATTGCTCCCATATCCCTGG  
TGACCACAGGCTTCATTCAAATTGTCCAACTGGTTAACATGTATGTGATGGGGTATCTCTGCATCTGTATGTCT  
GTCTGCGAGGTTCCCTGTATATTGGCTGTCCGCTGACTTGGGACAGATCTCTCTAGAAGTTGGGTTCAAGTCTCT  
GACATAGTCCACTCAGCCATAGGCTGAGTGGCTAAATATGCATAAATAAGCATGCCTAAATAGGCATATATAGGT  
TGGTGCAAAAGTAATTGCGGTTTTTGCCATTAAAAATGATGGCAAAAATCCCAATTACTTTTGGCTCAATCTAAT  
ATTACATTGCTGTAGATTAAGATCCCACAGGTTTAGGGTAGGACTGGATGCTCAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAA



54/550

**FIGURE 54**

MLLISLLLAAGLMHSDAGTSCPVLCTCRNQVVDCCSSQRLFSVPPDLPM DTRNLSLAHN RITAV  
PPGYLTCYMELQVLDLHNNSLMELPRGLFLHAKRLAHL DLSYNNF SHVPADMFQEAHGLVHID  
LSHNPWLRRVHPQAFQGLMQLRDL DLSYGGLAFLSLEALEGLPGLVTLQIGGNPWVCGCTMEP  
LLKWLRNRIQRCTADSQLAECRGPPEVEGAPLFSLTEESFKACHLTTLTDDYLFIAFVG FVVS  
IASVATN FLLGITANCCHRWSKASEEEEI

**Important features of the protein:****Signal peptide:**

amino acids 1-17

**Transmembrane domain:**

amino acids 241-260

**N-glycosylation sites.**

amino acids 52-55, 81-84, 107-110

**Tyrosine kinase phosphorylation site.**

amino acids 148-154

**N-myristoylation sites.**

amino acids 11-15, 263-268

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 175-185

**Leucine zipper pattern.**

amino acids 77-98

55/550

**FIGURE 55**

GGCTGCGCCCAGGCCGGCGGGCCCCAGCAGCTGCGAACC GCCGGCGCACCCACCTGTTTCCGCGC  
CCGGGGACTTCCCCGGCGGGGCTCAGAAGTGTGGGGTCGGTCGCTTGGCTTCCCCTGGCGTCA  
GCGACCCAGGGTAACCTCCTCCACTGCTGCGTGCCGTGCAGGCCTGCCTGTGTGAGAGCCACG  
TGTGCCGCGCTCTGGGCACAGCCTTGGAAGTCAGGACCGCGACGGCAGCAGAGCAGAAACCT  
TACAGAAACATGAAGCCCTCAACCATCTGCTACTCAGTTATTTCGGGGCTGACGGCGGCTTCTA  
GAACATCCAGGTGTTCTGCAGATGCGAGAACTCATCCTGTAGTCACCAGATGGAGTCCCAAAC  
AGCCAAGCAGATGTAAGGCCTGTGCTGTGGCTCTGAGGCCCTGAATACAGAAGGGTCACTTTC  
TTAGTGGCCAAAGAGCAGTTGTTGACATTGATGTCTAATTATTGAACACGACCAGTCATTTTA  
CTGAGCTGCAGTGAGGAAACACTGACCATAGAAGATCAAGCCAAATGAGGGATTGCAAATTTTC  
CTGATTCTTTTGAATTAGGATTCCAGATGGGGGCCCTCATTTCTACAGCCCCCAACATTCCTAT  
AGCCGTTATCACTGCCATCACCCTGCCACCAGCATCTTCTTGCAGATTCACCCCTGCTCCC  
CAGAGACTTCCTGCTTTGAAAGTGAGCAGAAAGGAAGCTCTCAGAAAAATCTCTAGTGGTGGC  
TGCCGTGCGTCCAGACAATCGGAATCCTGCCTTCACCACCATGGGCTGGCTTTTTCTAAAGGT  
TTTGTGCGGGGAGTGAGTTTCTCAGGATTTCTTTATCCTCTTGTGGATTTTTGCATCAGTGG  
GAAAACAAGAGGACAGAAGCCAAACTTTGTGATTATTTTGGCCGATGACATGGGGTGGGGTGA  
CCTGGGAGCAAACCTGGGCAGAAACAAAGGACACTGCCAACCTTGATAAGATGGCTTCGGAGGG  
AATGAGGTTTGTGGATTTCCATGCAGCTGCCTCCACCTGCTCACCCTCCCGGGCTTCCTTGCT  
CACCGGCCGGCTTGGCCTTCGCAATGGAGTCACACGCAACTTTGCAGTCACTTCTGTGGGAGG  
CCTTCCGCTCAACGAGACCACCTTGGCAGAGGTGCTGCAGCAGGCGGGTTACGTCACTGGGAT  
AATAGGCAAATGGCATCTTGGACACCACGGCTCTTATCACCCCAACTTCCTGTGGTTTTGATTA  
CTACTTTGGAATCCCATATAGCCATGATATGGGCTGTACTGATACTCCAGGCTACAACCACCC  
TCCTTGTCCAGCGTGTCCACAGGGTGATGGACCATCAAGGAACCTTCAAAGAGACTGTTACAC  
TGACGTGGCCCTCCCTCTTTATGAAAACCTCAACATTGTGGAGCAGCCGGTGAACCTGAGCAG  
CCTTGCCCAAGAAGTATGCTGAGAAAGCAACCCAGTTCATCCAGCGTGCAAGCACCAGCGGGAG  
GCCCTTCCTGCTCTATGTGGCTCTGGCCACATGCACGTGCCCTTACCTGTGACTCAGCTACC  
AGCAGCGCCACGGGGCAGAAGCCTGTATGGTGCAGGGCTCTGGGAGATGGACAGTCTGGTGGG  
CCAGATCAAGGACAAAGTTGACCACACAGTGAAGGAAAACACATTCCTCTGGTTTTACAGGAGA  
CAATGGCCCCGTGGGCTCAGAAGTGTGAGCTAGCGGGCAGTGTGGGTCCCTTCACTGGATTTTG  
GCAAACCTCGTCAAGGGGGAAGTCCAGCCAAGCAGACGACCTGGGAAGGAGGGCACCGGGTCCC  
AGCACTGGCTTACTGGCCTGGCAGAGTTCAGTTAATGTCACCAGCACTGCCTTGTTAAGCGT  
GCTGGACATTTTTTCCAACCTGTGGTAGCCCTGGCCCAGGCCAGCTTACCTCAAGGACGGCGCTT  
TGATGGTGTGGACGTCTCCGAGGTGCTCTTTGGCCGGTCACAGCCTGGGCACAGGGTGCTGTT  
CCACCCCAACAGCGGGGCAGCTGGAGAGTTTGGAGCCCTGCAGACTGTCCGCCTGGAGCGTTA  
CAAGGCCTTCTACATTACCGGTGGAGCCAGGGCGTGTGATGGGAGCATGGTGCCTGAGCTGCA  
GCATAAGTTTCTCTGATTTTCAACCTGGAAGACGATAACCGCAGAAGCTGTGCCCTAGAAAG  
AGGTGGTGCGGAGTACCAGGCTGTGCTGCCCAGGTCAGAAAGGTTCTTGCAGACGTCCTCCA  
AGACATTGCCAACGACAACATCTCCAGCGCAGATTACACTCAGGACCCTTCAGTAACTCCCTG  
CTGTAATCCCTACCAAATTGCCTGCCGCTGTCAAGCCGCATTAACAGACCAATTTTTATTCCAC  
GAGGAGGAGTACCTGGAAATTAGGCAAGTTTGCTTCCAAATTTTCATTTTTACCCTCTTTACAA  
ACACACGCTTTAGTTTAGTCTTGAGTTTAGTTTTGGAGTTAGCCTTGCAATATCCCTTCTGTA  
TCCTGTCCCCCTCCACGCCGACCCGAGAGCAGCTGAGCTGCGCTGGCTCTGGGCAGGGAGTG  
TGCCTTAATGGGAAGCACACGGGCTTTGGAGTCAGGCACAGGTGCCAGCTCCAGCTTTTGAAC  
TTGGGCAATTGTTTAACTAACCTGCAAGTTGATTTTGGGGTTAAATAAAGGCATACATGAA  
AATGCCTGGCAACTTTAAAAA

56/550

## FIGURE 56

MGWLFLKVLLAGVSFSGFLYPLVDFCISGKTRGQKPNFV IILADDMGWGDLGANWAETKDTAN  
LDKMASEGMRFVDFHAAASTCSPSRASLLTGRLGLRNGVTRNFAVTSVGGLPLNETTLAEVLQ  
QAGYVTGIIGKWHLGHHGSYHPNFRGFDYYFGIPYSHDMGCTDTPGYNHPPCPACPQGDGPSR  
NLQRDCYTDVALPLYENLNIVEQPVNLSSLAQKYAEKATQFIQRASTSGRPFLLYVALAHMHV  
PLPVTQLPAAPRGRSLYGAGLWEMDSLVGQIKDKVDHTVKENTFLWFTGDNGPWQAQKCELAGS  
VGPFTGFWQTRQGGSPAKQTTWEGGHRVPALAYWPGRVPVNVTSALLSVLDIFPTVVALAQA  
SLPQGRFRFDGVDVSEVLFGRSQPGHRVLFHPNSGAAGEFGALQTVRLERYKAFYITGGARACD  
GSMVPELQHKFPLIFNLEDDTAEAVPLERGGAEYQAVLPEVRKVLADVLQDIANDNISSADYT  
QDPSVTPCCNPYQIACRCQAA

### **Important features of the protein:**

#### **Signal peptide:**

amino acids 1-16

#### **Transmembrane domain:**

amino acids 353-373

#### **N-glycosylation sites.**

amino acids 117-120, 215-218, 356-359, 397-500

#### **N-myristoylation sites.**

amino acids 12-17, 33-38, 52-57, 97-102, 101-106, 113-118, 158-163, 328-333, 388-393, 418-423, 435-440, 436-441

#### **Amidation site.**

amino acids 382-385

#### **Sulfatases signature 2.**

amino acids 129-138

57/550

**FIGURE 57**

TGGACAAGACACCTCCAGGAGCCCAGCTCACAGCCACCGGTACCTTCTTCCAGGACAAGCTGG  
GGGCCTCCATGGGCGCCTGAGGGCCAGGCGCCAGGGCCGTGGGCACGAGT**ATG**GTGAGACACC  
AGCCCCCTGCAGTACTACGAGCCACAGCTGTGCCTCTCCTGCCTCACGGGCATCTACGGCTGCC  
GTTGGAAGCGCTACCAGCGCTCCCATGATGATAACACACCGGGCACAGCGCCATTCTGCATG  
TGGGGGCTGTGGCAGCAGTCACCATGCTCTCCTGGATCGTGGCAGGACAGTTTCGCCCCGTGCAG  
AGCGGACCTCCTCCCAGGTGACCATTCTCTGTACCTTCTTCACCGTGGTGTTCGCCCTCTACC  
TGGCCCCCTCTCACCATCTCCTCTCCCTGCATCATGGAGAAGAAAGACCTCGGCCCCAAGCCTG  
CTCTCATTGGCCACCGCGGGGGCCCCCATGCTGGCTCCAGAGCACACGCTCATGTCTTCCGGA  
AGGCCCTCGAGCAGAAGCTGTACGGGCTCCAGGCTGACATTACCATCAGCCTGGACGGCGTGC  
CCTTCTCATGCATGACACCACCTGCGGCGCACCAACAGTGGAGGAGGAGTTCCCGGAGC  
TGGCCCGCAGGCCTGCCTCCATGCTTAACTGGACCACCCTGCAGAGACTCAACGCTGGCCAGT  
GGTTCCTGAAGACTGACCCCTTCTGGACAGCCAGCTCCCTGTCACCCTCCGACCACAGAGAGG  
CCCAGAACCAGTCCATCTGCAGCCTGGCAGAGCTCCTGGAGCTGGCCAAGGGCAATGCCACAC  
TGCTGCTCAACCTGCGTGACCCGCCCCGGGAGCACCCCTACCGCAGCAGTTTTATCAACGTGA  
CTCTGGAGGCCGTGCTGCACTCCGGCTTCCCCCAGCACAGGTCATGTGGCTGCCTAGCAGGC  
AGAGGCCCTGGTGCAGGAAGGTGGCTCCCGGCTTCCAACAGACATCAGGCTCCAAGGAGGCAG  
TCGCCAGCCTGCGGAGAGGCCACATCCAGCGGCTGAACCTGCGCTACACTCAGGTGTCCCGCC  
AGGAGCTCAGGGACTACGCGTCTTGAACCTGAGTGTGAACCTCTACACAGTCAACGCACCGT  
GGCTCTTCTCCCTGCTGTGGTGTGCGGGGGTCCCATCCGTCACCTCTGACAACTCCACACCC  
TGTCCCAGGTGCCTTCCCCCCTCTGGATCATGCCCCCGGACGAGTACTGTCTCATGTGGGTCA  
CTGCCGACCTGGTCTCCTTCACCCTCATCGTGGGCATCTTCGTGCTCCAGAAGTGGCGCCTGG  
GTGGCATAACGAGCTACAACCCTGAGCAGATCATGCTGAGTGTGCGGTGCGCCGGACAGCC  
GGGACGTCAGCATCATGAAGGAGAAGCTTATTTTCTCAGAGATCAGCGATGGTGTAGAGGTCT  
CCGATGTGCTCTCCGTATGTTTACAGACAACAGTTATGACACATATGCCAACAGCACCGCCACCC  
CTGTGGGCCCCCGAGGGGGTGGCAGCCACACCAAGACCCTCATAGAGCGGAGTGGGCGT**TAG**C  
TGAAGACATGTCTGTCCACCTGTACCTGACACAGAAGCTGGGGAGCCTAGGAGAGCTGGTGG  
AAGTGTGTCTGAACTCGGAGTGCTCTGGGAGCGGGCTCCACAGCCTCCTTGTGGGCTCCAGCC  
CCTTGTGACCGCGAGCCTCTCTTGAGGGGGACTCCCTGTCTCCTGAGGCCAGCTGGGCCAGG  
ACTCCATCCTTTCAGATGCCCCCTGCAGGCCTGGGGCTCCTTCTGGGAAGTATGGGGCCTAGGG  
CTTGGTCCCCCTCTTCTGAGGCCCTCTCCTGTATCCCGACCTGGAAGCTTTGATGGGTATGG  
GCCATGCCATACCCCCTGTGGCAATGGAGTGTGTGGATGCTCACCTGTGCCATCTGTCTCCT  
GTCTGTGCCAGGAGGCACCTGAGTTCTCTGCTGTTATCCTGCCCCAAGGGCCTGGGCCGAGCC  
TCTACCTGAAGCAACTCTGCTCTTCTGTGCTCCTCAAGCACAAAGGAGGTTTACGCCAGGAG  
GAAGCCAGCTGCAATGTGGAGACACGTCTCCTCCCCAACCACCTCATGCCACCGCCAACCC  
CCTGCCCCAGGAGCGGGCCTGAGCCACGTCCCCTAGGAGCAGCTGGAGATGGCCAAAAGAGTG  
AGCTCAGGACTACTGGATCCCATGCCAGGTGTCCAGCAGACCTCAAGGCAGAAGGGTACCT  
AACCCAGGAGTCCACAGACTGATGTGACCTCAGGTTCCACATCAGTGGCCACAGGGCAGGGC  
CCACCTGGTAGAAGTGTCTGGATATGGCCAGGGTGGGTGTGTGGCTAAGTGGGCCTGAACAG  
AGGGAACCTAGGGCCCTTGGCCAATGTGATTAAAGCTGCCATCTTGAAA

58/550

**FIGURE 58**

MVRHQPLQYYEPQLCLSCLTGIYGCRWKRYQRSHDDTTPGTAPFLHVGAVAAVTMLSWIVAGQ  
FARAERTSSQVTILCTFFTUVFALYLAPLTISSPCIMEKKDLGPKPALIGHRGAPMLAPEHTL  
MSFRKALEQKLYGLQADITISLDGVPFLMHDTTLRRTTNVEEEFPELARRPASMLNWTTLQRL  
NAGQWFLKTDPFWTASSLSPSDHREAQNQSICSLAEELLEAKGNATLLNLRDPPREHPYRSS  
FINVTLEAVLHSGFPQHQVMWLP SRQRPLVRKVAPGFQQTSGSKEAVASLRRGHIQRLNLRYT  
QVSRQELRDYASWNLSVNLYTVNAPWLFSLLWCAGVPSVTSDNSHTLSQVPSPLWIMPPDEYC  
LMWVTADLVSFLLIVGIFVLQKWRLGGIRSYNPEQIMLSAAVRRTSRDVSIMKEKLIFSEISD  
GVEVSDVLSVCSDNSYDTYANSTATPVGPRGGGSHTKTLIERSGR

**Important features of the protein:****Signal peptide:**

amino acids 1-24

**Transmembrane domains:**

amino acids 47-61, 77-93, 335-350, 380-399

**N-glycosylation sites.**

amino acids 182-186, 217-221, 233-237, 255-259, 329-333, 462-466

**Tyrosine kinase phosphorylation site.**

amino acids 130-139

**N-myristoylation sites.**

amino acids 21-27, 48-54, 294-300, 404-410, 442-448, 473-479

59/550

**FIGURE 59**

CCTGAGCAAACACAGCAGCCCCGAGTGTTCCTCAAGGCCAAAATGCTGAGAACGTCCACTCCTAA  
TCTGTGTGGTGGTCTGCATTGCCGGGCCCCCTGGCTCTCTTCTGGCATTCTCTGCCTCTGCCT  
CATATTCTTGTTAGGCCAGGTGGGCTTGCTGCAGGGACACCCCCAGTGCCTGGATTACGGGCC  
CCCTTTCCAGCCCCCTCTGCACCTTGAGTTTTGCTCTGACTATGAGTCCTTCGGCTGCTGTGA  
TCAGCACAAGGACCGCCGCATCGCTGCCCGGTACTGGGACATCATGGAATATTTTGATCTGAA  
GAGACATGAGCTGTGTGGAGATTACATTAAAGACATCCTTTGCCAGGAGTGCTCGCCCTACGC  
AGCCACCTCTACGACGCCGAAAACACCCAGACGCCTCTCCGGAATCTCCCGGGCCTCTGCTC  
TGATTACTGCTCTGCCTTCCATTCTAACTGTCACTCAGCCATTTCCCTGCTGACCAATGACCG  
CGGCCTCCAGGAGTCTCATGGAAGGGACGGTACCCGCTTCTGCCACCTCCTGGACCTTCCTGA  
CAAGGACTATTGCTTCCCTAATGTCCTGAGGAACGACTATCTCAACCGCCACCTGGGCATGGT  
GGCCCAAGATCCTCAGGGCTGCCTGCAGCTCTGCCTGAGCGAGGTGGCCAACGGGCTGAGGAA  
CCCCGTCTCCATGGTCCATGCTGGGGACGGCACCCATCGCTTCTTTGTTGCCGAGCAGGTAGG  
AGTGGTGTGGGTCTACCTCCCTGATGGGAGTCGCTGGAGCAACCCCTTCTGGACCTCAAGAA  
CATCGTGTGACCACCCCATGGATCGGGGATGAGAGAGGCTTCTTGGGGTGGCTTTTACCCC  
CAAATTCCGCCACAATCGCAAGTTCTATATTTATTATTTCGTGCCTGGACAAGAAGAAGGTAGA  
AAAGATCCGAATTAGTGAGATGAAGGTTTCTCGGGCTGATCCTAACAAAGCTGACCTGAAATC  
AGAGAGGGTCATCTTGGAGATTGAAGAACCAGCCTCAAACCATAATGGCGGACAACCTTCTTTT  
TGGCCTGGATGGCTATATGTACATATTTACTGGGGACGGGGGACAGGCTGGAGATCCCTTTGG  
CCTGTTTGGAAATGCTCAGAACAAAAGTTCCCTGCTGGGAAAAGTTTTAAGGATCGATGTGAA  
CAGGGCAGGCTCACATGGCAAGCGGTACCGAGTCCCCTCGGACAATCCATTTGTTTCTGAGCC  
AGGGGCCCCACCCCGCCATCTATGCCTATGGGATCAGGAACATGTGGCGTTGTGCTGTGGACCG  
AGGGGACCCCATCACGCGCCAGGGCCGAGGCCGGATATTCTGTGGGGACGTGGGGCCAGAACAG  
GTTTGAAGAGGTTGACCTCATTTTGAAGGTGGAAACTATGGCTGGAGAGCAAAGGAAGGGTT  
TGCATGTTATGACAAAAAACTTTGTACAAATGCCTCTTTGGATGATGTTCTGCCAATCTATGC  
TTATGGCCATGCAGTGGGGAAGTCAGTCACTGGAGGTTATGTCTATCGTGGTTGTGAATCCCC  
AAATCTCAATGGCCTGTATATCTTTGGAGACTTCATGAGTGGTCGACTTATGGCTTTGCAGGA  
AGATAGAAAAAACAAGAAATGGAAGAAGCAGGATCTTTGCCTGGGCAGCACCACGTCCTGTGC  
CTTCCCAGGGCTGATCAGCACCCATAGCAAGTTCATCATCTCCTTTGCTGAAGATGAAGCAGG  
GGAGCTGTATTTCTTGGCGACCTCTTACCCAAGTGCCTATGCACCACGTGGATCTATTTACAA  
GTTTGTGACCCTCAAGGCGAGCACCCCCAGGCAAGTGCAAATACAAGCCAGTGCCCGTGAG  
AACCAAGAGTAAGCGGATCCCGTTCAGACCACTCGCCAAGACAGTCTTGGACTTGCTAAAGGA  
ACAATCAGAGAAAGCTGCTAGAAAATCTTCCAGTGCAACCTTAGCTTCTGGCCCAGCCCAGGG  
TTTGTCTGAGAAAGGCTCCTCCAAGAAGCTGGCTTCTCCTACAAGCAGCAAGAATACATTGCG  
AGGGCCTGGTACAAAGAAGAAAGCCAGAGTGGGGCCCCACGTCCGCCAGGGCAAGAGGAGGAA  
GAGCCTGAAAAGCCACAGTGGCAGGATGAGGCCATCAGCAGAGCAGAAGCGAGCTGGCAGAAG  
TCTCCCTTGACCTATTGGTCAAGGTGGCCGACAGGGTGACGTGAGAGAGGAGAGCCACCTCAT  
CAAATGAAAGTCACTGCTGAATAAAGACCTTAGAAGTCTGGGAAGCCAGGGTAGAGGTGGGGC  
AGGGCGGTTTTCTCTCCCTGGGAAATCTTGCTGTCTACTGAATAAATAAATGCACCTTCTCT  
GTATGCAGTGCTTCTGTGGGAGACCATATCCCAGATTGCTGGTGCACCTGGGTTATGGTAAGC  
ACTAGTCCATGAGCCTGCTTGAATCACACTGGATGTCTCCGTTTTGTCTTGTAATGCCTAC  
AACCTGAGGTAATAAATCAACATTTGCTCA

60/550

**FIGURE 60**

MLRTSTPNLCGGLHCRAPWLSSGILCLCLIFLLGQVGLLQGHPQCLDYGPPFQPPLHLEFCSD  
 YESFGCCDQHKDRRIAARYWDIMEYFDLKRHELCDYIKDILCQECSPYAAHLYDAENTQTPL  
 RNLPGLCSDYCSAFHSNCHSAISLLTNDRGLQESHGRDGTFRFCHLLDLDPKDYCFPNVLRNDY  
 LNRHLGMVAQDPQGCLQLCLSEVANGLRNPVSMVHAGDGTHRFFVAEQVGVVWVYLPDGSRL  
 QPFLDLKNIVLTTPWIGDERGFLGLAFHPKFRHNRKFYIYYSCLDKKKVEKIRISEMKVSRAD  
 PNKADLKSERVILEIEEPASNHNGGQLLFGLDGYMYIFTGDGGQAGDPFGLFGNAQNKSSLLG  
 KVLRIDVNRAGSHGKRYRVPSDNPFVSEPGAHPAIYAYGIRNMWRCVDRGDPITRQGRGRIF  
 CGDVGQNRFEVDLILKGGNYGWRAKEGFACYDKKLCHNASLDDVLPIYAYGHAVGKSVTGGY  
 VYRGCESPNLNGLYIFGDFMSGRLMALQEDRKNKKWKKQDLCLGSTTSCAFPGLISTHSKFII  
 SFAEDEAGELYFLATSYPSAYAPRGSYKFVDPSRRAPP GKCKYKVPVVRTKSKRIPFRPLAK  
 TVLDLLKEQSEKAARKSSSATLASGPAQGLSEKGSKKLASPTSSKNTLRGPGTKKKARVGPH  
 VRQ GKRRKSLKSHSGMRPSAEQKRAGRSLP

**Important features of the protein:****Signal peptide:**

amino acids 1-41

**Transmembrane domain:**

amino acids 17-36

**N-glycosylation sites.**

amino acids 372-376, 480-484

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 645-649, 699-703

**Tyrosine kinase phosphorylation site.**

amino acids 81-89

**N-myristoylation sites.**amino acids 11-17, 37-43, 156-162, 165-171, 357-363, 365-371,  
368-374, 408-414, 459-465, 548-554, 557-563**Amidation sites.**

amino acids 391-395, 696-700

**Cell attachment sequence.**

amino acids 428-431

**Leucine zipper pattern.**

amino acids 25-47

61/550

**FIGURE 61**

CTCCATTAAACCACCACCAGCTCCCCAAGCCACCCCTTCAGCCATGAAGTTCCTGCTCCTGGT  
CTTGGCAGCCCTCGGATTCCTGACCCAGGTGATCCCAGCCAGTGCAGGTGGGTCAAATGTGT  
GAGTAACACCCCAGGATACTGCAGGACATGTTGCCACTGGGGGGAGACAGCATTGTTTCATGTG  
CAACGCTTCCAGAAAATGCTGCATCAGCTACTCCTTCCTGCCGAAGCCTGACCTACCACAGCT  
CATCGGTAACCACTGGCAATCAAGGAGAAGAAACACACAAAGGAAAGACAAGAAGCAACAAAC  
GACCGTAACATCATAATAACCACTGCTATCGCCTCCACCAACTCAGAGAAATATCATTTCCAC  
AGTTCCAATTCCTCCTACATTGCTGAGTACTAGCCAAGGCTCCTCTTTATGGGGCAGATATCT  
ATAGCCAACCCCAAACCTTCTGTCTTCTATCATTCTGTCATTCATCTAGTAACTAATTTGGAG  
TTTGTATCTATCTTACGAGAACAATCATCATGCAGATTCGTCCACAGGGGATCTGTCAGTTTG  
GGTCTCCAAATGAAAAATGTCAAGACAGAATTGGACATGCAAAGATTGACTGGGAGAACAC  
ACCTCTGATGGACAAAGGTGAGACAGAGCAGCCACAGGCAGGGAGAGCCTTCAGACTGCAACG  
CTGGCCTGATACGTGTCAAAGGAGAGAGGGATAGAGGAGGATTGAATAGAAGGAGACTAAGAC  
TGCAGCTCTAAGAAAGTCTCAGCCAAACAGATGGGGAGGCCCAAAGCAAGGCTTGCCCCTCAG  
AGGAGCTCACGCAGGGCAGGAATAGCCAGGTTCTCATATCCCAGGGGTTTCAGACTTGGCTGAG  
AACAGCCCCCTGGAGAACATGGGGTGACTGCTACCATAGGTCTGGAAGTATGAGGCTGTCCACC  
AACTATCCCCTTGAAGCAAGTTCTCTTGAAAGGAAATCTAAACAGTGCACCCCCATGGCTGCC  
ACGGAGTATAAGGAGGGAGAGAAAGGAGCTGAAAGTCTAGGTTTGGCCAGCTAGGTAGACTGA  
CTTGTGAGGTATTTATTTATTCATTTGAGTAACAAAGCAGACAGAATACATAGCCACCATTGG  
TAGTACACCCCAAAGCAAGGATGGCATGATGCTGGTGACTCAAACGTGCCTACTCATGGTGT  
CAAATTGGCATAATCCTCTTGGAAGCTGTGTGGAAATAAGCACAGAGAAGCAGAACTCTAAT  
TGCTTAATCCACTAAACATTACTTCTGGGAATTGGCTCATCATAAATTATCCAAGAGAAAGCA  
CAAAGTTATGGGCACAAAGGTTTTCCATATAATATTATTTAAATGCTGAGAAAATGAAAAAA  
TCTAAATGGTGAAATATATACTAATGCCATCTATAAATACAAACAAATAGAATGTTTATAGAA  
TAATGGAACATAATAACATTATTCAAATTCATTTATGCTATAGTTGTCAAATTTGTCTCCT  
TATATGATACAAAACCTCATGAAAATTATGACTTTTTTTGTTTGGTTGGAAAGCAGAATTATGCA  
TAAATTTCTCTTACAGTTCGATGCCCATTAGTTTTATATAACATTTATTTGACACGTAAGTGA  
CTTCTATCTGAGAAGAACAACCAAAACACTCAGGCCTAAATAATTAAAAACGGTCCTAAAAA  
CTAGCAAACCAGATAAGAAAAGATGTTAATGCCCATTCCCTAACTTATGTCTTAGACCAAAAT  
TAATTCATAGATGGTTTTTAAATGACAGTGTAAGTAAAGTATTAAAGATTGTGTGGTCAAA  
TATTCAATTTAAGAGCAAGGAAATTCTTATAAATATAACAATAGAGGCAGAACTCATGTAAGA  
ATAAATTGATTAGGTGGTATTAAATATTAAGTTCTTATGTATGTCAAAGATATCATTTTGAA  
ATTCATCCATCTTATTGGGTATTGCAGGAGTTCATTCCTTTTTGTTTATAAATACTCTTCCGT  
CATATGAATAGTATTCATTTGTATACTGGTTTGTGATGGACATTTGGGTGTGTTCCAGTTTA  
TGGCTATTACAAATAAAGCTTCTATGAACATTTATGTACA



62/550

**FIGURE 62**

MKFLLLVLAALGFLTQVIPASAGGSKCVSNTPGYCRTCCHWGETALFMCNASRKCCISYSFLP  
KPDLPQLIGNHWQSRRRNTQRKDKKQQTTVTS

**Important features of the protein:****Signal peptide:**

amino acids 1-16

**Transmembrane domain:**

amino acids 1-22

**N-glycosylation site.**

amino acids 50-53

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 79-82

**N-myristoylation site.**

amino acids 23-28

63/550

**FIGURE 63**

GCGGAGCGCCTGGGAGAGGAGAAGGAGCCGACCTGCCGAGATGGAGGCGACCGGCACCTGGGC  
GCTGCTGCTGGCGCTGGCGCTGCTCCTGCTGCTGACGCTGGCGCTGTCCGGGACCAGGGCCCCG  
AGGCCACCTGCCCCCGGGCCCCACGCCGCTACCACTGCTGGGAAACCTCCTGCAGCTACGGCC  
CGGGGCGCTGTATTACAGGGCTCATGCGGCTGAGTAAGAAGTACGGACCGGTGTTACCATCTA  
CCTGGGACCCTGGCGGCCCTGTGGTGGTCCTGGTTGGGCAGGAGGCTGTGCGGGAGGCCCTGGG  
AGGTCAGGCTGAGGAGTTCAGCGGCCGGGGAACCGTAGCGATGCTGGAAGGGACTTTTGATGG  
CCATGGGGTTTTCTTCTCCAACGGGGAGCGGTGGAGGCAGCTGAGGAAGTTTACCATGCTTGC  
TCTGCGGGACCTGGGCATGGGGAAGCGAGAAGGCGAGGAGCTGATCCAGGCGGAGGCCCGGTG  
TCTGGTGGAGACATTCCAGGGGACAGAAGGACGCCCATTCGATCCCTCCCTGCTGCTGGCCCA  
GGCCACCTCCAACGTAGTCTGCTCCCTCCTCTTTGGCCTCCGCTTCTCCTATGAGGATAAGGA  
GTTCCAGGCCGTGGTCCGGGCAGCTGGTGGTACCCTGCTGGGAGTCAGCTCCAGGGGGGTCA  
GACCTACGAGATGTTCTCCTGGTTCCCTGCGGCCCTGCCAGGCCCCACAAGCAGCTCCTCCA  
CCACGTCAGCACCTTGGCTGCCTTCACAGTCCGGCAGGTGCAGCAGCACCAGGGGAACCTGGA  
TGCTTCGGGCCCCGCACGTGACCTTGTGATGCCTTCCTGCTGAAGATGGCACAGGAGGAACA  
AAACCCAGGCACAGAATTCACCAACAAGAACATGCTGATGACAGTCATTTATTTGCTGTTTGC  
TGGGACGATGACGGTCAGCACACCGGTGCGCTATAACCTCCTGCTCCTGATGAAATACCCTCA  
TGTCCAAAAGTGGGTACGTGAGGAGCTGAATCGGGAGCTGGGGGCTGGCCAGGCACCAAGCCT  
AGGGGACCGTACCCGCTCCCTTACACCGACGCGGTTCTGCATGAGGCGCAGCGGCTGCTGGC  
GCTGGTGGCCATGGGAATAACCCGACCCCTCATGCGGACCACCCGCTTCCGAGGGTACACCT  
GCCCCAGGGCACGGAGGTCTTCCCCCTCCTTGGCTCCATCCTGCATGACCCCAACATCTTCAA  
GCACCCAGAAGAGTTCAACCCAGACCGTTTCCTGGATGCAGATGGACGGTTCAGGAAGCATGA  
GGCGTTCTGCCCCTTCTCCTTAGGGAAGCGTGTCTGCCTTGGAGAGGGCCTGGCAAAAGCGGA  
GCTCTTCTCTTCTTACCACCATCCTACAAGCCTTCTCCCTGGAGAGCCCGTGCCCGCCGGA  
CACCTGAGCCTCAAGCCCACCGTCAGTGGCCTTTTCAACATTCCCCCAGCCTTCCAGCTGCA  
AGTCCGTCCCACTGACCTTCACTCCACCACGCAGACCAGATGAAGGAAGGCAACTTGGAAGTG  
GTGGGTGCCCAGGACGGTGCCTCCAGCCTCAACAGTGGGCATGGACAGGGTTAATGTCTCCAG  
AGTGTACACTGCAGGCAGCCACATTTACACGCCTGCAGTTGTTTTCCGGAGTCTGTCCACGG  
CCCACACGCTCACTTGACTCATGCTGCTAAGATGCACAACCGCACACCCATACACAACCTACAA  
GGGCCACAAAGCAACTGCTGGGTTAGCTTTCCACAGACATAAATATAGTCCATCTGCAATCAC  
AAGCACATAGCCAGGTAACCCACCAACTCCCCTGGATCTGCAGCCCACACGTGGGAGTCTGGC  
TGTCACCTTCACAAGCCACAGAAACGGCCACACATGTTACAGCTCACACGCCCTCTCCATTC  
ATCGAACTTCTCAGTGTCCCTGTCCCTGGTGCCTGGCACAGGGAACAGCATGCCCCCTCCGGG  
GTCATGCCACCCAGAGACTGTGCTGTCTATGGCCCCAACTCATGCTCCCTCTCTTGGCTACA  
CCACTCTCCCAGCCTGTGACCACCGATGTCCACACACCCCCAACCACTTGTCCACACAGCTAC  
CCACGTACAACATCGTCCTGGCTCCCCAGAGTATCTTCCCACTGAGACACGCGCCCCCACAG  
AGGCACAGTCCCCAGCCACCTCTGCAACTGCAGCCCTCAGTCACCCCTTTTTAAGCACCCCTGA  
TTCTACCAAATGCAAACACATCTGGGTCTGCGATTATGCACAGAGACTTTGGACATACGAGGA  
CCCTCAGACCGGAGGAACACCTGCCCAACCCCAACACGTGCTTATGTAACCACGTGGAAAGCG  
GCCCCTGCTGCCCCCTCCACACACACATAACACTCACTGATCTACAGCCCCTGTTCCGGCGTCA  
GAGTCCCCACTAGACCCAGTGGAAGGGGTAGAGACCAAGTAGGGGCCAGTTTCCAATTACC  
CTGTCAGGGAGTGAGCCGGATCTGACGTTCTTGTGACTTAAGGGTCCGGCTTGGGAATTAA  
GTTTGTCTTCTGGCCTTTAGCCTAAAAA

64/550

**FIGURE 64**

MEATGTWALLLALALLLLTLALS GTRARGHLPPGPTPLPLLGNLLQLRPGALYSGLMRLSKK  
YGPVFTIYLGPWRPVVVLVGQEA VREALGGQAE EFSGRGT VAMLEGTFDGHGVFFSNGERWRQ  
LRKFTMLALRDLGMGKREGEELIQAEARCLVET FQGTEGRPFDP SLLLAQATSNVVC SLLFGL  
RFSYEDKEFQAVVRAAGGTLLGVSSQGGQTYEMFSWFLRPLPGPHKQLLHHVSTLAAFTVRQV  
QQHQGNLDASGPARDLVDAFLLKMAQEEQNPGTEFTNKNMLMTVIYLLFAGTMTVSTTVGYTL  
LLMKYPHVQKWVREELNRELGAGQAPSLGDRTL PYTDAVLHEAQRLLALVPMGIPRTL MRT  
TRFRGYTL PQGTEVFPLLGSILHDPNIFKHPEEFNPDRFLDADGRFRKHEAFLPFSLGKRVCL  
GEGLA KAE LFLFFTILQAFSLES PCPPDTLSLKPTVSGLFNIPPAFQLQVRPTDLHSTTQTR

**Important features of the protein:****Signal peptide:**

amino acids 1-28

**Transmembrane domain:**

amino acids 294-313

**Glycosaminoglycan attachment site.**

amino acids 99-103

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 128-132

**N-myristoylation sites.**amino acids 51-57, 109-115, 115-121, 188-194, 207-213, 257-263,  
284-290, 339-345, 370-376, 444-450**Amidation sites.**

amino acids 140-144, 435-439

**Leucine zipper pattern.**

amino acids 32-54, 39-61

**Cytochrome P450 cysteine heme-iron ligand signature.**

amino acids 433-443

65/550

**FIGURE 65**

CGGACGCGTGGGGCCGT**ATG**CGCGGCTCTGTGGAGTGCACCTGGGGTTGGGGGCACTGTGCCC  
CCAGCCCCCTGCTCCTTTGGACTCTACTTCTGTTTGCAGCCCCATTTGGCCTGCTGGGGGAGA  
AGACCCGCCAGGTGTCTCTGGAGGTCATCCCTAACTGGCTGGGCCCCCTGCAGAACCTGCTTC  
ATATACGGGCAGTGGGCACCAATTCCACACTGCACTATGTGTGGAGCAGCCTGGGGCCTCTGG  
CAGTGGTAATGGTGGCCACCAACACCCCCACAGCACCTGAGCATCAACTGGAGCCTCCTGC  
TATCCCCTGAGCCCGATGGGGGCCTGATGGTGTCTCCCTAAGGACAGCATTCAAGTTTCTTCTG  
CCCTTGTTTTTACCAGGCTGCTTGAGTTTGACAGCACCAACGTGTCCGATACGGCAGCAAAGC  
CTTTGGGAAGACCATATCCTCCATACTCCTTGCCCGATTTCTCTTGGAACAACATCACTGATT  
CATTGGATCCTGCCACCCTGAGTGCCACATTTCAAGGCCACCCCATGAACGACCCTACCAGGA  
CTTTTGCCAATGGCAGCCTGGCCTTCAGGGTCCAGGCCTTTTCCAGGTCCAGCCGACCAGCCC  
AACCCCTCGCCTCCTGCACACAGCAGACACCTGTCAGCTAGAGGTGGCCCTGATTGGAGCCT  
CTCCCCGGGGAAACCGTTCCCTGTTTGGGCTGGAGGTAGCCACATTGGGCCAGGGCCCTGACT  
GCCCTCAATGCAGGAGCAGCACTCCATCGACGATGAATATGCACCGGCCGTCTTCCAGTTGG  
ACCAGCTACTGTGGGGCTCCCTCCCATCAGGCTTTGCACAGTGGCGACCAGTGGCTTACTCCC  
AGAAGCCGGGGGGCCGAGAATCAGCCCTGCCCTGCCAAGCTTCCCTCTTCATCCTGCCTTAG  
CATACTCTCTTCCCCAGTCACCCATTGTCCGAGCCTTCTTTGGGTCCCAGAATAACTTCTGTG  
CCTTCAATCTGACGTTTCGGGGCTTCCACAGGCCCTGGCTATTGGGACCAACACTACCTCAGCT  
GGTCGATGCTCCTGGGTGTGGGCTTCCCTCCAGTGGACGGCTTGTCCCCACTAGTCCTGGGCA  
TCATGGCAGTGGCCCTGGGTGCCCCAGGGCTCATGCTGCTAGGGGGCGGCTTGGTTCTGCTGC  
TGCACCACAAGAAGTACTCAGAGTACCAGTCCATAAAT**TAA**GGCCCGCTCTCTGGAGGGAAGG  
ACATTACTGAACCTGTCTTGCTGTGCCTCGAACTCTGGAGGTGGAGCATCAAGTTCCAGCC  
GGCCCCCTTCACTCCCCCATCTTGCTTTTCTGTGGAACCTCAGAGGCCAGCCTCGACTTCCTGG  
AGACCCCCAGGTGGGGCTTCCCTCATACTTTGTTGGGGGACTTTGGAGGCGGGCAGGGGACAG  
GGCTATTGATAAGGTCCCCTTGGTGTGCTTCTTGCACTCTCCACACATTTCCCTTGGATGGG  
ACTTGACAGGCCTAAATGAGAGGCATTCTGACTGGTGGCTGCCCTGGAAGGCAAGAAAATAGA  
TTTATTTTTTTTCACAGGGAAAAAAAAAAAA

66/550

**FIGURE 66**

MRGSVECTWGWGHCAPSPLLLWTL LLLFAAPFGLLG EKTRQVSLEVIPNWLGPLQNL LHIRAVG  
TNSTLHYVWSSLGPLAVVMVATNTPHSTLSINWSLLLSPEPDGGLMVL PKDSIQFSSALVFTR  
LLEFDSTNVSDTA AKPLGRPYPPYSLADFSWNNITDSLDPATLSATFQGH PMNDPTRTFANGS  
LAFRVQAFSRSSRPAQPPRLLHTADTCQLEVALIGASPRGNRSLFGLEVATLGQGPDCPSMQE  
QHSIDDEYAPAVFQLDQLLWGS LPSGFAQWRPVAYSQKPGGRESALPCQASPLHPALAYSLPQ  
SPIVRAFFGSQNNFCAFNLTFGASTGPGYWDQHYLSWSMLLG VGFPPVDGLSPLVLGIMAVAL  
GAPGLMLLGGLVLLLHHKKYSEYQSIN

**N-glycosylation sites:**

amino acids 65-69, 95-99, 134-138, 159-163, 187-191, 230-234,  
333-337

**cAMP- and cGMP-dependent protein kinase phosphorylation site:**

amino acids 397-401

**Casein kinase II phosphorylation sites:**

amino acids 151-155, 249-253, 255-259

**N-myristoylation sites:**

amino acids 3-9, 63-69, 235-241, 273-279, 292-298, 324-330

**Leucine zipper pattern.**

amino acids 371-393

FIGURE 67

BNSDOCID: <WO 0140466A2 | >

68/550

**FIGURE 68**

MFPLRALWLWVALLGVAGSCPEPCACVDKYAHQFADCAKELREVPEGLPANVTTLSSLSANKI  
TVLRRGAFADVTQVTSWLAHNEVRTVEPGALAVLSQLKNLDLSHNFISSFPWSDLRNLSALQ  
LLKMNHNRLGSLPRDALGALPDLRSLRINNRLRTLAPGTFDALSALSHLQLYHNPFHCGCGL  
VWLQAWAASTRVSLPEPDSIACASPPALQGVVYRLPALPCAPPSVHLSAEPPELEAPGTPLRA  
GLAFVLHCIADGHPTPRLQWQLQIPGGTVVLEPPVLSGEDDGVGAEEGEGEGDGDLLTQTQAAQ  
TPTPAPAWPAPPATPRFLALANGSLLVPLLSAKEAGVYTCRAHNELGANSTSIKVAVAATGPP  
KHAPGAGGEPDGQAPTSEKSTAKGRGNSVLPSKPEGKIKGQGLAKVSILGETETEPEDTSE  
GEEAEDQILADPAEEQRCGNGDPSRYVSNHAFNQSAELKPHVFELGVIALDVAEREARVQLTP  
LAARWGPGPGGAGGAPRPGRRPLRLLYLCPAGGGAHVQWSRVEEGVNAYWFRGLRPGTNYSVC  
LALAGEACHVQVVFSTKKELPSLLVIVAVSVFLLVLATVPLLGAACCHLLAKHPGKPYRLILR  
PQAPDPMEKRIAADFDPRASYLESEKSY PAGGEAGGEEPEDVQGEGLDEDAEQGDPSGDLQRE  
ESLAACSLVESQSKANQEEFEAGSEYSRRLPLGAEAVNIAQEINGNYRQTAG

**Important features of the protein:****Signal peptide:**

amino acids 1-19

**Transmembrane domain:**

amino acids 587-610

**N-glycosylation sites.**

amino acids 52-55, 121-124, 337-340, 364-367, 474-477, 563-566

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 397-400

**Casein kinase II phosphorylation sites.**amino acids 19-23, 202-205, 289-292, 246-249, 411-414, 431-434,  
433-436, 440-443, 544-547, 583-586, 650-653, 700-703**N-myristoylation sites.**amino acids 15-20, 48-53, 165-170, 296-301, 351-356, 362-367,  
390-395, 419-424, 514-519, 536-541, 557-562, 561-566, 610-615,  
661-666, 716-721**Amidation site.**

amino acids 522-525

**Prokaryotic membrane lipoprotein lipid attachment sites.**

amino acids 10-20, 603-613

69/550

**FIGURE 69**

GGCGGCGGGAGCAGCGAAGGGGGCGGCAGGGATCCTCCAGGCTGCCGGCTGGGAAGGCGTGGG  
CGACCCGGTGTGTGGCGCGCCCAGAGCCCCGCGTTCAGCCCTAGGGAAGGAAGCCAGTTGAG  
GGAAGTTCTCCATGAATGTACGTCACAATGATGATGACCGACCAAATCCCTCTGGAAGTGGCA  
CCATTGCTGAACGGAGAGGTAGCCATGATGCCCCACTTGGTGAATGGAGATGCAGCTCAGCAT  
GTTATTCTCGTTCAAGTTAATCCAGGTGAGACTTTCACAATAAGAGCAGAGGATGGAACACTT  
CAGTGCATTCAAGGACCTGCTGAAGTTCCCATGATGTCACCCAATGGATCCATTCTCCCAT  
CATGTGCCTCCAGGTTATATCTCACAGGTGATTGAAGATAGTACTGGAGTCCGCCGGGTGGTG  
GTCACACCCCCAGTCTCCTGAGTGTTATCCCCCAAGCTACCCCTCAGCCATGTCTCCAACCCAT  
CATCTCCCTCCCTATCTGACTCACCATCCACATTTTTATTTCATAACTCACACACGGCTTACTAC  
CCACCTGTTACCGGACCTGGAGATATGCCGCTCAGTTTTTTCCCCAGCATCATCTTCCCCAC  
ACAATATATGGTGAGCAAGAAATTATACCATTTTTATGGAATGTCAAGCTACATCACCCGAGAA  
GACCAGTACAGCAAGCCTCCGCACAAAAAACTGAAAGACCGCCAGATCGATCGCCAGAACCGC  
CTCAACAGCCCTCCTTCTTCTATCTACAAAAGCAGCTGCACAACAGTATACAATGGCTATGGG  
AAGGGCCATAGTGGTGGAAGTGGCGGAGGCGGCAGCGGTAGTGGTCCCGGAATTAAGAAAACA  
GAGCGACGAGCAAGAAGCAGCCCAAAGTCGAATGATTGAGACTTGCAAGAATATGAGTTGGAA  
GTAAAGAGGGTGCAAGACATTCTTTCGGGAATAGAGAAACCACAGGTTTCTAATATTCAGGCA  
AGAGCAGTTGTGTTGTCCTGGGCTCCCCCTGTTGGACTTTCCTGTGGACCCACAGTGGTCTT  
TCCTTCCCCCTACAGTTACGAGGTGGCCTTATCAGACAAAGGACGAGATGGAAAATACAAGATA  
ATTTACAGTGGAGAAGAATTAGAATGTAACCTGAAAGATCTTAGACCAGCAACAGATTATCAT  
GTGAGGGTGTATGCCATGTACAATTCCGTAAAGGGATCCTGCTCCGAGCCTGTTAGCTTCACC  
ACCCACAGCTGTGCACCCGAGTGTCTTTCCCCCTAAGCTGGCACATAGGAGCAAAAGTTCA  
CTAACCCCTGCAGTGGAAAGGCACCAATTGACAACGGTTCAAAAATCACCAACTACCTTTTAGAG  
TGGGATGAGGGAAAAAGAAATAGTGGTTTCAGACAGTGCTTCTTCGGGAGCCAGAAGCACTGC  
AAGTTGACAAAGCTTTGTCCGGCAATGGGGTACACATTCAGGCTGGCCGCTCGAAACGACATT  
GGCACCAGTGGTTATAGCCAAGAGGTGGTGTGCTACACATTAGGAAATATCCCTCAGATGCCT  
TCTGCACCAAGGCTGGTTCGAGCTGGCATCACATGGGTCACGTTGCAGTGGAGTAAGCCAGAA  
GGCTGTTACCCCGAGGAAGTGATCACCTACACCTTGGAATTCAGGAGGATGAAAATGATAAC  
CTTTTCCACCCAAAATACACTGGAGAGGATTTAACCTGTACTGTGAAAAATCTCAAAAGAAGC  
ACACAGTATAAATTCAGGCTGACTGCTTCTAATACGGAAGGAAAAAGCTGTCCAAGCGAAGTT  
CTTGTTTGTACGACGAGTCCTGACAGGCCTGGACCTCCTACCAGACCGCTTGTCAAAGGCCCA  
GTTACATCTCATGGCTTTAGTGTCAAATGGGATCCCCCTAAGGACAATGGTGGTTCAGAAATC  
CTCAAGTACTTGCTAGAGATTACTGATGGAAATCTGAAGGTGAAGTTTTTGGCAATTGTTTT  
ATTCAAATCCAAATAGCAAGCTCTGTTTTCTAATATAGTAAATGTCTTTATAGTAATAGTGAGT  
AATCATTAATTCTAAAGATAGAATTATTATTACAATAAACAACTTTAGTCACATATTGGCAG  
TTTTTCTATTTCAAACACAGCACCAGAGATCAGAGTCTACTTGAAACTTACATTTGTGTTATT  
TAACAATTTTTCTGTATCTTTTTTCATTGGTGTGTTTGTGTTTGTGTTATCTTTGTTTTTGTCT  
TTGGTTTTGGTTTTGTTTTGTTTTGTTTTGAGATACGATCTCTGTCACACAGGCTGGAGGGC  
AGTGGCACAGACATGGCCCATTCAGTCTCAGACTCCTGGGCTTAAGTGAAGTCTTCTGCCACA  
GAAGATGAGGAAGAATACATTTTTTCATAGTGATGGGGTCTCACTATGTTATCTAGGCTGGTCT  
CAAACCTCCTGGCCTCAAGCAACCCCTCCACCTTGGCCTCCCAAAGTGCTGGGACTATAGACATG  
AATCACCACTCAGCTTCCATGTCTTTTTATGAACTAGGGTTCCTAATTAATCAGATAAATT  
TGGTATTTTCATCTCCTAACTTGCCATATGTTTTCTGGAAATTCCTTATAAGCAGCCGAGAGTG  
GTGGCTCACGCTGTAGTCCCAGCACTTTGGGAGGCTGAGGTGGGTGGTCAGGAGATCAAGACC  
ATCCTGGCCAACATGGTGAAACCCCGTCTCTACTAAAAATACAAAAATTAGCTGGGTGTGGTG  
GCAGGCACCTGTAGTCCCAGCTACTTGGGAGGCTGAGGCAGAAGAATTGCTTGAACCCAGCAG  
GCGGAGGTGTCAGTGAGCTGAGATTGCACCACTGCACTCCAGCCTGGTGACAGAGTGAGACTC  
TGTCTCAAAAAAAAAAAAA



70/550

**FIGURE 70**

MMMTDQI PLELPPLLNGEVAMMPHLVNGDAAQHVILVQVNPGETFTIRAEDGTLOCIQGPAEV  
PMMSPNGSIPPIHVPPGYISQVIEDSTGVRRVVVTPQSPECYPPSYPSAMSPTHHLPPYLTHH  
PHFIHNSHTAYYPPVTGPGDMPPQFFPQHHLPHHTIYGEQEIIIPFYGMSSYITREDQYSKPPHK  
KLKDRQIDRQNRNLNSPPSSIIYKSSCTTVYNGYKGKHSGGSGGGSGSGPGIKKTERRARSSPK  
SNDSDLQEYELEVKRVQDILSGIEKPQVSNIQARAVVLSWAPPVGLSCGPHSGLSFPYSYEVA  
LSDKGRDGKYKIIYSGEELEC NLKDLRPATDYHVRVYAMYSVKGSCSEPVSFTHHSCAPECP  
FPPKLAHRSSKSSLTLQWKAPIDNGSKITNYLLEWDEGKRNSGFRQCFFGSQKHCKLTKLCPAM  
GYTFRLAARN DIGTSGYSQEVVCYTLGNIPQMPSAPRLVRAGITWVTLQWSKPEGCSPEEVIT  
YTLEIQEDENDNL FHPKYTGEDLTCTVKNLKRSTQYKFRLTASNTEGKSCPSEVLVCTTSPDR  
PGPPTRPLVKGPVTSHGFSVKWDPPKDNGGSEILKYLLEITDGNSEGEVFGNCFIQIQ

**Important features of the protein:****N-glycosylation sites.**

amino acids 69-73, 254-258, 401-405

**Glycosaminoglycan attachment sites.**

amino acids 229-233, 234-238, 236-240

**cAMP- and cGMP-dependent protein kinase phosphorylation sites.**

amino acids 416-420, 535-539

**Tyrosine kinase phosphorylation site.**

amino acids 319-326

**N-myristoylation sites.**amino acids 52-58, 227-233, 228-234, 230-236, 231-237, 232-238,  
235-241, 239-245, 402-408, 610-616**Amidation site.**

amino acids 414-418

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 290-301

**ATP/GTP-binding site motif A (P-loop).**

amino acids 546-554

**CUB domain proteins profile.**

amino acids 294-301

71/550

**FIGURE 71**

AAGTCATT CAGTGGATGTGATCTTGGCTCACAGGGGACGATGTC AAGCTCTTCCTGGCTCCTTCTCAGCCTTGTT  
GCTGTAAGTCTGCTCAGTCCACCATTGAGGAACAGGCCAAGACATTTTTGGACAAGTTTAAACCACGAAGCCGAA  
GACCTGTTCTATCAAAGTTCACTTGCTTCTTGGAATTATAACACCAATATTACTGAAGAGAATGTCCAAAACATG  
AATAATGCTGGGGACAAATGGTCTGCCTTTTAAAGGAACAGTCCACACTTGCCCAAATGTATCCACTACAAGAA  
ATTCAGAATCTCACAGTCAAGCTTCAGCTGCAGGCTCTTCAGCAAAAATGGGTCTTCAGTGTCTCAGAAGACAAG  
AGCAAACGGTTGAACACAATTCTAAATACAATGAGCACCATCTACAGTACTGGAAAAGTTTGTAAACCCAGATAAT  
CCACAAGAATGCTTATTACTTGAACCAGGTTTGAATGAAATAATGGCAAACAGTTTAGACTACAATGAGAGGCTC  
TGGGCTTGGGAAAGCTGGAGATCTGAGGTGCGCAAGCAGCTGAGGCCATTATATGAAGAGTATGTGGTCTTGAAA  
AATGAGATGGCAAGAGCAAATCATTATGAGGACTATGGGGATTATTGGAGAGGAGACTATGAAGTAAATGGGGTA  
GATGGCTATGACTACAGCCGCGGCCAGTTGATTGAAGATGTGGAACATACCTTTGAAGAGATTAAACCATTATAT  
GAACATCTTCATGCCTATGTGAGGGCAAAGTTGATGAATGCCTATCCTTCCTATATCAGTCCAAATGGGATGCCTC  
CCTGCTCATTTGCTTGGTGATATGTGGGGTAGATTTTGGACAAATCTGTACTCTTTGACAGTTCCCTTTGGACAG  
AAACCAAACATAGATGTTACTGATGCAATGGTGGACCAGGCCTGGGATGCACAGAGAATATTCAAGGAGGCCGAG  
AAGTTCTTTGTATCTGTTGGTCTTCCTAATATGACTCAAGGATTCTGGGAAAATTCATGCTAACGGACCCAGGA  
AATGTT CAGAAAGCAGTCTGCCATCCACAGCTTGGGACCTGGGGAAGGGCGACTTCAGGATCCTTATGTGCACA  
AAGGTGACAATGGACGACTTCCTGACAGCTCATCATGAGATGGGGCATATCCAGTATGATATGGCATATGCTGCA  
CAACCTTTTCTGCTAAGAAAATGGAGCTAATGAAGGATTCCATGAAGCTGTTGGGGAAATCATGTCACTTTCTGCA  
GCCACACCTAAGCATTTAAAATCCATTGGTCTTCTGTCAACCCGATTTTCAAGAAGACAATGAAACAGAAATAAAC  
TTCCTGCTCAAACAAGCACTCACGATTGTTGGGACTCTGCCATTTACTTACATGTTAGAGAAGTGGAGGTGGATG  
GTCTTTAAAGGGGAAATTCCTCAAGACAGTGGATGAAAAAGTGGTGGGAGATGAAGCGAGAGATAGTTGGGGTG  
GTGGAACCTGTGCCCCATGATGAAACATACTGTGACCCCGCATCTCTGTTCCATGTTTCTGATGATTACTCATTC  
ATTCGATATTACACAAGGACCCTTTACCAATTCAGTTTCAAGAAGCACTTTGTCAAGCAGCTAAACATGAAGGC  
CCTCTGCACAAATGTGACATCTCAAACCTCTACAGAAGCTGGACAGAACTGTTGTAAGAAATACCTCAAATGTT  
GAACCTCTCCTAGTATT CAGTATTACTCATTTCCATGCCTAGGTTTGTATTTGATTTCTTTGTTCTAAAAAGAAA  
ATTTTATGGCCTCAAATGTCTCATTTACAAACCAAACATTTAATTTGTGGTCAGACAGGAACCTAGACCATAC  
AACAAATGGGTGGGCCACCTCTTTTCTCCCTATCATAACTACAGCCCTCTCTTCCTGGTAATTGGAAGGAAAGAG  
CGGTTTAGGGTGGAAATATATCTGTTAATATGCATTCTTTTCTTATCTGCCAGAAGCAAATTTAGCCAAGTCAAAG  
AGAAGAAACCATAGATCATAGATGTAATATATGTACATCTGGAACCCCTCAAAGGCCCTGAACCCCTTTTTT  
TGTGTAGCAATATGCTGAGGCTTGGAATAATCAGAACCCTGGACCTAGCATTGGGAAATGTTGTAGGAGCAAGAA  
CATGAATGTAAGGCCACTGCTCAACTACTTTGAGCCCTTATTTACCTGGCTGAAAGACCAGAACAAGAATTCTTT  
TGTGGGATGGAGTACCGACTGGAGTCCATATGCAGACCCAAAGCATCAAAGTGAGGATAAGCCTAAATCAGCTC  
TTGGAGATAAAGCATATGAATGGAACGACAATGAAATGTACCTGTTCCGATCATCTGTTGCATATGCTATGAGGC  
AGTACTTTTTAAAGTAAAAAATCAGATGATTCTTTTTGGGGAGGAGGATGTGCGAGTGGCTAATTTGAAACCAA  
GAATCTCCTTTAATTTCTTTGTCACTGCACCTAAAAATGTGTCTGATATCATTCTTAGAACTGAAGTTGAAAAGG  
CCATCAGGATGTCCCGGAGCCGTATCAATGATGCTTCCGTCTGAATGACAACAGCCTAGAGTTTCTGGGGATAC  
AGCCAACACTTGGACCTCCTAACCAGCCCCCTGTTCCATATGGCTGATTGTTTTTGGAGTTGTGATGGGAGTGA  
TAGTGGTTGGCATTGTCTATCCTGATCTTCACTGGGATCAGAGATCGGAAGAAGAAAAATAAAGCAAGAAGTGGAG  
AAAATCCTTATGCCTCCATCGATATTAGCAAAGGAGAAAAATAATCCAGGATTCCAAAACACTGATGATGTT CAGA  
CCTCCTTTTAGAAAAATCTATGTTTTCTCTT GAGGTGATTTTGTGTATGTAATGTTAATTT CATGGTATAG  
AAAATATAAGATGATAAAGATATCATTAAATGTCAAACCTATGACTCTGTT CAGAAAAAAATGTCCAAAGACA  
ACATGGCCAAAGGAGAGAGCATCTTCATTGACATTGCTTTCAGTATTTATTTCTGTCTCTGGATTGACTTCTGTT  
CTGTTTCTTAATAAGGATTTTGTATTAGAGTATATTAGGGAAAGTGTGTATTTGGTCTCACAGGCTGTT CAGGGA  
TAATCTAAATGTAATGTCTGTTGAATTTCTGAAGTTGAAAACAAGGATATATCATTGGAGCAAGTGTGGATCT  
TGTATGGAATATGGATGGATCACTTGTAAAGGACAGTGCTTGGGAAGTGGTGTAGCTGCAAGGATTGAGAATGGCA  
TGCAATTAGCTCACTTTCAATTAATCCATTGTCAAGGATGACATGCTTCTT CACAGTAACTCAGTTCAAGTACTA  
TGGTGATTTGCCTACAGTGTGTTTGAATCGATCATGCTTTCTTCAAGGTGACAGGTCTAAAGAGAGAAGAATC  
CAGGGAACAGGTAGAGGACATTGCTTTTCACTTCCAAGGTGCTTGATCAACATCTCCCTGACAAACAAAACTA  
GAGCCAGGGGCTCCGTGAACTCCCAGAGCATGCCTGATAGAACTCATTTCTACTGTTCTCTA ACTGTGGAGT  
GAATGGAATTC AACTGTATGTTCAACCTCTGAAGTGGGTACCCAGTCTCTTAAATCTTTGTATTTGCTCACA  
GTGTTTGAGCAGTGCTGAGCACAAAGCAGACACTCAATAAATGCTAGATTTACAAA

72/550

**FIGURE 72**

MSSSSWLLLSLVAVTAAQSTIEEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEENVQNMN  
NAGDKWSAFLKEQSTLAQMYPLQEIQNLTVKLQLQALQQNGSSVLSEDKSKRLNTILNTMSTI  
YSTGKVCNPDNPQECLLLEPGLNEIMANSLDYNERLWAWESWRSEVGKQLRPLYEEYVVLKNE  
MARANHYEDYGDYWRGDYEVNGVDGYDYSRGQLIEDVEHTFEEIKPLYEHLHAYVRAKLMNAY  
PSYISPIGCLPAHLLGDMWGRFWTNLYSLTVPFQKPNIDVTDAMVDQAWDAQRIKFAEKFF  
VSVGLPNMTQGFWENSMLTDPGNVQKAVCHPTAWDLGKGDFRILMCTKVTMDDFLTAHHEMGGH  
IQYDMAYAAQPFLLRNGANEGFHEAVGEIMSLSAATPKHLKSIGLLSPDFQEDNETEINFLK  
QALTIVGTLPTFTYMLEKWRWMVFKGEIPKDQWMKKWWEMKREIVGVVEPVPHDETYCDPASLF  
HVSDDYSFIRYYTRTLYQFQFQEQEALCQAAKHEGPLHKCDISNSTEAGQKLL

**Important features of the protein:****Signal peptide:**

amino acids 1-17

**N-glycosylation sites.**

amino acids 53-57, 90-94, 103-107, 322-326, 432-438, 546-550

**N-myristoylation sites.**

amino acids 260-266, 286-292, 395-401

**Cell attachment sequence.**

amino acids 204-207

**Neutral zinc metallopeptidases, zinc-binding region signature.**

amino acids 371-381

73/550

FIGURE 73

CCCACGCGTCCGAGCGGGGTGGACAAGTGGCGTGTGTGCTGCGACCCCGAGGGAAGATGAACG  
GGACGCGGAACCTGGTGTACCCTGGTGGACGTGCACCCAGAGGACCAGGCGGCGGGCGGGCAGGA  
AGACCTATGCCATGGTGTCCAGCCACTCAGCTGGTCATTCTCTGGCTTCAGAACTGGTGGAGT  
CCCATGATGGACATGAGGAGATCATTAAAGGTGTACTTGAAGGGGAGGTCTGGAGACAAGATGA  
TTCACGAGAAGAATATTAACCAGCTGAAGAGTGAGGTCCAGTACATCCAGGAGGCCAGGAACT  
GCCTACAGAAGCTCCGGGAGGATATAAGTAGCAAGCTTGACAGGAACCTAGGAGATTCTCTCC  
ATCGACAGGAGATACAGGTGGTGTCTAGAAAAGCCAAATGGCTTTAGTCAGAGTCCCACAGCCC  
TGTACAGCAGCCCACCTGAGGTGGACACCTGTATAAATGAGGATGTTGAGAGCTTGAGGAAGA  
CGGTGCAGGACTTGCTGGCCAAGCTTCAGGAGGCCAAGCGGCAACACCAGTCAGACTGTGTGG  
CTTTTGAGGTCACTCAGCCGGTACCAGAGGGAAGCAGAACAAGTAATGTGGCCCTTCAGA  
GAGAGGAGGACAGATGTCCAGAGTGAATTGGAGAATGTCCTGGGGGAATGAAGTTCCTTCCACA  
AACACAGCTCAGTTCTTAGCAACAACTGTTTGTCTTTTCTACTTGCTCCATCTGCAGCCTACG  
CTGCCCTGGCCTCCTGCAGACAGATAGTGGGGTTACCTGGCAAGGCCTGGTGAGAGCCAGTGA  
ACCTAAGCTTTGACTGGGTGGCCTTGCTCTTTCTGGGGAGGAGGGAATGTACATTCAGGGAGTA  
GCCTTTTGCGGAAAAATTCTCTAGGGCTACAGACAGTCATGTGTGACTTCTCTCTGCTGTGAA  
AACTCCCAGAGTCTCTTTAGGGATTTTCCCTAAGGTGTACCACCAGGCACACCTCAGTCTTCT  
TGACCCAGAGCCTGAAAACCTGTTTTCACTGGGTTCCACCAGTCCCAGCAAAATCCTCTTTGTA  
TTTATTTTGCTAAGTTATTGGTGGTTTTGCTTACATCTCATGATTGATATAATACCAAAGTTC  
TATAGCCTTCTCTTGCAGTATTTGGATTTGCTTGAAACCGGGAAAACTGTTCCCATTAGGCTT  
GTTAATGTCAGAGTGACACTATTATGAATCTTTCTCTCCCTTTCTCTGCCTGTTTCTTCTCT  
CTTTCTCCTTCAAACCTTGCTCTGCAGCTAAGGAAGGTGAGTCTACTTTCCCTGAGGCTTTGGG  
GTCAGAGTATATGTTGTTTGGAGAAAGAGGGCAATCAGGACTCTTCTGGGACCCAGATGAGTT  
CTTCACTAGCCCTTCTGAACCCCTTGCTCCATAATTGGTCTTTTATCCTGGCTCTGAATGACC  
CTGCAGGTCATCATGGTTTTCTTTTTTTTATTGTTTTTTTTTTTTTTCTGAGACAGAGTCTCACT  
CTGTCACCCAGGCTGGAGTGCAGTGGCGCGATCTCAGCTCACTGCAACCTCTGCCTCCCGGAT  
TTAAGCGATTCTTCTGCCTCAGCCTCCCGAGTAGCTGGGACTACAGGTGTGCCACCACGCCTG  
GCTGATTTTTGTATTTTTAGTAGAGATGGGGTTTACCATACTGGCTAGGCTGGTCTCGAATT  
CCTGACCTCAGGTGATCCACCCACCTCGGCTTCCCAAAGTGCTAGGATTATAGGCTTGAGCTA  
CTGCGCCCGGCCCATGGTGTTTTTCTTTAGGGCTCTTCTACAGCCTTGAGAAGTAGATAGGC  
ATCAGAGTATGGTACTATAGGAATCAGAAAAATTCAAACAAATGTGGATTAAGTGTTTAGGC  
TCTATGTGGCTCACGCAGCCAGAATCCTTAAGTCTGTGTGTTTCTGTGTCTCAAGACTGGGCT  
CACATTCTGGCTTTGTCCATAACAATGCTCTGGGATTTTCAAGGAGTTCCTCATTTGTAAAAT  
GAGGGGGTCAGAGCAGGTGATATCCATGTTTCTTCCCTTCTGATATTGTTGTCTGTGGCATA  
TTCTTTGTATGGCGAATTTAATAAATTATATTAATGTGTCA

74/550

**FIGURE 74**

MNGTRNWCTLVDVHPEDQAAAGRKTYAMVSSHSAGHSLASELVESHGHEEIIKVYLKGRSGD  
KMIHEKNINQLKSEVQYIQEARNCLQKLREDISSKLDRNLGDSLHRQEIQVVLEKPNGFSQSP  
TALYSSPPEVDTCINEDVESLRKTVQDLLAKLQEAQRQHQSDCVAFEVTLSTRYQREAEQSNVA  
LQREEDRCPE

**Important features of the protein:****Signal peptide:**

amino acids 1-39

**N-glycosylation site.**

amino acids 2-6

**Amidation site.**

amino acids 21-25

75/550

**FIGURE 75**

GCTTGCACACATGGCTCCGGAGGCTCCGGTTGCCATCCGAGCCCCTGCCAGGCTCTAACGTTCCCAACTGACAA  
CACCAGTAACATAAATATAGGAGCAGATGGTGGGGACGGGCTGTGCGAGCGGCTCCTTTGCAGAGGTCTCCGGACT  
GCAGATAAGGCTCAGGCCCTTTTGTGAGAAGCAGACCAGCCTGGGGGCTGGCGGCAGGACACCTGTGTCTGCATG  
CTGAAGAAGATGGGTGAGGCCGTGGCCAGAGTAGCAAGGAAGGTCAACGAGACGGTGGAGAGCGGCTCTGACACT  
CTGGACCTGGCCGAGTGCAAGCTGGTCTCCTTTCCCATTTGGCATCTACAAGGTCTGCGGAATGTCTCTGGCCAG  
ATCCACCTCATCACCTGGCTAACAACGAGCTTAAGTCCCTCACCAGCAAGTTCATGACCACATTCAGTCAGCTC  
CGAGAGCTCCACCTGGAGGGGAACCTTCTACACCGCCTCCCCAGCGAGGTGAGTGCCCTGCAGCACCTCAAGGCC  
ATTGACCTGTCCCGGAACAGTTCCAGGACTTCCCTGAGCAGCTTACCGCCCTGCCGGCGCTGGAGACCATCAAC  
CTGGAGGAGAACGAGATCGTAGATGTGCCCGTGGAGAAGCTGGCCGCCATGCCAGCCTTGCGCAGCATCAACCTC  
CGCTTCAACCCACTCAACGCCGAGGTGCGCGTGATCGCCCCGCCGCTCATCAAGTTTGACATGCTCATGTCTCCG  
GAAGGCGCAAGAGCCCCCTACCTTAGGCCACCCCTCCTCATGCCACCCAGCAAGGGACAGAGGCCACAGGCCCTG  
GAACCCTGGAAGGGAGGGAGGCCCATGGGAGGCCAAGCCTGGGGGCTGGGGGCGGGTGGGCCGAGCAGCAGCTGG  
TGGGTGGGGTGCAGCTGGTCTGGATAGATAGCTTACAGCAGTAGTGGGCTCTGGAATGCCAAGGGAAGAGGCCAA  
GGTGGGGCTGCAGCCTGGACTCGGCACTCACAGCTGCTGTGCAAACTCAGGCAGATCTCCTGCCCTCTCTGAGC  
CTTGTCACTTGAAAAAACAGGACCCTTTCCCTCCTTTGGGCTCCCTGGAGGTTTTTAAGCAGTACGTGCCTCCA  
AGTTACCTCCAGATCAGCAGGCACAGGTGGGCATTGCCAGGTATTTTCTGAGCCCCTGCCGGTTTGAGGCCCTGT  
TTTTAGTGCTGAGAGCCAGTTGCTGCCCTGAGAAGAGAAGACAACCTCCATCTATTATTGCTTCTGAGACATG  
ACCTGGATGCGGCCCTCTGCAGGGCCAGTCTTCAGTCTGTGGTCCCTGGACTGGTGGGAACCTGAACTAGGAG  
TCCTGGGAGAGCTGTGGTGGGAATATGGGCTGGCACTGCTGCAGGGCAAGAACATTATGTAGGAGCCCGAGGAC  
CANCANGCTGGGAATGGGGAGCAAGTCACGTGAGCTCTGTCAATCCCCACAGTTAACAAATTGGCGGGGTGGGAA  
GTCTGTAGTGCTCCGTCCCTCTAGCATCACTCCTGAGCTGCGGGAGAGGTGGCCCCAGAGAACAGCAGAGTCAGTT  
ACACCTGCAGCTCTTGTCTAAAGTGATTAGATGGCCACCCCTCACCAGTGTCCAGTCCAGCAGCAGCCTGGCTGCC  
TTGTCTAGTGGCTCCTGGGGGAGCAAGGGCAGTGTGGACACGGGATTTGTAGCCAGCCAGTCCCAGGCCAACGCC  
CAAAGCCCTGATGACCTGGTTCTTCTGAGGCCCTCAACCTGGCATCTTAGGGTATGGTCAGGCAACAGGGTGACC  
AGCTGTCTGGTTTCCCAGGACATGGAACCTTTCAATGCTAAAACCTGGGACATTACCCAGCAAGTGGGGATGGTTG  
GTCCCCTACCAGGAGAGGGCCTGGGGCTCTTGCTTCCCAGAAACGCCCTGTGGCTTGAAGAACCTTGACTGCTTGG  
TCCTCAGGTATCTACCTCCCACCTTCTCCTCATCTGTGGAGCAAGCCAACTCAGTGCCCCAGACCCACCTGATC  
TGCATCTTTGTTTGTCTCCAGAGACACCTGAGGCCCCAGAGCTTGAGGCAAGCCAGGCCGTCCAAATCCTGTGTG  
CCGTGGACGAGTGGCCACTTTACTACTCCTAAGGCTAAGATGTTGAGAGCTCAGACCACTGCTCAGAGCAGTAAT  
CCCTGCTCAGAATGCTCCAGTTCCCTCGTCCCTGCCAGGTCTCTTGTCTCTTGGGAAGGAACCTGATAGGTGCG  
GCCATTGTTGGGCCATCACTGAGCGCTCAGTATCTCAAGAGACTCTGTTTATTCTGCTCGTATCCCAAGGCCTGG  
TTGGTCAAACCTCTGGGCAAAGGGTTTTTCAAGATGAGGAGGTCAAGACAGGATGTCCAGAGCTACCGAGTTCTATCT  
GTGGGTGTTGGGGCAAGTGGGGGCTGAAGTCTGTGCAAGCTGCGCTGGCCCCACCTGCCTTGTGCCCTGGAGT  
GGGGTTTTCTCCTTGTGTAAGAAGAGGCATCCTTCTGATGTGCACAAACACAATGTATGACCAGAGCCTTGCAA  
CTCAAAGTGTGGTCTGTGGACCAGCAGCGGCAGTGACACCTGGGAGCTTGTAGGAATGCAGAGTCTAGGCCTCA  
CCCTATACCTCCCGACTCAGACCCTGCATTTTAGCAAGACCCCCAGCTGATTCTATAAGCACTTTAGAGTTTGA  
GAAGCAAGGACCTAGGCTGGGGATGTCTCCGAGCAGAGGGTGAAGTTTCTCTCAGTTCTCTCCCTGCCACTTCC  
AGGGATCTGAGCCTGTGTTACGCTCCTCCCTAACCCACCCCTGGGAGACACTTGGCCTGTAGATTGTTCCAGAG  
TCTGCATGGCACTCCTGAAGAAGGGAGTGTGACCTGCAGTCACCAGGAGATGAGGGTTAGGTGTGCCAGCCCTC  
CAGACCCGGCCTTTCTGGTTAACCCTGCATGCCAAGCTGCCTGCTGCCCCAGGTCTCACCTCAGGCCTTTGAA  
GGGGCAGCTTCTGGAAGTTGTTTTCTCCTCTGCTTGGAGAGTTTGGCCTTGTCTGTCTTGGAAAGTGTGGGCAGC  
CACAGATGCCCCAAATCAGAGCTCACAGTGAGTGAGCCCCCTAAGCTTCAGTCTGCAATAAAGAATGCATTGGTT  
TCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

76/550

**FIGURE 76**

MLKKMGAEAVARVARKVNETVESGSDTLDLAECKLVSFPIGIYKVLNRNVSGQIHLITLANNELK  
SLTSKFMTTFSQLRELHLEGNFLHRLPSEVSALQHLKAIDLSRNQFQDFPEQLTALPALETIN  
LEENEIVDVPVEKLAAMPALRSINLRFNPLNAEVRVIAPPLIKFDMLMSPEGARAPLP

**Important features of the protein:**

**N-glycosylation sites.**

amino acids 17-21, 47-51

77/550

**FIGURE 77**

CACCAACAAGCAATCGTTTCATGAGAAAGCCGTGCACCCGCTGCAGTTGGGCCATGTGGTCCGCATCGTATTCCAC  
TAGGTCCCCATTGTACACCAAGTACTGTCCCGGCGTCTCCAGCAGATGCCTGCAGCCTTCCACCTTCTCAAGCAG  
GGTGGTGTGAGTGCCTGCTTTCTTCTCGCCTGGACCGGAGCCGTGCGGGGAGGCACCCCGGGGGTGGAGAA  
AAAGCCGGCCTGGCCTCGGAGGTGGTCTCGGCCCCCGCCCCACCGACTCCCTCCTCCCTCCAGAGCGGCGGC  
GGCTCCGGCGGCAGCAGCGGCAGGCAGCAACGTAAGCGGGATGCTCTCCAGGCTGCTTTTCTGCTCGGTACGCAA  
ATGGCTGAGCTGGTACATCTCGCTCTCCAGGTAGGAGATCTCGCGGGCCGTCTCTATGAAGTCCCGGTAGTTCTG  
GTAGACGTTGCGCTTCAGGTTCTGCGCCGTCTCCTCCGCCAGCGCCTGGATGCGCTGCCGGTGTCTCTGGAGGTC  
CCGGTCCCCATCCGACTGCTGCGAGAGCTGCTTACGTACAGCCGCGCCTCAAACCCCCCTGACTCCAGCTGCCG  
ACGCAGGCGGCTCGCCCCACTGTCCGACATCGCCATCGCCATTTCTCTCCGGGTCTCAGCCTCACTGTCACTA  
TCGGCGCCGAGCCGCGCGGCTGTCTAGACCCACCCAAGGCCAACCAGCTCCTGGGCTGAGGAAGCAGGAATG  
GGAACGAGACGAGTACGCTGCGCCGGGTCTGAGCGTCAGACACTGCGCCTGCGCAAGTGGGCCGAGCGCAGACA  
TTGCGCCTGCGCAGCAATGCCATCGGTTAAAGCGCATGCGCAAGATGAGCTATTGCGGAAGTGAGGGGAGGGAGA  
GGCCGAGAGAAATTTCCGGTACTGCGCATGAACCGAGCGTGACGTTGAGGTTTGAATAAACCAGCAAGAGTAAAG  
GCTGAAACTAGCTTCTGAAAGCTTCGTAGGGCCCGAGCCCTGTGAGCCAGGTTCTGCGCCCACTAGGAGGTGT  
CATGCTGACTGCTTTTTTTAAAGCCCTAGAATCCTTGGCTTCGGCGTTCGGGTAAGCTCCGTTCTCGTTCTCAA  
GCGCGTTTCCGCGAACTCTCGCGGATTGACGGGCCGTCTCGAGAGCCGCGCATCTCCTAGGAGCTAGTCTGGTC  
CTCGGCTAGGCGGCTTGGGGTCGCGCGCTAACTGGGGAGCCAGCCTGACGCGCGGACCCCGCCTGTGATCCTG  
GCAACGATGATGACTTGATGTTGGCACTGCGGCTTCAGGAGGAGTGGAACCTTGAGGAGGCGGAGCGCGAT  
CATGCCAGGAGTCCCTGTGCTAGTGGACGCGTCTGTTGGAGTTGGTGACCCACACCCGACTTGCAGGCACTG  
TTTGTTCACTTTAACGACCAATTCTTCTGGGGCCAGCTGGAGGCCGTGAGGTGAAGTGGAGCGTGCGAATGACC  
CTGTGTGCTGGGATATGAGCTATGAAGGGAAGGGTGAATGTGTTCCATCCGTCTCAGCGAACCCCTTTTGAAG  
TTGAGGCCAAGAAAGGATCTTGTAGAGACCTTCTGCATGAAATGATACATGCTATTTATTTGTCACTAATAAC  
GACAAAGACCGAGAAGGGCATGGTCCAGAATTTTGTAAACATATGCATCAACAGCCTGACTGGAGCCAAAT  
ATAACGGTATACATACTTTTACGATGAGGTGGATGAGTATCGGCGACACTGGTGGCGCTGCAATGGGCCGTGC  
CAGCACAGGCCACCGTATTACGGCTATGTCAAACGAGCTACTAACAGGGAACCCTCTGCTCATGACTATTGGTGG  
GCTGAGCACCAGAAAACCTGTGGAGGCACTTACATAAAAATCAAGGAACCAGAGAATTACTCAAAAAAGGCAAA  
GGAAAGGCAAACTAGGAAAGGAACAGTATTGGCCGCGAGAGATAAAGGTACCTTCGTGTATATTCTTCTGATT  
TTTATGTCATAGCTATGATGTAAGACAATCTGTCCTTCAGAGAAGTGGTATTAAGATAAACTTAAGGATC  
GTTTCTGGTGTAGAAGTCTTCAAGTGTAGACTTAAGGAAAAAATCCCACTGTCCATGAAATGATGGTAGGAAAAC  
AGACTTTGCTCTGTACAGAAGTAAGTAAAAGTAGGAATAGTTTCCATGGATATTTTTATTTTTATTAACTTTTT  
CAGTTTCTTTTTATTCAAGAAACAAAATTCAATCTCTGATAATATTTGAGGTAAAGTTCCTTTCCCTATCTTGA  
CTCACTGAGTTATTAGGAAACAGAAGGCAAAAAGATTGTCAAATAAAAAACAATAATTCAAGTAACAATGCCCGG  
AATATACGTCCTAACTACACCCCTTCTATCAGCTGGATTCTATCCAAGTGACTCTATTGATGTATGTATGTTCA  
TTCAAAGAAATGGGAAAAGGATATGACATATATTGGCAGTACTTCATCTTCAAGATTTACCCCTTTTCCGTGAAG  
TTCAGAGTTACTGAAGATGCTTCTTCCCTTGGGAAGTTGTTGACCCAAGAACATAGGTTATATTTCCCAAATCTT  
TAATTATTGAGTGAAAGAGCTATAGATGAATTGATATGGAAAGACCGTATCTTCATTTTCGTGAGTAGAAGGAAA  
GATAAGAATGAGGCAGCAGATTTTCCCTCCTGGAATTACACATAAAGGACACTAAGCAATTTTCAAGGTAAATGT  
TGCTTGTGTTGGTCTTTGGCATGATAAGATTCTTTATTTAAATATGAGAGAATTTTTTTTTATCCTTTATATT  
CTCTCAATATCAGAACTCCTGAATTCTGAAGATTGCCCTCCTCCCATTAATAGGATTGTATGGATGTAAGATGGA  
ATAAAATACTAGTTCTTCAATTTTGAGAAAACGTACATTAGTTTAAATGTTTGTACTGTATTTCTTTGAGTTGA  
GGCACTTACATAACAATCTTCTTTGCTTTTTTGGCAGATAAACCCAACAGAGGTGAGGCCAGCTAGTAATCCCT  
TTTAGTGGGAAAGGATATGTTCTAGGAGAAACAAGCAATTTACCTTCACCTGGGAAACTGATCACTTCACATGCC  
ATTAATAAAACCAAGATCTTTTAAATCAAAACCATTACAGCAATGCTGTAAGACCTAATTCTAAATCAAGGTG  
AAATTTGAACAGAATGGTTCAAGTAAAAATCTCATCTGGTCTCCCTGCTGTTAGTAACAGTCACCAAAATGTT  
CTAGTCAACTACTTTCTAGAGTATCATTTGCCAACCAAAAGGCTTTAGAGGTGTGAATGGATCTCCAAGGATA  
AGTGTAAACAGTTGGCAACATCCCTAAAAACTCAGTCTCTTCTAGTTCTCAGAGAAGGGTTTCATCTTCTAAGATA  
TCCCTAAGAAATCTTCAAAAGTAACGGAATCAGCATCTGTGATGCCATCCAGGATGTGAGTGGGTCTGAAGAT  
ACATTCCCAAATAAACGACCTAGGCTAGAAGATAAAAAAAA



78/550

**FIGURE 78**

MDDDLMLALRLQEEWNLQEAERDHAQESLSLVDASWELVDPTPDLOALFVQFNDQFFWGQLEA  
VEVKWSVRMTLCAGICSYEGKGGMCSIRLSEPLLKLRPRKDLVETLLHEMIHAYLFVTNNDKD  
REGHGPEFCKHMRINSLTGANITVYHTFHDEVDEYRRHWWRCNGPCQHRPPYYGYVKRATNR  
EPSAHDYWWAEHQKTCGGTYIKIKEPENYSKKGKGKAKLGKEPVLAAENKGTFFVYILLIFM

**Important features of the protein:****Signal peptide:**

amino acids 1-41

**N-glycosylation sites.**

amino acids 148-151, 217-220

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 184-187

**Casein kinase II phosphorylation sites.**

amino acids 30-33, 121-124, 154-157, 187-190, 192-195

**Tyrosine kinase phosphorylation site.**

amino acids 211-218

**N-myristoylation sites.**

amino acids 59-64, 85-90, 146-151

**Neutral zinc metallopeptidases, zinc-binding region signature.**

amino acids 108-117

79/550

**FIGURE 79**

CGGACGCGTGGGTGGCAACCAGGAGAAGCCAAACTTGGTCCCCCGGCTCGCGGAGTGCCTGCG  
AGCGGTGCTC**ATG**GCGCTCTATGAGGTCTTCTCTCACCCGGTCGAGCGCAGTTACCGCGCGGG  
GCTCTGCTCCAAAGCCGCGCTGTTCTGCTGCTGGCCGCTGCGCTCACGTACATCCCGCCGCT  
GCTGGTGGCCTTCCGGAGCCACGGGTTTTGGCTGAAGCGGAGCAGCTACGAGGAGCAGCCGAC  
CGTGCGCTTCCAACACCAGGTGCTGCTCGTGGCCCTGCTCGGACCCGAAAGCGACGGGTTCTCT  
CGCCTGGAGCACGTTCCCCGCCTTCAACCGGCTGCAAGGGGATCGCCTGCGCGTCCCGCTCGT  
TTCGACTAGAGAAGAAGACAGGAACCAGGATGGGAAGACGGACATGTTACATTTTAAGCTGGA  
GCTTCCCCCTGCAGTCCACGGAGCACGTTCTCGGTGTGCAGCTCATCCTGACTTTCTCCTATCG  
ATTACACAGGATGGCGACCCTCGTGATGCAGAGCATGGCGTTTCTCCAGTCCTCCTTTCTGT  
CCCGGGATCCCAAGTTATACGTGAACGGAGACCTGAGGCTGCAGCAGAAGCAGCCGCTGAGCTG  
TGGTGGCCTAGATGCCCGATACAACATATCCGTGATCAACGGGACCAGCCCCCTTTGCCTATGA  
CTACGACCTCACCCATATTGTTGCTGCCTACCAGGAGAGGAACGTTACCACCGTCTGAATGA  
TCCCAACCCCATCTGGCTGGTGGGCGAGGGCCGAGATGCTCCATTTGTGATTAATGCTATCAT  
CCGATACCCTGTGGAAGTCATTTCTTATCAGCCAGGATTCTGGGAGATGGTAAAGTTTCGCCTG  
GGTACAGTATGTCAGCATCCTGCTTATCTTCTCTGGGTGTTTGAAAGAATCAAGATCTTCGT  
GTTTCAGAATCAGGTGGTGACCACCATTCCTGTGACAGTGACGCCCCGGGGAGACTTGTGTAA  
GGAGCACTTATCC**TAG**AAAGGCCATTTCTGAAGACTCAGCAGGACCCTGGCTGCCTCATTGTC  
ATCTTCTGGGAACATCTTAGGACCTTTTGAAAGAGCCCAGCGGACACCTGCGGGCTTGTGTGC  
TTTTCCCTCAGAGACAACGGTTCTTTCCGGTTTTGCTCTACACAGTTCCTGATCTTCAGAGCT  
CCTGCAGAATTGTCAGGGACTAGTTTGTGGAAAGGTCTGAGAGTTCTGGAGGCTATAATTAG  
CTTTTTGGGTTTTCTTCTTTGCCTTAGCGTTGAATTTTCAGGAGAAAATTGCAGTCAGTTCAG  
ACATCTTGGAAGAGTCCCATCTCTGGTCAAGCAGAGACTTTTCTCTGTTGAACTGAGGAAC  
AACTGTGCATTTCTTCTTCTGTTGTGAGCCACTCTTACTCTTTTCAGGGCTCTCTTGTGAC  
AAACATGCCAATCACTAGCACTTTGCACCCCTGGGCTTCTCCATTTCCCATTCACAGCTTTGA  
TTTCCAGAGCTGAGGCCTTTAACTGGAGACCTGGAGGGGCGAGGGCCCAAGGGCAAGGGCCGCA  
TTAGCACAGGCAATCAGGGAGGGCCGCTGAAGGACACTTGGACCGTCCACCTGCCCCAGCCCA  
ACAGTCAGTCATCTGTCATCAGCTCAGCTGAGCAGCCCTGGATCTTTGCCGTACTGTGACTGG  
GCTCTTTGCCCTATTTTTCCCTCTGTCTGTGCCCTGGATGGCAGGCTGAAGTCAGAGGGGCT  
GTTTCATTCTCAGCCCCCTCAGCAGCACTGGGGGAAGAAAGCATTGTCACAACAGGTTCTTTC  
TGGCCCTCACCCAACAGCCTGGGCACTTGGCCCTCCTCCTCCTTGACAGCCCTCCCCCTCCT  
GCAAAGGACAGGGGCGACAGGGGTTGGTGTGGGATTGGCTCCCGCTGCCTGACAACCACAAG  
TTTATTTGGAAGGCTAGCGGGAAGCCCAGCGGCTGGCGTTTCCCTTGACTAAGGAACAGGGTG  
CCCATCAGAGTGGGGCGGGCAGCTTTGGGAAGGACACAAGAAGCAGTAAGAGTGTAAGAGGA  
TGCTGGCCTGGGCAGGCCAGTCCAGCCTGGCCACTAGCAGAATACCAAGCAGTCCAGTGGATT  
ACCTCTGTGGCTAAGCAAGTGTCTGCAGGAGCAGAGATGGCTGGAAGGGGCTCTGCACACGG  
AAGATGGCTTGTTTCAGCCCATTCACCTCCTGAGGATGTGGGCAGTCTCCTCCAAGAACACATG  
GAGCTGCTTCCTGATCCCAAGCAGGTCAATGCCACTGGAAGGACATGGCCCCGGTGATCCATG  
CTTCATGCCACCCAGAAACACACCCCTCAGTGTGTGCCTCAGTTTACTTTGGAGATCAGTTG  
TCGTTTTTAGTGCTCCTTTAGGCTTACTAAAACAGTTTTGGAAACAAAGCTATTTTGAAGTAT  
TCAAGCAGAGGAATTCCCTAACACTGACCCCTTGCTTTTTTTTAAATATTCAGGCTGTTTTAT  
ATGCCTAAATTTTTTTCTTAAGATCTAAACGAAAAATAGTTTCTTGTTTAAATTCACATAAGG  
CAATGAGATATGGAAAGATGACAAGATACGTATAAACATTGGTTTGCATCTTATTAAATTATT  
CTAATGCAATCTTGTATAAAGAACCCATGATGTTTTGTAACCTTCTAATTAAATGTTCAA  
ATGAG

80/550

**FIGURE 80**

MALYEVFSHPVERSYRAGLCSKAALFLLAAALTYIPPLLVAFRSHGFWLKRSSYEEQPTVRF  
QHQVLLVALLGPESDGFLAWSTFPAFNRLQGDRLRVPLVSTREEDRNQDGKTDMLHFKLELPL  
QSTEHLGVQLILTFSYRLHRMATLVMQSMALQSSFPVPGSQLYVNGDLRLQQKQPLSCGGL  
DARYNISVINGTSPFAYDYDLTHIVAAYQERNVTTVLNDPNPIWLVGRAADAPFVINAIIRYP  
VEVISYQPGFWEMVKFAWVQYVSILLIFLWVFERIKIFVFQNVVTTIPVTVTPRGDLCKEHL

**Important features of the protein:****Signal peptide:**

amino acids 1-34

**Transmembrane domain:**

amino acids 268-284

**N-glycosylation sites.**

amino acids 194-198, 199-203, 221-225

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 51-55

**Tyrosine kinase phosphorylation site.**

amino acids 250-259

**N-myristoylation site.**

amino acids 187-193

**Cell attachment sequence.**

amino acids 307-310

81/550

**FIGURE 81**

GCCGGGAGCTTCCCTGATGGTGCCGCCGCCCTCCGAGCCGGGGAGGAGCTGCCAGGGGCCAGCTGGGCAGGAGCCT  
GGGTCCGCTGCTGCTGCTCCTGGCGTTGGGACACACGTGGACCTACAGAGAGGAGCCGGAGGACGGCGACAGAGA  
AATCTGCTCAGAGAGCAAAATCGCGACGACTAAATACCCGTGTCTGAAGTCTTCAGGCGAGCTCACCACATGCTA  
CAGGAAAAAGTGTGCAAAGGATATAAATTTGTTCTTGGACAATGCATCCCAGAAGATTACGACGTTTGTGCCGA  
GGCTCCCTGTGAACAGCAGTGCACGGACAACCTTTGGCCGAGTGCTGTGTACTTGTATCCGGGATACCGATATGA  
CCGGGAGAGACACCGGAAGCGGGAGAAGCCATACTGTCTGGATATTGATGAGTGTGCCAGCAGCAATGGGACGCT  
GTGTGCCACATCTGCATCAATACCTTGGGCAGCTACCGCTGCGAGTGCCGGGAAGGCTACATCCGGGAAGATGA  
TGGGAAGACATGTACCAGGGGAGACAAATATCCCAATGACACTGGCCATGAGAAGTCTGAGAACATGGTGAAAGC  
CGGAACCTTGCTGTGCCACATGCAAGGAGTTCTACCAGATGAAGCAGACCGTGCTGCAGCTGAAGCAAAGATTGC  
TCTGCTCCCCAACATGCAGCTGACCTGGGCAAGTATATCACTGGTGACAAGGTGCTGGCCTCAAACACCTACCT  
TCCAGGACCTCCTGGCCTGCCTGGGGGCCAGGGCCCTCCCGGCTCACCAGGACCAAAGGGAAGCCAGGCTTCCC  
CGGTATGCCAGGCCCTCCTGGGCAGCCCCGGCCACGGGGCTCAATGGGACCCATGGGACCATCTCCTGATCTGTC  
CCACATTAAGCAAGGCCGGAGGGGCCCTGTGGGTCCACCAGGGGCACCAGGAAGAGATGGTTCTAAGGGGGAGAG  
AGGAGCGCCTGGGCCAGAGGGTCTCCAGGACCCCTGGTTCTTTCGACTTCTGCTACTTATGCTGGCTGACAT  
CCGCAATGACATCACTGAGCTGCAGGAAAAGGTGTTCCGGCACCAGGACTCACTCTTCAGCAGAGGAGTTCCCTTT  
ACCTCAGGAATTTCCAGCTACCCAGAAGCCATGGACCTGGGCTCTGGAGATGACCATCCAAGAAGAACTGAGAC  
AAGAGACTTGAGAGCCCCCAGAGACTTCTACCCATAGCACATCCCAACACCGTCACGCCAAAGGAAGAGAAAGAT  
CAACTCACCTGCAGTTAAACCATCTAAAGAGAAAGAACCACTGGAGACCTAGAAAACATACATTTTTCTCTTC  
TCTTCTCCTGACGTCTCTCCACTCCTCTTCTTCCAAATACGATGCTATTTTTCAGAGTCCCTCCTAGGCCCTGCAG  
ACATGAGGGAGTGAATGATTGATTTACCTGCTTCTCACTAAGAGTCCATTGGGGTGGTTTGCATTGTAACTTTTTC  
TTTTACATCCTATTTTTCCAGGAACCTTTGGATTTAAGTACTCTCACAGTGTCTTAAATCATAAATTTCTGAAGTT  
AAATTTGGCAGAGTATCAAAGGGGGAAAATGACAAAGTGAGCTCTAAGAAAATGTGAGGCTACTTCTAAGATGT  
GTGTTACAAATAGACCATAACTCCTCTAGTATCAAAATTGGGGCTCTTCAGTTAAAAAGGGGTGGGGAGGACAAA  
CGTGTGATGTGCTTTGGTGGAGAATTTTTCTTGTGCTTCTAGTAGACTTTAAATATTGTATCCCTTTGTCAA  
ACCTTGTTTCCCAAATTCAATTAAGAGAGGAGAGAATTGAATGGCGTTTAGAGAAGATAGAAAAGAATCACAGT  
CATATATTTACTGTTATATAGATTGCCACATTCTAAATTCAAATACGGTGCTTAAGGTTTCATGCCATGCTTAT  
CTGTAAGTATCCTATTTAGGGAAGAAGATTAAGTCTCTTTTCAAAAAACAAAGTGAAATGCCTGGATTTCACAT  
TAAACAATGGGCTCTCGTTTGCTATAATATTTTAAAGCTGTTTAAACACAGTGGAGTCTGCTCTATAAATATA  
GATTATTTGTTCATAAACTGGCTGAGCTTAGAGAGAGGTGCAGAATTCTGGTTCTGAGCAGGTGCCAGAAAGG  
TACCATTAGGTGCCATGATCCAGGCTGAACCAATATACAGTGGGGCTGAAGTCTGCAAGGAGGTTGCTGGCTTGG  
GCTGACCTCACTAATGCCATCAGCAGCGGTAGGTAAATTTTTCTCCTTGGGTATTACAAGTTTTGTCTGGAGC  
CAACCAAGCTTGCCACCAACATATTGAGAGTAATACACTATTGAAAGTTATCTTGGATGGGGAGAAAAAAAATA  
GTGGTTTTCTTGTGTTGCAAAAACCTCCTTCTTATTCTCATTTTTTTCTTAATTTTTCTTAATTTAGTCCAAGTTC  
CAGTTCTTTTAGGCCTTCTCTTTGATTTATTTTCCCCTGCATGTGAGAAGCAGTTTCAAGAAAAGGCTATATCTC  
CACCTCCTAGTGAGTTAGAGTGTTTTCTCAGAGCACCTCTGGGTGGCAAAGGGAAGCATGTTCTCGCCAAAGGTTT  
GCTGTGGATTGAGAAGCACCAGGAGCAAGAGACCAGAAGGATGATCTGCTCCTTTGTAACGTTGTTGAGGGCCCT  
CTTGTGTTTCAATGAGCAGCTTATAGGTTACTCACAGTCCACTTTCTCACTGGACACACAAAGTGGCTCTTTATCT  
ACCTTTGCGGGAGATTTTCACTCTCCTGCAATGATCGTTCTCACACTCATATTAGCTCATGTTGGAATTTCCCA  
TCCTGCCATGTCCTTTCCCATTTCTTTTTGGCTTTTTTGCCCTCCACCTTTTAGCCACATCATTTAACTCCACTA  
CTGTGAAAGCTTGCTTAAAGAAAATCCCTCTTGCCGGGTGTGGTAGCCACGCCTCTAATCCCAGCACTTTGGG  
AGGCTGAGGCGGGGAGATCAAGGTCAGGAGATCGAGACCAGCCTGACCAACATGGTGAAACCCCTGTCTCTACT  
AAAAATACAAAAATTAGCTGGGCGTGTTGGCACACACCTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGAA  
TTACTTTAACCTGCGGGGGGAGCCTAGATTGCGCTACTGCACTCCAGCCTAGGCAACAGAGGGAGACTCTGTCTC  
ATTAAAAA

82/550

**FIGURE 82**

MVPPPPSRGGAARGQLGRSLGPLLLLLALGHTWTYREEPEDGDREICSESKIATTKYPCLKSS  
GELTTCYRKKCKCKGYKFVLGQCIPEDYDVCAEAPCEQQCTDNFGRVLCTCYPGYRYDRERHRK  
REKPYCLDIDECASSNGTLCAHICINTLGSYRCECREGYIREDDGKTCTRGDKYPNDTGHEKS  
ENMVKAGTCCATCKEFYQMKQTVLQLKQKIALLPNNAADLGKYITGDKVLASNTYLPGPPGLP  
GGQGPSPGSPGKSPGFPMPGPPGQPGPRGSMGPMGSPDL SHIKQGRRGPVGP PGAPGRDG  
SKGERGAPGPRGSPGPPGSFDFLLMLADIRNDITELQEKVFGHRT HSSAEEFPLPQEFPSYP  
EAMD LGSGDDHPRRTETRD LRAPRDFYP

**Important features of the protein:****Signal peptide:**

amino acids 1-34

**N-glycosylation sites.**

amino acids 142-148, 182-188

**Tyrosine kinase phosphorylation site.**

amino acids 125-132

**N-myristoylation sites.**

amino acids 10-16, 143-149, 155-161, 196-202, 250-256

**Amidation site.**

amino acids 299-303

**Aspartic acid and asparagine hydroxylation site.**

amino acids 150-162

**Cell attachment sequence.**

amino acids 176-179

**Clq domain proteins.**

amino acids 247-280

**Calcium-binding EGF-like domain proteins pattern proteins.**

amino acids 144-165

83/550

**FIGURE 83**

ATCTGAGTGAGCTAACTGACACAATGAACTGTCAGGCATGTTTCTGCTCCTCTCTCTGGCTC  
TTTTCTGCTTTTAAACAGGTGTCTTCAGTCAGGGAGGACAGGTTGACTGTGGTGAGTTCCAGG  
ACCCCAAGGTCTACTGCACTCGGGAATCTAACCACACTGTGGCTCTGATGGCCAGACATATG  
GCAATAAATGTGCCTTCTGTAAGGCCATAGTGAAAAGTGGTGGAAAGATTAGCCTAAAGCATC  
CTGGAAAATGCTTGAGTTAAAGCCAATGTTTCTTGGTGACTTGCCAGCTTTTGCAGCCTTCTTT  
TCTCACTTCTGCTTATACTTTTGCTGGTGGATTCCCTTTAATTCATAAAGACATACCTACTCTG  
CCTGGGTCTTGAGGAGTTCAATGTATGTCTATTTCTCTTGATTCACTTGTCATAAAGTACATTC  
TGCAAAAGCAAAAA

84/550

## **FIGURE 84**

MKLSGMFLLLSLALFCFLTGVFSQGGQVDCGEFQDPKVYCTRESNPFCGSDGQTYGNKCAFCK  
AIVKSGGKISLKHPGKC

**Important features of the protein:**

**Signal peptide:**

amino acids 1-23

**N-myristoylation sites.**

amino acids 26-32, 52-58, 56-62, 69-75

**Kazal serine protease inhibitors family signature.**

amino acids 40-63

FIGURE 85

BNSDOCID: <WO\_\_\_0140466A2 | >



86/550

**FIGURE 86**

MQAPGRGPLGLRLMMPGRRGALREPGGCGSCLGVALALLLLLLPACCPVRAQNDTEPIVLEGK  
CLVVCDSPPSADGAVTSSLGISVRSGSAKVAFSATRSTNHEPSEMSNRTMTIYFDQVLVNIGN  
HFDLASSIFVAPRKGIYSFSFHVVKVYNRQTIQVSLMQNGYPVISAFAGDQDVTREAASNGVL  
LLMEREDKVHLKLERGNLMGGWKYSTFSGFLVFPL

**Important features of the protein:****Signal peptide:**

amino acids 1-48

**N-glycosylation sites.**

amino acids 53-57, 110-114

**N-myristoylation sites.**

amino acids 26-32, 27-33, 29-35, 33-39, 76-82, 205-211

**Amidation site.**

amino acids 16-20

**Clq domain signature.**

amino acids 117-148

**Clq domain proteins.**

amino acids 115-149

87/550

**FIGURE 87**

AGGGCCCGCGGGTGGAGAGAGCGACGCCCCGAGGGGATGGCGGCAGCGTCCCGGAGCGCCTCTG  
GCTGGGCGCTACTGCTGCTGGTGGCACTTTGGCAGCAGCGCGCGGCGGCTCCGGCGTCTTCC  
AGCTGCAGCTGCAGGAGTTCATCAACGAGCGCGGCGTACTGGCCAGTGGGCGGCCTTGCGAGC  
CCGGCTGCCGGACTTTCTTCCGCGTCTGCCTTAAGCACTTCCAGGCGGTCTCTCGCCCCGAC  
CCTGCACCTTCGGGACCGTCTCCACGCGCGTATTGGGCACCAACTCCTTCGCTGTCCGGGACG  
ACAGTAGCGGCGGGGGGCGCAACCCTCTCCAAGTGCCTTCAATTTACCTGGCCGGGTACCT  
TCTCGCTCATCATCGAAGCTTGGCACGCGCCAGGAGACGACCTGCGGCCAGAGGCCTTGCCAC  
CAGATGCACTCATCAGCAAGATCGCCATCCAGGGCTCCCTAGCTGTGGGTGAGAAGTGGTTAT  
TGGATGAGCAAACCAGCACCTCACAAGGCTGCGCTACTCTTACCGGGTCATCTGCAGTGACA  
ACTACTATGGAGACAACTGCTCCCGCCTGTGCAAGAAGCGCAATGACCACTTCGGCCACTATG  
TGTGCCAGCCAGATGGCAACTTGTCTGCTGCCCCGGTTGGACTGGGGAATATTGCCAACAGC  
CTATCTGTCTTTCGGGCTGTCTGAACAGAATGGCTACTGCAGCAAGCCAGCAGAGTGCCTCT  
GCCGCCCAGGCTGGCAGGGCCGGCTGTGTAACGAATGCATCCCCCACAATGGCTGTGCGCCACG  
GCACCTGCAGCACTCCCTGGCAATGTACTTGTGATGAGGGCTGGGGAGGCCTGTTTTGTGACC  
AAGATCTCAACTACTGCACCCACCACTCCCCATGCAAGAATGGGGCAACGTGCTCCAACAGTG  
GGCAGCGAAGCTACACCTGCACCTGTGCGCCAGGCTACACTGGTGTGGACTGTGAGCTGGAGC  
TCAGCGAGTGTGACAGCAACCCCTGTGCAATGGAGGCAGCTGTAAGGACCAGGAGGATGGCT  
ACCACTGCCTGTGTCTCCCGGCTACTATGGCCTGCACTGTGAACACAGCACCTTGAGCTGCG  
CCGACTCCCCCTGCTTCAATGGGGGCTCCTGCCGGGAGCGCAACCAGGGGGGCCAACTATGCTT  
GTGAATGTCCCCCAACTTCACCGGCTCCAAGTGCAGAGAAGAAAGTGGACAGGTGCACCAGCA  
ACCCCTGTGCCAACGGGGGACAGTGCCTGAACCGAGGTCCAAGCCGCATGTGCCGCTGCCGTC  
CTGGATTACGGGACCTACTGTGAAGTCCACGTGAGCGACTGTGCCCCGTAACCCCTTGCGCCC  
ACGGTGGCACTTGCCATGACCTGGAGAATGGGCTCATGTGCACCTGCCCTGCCGGCTTCTCTG  
GCCGACGCTGTGAGGTGCGGACATCCATCGATGCCTGTGCCTCGAGTCCCTGCTTCAACAGGG  
CCACCTGCTACACCGACCTCTCCACAGACACCTTTGTGTGCAACTGCCCTTATGGCTTTGTGG  
GCAGCCGCTGCGAGTTCCCCGTGGGCTTGCCGCCCAGCTTCCCCTGGGTGGCCGTCTCGCTGG  
GTGTGGGGCTGGCAGTGTGCTGGTACTGCTGGGCATGGTGGCAGTGGCTGTGCGGCAGCTGC  
GGCTTCGACGGCCGGACGACGGCAGCAGGGAAGCCATGAACAAGTGTGCGGACTTCCAGAAGG  
ACAACCTGATTCCTGCCGCCCAGCTTAAAAACACAAACCAGAAGAAGGAGCTGGAAGTGGACT  
GTGGCCTGGACAAGTCCAAGTGTGGCAAACAGCAAAACCACACATTGGACTATAATCTGGCCC  
CAGGGCCCCCTGGGGCGGGGGACCATGCCAGGAAAGTTTCCCCACAGTGACAAGAGCTTAGGAG  
AGAAGGCGCCACTGCGGTTACACAGTGAAAAGCCAGAGTGTGCGATATCAGCGATATGCTCCC  
CCAGGGACTCCATGTACCAGTCTGTGTGTTTGATATCAGAGGAGAGGAATGAATGTGTGATTG  
CCACGGAGGTATTAAGGAGGAGCCTACCTGGACATCCCTGCTCAGCCCCGCGGCTGGACCTTC  
CTTCTGCATTGTTTACA

88/550

**FIGURE 88**

MAAASRSASGWALLLLVALWQQRAAGSGVFQLQLQEFINERGVLASGRPCEPGCRTFFRVCLK  
 HFQAVVSPGPCTFGTVSTPVLGTNSFAVRDDSSGGGRNPLQLPFNFTWPGTFSLIIEAWHAPG  
 DDLRPEALPPDALISKIAIQGSLAVGQNWLLDEQTSTLTRLRYSYRVICSDNYYGDNCSRLCK  
 KRNDHFGHYVCQPDGNLSCLPGWTGEYCQQPICLSGCHEQNGYCSKPAECLCRPGWQGRLCNE  
 CIPHNGCRHGTCSTPWQCTCDEGWGGLFCDQDLNYCTHSPCKNGATCSNSGQRSYTCTCRPG  
 YTGVDCELELSECDNPNCRNGGSKDQEDGYHCLCPPGYGLHCEHSTLSCADSPCFNGGSCR  
 ERNQGANYACECPPNFTGSNCEKKVDRCTSNPCANGGQCLNRGPSRMCRCRPGFTGTYCELHV  
 SDCARNPCAHGGTCHDLENGLMCTCPAGFSGRRCVRTSIDACASSPCFNRTCYTDLSTDTF  
 VCNCYPYGFVGSRCFFVGLPPSFPWVAVSLGVGLAVLLVLLGMVAVAVRQLRLRRPDDGSREA  
 MNNLSDFQKDNLI PAAQLKNTNQKKELEVDCGLDKSNCGKQQNHTLDYNLAPGPLGRGTM PGK  
 FPHSDKSLGEKAPLRLHSEKPECRISAICSPRDSMYQSVCLISEERNECVIATEV

**Important features of the protein:****Signal peptide:**

amino acids 1-26

**Transmembrane domain:**

amino acids 530-552

**N-glycosylation sites.**

amino acids 108-112, 183-187, 205-209, 393-397, 570-574, 610-614

**Glycosaminoglycan attachment site.**

amino acids 96-100

**Tyrosine kinase phosphorylation site.**

amino acids 340-347

**N-myristoylation sites.**amino acids 42-48, 204-210, 258-264, 277-283, 297-303, 383-389,  
415-421, 461-467, 522-528, 535-541, 563-569, 599-605, 625-631**Amidation site.**

amino acids 471-475

**Aspartic acid and asparagine hydroxylation site.**

amino acids 339-351

**EGF-like domain cysteine pattern signature.**amino acids 173-185, 206-218, 239-251, 270-282, 310-322, 348-360,  
388-400, 426-438, 464-476, 506-518**Calcium-binding EGF-like:**amino acids 224-245, 255-276, 295-316, 333-354, 373-394, 411-432,  
449-470

89/550

**FIGURE 89**

GTCTCCGCGTCACAGGAACCTTCAGCACCCACAGGGCGGACAGCGCTCCCCTCTACCTGGAGAC  
TTGACTCCCGCGCGCCCCAACCCCTGCTTATCCCTTGACCGTCGAGTGTGAGAGATCCTGCAGC  
CGCCAGTCCCGGCCCCCTCTCCCGCCCCACACCCACCCTCCTGGCTCTTCCTGTTTTTACTCC  
TCCTTTTCATTTCATAACAAAAGCTACAGCTCCAGGAGCCCAGCGCCGGGCTGTGACCCAAGCC  
GAGCGTGGAAGAATGGGGTTCCTCGGGACCGGCACTTGGAATTCTGGTGTTAGTGCTCCCGATT  
CAAGCTTTCCCCAAACCTGGAGGAAGCCAAGACAAATCTCTACATAATAGAGAATTAAGTGCA  
GAAAGACCTTTGAATGAACAGATTGCTGAAGCAGAAGAAGACAAGATTAAAAAACATATCCT  
CCAGAAAACAAGCCAGGTCAGAGCAACTATTCTTTTGTGATAACTTGAACCTGCTAAAGGCA  
ATAACAGAAAAGGAAAAAATTGAGAAAGAAAGACAATCTATAAGAAGCTCCCCACTTGATAAT  
AAGTTGAATGTGGAAGATGTTGATTCAACCAAGAATCGAAAACCTGATCGATGATTATGACTCT  
ACTAAGAGTGGATTGGATCATAAATTTCAAGATGATCCAGATGGTCTTCATCAACTAGACGGG  
ACTCCTTTAACCGCTGAAGACATTGTCCATAAAATCGCTGCCAGGATTTATGAAGAAAATGAC  
AGAGCCGTGTTTGACAAGATTGTTTCTAACTACTTAATCTCGGCCTTATCACAGAAAGCCAA  
GCACATACACTGGAAGATGAAGTAGCAGAGGTTTTACAAAAATTAATCTCAAAGGAAGCCAAC  
AATTATGAGGAGGATCCCAATAAGCCCACAAGCTGGACTGAGAATCAGGCTGGAAAAATACCA  
GAGAAAGTGACTCCAATGGCAGCAATTCAAGATGGTCTTGCTAAGGGAGAAAACGATGAAACA  
GTATCTAACACATTAACCTTGACAAATGGCTTGGAAGGAGAACTAAAACCTACAGTGAAGAC  
AACTTTGAGGAACTCCAATATTTCCCAAATTTCTATGCGCTACTGAAAAGTATTGATTCAGAA  
AAAGAAGCAAAAGAGAAAGAAACACTGATTACTATCATGAAAACACTGATTGACTTTGTGAAG  
ATGATGGTGAAATATGGAACAATATCTCCAGAAGAAGGTGTTTCCTACCTTGAAAACCTGGAT  
GAAATGATTGCTCTTCAGACCAAAAACAAGCTAGAAAAAAATGCTACTGACAATATAAGCAAG  
CTTTTCCCAGCACCATCAGAGAAGAGTCATGAAGAAACAGACAGTACCAAGGAAGAAGCAGCT  
AAGATGGAAAAGGAATATGGAAGCTTGAAGGATTCCACAAAAGATGATAACTCCAACCCAGGA  
GGAAAGACAGATGAACCCAAGGAAAAACAGAAGCCTATTTGGAAGCCATCAGAAAAAATATT  
GAATGGTTGAAGAAACATGACAAAAAGGGAAATAAAGAAGATTATGACCTTTCAAAGATGAGA  
GACTTCATCAATAAACAAGCTGATGCTTATGTGGAGAAAGGCATCCTTGACAAGGAAGAAGCC  
GAGGCCATCAAGCGCATTTATAGCAGCCTGTAAAAATGGCAAAAGATCCAGGAGTCTTTCAAC  
TGTTTCAGAAAACATAATATAGCTTAAACACTTCTAATTCTGTGATTAAATTTTTTGACCC  
AAGGGTTATTAGAAAGTGCTGAATTTACAGTAGTTAACCTTTTACAAGTGGTTAAACATAGC  
TTTCTTCCCGTAAAAACTATCTGAAAGTAAAGTTGTATGTAAGCTGAAAAAAAAAAAAAAAAA  
AAA

90/550

**FIGURE 90**

MGFLGTGTWILVLVLPIQAFPKPGGSQDKSLHNRELSAERPLNEQIAEAEEDKIKKTYPPENK  
PGQSNYSFVDNLNLLKAITEKEKIEKERQSIRSSPLDNKLNVEDVDSTKNRKLIDDYDSTKSG  
LDHKFQDDPDGLHQLDGTPLTAEDIVHKIAARIYEENDRAVFDKIVSKLLNLGLITESQAHTL  
EDEVAEVLQKLISKEANNYEEDPNKPTSWTENQAGKIPEKVTPMAAIQDGLAKGENDETVSNT  
LTLTNGLERRTKTYSEDNFEELQYFPNFYALLKSIDSEKEAKEKETLITIMKTLIDFVKMMVK  
YGTISPEEGVSYLENLDEMIALQTKNKLEKNATDNISKLFAPSEKSHEETDSTKEEAAKMEK  
EYGSLKDSTKDDNSNPGGKTDEPKGKTEAYLEAIRKNIEWLKKHDKKGNKEDYDLSKMRDFIN  
KQADAYVEKGILDKEEAIAIKRIYSSL

**Important features:****N-glycosylation sites:**

amino acids 68-71, 346-349, 350-353

**Casein kinase II phosphorylation site:**

amino acids 70-73, 82-85, 97-100, 125-128, 147-150, 188-191, 217-  
220, 265-268, 289-292, 305-308, 320-323, 326-329, 362-365, 368-  
341, 369-372, 382-385, 386-389, 387-390

**N-myristoylation sites:**

amino acids 143-148, 239-244

91/550

**FIGURE 91**

TGCATCAGTGCCCAGGCAAGCCCAGGAGTTGACATTTCTCTGCCCAGCC**ATG**GGCCTCACCCCT  
GCTCTTGCTGCTGCTCCTGGGACTAGAAGGTCAGGGCATAGTTGGCAGCCTCCCTGAGGTGCT  
GCAGGCACCCGTGGGAAGCTCCATTCTGGTGCAGTGCCACTACAGGCTCCAGGATGTCAAAGC  
TCAGAAAGGTGTGGTGCCGGTTCTTGCCGGAGGGGTGCCAGCCCCTGGTGTCTCAGCTGTGGA  
TCGCAGAGCTCCAGCGGGCAGGCGTACGTTTCTCACAGACCTGGGTGGGGGCTGCTGCAGGT  
GGAAATGGTTACCCTGCAGGAAGAGGATGCTGGCGAGTATGGCTGCATGGTGGATGGGGCCAG  
GGGGCCCCAGATTTTGCACAGAGTCTCTCTGAACATACTGCCCCCAGAGGAAGAAGAAGAGAC  
CCATAAGATTGGCAGTCTGGCTGAGAACGCATTCTCAGACCCTGCAGGCAGTGCCAACCCTTT  
GGAACCCAGCCAGGATGAGAAGAGCATCCCCTTGATCTGGGGTGCTGTGCTCCTGGTAGGTCT  
GCTGGTGGCAGCGGTGGTGCTGTTTGCTGTGATGGCCAAGAGGAAACAAGAATCCCTCCTCAG  
TGGTCCACCACGTCAG**TGA**CTCTGGACCGGCTGCTGAATTGCCTTTGGATGTACCACACATTA  
GGCTTGACTCACCACCTTCATTTGACAATACCACCTACACCAGCCTACCTCTTGATTCCCCAT  
CAGGAAAACCTTCACTCCCAGCTCCATCCTCATTGCCCCCTCTACCTCCTAAGGTCCTGGTCT  
GCTCCAAGCCTGTGACATATGCCACAGTAATCTTCCCGGGAGGGAACAAGGGTGGAGGGACCT  
CGTGTGGGGCCAGCCCAGAATCCACCTAACAATCAGACTCCATCCAGCTAAGCTGCTCATCACA  
CTTTAAACTCATGAGGACCATCCCTAGGGGTCTGTGCATCCATCCAGCCAGCTCATGCCCTA  
GGATCCTTAGGATATCTGAGCAACCAGGGACTTTAAGATCTAATCCAATGTCCTAACTTTACT  
AGGGAAAGTGACGCTCAGACATGACTGAGATGTCTTGGGGAAGACCTCCCTGCACCCAACTCC  
CCCCTGGTTCTTCTACCATTAACACTGGGCTAAATAAACCTAATAATGATGTGCAAAAAA  
AAA

92/550

**FIGURE 92**

MGLTLLLLLLLLLGLEGQGIVGSLPEVLQAPVGSSILVQCHYRLQDVKAQKVWCRFLPEGCQPLV  
SSAVDRRAPAGRRTFLTDLGGGLLQVEMVTLQEEDAGEYGCMVDGARGPQILHRVSLNILPPE  
EEEETHKIGSLAENAFSDPAGSANPLEPSQDEKSIPLIWGAVLLVGLLVAAVVLFAVMAKRKQ  
ESLLSGPPRQ

**Important features of the protein:****Signal peptide:**

amino acids 1-15

**Transmembrane domain:**

amino acids 161-181

**N-myristoylation sites.**

amino acids 17-23, 172-178

**Amidation site.**

amino acids 73-79

93/550

FIGURE 93

GGCGGCGTTGCCGGGCTCTCCGGAAGGAGACGTGGCGGCGGTTGGGCGGTTGATACCCGGGCG  
CTTTATAGTCCCGCCGCCTCCTCCTCCACCTCCTCCTCCTCCTCCTCCTCCTGGGGCAGAG  
GAGGTTGTGGCGGTGGCTGGAGAAAGCGGCGGCGGAGGATGAGGAAGGAGGCGGCGGCGTAC  
GGAGTCTGGTCCCGGGCGGGCCGGTGTTACTGGTCTCTGCGGCCCTCTGGAGGCGTCCGGCG  
GCGGCCGAGCCCTTCTCAACTCAGCGATGACATCCCTTTCCGAGTCAACTGGCCCGGCACCG  
AGTTCTCTCTGCCCACAACCTGGAGTTTTATATAAAGAAGATAATTATGTCATCATGACAACCTG  
CACATAAAGAAAAATATAAATGCATACTTCCCCTTGTGACAAGTGGGGATGAGGAAGAAGAAA  
AGGATTATAAAGGCCCTAATCCAAGAGAGCTTTTGGAGCCACTATTTAAACAAAGCAGTTGTT  
CCTACAGAATTGAGTCTTATTGGACTTACGAAGTATGTCATGGAAAACACATTCGGCAGTACC  
ATGAAGAGAAAGAACTGGTCAGAAAATAAATATTCACGAGTACTACCTTGGGAATATGTTGG  
CCAAGAACCTTCTATTTGAAAAAGAACGAGAAGCAGAAGAAAAGGAAAAATCAAATGAGATTC  
CCACTAAAAATATCGAAGGTCAGATGACACCATACTATCCTGTGGGAATGGGAAATGGTACAC  
CTTGTAGTTTGAAACAGAACC GGCCCGAGATCAAGTACTGTGATGTACATATGTCATCCTGAAT  
CTAAGCATGAAATTCTTTCAAGTAGCTGAAGTTACAACCTGTGAATATGAAGTTGTCATTTTGA  
CACCCTCTTGTGCAGTCATCCTAAATATAGGTTTCAAGCATCTCCTGTGAATGACATATTTT  
GTCAATCACTGCCAGGATCTCCATTTAAGCCCCCTCACCCTGAGGCAGCTGGAGCAGCAGGAAG  
AAATACTAAGGGTGCCTTTTAGGAGAAATAAAGAGGGTGTCGGTTGGTGGAAATATGAATTCT  
GCTATGGCAAACATGTACATCAATACCATGAGGACAAGGATAGTGGGAAAACCTCTGTGGTTG  
TCGGGACATGGAACCAAGAAGAGCATATTGAATGGGCTAAGAAGAATACTGCTAGAGCTTATC  
ATCTTCAAGACGATGGTACCCAGACAGTCAGGATGGTGTACATTTTTTATGGAAATGGAGATA  
TTTGTGATATAACTGACAAACCAAGACAGGTGACTGTAAACTAAAGTGCAAAGAATCAGATT  
CACCTCATGCTGTTACTGTATATATGCTAGAGCCTCACTCCTGTCAATATATTCTTGGGGTTG  
AATCTCCAGTGATCTGTAAAATCTTAGATACAGCAGATGAAAATGGACTTCTTTCTCTCCCA  
ACTAAAGGATATTAAGTTAGGGGAAAGAAAAGATCATTGAAAGTCATGATAATTTCTGTCCC  
ACTGTGTCTCATTATAGAGTTCTCAGCCATTGGACCTCTTCTAAAGGATGGTATAAAATGACT  
CTCAACCACTTTGTGAATACATATGTGTATATAAGAGGTTATTGATAAACTTCTGAGGCAGAC  
ATTTGTCTCGCTTTTTTTTCATTTTTGTTGTGTCTTATAAACTGACTGTTTTTCTTTGCTTGGA  
TACTGTGATTCCAAAATAAATCTCATCCAAGCAAGTTAGAGTCCAGCCTAATCAAATGTCATA  
ATTGTTGTACCTATTGAAAGTTTTTAAATAATAGATTTATTATGTAAATTATAGTATATGTAA  
GTAGCTAATGAAGTAAAGATCATGAAGAAAGAAATTGATAGGTGTAAATGAGAGACCATGTAA  
AATATGTAAATTCTAGTACCTGAAATCCTTTCAACAGATTTTTATATAGCAACTGCTCTCTGC  
AAGTAGTTAACTAGAACTGGGCACATGGTAGAGGCTCACATGGGAGTTGTCCTCACCCTTG  
TTAATCTCAAGAACTCTTATTTATAATAGGTTGCTTCTCTCTCAGAACTTTTATCTATTACT  
TTTTTCTTCTTATGAGTATGTTTACTCTCAGAGTATCTATCTGATGTAGACAGTTGGTGTATGC  
TTCTGAGACTCAGAATGGTTTACTCTAACAAAACACTGTGCTGTCTATCCCTTGTACTTGCCT  
ACTGTAATATGGATTTCACTTCTGAACAGTTTACAGCACAATATTTATTTTAAAGTGAATAAA  
ATGTCCACAAGCAAAA



94/550

**FIGURE 94**

MEEGGGGVRSLSVPGGPVLLVLCGLLEASGGGRALPQLSDDIPFRVNWPGTEFSLPTTGVLVLYKE  
DNYVIMTTAHKEKYKCILPLVTSGDEEEEEKDYKGPNPRELLEPLFKQSSCSYRIESYWYEVVC  
HGKHIRQYHEEKETGQKINIHEYLLGNMLAKNLLFEKEREAEKEKSNEIPTKNIEGQMTPLY  
PVGMGNGTPCSLKQNRPRSSTVMYICHPESKHEILSVAEVTTCYEVVILTPLLCSHPKYRFR  
ASPVNDIFCQSLPGSPFKPLTLRQLEQQEEILRVPFRRNKEGVGWWKYEFCYGKHVHQYHEDK  
DSGKTSVVVGWTWNQEEHIEWAKKNTARAYHLQDDGTQTVRMVSHFYGNNGDIDITDKPRQVTV  
KLKCKESDSPHAVTVYMLEPHSCQYILGVESPVICKIILDTADENGLLSLPN

**Important features of the protein:****Signal peptide:**

amino acids 1-30

**Glycosaminoglycan attachment site.**

amino acids 28-32

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 337-341

**N-myristoylation sites.**amino acids 6-12, 23-29, 29-35, 49-55, 141-147, 152-158, 192-198,  
196-202**Gram-positive cocci surface proteins 'anchoring' hexapeptide.**

amino acids 54-60

95/550

**FIGURE 95**

TTCCGTTTCTGGGAGGAGTGAGGGGCAACGGGTCGGAGAAAAAGGAAAAAAGAAGGGCTCAGC  
GCCTCCCCGCCGGGCGGTGGACAGAGGGGACAGTTTCGGCAGGCGGGTGAGGTCGCTGAGGG  
CCCGCCGGAGATGTTTTCTTGTGCGAGCACGGTGCAACCCCAGGTTACAGTTCCTCTGAGTCA  
TCTCATCAATGCCTTCCATACACCAAAAAACACTTCTGTTTCTCTCAGTGGAGTGTGAGTTTC  
TCAAAACCAGCATCGAGATGTAGTTCCTGAGCATGAGGCTCCCAGCAGTGAGCCTTCACTTAA  
CTTAAGGGACCTTGGATTATCTGAACTAAAAATTGGACAGATTGATCAGCTGGTAGAAAATCT  
ACTTCTGGATTTTGTAAAGGCAAAAAACATTTCTTCCCATTGGCATAACATCCCATGTCTCTGC  
ACAATCCTTCTTTGAAAATAAATATGGTAACTTAGATATATTTAGTACATTACGTTCTCTTG  
CTTGATCGACATCATTCAAGAGCTCTTCAAAGCATTGTTCAGATCTTCAGTACTGGCCAGT  
TTTCATACAGTCTCGGGGTTTTAAACTTTGAAATCAAGGACACGACGTCTCCAGTCTACCTC  
CGAGAGATTAGCTGAAACACAGAATATAGCGCCATCATTTCGTGAAGGGGTTTTCTTTTGCGGGA  
CAGAGGATCAGATGTTGAGAGTTTGGACAACTCATGAAAACCAAAAATATACCTGAAGCTCA  
CCAAGATGCATTTAAACTGGTTTTGCGGAAGGTTTTCTGAAAGCTCAAGCACTCACACAAAA  
AACCAATGATTCCCTAAGGCGAACCCGTCTGATTCTCTTCGTTCTGCTGCTATTTCGGCATTTA  
TGGACTTCTAAAAAACCCATTTTTATCTGTCCGCTTCGGGACAACAACAGGGCTTGATTCTGC  
AGTAGATCCTGTCCAGATGAAAAATGTCACCTTTGAACATGTTAAAGGGGTGGAGGAAGCTAA  
ACAAGAATTACAGGAAGTTGTTGAATTCTTGAAAAATCCACAAAAATTTACTATTCTTGAGG  
TAACTTCCAAAAGGAATTCTTTTAGTTGGACCCCCAGGGACTGGAAAGACACTTCTTGCCCG  
AGCTGTGGCGGGAGAAGCTGATGTTCTTTTTATTATGCTTCTGGATCCGAATTTGATGAGAT  
GTTTGTGGGTGTGGGAGCCAGCCGTATCAGAAATCTTTTTAGGGAAGCAAAGGCGAATGCTCC  
TTGTGTTATATTTATTGATGAATTAGATTCTGTTGGTGGGAAGAGAATTGAATCTCCAATGCA  
TCCATATTCAAGGCAGACCATAAATCAACTTCTTGCTGAAATGGATGGTTTTAAACCCAATGA  
AGGAGTTATCATAATAGGAGCCACAACTTCCCAGAGGCATTAGATAATGCCTTAATACGTCC  
TGGTCGTTTTTGACATGCAAGTTACAGTTCGAAGGCCAGATGTAAAAGGTCGAACAGAAATTTT  
GAAATGGTATCTCAATAAAATAAAGTTTGATCAATCCGTTGATCCAGAAATTATAGCTCGAGG  
TACTGTTGGCTTTTTCCGGAGCAGAGTTGGAGAATCTTGTGAACCAGGCTGCATTTAAAGCAGC  
TGTTGATGGAAAAGAAATGGTTACCATGAAGGAGCTGGAGTTTTCCAAAGACAAAATTCTAAT  
GGGGCCTGAAAGAAGAAGTGTGGAAATTGATAACAAAAACAAAACCATCACAGCATATCATGA  
ATCTGGTCATGCCATTATTGCATATTACACAAAAGATGCAATGCCTATCAACAAAGCTACAAT  
CATGCCACGGGGGCCAACACTTGGACATGTGTCCCTGTTACCTGAGAATGACAGATGGAATGA  
AACTAGAGCCCAGCTGCTTGCACAAATGGATGTTAGTATGGGAGGAAGAGTGGCAGAGGAGCT  
TATATTTGGAACCGACCATATTACAACAGGTGCTTCCAGTGATTTTGATAATGCCACTAAAAT  
AGCAAAGCGGATGGTTACCAAATTTGGAATGAGTGAAAAGCTTGGAGTTATGACCTACAGTGA  
TACAGGGAAACTAAGTCCAGAAACCAATCTGCCATCGAACAAAGAAATAAGAATCCTTCTAAG  
GGACTCATATGAACGAGCAAAACATATCTTGAAAACCTCATGCAAAGGAGCATAAGAATCTCGC  
AGAAGCTTTATTGACCTATGAGACTTTGGATGCCAAAGAGATTCAAATTGTTCTTGAGGGGAA  
AAAGTTGGAAGTGAGATTGATAACTCTCTTGATATGGATGCTTGCTGGTTTTATTGCAAGAATA  
TAAGTAGCATTGCAGTAGTCTACTTTTACAACGCTTTCCCCTCATTCTTGATGTGGTGTAATT  
GAAGGGTGTGAAATGCTTTGTCAATCATTTGTACATTTATCCAGTTTGGGTTATTCTCATT  
TGACACCTATTGCAAATTAGCATCCCATGGCAAATATATTTTGAAAAATAAAGAACTATCAG  
GATTGAAAACAAAAA

96/550

**FIGURE 96**

MFSLSSSTVQPQVTVPLSHLINAFHTPKNTSVSLSGVSVSQNQHRDVVPEHEAPSSEPSLNLRD  
LGLSELKIGQIDQLVENLLPGFCKGKNISSHWHTSHVSAQSFFENKYGNLDIFSTLRSSCLYR  
HHSRALQSICSDLQYWPVFIQSRGFKTLKSRTTRRLQSTSERLAETQNIAPSFVKGFLLRDRGS  
DVESLDKLMKTKNIPEAHQDAFKTGFAEGFLKAQALTQKTNDLSLRTRLILFVLLLFGIYGLL  
KNPFLSVRFRTTTGLDSAVDPVQMKNVTFEHVKGVEEAKQELQEVVEFLKNPQKFTILGGKLP  
KGILLVGPPGTGKTLLARAVAGEADVPFYYASGSEFDEMFGVGASRIRNLFREAKANAPCVI  
FIDELDSVGGKRIESPMHPYSRQTIHQLLAEMDGFKPNEGVIIGATNFPEALDNALIRPGRF  
DMQVTVPRPDVKGRTEILKWYLNKIKFDQSVDPETIARGTVGFGAELENLVNQAAALKAAVDG  
KEMVTMKELEFSKDKILMGPERRSVEIDNKNKTITAYHESGHAIAYYTKDAMPINKATIMPR  
GPTLGHVSLLPENDRWNETRAQLLAQMDVSMGGRVAEELIFGTDHITTGASSDFDNATKIAKR  
MVTKFGMSEKLGVMYSDTGKLSPETQSAIEQEIRILLRDSYERAKHILKTHAKEHKNLAEAL  
LTYETLDAKEIQIVLEGKKLEVR

**Important features of the protein:****Transmembrane domain:**

amino acids 238-259

**N-glycosylation sites.**amino acids 28-32, 90-94, 230-234, 278-282, 535-539, 584-588,  
623-627**N-myristoylation sites.**

amino acids 35-41, 266-272, 286-292, 325-331, 357-363, 599-605

**Amidation site.**

amino acids 387-393, 709-713

**ATP/GTP-binding site motif A (P-loop).**

amino acids 322-330

**AAA-protein family proteins**

amino acids 315-336, 343-386, 405-451

97/550

**FIGURE 97**

GATGGCGCAGCCACAGCTTCTGTGAGATTGATTTCTCCCCAGTTCCCCTGTGGGTCTGAGGG  
GACCAGAAGGGTGAGCTACGTTGGCTTTCTGGAAGGGGAGGCTATATGCGTCAATCCCCAAA  
ACAAGTTTTGACATTTCCCCTGAAATGTCATTCTCTATCTATTCAGTCAAGTGCCTGCTGTT  
CCAGGCCTTACCTGCTGGGCACTAACGGCGGAGCCAGGATGGGGACAGAATAAAGGAGCCACG  
ACCTGTGCCACCAACTCGCACTCAGACTCTGAACTCAGACCTGAAATCTTCTCTTCACGGGAG  
GCTTGGCAGTTTTTCTTACTCCTGTGGTCTCCAGATTTTCAGGCCTAAGATGAAAGCCTCTAGT  
CTTGCCCTTCAGCCTTCTCTCTGCTGCGTTTTATCTCCTATGGACTCCTTCCACTGGACTGAAG  
ACACTCAATTTGGGAAGCTGTGTGATCGCCACAAACCTTCAGGAAATACGAAATGGATTTTCT  
GAGATACGGGGCAGTGTGCAAGCCAAAGATGGAAACATTGACATCAGAATCTTAAGGAGGACT  
GAGTCTTTGCAAGACACAAAGCCTGCGAATCGATGCTGCCTCCTGCGCCATTTGCTAAGACTC  
TATCTGGACAGGGTATTTAAAACTACCAGACCCCTGACCATTATACTCTCCGGAAGATCAGC  
AGCCTCGCCAATTCCTTTCTTACCATCAAGAAGGACCTCCGGCTCTCTCATGCCACATGACA  
TGCCATTGTGGGGAGGAAGCAATGAAGAAATACAGCCAGATTCTGAGTCACTTTGAAAAGCTG  
GAACCTCAGGCAGCAGTTGTGAAGGCTTTGGGGGAACTAGACATTCTTCTGCAATGGATGGAG  
GAGACAGAAATAGGAGGAAAGTGATGCTGCTGCTAAGAATATTCGAGGTCAAGAGCTCCAGTCT  
TCAATACCTGCAGAGGAGGCATGACCCCAAACCACCATCTCTTTACTGTACTAGTCTTGTGCT  
GGTCACAGTGTATCTTATTTATGCATTACTTGCTTCCTTGCATGATTGTCTTTATGCATCCCC  
AATCTTAATTGAGACCATACTTGTATAAGATTTTTGTAATATCTTTCTGCTATTGGATATATT  
TATTAGTTAATATATTTATTTATTTTTTGGCTATTTAATGTATTTATTTTTTTACTTGGACATG  
AACTTTAAAAAAATTCACAGATTATATTTATAACCTGACTAGAGCAGGTGATGTATTTTTAT  
ACAGTAAAAAAAACCTTGTAATTCTAGAAGAGTGGCTAGGGGGGTATTTCATTTGTAT  
TCAACTAAGGACATATTTACTCATGCTGATGCTCTGTGAGATATTTGAAATTGAACCAATGAC  
TACTTAGGATGGGTGTGGAATAAGTTTTGATGTGGAATTGCACATCTACCTTACAATTACTG  
ACCATCCCCAGTAGACTCCCCAGTCCCATAATTGTGTATCTTCCAGCCAGGAATCCTACACGG  
CCAGCATGTATTTCTACAAATAAAGTTTTCTTTGCATACCAAAAAAAAAAAAAAAAAAAAAA

98/550

**FIGURE 98**

MKASSLAFSLLSAAFYLLWTPSTGLKTLNLGSCVIATNLQEIRNGFSEIRGSVQAKDGNIDIR  
ILRRTESLQDTKPANRCCLLRHLLRLYLDRVFKNYQTPDHYTLRKISSLANSELTIKKDLRLC  
HAHMTCHCGEEAMKKYSQILSHFEKLEPQAQAVVKALGELDILLQWMEETE

**Signal sequence:**

amino acids 1-24

**cAMP- and cGMP-dependent protein kinase phosphorylation sites.**

amino acids 107-110, 140-143

**N-myristoylation site.**

amino acids 51-56

**Interleukin 10:**

amino acids 9-176

99/550

**FIGURE 99**

GCGCCGGCTCCGCGCCTCGCGCCAGTCCGCGGGCCGCGCCGCGCTCCCGCCGCTCCCGCCG  
CTCCCGCAGCCGCCCCGCGCCCGCCCGGAGCCCCGCGTCCCTAGGCCTGGCTCCCGCCTGCC  
CGAGACCCGCCCAGCCTGCCCCGCTCAGCCGCCAGAGAAG**ATG**CGGCTGCTCCCGGAATGGTT  
CCTCTTGCTCTTTGGCCCCGTGGCTCCTTAGGAAGGCCGTCACTGCCAGATAACCAGAGTCCGG  
AAGGCCGCAGTACCTGGGGCTGCGCCCCGCGCGGGCCGGAGCGGGTGCCCCCGGCCAGCAGCT  
CCCAGAGCCAAGGTCTTCGGACGGCCTAGGCGTGGGGCCGCGCCTGGAGCTGGGCCTGGCCGAC  
CAACCACACGGGGGCGCTGGCCCCGGGCAGGGGCAGCCGGGGCGTTGCCCGCGCAGCGCACCAA  
GAGGAAGCCGTCCATCAAGGCGGCGCGCGCCAAAAAGATCTTCGGCTGGGGGGACTTCTACTT  
TCGGGTGCATACCCTCAAGTTTTCGCTGCTGGTGACCGGCAAGATCGTGACCATGTGAACGG  
TACCTTCAGTGTGTATTTCCGCCACAACCTCGTCCAGCCTGGGCAACCTCAGTGTACGCATCGT  
GCCGCCCTCCAAGCGTGTGAGTTCGGAGGAGTCTGGCTGCCCGGGCCTGTCCCCACCCTCT  
GCAGTCTACGCTCGCCCTGGAGGGGGTGCTTCCTGGGCTGGGGCCCCCGCTGGGGATGGCAGC  
AGCAGCGGCGGGGCGGGGCTTGGGGGCTCCCTCGGGGGCGCACTGGCGGGGCGCTTGGGGG  
CGCGTTGGGAGTGCTGGGGCCAAAGAGTCACGCGCTTTC AATTGCCACGTGGAGTATGAGAA  
GACAAACCGCGCGCGCAAGCACCGACCGTGCCTGTACGACCCGTCGCAGGTGTGTTTCACCGA  
GCACACGCAGAGCCAGGCCGCTGGCTCTGTGCCAAGCCCTTCAAAGTCATCTGTATCTTCGT  
CTCTTTCTCAGCTTTGACTACAACTGGTGAGAAGGTGTGCCCAGACTATAACTTCCAGAG  
TGAGCACCCCTACTTCGGAT**TAG**CGCCCCCTCCCCAGCCAGTCCTGAGCCTCCCGCCAAATCCCA  
GCCTCACTAGGTGGGACCCCCTTCCCAGTGTTCTGCCGCTCCTGTGGCCATGTGCCCCACTCC  
TTCCACTCTGGGGGCGGAGGGGAATGGCTTCTCGGGACCCCTCAGCTAGCGTGGGTGCCCTTTT  
CCTTATGCGGAGTGCCCGCAAGGCTGGGGTAGCCCCCTCCAGTACACCCCAAAGTGAAAGGGA  
TAAGAGTGCAGCCCCAGAATAGGCGGGGCTTGGAGGCGGTCCCAATGTCCCCTGGGTCCACAG  
TGGGTCCCCTTTTCACCCTTGGCGCTAGGCTGCGCACTCCCTTTCCCCGCAGCTTTAATAACT  
CCTGGCCTGGCACCCCTCACCCACCCTGACTTTCCCATCCCCAGCGCTTGTCTGCTTCACC  
ATACCCCGCCTAAGACTGTAAAGGCCTAAAAACCTCGGCCTGTCTCTCCACCATTCTGCCTGC  
CATATGCCTGTCCCCTTTTCTCCAAACCCTATTAGGGTACCGGAAGCAGAACCCCTGGGCTG  
AGGCCCTGGCCCTGCCCCCGGCCCTGCCCCTGCCCGCCCCCTCCAGTCCAGGCAGTCGAGC  
TCCACCTGCCCTCTCCTGCTGCTTCCTCTCGGTGATATTTTTTCTACGCCAAAACAGACGGGA  
AAGGGAACAAAATAAAGTGAAATCCCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AA  
AAAAAAAAAAAAAAAA

100/550

**FIGURE 100**

MRLLPWFLLLFPGWLLRKAVSAQIPESGRPQYLGLRPAAAGAGAPGQQLPEPRSSDGLGVGR  
AWSAWPTNHTGALARAGAAGALPAQRTKRKPSIKAARAKKIFGWGDFYFRVHTLKFSLLVTG  
KIVDHVNGTFSVYFRHNSSSLGNLSVSIVPPSKRVEFGGVWLPGPVPHPLQSTLALEGVLPGL  
GPPLGMAAAAAGPGLGGSLLGGALAGPLGGALGVPGAKESRAFNCHVEYEKTNRARKHRPCLYD  
PSQVCFTTEHTQSQAAWLCAKPFKVICIFVSFLSFDYKLVQKVC PDYNFQSEHPYFG

**Important features of the protein:****Signal peptide:**

amino acids 1-22

**Transmembrane domain:**

amino acids 273-288

**N-glycosylation sites.**

amino acids 72-76, 133-137, 143-147, 149-153

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 93-97

**N-myristoylation sites.**amino acids 35-41, 58-64, 60-66, 81-87, 84-90, 184-190, 194-200,  
203-209, 205-211, 206-212, 209-215, 217-223, 221-227, 224-230**Cytochrome b/b6 Qo site signature.**

amino acids 5-11

101/550

FIGURE 101

AATGCCCCATGCGCACCCACAGCTCGCGCTCCTGCAAGTGTTCTTTCTGGTGTTCCCCGATG  
GCGTCCGGCCTCAGCCCTCTTCTCCCCATCAGGGGCAGTGCCACGTCTTTGGAGCTGCAGC  
GAGGGACGGATGGCGGAACCCTCCAGTCCCCTTCAGAGGCGACTGCAACTCGCCCGGCCGTGC  
CTGGACTCCCTACAGTGGTCCCTACTCTCGTGACTCCCTCGGCCCTGGGAATAGGACTGTGG  
ACCTCTTCCCAGTCTTACCGATCTGTGTCTGTGACTTGACTCCTGGAGCCTGCGATATAAATT  
GCTGCTGCGACAGGGACTGCTATCTTCTCCATCCGAGGACAGTTTTCTCCTTCTGCCTTCCAG  
GCAGCGTAAGGTCTTCAAGCTGGGTTTGTGTAGACAACTCTGTTATCTTCAGGAGTAATTCCC  
CGTTTCCTTCAAGAGTTTTTCATGGATTCTAATGGAATCAGGCAGTTTTGTGTCCATGTGAACA  
ACTCAAACCTTAACTATTTCCAGAAGCTTCAAAGGTCAATGCAACCAACTTCCAGGCCCTGG  
CTGCAGAGTTTGGAGGCGAATCATTCACTTCAACATTCCAAACCTCAATCACCACCATCTTTTT  
ACAGGGCTGGGGACCCCATTTCTTACTTACTTCCCCAAGTGGTCTGTAATAAGCTTGCTGAGAC  
AACCTGCAGGAGTTGGAGCTGGGGGACTCTGTGCTGAAAGCAATCCTGCAGGTTTCCTAGAGA  
GTAAAGTACAACCTTGACTCGTTTTTTCAAGAACCTGGCTAGTAGCTGTACCTTGGAATTCAG  
CCCTCAATGCTGCCTCTTACTATAACTTCACAGTCTTAAAGGTTCCAAGAAGCATGACTGATC  
CACAGAATATGGAGTTCCAGGTTCCGTGTAATACTTACCTCACAGGCTAATGCTCCTCTGTTGG  
CTGGAAACACTTGTCAGAATGTAGTTTCTCAGGTCACCTATGAGATAGAGACCAATGGGACTT  
TTGGAATCCAGAAAGTTTCTGTCAAGTTTGGGACAAACCAACCTGACTGTTGAGCCAGGCGCTT  
CCTTACAGCAACACTTCATCCTTCGCTTCAGGGCTTTTCAACAGAGCACAGCTGCTTCTCTCA  
CCAGTCCTAGAAGTGGGAATCCTGGCTATATAGTTGGGAAGCCACTCTTGGCTCTGACTGATG  
ATATAAGTTACTCAATGACCCTCTTACAGAGCCAGGGTAATGGAAGTTGCTCTGTTAAAAGAC  
ATGAAGTGCAGTTTGGAGTGAATGCAATATCTGGATGCAAGCTCAGGTTGAAGAAGGCAGACT  
GCAGCCACTTGCAAGCAGGAGATTTATCAGACTCTTCATGGAAGGCCAGACCAGAGTATGTTG  
CCATCTTTGGTAATGCTGACCCAGCCAGAAAGGAGGGTGGACCAGGATCCTCAACAGGCACT  
GCAGCATTTAGCTATAAACTGTACTTCTGCTGTCTCATACCAGTTTCCCTGGAGATCCAGG  
TATTGTGGGCATATGTAGGTCTCCTGTCCAACCCGCAAGCTCATGTATCAGGAGTTTCGATTCC  
TATACCAGTGCCAGTCTATACAGGATTCTCAGCAAGTTACAGAAGTATCTTTGACAACTCTTG  
TGAACCTTGTGGACATTACCCAGAAGCCACAGCCTCCAAGGGGCCAACCCAAAATGGACTGGA  
AATGGCCATTGCACTTCTTTCCCTTCAAAGTGGCATTGAGCAGAGGAGTATTCTCTCAAAAAT  
GCTCAGTCTCTCCCATCCTTATCCTGTGCCTCTTACTACTTGAGATTCTCAACCTAGAGACTA  
TGTGAAGAAAAGAAAATAATCAGATTTTCAGTTTTCCCTATGAGAACTCTGAGGCAGCCACTT  
ATCTTGGCTAAATAGAACCTCACCTGCTCATGACCAGAGAGCATTTAGGATAATAGATGACCT  
AACTGAAGGAATCCTTGTATATGAAAGGAGTTATTTTAGAAAAGCAATAAAAATATTTTATTC  
ATCNTAAAAAAA



102/550

**FIGURE 102**

MRTPQLALLQVFFLVFPDGVRPQPSSSPSGAVPTSLELQRGTDGGTLQSPSEATATRPVAVPGL  
PTVVPTLVTPSAPGNRTVDLFPVLPICVCDLTPGACDINCCCDRDCYLLHPRTVFSFCLPGSV  
RSSSWVCVDNSVIFRSNSPFPSRVFMDSNQIRQFCVHVNNNSNLNYFQKLQKVNATNFQALAAE  
FGGESFTSTFQTQSPPSFYRAGDPILTYFPKWSVISLLRQPAGVGAGGLCAESNPAGFLESKS  
TTCTRFFKNLASSCTLDSALNAASYNFTVLKVPRSM TDPQNMEFQVPVILTSQANAPLLAGN  
TCQNVVSQVTYEIETNGTFGIQKVS VSLGQTNLTVEPGASLQQHFILRFRAFQQSTAASLTSP  
RSGNPGYIVGKPLLALTDDISYSMTLLQSQNGSCSVKRHEVQFGVNAISGCKLRLKKADCSH  
LQQEIIYQTLHGRPRPEYVAIFGNADPAQKGGWTRILNRHCSISAINCTSCCLIPVSLEIQVLW  
AYVGLLSNPQAHVSGVRFLYQCQSIQDSQQVTEVSLTTLVNFVDITQKPQPPRGQPKMDWKWP  
FDFFPFKVAFSRGVFSQKCSVSPILILCLLLLGVLNLETM

**Important features of the protein:****Signal peptide:**

amino acids 1-22

**Transmembrane domains:**

amino acids 484-505, 581-600

**N-glycosylation sites.**amino acids 78-82, 165-169, 179-185, 279-285, 331-337, 347-351,  
410-414, 487-491**N-myristoylation sites.**

amino acids 30-36, 41-47, 124-130, 232-238, 236-242, 409-415

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 420-431

103/550

FIGURE 103

CCTAATTCTCAAGGTGATGCTATTTAGGAAGTCATAACTCATGTGAGTGGAGCCATGTGGGAT  
TAAGAAGTGATAGGAGAGCTTGCTGTCTGTCTCTGCTCTCCACTGTGTGAGGATACAACAGGA  
AGACAGCCATCTGGTGAGGAAGAGAGGGCCCTCGCCAGATACCGGACCTGCTGACACCTTGAT  
CTTGGA CT TCCCATCTTCCAGGAAGGCCTGACCTCAGTTGTTCCAGGGTAAAGAATTTGGGCA  
GTGCCCACACCCACGCTGTTGGATAACATTTCTTCACCATAACCAGTGAGGGTGAATGTGTACA  
CGCCCAGCTTCCTGCCTGTTACTCTCCACAGTATGCGAAGAATATCCCTGACTTCTAGCCCTG  
TGCGCCTTCTTTTGT TTTCTGCTGTTGCTACTAATAGCCTTGAGATCATGGTTGGTGGTCACT  
CTCTTTGCTTCAACTTCACTATAAAATCATTGTCCAGACCTGGACAGCCCTGGTGTGAAGCGC  
AGGTCTTCTTGAATAAAAATCTTTTCTTTCAGTACAACAGTGACAACAACATGGTCAAACCTC  
TGGGCCTCCTGGGGAAGAAGGTATATGCCACCAGCACTTGGGGAGAATTGACCCAAACGCTGG  
GAGAAGTGGGGCGAGACCTCAGGATGCTCCTTTGTGACATCAAACCCAGATAAAGACCAGTG  
ATCCTTCCACTCTGCAAGTCGAGATGTTTTGTCAACGTGAAGCAGAACGGTGCCTGGTGCAT  
CCTGGCAGTTCGCCACCAATGGAGAGAAATCCCTCCTCTTTGACGCAATGAACATGACCTGGA  
CAGTAATTAATCATGAAGCCAGTAAGATCAAGGAGACATGGAAGAAAGACAGAGGGCTGGAAA  
AGTATTTTCAGGAAGCTCTCAAAGGGAGACTGCGATCACTGGCTCAGGGAATTCTTAGGGCACT  
GGGAGGCAATGCCAGAACCGACAGGCAGAAGATCCACCTTAGAGGTGATACCACGGCGGCGCAG  
AGTTGTTACCTGTGGTCCTCGATCGCTGACAGCCTTGCTCCCCTGCTGTGTGTTCCCTGA  
GTCAAGTGGAGGCGGAGCCTGCAATGAGCGGAGATCGCGCCTCTGCATTCCAGTCTTGGCAAC  
AGAGCAAGACTCCGTCTCAAAAAAAAAAAAAATTTTTTTTCAGTACATATTTTTTAAAGATAGG  
GCTGGGCACAGCAGCTCACATCTATAATCCCAACACTTTGGGAGGCCTAGGCAGGAGGATCAC  
TTGAGCCCAGGAATCTGAAGCTGCAGTGAGCCTTTGCTCGTGAGATTGTGGACCTATGATCCT  
ACCACCAGCCACCTGGTTCTAACACCCCCTCCTCTATGTGTGAGAGGGAGAGAAGAAAAGTG  
AGGGAGAAAAGAGAGATAAGCAAAGAACAGAGAGGAAAAATGGAATAAAGAGGAAATTGGGG  
GAATTAAACAGAGGGGAGGGCATGGATCCCCGGGAGTTAGAAGAGTAGCAGCTTGTGGATTAC  
TACGCAGTGGAGGAAGAAGAGTTGTTGGAAATTATTTGAGAGGTAGTATAATCATTTGTGAGG  
CAGTTTTCTGCATTACCATTTCTCACAGACTAAGTTACTCATAAGCAAACGTGCAATTCACA  
TTACACTGAAATTCTTCCCTAATACATCATTTGCATTGGAATAAAGTACGGTTTTCAAACAAC  
CTGATATAGCAGAACTGACTGTATAAATTATGTGAGCACAGTGCAAGTAATTCTTTGTTTGT  
TGTTTGT TTTTGTGAGACAGAGTCTCACTCTATCTCCAGGCTGGAGTGTAGTGGTGCGATCC  
CGGCTCACTGCAACCTCGATCTCCAGGCTCAAGCGATTCCCCTGCCTCAGCCTCCTGAGTAG  
CTGGGATTACAGGCATGAGCCACCACGCCCGGCTAATTTTTGTATTTTTAGTAGAGACGGGGT  
TTCACCCTGTTGGCCAGGCTGGTCTCGAACTACGGACCTCAGGTGATCTGCCCCCTCAGCCT  
CTCAAAGTGCTGGGATTATAGCATGAGCCACTGAGCCAGACACAAGTAGTTCTTTCTGATAA  
ACACTTTAACTGAATGCA

104/550

**FIGURE 104**

MRRISLTSSPVRLLLFLLLLLLIALEIMVGGHSLCFNFTIKSLSRPGQPWCEAQVFLNKNLFLQ  
YNSDNNMVKPLGLLGKKVYATSTWGELTQTLGEVGRDLRMLLCDIKPQIKTSDPSTLQVEMFC  
QREAEERCTGASWQFATNGEKSLLFDAMNMTWTVINHEASKIKETWKKDRGLEKYFRKLSKGDC  
DHWLREFLGHWPEAMPEPTGRRST

**Important features of the protein:****Signal peptide:**

amino acids 1-23

**Transmembrane domain:**

amino acids 11-30 (possible type II protein)

**N-glycosylation site.**

amino acids 36-39, 154-157

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 2-5, 182-185, 209-212

**Casein kinase II phosphorylation site.**

amino acids 86-89, 93-96, 142-145, 185-188

**N-myristoylation site.**

amino acids 46-51

**Amidation site.**

amino acids 77-80, 207-210

105/550

**FIGURE 105**

TTTTCCGAGTGACCTTCTTGATGCTGGCTGTTTCTCTCACCGTTCCCCTGCTTGGAGCCATGA  
TGCTGCTGGAATCTCCTATAGATCCACAGCCTCTCAGCTTCAAAGAACCCCCGCTCTTGCTTG  
GTGTTCTGCATCCAAATACGAAGCTGCGACAGGCAGAAAGGCTGTTTGAAAATCAACTTGTTG  
GACCGGAGTCCATAGCACATATTGGGGATGTGATGTTTACTGGGACAGCAGATGGCCGGGTCG  
TAAAACTTGAAAATGGTGAAATAGAGACCATTGCCCGGTTTGGTTCGGGCCCTTGCAAAACCC  
GAGATGATGAGCCTGTGTGTGGGAGACCCCTGGGTATCCGTGCAGGGCCCAATGGGACTCTCT  
TTGTGGCCGATGCATACAAGGGACTATTTGAAGTAAATCCCTGGAAACGTGAAGTGAACTGC  
TGCTGTCCTCCGAGACACCCATTGAGGGGAAGAACATGTCCTTTGTGAATGATCTTACAGTCA  
CTCAGGATGGGAGGAAGATTTATTTACCGATTCTAGCAGCAAATGGCAAAGACGAGACTACC  
TGCTTCTGGTGATGGAGGGCACAGATGACGGGCGCCTGCTGGAGTATGATACTGTGACCAGGG  
AAGTAAAAGTTTTATTGGACCAGCTGCGGTTCCTGAATGGAGTCCAGCTGTCTCCTGCAGAAG  
ACTTTGTCCTGGTGGCAGAAACAACCATGGCCAGGATACGAAGAGTCTACGTTTCTGGCCTGA  
TGAAGGGCGGGGCTGATCTGTTTGTGGAGAACATGCCTGGATTTCCAGACAACATCCGGCCCA  
GCAGCTCTGGGGGGTACTGGGTGGGCATGTCGACCATCCGCCCTAACCTGGGTTTTCCATGC  
TGGATTTCTTATCTGAGAGACCCTGGATTAAAAGGATGATTTTTAAGCTCTTTAGTCAAGAGA  
CGGTGATGAAGTTTGTGCCGCGGTACAGCCTCGTCCTAGAACTCAGCGACAGCGGTGCCTTCC  
GGAGAAGCCTGCATGATCCCGATGGGCTGGTGGCCACCTACATCAGCGAGGTGCACGAACACG  
ATGGGCACCTGTACCTGGGCTCTTTCAGGTCCCCCTTCCTCTGCAGACTCAGCCTCCAGGCTG  
TTTAGCCCCCTCCAGATAGCTGCCCTGCCACGCAGGCCAGGAGTCTTCACACTCAGGCACCAG  
GCCTGGTCCAGGAGGAGCTGTGGACACAGTCGTGGTTCAAGTGTCCACATGCACCTGTTAGTC  
CCTGAGAGGTGGTGGGAATGGCTGCTTCATTCCTCGAGGATGCCCGGGCCCCACCTGGGCTTG  
TCTTTCTGTTTAGAGGGAAGTGTAACATATCTGCCATGAGGAACATAAATTCATGTAAAGCCA  
TTTTCTCTTAAACAAAACAAAACCTTTCTAAGTACAATCATTCTCTAGGATTTGGGAAGCTCCT  
TGCACTTGGAACAGGGCTCAGGTGGGTGGAGCAGTAAGGCACTACCCAGAGAGCTTGCTGCTG  
CGGCCCTGTCTGCGGCCTCAAAGTTCTTCTTTACTATATATAACGTGCGGTCATACCTTTCT  
TCGTTGTGGTGGGGATGGAAGAGCAGAGGGAGCATGGCCCAGGGGTGTTGAGGCCAGCGGTGA  
GAGCCGTGTTAGCCAAGACATGGAAGTGTGTTCTCAAGGGTTATGTGGGGCGTGGGCTCTCCA  
TAGTGTGTATGAAAAGCTTGTTGACTCTAGCGGCTCAGAGAGGACTTTGCTGGGTTTCTTTCT  
GTGAATATCTCCGTGCTGACCATGCTGGAATTGGATGATTCTGCAATTCGGGACCTACTGCAG  
GGGTCCGTTTAGTAACGTCTTGTCTGTGATCTTTGTTCTTGACCTCTAGACCCCAAGATGTGA  
ACAGTGCACGTGTTAATGTCATCTTTGCTCATGTGTTATAAGCCCCAAGTTGCTGTATATTTT  
CACAAGTATGTCTACACACTGG

106/550

**FIGURE 106**

MLAVSLTVPLL GAMMLLES PIDPQPLSFKEPPLLGLV LHPNTKLRQAERLFENQLVGPESIAH  
IGDVMFTGTADGRVVKLENGEIETIARFGSGPCKTRDDEPVCGRPLGIRAGPNGTLFVADAYK  
GLFEVNPWKREVKLLLSSETPIEGKNMSFVNDLTVTQDGRKIYFTDSSSKWQRRDYLLVMEG  
TDDGRLL EYDTVTREVKVLLDQLRFPNGVQLSPAEDFVLVAETTMARIRRVYVSGLMKGGADL  
FVENMPGFPDNIRPSSSGGYWVG MSTIRPNPGFSMLDFL SERPWI KRMIFKLFSQETVMKFVP  
RYSLVLELSDSGAFRRSLHDPDGLVATYISEVHEHDGHLYLG SFRSPFLCRLSLQAV

**Important features of the protein:****Signal peptide:**

amino acids 1-13

**Transmembrane domain:**

amino acids 1-21 (possible type II)

**N-glycosylation sites.**

amino acids 116-119, 152-155

**Casein kinase II phosphorylation sites.**

amino acids 19-22, 27-30, 98-101, 146-149, 221-224, 286-289, 332-335

**N-myristoylation sites.**

amino acids 71-76, 92-97, 189-194, 244-249, 338-343

**Amidation site.**

amino acids 164-167

107/550

**FIGURE 107**

AACGAAGCGTGCGCGCTTTGGTAACCGGCTAGAAATCCCGCACGCGCGCCTGCCTCCTCTCCC  
CAGGCCTGAGCTGCCCCCTCCCCTGCTTTCTTTCTTCCCGCGAGTCAGAAGCTTCGCGAGGG  
CCCAGAGAGGCGGTGGGGTGGGCGACCCCTACGCCAGCTCCGGGCGGGAGAAAGCCCACCCTCT  
CCCGCGCCCCAGGAAACCGCGCGCTTCGGCGCTGCGCAGAGCC**ATGGAATTCTCCTGGCTGG**  
AGACGCGCTGGGCGCGGCCCTTTTACCTGGCGTTTCGTGTTCTGCCTGGCCCTGGGGCTGCTGC  
AGGCCATTAAGCTGTACCTGCGGAGGCAGCGGCTGCTGCGGGACCTGCGCCCCCTTCCCAGCGC  
CCCCACCCCTGGTTTCTTGGGCACCAGAAGTTTATTTCAGGATGATAACATGGAGAAGCTTG  
AGGAAATTATTGAAAAATACCCTCGTGCCTTCCCTTTCTGGATTGGGCCCTTTTCAGGCATTTT  
TCTGTATCTATGACCCAGACTATGCAAAGACACTTCTGAGCAGAACAGATCCCAAGTCCCAGT  
ACCTGCAGAAATTCTCACCTCCACTTCTTGAAAAGGACTAGCGGCTCTAGACGGACCCAAGT  
GGTTCAGCATCGTCGCCTACTAACTCCTGGATTCCATTTTAACATCCTGAAAGCATAACATTG  
AGGTGATGGCTCATTCTGTGAAAATGATGCTGGATAAGTGGGAGAAGATTTGCAGCACTCAGG  
ACACAAGCGTGGAGGTCTATGAGCACATCAACTCGATGTCTCTGGATATAATCATGAAATGCG  
CTTTCAGCAAGGAGACCAACTGCCAGACAAACAGCACCCATGATCCTTATGCAAAAGCCATAT  
TTGAACTCAGCAAAATCATATTTTACCGCTTGTACAGTTTGTGTATCACAGTGACATAATTT  
TCAAACCTCAGCCCTCAGGGCTACCGCTTCCAGAAGTTAAGCCGAGTGTTGAATCAGTACACAG  
ATACAATAATCCAGGAAAGAAAGAAATCCCTCCAGGCTGGGGTAAAGCAGGATAACACTCCGA  
AGAGGAAGTACCAGGATTTTCTGGATATTGTCTTTTCTGCCAAGGATGAAAGTGGTAGCAGCT  
TCTCAGATATTGATGTACACTCTGAAGTGAGCACATTCCTGTTGGCAGGACATGACACCTTGG  
CAGCAAGCATCTCCTGGATCCTTTACTGCCTGGCTCTGAACCCTGAGCATCAAGAGAGATGCC  
GGGAGGAGGTGAGGGGCATCCTGGGGGATGGGTCTTCTATCACTTGGGACCAGCTGGGTGAGA  
TGTCGTACACCACAATGTGCATCAAGGAGACGTGCCGATTGATTCCTGCAGTCCCGTCCATTT  
CCAGAGATCTCAGCAAGCCACTTACCTTCCCAGATGGATGCACATTGCCTGCAGGGATCACCG  
TGGTTCTTAGTATTTGGGGTCTTCACCACAACCCTGCTGTCTGGAAAAACCCAAAGGTCTTTG  
ACCCCTTGAGGTTCTCTCAGGAGAATTCTGATCAGAGACACCCCTATGCCTACTTACCATTCT  
CAGCTGGATCAAGGAAGTGCATTGGGCAGGAGTTTGCCATGATTGAGTTAAAGGTAACCATTG  
CCTTGATTCTGCTCCACTTCAGAGTGAATCCAGACCCACCAGGCCTCTTACTTTCCCCAACC  
ATTTTATCCTCAAGCCCAAGAATGGGATGTATTTGCACCTGAAGAACTCTCTGAATGT**TAGA**  
TCTCAGGGTACAATGATTAAACGTACTTTGTTTTTCGAAGTTAAATTTACAGCTAATGATCCA  
AGCAGATAGAAAGGGATCAATGTATGGTGGGAGGATTGGAGGTTGGTGGGATAGGGGTCTCTG  
TGAAGAGATCCAAAATCATTTCTAGGTACACAGTGTGTCAGCTAGATCTGTTTCTATATAACT  
TTGGGAGATTTTCAGATCTTTTCTGTTAAACTTTCACTACTATTAATGCTGTATACACCAATA  
GACTTTTCATATATTTTCTGTTGTTTTTAAATAGTTTTTCAGAATTATGCAAGTAATAAGTGCA  
TGTATGCTCACTGTCAAAAATTCCCAACACTAGAAAATCATGTAGAATAAAAAATTTAAATCT  
CACTTCACCTAGCCGACATTCCATGCCCTGACCAATCCTACTGCTTTTCTTAAAAACAGAATA  
ATTTGGTGTGCATTCTTTCAGACTTTTTCTTATACATTTTATATGTAGAAATGTAGCAATGTA  
TTTGTATAGATGTGATCATTCTATATTGTTATTGATTTTTTTCACTTAATAAAAAATTCACCT  
TATTCCTTAAAA

108/550

**FIGURE 108**

MEFSWLETRWARPFYLA FVFCLALG LLQA IKLYLRRQRLLRDLRPF PAPP THWFLGHQKFIQD  
DNMEKLEEIIEKY PRAFPFWIGPFQAFFCIYDPDYAKTLLSRTDPKSQYLQKFSPPLL GKGLA  
ALDGPKWFQHRLLTPGFHFN ILKAYIEVMAHSVKMMLDKWEKICSTQDTSVEVYEHINSMSL  
DIIMKCAFSKETNCQTNSTHDPYAKAIFELSKII FHRLYSLLYHSDIIFKLSPQGYRFQKLSR  
VLNQYTD TIIQERKKSLQAGVKQDNTPKRKYQDFLDIVLSAKDESGSSFSDDIVHSEVSTFLL  
AGHDTLAASISWILYCLALNPEHQERCREEVRGILGDGSSITWDQLGEMSYTTMCIKETCR LI  
PAVPSISRDL SKPLTFPDGCTLPAGITVVL SIWGLHHNPAVWKNPKVFDPLRFSQENS DQRHP  
YAYLPFSAGSRNCIGQEFAMIELKVTIALILLHFRVTPDPTRPLTFPNHFILKPKNGMYLHLK  
KLSEC

**Important features of the protein:****Signal peptide:**

amino acids 1-29

**Transmembrane domains:**

amino acids 310-330, 397-413, 459-473

**N-glycosylation site.**

amino acids 206-210

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 265-269, 504-520

**N-myristoylation sites.**

amino acids 25-31, 298-304, 353-359, 450-456, 456-462

**Cytochrome P450 cysteine heme-iron ligand signature.**

amino acids 447-457

**Cytochrome P450 cysteine heme-iron ligand proteins.**

amino acids 444-475

109/550

**FIGURE 109**

GGCGTTCGGGCCTCAACTTTGGCGTCGTGAGATTCTTGTGAGGCGTCTGCCTGGAAGCCGGC  
AGCAATTTTGCTTCTTTAAAGAGAAAAAGAAGGCTAGGGACTCAGATTCCTGGATTCTGAGAT  
CCAGACCAGCTCCTCCCAGACCTCTCCAGAAGAAGCCATGGGGAACCCCTCGTATCCAGCATTT  
GCTGATCCTCCTGGTCCTAGGAGCCTCCCTCCTGACCTCGGGCCTAGAGCTGTATTGTCAAAA  
GGGTCTGTCCATGACTGTGGAAGCAGATCCAGCCAATATGTTTAACTGGACCACAGAGGAAGT  
GGAGACTTGTGACAAAGGGGCACTTTGCCAGGAAACCATACTAATAATTAAAGCAGGGACTGA  
GACAGCCATTTTGGCCACGAAGGGCTGCATCCCGGAAGGGGAGGAGGCCATAACAATTGTCCA  
GCACTCTTCACCTCCCGGCCTGATCGTGACCTCCTACAGTAACTACTGTGAGGATTCCTTCTG  
TAATGACAAAGACAGCCTGTCTCAGTTTTGGGAGTTCAGTGAGACCACAGCTTCCACTGTGTC  
AACAACCCTCCATTGTCCAACCTGTGTGGCTTTGGGGACCTGTTTCAGTGCTCCTTCTCTTCC  
CTGTCCCAATGGTACAACCTCGATGCTATCAAGGAAAACCTTGAGATCACTGGAGGTGGCATTGA  
GTCGTCTGTGGAGGTCAAAGGCTGTACAGCCATGATTGGCTGCAGGCTGATGTCTGGAATCTT  
AGCAGTAGGACCCATGTTTGTGAGGGAAGCGTGCCACATCAGCTGCTCACTCAACCTCGAAA  
GACTGAAAATGGGGCCACCTGTCTTCCCATTCTGTTTGGGGGTACAGCTACTGCTGCCATT  
GCTGCTGCCATCATTTATTCACTTTTCCTAAGAAGGCACTTCTGGGCCTGGGTCTGAGGACAT  
CTTTTTTGA CTGGGAGCCTTCTTACTGTTGAGGTTCAACAAGCTGAGGAGTAGATGGGAATTT  
GAGGGAGAATACAGAGATACTATGAACGTATTTGACATTTTAAATACAATTTCTGCTATAATT  
TTTGTATGCAGTAGGCGTTACTAATAAACATTTCTGCTGTGA



110/550

FIGURE 110

MGTPRIQHLLILLVLGASLLTSGLELYCQKGLSMTVEADPANMFNWTTEEVEETCDKGALCQET  
ILIIKAGTETAILATKGCIPEGEEAITIVQHSSPPGLIVTSYSNYCEDSFNDKDSLSQFWEF  
SETTASTVSTTLHCPTCVALGTCFSAPSLPCPNGTTRCYQGKLEITGGGIESSVEVKGCTAMI  
GCRLMSGILAVGPMFVREACPHQLLTQPRKTENGATCLPIPVWGLQLLLPLLLPSFIHFS

**Important features of the protein:****Signal peptide:**

amino acids 1-23

**Transmembrane domain:**

amino acids 184-201

**N-glycosylation sites.**

amino acids 45-49, 159-163

**N-myristoylation sites.**amino acids 31-37, 70-76, 99-105, 147-153, 160-166, 174-180,  
175-181

111/550

**FIGURE 111**

CGAGAAGAGGACAGAGGAGACTGAGCAAAGGGGGGTGGGCTCCAGGGCGACCCCTAGCCCAATTCTGCCCCCTCCAT  
CCCAAGGGGACAGAGAAATTGTCTTTCTTTGCTGACTCCTACGAGGAAAAAAAAAAAAAAAAAAAAACCATTATA  
AGGGAAAGATAAACGGAGACGGAGGAAAGGTGGCAGCCAGATTACTTAGAGAGGCACAGAGGAGAGATCGGGG  
TGAGTCGCCATCGGGGACTCCAGGGCCAGCACCCGCGCCTCCCCAGCTGCTGTTCTAATTCTGCTGAGCTGT  
CCCTGGATCCAGGGTCTGCCCCGAAGGAGGAGAGATATTGCCAGAGCCTGGAAGTGAGACCCCCACGGTGGCC  
TCTGAGGCCCTGGCTGAAGTCTTCATGGGGCCCTGCTGAGGAGGGGCCAGAGATGGGCTACCTGCCAGGATCT  
GATCCGGACCCCCACGCTAGCCACCCCTCCGGCCGCCAGACTCTCGCAGTGCCCTCCCTGCCACGGGCCACTGAG  
CCGGGGACAGGGCCTCTGACAAACAGCCGTACCCCTAACGGGGTCAGGGGGGACGGCCCCACTGCGCCAGAACTG  
CTGACCCCGCCCCCAGGAACCACAGCCCCACCCCTACCCAGCCCTGCCTCCCCAGGGCCTCCCTTGGGCCTGAG  
GGAGGAGAGGAGGAGACGACGACCACCATCATCACCACGACAACCTGTTACCACTACGGTGACCAGCCAGTTCTG  
TGTAATAACAACATCTCCGAGGGCGAAGGGTATGTGGAGTCTCCAGATCTGGGGAGCCCCGTGAGCCGACCCCTG  
GGGCTCCTGGACTGCACTTACAGCATCCATGTCTACCCCTGGCTACGGCATTGAGATCCAGGTGACAGCGTGAAC  
CTGTACAGGAAGAGGAGCTCCTGGTGTGGTGGTGGGGGATCCCCAGGCCTGGCCCCCGACTCCTGGCCAAAC  
TCATCCATGCTTGGAGAAGGACAAGTCCTTCGGAGCCCAACCAACCGGCTGCTTCTGCACTTCCAGAGCCACGG  
GTCCCAAGGGGCGGTGGCTTCAGGATCCACTATCAGGCCTACCTCCTGAGCTGTGGCTTCCCTCCCCGGCCGGCC  
CATGGGGACGTGAGTGTGACGGACCTGCACCCCTGGGGGCACTGCCACCTTTCAGTGTGATTGGGGCTACCAGCTG  
CAGGGAGAGGAGACCCCTCATCTGCCTCAATGGCACCCGGCCATCCTGGAACGGTGAACCCCCAGCTGCATGGCA  
TCCTGTGGTGGCACCATCCACAATGCCACCTGGGGCCGCATCGTGTCCCCAGAGCCTGGGGAGCCGTAGGGGCC  
AACCTCACCTGCCGTTGGGTCAATTGAAGCAGCTGAGGGGCGCCGGCTGCACCTGCACCTTGAAGGGTCTCGCTG  
GATGAGGACAATGACCGGCTGATGGTGGCTCAGGGGGCAGCCCCCTATCCCCGTGATCTATGATTGGACATG  
GACGATGTCCCCGAGCGGGGTCTCATCAGTGACGCCAGTCCCTCTACGTGGAGCTGCTGTGAGAGACACCTGCC  
AATCCCCCTGCTGTAAAGCCTTCGATTTGAAGCCTTTGAGGAGGATCGCTGCTTCGCCCCCTTCTGGCACATGGA  
AATGTCACTACACGGACCCCTGAGTATCGCCAGGGGCACTGGCAACCTTCTCGTGCCCTCCAGGATATGCCCTG  
GAGCCCCCTGGGGCCCCCAATGCCATCGAATGTGTGGATCCACAGAACCCCACTGGAACGACACAGAGCCGGCC  
TGCAAAGCCATGTGTGGAGGGGAGCTGTGGAACAGCTGGCGTGGTCTCTCTCCGACTGGCCCCAGAGCTAT  
AGCCCGGGCCAAGACTGCGTGTGGGGCGTGCACGTCCAGGAAGAGAAGCGCATCTTGCTCCAAGTTGAGATATTG  
AATGTGCGGGAAGGGGACATGCTGACGCTGTTCGACGGGGACGGTCCAGCGCCCGAGTCTTGGCCAGCTGCGG  
GGACCTCAGCCGCGCCGCGCCCTTCTCTCTCTGGGCCGACCTCACACTGCAGTTTCAGGCACCGCCCGGGCCC  
CCAAATCCAGGCCTGGGCCAGGGCTTCGTATTGCACTTCAAAGAGGTCCCGAGGAACGACACGTGCCCCGAGCTG  
CCACCTCCGGAGTGGGGCTGGAGAACGGCATCCACGGGGACCTGATCCGGGGCACGGTGTCTACCTACCAGTGC  
GAGCCTGGCTACGAGCTGCTAGGCTCCGACATTCTCACTTGCCAGTGGGACCTGTCTTGGAGCGCCGCGCCGCC  
GCCTGCCAAAAGATCATGACTTGTGCTGACCCCTGGCGAGATTGCCAACGGGCACCGCACCGCCTCGGACGCCGGC  
TTCCCCGTGGCTCCACAGTCCAGTACCGCTGCCTGCCAGGGTACAGCCTCGAGGGGGCAGCCATGCTCACCTGC  
TACAGCCGGGACACAGGCACACCCAAAGTGAGCGATAGGGTCCCCAAATGCGCCTTGAAGTACGAGCCGTGCCTG  
AACCCGGGGGTTCCTCGAGAATGGCTACCAGACGCTGTACAAGCACCCTACCAGGCGGGCGAGTCTCTGCGCTTC  
TTCTGCTATGAGGGCTTTGAGCTTATCGGCGAGGTACCATCACCTGTGTGCCCGGCCACCCCTCCAGTGGACC  
AGCCAGCCCCCACTCTGCAAAGTGACCCAGACCACAGATCCATCACGGCAGCTGGAAGGGGGGAACCTGGCCCTG  
GCCATCCTGCTGCCTCTAGGCTTGGTCATTGTCTCGGCAGTGGCGTTTACATCTACTACCAAGCTTCAGGGA  
AAGTCCCTTTTCGGCTTCTCGGGCTCCCACTCCTACAGCCCCATCACCGTGGAGTCCGACTTCAGCAACCCGCTG  
TATGAAGCTGGGGATACGCGGGAGTATGAAGTTTCCATCTGAACCCCAAGACTACAGCTGCAGGACCCAGGACGC  
CCCTCCCCCTCCTCATTCGGGCAGAGGGAAATACGGGACCCGGTCTCTGCCTCCTGGCTGCCCTCCTCCCTGGCTG  
TGTAATAAGTCTCCCTATCCACAGAGGGGGCTTTGATGGCCCTGGAGATCCTACAGTAAATAAACCAGCATCCTG  
CCGCCCAAAAA

112/550

**FIGURE 112**

MGTPRAQHPPPPQLLFLILLSCPWIOGLPLKEEEILPEPGSETPTVASEALAEELLHGALLRRG  
PEMGYLPGSDDPDLATPPAGQTLAVPSLPRATEPGTGPLTTAVTPNGVRGAGPTAPELLTTP  
PGTTAPPPPPSPASPGPPLGPEGGEEETTTTIIITTTVTTTVTSPVLCNNNISEGEGYVESPD  
GSPVSRITLGLLDCTYSIHVYPGYGIEIQVQTLNLSQEEELLVLAGGGSPGLAPRLLANSSMLG  
EGQVLRSPITNRLLLHFQSPRVPRGGGFRIHYQAYLLSCGFPPRPAHGDVSVTDLHPGGTATFH  
CDSGYQLQGEETLICLNTRPSWNGETPSCMASCGGTIHNATLGRIVSPEPGGAVGPNLTCRW  
VIEAAEGRRLLHLHFERSLDEDNDRLMVRSGGSPLSPVIYDSMDDDVPERGLISDAQSLYVEL  
LSETPANPLLLSLRFEAFEEDRCFAPFLAHGNVTTTDPEYRPGALATFSCLPGYALEPPGPPN  
AIECVDPTPEPHWNTTEPACKAMCGGELSEPAGVVLSPDWPOSYSPGQDCVWGVHVQEEKRILL  
QVEILNVREGDMLTLFDGDGPSARVLAQLRGPQPRRLLSSGPDLTLLQFQAPPGPPNPGLGQG  
FVLHFKEVPRNDTCPELPPPEWGWRTASHGDLIRGTVLTYQCEPGYELLGSDILTCQWDLWS  
AAPPACQKIMTCADPGEIANGHRTASDAGFPVGSVQYRCLPGYSLEGAAMLTCYSRDTGTPK  
WSDRVPKCALKEYEPCLNPGVPENGYQTLKYHHYQAGESLRFFCYEGFELIGEVTITCVPGHPS  
QWTSQPPLCKVTQTTDPSRQLEGGNLAAILLPLGLVIVLGSVYIYYTKLQKSLFGFSGSH  
SYSPITVESDFSNPLYEAGDTREYEVSI

**Important features of the protein:****Signal peptide:**

amino acids 1-27

**Transmembrane domain:**

amino acids 842-864

**N-glycosylation sites.**amino acids 176-180, 222-226, 247-251, 332-336, 355-359, 373-377,  
473-477, 517-521, 641-645**Tyrosine kinase phosphorylation site.**

amino acids 61-69

**N-myristoylation sites.**amino acids 2-8, 84-90, 111-117, 114-120, 190-196, 198-204,  
235-241, 309-315, 333-339, 351-357, 472-478, 484-490, 528-534,  
626-632, 665-671, 775-781, 842-848**Amidation site.**

amino acids 384-388

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 12-23

**CUB domain proteins profile.**

amino acids 202-218, 376-392, 553-569

113/550

**FIGURE 113**

GCCGCGGGCGGAGCTGCCTGCCGGTCCCGCGCCGCGCGCTCCGCACTCCTCGGCCCTCGGGCGGTGATGGGACGG  
GGCGCCGCGGAGCAGGAGGCGGCGCCCGTCCGGGGTCTCGGGCCGCGCGGGAGCCACTGTGGGGCTCGGGCATG  
GCGGGCCGAGGACCTGAGCTCTCCTCAGGGGAGCGGGGAGGAGCTGCTGGCCGGCGATGGGGACGGAGTGGGG  
CCGTCCGCGCGCGCGCGGAGCCGTGAGCGCCGAGCCACCGCCGCGCTACCTCAGCCCTTCGCGAAGCGCCGGGA  
GCTCGGGAACATGGCCCTGGAGCGGCTCTGCTCGGTCCCTCAAAGTGTGTTAATAACAGTACTGGTAGTGGAAGG  
GATTGCCGTGGCCCAAAAAACCAAGATGGACAAAATATTGGAATCAAGCATATTCTGCAACCCAGTGTGGCAT  
TTGGGTTTCAACCAGCAATGGAGGTCATTTTGCTTCGCCAAATTATCCTGACTCATATCCACCAACAAGGAGTG  
TATCTACATTTTGAAGCTGCTCCACGTCAAAGAATAGAGTTGACCTTTGATGAACATTATTATATAGAACCATC  
ATTTGAGTGTGCGTTTGTACTTGGAGTTTCGAGATGGGCCATTTGGTTTCTCTCCTCTTATAGATCGTTACTG  
TGGCGTGAAAAGCCCTCCATTAAATAGATCAACAGGGAGATTTCATGTGGATTAAGTTTAGTTCTGATGAAGAGCT  
TGAAGGACTGGGATTTTCGAGCAAAATATTTCATTTATTTCCAGATCCAGACTTTACTTACCTAGGAGGTATTTTAA  
TCCCATTCCAGATTGTGAGTTCGAGCTCTCGGGAGCTGATGGAATAGTGCCTCTAGTCAGGTAGAACAAGAGGA  
GAAAACAAAACAGGCCAAGCCGTTGATTGCATCTGGACCATTAAAGCCACTCCAAAAGCTAAGATTTATTTGAG  
GTTCTAGATTATCAAATGGAGCACTCAAATGAATGCAAGAGAACTTCGTTGCAGTCTATGATGGAAGCAGTTC  
TATTGAAAACCTGAAGGCCAAGTTTTCGAGCACTGTGGCCAATGATGTAATGCTTAAACAGGAATTGGAGTGAT  
TCGAATGTGGGCAGATGAAGGTAGTCGGCTTAGCAGGTTTCGAATGCTCTTTACTTCCCTTTGTGGAGCCTCCCTG  
CACAAGCAGCACTTTCTTTTGCCATAGCAACATGTGCATCAATAATTCTTTAGTCTGTAATGGTGTCCAAAATTG  
TGCATACCCTTGGGATGAAAATCATTGTAAAGAAAAGAAAAAGCAGGAGTATTTGAACAAATCACTAAGACTCA  
TGGAACAATTATTGGCATTACTTCAGGGATTGTCTTGGTCTTCTCATTATTTCTATTTTAGTACAAGTGAAACA  
GCCTCGAAAAAGGTTCATGGCTTGCAAAACCGCTTTTAATAAAACCGGGTTCCAAGAAGTGTTTGATCCTCCTCA  
TTATGAAGTGTTCCTAAGGGACAAAGAGATTTCTGCAGACCTGGCAGACTTGTGCGAAGAATTGGACAACCTA  
CCAGAAGATGCGGCGCTCCTCCACCGCTCCCGTGCATCCACGACCACCCTGTTGGTTCGAGGCCCTCCAGCGT  
CAAACAAAGCAGGACCAACCTCAGTTCCATGGAACCTTCTTTCCGAAATGACTTTGCACAACCACAGCCAATGAA  
AACATTTAATAGCACCTTCAAGAAAAGTAGTTACACTTTCAAACAGGGACATGAGTGCCTGAGCAGGCCCTGGA  
AGACCGAGTAATGGAGGAGATTCCCTGTGAAATTTATGTGAGGGGGCGAGAAGATTCTGCACAAGCATCCATATC  
CATTGACTTCTTAATCTTCTGCTAATGGTGTGTAATTCCTAGGGTGTGTACGTACGCAGCCTCCAGGGCACCAT  
ACTGTTTCCAGCAGCCAACCTTTTCTCCCATCACAACACGAAGACCTTGATTTACCGTTAACCTATTGTATGG  
TGATGTTTTTATTCTCTCAGGCAGTCTATATATGTTAAACCAATCAAGGAACCTACTCTATTTCAGTGGAACAAT  
AATCATCTCTATTGCTTGGTGTCAATTTATAGGAAGCACTGCCAGTTAAAGAGCATTAGAAGAGGTGGTTGGATGG  
AGCCAGGCTCAGGCTGCCTCTTCGTTTTAGCAACAAGAAGACTGCTCTTGAAGTATAACAGCTCTGTCAATATTT  
TGATGCCACAATAAACTTGATTTTTTTTACATTCCCTTTATTTTTCTTTCTCTAAATTTAATTTGTTTTATAA  
GCCTATCGTTTTTACCATTTTCAATTTCTTACATAAGTACAAGTGGTTAATGTACCACATACTTCAGTATAGGCATT  
TGTTCTTGAGTGTGTCAAAATACAGCTAGTTACTGTGCCAATTAAGACCCAGTTGTATTTACCCATCTGTTTCT  
TCTTGGCTAATCTCTGACTTCTGCCTTTTAATTACTGGGCCCTTATTCCTTATTTTCTGTGAGAAATAATAGAT  
GATATGATTTATTACCTTTCAATTATATTTTTCTCAGTTATACTAGAAAATTTATAATCCTGGGATATATGTAC  
CATGTGCAGCTATGACTAAAAATTTGAAAAAGATAAAAAATTTCTAGCAAGCCTTTGAAGTTTACCAAGTATAGTC  
ACATTTCAGTGACAGCCCATTCATTCCAGTAAAGAATCATTTCACTTTGGGAGAGGCCTATAATTACATTTA  
TTTGCAATGTTTCTCTTCGCTAGATTGTTACATAGCTCCCATTCCTGTTGGTTTTGCTTACAGCATATGGTAACCA  
AGGTTAGATGCCAGTTAAATTCCTTAGAAATTTGGATGAGCCTTGAGATTGCTTCTTAAGTGGGACATGACATTT  
TTCTAGCTCTTATCAAGAATAACAACCTTCCACTTTTTTTTAACTGCACCTTTTGAATTTTATGGTATAAAAA  
CAATAATTTATAAACATAAAAGCTCATTGTGTTTTTTAGACTTTTGATATTATTTGATACTGTACAACTTTATT  
AAATCAAGATGAAAGACCTACAGGACAGATTCTTTTCAGTGTTACATCAGTGGCTTTGTATGCAAATATGCTGT  
GTTGGACCTGGACGCTATAAATTATTGTAAAGACCTTGGAAATGTGGACATAAGCTCTTTCTTTCTTTGTTAC  
TGTATTTAGTTTGTGATAAATTTTCTACTGTGTGATATTTATGCTCTAAATCACTACACAAATCCCATATTTAAA  
TATACATTGTACCTGAAAAAAA

114/550

**FIGURE 114**

MALERLCSVLKVLLITVLVVEGIAVAQKTQDGQNIGIKHIPATQCGIWVRTSNGGHFASPNYP  
DSYPPNKECIYILEAAPRQRIELTFDEHYIIEPSFECRFDHLEVRDGPFGFSPLIDRYCGVKS  
PPLIRSTGRFMWIKFSSDEELEGLGFRAKYSFIPDPDFTYLGGILNPIPDQCQFELSGADGIVR  
SSQVEQEEKTKPGQAVDCIWTIKATPKAKIYLRFLDYQMEHSNECKRNFVAVYDGSSSIENLK  
AKFCSTVANDVMLKTGIGVIRMWADDEGSRLSRFRMLFTSFVEPPCTSSTFFCHSNMCINNSLV  
CNGVQNCAYPWDENHCKEKKKAGVFEQITKTHGTIIGITSGIVLVLLIISILVQVKQPRKKVM  
ACKTAFNKTGFQEVFDPPHYELFSLRDKEISADLADLSEELDNYQKMRRSSTASRCIHDHHC  
SQASSVKQSRTNLSSMELPFRNDEAQPQPMKTFNSTFKKSSYTFKQGHECPEQALEDRVMEEI  
PCEIYVRGREDQAQASISIDF

**Important features of the protein:****Signal peptide:**

amino acids 1-22

**Transmembrane domain:**

amino acids 348-369

**N-glycosylation sites.**

amino acids 311-315, 385-389, 453-457, 475-479

**cAMP- and cGMP-dependent protein kinase phosphorylation sites.**

amino acids 426-430, 479-483

**N-myristoylation sites.**amino acids 22-28, 32-38, 54-60, 186-192, 279-285, 318-324,  
348-354, 352-358, 441-447

115/550

FIGURE 115

GGTCTCTGTCCTTGGCTGTGGCTCCTGCGCTCTGGCTGAGCCATGTTTCCTTCTCCTCGCCCTC  
CTCACTGAGCTTGGAAGACTGCAAGCCCACGAAGGTTCTGAAGGAATATTTCTGCATGTCACA  
GTTCCACGGAAGATTAAGTCAAATGACAGTGAAGTTTTCAGAGAGGAAGATGATTTACATCATT  
ACAATTGATGGACAACCTTACACTCTACATCTCGGAAAACAATCATTCTTACCCCGAACTTT  
TTGGTTTATACATATAATGAAACTGGATCTTTGCATTCTGTGTCTCCATATTTTATGATGCAT  
TGCCATTACCAAGGATATGCTGCCGAATTTCCAAATTCATTTGTGACACTCAGTATATGTTCT  
GGTCTCAGGGGATTTCTCCAGTTTGAAAATATCAGTTATGGAATTGAACCAGTAGAATCTTCA  
GCAAGATTTGAGCATATAATTTATCAAATGAAAAATAATGATCCAAATGTATCCATTTTAGCA  
GTAAATTACAGTCATATTTGGCAGAAAAGACCAGCCCTACAAAGTTCCTTTAACTCACAGATA  
AAAAATCTTTCAAAACCTATTACCCCAATATCTGGAAATATACATTATAGTGGA AAAAGCTTTG  
ATGTTTACCCAGTTCAAATTGACTGTTATACTGTCTTCTTGGAAATTGTGGTCAAATGAAAAC  
CAGATTTCCACCAGTGGGGATGCTGATGATATATTACAAAGATTTTTGGCATGGAAACGGGAC  
TATCTCATCCTACGGCCCCATGACATAGCATACTTACTTGTTTACAGGAAACATCCTAAATAT  
GTGGGAGCAACATTTCTTGGCACCGTATGCAATAAAAGCTATGATGCAGGTATTGCTATGTAT  
CCAGATGCAATAGGTTTGGAGGGATTTTCGGTTATTATAGCTCAACTGCTTGGCCTTAATGTA  
GGATTAACATATGATGACATCACTCAGTGTCTGTCTGAGAGCTACATGCATCATGAATCAT  
GAAGCAGTGAGTGCCAGTGGTAGAAAGATTTTTAGCAACTGCAGCATGCACGACTATAGATAT  
TTTGTTCAAAATTTGAGACTAAATGCCTTCAGAAGCTTTCAAATTTGCAACCATTACATCAA  
AATCAACCAGTGTGTGGTAATGGGATTTTGGAAATCCAATGAAGAATGTGACTGTGGTAATAAA  
AATGAATGTCAATTTAAGAAGTGCTGTGATTATAACACATGTAACTGAAGGGCTCAGTAAAA  
TGTGGTTCTGGACCATGTTGTACATCAAAGTGTGAGTTGTCAATAGCAGGCACTCCATGTAGA  
AAGAGTATTGATCCAGAGTGTGATTTTACAGAGTACTGCAATGGAACCTCTAGTAATTGTGTT  
CCTGACACTTATGCACTGAATGGCCGTTTGTGCAAGTTGGGAACTGCCTATTGCTATAACGGA  
CAATGTCAAACCTACTGATAACCAGTGTGCCAAGATATTTGGAAAAGGTGCTCAAGGTGCTCCA  
TTTGCCTGTTTTAAAGAAGTTAATTCTCTGCATGAAAGATCTGAAAACCTGTGGTTTTAAAAAT  
TCACAACCATTACCTTGTGAACGGAAGGATGTTCTCTGTGGAAAATTAGCTTGTGTTTCAGCCA  
CATAAAAATGCTAATAAAAGTGACGCTCAATCTACAGTTTATTTCATATATTCAAGACCATGTA  
TGTGTATCTATAGCCACTGGTTCCCTCCATGAGATCAGATGGAACAGACAATGCCTATGTGGCT  
GATGGCACCATGTGTGGTCCAGAAATGTACTGTGTAAATAAAACCTGCAGAAAAGTTCATTTA  
ATGGGATATAACTGTAATGCCACCACAAAATGCAAAGGGGAAAGGGATATGTAATAATTTTGGT  
AATTGTCAATGCTTCCCTGGACATAGACCTCCAGATTGTAAATTCCAGTTTGGTTCCCCAGGG  
GGTAGTATTGATGATGGAAATTTTCAGAAATCTGGTGACTTTTATACTGAAAAGGCTACAAT  
ACACACTGGAACAACCTGGTTTATTCTGAGTTTCTGCATTTTTCTGCCGTTTTTCATAGTTTTC  
ACCACTGTGATCTTTAAAGAAATGAAATAAGTAAATCATGTAACAGAGAGAATGCAGAGTAT  
AATCGTAATTCATCCGTTGTATCAGAAAGCGATGACGTGGGACATTAATATTGCACAGAAGCTT  
CCATAGCAAATAACCTAAAGGAACGAATGTGCTTTATTTATAACCTTACGTTATCCCCAATGC  
ATTGTAAATGTCAAACCTTTTGGAAAATAAAGCCTGCGTGCCCTCCC

116/550

**FIGURE 116**

MFLLLALLTELGRQLQAHEGSEGIFLHVTVPRIKISNDSEVSEKMIYIITIDGQPYTLHLGKQ  
SFLPQNFLVYTYNETGSLHSVSPYFMMHCHYQGYAAEFNSFVTLISICSGLRGFLQFENISYG  
IEPVESARFEHIIYQMKNNDPNVSI LAVNYSHIWQKDQPYKVPLNSQIKNLSKLLPQYLEIY  
IIVEKALMFTQFKLTVILSSLELWSNENQISTSGDADDILQRFLAWKRDYLILRPHDIAYLLV  
YRKHPKYVGATFPGTVCNKSYDAGIAMYPDAIGLEGFSVIIAQLLGLNVGLTYDDITQCFCLR  
ATCIMNHEAVSASGRKIFSNCSMHDYRYFVSKFETKCLQKLSNLQPLHQNPVCGNGILESNE  
ECDCGNKNECQFKKCCDYNTCKLKGSVKCGSGPCCTSKCELSIAGTPCRKSIDPECDFTEYCN  
GTSSNCVPDITYALNGRLCKLGTAYCYNGQCQT TDNQCAKIFGKGAQGAPFACFKEVNSLHERS  
ENCGFKNSQPLPCRKDVLCGKLACVQPHKNANKSDAQSTVYSYIQDHVCVSIATGSSMRSDG  
TDNAYVADGTMCGPEMYCVNKTCRKVHLMGYNCNATTKCKGKGICNNEFGNCQCFPGHRPPDCK  
FQFGSPGGSIDGDNFQKSGDFYTEKGYNTHWNNWFILSFCIFLPFFIVFTTVIFKRNEISKSC  
NRENAEYNRNSSVSESDDVGH

**Important features of the protein:****Signal peptide:**

amino acids 1-16

**Transmembrane domain:**

amino acids 665-684

**N-glycosylation sites.**amino acids 36-39, 76-79, 122-125, 149-152, 156-159, 177-180,  
270-273, 335-338, 441-444, 537-540, 587-590, 601-604, 703-706**Casein kinase II phosphorylation sites.**amino acids 74-77, 208-211, 221-224, 304-307, 337-340, 346-349,  
376-380, 415-418, 499-502, 639-642, 708-711**Tyrosine kinase phosphorylation site.**

amino acids 243-249

**N-myristoylation sites.**amino acids 53-58, 79-84, 266-271, 298-303, 372-377, 403-408,  
408-413, 442-447, 462-467, 469-474, 488-493, 567-572, 610-615,  
616-621, 634-639**Amidation site.**

amino acids 328-331

117/550

**FIGURE 117**

CCCACGCGTCCGCGGACGCGTGGGGCTCAGTGGGCGTCGCGCGAAGGCTAAGGGAGTGTGGCG  
GGCGGCTCCGGGAGCCAACATGCCTCGGTATGCGCAGCTGGTCATGGGCCCCGCGGGCAGCGG  
GAAGAGCACCTACTGTGCCACCATGGTCCAGCACTGTGAAGCCCTCAACCGGTCTGTCCAAGT  
TGTAACCTGGATCCAGCAGCAGAACACTTCAACTACTCCGTGATGGCTGACATCCGGGAACT  
GATCGAGGTGGATGATGTAATGGAGGATGATTCTCTGCGATTCCGGTCCCAACGGAGGATTGGT  
ATTTTGCATGGAGTACTTTGCCAATAATTTGACTGGCTGGAGAACTGTCTTGGCCATGTAGA  
GGACGACTATATCCTTTTTGATTGTCCAGGTCAGATTGAGTTGTACACTCACCTGCCTGTGAT  
GAAACATCTGGTCCAGCAGCTCGAGCAGTGGGAGTTCCGAGTCTGTGGAGTTTTTCTTGTTGA  
TTCTCAGTTCATGGTGGAGTCATTCAAGTTTATTTCTGGCATCTTGGCAGCCCTGAGTGCCAT  
GATCTCTCTAGAAATTCCGCAAGTCAACATCATGACAAAAATGGATCTGCTGAGTAAAAAGC  
AAAAAAGGAAATTGAGAAATTTTTAGATCCAGACATGTATTCTTTATTAGAAGATTCTACAAG  
TGACTTAAGAAGCAAAAAATTCAAGAACTGACTAAAGCTATATGTGGACTGATTGATGACTA  
CAGCATGGTTCGATTTTTTACCTTACGATCAGTCAGATGAAGAAAGCATGAACATTGTATTGCA  
GCATATTGATTTTGCCATTCAATATGGAGAAGACCTAGAATTTAAAGAACCAAAGGAACGTGA  
AGATGAGTCTTCCTCTATGTTTGACGAATATTTTCAAGAATGCCAGGATGAATGAAGAGTTTA  
CTAAAAGTAACCATCTAAAGAGCTTGTGGCCAAACCAGCAGAACATTCTTCTCTTCAAAGGAT  
GCAATAGTAGAAAGCTACTTATTTTAATGAAAAAAGTAAACTTCGTTCTTTATCAGCCTCA  
TGCCTGAATCAAATTTTTAATTATTCTGAAACTGCTGCTGTTTAAAGTGGAATCTTTTAGTAT  
TATAACAGCATCACTTTAGATTTTGTAAGTCAAAATTGAAATGAATGCACATAGATTTATATA  
TAAATTAGCACCTGAGCTAAGGTTAAGGCCGGTCTAAACTTATTTTCACTTTTTGTATTATTT  
TTGAGATGCAGGAATTACTGTAACAAAATATGTATGTCCGAAGGGAAAAAGCTGCAAGGATAT  
ATATAAGACCACTGCTTATCTGTATCTTCCCATTTTCCTATATTGAAAATGTATATTATTTAT  
ATAACTTAAAAAGTAAAAATAACTATGTTTTGAGAT



118/550

**FIGURE 118**

MPRYAQLVMGPAGSGKSTYCATMVQHCEALNRSVQVVNLDPAAEHFNYSVMADIRELIEVDDV  
MEDDSLRFPGPNGGLVFCMEYFANNFDWLENCLGHVEDDYILFDCPGQIELYTHLPVMKHLVQQ  
LEQWEFRVCGVFLVDSQFMVESFKFISGILAALSAMISLEIPQVNIMTKMDLLSKKAKKEIEK  
FLDPDMYSLLEDSTSDLRSKKFKKLTKAICGLIDDYSMVRFLPYDQSDEESMNIVLQHIDFAI  
QYGEDLEFKEPKEREDESSMFDEYFQECQDE

**Important features of the protein:****Signal peptide:**

amino acids 1-29

**Transmembrane domain:**

amino acids 151-170

**N-glycosylation sites.**

amino acids 31-35, 47-51

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 212-216

**Tyrosine kinase phosphorylation site.**

amino acids 189-197

**N-myristoylation sites.**

amino acids 13-19, 76-82, 154-160

**ATP/GTP-binding site motif A (P-loop).**

amino acids 10-18

119/550

**FIGURE 119**

GGGCGCTGGGAGACACCGGACGCCCCGCTCGGCTGCGCTGCGGCTCAGGCCCCCGCTCGGGCCC  
GACCCGCTCGGTACCGCCGGCTCGGGCGCGCACCTGCCGGCTGCGGCCCCAGGGCCATGCGG  
AGGCCCACGAGGAGGCCGGCGGCCACGCGCATCCCGTAGCCAGGTGGCCCAGGTCTGCACCG  
CGGCGGCCTCGGCGCCATGGAGCCCCCGTATTGCTGACGGCGCACTACGATGAGTTCCAAGA  
GGTCAAGTACGTGAGCCGCTGCGGCGCGGGGGGCGCGCGGGGCTCCCTGCCCCGGGCTT  
CCCGTTGGGCGCTGCGCGCAGCGTCACCGGGGCCCCGGTCCGGGCTGCCGCGCTGGAACCGGCG  
CGAGGTGTGCTGTGTCGGGGCTGGTGTTCGCCGCCGGCCTCTGCGCCATTCTGGCGGCTAT  
GCTGGCCCTCAAGTACCTGGGCCCCGGTCGCGGCCGGCGGGCGGCGCTGTCCCGAGGGCTGCCC  
TGAGCGCAAGGCCTTCGCGCGCGCCGCTCGCTTCCTGGCCGCCAACCTGGACGCCAGCATCGA  
CCCATGCCAGGACTTCTACTCGTTTCGCCTGCGGCGGTTGGCTGCGGGCGCCACGCCATCCCCGA  
CGACAAGCTCACCTATGGCACCATCGCGGCCATCGGCGAGCAAAACGAGGAGCGCCTACGGCG  
CCTGCTGGCGCGGCCCCGGGGGTGGGCCTGGCGGCGCGGCCAGCGCAAGGTGCGCGCCTTCTT  
CCGCTCGTGCCTCGACATGCGCGAGATCGAGCGACTGGGCCCCGCGACCCATGCTAGAGGTCAT  
CGAGGACTGCGGGGGCTGGGACCTGGGCGGCGCGGAGGAGCGTCCGGGGGTGCGGGCGCGATG  
GGACCTCAACCGGCTGCTGTACAAGGCGCAGGGCGTGTACAGCGCCGCCGCGCTCTTCTCGCT  
CACGGTCAGCCTGGACGACAGGAACCTCGCGCTACGTCATCCGCATTGACCAGGATGGGCT  
CACCTGCCAGAGAGGACCCTGTACCTCGCTCAGGATGAGGACAGTGAGAAGATCCTGGCAGC  
ATACAGGGTGTTTCATGGAGCGAGTGCTCAGCCTCCTGGGTGCAGACGCTGTGGAACAGAAGGC  
CCAAGAGATCCTGCAAGTGGAGCAGCAGCTGGCCAACATCACTGTGTGAGAGTATGACGACCT  
ACGGCGAGATGTGAGCTCCATGTACAACAAGGTGACGCTGGGGCAGCTGCAGAAGATCACCCC  
CCACTTGCGGTGGAAGTGGCTGCTAGACCAGATCTTCCAGGAGGACTTCTCAGAGGAAGAGGA  
GGTGGTGCTGCTGGCGACAGACTACATGCAGCAGGTGTGCGAGCTCATCCGCTCCACACCCCA  
CCGGGTCTGCACTACCTGGTGTGGCGCGTGGTGGTGGTCTGAGTGAACACCTGTCCCC  
GCCATTCCGTGAGGCACTGCACGAGCTGGCACAGGAGATGGAGGGCAGCGACAAGCCACAGGA  
GCTGGCCCCGGGTCTGCTTGGGCCAGGCCAATCGCCACTTTGGCATGGCGCTTGGCGCCCTCTT  
TGTACATGAGCACTTCTCAGCCGCCAGCAAAGCCAAGGTGCAGCAGCTAGTGGAAGACATCAA  
GTACATCCTGGGCCAGCGCCTGGAGGAGCTGGACTGGATGGACGCCGAGACCAGGGCTGCTGC  
TCGGGCCAAGCTCCAGTACATGATGGTGTGGTGGCTACCCGGACTTCTGCTGAAACCCGA  
TGCTGTGGACAAGGAGTATGAGTTTGAGGTCCATGAGAAGACCTACTTCAAGAACATCTTGAA  
CAGCATCCCCTTCAGCATCCAGCTCTCAGTTAAGAAGATTCCGGCAGGAGGTGGACAAGTCCAC  
GTGGCTGCTCCCCCACAGGCGCTCAATGCCTACTATCTACCCAACAAGAACCAGATGGTGT  
CCCCGCGGGCATCCTGCAGCCCACCCTGTACGACCCTGACTTCCCACAGTCTCTCAACTACGG  
GGGCATCGGCACCATCATTGGACATGAGCTGACCCACGGCTACGACGACTGGGGGGGCCAGTA  
TGACCGCTCAGGGAACCTGCTGCACTGGTGGACGGAGGCCTCCTACAGCCGCTTCTGCGAAA  
GGCTGAGTGCATCGTCCGTCTCTATGACAACCTCACTGTCTACAACCAGCGGGTGAACGGGAA  
ACACACGCTTGGGGAGAACATCGCAGATATGGGEGTCTCAAGCTGGCCTAECACGCCTATCA  
GAAGTGGGTGCGGGAGCACGGCCCAGAGCACCCACTTCCCCGGCTCAAGTACACACATGACCA  
GCTCTTCTTCATTGCCTTTGCCAGAACTGGTGCATCAAGCGGCGGTGCGAGTCCATCTACCT  
GCAGGTGCTGACTGACAAGCATGCCCCTGAGCACTACAGGGTGTGGGCAGTGTGTCCAGTT  
TGAGGAGTTTGGCCGGGCTTTCCACTGTCCCAAGGACTCACCCATGAACCCTGCCACAAAGTG  
TTCCGTGTGGTGAGCCTGGCTGCCCCGCTGCACGCCCCCACTGCCCCCGCACGAATCACCTCC  
TGCTGGCTACCGGGGAGGCATGCACCCGGTGCCAGCCCCGCTCTGGGCACCACTGCCTTCC  
AGCCCCCTCAGGACCCGGTCCCCCTGCTGCCCCCTCACTTCAGGAGGGGCCTGGAGCAGGGTGA  
GCTGGACTTTGGGGGGCTGTGAGGGAAATATACTGGGGTCCCCAGATTCTGCTCTAAGGGGG  
CCAGACCCTCTGCCAGGCTGGATTGTACGGGCCCCACCTTCGCTGTGTTCTTGCTGCAAAGTC  
TGGTCAATAAATCACTGCACTGTAAAAA

20/550

**FIGURE 120**

MEPPYSLTAHYDEFQEVKYVSRGAGGARGASLPPGFPPLGAARSVTGARSGLPRWNRREVCLL  
 SGLVFAAGLCAILAAMLALKYLGPVAAGGGACFEGCPERKAFARAARFLAANLDASIDPCQDF  
 YSFACGGWLRRAIPDDKLTGTIAAIGEQNNEERLRLLARPGGGPGGAAQRKVRAFFRSCLD  
 MREIERLGPRPMLEVIEDCGGWDLGGAERPGVAARWDLNRLLYKAQGVYSAAALFSLTVSLD  
 DRNSSRYVIRIDQDGLTLPERTLYLAQDEDSEKILAAAYRVFMERVLSLLGADAVEQKAQEILQ  
 VEQQLANITVSEYDDLRRDVSSMYNKVELGQLQKITPHLRWKWLLDQIFQEDFSEEEEVVLLA  
 TDYMQQVSQILIRSTPHRVLHNYLVWRVVLSEHLSPPFREALHELAQEMEGSDKQPQELARVC  
 LGQANRHFGMALGALFVHEHFSAAASKAKVQQLVEDIKYILGQRLEELDWMDAETRAAARAKLO  
 YMMVMVGYPDFLLKPDADVKEYEFEVHEFTYFKNILNSIPFSIQLSVKKIRQEVDKSTWLLPP  
 QALNAYYLPNKNQMVFPAGILQPTLYDPDTPQSLNYGGIGTIIGHELTHGYDDWGGQYDRSGN  
 LLHWWTEASYSRFLRKAECIVRLYDNFTVINQRVNGKHTLGENIADMGVCLKLAYHAYQKWVRE  
 HGPEHPLPRLKYTHDQLFFIAFAQNWCIKRRSQSIYLQVLTDKHAPEHYRVLGSVSQFEEFGR  
 AFHCPKDSMPNPAHKCSVW

**Important features of the protein:****Transmembrane domain:**

amino acids 64-88

**N-glycosylation sites.**

amino acids 255-259, 322-326, 656-660

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 722-726

**N-myristoylation site.**amino acids 24-30, 26-32, 27-33, 40-46, 47-53, 65-71, 148-154,  
169-175, 170-176, 237-243, 450-456, 604-610, 607-613**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 85-96

**Prenyl group binding site.**

amino acids 772-777

**Neutral zinc metalloproteinases, zinc-binding region signature.**

amino acids 609-619

**Neutral zinc metalloproteinases, zinc-binding region proteins.**

amino acids 609-619

121/550

**FIGURE 121**

CGGACTGCCCGGACCGCGCGATGGAGTCGACCGGCAGCGTCGGGGAGGCCCCGGGCGGACCCC  
GGGTGCTGGTGGTGGGCGGCGGCA<sup>1</sup>CGCGGGGCTGGGCGCGGCGCAGAGGCTCTGCGGCCACT  
CCGCCTTCCCGCACCTGCGGGTCC TGGAGGCCACGGCCCGCGCCGGGGGCCGCATCCGCTCGG  
AGCGCTGCTTCGGTGGCGTGGTG GAGGTGG<sup>2</sup>CGCGCACTGGATCCATGGGCCCCTCCCGGGGTA  
ACCCCGTCTTCCAGCTGGCTGCTGAGTACGGGCTGCTGGGGGAGAAGGAGCTGTCCCAGGAGA  
ACCAGCTGGTGGAGACCGGGGGTACAGTGGGCCTGCCCTCCGTGAGCTACGCCAGCTCCGGGG  
CCAGCGTGAGCCTCCAGCTGGTGGCGGAGATGGCGACTCTGTTCTACGGCCTGATAGACCAGA  
CCCGGGAGTTCCTGCACGCTGCAGAGACC CCGGTGCCAGCGTCGGGGAGTACCTCAAGAAGG  
AGATTGGCCAGCACGTGGCCGGCTGGACAGAGGATGAGGAGACCAGGAAGCTGAAGCTGGCCG  
TCCTGAACTCCTTCTTCAACCTGGAATG CTGTGTGAGCGGCACCCACAGCATGGACCTGGTGG  
CCCTGGCACCCCTTTGGGGAGTATACCG<sup>3</sup> GCTGCCGGGGCTGGACTGCACCTTTTCTAAGGGCT  
ATCAAGGACTCACAACTGCATGATGG CCGCCCTGCCGGAGGACACTGTAGTTTTTGTAGAAGC  
CTGTGAAGACCATCCACTGGAACGGG<sup>4</sup>CTTCCAGGAGGCAGCCTTTCCCGGGGAGACCTTTC  
CAGTGTCCGTAGAGTGTGAGGATGGAAGACCGGTTCCCGGCGCACCATGTCATCGTCACCGTGC  
CCTTAGGTTTTCTTAGGGAACATTTGGACACCTTCTTTGACCCTCCCCTGCCGGCTGAGAAGG  
CAGAAGCAATCAGGAAGATAGGCTTTGGGACCAACAACAAAATCTTCCTGGAGTTTGAGGAGC  
CCTTCTGGGAGCCAGACTGCCAGCTGATCCAGCTGGTGTGGGAGGACACGTCGCCCCCTGGAGG  
ATGCTGCCCCTGAGCTACAGGACGCCTGGTTCCGGAAGCTCATTGGCTTTGTGGTCCTGCCTG  
CCTTTGCGTCTGTCCACGTTCTCTGTGGGTTCA<sup>5</sup>TGCGGACTTGAGTCTGAGTTCATGGAGA  
CTCTGTCCGATGAAGAAGTACTTCTGTGTCTCACCCAAGTGCTCCGGAGAGTGACAGGAAACC  
CACGGCTCCCCGCGCCCAAGAGCGTCTGCGGTCTCGCTGGCACAGCGCCCGTACACTAGGG  
GGTCCTACAGCTACGTGGCCGTGGGCAGTACTGGGGGCGACCTGGACCTGCTGGCTCAGCCCC  
TCCCTGCAGACGGCGCCGGCGCCAGCTCCAGATCCTGTTTGGGGGGAAGCCACACATCGCA  
CGTTTTACTCCACGACGCACGGGGCTCTGCTGTGGGGATGGAGGGAGGCCGACCGCCTCCTCA  
GTCTGTGGGCCCCCGCAGGTGCAGCAGCCCAGGCCGAGGCTCTAG<sup>6</sup>CTGGGCCAGCCTACTCTG  
TTCCACCCGTGTCGGGGGTAGGCTGGGACCGTCATTTCTTCTGACAGATTTCAGTCTGGCTTG  
AAATTTGGGGATGTTAATGAGGGTCCTCTGGTTTTTGGTAACCAGGGCCACCTTCTCAGTTCT  
TGTGTCTGTTATTGGAGTCTGGCCAGGGTTGACTTGAGCTGAGACACCAGATGCTCACGGAGA  
TGCTGGACACATAAAGCAAGTTACAGCCACAAAAA

122/550

**FIGURE 122**

MESTGSGEAPGGPRVLVVGGGIAGLGAAQRLCGHSAPPHLRVLEATARAGGRIRSERCFGV  
VEVGAHWIHGPSRGNPVFQLAAEYGLLGEKELSQENQLVETGGHVGLPSVSYASSGASVSLQL  
VAEMATLFYGLIDQTREFLHAAETPVPSVGEYLLKKEIGQHVAGWTEDEETRKLKLAVLNSFFN  
LECCVSGTHSMDLVALAPFGEYTVLPGLDCTFSKGYQGLTNCMMAALPEDTVVFEKPVKTIHW  
NGSFQEAAFPGETFPVSVECEDGDRFPAHHVIVTVPLGFLREHLDTFFDPPLPAEKAEAIRKI  
GFGTNNKIFLEFEEPFWEPCQLIQLVWEDTSPLEDAAPELQDAWFRKLIGFVVLPAFASVHV  
LCGFIAGLESEFMETLSDEEVLLCLTQVLRRTGNPRLPAPKSVLRSRWHSAPYTRGSYSYVA  
VGSTGGDLDLLAQPLPADGAGAQLQILFAGEATHRTFYSTTHGALLSGWREADRLLSLWAPQV  
QQPRPRL

**Signal peptide:**

amino acids 1-28

**Transmembrane domain:**

amino acids 364-385

**N-glycosylation site.**

amino acids 253-257

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 408-412

**N-myristoylation sites.**amino acids 20-26, 21-27, 25-31, 105-111, 119-125, 164-170,  
216-222, 227-233, 443-449, 484-490**Aminooxidase Flavin containing amine oxidase:**

amino acids 23-497

123/550

**FIGURE 123**

CGGACGCGTGGGGGAAGATGGATAAATAATTCTGTACACGTGCCCTGGCCTCTGGAGCTCAGCTGCCAGTCCAC  
GTCTAGGGAATCTTAGCATCTGGGACCAAGACACTTTACAGCAATCATCACCTTTGCAGAGGAGGTGAGCTCAC  
CAGGACTCATCTGCCATTTTACAGACCTTTTGTCTGCTACCTGCCAGGTGGCCCCCACTGCTGACGAGAGATGGTGA  
TCTCTCAGTCTCCCCGGAATCCTTGAAGCCAGTATCGCTGACCAGCAGTCTTGTCTTCTCATGCACCTCCTCCT  
CCTTCAGCCTGGGGAGCCGAGCTCAGAGGTCAAGGTGCTAGGCCCTGAGTATCCCATCCTGGCCCTCGTCGGGGA  
GGAGGTGGAGTTCCCGTGCCACCTATGGCCACAGCTGGATGCCAGCAAATGGAGATCCGCTGGTTCCGGAGTCA  
GACCTTCAATGTGGTACACCTGTACCAGGAGCAGCAGGAGCTCCTGGCAGGCAGATGCCGGCGTTCCGGAACAG  
GACCAAGTTGGTCAAGGACGACATCGCCTATGGCAGCGTGGTCTGTCAGCTTACAGCATCATCCCCCTCTGACAA  
GGGCACATATGGCTGCCGCTTCCACTCCGACAACCTTCTCTGGCGAAGCTCTCTGGGAACCTGGAGGTAGCAGGGCT  
GGGCTCAGACCCTCACCTCTCCCTTGAGGGCTTCAAGGAAGGAGGCATTAGCTGAGGCTCAGATCCAGTGGCTG  
GTACCCCAAGCCTAAGGTTTCAAGTGGAGAGACCACAGGGACAGTGCCTCCAGAGTTTGAAGCCATCGTCTG  
GGATGCCCAGGACCTGTTTCAAGTCTGGAAACATCTGTGGTTGTCCGAGCGGGAGCCCTCAGCAATGTGTCCGTCTC  
CATCCAGAATCTCCTCTTGAGCCAGAAGAAAGAGTTGGTGGTCCAGATAGCAGACGTGTTCTGACCCGGAGCCTC  
TGCGTGGAAAGAGCGCGTTCGTGCGACCCCTGCCGCTGCTGTTGGTCTCGCGGCGCTGGCGCTGGGCGTCTCCG  
GAAGCAGCGGAGAAGCCGAGAAAAGCTGAGGAAGCAGGCGGAGAAGAGACAAGAGAACTCACTGCAGAGCTGGA  
AAAGCTTCAACAGAGCTTGAAGGAGACGGGCTGAAGGCCAGGCTGAGTGGAGAGCAGCCCAAAATATGCAGT  
GGATGTGACGCTGGACCCGCTCGGCCACCCAGCCTGGAGGTGTCGGAGGATGGCAAGAGCGTGTCTTCCCG  
CGGGGCGCCGAGGCGCGCCTGGCCACCCGCGAGCGTTCTCGGAGCAGACGTGCGCGCTGAGCCTGGAGCG  
GTTCTCCGCGCGCCGCACTACTGGGAGGTGCACGTGGGCGCGCGCAGCCGCTGGTCTCTGGGCGCCTGCCTGGC  
CGCGGTGCCGCGCGCGGGGCTGCGCGCCTGAGCCCTGCGGCGCGCTACTGGGTGCTGGGCTGTGGAACGGCTG  
CGAGTACTTCGTCTGGCCCCGACCCGCTGCGGCTCACCTGCGCGTGGCCCCGCGCGCCTGGGCGTCTTCT  
GGATACGAGGCGGAGAGCTGTCTTCTCAACGTGTCCGACGGCTCCCACATCTTCACTTCCACGACACCT  
CTCGGGCGCGCTCTGTGCGTACTTCAGGCCAGGGCCACGACGCGCGGCAACATCCGGATCCCTGACCATCTG  
CCCCTGCCGTTAGAGGGACGGGCGTCCCCGAAGAGAACGACAGTACACCTGGCTACAGCCCTATGAGCCCGC  
GGACCCCGCCCTGGACTGGTGGTGAAGGCGCCCTCGTGGCCGCGGGACTGGCCCCGGGGGCCCCCTGGATCCAG  
GCCAGCGCTTTGCTCTCCTGCTCCGTCTGAAGGGAGCAGGTGCACCAGCCAAAATGTGACGAGGGGGACAAAGA  
GAGGGACCTTTGCCTACGTAGATGTGTATGTGTAGTGGGATTTTCTTCAAGGAAAGGAGACAAGTCCAAAGCTCG  
TTTGTGGATTGTGGGACTGAGCGAAGGAGTACAAATATATCCACGTGCTCAGAGCTGGGGTGTGCTACGGTGGGC  
GGTGGGCAAGAAGCCAGCATGGAAGAAAGAGGAGAAAACCTTTGGTGAAGTGCCTTAGAGGGATCAGTTAATTTG  
TATAGTTTATATTTTTTGTATATGTTTGTAGTCTAAAAAGGTGAGATGCAATAACACTTCGTAAGCAACGA  
GTTACCTAAGTAAGGCTCAGATCCTAGTTTAAAAACCATTTCCTTAAATGAAGTTGAGGGAACAGCTGCT  
TCTGAGCCGGGGCAAAAATTTCAAGGTGAGCCTGGAGCATTGTGTGTGGTGAAGTAAATAAAGGCTCAAAACGT  
GACGGCAACCCGGCAAAAGGTTAGGGAGCCAGGCCGAAGGGGCTCACTGACCAATTGTGGGACAATTTGAACAT  
CAGGATGAATAATGACAGGAGAGATTATAACACACTGAATAAAAACATAATCCATGAGTTCATGCTGATACTCAA  
ATTTCTTTTTAAAAAGGAGAAACAGGAAGGTTTCTTTGGAGGTGAAATCTAATTATTGGTGAGAGTCTTGGAGA  
ACAGGCTGTTTCCAGTCTCAAAGCAGTAACCTTATACACTACTTATAAGTTTGAAGGGGAAAGGTTACCTTTAC  
AATGGAGACATCTACCAGATCATCCAAGTGATTAAATTTAACATCATCAATGATGGGACCAAGGACATTATTAGT  
TTGACAACCTGGGGAAAGAAGTGTCTTACCCCTACCCCAAGACATTCTCTCTGTCGGCCAGGCTGGAGTGCA  
GCCTCAACCTCCTGGGCCAAGTATCCTCCACCTCAGCACACAACACCATGCCCAATTTAAGTGGCTTATAG  
AGACGGGGTCTCACTTTGTTACCCAGGCTGGTCTCAAACTCCTGCGCTCAAGCAATCCTCCCACTGGGCTCC  
CAAAATGCTGGGTGTACAGGCATGAGCCGCTGTGCTGGCTTCATTTTCAAGTGTGAGACATTTGTACTGTGGCTA  
TGTAGGAGAACATTCTTGTCTTAGCAAAACATACTGAAGTTTTTAGATATTAATTACCACAGTGTCTGCCACTGA  
ATTTCCAGTGACTAAGTGGAAAAATATAAAACATATGAATATAAAGAAAGAAAGAGACAAGTCAAATGTAGTAAA  
ATGACAACACTTGGTGAAGTCTAGGTGACTGGTTCGACAGATGTTTCAATGTACTATCAATGTGGCTTTGCTGTGGT  
TTGAAATTTTGCAAACTAAGAGTTGGGTGGCGGGGAGAAGGATACACCAAAAACTAAGTGAATATCTTTGGATG  
GAAAAATGTTTGGTAATTGCATTCTTAAATGTCTTCTTTGTATTTTTTAATGTTCAATAATGTATATGTATCAG  
TTCTGTAATAAAGGGGAAACACTTTTCA

124/550

**FIGURE 124**

MVDLSVSPDSLKPVSILTSSLVFLMHLLLLQPGEPSSEVKVLGPEYPILALVGEEVEFPCHLWP  
QLDAQQMEIRWFRSQTFNVVHLYQEQQELPGRQMPAFRNRTKLVKDDIAYGSVVLQLHSIIPS  
DKGTYGCRFHSDNFSGEALWELEVAGLGSDPHLSLEGFKEGGIQLRLRSSGWYPKPKVQWRDH  
QGQCLPPEFEAIVWDAQDLFSLETSSVVVRAGALSNVSVSIQNLLLSQKKELVVQIADVFPVGA  
SAWKSAFVATLPLLLVLAALALGVLRKQRRSREKLRKQAEKRQEKLTAELEKLQTELDWRRAE  
GQAEWRRAAQKYAVDVTLDPASAHPSLEVSEDGKSVSSRGAPPGPAPGHPQRFSEQTCALSLE  
FSAGRHYWEVHVGRRSRWFLGACLAAPRAGPARLSPAAGYWVLGLWNGCEYFVLAPHRVALT  
LRVPPRRLGVFLDYEAGELSFFNVSDGSHIFTFHDTFSGALCAYFRPRAHDGGEHPDPLTICP  
LPVRGTGVPEENDSDTWLQPYEPADPALDWW

**Important features of the protein:****Signal peptide:**

amino acids 1-34

**Transmembrane domain:**

amino acids 247-272

**N-glycosylation sites.**

amino acids 102-106, 139-143, 224-228, 464-468, 516-520

**Tyrosine kinase phosphorylation site.**

amino acids 105-114

**N-myristoylation sites.**

amino acids 129-135, 220-226, 399-405, 423-429, 480-486

**Amidation site.**

amino acids 390-394

125/550

**FIGURE 125**

TATAGTCCCAGCTACTCATGGGGCTGATGCAGGTTGAGGCAGGAGGTTTCATGAGCCCAGGAGGTTGGAGCTGTAA  
TGAGCTAGGATTCTGCCTCTGCACTCCTAGCTGGATGACAGAGCAAGACCCTGTCTCAAAAAAGAAAAA  
AAAAAGAATGCATGAACCAGACATGACAGTTCCTGGCCTCAAAGATCTTCCAAAGGAAATGATTTTTTTTAAACC  
ACCAATGCTGCAGGAAAAAGCAACATATTTAAGTTATCCAATAACACCTATCCAATAATTGTAAATCATTATCAT  
GACATGGTAGAGTTGTTTATATTTCTTTTCTTTTAGGTGAAACACCATTCAAAGTCGTAGTCAAATCTCTTTCA  
CCTAAAGAGTTGGTCCGGATACATGTCCCTAAACCTTTGGACAGGAATGATGGAACATTTTTTGATGAGATATAGG  
ATGTATGAAACTGTCTGATGAAGGCCTGAAGATAGAGGTCCTTTATGGTGATGAACATGTGGCTCAGTCTCCCTAT  
ATTTTGAAAGGACCAGTGATACCATGAGTACTGTGAGTGTCCGGAAGATCCTCAGGCCTGGCAGAAGACTCTTTCT  
TGTCACCAACCAAGGAACACAGATTGCAAAAGATTTTGCTTCTTTCCAGCATCAATCTCCAGCAAATGCTAAAA  
GAAGTCCCCAAAAGGTTTGGGGATGAGAGAGGTGCCATTGTTTATTACACGATTCTCAATAACCATGTTTACCGG  
AGATCTTTAGGGAAATACACAGACTTCAAGATGTTCTCTGATGAGATTTTGTATCATTGACAAGAAAGGTCCTT  
CTCCCAGATTTAGAATTTTATGTTAATCTTGGAGATTGGCCCTTGGAGCATCGAAAAGTCAATGGAACCCCTAGC  
CCCATACCTATCATTTTCATGGTGTGGCTCTCTGGATTCAAGAGATGTTGTCTTCCAACGTATGACATCACCCAC  
TCCATGCTTGAAGCCATGCGGGGTGTACAAATGATCTCCTCTCTATTTCAGGGAAATACAGGGCCTTCTGGATC  
AATAAACAGAGAGAGCTTTCTTCAGAGGTAGAGACAGCCGAGAGGAGAGGCTCCAGTTGGTACAGCTGTCCAAA  
GAAATCCTCAGTCTAGATGCAGGAATTACAGGATATTTCTTTTCCAAGAGAAAGAAAGGAGCTTGGAAAA  
GCCAAGTTGATGGGTTTCTTTGATTTCTTTAAGTACAAGTAAATGAGTAAATGTGGACCGTGGCTGCTTAC  
AGATATCCATATCTCATGCTGGGCGACAGTCTGGTTTTAAAGCAGGACTCGCCATATTATGAACATTTCTACATG  
GCACTAGAACCTTGAAGCATTATGTTCCAATTAAGAAATCTGAGTGATTATTAGAGAAAGTTAAATGGGCT  
AAGGAAATGATGAAGAAGCCAAGAAGATTGCAAAAGAAGGACAGTTGATGGCTAGGGACCTACTACAGCCACAC  
AGGCTTACTGCTACTATTACCAAGTACTGCAGAAATATGCCGAGCGCCAGTCCAGCAAACCCGAAGTACGTGAT  
GGAATGGAACTTGTTCCTCAGCCAGAAGATAGCACAGCCATCTGCCAGTGCCACAGGAAAAAGCCTTCAAGAGAA  
GAACCTTGAAGTACAGCCAGAATCACACTCCTGTGTATCCCGGTACACTTTAAGGAAAGATTGAATCTAAGCTGT  
GAAGGACAGTATAGAAGACTGCACCAAGTGGACTAGTTCTCCCGGTGGCTTTATATATGTAGATGGATATAGCAG  
TACTGGTTGAGTATCCCTCATCTGAAATGCTTAGGACCAGGAGTGTTTCAGGCTTCAGATTTTTTAAGATTTGGG  
AATATTTGCATGTACATAATGAGGTATCTTGGGGATGAGATCCAAGTCTAAACACAAAATTCATTTATATTTTAT  
ATATACCTTGTTTACATACCTGAAGGTAATTTTATATAATATTTTAAATAATTTGTGCATGAAACAAAGTTTGT  
ATACATTGAACGTGCAGAAAGCAAAGGTCTCACTATTCTAGCGACCCAAGTGGTGGTGTGAGCACTCAAAAGTT  
TTGGATTTTGGGGTATTTTCAGATTTTATAGATTTTGTATGAGGAATGTTCAACCTGTATTTGAACAAGCATTACCA  
AATATCATTGAATATTAATATCTTTTGGCTAAAACTGCTATTATCAGCATCATAGTTTCTCTAAAAAGAAAAT  
TGGGGATCATAGCCGATAGAGAGACTTGCTAAATATAAATCAGCCTCTGCAAACTGTTTACATATTTATTGGT  
TTACATATTTTATTGGTTTATTTCTATCCCTGTTCACTTTTTCTCTTCCACTTCCAATTATGAAGAGAAAATAT  
TTGTTCAAGGTTGTCCCCCGCCCCCGCTCACTGCATAATTTCTCCTCTTACAAGCTGCTTTTGGCTTTTATTAA  
TAACAGCTTCTTTTGAAGGTCTGATAAGGATTTTAAAGGAAGAGAATGACTCTGTATTAAAGGTGGCAT  
GGAGACTGTGGAGGGAATATTTTAAAGCACTACTCATATCCTTTAAACTAAATTTTGCACAAAGCCGAGACAA  
CATTAAAGGAGAAATTGTACCTTAAGTTAGTAATTCAAATCTATCTGAGTTGTATACCCATCAAAGACAATACAG  
TTATTAACATAGATGAAGGTATGCTATAGGCATCATTCATTATCTCTATATTGAATAGGTGAAAGATAACTGTAG  
TCAGGTGAAAGGCATTCATCATTTTAAAGCTGAAAAGGGGATCCTTGAAAACACTGAAAACCTCTACAACAATCT  
TCAGGAAGCCTGCTATCTTGGGATTCACTAATAATAGGCCAAGAACAAGGCAAGCATCCATTCTCACTCCACC  
ACTTTTCTATTTTCAGTGGGTGCTATTGCTACGATGAAGCTTGGAAATTTTCTTTCTTTTAGGACAGGGTCA  
GGATTTAGGACTCATAGCCTGAAAGCTCATTACATACTCCTTGTAACCATCAGTCCAAGGTTTCAAGTCACTAAAG  
TGCATGTTCTAAAACAAGAGCTATCCTCATTCCAAATTTTAAATATGTACTCTGGCCGGTTCAGTGGCTCACG  
CCTGTAATCCCAGCACTTTGGCAGGCCGAGATGGGCGGATCTTTTGAGGTGAGGAGTTTGAGACCAGCCTGGCCA  
ACATGCTGAAACCCCGTCTCTACTAAAAATACAAAATTAGCCAGGCATGGTGGCATTGTGCTGTAATCCCAGCT  
ACTCGGAGGCTGAGGCAGGAGAATCACTTGAACCTGGGAGGCAGAGGTTGCAGTGAGCTGAGATTACACCACCTG  
CACTCCAGCCTGGGTGACAGAGTGAGACTCCATCTCAAAAACCTGAAAATAAAAATAAAAATATGATTCTCTCTAA  
CTGAAATATTTACTTAATCTGGAACAATGTAATATTTTAAAGTGGTTACATCTATTCTTGCTGAAGAACA  
TAAACAGAATTTTTTGAAGTAAAGCATAACCAATTTTCAAGACAGTCTAATCAATGCAAGTATCCAAGGCAAACTC  
TAATACCCATCCATTGTGCAAAACCACAAGCAGCAAGTATTAATAAGAGCAAGCTGTCTGAGCCATACCTA  
ATGAATTTGTGCTTAAATATTGTACATTGTGTTTGGGCTTGTCAAACTGGGATTATGGCAAGAAAGGTTGGC  
TAACCTACACCTTTCTGCCTCAAATTCAGGTGCTAAAGGCTAATGGCATTTTAAACATCTTACATTTTAAAA  
TTTATATTGCTCTGCCAAACAGGCCTAATAGTTTAAAGCAAGTTGAGACAAACCAGGCAGATTCAAGTGTGGA  
ACAGGAAGGATGTGCTTTAAAAAAGGTGGAATCCCTCAAAAATTTCTATAGGGAGACAGCAGCCTTAATCTACA  
TAATTTCTTCATCTCGCCAATTCAGCCGAGCCTTTAAAGAGTTAGTGTTAATGGCTTTCTGGTTTGAACAAAA  
ATGCATCTATGTGGTTGAAAGTTTGGGAGGAGATTACCAATATCTGAGGAGAAGATGGAGTGAAGGGAATCTT  
ACTTTTGGCTTTTACCTTTCTATAATATTTAGATTTTTTTTTTACTGTAAGTATGGATCAAATTGCAAAATAAG  
AAAAATGCCAACCTTAGAAAGACAATAAGTGCACAAAAGATATAAACAGGAACAGCAAATATTTATATTTTTTC  
CATTTTGGCTCTTTTAAATCTATGTTTAAAGCTTTATGTTTGGGACTTATGTATATATATACCTTTTAAATAAA  
ATAAATTTTCTAAATAAAAAGTTG



126/550

**FIGURE 126**

MVELFIFLFLLLGETPFKVVVKSLSPKELVRIHVPKPLDRNDGTFLMRYRMYETVDEGLKIEVL  
YGDEHVAQSPYILKGPVYHEYCECPEDPQAWQKTLSCPTKEPQIAKDFASFPSINLQQMLKEV  
PKRFGDERGAIVHYTILNNHVYRRSLGKYTDFKMFSEILLSLTRKVLLPDLEFYVNLGDWPL  
EHRKVNGTPSPIPIISWCGSLDSRDVVLPTYDITHSMLEAMRGVTNDLLSIQGNTGPSWINKT  
ERAFRGRDSREERLQLVQLSKENPQLLDAGITGYFFFQEKELGKAKLMGFFDFFKYKYQV  
NVDGTVAAYRYPYLMLGDSLVLKQDSPYYEHFYMALEPWKHYVPIKRNLSDLLEKVKWAKEND  
EEAKKIAKEGQLMARDLLQPHRLYCYYYQVLQKYAERQSSKPEVRDGMELVPQPEDSTAICQC  
HRKKPSREEL

**Important features of the protein:****Signal peptide:**

amino acids 1-16

**N-glycosylation sites.**

amino acids 250-254, 363-367

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 444-448

**N-myristoylation site.**

amino acids 208-214, 319-325, 388-394

**Endoplasmic reticulum targeting sequence.**

amino acids 448-453

**Mitochondrial energy transfer proteins signature.**

amino acids 25-34

127/550

FIGURE 127

AGCCGTCGGAGGGAGCCGGAGCGCTTCTCCCGAGTTGGTGATAGATTGGTGGTCATCCAACAT  
GCAGAAATGAATGAGCAGTGAAAAGCAGCAGAGCCGATGGGTTCATGAGGATGTAAGTGCGTTT  
GAAGGCTTCCACACCCTCTACTCCAGGAATCATGAATAAACTGGAGGATAAGCAGGACCAGAT  
GATACCATGAAGAGAAGTTTACAGGCCCTCTATTGCCAACTGTTAAGTTTCCTGCTGATCTTG  
GCACTGACCGAAGCGCTGGCATTGTCATCCAGGAACCATCTCCCAGGGAATCTCTTCAGGTC  
CTCCCTTCAGGCACTCCCCCGGAACCATGGTGACAGCACCCACAGCTCTACCAGACATACT  
TCTGTGGTGATGCTGACCCCCAATCCCGATGGACCCCCCTCACAGGCTGCAGCTCCCATGGCA  
ACACTGACACCCCGTGCAGAGGGGCACCTCCTACGCACACCATCTCCACCATCGCTGCGACA  
GTAACCGCCCCCTATTCTGAAAGCTCCCTGTCCACAGGGCCCGCTCCAGCAGCCATGGCAACC  
ACATCCTCCAAGCCAGAGGGCCGCCCTCGAGGGCAGGCTGCCCCACCATCCTGCTGACAAAG  
CCACCGGGGGCCACCAGCCGCCCCACCACAGCGCCCCCGCACTACCACACGCAGGCCCCCC  
AGGCCCCAGGCTCTTCCCGAAAAGGGGCTGGTAATTCATCACGCCCTGTCCCGCCTGCACCT  
GGTGGCCACTCCAGGAGTAAAGAAGGACAGCGAGGACGAAATCCAAGCTCCACACCTCTGGGG  
CAGAAGCGGCCCTGGGGAAAATCTTTTCAGATCTACAAGGGCAACTTCACAGGGTCTGTGGAA  
CCAGAGCCCTCTACCCTCACCCCCAGGACCCCACTCTGGGGTACTCCTCTTCACCACAGCCC  
CAGACAGTGGCTGCGACCACAGTGCCAGCAATACCTCATGGGCACCCACCACCACCTCCCTG  
GGGCCTGCAAAGGACAAGCCAGGCCTTCGCAGAGCAGCCAGGGGGGTGGTTCTACCTTCACC  
AGCCAAGGAGGGACACCAGATGCCACAGCAGCCTCAGGTGCCCTGTGAGTCCACAAGCTGCC  
CCAGTGCCTTCTCAGCGCCCCCACCACGGTGACCCACAGGATGGCCCCAGCCATAGTGACTCT  
TGGCTTACTGTTACCCCTGGCACCAGCAGACCTCTGTCTACCAGCTCTGGGGTCTTCACGGCT  
GCCACGGGGGCCACCCAGCTGCCTTCGATACAGTGTCTCAGCCCCTTCCCAGGGGATTCTCT  
CAGGGAGCATCCACAACCCACAAGCTCCAACCCATCCCTCCAGGGTCTCAGAAAGCACTATT  
TCTGGAGCCAAGGAGGAGACTGTGGCCACCCTCACCATGACCGACCGGGTGCCCAGTCCTCTC  
TCCACAGTGGTATCCACAGCCACAGGCAATTTCTCAACCGCCTGGTCCCCGCCGGGACCTGG  
AAGCCTGGGACAGCAGGGAACATCTCCCATGTGGCCGAGGGGGACAAACCGCAGCACAGAGCC  
ACCATCTGCCTGAGCAAGATGGATATCGCCTGGGTGATCCTGGCCATCAGCGTGCCCATCTCC  
TCCTGCTCTGTCTGCTGACGGTGTGCTGCATGAAGAGGAAGAAGAAGACCGCCAACCCGGAG  
AACAACCTGAGCTACTGGAACAACACCATCACCATGGACTACTTCAACAGGCATGCTGTGGAG  
CTGCCCAGGGAGATCCAGTCCCTTGAAACCTCTGAGGACCAGCTCTCAGAGCCCCGCTCCCCA  
GCCAATGGCGACTATAGAGACACTGGGATGGTCCTTGTTAACCCTTCTGTCAAGAAACACTG  
TTTGTGGGAAACGATCAAGTATCTGAGATCTTAACTACAGCAGGCATCACTTTGCCATTCCGTA  
TTTTTCGTCTCTAAATTATAAATATACAAATATATATATTATAAATATAACCTTGTGTAACCC  
TGACTTAATGAGAAACATTTTTCAGCTTTTTTTCCTATGAATTGTCAACATCTTTTTTTACAAGT  
GTGGTTTAAAAAAAAAAAAAATTTACAGAATGATCTGTGGCTTTATAAAATAAAGGTATTTCT  
AAGCAAAAAAAAAAAAAAAAAA

128/550

**FIGURE 128**

MKRS LQALYCQLLSFLLILALTEALAFAIQE P SPRESLQVLPSGTPPGTMVTAPHSSSTRHTSV  
VMLTPNPDGPPSQAAAPMATLT PRAEGHPPTH TISTIAATVTAPYSESSLSTGPAPAAMATT S  
SKPEGRPRGQAAPTILLTKPPGATSRPTTAPPRTTTRRPPRPPGSSSRKGAGNSSRPVPPAPGG  
HSRSKEGQRGRNPSSTPLGQKRPLGKIFQIYKGNFTGSVEPEPSTLT PRTPLWGYSSSPQPQT  
VAATTVP SNTSWAPT TTTSLGPAKDKPGLRRAAQGGGSTFTSQQGTPDATAASGAPVSPQAAPV  
PSQRPHHGDPQDGP SHSDSWLTVTPGTSRPLSTSSGVFTAATGPTPAAFDTSVSAPSQGI PQG  
ASTTPQAPTHPSRVSESTISGAKEETVATLTMTDRVPSPLSTVVSTATGNFLNRLVPAGTWKP  
GTAGNISHVAEGDKPQHRATICLSKMDIAWVILAISVPISSCSVLLTVCCMKRKKKTANPENN  
LSYWNNTITMDYFN RHAVELPREIQSLETSEDQLSEPRSPANGDYRDTGMVLVNPFCQETLFV  
GNDQVSEI

**Important features of the protein:****Signal peptide:**

amino acids 1-28

**Transmembrane domain:**

amino acids 469-487

**N-glycosylation sites.**

amino acids 178-182, 223-227, 261-265, 446-450, 504-508, 509-513

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 495-499

**N-myristoylation sites.**amino acids 44-50, 48-54, 175-181, 222-228, 279-285, 286-292,  
288-294, 296-302, 351-357, 374-380, 427-433, 442-448**TonB-dependent receptor proteins signature 1.**

amino acids 1-44

129/550

**FIGURE 129**

AGGCGAGGCGCGGCGCCGCTGCACACACGCACACGGAGCT**ATG**GGGTGCCATGTTGCCACCAG  
CTGCCACGTGGCCTGGCTTTTGGTGCTGATCTCTGGATGCTGGGGCCAGGTGAACCGGCTGCC  
CTTCTTCACCAACCACTTCTTTGATACATACCTGCTGATCAGCGAGGACACGCCTGTGGGTTC  
TTCTGTGACCCAGTTGCTGGCCCAAGACATGGACAATGACCCCTGGTGTTTGGCGTGTCTGG  
GGAGGAGGCCTCTCGCTTCTTTGCAGTGGAGCCTGACACTGGCGTGGTGTTGGCTCCGGCAGCC  
ACTGGACAGAGAGACCAAGTCAGAGTTCACCGTGGAGTTCTCTGTGACGACCACCAGGGGGT  
GATCACACGGAAGGTGAACATCCAGGTGCGGGATGTGAATGACAACGCGCCACATTTACAA  
TCAGCCCTACAGCGTCCGCATCCCTGAGAATACACCAGTGGGGACGCCATCTTCATCGTGAA  
TGCCACAGACCCCGACTTGGGGGCAGGGGGCAGCGTCCTCTACTCCTTCCAGCCCCCTCCCA  
ATTCTTCGCCATTGACAGCGCCCGCGGTATCGTCACAGTGATCCGGGAGCTGGACTACGAGAC  
CACACAGGCCTACCAGCTCACGGTCAACGCCACAGATCAAGACAAGACCAGGCCTCTGTCCAC  
CCTGGCCAACTTGGCCATCATCATCACAGATGTCCAGGACATGGACCCCATCTTCATCAACCT  
GCCTTACAGCACCAACATCTACGAGCATTCTCCTCCGGGCACGACGGTGCGCATCATCACCGC  
CATAGACCAGGATAAAGGACGTCCCCGGGGCATTGGCTACACCATCGTTTCAGGGAATACCAA  
CAGCATCTTTGCCCTGGACTACATCAGCGGAGTGCTGACCTTGAATGGCCTGCTGGACCGGGA  
GAACCCCTGTACAGCCATGGCTTCATCCTGACTGTGAAGGGCACGGAGCTGAACGATGACCG  
CACCCCATCTGACGCTACAGTCACCACGACCTTCAATATCCTGGTTATTGACATCAATGACAA  
TGCCCCGGAGTTCAACAGCTCCGAGTACAGCGTGGCCATCACTGAGCTGGCACAGGTGCGCTT  
TGCCCTTCCACTCTTCATCCAGGTGGTGGACAAGGATGAGAATTTGGGCCTGAACAGCATGTT  
TGAGGTGTACTTGGTGGGGAACAACTCCCACTTTCATCATCTCCCCGACCTCCGTCCAGGG  
GAAGGCGGACATTTCGTATTCGGGTGGCCATCCCACTGGACTACGAGACCGTGGACCGCTACGA  
CTTTGATCTCTTTGCCAATGAGAGTGTGCCTGACCATGTGGGCTATGCCAAGGTGAAGATCAC  
TCTCATCAATGAAAATGACAACCGGCCCATCTTCAGCCAGCCACTGTACAACATCAGCCTGTA  
CGAGAACGTCACCGTGGGGACCTCTGTGCTGACAGTCCTGGTGAGTCCCCGCTTCACTGCAGG  
GCCACTGAGCTCTCCAGGGCCGACTGTGGTGAGGCACCCAGAGGGATTTTGTCCAAGGGACCT  
CAGCAATCAGGGAAGGAGGCACCCCCAAATCCCTGAGCTGTGTTTGTGGTGTAT**TAA**AATAAA  
GTTTTTGGACTCTTCAGGAAGGGGCTCCCTTGACCTAGGTGCAATATGGAAAAGGAGCCAAC  
CTGAGGGGTGACGAGACTGAGCTGAGGACACTGGTTTTCTGCCTTTCCTGAGAGAGACTCAG  
TGAGGGTGGGCTGGGAGCCCTGGAAGCCCCCTCAAATGGGTGGGAAGGTGCCAGCCATCCTTG  
AGAAGGGCAACCCTCTCCATGTGAGCACAGGCACCAGAGAGGGGCAGGCGCCTGGAGGGTACC  
GGGGCACCCCACTGCCCATGGCTGGACTTGCCCTTTGACAAGGGGGCCCTCCAGTGTCATT  
TGTATCTGTGCTAGTACTCTTGGTTGCAAGGGACAGAAACCCTTAAGTAGTTCAAGCAAAAAGG  
ATTGGCTCATGTAACCAAAAGTATAAGTGATTTAGGCCGGGCTCGGTGGCTCACGCCTGTC  
ATCCAACACCTTGAGAAAGCCGAGGTGGGCGGATCACTTGAGGTGCGGAGTTTGAGACCAGCC  
TGGCCAACATGGCAAAACCCCGTCTCTACTAAAAATAAAAAATTAGCCGGGTGTGGTGGCAC  
ACGCCTGTAGTCCCAGCTACTAGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGGAGGCGG  
AGGTTGCAGTGAGCCGAGATTGTGTCACTGCCCTCCAGCCTGGGCGACAGAGCCAGATTCTGT  
CTC

130/550

FIGURE 130

MGCHVATSCHVAWLLVLIS CWGQVNRLPFFTNNHFFDTYLLISEDTPVGSSVTQLLAQDMDND  
 PLVFGVSGEEASRFFAVEP. TGVVWLRQPLDRETKSEFTVEFSVSDHQGVITRKVNIQVGDVN  
 DNAPTFHNQPYSVRIPENTF GTPIFIVNATDPDLGAGGSVLYSFQPPSQFFAIDSARGIVTV  
 IRELDYETTQAYQLTVNATD DKTRPLSTLANLAIITDVQDMDPIFINLPYSTNIYEHSPPG  
 TTVRIITAIDQDKGRPRGIGY TIVSGNTNSIFALDYISGVLTNLGLLDRENPLYSHGFILTVK  
 GTELNDDRTPSDATVTTTFNII VIDINDNAPEFNSSEYSVAITELAQVGFALPLFIQVVDKDE  
 NLGLNSMFEVYLVGNNSHFIISPTSVQKGADIRIRVAIPLDYETVDRYDFDLFANESVPDHV  
 GYAKVKITLINENDNRPLFSQPLYNISLYENVTVGTSVLTVLVSPRFTAGPLSSPGPTVVRHP  
 EGFCPRDLSNQRRHPQIPELCLIVY

**Important features of the protein:****Signal peptide:**

amino acids 1-23

**Transmembrane domain:**

amino acids 355-374

**N-glycosylation sites:**amino acids 155-159, 205-210, 349-353, 393-397, 434-438, 466-470,  
472-476**N-myristoylation sites:**

amino acids 2-8, 49-55, 162-168, 270-276, 278-284, 316-322

**Amidation site:**

amino acids 515-519

**Prokaryotic membrane lipid protein lipid attachment site:**

amino acids 11-22

**Leucine zipper pattern:**

amino acids 298-320

**PTS HPR component serine phosphorylation site signature:**

amino acids 377-393

**Cadherins extracellular repeated domain signature:**

amino acids 120-131, 336-347

**Cadherins extracellular**

amino acids 120-144, 336-360

131/550

**FIGURE 131**

GTGGGCCGCCCCCTGCTGCTGCCGTCCATGCTGATGTT TGGGGTGATCGTGGCCTCCAGCGGGC  
TGCTGCTCATGATCGAGCGGGGCATCCTGGCCGAGA :GAAGCCCCTGCCCTGCACCCGCCCCG  
GCCGCGAGGGCACAGCCTGGCGCGGGAAAGCCCCC? AGCCTGGGGGCTGTCCCTCAGGGCTG  
GGGACGCGGACTTGCAAGTGCGGCAGGACGTCCGG. ACAGGACCCTGCGGGCGGTGTGCGGAC  
AGCCAGGCATGCCCCGGGACCCCTGGGACTTGCCG GTGG?GCAGCGGCGCACCCCTGCTGCGCC  
ACATCCTCGTAAGTGACCGTTACCGCTTCCTCTAC TGCT ACGTCCCCAAGGTGGCCTGCTCTA  
ACTGGAAGCGGGTGATGAAGGTGCTGGCAGGCGT :CTGC ACAGCGTGGACGTCCGCCTCAAGA  
TGGACCACCGCAGTGACCTGGTGTTCCTGGCCG? CCTGC GGCCTGAGGAGATTCGCTACCGCC  
TGCAGCACTACTTTAAGTTCCTGTTTGTGCGGGAGCCCT TGGAACGCCTCCTCTCTGCCTACC  
GCAACAAGTTTGGCGAGATCCGAGAGTACCAG?AACGC? ATGGGGCTGAGATAGTGAGGCGGT  
ACAGGGCTGGAGCGGGGGCCAGCCCTGCAGG?GACGAT?TCACATTCCCCGAGTTCCTGAGAT  
ACCTGGTGGATGAGGACCCCTGAGCGCATGAA?TGAGCAT TGGATGCCCCGTGTACCACCTGTGCC  
AGCCTTGTCGCGTGCACTATGACTTTGTGG?CTCCTA? GAGAGGCTGGAGGCTGATGCAAATC  
AGGTGCTGGAGTGGGTACGGGCACCACCT?ACGTCCG. TTTCCAGCTCGCCAGGCCTGGTACC  
GGCCAGCCAGCCCCGAAAGCCTGCATTACCACTTGTG :AGTGCCCCCGGGGCCCTGCTGCAGG  
ATGTGCTGCCTAAGTATATCCTGGACTTCTCCCT :T? TGCCTACCCACTGCCTAATGTCACCA  
AGGAGGCGTGTGAGCAGTGACCATGGGTGTGGGG :C :GCAGCTGGTGGGGACTGGTTTCAACG  
CCAGCTTTCTGTGCTTCTGCCTGTGCTATTCGGAGAAA :TCTGGCTCTGGGGCTTGGGGCTTCTC  
AGGATCCTGGATGGCAGAGACTGCCCTCAGAAG? TC :TTGTCCAGGGTGGGCACCCACAGTGA  
CTCAGAGGACAGGGCTAGGCAGGAGACCTGCTG :TCCTCATTGGGGGGATCTCTTGGGGGGCA  
GACACCAGTTTGCCAATGAAGCAACACATCTG? TC?AAAGACTGGCTCCAGACCCCGGGCTGC  
CAGGATTATGCAGTCCACTTGGTCTACCTTAA? TTAACCTGTGGCCAAACTCAGAGATGGTAC  
CAGCCAGGGGCAAGCATGACCAGAGCCAGGGA :CCTGTGGCTCTGATCCCCCATTTATCCACC  
CCATGTGCCTCAGGACTAGAGTGAGCAATCAT ACCTTATAAATGACTTTTGTGCCTTTCTGCT  
CCAGTCTCAAAATTTCTACACCTGCCAGTTCT?T? ACATTTTTC AAGGAAAGGAAAACGGAA  
GCAGGGTTCTTGCTGGTAGCTCCAGGACCC?GC :CTGCAGGCACCCAAAGACCCCTCTGTGCC  
CAGCCTCTTCCTTGAGTTCTCGGAACCTCCT :CC?AATTCTCCCTTCCTTCCCCACAAGGCCT  
TTGAGGTGTGACTGTGGCTGGTATATCTGGCTG :CATTTTTCTGATGCATTTATTTAAATT  
TGTACTTTTTGATAGAACCCTTGTAAGGGCTTT? :TTTCCTAATAGCTGACTTTTAAATAAG  
CAGTTTTATATAT

132/550

**FIGURE 132**

MLMFAVIVASSGLLLMIERGILAE MKPLPLHPPGREGTAWRGKAPKPGGLSLRAGDADLQVRQ  
DVRNRTLRAVCGQPGMPRDPWDLVVGQRRTLLRHILVSDRYRFLYCYVPKVACSNWKRV MKVL  
AGVLDSVDVRLKMDHRSDLVFLADLRPEEI RYRLQHYFKFLFVREPLERLLSAYRNKFGEIRE  
YQQRYGAEIVRRYRAGAGPSPAGDDVTFPEFLRYLVDEDPERMNEHWMPVYHLCQPCAVHYDF  
VGSYERLEADANQVLEWVRAPPHVRFPARQAWYRPASPESLHYHLC SAPRALLQDVL PKYILD  
FSLFAYPLPNVTKEACQQ

**Important features of the protein:****Signal peptide:**

amino acids 1-23

**N-glycosylation sites.**

amino acids 67-71, 325-329

**Tyrosine kinase phosphorylation sites.**

amino acids 152-159, 183-183

**N-myristoylation sites.**

amino acids 89-95, 128-134

133/550

**FIGURE 133**

CGGCAGTTCTGGCCCCTGCAGCTGGAGGTACCCTGAGTTCTGAGGGTCGTAGTGCTGTTTCTG  
GTATTCTCATCGCGGTACCTCTACCGGTGTGGACAAGTAAAGTTTGAATCAGCTTCTCCATG  
GCCTGGGCACCAAGTTCCCGGCTGAGCCATTTTCCTTTTGGCTAAAAGTCCCCGCCCAGAGGCC  
AATTCGTCGCGGCGGCGGTGGAGATCGCAGGTGCTCAGGCTTGCAGATGGGTCAAGGGTTGT  
GGAGAGTGGTCAGAAACCAGCAGCTGCAACAAGAAGGCTACAGTGAGCAAGGCTACCTCACCA  
GAGAGCAGAGCAGGAGAATGGATGCGAGCAACATTTCTAACACCAATCATCGTAAACAAGTCC  
AAGGAGGCATTGACATATATCATCTTTTGAAGGCAAGGAAATCGAAAGAACAGGAAGGATTCA  
TTAATTTGGAAATGTTGCCTCCTGAGCTAAGCTTTACCATCTTGTCTTACCTGAATGCAACTG  
ACCTTTGCTTGGCTTCATGTGTTTGGCAGGACCTTGCGAATGATGAACTTCTCTGGCAAGGGT  
TGTGCAAATCCACTTGGGGTCACTGTTCCATATACAATAAGAACCACCTTTAGGATTTTCTT  
TTAGAAAATTGTATATGCAGCTGGATGAAGGCAGCCTCACCTTTAATGCCAACCAGATGAGG  
GAGTGAACACTACTTTATGTCCAAGGGTATCCTGGATGATTGCGCAAAGGAAATAGCAAAGTTA  
TCTTCTGTACAAGAACAATAAATTGGAAAAAACTGAGAATCTATCTTGATGAAAGGAGAGATG  
TCTTGGATGACCTTGTAACATTGCATAATTTTAGAAATCAGTTCTTGCCAAATGCACTGAGAG  
AATTTTTTCGTCATATCCATGCCCCTGAAGAGCGTGGAGAGTATCTTGAAACTCTTATAACAA  
AGTTCTCACATAGATTCTGTGCTTGCAACCCTGATTTAATGCGAGAACTTGGCCTTAGTCCTG  
ATGCTGTCTATGTACTGTGCTACTCTTTGATTCTACTTTCCATTGACCTCACTAGCCCTCATG  
TGAAGAATAAAATGTCAAAAAGGGAATTTATTCGAAATACCCGTCGCGCTGCTCAAAATATTA  
GTGAAGATTTTGTAGGGCATCTTTATGACAATATCTACCTTATTGGCCATGTGGCTGCATTAAA  
AAGCACAATTGCTAGGACTTCAGTTTTTACTTCAGACTAAAGCTACCCAAGGACTTAGCAGAT  
ATGGGGGTACATCAGTGCTGGTCATTGTAGCCTGAGTATACAATCAAGCTTCAGTGTGCAAC  
CTTTTTTCTTTTGCCATTTTCTATTTTAGTAATTTCTTGGGGAACTAAATAATTTTGCAGA  
ATTTTTCCTAATTTTGTATTATCACGTTTTGCACAAAGCAGAGCCACTGTCTAACACAGCTGTT  
AACGAATGATAAACTGACATTATACTCTAAAAGATGGTGTATTTGTGCATTAGATTTGCCTGA  
AAAACCTTTATCCATTTCCATTCTTTATACAAATACCATGTAATGTGTACATATTTAACTAAAG  
AGATTTATAGTCATAATTATTTTATTGTAAAGATTTTAACTAAAGTTTTTCCTTTTCTCTC



134/550

**FIGURE 134**

MGQGLWRVVRNQQLQQEGYSEQGYLTREQSRRMDASNISNTNHRKQVQGGIDIYHLLKARKSK  
EQEGFINLEMLPPELSFTILSYLNATDLCLASCWQDLANDELLWQGLCKSTWGHCSIYNKNP  
PLGFSFRKLYMQLDEGSLTFNANPDEGVNYFMSKGILDDSPKEIAKFIFCTR TLNWKKLRIYL  
DERRDVLDDLVT LHNFRNQFLPNALREFFRHIHAPEERGEYLET LITKFSHRFCACNPDL MRE  
LGLSPDAVYVLCYSLILLSIDLTS PHVKNKMSKREFIRNTRRAAQNISEDFVGHLYDNIY LIG  
HVAA

**Important features of the protein:****Transmembrane domain:**

amino acids 253-272

**N-glycosylation sites.**

amino acids 37-41, 87-91, 298-302

**N-myristoylation site.**

amino acids 110-116

135/550

**FIGURE 135**

GGCACGAGGGAGCCTCCGTTAGGGGGTGGGAAAGGACTTTGCCATAGGTCGCTGAGGCCACCA  
TCTGCTCTCTTACTGGCCAAGGGCGTAAAAAGATAGTCTTCCCATTAGCTAGAGAGCAAACCC  
CAGAAAGCCTATTGGCTGCGCCGTCCGCGGGCCTTGGTCCGCTTTGAAGGCGGGCTGCGGCTG  
CGAGAGGAGGGCGGGCGGGAGGCTAGCTGTTGTCGTGGTTGCTCGGAGGCACGTGTGCAGTCC  
CGGAAGCGGCGAGGGGAACTGCTCCGCGCGCGCCGCGGGAGGAGGAACCGCCCGGTCCTTTA  
GGGTCCGGGCCCCGGCCGGGCC**ATG**GATTCAATGCCTGAGCCCCGCGTCCCGCTGTCTTCTGCTT  
CTTCCCTTGCTGCTGCTGCTGCTGCTGCTGCTGCCGGCCCCGGAGCTGGGCCCCAGCCAGGCC  
GGAGCTGAGGAGAACGACTGGGTTTCGCTGCCAGCAAATGCGAAGTGTGTAAATATGTTGCT  
GTGGAGCTGAAGTCAGCCTTTGAGGAAACCGGCAAGACCAAGGAGGTGATTGGCACGGGCTAT  
GGCATCCTGGACCAGAAGGCCTCTGGAGTCAAATACACCAAGTCGGACTTGCGGTTAATCGAA  
GTCACTGAGACCATTTGCAAGAGGCTCCTGGATTATAGCCTGCACAAGGAGAGGACCGGCAGC  
AATCGATTTGCCAAGGGCATGTCAGAGACCTTTGAGACATTACACAACCTGGTACACAAAGGG  
GTCAAGGTGGTGATGGACATCCCCTATGAGCTGTGGAACGAGACTTCTGCAGAGGTGGCTGAC  
CTCAAGAAGCAGTGTGATGTGCTGGTGGAAGAGTTTGAGGAGGTGATCGAGGACTGGTACAGG  
AACCACCAGGAGGAAGACCTGACTGAATTCCTCTGCGCCAACCACGTGCTGAAGGGAAAAGAC  
ACCAGTTGCCTGGCAGAGCAGTGGTCCGGCAAGAAGGGAGACACAGCTGCCCTGGGAGGGAAG  
AAGTCCAAGAAGAAGAGCAGCAGGGCCAAGGCAGCAGGCGGCAGGAGTAGCAGCAGCAAACAA  
AGGAAGGAGCTGGGTGGCCTTGAGGGAGACCCAGCCCCGAGGAGGATGAGGGCATCCAGAAG  
GCATCCCCTCTCACACACAGCCCCCTGATGAGCTCT**TGA**GCCCCACCCAGCATCCTCTGTCCTG  
AGACCCCTGATTTTGAAGCTGAGGAGTCAGGGGCATGGCTCTGGCAGGCCGGGATGGCCCCGC  
AGCCTTCAGCCCCCTCCTTGCCCTTGGCTGTGCCCTCTTCTGCCAAGGAAAGACACAAGCCCCAG  
GAAGAACTCAGAGCCGTCATGGGTAGCCACGCCGTCCTTTCCCCTCCCAAGTGTTTCTCTC  
CTGACCCAGGGTTCAGGCAGGCCTTGTGGTTTCAGGACTGCAAGGACTCCAGTGTGAACTCAG  
GAGGGGCAGGTGTCAGAACTGGGCACCAGGACTGGAGCCCCCTCCGGAGACCAAACTCACCAT  
CCCTCAGTCCTCCCCAACAGGGTACTAGGACTGCAGCCCCCTGTAGCTCCTCTCTGCTTACCC  
CTCCTGTGGACACCTTGCACTCTGCCTGGCCCTTCCCAGAGCCCAAAGAGTAAAAATGTTCTG  
GTTCTGATTTCTGAAAAAAAAAAAAAAAAAAATTCCT

136/550

FIGURE 136

MDSMPEPASRCLLLLPLLLLLLLLLLPAPELGPSQAGAEENDWVRLPSKCEVCKYVAVELKSAF  
EETGKTKEVIGTGYGILDQKASGVKYTKSDLRLIEVTETICKRLLDYSLHKERTGSGNRFAKGM  
SETFETLHNLVHKGVKVVMDIPYELWNETSAEVADLKKQCDVLVEEFEEVIEDWYRNHQEEDL  
TEFLCANHVLKKGKDTSCLAEQWSGKKGDTAALGGKKSKKKSSRAKAAGGRSSSSKQRKELGGL  
EGDPSPEEDEGIQKASPLTHSPPEL

**Important features of the protein:****Signal peptide:**

amino acids 1-26

**N-glycosylation site.**

amino acids 153-157

**cAMP- and cGMP-dependent protein kinase phosphorylation sites.**

amino acids 227-231, 228-232

**Tyrosine kinase phosphorylation site.**

amino acids 142-150

**N-myristoylation sites.**amino acids 36-42, 74-80, 86-92, 125-131, 222-228, 237-243,  
250-256, 263-269**Amidation sites.**

amino acids 212-216, 222-226

**ATP/GTP-binding site motif A (P-loop).**

amino acids 62-70

137/550

FIGURE 137

CACGCCTCCCGCTGCCAGCCCGGCACCGGGATCTTAATCAGTCACTATGAAAACCTCATTAGCT  
CCACAGCAATGAGTCCTCCACTGCTGAAGCTTGGCGCTGTGCTTAGTACCATGGCAATGATCT  
CAAACCTGGATGTCCCAAACCTCTCCCATCCTTGGTGGGACTGAACACCACGAGGCTGTGCTGACTC  
CGGATACCTTAACTCAGATTAGTCCTAAAGAAGGGTGGCAGGTGTACAGCTCAGCTCAGGATC  
CTGATGGGCGGTGCATTTGCACAGTTGTTGCTCCAGAACAACCTGTGTTCCCGGGATGCCA  
AAAGCAGGCAACTTCGCCAACTACTGGAAAAGGTTTCAAGACATGTCCCAGTCTATTGAAGTCT  
TAAACTTGAGAACTCAGAGAGATTTCCAATATGTTTTAAAAATGGAAACCCAAATGAAAGGGC  
TGAAGGCAAAATTTCCGCGAGATTGAAGATGATCGAAAGACACTTATGACCAAGCATTTCAGG  
AGTTGAAAGAGAAAATGGACGAGCTCCTGCCTTTGATCCCCGTGCTGGAACAGTACAAAACAG  
ATGCTAAGTTAATCACCCAGTTCAAGGAGGAAATAAGGAATCTGTCTGCTGTCCTCACTGGTA  
TTCAGGAGGAAATTTGGTGCCTATGACTACGAGGAACTACACCAAAGAGTGTGAGCTTGGAAA  
CAAGACTTCGTGACTGCATGAAAAAGCTAACATGTGGCAAACCTGATGAAAATCACAGGCCCCAG  
TTACAGTCAAGACATCTGGAACCCGATTTGGTGTCTGGATGACAGACCCTTTAGCATCTGAGA  
AAAACAACAGAGTCTGGTACATGGACAGTTATACTAACAATAAAATTGTTTCGTGAATACAAAT  
CAATTGCAGACTTTGTCTAGTGGGGCTGAATCAAGGACATACAACCTTCCTTTCAAGTGGGCAG  
GAACTAACCATGTTGTCTACAATGGCTCACTCTATTTTAAACAAGTATCAGAGTAATATCATCA  
TCAAATACAGCTTTGATATGGGGAGAGTGCTTGCCCAACGAAGCCTGGAGTATGCTGGTTTTTC  
ATAATGTTTACCCCTACACATGGGGTGGATTCTCTGACATCGACCTAATGGCTGATGAAATCG  
GGCTGTGGGCTGTGTATGCAACTAACCGAATGCAGGCAATATTGTCTATCAGCCAACTTAACC  
AAGATACCTTGGAGGTGATGAAGAGCTGGAGCACTGGCTACCCCAAGAGAAGTGCAGGGGAAT  
CTTTCATGATCTGTGGGACACTGTATGTCACCAACTCCCACTTAACCTGGAGCCAAGGTGTATT  
ATTCCCTATTCCACCAAACCTCCACATATGAGTACACAGACATTCCCTTCCATAACCAATACT  
TTCACATATCCATGCTTGACTACAATGCAAGAGATCGAGCTCTCTATGCCTGGAACAATGGCC  
ACCAGGTGCTGTTCAATGTCACCCTTTTCCATATCATCAAGACAGAGGATGACACATAGGCAA  
ATGTGACATGTTTTTCATTGATTTAAACAGTGTGATTTGTGATAAACTCTATAAGACCCCTTCC  
GTTTTTTTTCTTCACTATTATTTTTTCATCATTTCTCCAAAGCAAAGCATTTTTTATTGTAAAGTT  
GGTGTTCAAAAACATAGCTGAGCTTGTCTAACTTACCATGTTGGAAACACATCTTAACTTCT  
AAATTTACAAGGCCTATCATGTCCTTGTCTATGAAAAGCACTAAAAAAAAAAAAAGAGTTTAAGT  
GGCTAAAGTCATAGTTTTGCAAGAGATTAATGATCTGCCTTATATTAGAGTCAGAGACTAATG  
GTGGCTTAAATGCACGAATGTCTTTTTTTTTTAAACTGTCATTTTTTTACTGTCTTTTGCTCCA  
TCTCAGGAAATATTTTGGTAGGAATTAGGAGAACAAAAAGCACTTTTATCCCATTTATTTCTT  
TAAAAAATGTAAGGATTTTCAATTTATATTGAAAAATAATATTAATCATTTTGTGCTGTTAACACAA  
TTCTCTGATGCGGTGCTGTACAGTCATTTTTTAAATCTCTTGCTAACATTTTATTGGCAGTATG  
TATTTCTACCATTTGTAACCACCATTTGTGCTATTGTATCTCTTCACTTCTGTGAAAGTAATATT  
TTTTATAAANACACTGNAATTTTAAAAAAAAAAAAAAAAAAAAA

138/550

**FIGURE 138**

MSPPLLKLGAVLSTMAMISNWMSQTLPSLVGLNTTRLSTPDTLTQISPKEGWQVYSSAQDPDG  
RCICTVVAPEQNLCSDAKSRQLRQLLEKVQNMSQSIEVLNLRTQRDFQYVLKMETQMKGLKA  
KFRQIEDDRKTLMTKHFQELKEKMDSELLPLIPVLEQYKTDAKLITQFKEEIRNLSAVLTG IQE  
EIGAYDYEELHQRVLSLETRLRDCMKKLTGKLMKITGPVTVKTSGTRFGAWMTDPLASEKNN  
RVWYMDSYTNKIVREYKSIAD FVSGAESRTYNLPFKWAGTNHVVYNGSLYFNKYQSNII IKY  
SFDMGRVLAQRSLEYAGFHNVPYPTWGGFSDIDLMADEIGLWAVYATNQ NAGNIVISQLNQDT  
LEVMSKSWSTGYPKRSAGESFMICGTLVVTNSHLTGAKVYYSYSTKTSTYEYTDIPFHNQYFHI  
SMLDYNARDRALYAWNNGHQVLFNVTLFHHIKTEDDT

**Important features of the protein:****Signal peptide:**

amino acids 1-16

**N-glycosylation sites.**

amino acids 33-37, 95-99, 179-183, 299-303, 465-469

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 215-219

**Tyrosine kinase phosphorylation site.**

amino acids 106-114

**N-myristoylation sites.**

amino acids 9-15, 31-37, 235-241, 239-245

139/550

**FIGURE 139**

GAAGCAGTGCAGAGAGGAGAGCGGAGCGGAGCTGCCGCTGAGCAAAGGCCTTCACCATGCGCCG  
AGTCCCCCGGCTGCTGCTCCGTCTGGGCCCCGCTGCCTCCACTGCCTGTATAGCTGCCACTGGA  
GGAAATGCCCCAGAGAGAGGATGCAAACCAGCAAGTGCGACTGTATCTGGTTTGGCCTGCTCT  
TCCTCACCTTCCTCCTTTCCCTGAGCTGGCTGTACATCGGGCTCGTCTTCTCAATGACCTGC  
ACAACCTTCAATGAATTCTCTTCCGCCGCTGGGGACACTGGATGGACTGGTCCCTGGCATTCC  
TGCTGGTCATCTCTCTACTGGTCACATATGCATCCTTGCTATTGGTCTTGGCCCTGCTCCTGC  
GGCTTTGTAGACAGCCCCCTGCATCTGCACAGCCTCCACAAGGTGCTGCTGCTCCTCATTATGC  
TGCTTGTGGCGGCTGGCCTTGTGGGACTGGACATCCAATGGCAGCAGGAGTGGCATAGCTTGC  
GTGTGTCACTGCAGGCCACAGCCCCATTCTTCATATTGGAGCAGCCGCTGGAATTGCCCTCC  
TGGCCTGGCCTGTGGCTGATACCTTCTACCGTATCCACCGAAGAGGTCCCAAGATTCTGCTAC  
TGCTCCTATTTTTTGGAGTTGTCCTGGTCATCTACTTGGCCCCCTATGCATCTCCTCACCT  
GCATCATGGAACCCAGAGACTTACCACCCAAGCCTGGGCTGGTGGGACACCGAGGGGCCCCCA  
TGCTGGCTCCCGAGAACACCCTGATGTCCTTGCGGAAGACAGCTGAATGCGGAGCTACTGTGT  
TTGAGACTGATGTGATGGTCAGCTCCGATGGGGTCCCCTTCCTCATGCATGATGAGCACCTCA  
GCAGGACCACGAATGTAGCCTCTGTATTCCCAACCCGAATCACAGCCCACAGCAGTGACTTCT  
CCTGGACTGAACTGAAGAGACTCAATGCTGGATCCTGGTTCCTAGAGAGGCGACCCTTCTGGG  
GGGCCAAACCGCTGGCAGGCCCTGATCAGAAAGAGGCTGAGAGTCAGACGGTACCAGCATTAG  
AAGAGCTATTGGAGGAAGCTGCAGCCCTCAACCTTTCCATCATGTTCGACTTGCGCCGACCCC  
CACAGAACCACACATACTATGACACTTTTGTGATCCAGACATTGGAGACTGTGCTGAATGCAA  
GGGTGCCCCAAGCCATGGTCTTTTGGCTACCAGATGAAGATCGGGCTAATGTCCAACGACGGG  
CACCTGGAATGCGCCAGATATATGGACGTCAGGGAGGCAACAGAACGGAGAGGCCCCAGTTTC  
TTAACCTCCCCTATCAAGATCTGCCACTATTGGATATCAAGGCATTGCATAAGGATAATGTCT  
CGGTGAACCTATTTGTAGTGAACAAGCCCTGGCTCTTCTCTCTGCTTTGGTGTGCAGGGGTGG  
ATTGGGTCACCACCAACGACTGCCAGCTGCTGCAGCAGATGCGTTACCCTATCTGGCTTATTA  
CCCCTCAAACCTACCTAATCATATGGGTCATTACCAATTGTGTTTCCACCATGCTGCTTTTGT  
GGACCTTCCTCCTCCAAAGGAGATTTGTTAAGAAGAGAGGGGAAACTGGCTTAGAAACAGCAG  
TGCTGCTGACAAGGATCAACAATTTTCATGATGGAGTGAATGCCCTGCCCTGCTTCCCCACCCA  
AGCCAGTCTACATTGCCCAAACAGCAAGGGTTGGAGAGTGGCTTAAGTGAATGCTTCAGGGG  
TGGTGGGTGCAAGTGGGGGGAGCTTTGCCAACAGGAGGTTTGAACCATGAGGGCCCTCTGC  
CCAGGTGATGGGCATTCCCTAAGCTGCTATGGAATCTGCTCCCTTTGGGGTTTTGACCTGAGA  
TGTTTGGGAAGAGAGTGAGTAATGAGAAGTTTCTCCTCAAATGAACTAGAACAGAGGAAGTA  
AAAGGGAGATTGCTCGGA

140/550

FIGURE 140

MAESPG CSVWARCLHCLYSCHWRKCPRERMQTSKDCIWFGLLFLTFLLSLSWLYIGLVLLN  
 DLHNFN FLFRRWGHWMDSLAFLLVISLLVTYASLLLVLALLRLCRQPLHLHSLHKVLLLL  
 IMLLVA ELVGLDIQWQQEWHSLRVSLQATAPFLHIGAAAGIALLAWPVADTFYRIHRRGPKI  
 LLLLLF VVLVIYLAPLCISSPCIMEPRDLPPKPGLVGHRGAPMLAPENTLMSLRKTAECGA  
 TVFETDV VSSDGV PFLMHDEHLSRTTNVASVFPTRIHSSDFSWTELKRLNAGSWFLERRP  
 FWGAKPL PDQKEAESQTVPALEELLEAAALNLSIMFDLRRPPQNHTYYDTFVIQTLETVL  
 NARVPQAM FWLPDED RANVQRRAPGMRQIYGRQGGNRTERPQFLNLPYQDLPLLDIKALHKD  
 NVSVNL FV IKPWLF SLLWCAGVDSVTTNDCQLLQQMRYPIWLITPQTYLIIWVITNCVSTML  
 LLWTFLLQ FVKKRGKTGLETAVLLTRINNEMME

**Important features of the protein:****Transmembrane domains:**

amino acids 38-60, 83-107, 122-138, 156-173, 189-210, 484-506

**N-glycosylation sites.**

amino acids 349-353, 362-366, 415-419, 442-446

**N-myristoylation sites.**

amino acids 63-169, 413-419, 523-529

**Leucine zipper pattern.**

amino acids 93-115, 109-131

**Glutamine amidotransferases class-II active site.**

amino acids 1-11

**FIGURE 141**

BNSDOCID: <WO\_\_0140466A2\_I\_>



142/550

FIGURE 142

MYLVAGDRGLAGCGHLLVSLGLLLLLLARSSTRALVCLPCDESKCEEPRNCPGSI VQGVCGCC  
 YTCASQRNESC GGTFGIYGTCDRGLRCVIRPPLNGDSLTEYEAGVCEDENWTDDQLLGFKPCN  
 ENLIAGCNIINGKCECNTIRTCSNPF EFPSQDMCLSALKRIEEEEKPDCKARCEVQFSPRCPE  
 DSVLIEGYAPPGECCPLPSRCVCNPAGCLRKVCQPGNLNILVSKASGKPGECDDL YECKPVFG  
 VDCRTVECPVQQTACPPDSYETQVRLTADGCCTLPTRCECLSGLCGFPVCEVGSTPRIVSRG  
 DGTPGKCCDVFEVCVNDTKPACVFNNVEYYDGMFRMDNCRFCRCQGGVAICFTAQCGEINCER  
 YYVPEGECCPVCEDPVYFPNNPAGCYANGLILAHGDRWREDDCTFCQCVNGERHCVATVCGQT  
 CTNPVKVPGECCPVCEEPTIITVDPPACGELSNCTLTGKDCINGFKRDHNGCRTQCQINTEEL  
 CSERKQGCTLNCPFGFLTDAQNCEICECRPRPKKCRPIICDKYCPLGLLKNKHGCDICRCKK  
 PELSCSKICPLGFQQDSHGCLCKCREASASAGPPILSGTCLTVDGHHHKNEESWHDGCRECY  
 CLNGREMCALITCPVPACGNPTIHPGQCCPSCADDFVQKPELSTPSICHAPGGEYFVEGETW  
 NIDSTQCTCHSGRVLCETEVCPPLLQNPSRTQDSCCPQCTDQPFPSLSRNNNSVPNYCKND  
 EGDIFLAAESWKPDVCTSCICIDSVISCFSESCPSVSCERPVL RKGQCCPYCIEDTIPKKVVC  
 HFSGKAYADEERWDLDSTHCYCLQGQTLCTVSCPPLPCVEPINVEGSCCPMCPEMYVPEPT  
 NIPIEKTNHRGEVDLEVPLWPTPSENDIVHLPRDMGHLQVDYRDNRLHPSEDSSLDSIASVVV  
 PIIICLSIIIAFLFINQKKQWIPLLCWYRTPTKPSSLNNQLVSVDCCKKGTRVQVDSSQRMLRI  
 AEPDARFSGFYSMQKQNHQLQADNFYQTV

**Important features of the protein:****Signal peptide:**

amino acids 1-34

**Transmembrane domain:**

amino acids 940-962

**N-glycosylation sites.**

amino acids 71-75, 113-117, 330-334, 474-478, 746-750

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 992-996

**N-myristoylation site.**

amino acids 9-15, 58-64, 61-67, 75-81, 79-85, 362-368, 402-408, 407-413,  
 439-445, 492-498, 511-517, 551-557, 558-564, 586-592, 606-612, 625-631,  
 845-851

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 52-63, 844-855

**Cell attachment sequence.**

amino acids 314-317

**Leucine zipper pattern.**

amino acids 3-25

**Eukaryotic thiol (cysteine) proteases cysteine active site.**

amino acids 57-69

**VWFC domain proteins.**

amino acids 448-456, 382-390

**C-terminal cystine knot proteins**

amino acids 60-86

143/550

FIGURE 143

GACGTCTGGCCGGCTCCCGGCGAAGGGCAGCGGAGGAGCGGCCAGAGCGCGCAGCTAGGGCA  
CTGGCGAAACCCCGGGACAGTCCCTCTCCGTGCGGGGGCGGCGCAGAGCAGTCCCATCCCCGG  
GGTCCCGGGCGCGGCTGACTGCCGGCTGGTTCCCTGCGCGCAGTAGCTCCCCGAGCCGGGCTG  
CACCGGAGGGCGCGAGATGGTCGCGCGCGTCTGGCCTCCTGCTGCGCGCCCTGCAGCTGCTACT  
GTGGGGCCACCTGGACGCCCAGCCCGCGGAGCGCGGAGGCCAGGAGCTGCGCAAGGAGGCGGA  
GGCATTTCCTAGAGAAGTACGGATACCTCAATGAACAGGTCCCCAAAGCTCCCACCTCCACTCG  
ATTCAGCGATGCCATCAGAGCGTTTCAGTGGGTGTCCCAGCTACCTGTCAGCGGCGTGTGGA  
CCGCGCCACCCTGCGCCAGATGACTCGTCCCCGCTGCGGGGTACAGATACCAACAGTTATGC  
GGCCTGGGCTGAGAGGATCAGTGACTTGTGTGCTAGACACCGGACCAAAATGAGGCGTAAGAA  
ACGCTTTGCAAAGCAAGGTAACAAATGGTACAAGCAGCACCTCTCCTACCGCCTGGTGAAGTG  
GCCTGAGCATCTGCCGAGCCGGCAGTTCGGGGCGCCGTGCGCGCCGCCTTCCAGTTGTGGAG  
CAACGTCTCAGCGCTGGAGTTCTGGGAGGCCCCAGCCACAGGCCCCGCTGACATCCGGCTCAC  
CTTCTTCCAAGGGGACCACAACGATGGGCTGGGCAATGCCTTTGATGGCCCAGGGGGCGCCCT  
GGCGCACGCCTTCCTGCCCCGCCGCGCGGAAGCGCACTTCGACCAAGATGAGCGCTGGTCCCT  
GAGCCGCCGCCGCGGGCGCAACCTGTTTCGTGGTGCTGGCGCACGAGATCGGTACACGCTTGG  
CCTCACCCACTCGCCCCGCGCGCGCGCTCATGGCGCCCTACTACAAGAGGCTGGGCCGCGA  
CGCGCTGCTCAGCTGGGACGACGTGCTGGCCGTGCAGAGCCTGTATGGGAAGCCCCCTAGGGGG  
CTCAGTGGCCGTCCAGCTCCCAGGAAAGCTGTTCACTGACTTTGAGACCTGGGACTCCTACAG  
CCCCAAGGAAGGCGCCCTGAAACGCAGGGCCCTAAATACTGCCACTCTTCCTTCGATGCCAT  
CACTGTAGACAGGCAACAGCAACTGTACATTTTTTAAAGGGAGCCATTTCTGGGAGGTGGCAGC  
TGATGGCAACGTCTCAGAGCCCCGTCCACTGCAGGAAAGATGGGTGCGGCTGCCCCCAACAT  
TGAGGCTGCGGCAGTGTCAATTGAATGATGGAGATTTCTACTTCTTCAAAGGGGGTCGATGCTG  
GAGGTTCCGGGGCCCCAAGCCAGTGTGGGTCTCCACAGCTGTGCCGGGCAGGGGGCCTGCC  
CCGCCATCCTGACGCCGCCCTCTTCTTCCCTCCTCTGCGCCGCCTCATCCTCTTCAAGGGTGC  
CCGCTACTACGTGCTGGCCCCAGGGGGACTGCAAGTGGAGCCCTACTACCCCCGAAGTCTGCA  
GGACTGGGGAGGCATCCCTGAGGAGGTGAGCGGCGCCCTGCCGAGGCCCCGATGGCTCCATCAT  
CTTCTTCCGAGATGACCGCTACTGGCGCCTCGACCAGGCCAACTGCAGGCAACCACCTCGGG  
CCGCTGGGCCACCGAGCTGCCCTGGATGGGCTGCTGGCATGCCAACTCGGGGAGCGCCCTGTT  
CTGAAGGCACCTCCTCACCTCAGAACTGGTGGTGCTCTCAGGGCAAATCATGTTCCCCACC  
CCCGGGGCAGAACCCCTCTTAGAAGCCTCTGAGTCCCTCTGCAGAAGACCGGGCAGCAAAGCC  
TCCATCTGGAAGTCTGTCTGCCTTTGTTCCCTGGGAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

144/550

**FIGURE 144**

MVARVGLLLRALQLLLWGHLDQAQPAERGGQELRKEAEAFLEKYGYLNEQVPKAPTSTRFSDAI  
RAFQWVSQLPVSGVLDRA TL RQMTRPRCGVTD TNSYA AWAERISDLFARHRTKMRRKKRFAKQ  
GNKWKYQHLSYRLVNWPEHLPEPAVRGAVRAAFQLWSNVSALEFW EAPATGPADIRLTFFQGD  
HNDGLGNAFDGPGGALAHAF LPRRGEAHFDQDERWSLSRRRGRNLFVVL AHEIGHTLGLTHSP  
APRALMAPYYKRLGRDALLSWDDVLAVQSLYGKPLGGSVAVQLPGKLFTDFETWDSYSPQGRR  
PETQGPKYCHSSFDAITVDRQQQLYIFKGSHFEVAADGNVSEPRPLQERWVGLPPNIEAAAV  
SLNDGDFYFFKGGRCWRFRGPKPVWGLPQLCRAGGLPRHPDAALFFPPLRRLILFKGARYYVL  
ARGGLQVEPYYP RSLQDWGGIPEEVSGALPRPDGSIIFRDDRYWR L DQAKLQATTSGRWATE  
LPWMGCWHANSGSALF

**Important features of the protein:****Signal peptide:**

amino acids 1-22

**N-glycosylation sites.**

amino acids 164-168, 355-359

**N-myristoylation sites.**amino acids 92-98, 153-159, 193-199, 202-208, 288-294, 368-374,  
509-515**Amidation site.**

amino acids 312-316

**Neutral zinc metallopeptidases, zinc-binding region signature.**

amino acids 237-247

**Matrixins cysteine switch**

amino acids 231-262, 271-284

**Hemopexin domain protein**

amino acids 66-108, 231-262

145/550

**FIGURE 145**

GCCGGCTAGGGCGCCGGAGCCGCACGCAGCCGCGGGGCTCCGAGAGGCGCGCACTGGGGCTGGGACTGCGCGGCG  
CCGCCGCTGCGAGCGCCACTGAGCGGTGCGCAACTTCGGAGGACACAGCGCCGGAGCCAGGCGAGCGCTCAGAGA  
CCCGGAGCCAGAGGGGCGCGCCGGAGCCTCGTTGAGAGCGCGCCAGGCACCCACCGCGCTCCGAGTGCCAGG  
CGGCCCTCCGCGCAGCGTGGCTTCCGCTGCCCCACGGAAGGCACGGGCTGGCGCTGCCGGGCGCCGGGGAGGAC  
GGCGAGGAGGAGGCGGCGGCGGAGACGGCGGCGGCGAGACTGGGGCCAGGGAGACAGCCCTGGGGGAGAGGC  
GCCCCAACCAGGCCGCGGGAGC**ATG**GGGGGCCCCGGAGCGGAGCTCGGGGCGCGCTGCTGCTGGCACTGCTGCTCTG  
CTGGGACCCGAGGCTGAGCCAAGCAGGCACTGATTCTGGCAGCGAGGTGCTCCCTGACTCCTTCCCGTCAGCGCC  
AGCAGAGCCGCTGCCCTACTTCTGCAAGGAGCCACAGGACGCTACATTGTGAAGAACAAGCCTGTGGAGCTCCG  
CTGCCGCGCCTTCCCCGCCACACAGATCTACTTCAAGTGCAACGGCGAGTGGGTGAGCCAGAACGACCACGTCAC  
ACAGGAAGGCCTGGATGAGGGCCACCGGCCTGCGGGTGCGCGAGGTGCAGATCGAGGTGTGCGGCGCAGCAGGTGGA  
GGAGCTCTTTGGGCTGGAGGATTACTGGTGCCAGTGCCTGGCCTGGAGCTCCGCAAGGAGGAGTGGCCCTGGACCA  
AGCCTACGTCCGCGCATCGCCTACCTGCGCAAGAAGCTTCGATCAGGAGCCTCTGGGCAAGGAGGTGCCCTGGACCA  
TGAGGTTCTCCTGCAGTGCCGCCCCGCGGAGGGGTGCTGTGGCCGAGGTGGAATGGTCAAGAATGAGGATGT  
CATCGACCCCAACCCAGGACACCAACTTCTGCTCACCATCGACCACAACCTCATCATCCGCCAGGCCCCGCTGTC  
GGACACTGCCAACTATACCTGCGTGGCCAAGAACATCGTGGCCAAACGCCGAGCAGCAGTGCACCGTCATCGT  
CTACGTGAATGGCGGCTGGTCCAGCTGGGCAGAGTGGTCACCCCTGCTCCAACCGCTGTGGCCGAGGCTGGCAGAA  
CGCACCCCGGACCTGCACCAACCCCGCTCCACTCAACGGAGGGGCTTCTGCGAGGGCCAGGCATTCCAGAAGAC  
CGCCTGCACCAACCATCTGCCAGTCGATGGGGCGTGGACGGAGTGGAGCAAGTGGTCAGCCTGCAGCACTGAGTG  
TGCCCACTGGCGTAGCCGCGAGTGATGGCGCCCCACCCAGAACGGAGGCGGTGACTGCAGCGGGACGCTGCT  
CGACTCTAAGAACTGCACAGATGGGCTGTGCATGCAAAATAAGAAAACCTAAGCGACCCCAACAGCCACCTGCT  
GGAGGCCTCAGGGGATGCGGCGCTGTATGCGGGGCTCGTGGTGGCCATCTTCGTGGTGTGGCAATCCTCATGGC  
GGTGGGGGTGGTGGTGTACCGCCGCAACTGCCGTGACTTCGACACAGACATCACTGACTCATCTGCTGCCCTGAC  
TGGTGGTTTCCACCCCGTCAACTTTAAGACGGCAAGGCCAGCAGCAGCAGCTCCTACACCCCTCTGTGCCCTCC  
TGACCTGACAGCCAGCGCCGCGCATCTACCGCGGACCCGTGTATGCCCTGCAGGACTCCACCGACAAAATCCCCAT  
GACCAACTCTCCTCTGCTGGACCCCTTACCCAGCCTTAAGGTCAAGGTCTACAGCTCCAGCACCACGGGCTCTGG  
GCCAGGCCTGGCAGATGGGGCTGACCTGCTGGGGGTCTTGCCGCTGGCACATACCCTAGCGATTTCCGCCGGGA  
CACCCACTTCTCTGCACCTGCGCAGCGCCAGCCTCGGTTCCAGCAGCTCTTGGGCCTGCCCGAGACCCAGGGAG  
CAGCGTCAGCGGCACCTTTGGCTGCTGGGTGGGAGGCTCAGCATCCCCGGCACAGGGGTGAGTTGCTGGTGGC  
CAATGGAGCCATTCCCCAGGGCAAGTTCTACGAGATGTATCTACTCATCAACAAGGCAGAAAGTACCCTCCCGCT  
TTCAGAAGGGACCCAGACAGTATTGAGCCCTCGGTGACCTGTGGACCCACAGGCCTCCTGCTGTGCCGCCCCGT  
CATCCTCACCATGCCCCACTGTGCCGAAGTCAGTGCCCGTGAAGTCTTTCAGCTCAAGACCCAGGCCCCACCA  
GGGCCACTGGGAGGAGGTGGTGACCTGGATGAGGAGACCCTGAACACACCCTGCTACTGCCAGCTGGAGCCAG  
GGCCTGTACATCCTGCTGGACAGCTGGGCACCTACGTGTTACGGGCGAGTCCCTATTCGGCTCAGCAGTCAA  
GCGGCTCCAGCTGGCCGTCTTCGCCCGCCCTCTGCACCTCCCTGGAGTACAGCCTCCGGGTCTACTGCCTGGA  
GGACACGCCTGTAGCACTGAAGGAGGTGCTGGAGCTGGAGCGGACTCTGGGCGGATACTTGGTGGAGGAGCCGAA  
ACCGCTAATGTTCAAGGACAGTTACCACAACCTGCGCCTCTCCCTCCATGACCTCCCCCATGCCATTGGAGGAG  
CAAGCTGTGGCCAAATACCAGGAGATCCCTTCTATCACATTTGGAGTGGCAGCCAGAAGGCCCTCCACTGCAC  
TTTACCCCTGGAGAGGCACAGCTTGGCCTCCACAGAGCTCAGCTGCAAGATCTGCGTGCGGCAAGTGGAAGGGGA  
GGGCCAGATATTCCAGCTGCATACCACTCTGGCAGAGACACCTGCTGGCTCCCTGGACACTCTCTGCTCTGCCCC  
TGGCAGCACTGTCAACCCAGCTGGGACCTTATGCCTTCAAGATCCCACTGTCCATCCGCCAGAAGATATGCAA  
CAGCCTAGATGCCCCCAACTCACGGGGCAATGACTGGCGGATGTTAGCACAGAAGCTCTCTATGGACCGGTACCT  
GAATTACTTTGCCACCAAAGCGAGCCCCACGGGTGTGATCCTGGACCTCTGGGAAGCTCTGCAGCAGGACGATGG  
GGACCTCAACAGCCTGGCGAGTGCTTGGAGGAGATGGGCAAGAGTGAGATGCTGGTGGCTGTGGCCACCGACGG  
GGACTGCT**AG**GCCTCCTGGGACAGCGGGCTGGCAGGGACTGGCAGGAGGCAGGTGCAGGGAGGCCTGGGGCAGCC  
TCCTGATGGGGATGTTTGGCCTCTGCTTCTCTCCAGTTACAGCCAGAGTTGCCTCTCCTCCTCTCTCCCCAA  
CCCCAGACCATGACCAGCCTTAGAAAATCCATGACTCTGTTGTTAGAGGGCCCAGAGTTCTTCTCCACCCCC  
GCTCTCTCTCTTGGCCTGAGATCTCTGTGCAGGAACCAAGATGGGGCTGAAGCCTTGGAGGCAAGTTGGTTGG  
GGGCGGGCAGGCAGGAGGCCCCCTCCCTCCACCCCCCACCCTCAGCCCCGCAACTTCTGGGTTCGGTGGGTTTTAG  
TTCCGTTCTTCGTTTTCTTCTCCGTTATTGATTTCTCTTTCTCCCTAAGCCCCCTTCTGCTTCCACGCCCTTT  
TCCTCTTTGAAGAGTCAAGTACAATTGACACAACTGCTTTCTCTGTCCAAAAGCAAAAAGGCAAGGAAAGAA  
AGAAAGCTTCAGACCGCTAGTAAGGCTCAAAGAAGAAGAAAAACACCAAAACCACAAGGGAAAAAGAAAAACCCAG  
TTCTTAGGAAACGCAACGATTATTATCCAGATTATTTGGATAAGTCCTTTTTAAAA

146/550

**FIGURE 146**

MGARSGARGALLLALLLCWDPRLSQAGTDSGSEVLDPDSFPSAPAEPLPYFLQEPQDAYIVKNK  
 PVELRCRAFPATQIYFKCNGEWSQNDHVTQEGLEATGLRVREVQIEVSRQQVEELFGLEDY  
 WCQCVAWSSAGTTKSRRAYVRIAYLRKNFDQEPLGKEVPLDHEVLLQCRPPEGVPVAEVEWLK  
 NEDVIDPTQDTNFLTIDHNLIIRQARLSDTANYTCVAKNIVAKRRSTTATVIVYVNGGWSSW  
 AEWSPCSNRCGRGWQKRTRTCTNPAPLNGGAFCEGQAFQKTACTTICPVDGAWTEWSKWSACS  
 TECAHWSRECMAPPPQNGGRDCSGTLLDSKNCTDGLCMQNKKTLSDPNSHLLEASGDAALYA  
 GLVVAIFVVAIVAILMAVGVVVYRRNCRDFDITDSSAALTGGFHPVNFKTARPSNPQLLHPSV  
 PPDLTASAGIYRGPVYALQDSTDKIPMTNSPLLDPLPSLKVKVYSSSTTGSGPGLADGADLLG  
 VLPPGTYPSPDFARDTHFLHLRSASLGSQQLLGLPRDPGSSVSGTFGCLGGRLSIPGTGVSLLV  
 PNGAIPQGKFYEMYLLINKAESTLPLSEGTQTVLSPSVTCGPTGLLLCRPVILTMPHCAEVSA  
 RDWIFQLKTOAHQGHWEVVTLDEETLNTPCYCQLEPRACHILLDQLGTYVFTGESYSRSAVK  
 RLQLAVFAPALCTSLEYSRLVYCLEDTPVALKEVLELERTLGGYLVEEPKPLMFKDSYHNLRL  
 SLHDLPHAHWSKLLAKYQEIIPFYHIWSGSQKALHCTFTLERHSLASTELTCKICVRQVEGEG  
 QIFQLHTTLAETPAGSLDTLCSAPGSTVTTQLGPYAFKIPLSIRQKICNSLDAPNSRGNDWRM  
 LAQKLSMDRYLNYFATKASPTGVILDLWEALQDDGDLNSLASALEEMGKSEMLVAVATDGDC

**Important features of the protein:****Signal peptide:**

amino acids 1-26

**Transmembrane domain:**

amino acids 374-395

**N-glycosylation sites.**

amino acids 222-225, 347-350

**Glycosaminoglycan attachment site.**

amino acids 492-495

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 233-236, 234-237

**Casein kinase II phosphorylation sites.**

amino acids 30-33, 87-90, 251-254, 341-344, 359-362, 629-632, 651-654, 706-709, 757-760, 827-830, 925-928, 941-944

**Tyrosine kinase phosphorylation sites.**

amino acids 216-223, 773-780

**N-myristoylation sites.**

amino acids 2-7, 6-11, 27-32, 96-101, 137-142, 179-184, 247-252, 281-286, 334-339, 379-384, 491-496, 495-500, 509-514, 542-547, 547-552, 550-555, 553-558, 560-565, 611-616, 785-790, 834-839, 844-849

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 541-551

**ATP/GTP-binding site motif A (P-loop).**

amino acids 926-933

**Growth factor and cytokines receptors family signature 2.**

amino acids 306-312

147/550

**FIGURE 147**

GAGAGGGACAGAGGCTGGAGAAGGATGTATGGCCTGCCCTGGGCTTGTCTGTTCCCTCCTGAGCCTGAGCCCCCTT  
ACCTTCCTGACCCCATGAAGCACACACTGGCTCTGCTGGCTCCCCCTGCTGGGCCTGGGCCTGGGGCTGGCCCTGA  
GTCAGCTGGCTGCAGGGGGCCACAGACTGCAAGTTCTTGGCCCCGGCAGAGCACCTGACATTACCCAGCAGCCA  
GGGCCCCGTGGCTGGCCCCCTCGAGTTCGTGCGCCAGGACTCCTGGACTCCCTCTATGGCACCGTGCGCCGCTTCC  
TCTCGGTGGTGCAGCTCAATCCTTCCCTTCAGAGTTGGTAAAGGCCCTACTGAATGAGCTGGCCTCCGTGAAGG  
TGAATGAGGTGGTGCGGTACGAGGCGGGCTACGTGGTATGCGCTGTGATCGCGGGCCTCTACCTGCTGCTGGTGC  
CCACTGCCGGGCTTTGCTTCTGCTGCTGCCGCTGCCACCGGCGCTGCGGGGGACGAGTGAAGACAGAGCACAAAGG  
CGCTGGCCTGTGAGCGCGCGGCCCTCATGGTCTTCTGCTGCTGACCACCCTCTTGCTGCTGATTGGTGTGGTCT  
GTGCCTTTGTACCAACCAGCGCACGCATGAACAGATGGGCCCCAGCATCGAGGCCATGCCTGAGACCCTGCTCA  
GCCTCTGGGGCCTGGTCTCTGATGTCCCCAAGAGCTGCAGGCCGTGGCACAGCAATTCTCCCTGCCCCAGGAGC  
AAGTCTCAGAGGAGCTGGATGGTGTGGTGTGAGCATTGGGAGCGCGATCCACACTCAGCTCAGGAGCTCCGTGT  
ACCCCTTGGCTGGCGGCCGTGGGCAGTTTGGGGCCAGGTCTCTGAGGTCTCCGTGCACCACCTGCAAACTTGAATG  
CTACAGTGGTAGAGCTGCAGGCCGGGCAGCAGGACCTGGAGCCAGCCATCCGGGAACACCGGGACCGCCTCCTTG  
AGCTGCTGCAGGAGGCCAGGTGCCAGGGAGATTGTGCAGGGGCCCTGAGCTGGGCCCCGACCCCTGGAGCTGGGTG  
CTGACTTCAGCCAGGTGCCCTCTGTGGACCATGTCTGCAACAGCTAAAAGGTGTCCCCGAGGCCAACTTCTCCA  
GCATGGTCCAGGAGGAGAACAGCACCTTCAACGCCCTTCCAGCCCTGGCTGCCATGCAGACATCCAGCGTGGTGC  
AAGAGCTGAAGAAGGCAGTGGCCCAGCAGCCGGAAGGGGTGAGGACACTGGCTGAAGGGTTCCCGGGCTTGGAGG  
CAGCTTCCCGCTGGGCCCCAGGCACTGCAGGAGGTGGAGGAGAGCAGCCGCCCTACCTGCAGGAGGTGCAGAGAT  
ACGAGACCTACAGGTGGATCGTGGGCTGCGTGTGCTGCTCCGTGGTCTTATTCGTGGTGTCTGCAACCTGCTGG  
GCCTCAATCTGGGCATCTGGGGCCTGTCTGCCAGGGACGACCCAGCCACCAGAGCCAAGGGCGAGGCTGGAG  
CCCGCTTCCTCATGGCAGGTGTGGGCCTCAGCTTCCTCTTTGCTGCACCCCTCATCTCTCTGGTGTTCGCCACCT  
TCCTGGTGGGTGGCAACGTGCAGACGCTGGTGTGCCGGAGCTGGGAGAACGGCGAGCTCTTTGAGTTTGCAGACA  
CCCCAGGGAACCTGCCCCCGTCCATGAACCTGTGCAACTTCTTGGCCTGAGGAAGAACATCAGCATCCACCAAG  
CCTATCAGCAGTGCAAGGAAGGGGCAGCGCTCTGGACAGTCTGCAGCTCAACGACTCCTACGACCTGGAGGAGC  
ACCTGGATATCAACCAGTATACCAACAAGCTACGGCAGGAGTTGCAGAGCCTGAAAGTAGACACACAGAGCCTGG  
ACCTGCTGAGCTCAGCCGCCCCGCCGGGACCTGGAGGCCCTGCAGAGCAGTGGGCTTCAGCGCATCCACTACCCCG  
ACTTCCTCGTTTCAATCCAGAGGCCCGTGGTGAAGACCAGCATGGAGCAGCTGGCCCAGGAGCTGCAAGGACTGG  
CCCAGGCCCAAGACAATTCTGTGCTGGGGCAGCGGCTGCAGGAGGAGGCCCAAGGACTCAGAAACCTTCACCAGG  
AGAAGGTCCGTCCTCCCCAGCAGAGCCTTGTGGCAAAGCTCAACCTCAGCGTCAGGGCCCTGGAGTCTCTGCCCCGA  
ATCTCCAGCTGGAGACCTCAGATGTCTTAGCCAATGTACCTACCTGAAAGGAGAGCTGCCTGCCTGGGCAGCCA  
GGATCCTGAGGAATGTGAGTGAAGTGTTCCTGGCCCCGGGAGATGGGCTACTTCTCCAGTACGTGGCCTGGGTGA  
GAGAGGAGGTGACTCAGCGCATTGCCACCTGCCAGCCCCCTCTCCGGAGCCCTGGACAACAGCCGTGTGATCCTGT  
GTGACATGATGGCTGACCCCTGGAATGCCTTCTGGTCTGCCTGGCATGGTGCACCTTCTTCCTGATCCCCAGCA  
TCATCTTTGCCCTCAAGACCTCCAAATACTTCCGTCTATCCGGAAACGCCCTCAGCTCCACCAGCTCTGAGGAGA  
CTCAGCTCTTCCACATCCCCCGGTTACCTCCCTGAAGCTGTAGGGGCCTTGTGGGGTGAGGTGACCCTGAGGCTG  
CCTGTCTCTCCCTTTGATTTAGCCTGGGCCACAGGACTTCGGTAGCTCTTGCCCCAGAGCCCAGGCTGGCATCCA  
GGCCTGGACTGTCCCCAGTTCCGGCTTACCTGGCCCCACCTTGCTGCTCTTTCCACCCCTTTCTGCTCACGAC  
CCCCATCATTCACGCTCAGAATCACATGGGACTTCTGTGCAGCTGCAGAGCCAGCAAGTCCCTACAGGTGTCACC  
CGTTACCCCCATGCTGGTGGCATCCTCACAGGAAGAGCCTGTTCTCCACCTGCTGGAGCCTGGACCTGGGGTGG  
GACAGAGGCCCTCGTCCAACCCCACTCCCTTCCCGTGTGCTTCCCCCTGCCAAGCCTCCCCCTGCCAAGCCTCC  
CCCTGCCCCCTCTCTGAGCCCCCTCGCCCCCACACCGTCTCATCTGGCCTCCCCCTGGCCCCCACTTCCCTCTT  
ATGCCCTTCTGGCCCTTTGCTTCTCTCCCTTAGTCCCTCTTACCATATCTCCACTGCTACCTTGCTGGCCCCA  
GAGACCACCTGCCCAACCAACCCTCAGGTAACGCCACTAATCAGGCAGGGGCCACCATGGCCTAGGTCTGGG  
CTGGCTGCAGGCCCTGCCTCATGGCCTCTGAGCCCTCCACTGCCCCAGGGCCTTGGGCCCTCTGCAGATCTCATC  
CAGGATTTATTGTTGTCCAGTGGGGTGAGGGAGGCCTGTCTGAAGGCCGAGCCTCCCTGCCTGCACCCAAGTTAG  
AAATGGGGGTACCAGCACTTAGCTTCTCTCTGAGTGTGCTGCCAAGGAAGGGACCTGGGACCTGGGCCACAGT  
GGGGGCTTGCCCTTACCTCTTCAAGGAAGCATCTTCCACAGCCCCCACCCTTCTTAGGAGTGATCTGGT  
GGCCAGAACAGGATTTTGACGGCCCCCTTTTATCCTGCGCATGTGGCCTAGGGTCATCCCCAGCCCATCCCTGTG  
TCAGCCCTGAGTGTGGACACTGCGTTCAGAAATGAGGAAGAGGAGAGAGAAGAGATGGACAGACCTCAGATCC  
ATTAAAGTGTTCTCACTTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

148/550

**FIGURE 148**

MKHTLALLAPLLGLGLGLALSQLAAGATDCKFLGPAEHLTFTPAARARWLAPRVRAPGLL  
 DSLYGTVRRFLSVVQLNPPFSELVKALLNELASVKVNEVVRYEAGYVVCVAVIAGLYLLLV  
 PTAGLCFCCCRCHRRCGGRVKTEHKALACERAALMVFLLLTLLLLIGVVCAFVTNQRTH  
 EQMGPSIEAMPETLLSLWGLVSDVPQELQAVAQQFSLPQEQVSEELDGVGVSIGSAIHTQ  
 LRSSVYPLLAAVGSLGQVLQVSVHHLQTLNATVVVELQAGQQDLEPAIREHRDRLELLQE  
 ARCQGDCAALSWARTLELGADFSQVPSVDHVLHQLKGVPEANFSSMVQEENSTFNALPA  
 LAAMQTSSVVQELKKAVAQQPEGVRTLAEGFPGLEAASRWAQALQVEEESRPYLQEVQR  
 YETRWIVGCVLCSVVLFFVLCNLLGLNLGIWGLSARDDPSHPEAKGEAGARTLMAGVGL  
 SFLFAAPLILLVFATFLVGGNVQTLVCRSWENGELFEFADTPGNLPPSMNLSQLLGLRKN  
 ISIHQAYQQCKEGAALWTVLQNLDSYDLEHLDINQYTNKLRQELQSLKVDTSQSLDLLSS  
 AARRDLEALQSSGLQRIHYPDFLVQIQRPVVKTSMEQLAQELQGLAQADNSVLGQRLQE  
 EAQGLRNHLHQEKVVPQQSLVAKNLNLSVRALESSAPNLQLETSDVLANTYLYKGELPAWAA  
 RILRNVSECFLAREMGYFSQYVAWVREEVTQRIATCQPLSGALDNSRVILCDMMADPWNA  
 FWFCLAWCTFFLIPSIIFAVKTSKYFRPIRKRLSSTSSEETQLFHIPRVTSCLK

**Signal peptide:**

amino acids 1-17

**Transmembrane domain:**

amino acids 105-125, 153-173, 428-449, 476-500, 778-797

**N-glycosylation sites:**amino acids 270-273, 343-347, 352-356, 530-534, 540-546, 563-567,  
684-688, 707-711, 725-729**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 811-815

**Tyrosine kinase phosphorylation site.**

amino acids 95-103

**N-myristoylation sites.**amino acids 13-19, 15-21, 17-23, 26-32, 58-64, 124-130, 168-174,  
228-234, 230-236, 320-326, 338-344, 393-399, 429-435, 446-452,  
477-483, 500-506, 536-542, 644-650, 761-767**Phospholipase A2 histidine active site.**

amino acids 129-137

**4Fe-4S ferredoxins, iron-sulfur binding region signature.**

amino acids 126-138

**Mitochondrial energy transfer proteins signature.**

amino acids 80-89

149/550

**FIGURE 149**

CACAGCTCCCTTCCCAGGACGTGAAAATCTGCCTTCTCACCATGAGGCTTCTAGTCCTTTCCA  
GCCTGCTCTGTATCCTGCTTCTCTGCTTCTCCATCTTCTCCACAGAAGGGAAGAGGCGTCCTG  
CCAAGGCCTGGTCAGGCAGGAGAACCAGGCTCTGCTGCCACCGAGTCCCTAGCCCCAACTCAA  
CAAACCTGAAAGGACATCATGTGAGGCTCTGTAAACCATGCAAGCTTGAGCCAGAGCCCCGCC  
TTTGGGTGGTGCCTGGGGCACTCCCACAGGTGTAGCACTCCCAAAGCAAGACTCCAGACAGCG  
GAGAACCTCATGCCTGGCACCTGAGGTACCCAGCAGCCTCCTGTCTCCCCTTTCAGCCTTCAC  
AGCAGTGAGCTGCAATGTTGGAGGGCTTCATCTCGGGCTGCAAGGACCCTGGGAAAGTTCCAG  
AACTCCACGTCCTTGTCTCAATTGTGCCATCAACTTTCAGAGCTATCATGAGCCAACCTCACC  
CCACAGGGCCTCAGTCGCCACCATGTGGGCCTCTCCAGTGCAAACCACCGAGCATTCCACCAT  
GACCGGTCACAGCTACAAATCCAGAGACCATCAATCCTGCTAGAGTGCAGGGTGGCAAGCACC  
CAAGGGTGGCTGACCAAGACTGCAGAGTCTCCTCCATCTTCAGGTCCATTGAGCCTCCTGGCA  
TTTAACTACCAGCATCCAGTGGTCCCCAAGGAATCCCTTCCTAGCCTCCTGACATGAGTCTGC  
TGGAAAGAGCATCCAAACAAACAAGTAATAAATAAATAAATAAATAA



150/550

## **FIGURE 150**

MRLVLSSLLCILLLCFSIFSTEGKRRPAKAWSGRRTRLCCHRVSPNSTNLKGHHVRLCKPC  
KLEPEPRLWVVP GALPQV

**Important features of the protein:**

**Signal peptide:**

amino acids 1-21

**N-glycosylation site.**

amino acids 48-52

**Amidation sites.**

amino acids 23-27, 33-37

151/550

**FIGURE 151**

CACCGGAGGGGCACGCAGCTGACGGAGCTGCGCTGCGTTTCGCCTCGTTTGCCTCGCGCCCTCCA  
CTGGAGCTGTTTCGCGCCTCCCGGCTCCACCGCAGCCCACCCGGCAGAGGAGTCGCTACCAGC  
GCCCAGTGCCTCTGTGAGTCCGCAAACTCCTTGCCGCCCCGGGCTGGGCACCAAATAC  
CAGGCTACCA**ATGGT**CTACAAGACTCTCTTCGCTCTTTGCATCTTAACTGCAGGATGGAGGGTA  
CAGAGTCTGCCTACATCAGCTCCTTTGTCTGTTTCTCTTCCGACAAACATTGTACCACCGACC  
ACCATCTGGACTAGCTCTCCACAAAACACTGATGCAGACACTGCCTCCCCATCCAACGGCACT  
CACAACAACCTCGGTGCTCCAGTTACAGCATCAGCCCCAACATCTCTGCTTCCTAAGAACATT  
TCCATAGAGTCCAGAGAAGAGGAGATCACCAGCCCAGGTTTGAATTGGGAAGGCACAAACACA  
GACCCCTCACCTTCTGGGTCTCTCGTCAACAAGCGGTGGAGTCCACTTAACAACCACGTTGGAG  
GAAACACAGCTCGGGCACTCCTGAAGCAGGCGTGGCAGCTACACTGTCGCAGTCCGCTGCTGAG  
CCTCCACACTCATCTCCCCTCAAGCTCCAGCCTCATCACCTCATCCCTATCAACCTCACCF  
CCTGAGGTCTTTTCTGCCTCCGTTACTACCAACCATAGCTCCACTGTGACCAGCACCCAAACC  
ACTGGAGCTCCAACAGTGCACCAGAGTCCCCGACAGAGGAGTCCAGCTCTGACCACACACCCAC  
TCACATGCCACAGCTGAGCCAGTGCCCCAGGAGAAAACACCCCCAACAACTGTGTGAGGCA  
GTGATGTGTGAGCTCATAGACATGGAGACCACCACCACCTTTCCAGGGTGATCATGCAGGA  
GTAGAACATGCATTAAGTTCAGGCAGCATCGCCGCCATTACCGTGACAGTCATTGCCGTGGT  
CTGCTGGTGTGGAGTTGCAGCCTACCTAAAAATCAGGCATTCTCCTATGGAAGACTTT  
GACGACCATGACTACGGGTCCTGGGGAACTACAACAACCCTCTGTACGATGACTCCT**TAAC**  
TGGAATATGGCCTGGGATGAGGATTAAGTCTTTTATTTATAAGTGCTTATCCAGTAGAA  
AATAAGTACCTGATGCGCATTGAACGACAATCTTAAGCCCTGTTTTGTTGGTATGGTTGT  
TGTTTTCTCCTCCTCTCCTCTGGCTGCTACAACCTCCCCTTTCTGGTACAAGAAGAACCATT  
TTAAAGGTGAGTGGAGGCTGATTTGCAGCTGAAGTGGGCCAGCCTTGACCCAGCCAGGCC  
CCACCATGGTGAAGGCTTCTTTCCCCACTGCAGGACCCACTTTGAGAAGGATCGAGGAGG  
ATTTGGGTGTTTTGTTAGGGGTTACTTTAGGGGAACATTTTCAATTTGTGTTATTTCTTA  
TTCTATTTAGGAAATTACATTAAGTATTAATGAGGGGAAAGGAAATGAGCTCTACGAGGA  
CACCTTGATGGGAGAGAGCAGGGTTTTCTCAGATTCTTTTAAATCTCTATTTATCTGCTG  
TTTCTGACAGGATGCTGCCTGCTTGGCTCTACGAGCTGGAAAGCAGCTTCTTAGCTGCC  
TAATGAAAGATGAAAATAGGAAGTGCCCTGGAGGGGGCCAGCAGGTCACGGGGCAGAAT  
CAGGTTGCTGTGGGATCTCAGTGTGCCCTACCTGTTCTCCCCTCCAGGCCACCTGTCT  
AAAGGATGTCTGCTCTGTTCAAAAGGCAGCTGGGATCCCAGCCCACAAGTGATCAGCAG  
GCATTTCCAAAGAAAAAGGCTATGAGATGAGCTGAGTTATAGAGAGAAAGGGAGAGGCA  
CGGTGTGGGGAAGTGGAAGAGAAGCTGGCGGGGGAGAAGGAGGCTAACCTGCACTGAGT  
CATTAGGACAAGTGAGAATCAGCTATTGATAATGGCCAGAGATATCCACAGCTTGGAG  
CAGAGACTGTTTGCTTTATACCCACACAGCAACTGGTCCACTGCTTTACTGTCTGTTG  
TGGCTGTAAATGTTTAAAAAC

152/550

**FIGURE 152**

MVYKTLFALCILTAGWRVQSLPTSAPLSVSLPTNIVPPTTIWTSSPQNTDADTASPSNGTHNN  
SVLPVTASAPTSLLPKNISIESREEEITSPGSNWEGTNTDPSPSGFSSTSGGVHLTTTLEEHS  
SGTPEAGVAATLSQSAAEPPTLISPQAPASSPSSLSTSPPEVFSASVTTNHSSTVTSTQPTGA  
PTAPESPTEESSSDHTPTSHATAEPVPQEKTPPTTVSGKVMCELIDMETTTTFPRVIMQEVEH  
ALSSGSIAAITVTVIAVLLVFGVAAYLKIRHSSYGRLLDDHDYGSWGNYNPNPLYDDS

**Important features of the protein:****Signal peptide:**

amino acids 1-20

**Transmembrane domain:**

amino acids 258-278

**N-glycosylation sites.**

amino acids 58-61, 62-65, 80-83, 176-179

**Casein kinase II phosphorylation sites.**

amino acids 49-52, 85-88, 95-98, 100-103, 120-123, 121-124, 141-144, 164-167, 191-194, 195-198, 200-203

**Tyrosine kinase phosphorylation site.**

amino acids 289-296

**N-myristoylation sites.**

amino acids 59-64, 115-120, 128-133, 133-138, 257-262, 297-302

153/550

**FIGURE 153**

ACGTCACTGTCTTGAAGCAGCAGTAGCCTGGGAAGTGAGGCAGGAGGAATTGAGAGGCAGGAA  
GGNGCTGGAGACACAGCTGAGCCTGGAAATGAGAGTGGGCATCGCCGTGGTCATCATGACTC  
CTCTGCGGCGTGGTCACCATGTTGGTTCACTGTGTTGGGCTCTTATTGACGGGTCTCCTGCTA  
GGCCTGACCTTGGGTGCCGGAGCCCTGCTGGCTTCTGAGCCTATCTACCAACCACCTTCAGCC  
TGGGTGCCAGCTGGGGGGCTGGTGGGGCTGGCGCTGCTGGGAGCCCTGCTCACACTTCGGTGG  
CCACGTCCATTACAGTTCTGGGCACAACCCTGCTGGGTTCCTGCAGTGCTTGTGGCCTGTGTT  
GACTACTTCCTGGAGGGGCTGGCACTGGGGAGTTGGCTGGGCCAACGCCTGCAGACACTTCCA  
GCCTTGCCTTCTCTCTGCTTGATATAGCTGGGTCTTACTGGGGATCTGGCCAGCCTTGGGGGCC  
CTTGAGCCCTGGCCCAGTGGAAGCTCGTGCCTGAGGAACATGGAGGCCACGCTAATGGGTCT  
GTTCTGGTTTCCCAGATGCATAAAGGAAGACATATCCCTCCCCTGGGCAGCAAGGCTACAAT  
GGGAGGGAGGGAGAACATGGGAGCATGTGAATAAAATGGCATTAAATACTGAAAAAAAAAAAA  
AAA

154/550

## **FIGURE 154**

MLVHCVGLLLLTGLLLGLTLGAGALLASEPIYQPPSAWVPAGGLVGLALLGALLTLRWPRPFTV  
LGTTLGSAVLVACVDYFLEGLALGSWLGQRLQTLPALPSLC

**Signal peptide:**

amino acids 1-20

**Transmembrane domain:**

amino acids 38-55, 60-78

**N-myristoylation sites.**

amino acids 7-13, 12-18, 16-22, 22-28, 41-47, 50-56, 84-90, 88-94

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 67-78

155/550

**FIGURE 155**

TGCAATTAAAGGAGTCGGGTCTCTAACTGTTGATCTGTTTTTTTCCCTTCTGAGCAATGGAGC  
TTACCATCTTTATCCTGAGACTGGCCATTTACATCCTGACATTTCCCTTGTACCTGCTGAACT  
TTCTGGGCTTGTGGAGCTGGATATGCAAAAAATGGTTCCTTACTTCTTGGTGAGGTTCACTG  
TGATATACAACGAACAGATGGCAAGCAAGAAGCGGGAGCTCTTCAGTAACCTGCAGGAGTTTG  
CGGGCCCCCTCCGGGAAACTCTCCCTGCTGGAAGTGGGCTGTGGCACGGGGGCCAACTTCAAGT  
TCTACCCACCTGGGTGCAGGGTGACCTGTATTGACCCCAACCCCAACTTTGAGAAGTTTTTGA  
TCAAGAGCATTGCAGAGAACCGACACCTGCAGTTTGAGCGCTTTGTGGTAGCTGCCGGGGAGA  
ACATGCACCAGGTGGCTGATGGCTCTGTGGATGTGGTGGTCTGCACCCTGGTGCTGTGCTCTG  
TGAAGAACCAGGAGCGGATTCTCCGCGAGGTGTGCAGAGTGCTGAGACCGGGAGGGGCTTTCT  
ATTTTCATGGAGCATGTGGCAGCTGAGTGTTGACTTGGAATTACTTCTGGCAACAAGTCCTGG  
ATCCTGCCTGGCACCTTCTGTTTGATGGGTGCAACCTGACCAGAGAGAGCTGGAAGGCCCTGG  
AGCGGGCCAGCTTCTCTAAGCTGAAGCTGCAGCACATCCAGGCCCCACTGTCCTGGGAGTTGG  
TGCGCCCTCATATCTATGGATATGCTGTGAAATTAGTGTGAGCTGGCAGTTAAGAGCTGAATGG  
CTCAAAGAATTTAAAGCTTCAGTTTTACATTTAAAATGCTAAGTGGGAGAAGAGAAACCTTTT  
TTTTGGGGGGCGGTTTTTTTTGGTTTGTTGTTGGTTTTTTTTTTTTTTTTTTGGCAGGAGAATCTC  
TTGAACCCAGAAGGCGAAGGTTGCAGTGAACCGAGATCATGCCATTGTACTCTAGCCTGGGTG  
ACAAGAGCAAGACTCCGTCTCAAAAAAAAAAAAAAAAAAAAAAAGAAGTAGAGACAGGGAGAC  
GGGTCTCACTGTGTTGCCTAGGCCGGTCTTGAACCTCCTGGGCTCAAGTGATTCTCCACCTT  
GACCTCCTAAATTGTTGGGATTACAGGTGTGAGACAGTGCACCTGGCCGAAATAGCTCAAGTT  
TCTGAAAAACAAATCTGAATCTATTTGTTATTCTTAGCGTCACTGGTCTGGCTTTCAGAATTA  
ACATACAAGGTTGCCACACCTAGTTCTGCCCAGCTTTATGTCTTTTATTCCAGTATTCCACCA  
AAGTTTGTTTTCTTGCATTCCAGTTCTCAAGTCTTAAGATAAAGATTGTACTTGACAGTTTAG  
TATATCCATAAAACTATTTGAGGTGGTTAAGGTTCTTGGGTTCATTTTCTTAATACTTTGCT  
GAATATTGTAGATTGTAGGCAATGAAAAAGTCTACTAAATTAGGAAAACCTTGAATAATTAGG  
TATCCTAGGTAAGAGCCCCCTAAACATCAAGCAATCTGTGAGTCTGTAAAGAAATAAATATTTT  
TTGGATTATTCTTATCTAATTCCACCCCTGTTGGAAGATGATTTCTTTGTTCTTTGCAACTAT  
GGAAGCTGTGAAAATCATCACAAGTGCCTCTGAAAGCGAGTGTTAGGTTGGTTAGAGGGTTTA  
ATATTTTCTGCAATGGTTTGTAGGAATTTTAATAAATGTAGTATATTTTCTGAGATGATTTTG  
TAAAAGTACTATTTTAAATATCAAATCAACCAATAAATTCACATTTGTGTTAGGAACAAAA

156/550

# **FIGURE 156**

MELTIFILRLAIYILTFFPLYLLNFLGLWSWICKKWFYFLVRFTVIYNEQMASKKRELFNSNQ  
EFAGPSGKLSLLEVGCCTGANFKFYPPGCRVTCIDPNPNFEKFLIKSIAENRHLQFERFVVAA  
GENMHQVADGSVDVVVCTLVLCVKNQERILREVCRLVRPGGAFYFMEHVAAECSTWNYFWQQ  
VLDPAWHLLFDGCNLTRESWKALERASFSLKLQHIQAPLSWELVRPHIYGYAVK

## **Signal peptide:**

amino acids 1-29

## **N-glycosylation site.**

amino acids 203-207

## **N-myristoylation sites.**

amino acids 78-84, 80-86, 91-97, 201-207

157/550

**FIGURE 157**

CCGCTGAGATGTACGAACTTCCGGTTCTCCGGGCAGCTGCCACTGCTGTAGCTTCTGCCACCT  
GCCACGACCGGGCCTCTCCCTGGCGTTTGGTCACCTCTGCTTCATTCTCCACCGCGCCTATGG  
TCCCTCTTGAGCCAGCGTGGCGGGCCTGGCGGCTCCCGGGTGGTGAGAGAGCGGTCCGGGAA  
CGATGAAAGGCCTCGCAGTGCTGCTGCTGTCTCAGCCACCTCTTGGCTTCCGTCCTCCTCCTGC  
TGTTGCTGCCTGAACTAAGCGGGCCCCCTGGCAGTCCTGCTGCAGGCAGCCGAGGCCGCGCCAG  
GTCTTGGGCCTCCTGACCCTAGACCACGGACATTACCGCCGCTGCCACCGGGCCCTACCCCTG  
CCCAGCAGCCGGGGCCGTGGTCTGGCTGAAGCTGCGGGGCCGCGGGGCTCCGAGGGAGGCAATG  
GCAGCAACCCTGTGGCCGGGCTTGAGACGGACGATCACGGAGGGAAGGCCGGGGAAGGCTCGG  
TGGGTGGCGGCCTTGCTGTGAGCCCCAACCTGGCGACAAGCCCATGACCCAGCGGGCCCTGA  
CCGTGTTGATGGTGGTGAGCGGCGCGGTGCTGGTGTACTTCGTGGTCAGGACGGTCAGGATGA  
GAAGAAGAAACCGAAAGACTAGGAGATATGGAGTTTTTGGACACTAACATAGAAAATATGGAAT  
TGACACCTTTAGAACAGGATGATGAGGATGATGACAACACGTTGTTTGATGCCAATCATCCTC  
GAAGATAAGAAATGTGCCTTTTGATGAAAGAACTTTATCTTTCTACAATGAAGAGTGGAATTC  
TATGTTTAAGGAATAAGAAGCCACTATATCAATGTTGGGGGGGTATTTAAGTTACATATATTT  
TAACAACCTTTAATTTGCTGTTGCAATAAATACCGTATCCTTTTATTATATCTTTATATGTAT  
AGAAGTACTCTATTAATGGGCTCAGAGATGTTGGGGATAAAGTATACTGTAATAATTTATCTG  
TTTGAAAATTACTATAAAACGGTGTTTTCTGGTCGGTTTTTGTTCCTGCTTACCATATGATT  
GTAAATTGTTTTATGTATTAATCAGTTAATGCTAATTATTTTTGCTGATGTCATATGTTAAAG  
AGCTATAAATTCCAACAACCAACTGGTGTGTAAAAATAATTTAAATTTTCCTTTACTGAAAGG  
TATTTCCCATTTTTGTGGGGAAAAGAAGCCAAATTTATTACTTTGTGTTGGGGTTTTTAAAT  
ATTAAGAAATGTCTAAGTTATTGTTTGCAAAACAATAAATATGATTTTAAATTCTCTTAAAA  
AAAAA



158/550

**FIGURE 158**

MKASQCCCCLSHLLASVLLLLLLPELSGPLAVLLQAEEAAPGLGPPDPRPRTLPPPLPPGPTPA  
QQPGRGLAEAAGPRGSEGGNGSNPVAGLETDDHGGKAGEGSVGGGLAVSPNPGDKPMTQRALT  
VLMVVS GAVLVYFVVRTVRMRRNRKTRRYGVLD TN IENMELT PLEQDDEDDNTLFDANHPRR

**Signal peptide:**

amino acids 1-28

**Transmembrane domain:**

amino acids 124-140

**N-glycosylation site.**

amino acids 83-87

**N-myristoylation sites.**amino acids 69-75, 78-84, 81-87, 97-103, 103-109, 106-112,  
157-160

159/550

**FIGURE 159**

GCTGCAGGCGGCGACGGCTACACCATGGGCCGGCTGCTGCGGGCCGCCCGGCTGCCGCCGCTG  
CTTTCGCCGCTGCTGCTTCTGCTGGTTGGGGGAGCGTTCCTGGGTGCCTGTGTGGCTGGGTCT  
GATGAGCCTGGCCCAGAGGGCCTCACCTCCACCTCCCTGCTAGACCTCCTGCTGCCACTGGC  
TTGGAGCCACTGGACTCAGAGGAGCCTAGTGAGACCATGGGCCTGGGAGCTGGGCTGGGAGCC  
TCTGGCTCAGGCTTCCCCAGCGAAGAGAATGAAGAGTCTCGGATTCTGCAGCCACCACAGTAC  
TTCTGGGAAGAGGAGGAAGAGCTGAATGACTCAAGTCTGGACCTGGGACCCACTGCAGATTAT  
GTTTTTCTGACTTAAGTGAAGAGCAGGTTCCATTGAAGACACTAGCCAGGCTCAAGAGCTG  
CCAAACCTCCCCTCTCCCTTGCCCAAGATGAATCTGGTTGAGCCTCCCTGGCATATGCCTCCC  
AGAGAGGAGGAAGAAGAGGAAGAGGAGGAGAGGGAGAAGGAAGAGGTAGAGAAACAA  
GAGGAGGAGGAAGAGGAGGAGCTGCTCCCTGTGAATGGATCCCAAGAAGAAGCCAAGCCTCAG  
GTCCGTGACTTTTCTCTCACCAGCAGCCAGACCCAGGGGCCACCAAAAGCAGGCATGAA  
GACTCCGGGGACCAGGCCTCATCAGGTGTGGAGGTGGAGAGCAGCATGGGGCCCAGCTTGCTG  
CTGCCTTCAGTCACCCCAACTACAGTGAATCCGGGGGACCAGGACTCCACCAGCCAAGAGGCA  
GAGGCCACAGTGCTGCCAGCTGCAGGGCTTGGGGTAGAGTTCGAGGCTCCTCAGGAAGCAAGC  
GAGGAAGCCACTGCAGGAGCAGCTGGTTTGTCTGGCCAGCAGGAGGAGGTCGGGCTTGCT  
TCATTCCCTCAAACCACAGCTCCAGTGGGGGCCGAGCACCAGATGAAGATCCCCTTGCTCT  
AGAACCTCAGCCTCTTCCCCACTGGCCCTGGAGACATGGAACCTGACACCTTCTCTGCTACC  
TTGGGACAAGAAGATCTCAACCAGCAGCTCCTAGAAGGGCAGGCAGCTGAAGCTCAATCCAGG  
ATACCCTGGGATTCTACGCAGGTGATCTGCAAGGACTGGAGCAATCTGGCTGGGAAAACTAC  
ATCATTCTGAACATGACAGAGAACATAGACTGTGAGGTGTTCCGGCAGCACCGGGGGCCACAG  
CTCCTGGCCCTGGTGGAGAGGTGCTGCCCCGCCATGGCAGTGGCCACCATGGGGCCTGGCAC  
ATCTCTCTGAGCAAGCCCAGCGAGAAGGAGCAGCACCTTCTCATGACACTGGTGGGCGAGCAG  
GGGGTGGTGCCCACTCAAGATGTCCTTTCCATGCTGGGTGACATCCGCAGGAGCCTGGAGGAG  
ATTGGCATCCAGAACTATTCCACAACCAGCAGCTGCCAGGCGCGGGCCAGCCAGGTGCGCAGC  
GACTACGGCACGCTCTTCGTGGTGCTGGTGGTCATTGGGGCCATCTGCATCATCATCATTGCG  
CTTGGCCTGCTCTAACAAGTGGTGGCAGCGCCGGCTGCCCAAGCTCAAGCACGTGTCGCACGGC  
GAGGAGCTGCGCTTCGTGGAGAACGGCTGCCACGACAACCCACGCTGGACGTGGCCAGCGAC  
AGCCAGTCGGAGATGCAGGAGAAGCACCCAGCCTGAACGGCGGGCGGGGCCCTCAACGGCCCG  
GGGAGCTGGGGGGCGCTCATGGGGGGCAAGCGGGACCCGAGGACTCGGACGTGTTTCGAGGAG  
GACACGCACCTGTGAGCGCAGCCGAGGCGCAGGCCGAGTGGGCCGCCAGGACCAAGCGAGGTG  
GACCCCGAAACGGACGGCCCGGAGCCCGCACCAGCCCCGCGCCTACCCGGGCGGCCCGCGG  
CCTGGCCCTCGGCGCGGGCTCCTTCCCGCTTCCCCCGACTTCACACGGCGGGCTTCGGACCAAC  
TCCCTCACTCCCGCCCGAGGGGAGGCCTCAAAGCCCGCCTTGGCCCCGCTTTCCCGCCCCTG  
AACCCCGGCCCGCGGGCGGGCGGGCGGCTTCCTGCGCCCCGGGACTCAATTAAACCCGCC  
GGAGACCACGCCGGGCCAGCAAAA

160/550

**FIGURE 160**

MGRLLRAARLPPLLSPLLLLLLVGGAFLGACVAGSDEPGPEGLTSTSLDLLLPTGLEPLDSEE  
PSETMGLGAGLGASGSGFPSEENEESRILQPPQYFWEEEEELNDSSLDLGPTADYVFPDLTEK  
AGSIEDTSQAQELPNLPSPLPKMNLVEPPWHMPPREEEEEEEEEEREKEEVEKQEEEEEEEL  
LPVNGSQEEAKPQVRDFSLTSSSQTPGATKSRHEDSGDQASSGVEVESSMGPSLLLPSVTPTT  
VTPGDQDSTSQEAETVLPAAAGLGVEFEAPQEASEEATAGAAGLSGQHEEVPALPSFPQTAP  
SGAEHPDEDPLGSRTSASSPLAPGDMELTPSSATLGQEDLNQQLLEGQAEEAQSRIPWDSTQV  
ICKDWSNLAGKNYIILNMTENIDCEVFRQHRGPQLLALVEEVLPRHSGSHHGAWHISLSKPSE  
KEQHLLMTLVGEQGVVPTQDVLSMLGDIRRSLEEIGIQNYSTTSSCQARASQVRSDYGTLFVV  
LVVIGAICIIIIALGLLYNCWQRRLPKLKHVSHGEELRFVENGCHDNPTLDVASDSQSEMQEK  
HPSLNGGGALNGPGSWGALMGGKRPEDSDVFEEEDTHL

**Signal peptide:**

amino acids 1-29

**Transmembrane domain:**

amino acids 499-521

**N-glycosylation sites.**

amino acids 106-110, 193-197, 395-399, 480-484

**Glycosaminoglycan attachment site.**

amino acids 77-81

**N-myristoylation sites.**amino acids 24-30, 28-34, 41-47, 69-75, 71-77, 73-79, 75-81,  
216-222, 327-333, 455-461, 519-525, 574-580, 581-587, 584-590**Amidation site.**

amino acids 588-592

161/550

**FIGURE 161**

CCAGGGCGGAGCGCAGCTGCGCCGGGCTTGGGCGCCTGGGGCCGCGCTCCCCACCGTCGTTT  
TCCCCACCGAGGCCGAGGCGTCCCGGAGTC**ATG**GCCGGCCTGAACTGCGGGGTCTCTATCGCA  
CTGCTAGGGGTCTGCTGCTGGGTGCGGCGCGCCTGCCGCGCGGGGCAGAAGCTTTTGAGATT  
GCTCTGCCACGAGAAAGCAACATTACAGTTCTCATAAAGCTGGGGACCCCGACTCTGCTGGCA  
AAACCCTGTTACATCGTCATTTCTAAAAGACATATAACCATGTTGTCCATCAAGTCTGGAGAA  
AGAATAGTCTTTACCTTTAGCTGCCAGAGTCCTGAGAATCACTTTGTCATAGAGATCCAGAAA  
AATATTGACTGTATGTCAGGCCCATGTCCTTTTGGGGAGGTTCACTTCAGCCCTCGACATCG  
TTGTTGCCTACCCTCAACAGAACTTTCATCTGGGATGTCAAAGCTCATAAGAGCATCGGTTTA  
GAGCTGCAGTTTTCCATCCCTCGCCTGAGGCAGATCGGTCCGGGTGAGAGCTGCCCAGACGGA  
GTCCTCACTCCATCAGCGGCCGAATCGATGCCACCGTGGTCAGGATCGGAACCTTCTGCAGC  
AATGGCACTGTGTCCCGGATCAAGATGCAAGAAGGAGTGAAAATGGCCTTACACCTCCCATGG  
TTCCACCCCAGAAATGTCTCCGGCTTCAGCATTGCAAACCGCTCATCTATAAAACGTCTGTGC  
ATCATCGAGTCTGTGTTTGAGGGTGAAGGCTCAGCAACCCTGATGTCTGCCAACTACCCAGAA  
GGCTTCCCTGAGGATGAGCTCATGACGTGGCAGTTTGTCTTCCTGCACACCTGCGGGCCAGC  
GTCTCCTTCCTCAACTTCAACCTCTCCAAGTGTGAGAGGAAGGAGGAGCGGGTTGAATACTAC  
ATCCCGGGCTCCACCACCAACCCGAGGTGTTCAAGCTGGAGGACAAGCAGCCTGGGAACATG  
GCGGGGAAGTTCAACCTCTCTCTGCAAGGCTGTGACCAAGATGCCCAAAGTCCAGGGATCCTC  
CGGCTGCAGTTCCAAGTTTTGGTCCAACATCCACAAAATGAAAGCAGTGAG**TGAG**CCCCACTT  
TCCTTTTTCTTCCTCCTCCAGCACCTTCGTTGTTTCCTGGGTAGTCTGCCTGGGTGAGGCTCC  
CTTCCTGTTTCTCATCTGTGGCTTCTGAAACACTTAGACTCTGGACCCAGCAAGAGTTTCAGG  
AAGTGGGTTGCTAGGCAGTTAGACAGGCTTGTTGGTGAACACCCGGTATGTAGTTCCATTTCA  
GCACAATAAAAAGAAATCTTGCATTCAAGATGCTAAATTGTTTTTAACGAAAA

162/550

**FIGURE 162**

MAGLNCGVSIALLGVLLLGAARLPRGAFAFEIALPRESNITVLIKLGTPDLLAKPCYIVISKR  
HITMLSIKSGERIVFTFSCQSPENHFVIEIQKNIDCMMSGPCPFGEVQLQPSTSLPPTLNRTFI  
WDVKAHKSIGLELQFSIPRLRQIGPGESCPDGVTHSISGRIDATVVRIGTFCSNGTVSRIKMQ  
EGVKMALHLPWFHPRNVSGFSIANRSSIKRLCIIESVFEGEGSATLMSANYPEGFPEDELMTW  
QFVVPAPHLRASVSFLNFNLSNCERKEERVEYYYIPGSTTNPEVFKLEDKQPGNMAGNFNLSLQG  
CDQDAQSPGILRLQFQVLVQHPQNESSE

**Signal peptide:**

amino acids 1-29

**N-glycosylation sites.**amino acids 39-43, 122-126, 180-184, 205-209, 213-217, 270-274,  
310-314, 339-343**Tyrosine kinase phosphorylation site.**

amino acids 276-284

**N-myristoylation sites.**

amino acids 3-9, 7-13, 158-164, 175-181, 191-197, 303-309

163/550

**FIGURE 163**

CAACCACACACCTGGGGAATTGCTGGCCTGACTTCTGACCCCTGACTCCTCATACCCTTCCTC  
CAGAGCATGACATTTGACCACCAACTGAAACCTGACCTCTGACCCAGACCACTGGCCCTTCC  
CCCGCCCTGTGGTGACTTCATAAAGGTTACTAGCTTCTCCCCTGGCCTTGAGACCCACACGAT  
GGCCCTGCTGGCTCTGGCCAGTGCCGTCCCCTCTGCCCTGCTGGCCCTGGCTGTCTTCAGGGT  
GCCCCCTGGGCCTGTCTCCTCTGCTTCACAACCTACTCTGAGCGCCTCCGCATCTGCCAGAT  
GTTTGTGGGATGCGGAGCCCCAAGCTTGAAGAGTGTGAGGAGGCCTTCACGGCCGCCTTCCA  
GGGCCTCTCTGACACCGAAATCAGTGAGGAGACCATCCACACTTCATCAGTGTCTTGGGGAAG  
GTGCAGAGGGAGGGCAGGAGAGGGCCAGAGGGTCAAGGCTGAGGGACAGACAGAGAGAAACAGT  
CAGAGGAGAAAGGCTCAAAGACCATGAGAACAACAGAGACTTAGGGACAGAGAGACACAGACA  
GGGGAAGACAGCAGGGCAAAGACTCAGAGAGGGGAGGATGGAGAGTCAGAGAGGGGAAGATGG  
AGACTCAGAGAGAGGGGAGGATGGAGACTCAGAGAGAGAGGAAGATGGAGACTCAGAGGGAAA  
GATGGAGACTCAGGAGTATGGAGAGTCAGAGAGGGGAGGATGGACACTCAGGGGAGGATGGAG  
AGTCAGGAGGATGGAGACTCATAGAAAGGGGAGGATGGAGAGTCAGGAGAGGTTGGAGACTGG  
AGAGGGAATAGAGACCCAGAAAGGGGAGGATGGAGACTCAGAGGGTGGAAGATGGAGACTCAA  
AGAGGATGGAAACCCAGAGAGAGGAGGACAGAGATGAGGACAGAGACTAGGGGAAGCAGGATAG  
CGACTGGTTCGGGGGCAGAGACTCAGGGAGGATAGAGACTCACAGAGAGGTGAGGATAGAGACT  
TGGGAGGGACTCAGGAAGCATAGCGACTGTGGGGCAAAGAGTCAGAGAGGGGAGGATACAGAC  
TTGGGAGGGCAGAGACTCAGAAACAGAATGTTTCGATTAGGGACATGGTGTTCGGGGGAGCTG  
CCTCCCCCAGCCCCCTGCTCCCTCCCTCACC GCCAGACTATGATGAGAGAAGCCACCTGCATGA  
CACCTTCACCCAGATGACCCATGCCCTGCAGGAGCTGGCTGCTGCCCAGGGATCCTTTGAGGT  
TGCCTTCCCTGATGCTGCAGAGAAAATGAAGAAGGTCATTACACAGCTTAAAGAAGCCCAGGC  
TTGCATCCCTCCCTGCGGTCTCCAGGAGTTCGCCCCGCGTTTCCTCTGCAGCGGGTGCTACTC  
TAGGGTCTGCGACCTCCCGCTGGACTGCCAGTTCAGGATGTGACAGTGA CTGCGGGCGACCA  
GGCTATGTTTTCTTG CATCGTAAACTTCCAGCTGCCAAAGGAGGAGATCACCTATTCCTGGAA  
GTTCGCAGGAGGAGGTCTCCGACTCAGGACTTGTCTTATTTCCGAGATATGCCGCGGGCCGA  
AGGATACCTGGCGCGGATCCGGCCGGCTCAGCTCACGCACCGCGGGACGTTCTCCTGCGTGAT  
CAAGCAAGACCAGCGCCCCCTGGCCCGGCTCTACTTCTTTCTTAACGTCCTCGGGGCCCTCGC  
ATCAGCGAGTGCGACAGTGTTGGCGTGGTGAGTTCTGGGGACTCCGGAGCCCCAGCATCTAGC  
TCCCCGCTGTCTCAGATCCCACCGAGAAGTCTGGGTTCCAGCAACCTCCAACCCAGGAGGAT  
GTTCTTTTCGATGGTACTGCAGTGGCAACTAACAAAGGTATCTTTCCTCCTTCCCTATCCTATT  
TCCATCCTGAAAATAAAGAATATATTTCAACTCTAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAA

164/550

**FIGURE 164**

MALLALASAVPSALLALAVFRVPAWACLLCFTTYSERLRICQMFVGMRS PKLEECEEAF TAAF  
QGLSDTEISEETIHTSSVSWGRCRGRAGEAQRVRLRDRQRETVRGERLKD HENN RDLGTERHR  
QGKTAGQRLREGRMESQRGEDGDSERGEDGDSEREEDGDSEGKMETQEYGESERGGWTLRGGW  
RVRRMETHRKGRMESQERLETGEGIETQKGEDGDSEGGRWRLKEDGNPERGGQR

**Signal peptide:**

amino acids 1-26

**N-myristoylation site.**

amino acids 65-71

165/550

**FIGURE 165**

CAGAATCGCAGATTGCCAGCCCTTTTCCCGACCCCTACGGAAAGACGAGTCCAGGGGCCGTCC  
TGGCGAGGTCAAAACATTTAGTCTGGTCTTTTCAGCGTGGACCCTGCCAGCAGCCAGGCC**ATG**  
GAGCTCTCTGATGTCACCCTCATTGAGGGTGTGGGTAATGAGGTGATGGTGGTGGCAGGTGTG  
GTGGTGCTGATTCTAGCCTTGGTCTAGCTTGGCTCTCTACCTACGTAGCAGACAGCGGTAGC  
AACCAGCTCCTGGGCGCTATTGTGTCAGCAGGCGACACATCCGTCTCCACCTGGGGCATGTG  
GACCACCTGGTGGCAGGCCAAGGCAACCCCGAGCCAACTGAACTCCCCATCCATCAGAGGGT  
AATGATGAGAAGGCTGAAGAGGCGGGTGAAGGTCGGGGGAGACTCCACTGGGGAGGCTGGAGCT  
GGGGGTGGTGTGAGCCCAGCCTTGAGCATCTCCTTGACATCCAAGGCCTGCCCAAAGACAA  
GCAGGTGCAGGCAGCAGCAGTCCAGAGGGCCCCCTGAGATCTGAGGATAGCACCTGCCTCCCT  
CCCAGCCCTGGCCTCATCACTGTGCGGCTCAAATTCCTCAATGATACCGAGGAGCTGGCTGTG  
GCTAGGCCAGAGGATACCGTGGGTGCCCTGAAGAGCAAATACTTCCTGGACAAGAAAGCCAG  
ATGAAACTGATCTACCAGGGCCGCTGCTACAAGACCCAGCCCGCACACTGCGTTCTCTGAAC  
ATTACCGACAACCTGTGTGATTCACTGCCACCGCTCACCCCCAGGGTCAGCTGTTCCAGGCCCC  
TCAGCCTCCTTGGCCCCCTCGGCCACTGAGCCACCCAGCCTTGGTGTCAATGTGGGCAGCCTC  
ATGGTGCCTGTCTTTGTGGTGCTGTTGGGTGTGGTCTGGTACTTCCGAATCAATTACCGCCAA  
TTCTTCACAGCACCTGCCACTGTCTCCCTGGTGGGAGTCACCGTCTTCTTCAGCTTCCTAGTA  
TTTGGGATGTATGGACGA**TAA**GGACATAGGAAGAAAATGAAAGGCATGGTCTTTCTCCTTTAT  
GGCCTCCCCACTTTTCCTGGCCAGAGCTGGGCCCCAAGGGCCGGGGAGGGAGGGGTGGAAAGGA  
TGTGATGGAAATCTCCTCCATAGGACACAGGAGGCAAGTATGCGGCCTCCCCTTCTCATCCAC  
AGGAGTACAGATGTCCCTCCCGTGCGAGCACAACTCAGGTAGAAATGAGGATGTCATCTTCCT  
TCACTTTTAGGGTCTCTGAAGGAGTTCAAAGCTGCTGGCCAAGCTCAGTGGGGAGCCTGGGC  
TCTGAGATTCCCTCCCACCTGTGGTTCTGACTCTTCCCAGTGTCTGTCATGTCTGCCCCCAGC  
ACCCAGGGCTGCCTGCAAGGGCAGCTCAGCATGGCCCCAGCACAACTCCGTAGGGAGCCTGGA  
GTATCCTTCCATTTCTCAGCCAAATACTCATCTTTTGAGACTGAAATCACACTGGCGGGAATG  
AAGATTGTGCCAGCCTTCTCTTATGGGCACCTAGCCGCCTTCACCTTCTTCCTCTACCCCTTA  
GCAGGAATAGGGTGTCTCCCTTCTTTCAAAGCACTTTGCTTGCATTTTATTTTATTTTTTTA  
AGAGTCCTTCATAGAGCTCAGTCAGGAAGGGGATGGGGACCAAGCCAAGCCCCCAGCATTTGG  
GAGCGGCCAGGCCACAGCTGCTGCTCCCGTAGTCCTCAGGCTGTAAGCAAGAGACAGCACTGG  
CCCTTGGCCAGCGTCCTACCCTGCCCAACTCCAAGGACTGGGTATGGATCGCTGGGCCCTAGG  
CTCTTGCTTCTGGGGCTATTGGAGGGTCAGTGTCTGTGACTGAATAAAGTTCCATTTTGTGGA  
AA



166/550

FIGURE 166

MELSDVTLIEGVGNEVMVVAGVVVLILALVLAWLSTYVADSGSNQLLGAIVSAGDTSVLHLGH  
VDHLVAGQGNPEPTELPHPSEGNDEKAEAEAGEGRGDSTGEAGAGGGVEPSLEHLLDIQGLPKR  
QAGAGSSSPEAPLRSEDSTCLPPSPGLITVRLKFLNDTEELAVARPEDTVGALKSKYFPGQES  
QMKLIYQGRLLQDPARTLRSLNITDNCVHCHRSPPGSAVPGPSASLAPSATEPPSLGVNVGS  
LMVPVFVLLGVVWYFRINYRQFFTAPATVSLVGVTVFFSFLVFGMYGR

**Signal peptide:**

amino acids 1-36

**Transmembrane domains:**

amino acids 246-267, 275-301

**N-glycosylation sites.**

amino acids 162-166, 211-215

**N-myristoylation sites.**

amino acids 48-54, 105-111, 109-115, 129-135, 177-183, 247-253

**Cell attachment sequence.**

amino acids 97-100

167/550

**FIGURE 167**

GGCGGCTGTGTGTCGCCGGAGCCGAAGCGCGCAGGCCCGTCCCGGTGGCCGGGGAGCGGGCGGGTGGGGGCGCCA  
TGTGGTTTCATGTACCTGCTGAGCTGGCTGTGCTCTTCATCCAGGTGGCCTTCATCACGCTGGCTGTGCGGGCTG  
GACTCTATTACCTGGCAGAACTGATAGAAGAATACACAGTGGCCACCAGCAGGATCATAAAATACATGATCTGGT  
TCTCCACCGCTGTACTGATTGGCCTCTACGTCTTTGAGCGCTTCCCCACCAGCATGATTGGAGTGGGCCTATTCA  
CCAACCTCGTCTACTTTGGCCTCCTCCAGACCTTCCCCTTCATCATGCTGACCTCGCCTAACTTCATCCTGTCTG  
GTGGACTAGTGGTGGTGAATCATTACCTAGCATTTCAGTTTTTTGAGAGAATAATTATCCCTTCTCAGAGGTCC  
TGGCCTATTTCACTTTCTGCCTGTGGATAATTCCGTTTTCGTTTTTTGTGTCACTTTTCGGCCGGGGAGAACGTCC  
TGCCCTCTACCATGCAGCCAGGAGATGATGTCGTCTCCAATTATTTACCAAAGGCAAGCGGGGCAAACGCTTAG  
GGATCCTGGTTGTCTTCTCCTTCATCAAAGAGGCCATTCTACCCAGTCGTCAGAAGATATACTTGACCCCCATGCA  
GGCAGGATGTGGGGGGCAAGATCAGGAGAGTCAGGCCCCCTGGGCCTCTATGCCAGGTGGGGACCAGAAGTCGGGA  
AGGCACCTACCACCTGCCCTGGCTTTCTTCCCCTCAACTCTGGAGCCCCATCCCCACCCTCCTTGGGGGGCTCAG  
CTTGGCTCAGATCTGATGCTTCAAGAGGCTGTAACCTCAGAGGGCACCAAGGAGGGTGGCAGAGCCTGCTTAGCC  
AGGAGGCCGAGGTCCCTCAGTCCCTCCCCTGTCCCTTCCAAGGTGGGTGAGGAGTTCTGGCCCCGCTGGGGCAGG  
CAGGGCAGGGTCTGTGAAGCTTAAGAGCAGATGGTGACAAGTTCTCTGGGCAGGTGGCCATGGGGAGGGGGCCATG  
GCTTGGCATGTCCAACAGAAATAGTTTTTGTCTGTTGAACGGTGATTTCTGTCCAAGTGCAGATTTCCGTTTGAAT  
AAAGCTTCGCTTCTAGGTGGCACTGTTTGCCTTAATACCCTGACAGTTTCATCTTCCCTTCTTCTCTGCTAACCTTC  
TGCTCTGGACTGGACTCACTTTTCTGCTCCAGGGACTCCTTTTCTGGGTTTGGGTCTTGCCCTTCCCAAGGGACT  
GTTCTTGTGGCCCTTAATGGGAAGGGGGCAGGGGTGAGGAGCTGAGCCTGCTCAAGGAGTGGGAAGTGGGGCTAT  
AGGCAGCCTCTCTGATGCACTCTCTTCCATCTCTTTCCCAAGGCTCCGTGACTGTCAAAGTGGGAGTAGGAGAG  
GGGACAATTTAGGACTGGGCTAGATTTTCAAGAAGACATCTACAATATCCTATTTATAAATCTTCTCTGGGAAA  
AGGAGTGGTTTCTGGCTGAATACTATCTTAGGCTCAAGGAGAAACAAAATAAAATAGCTTCCAGGCAGCCTGT  
TTTTAAAGAAATGGGACTAATGGGAGAAGCTGTTTGTCACTCTAAGAGCATCCAAGCCCTGGCCCCGTCTGTGCAC  
TCTTGGCTCCTGGGGAGATATATCTGCCTTCTAAGAAGGCAGGCCAGGTCTTGGGCACAGACCTGCATTTGTTGA  
CCTTGCACTCCAACATAGTGCCCTTGCAAGTGCTCAACAGTACATATTGGAATGAAGTCCCTATGAGAGCCATT  
CTGGCCATGTTCTATACCTCAAAGTGAGGCTGGCAGGTACAGAGATGAAGTGTACACATGTGATACATTTAAGCC  
ACTGGAAAAACCCCTGTGCTTGAAAATATTTCTCTATATCATGCCTGGAGTTCATCATAGCCCTTCATTTCT  
TGGCTTTAGCATTTACCTTCTCTTAAGAATACCAGCTTTCCCTTTCCCTGAGAGGAAGAGCACATGTTGGTCTC  
CTCTTAGTGTGAACGAGATTGCCAGGCCCTTTTCTCCTATGCACACCAGGATAGACAAGGCAGGGGATACTGGCA  
GCCTGCATCATCCTCCCATTGGGCTGACAGCTGGCCCTACTTTCTCCTCTGCTGCTTGGTCCCTCACCTTGAT  
GATGTGGCTTCGCCCCCTCCACTCTACTGCCAGTGTTCTCCAGGGGTGCTAAATCCAGCAGACCCCTTTCCTG  
TCTTACTAGATCTGGGCAGCATTTGACATGGCTGATCACCCCTTGCTTCTTGGATGGCACTTCCCTGGCACCTCT  
GTGGCTAGTTGTCTACCTCCCTGGCTGTTTCTTTAGGCTTCCGTGCAGGCTTCTCCACTTGCCCATGCACAGT  
AGGGTCTTTAGGGTTCTGCTGTGGGCTCCCTAGGGAAGCCCATCCATCTGGATGGTTTCAAGGATGGTGAGGAA  
TTTAGAGTTGACCTCCAGCCCCAACATCCTTCTGATCACCTGAACCACAGTTTGTGCTGCCCTCTAGGTGCACAG  
ACAATTCAGGTCCATG3CCCAGATGGTACTTGCTGTCTTCTGCAAACCTGCCCTTCTGGGTACTTCCCTTGACC  
CCGAGATCACTCAGGAGCCAGACAGGAACTTATTCTATTCTGTTTTCTCTTCTGCCCACCACATCCAATCTC  
TCAAAACGGTCAGGTCTACCTTAACATCTCTTGATTTGAGCCACTCCACTGTCATCAGCTTTCACCTGGATTAT  
CGTGACAGCCTCCTACTGCTTCTCTATCATGTGGCCAGAGCTATCTTCTTAAAATGCATTGCATAGTTGATCAAG  
TCACTCTCTGGCCTAAAACCTTCCCTGGCTCCCTGCTGCCCTCAGGATAAAGTCTGGACCCCTCAGCATGGCTTG  
TGAGACTCATGGTGTCTTGTCCCTGCTCACCTCTCTGGTCTCATCACTTGCTTCTTGCATTCTGGGTCCCAGC  
CTCCTGTATCCAGAGATGCAGTGGCTCTCCATTGCCACTCTGATTCTCTTCTTTTGGTACAGAGAAAGGGT  
ACTTTCTCTGTCAAATCTCAACTTAGACTTGACTTCTTCCAAGGAGCTTTGGCTATACTCTCTCCTCCCGACCCC  
CACCTGGCATACTACACAGATCACTCTGGGCTCACTTGCTGCTAATGGTCATCTCCCCAGTAGACTGTAAGC  
TCCTTGAGGGCAAGGATTGTGTTGGAATTTTTGTATTAAACAGTGCCTGGCTTGGTGCCTGGCACCTAGAAAGCAC  
TCAATAAATGTTTGTGTTAATGAA

168/550

# FIGURE 168

MWFMYLLSWLSLFIQVAFITLAVAAGLYYLAELIEEYTVATSRIIKYMIWFSTAVLIGLYVFE  
 RFPTSMIGVGLFTNLVYFGLLQTFPFIMLTSPNFILSCGLVVVNHYLAFQFFAEYYPFSEVL  
 AYFTFCLWIIIPFAFFVSLSAGENVLPSTMQPGDDVVSNYFTKGKRGKRLGILVVFSFIKEAIL  
 PSRQKIY

## **Signal peptide:**

amino acids 1-25

## **Transmembrane domain:**

amino acids 126-146

## **Casein kinase II phosphorylation site.**

amino acids 145-148

## **N-myristoylation sites.**

amino acids 73-78, 82-87

## **Amidation sites.**

amino acids 168-171, 171-174

## **Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 91-101

169/550

**FIGURE 169**

CAAAGCCCTACCCTCACCATTACACAGGTCCTGTGGGAAGAGCAGCGTGGAGGTGGGCTGAGG  
TTAGAAGGTGCAGAGCGTGGAAGAAGATTGTGAGCTGAGTATTGGACATCTGTTCTTGAATAG  
TCCCTGGGCCTGCCATAGGAAAGGAAGTTCTCCAGGGTTACAGTTCTTATCCGCGTGAATACA  
**CATGG**CTCTGTTACGAAAAATTAATCAGGTGCTGCTGTTTCCTTCTGATCGTGACCCTCTGTGT  
GATTCTGTATAAGAAAGTTCATAAGGGGACTGTGCCCAAGAATGACGCAGATGATGAATCCGA  
GACTCCTGAAGAACTGGAAGAAGAGATTCTGTGGTGATTGTGCTGCAGCAGGGAGGATGGG  
TGCCACTATGGCTGCCATCAATAGCATCTACAGCAACACTGACGCCAACATCTTGTTCTATGT  
AGTGGGACTCCGGAATACTCTGACTCGAATACGAAAATGGATTGAACATTCCAACTGAGAGA  
AATAAACTTTAAAATCGTGGAATTCAACCCGATGGTCCTCAAAGGGAAGATCAGACCAGACTC  
ATCGAGGCCTGAATTGCTCCAGCCTCTGAACCTTGTTCGATTTTATCTCCCTCTACTTATCCA  
CCAACACGAGAAAGTCATCTATTTGGACGATGATGTAATTGTACAAGGTGATATCCAAGAACT  
GTATGACACCACCTTGGCCCTGGGCCACGCGGCGGCTTTCTCAGATGACTGCGATTTGCCCTC  
TGCTCAGGACATAAACAGACTCGTGGGACTTCAGAACACATATATGGGCTATCTGGACTACCG  
GAAGAAGGCCATCAAGGACCTTGGCATCAGCCCCAGCACCTGCTCTTCAATCCTGGTGTGAT  
TGTTGCCAACATGACAGAATGGAAGCACCAGCGCATCACCAAGCAATTGGAGAAATGGATGCA  
AAAGAATGTGGAGGAAAACCTCTATAGCAGCTCCCTGGGAGGAGGGGTGGCCACCTCCCCAAT  
GCTGATTGTGTTTCATGGGAAATATTCCACAATTAACCCCCTGTGGCACATAAGGCACCTGGG  
CTGGAATCCAGATGCCAGATATTCGGAGCATTTTCTGCAGGAAGCTAAATTACTCCACTGGAA  
TGGAAGACATAAACCTTGGGACTTCCTAGTGTTTACAACGACTTATGGGAAAGCTGGTTTGT  
TCCTGACCCTGCAGGGATATTTAAACTCAATCACCATAGCT**TGA**TATAACTCTACCCTTAAAAT  
ATTCCCTGTATAGAAATGTGGAATTGTCCCTTGTAGCCAACCTATAACATTGTTCTTTATGAA  
TATTACCTTTGATACATATGATCCACAATATAAAAACCAAAAACCTACTGTGTGCAAATTATAC  
CTTGGAACATATAGGCATTGATTAACCTCTTTAAGTACATGTGATAACTATGGAAATCAAGAT  
TATGTGACTGAAAAACATAAAGGAAGAGACCCATCTAGATAACAGCAATCAACCTGCTTAATT  
CTGAATGACAATTATATCCACAAATTTTTTAAAACCTTCTACATGTATTTTTCACATGAAGATCT  
CCTTAACAGGTTGCCAACCTTTTCTTTTATAAAAACCTATTACATTTAAAATATGGACGTCTGAA  
AAATAAAATATTCATCATTTTTTAAAA

170/550

**FIGURE 170**

MALLRKINQVLLFLLIVTLCVILYKKVHKGTVPKNDADDESETPEELEEEIIPVVICAAAGRMG  
ATMAAINSIIYSNTDANILFYVVGRLNLTTRIRKWIEHSLREINFKIVEFNPMVLKGKIRPDS  
SRPELLQPLNFVRFYLPLLIHQHEKVIYLDLDDVIVQGDIQELYDTTLALGHAAAFSDDCDLPS  
AQDINRLVGLQNTYMGYLDYRKKAIKDLGISPSTCSFNPVGIVANMTEWKHQIRITKQLEKWMQ  
KNVEENLYSSSLGGGVATSPMLIVFHGKYSTINPLWHIRHLGWNPDARYSEHFLQEAKLLHWN  
GRHKPWDFPSVHNDLWESWFPDPAGIFKLNHHS

**Signal peptide:**

amino acids 1-20

**N-glycosylation site.**

amino acids 234-238

**Tyrosine kinase phosphorylation site.**

amino acids 253-261

**N-myristoylation sites.**amino acids 63-69, 86-92, 198-204, 218-224, 229-235, 265-271,  
266-272

171/550

**FIGURE 171**

GCCAGAGGCTGCAGCTGGAGCCCAGAGCCCAAG**ATG**GAGCCCCAGCTGGGGCCTGAGGCTGCC  
GCCCTCCGCCCTGGCTGGCTGGCCCTGCTGCTGTGGGTCTCAGCCCTGAGCTGTTCTTTCTCC  
TTGCCAGCTTCTTCCCTTTCTTCTCTGGTGCCCCAAGTCAGAACCAGCTACAATTTTGAAGG  
ACTTTCCTCGGTCTTGATAAATGCAATGCCTGCATCGGGACATCTATTTGCAAGAAGTTCTTT  
AAAGAAGAAATAAGATCTGACAACTGGCTGGCTTCCACCTTGGACTGCCTCCCGATTCTTG  
CTTTCTTATCCTGCAAATTACTCAGATGATTCCAAAATCTGGCGCCCTGTGGAGATCTTTAGA  
CTGGTCAGCAAATATCAAACGAGATCTCAGACAGGAGAATCTGTGCCTCTGCATCAGCCCCA  
AAGACCTGCAGCATTGAGCGTGTCTGCGGAAAACAGAGAGGTTCCAGAAATGGCTGCAGGCC  
AAGCGCCTCACGCCGGACCTGGTGCAGGACTGTCACCAGGGCCAGAGAGAACTAAAGTTCCTG  
TGTATGCTGAGAT**TAA**CACCAGTGAAAAAGCCTGGCATGGAGCCCAGCACTGAGAACTTCCAGA  
AAGTGTTAGCCTTCTCCCAACTGTGTTATACCAACCACATTTTCAAATAGTAATCATTAAGA  
GGCTTCTGCATCAA

172/550

**FIGURE 172**

MEPQLGPEAAALRPGWLALLLWVSALSCSFSLPASSLSSLVPQVRTSYNFGRTFLGLDKCNAC  
IGTSICKKFFKEEIRSDNWLASHLGLPPDSLLSYPANYSDDSKIWRPVEIFRLVSKYQNEISD  
RRICASASAPKTCSIERVLRKTERFQKWLQAKRLTPDLVQDCHQGQRELKFLCMLR

**Signal peptide:**

amino acids 1-28

**N-glycosylation site.**

amino acids 100-103

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 158-161

**N-myristoylation sites.**

amino acids 56-61, 65-70

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 18-28

**Prenyl group binding site (CAAX box).**

amino acids 179-182

**Leucine zipper pattern.**

amino acids 5-26

173/550

**FIGURE 173**

GCTGGACTGCTCGCTGGCCGGCAGCGCACCGTTTTGAAGGTCTAGCCACCTGGGCTGGCTC  
ACGCGCACGACTAGCCGCTCCCATACAGCACGCCCGGACTCTGTCTGCTCGCTTAAGGCCACTCC  
TATTCTACGGCTGACCCCTGGTGGTCACGTGGATCTGTTCGCCACGCAAGTCTGGGTCCTTCG  
GCGATTGACCGGGGTCCCTTGCTGTTCTGGGAGCCTCTCCTAAGCTGCCTGTTCTGCGCGAGAGTT  
TGGAGGGGCGGGTTTGGGGTCTGGTGTCTGATTGGGGCTCGCACCGCAGCACGCTGGAGTCCCG  
CTTAGGTACCAGTTAGCGTCAGGGGAGCTGGGTCAGGCGGTCTGCCGGGACACCCCGTGTGTGG  
CAGGCGGCGAAGCGCTCTGGAGAATCCCGGACAGCCCTGCTCCCTGCAGCCAGGTGTAGTTTC  
GGGAGCCACTGGGGCCAAAGTGAGAGTCCAGCGGTCTTCCAGCGCTTGGGCCACGGCGGCGGC  
CCTGGGAGCAGAGGTGGAGCGACCCCATACGCTAAAGATGAAAGGCTGGGGTTGGCTGGCCC  
TGCTTCTGGGGGCCCTGCTGGGAACCGCCTGGGCTCGGAGGAGCCAGGATCTCCACTGTGGAG  
CATGCAGGGCTCTGGTGGATGAACTAGAATGGGAAATTGCCCAGGTGGACCCCAAGAAGACCA  
TTCAGATGGGATCTTTCCGGATCAATCCAGATGGCAGCCAGTCAGTGGTGGAGGTGCCTTATG  
CCCGCTCAGAGGGCCACCTCACAGAGCTGCTGGAGGAGATATGTGACCGGATGAAGGAGTATG  
GGGAACAGATTGATCCTTCCACCCATCGCAAGAACTACGTACGTGTAGTGGGCCGGAATGGAG  
AATCCAGTGAACTGGACCTACAAGGCATCCGAATCGACTCAGATATTAGCGGCACCCTCAAGT  
TTGCGTGTGAGAGCATTGTGGAGGAATACGAGGATGAACTCATTGAATTCTTTTCCCGAGAGG  
CTGACAATGTTAAAGACAACTTTGCAGTAAGCGAACAGATCTTTGTGACCATGCCCTGCACA  
TATCGCATGATGAGCTATGAACCACTGGAGCAGCCCACACTGGCTTGATGGATCACCCCCAGG  
AGGGGAAAATGGTGGCAATGCCTTTTATATATTATGTTTTTACTGAAATTAAGTAAAAAATA  
TGAAACCAAAAGT



174/550

## **FIGURE 174**

MKGWGWLALLLGALLGTAWARRSQDLHCGACRALVDELEWEIAQVDPKKTIQMGsFRINPDGS  
QSVVEVPYARSEAHLTELEEICDRMKEYGEQIDPSTHRKNYVRVVGRNGESSELDLQGIRID  
SDISGTLKFACESIVEEYEDELIEFFSREADNVKDKLCSKRTDLCDHALHISHDEL

**Signal peptide:**

amino acids 1-20

**N-myristoylation sites.**

amino acids 12-18, 16-22, 29-35

**Endoplasmic reticulum targeting sequence.**

amino acids 179-184

175/550

**FIGURE 175**

CGCAGCGCGGCAGTCCTGATGGCCCCGGCATGGGTTACCGCTGCTGCCCCCTGCTGTCGCTCCTG  
GTCGGCGCGTGGCTCAAGCTAGGAAATGGACAGGCTACTAGCATGGTCCAACCTGCAGGGTGGG  
AGATTCTGATGGGAACAAATTCTCCAGACAGCAGAGATGGTGAAGGGCCTGTGCGGGAGGCG  
ACAGTGAAACCCTTTGCCATCGACATATTTCTGTACCAACAAAGATTTTCAGGGATTTTGTC  
AGGGAGAAAAAGTATCGGACAGAAGCTGAGATGTTTGATGGAGCTTTGTCTTTGAGGACTTT  
GTCTCTGATGAGCTGAGAAACAAAGCCACCCAGCCAATGAAGTCTGTACTCTGGTGGCTTCCA  
GTGAAAAGGCATTTTGGAGGCAGCCTGCAGGTCCTGGCTCTGGCATCCGAGAGAGACTGGAG  
CACCCAGTGTTACACGTGAGCTGGAATGACGCCCCGTGCCTACTGTGCTTGGCGGGGAAAACGA  
CTGCCCACGGAGGAAGAGTGGGAGTTTGCCGCCCCGAGGGGGCTTGAAGGGTCAAGTTTACCCA  
TGGGGGAACTGGTTCCAGCCAAACCGCACCAACCTGTGGCAGGGAAAGTTCCCCAAGGGAGAC  
AAAGCTGAGGATGGCTTCCATGGAGTCTCCCCAGTGAATGCTTTCCCCGCCGAGAACAACACTAC  
GGGCTCTATGACCTCCTGGGGAACGTGTGGGAGTGGACAGCATCACCGTACCAGGCTGCTGAG  
CAGGACATGCGCGTCCTCCGGGGGGCATCCTGGATCGACACAGCTGATGGCTCTGCCAATCAC  
CGGGCCCCGGGTACCAACCAGGATGGGCAACACTCCAGATTCAGCCTCAGACAACCTCGGTTTC  
CGCTGTGCTGCAGACGCAGGCCGGCCGCCAGGGGAGCTGTAAGCAGCCGGGTGGTGACAAGGA  
GAAAAGCCTTCTAGGGTCACTGTCATTCCCTGGCCATGTTGCAAACAGCGCAATTCCAAGCTC  
GAGAGCTTCAGCCTCAGGAAAGAACTTCCCCTTCCCTGTCTCCCATCCCTCTGTGGCAGGCGC  
CTCTCACCAGGGCAGGAGAGGACTCAGCCTCCTGTGTTTTGGAGAAGGGGCCCAATGTGTGTT  
GACGATGGCTGGGGGCCAGGTGTTTCTGTTAGAGGCCAAGTATTATTGACACAGGATTGCAAA  
CACACAAACAGTTGGAACAGAGCACTCTGAAAGGCCATTTTTTAAGCATTTTAAAATCTATTC  
TCTCCCCCTTTCTCCCTGGATGATTCAGGAAGCTGACATTGTTTCCTCAAGGCAGAATTTTCC  
TGGTTCTGTTTTCTCAGCCAGTTGCTGTGGAAGGAGAATGCTTTCTTTGTGGCCTCATCTGTG  
GTTTCGTGTCCCTCTGAAGGAACTAGTTTCCACTGTGTAACAGGCAGACATGTAACATATTTA  
AAGCACAGTTCAGTCCTAAAAGGGTCTGGGAGAACCAGATGATGTACTAGGTGAAGCATTGCA  
TTGTGGGAATCACAAAGCAAATAGTACTCCAGAAAGACAAATATCAGAAGCTTCCTATTCTTT  
TTTTTTTTTTTTTTTTTTTTTTTTTTGAGACAGGGTCTTTCTCTGTTGCCAGGCTAGAGTGCACTG  
GTGATCACGGCTCACTCTAGCCTTGAATTCCTGGGCCCAAGCAATTCTCCACCTCAGCCTCC  
TGAGTAGCTGGGACTACAAGTGTGCACCACCATGCCTGGCTAATTTTTTGAATTTTTGTAGTG  
ATGGGATCTCGCTCTGTTGCCAGGGTGGTCTCGAACTCCTGGCCTCAAGCGATCCTCCCACC  
TCGACCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCACCTCGCCTGGGCCCCCTTCTCCATA  
TGCCTCCAAAACATGTCCCTGGAGAGTAGCCTGCTCCACACTGTCACTGGATGTCATGGGG  
CCAATAAAATCTCCTGCAATTGTGTATCTCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAA

176/550

FIGURE 176

MARHGLPLLPLLSLLVGAWLKLGNQATSMVQLQGGRFLMGTNSPDSRDGEGPVREATVKPFA  
IDIFPVTNKDFRDFVREKKYRTEAEMFGWSFVFEDFVSDEL RNKATQPMKSVLWWLPVEKA FW  
RQPAGPGSGIRERLEHPVLHVS WN DARAYCAWRGKRLPTEEEWEFAARGGLKGQVYPWGNWFQ  
PNRTNLWQGKFPKGDKAEDGFHGVSPVNAFFPAQN NYGLYDLLGNVWEWTASPYQAAEQDMRVL  
RGASWIDTADGSANHRARVTTRMGNTPD SASDNLGFRCAADAGRPPGEL

**Signal peptide:**

amino acids 1-20

**N-glycosylation site.**

amino acids 191-195

**N-myristoylation sites.**

amino acids 23-29, 25-31, 175-181

**Amidation site.**

amino acids 159-163

177/550

**FIGURE 177**

GCCTTCTCGCGCCTGACCATGCACCCCTGCATCTTCCTGCTGGGCCACAGGCGAGCGCTTTAT  
TTCTGGAGCTGAGGGCTAAACTTTTTTGAAGTTTTCTTCTCCTCAACATCTGAATCATGCCAT  
GTGCCCAGAGGAGCTGGCTTGCAAACCTTTCCGTGGTGGCTCAGCTCCTTAACCTTGGGGCGC  
TTTGCTATGGGAGACAGCCTCAGCCAGGCCCGGTTTCGCTTCCCGGACAGGAGGCAAGAGCATT  
TTATCAAGGGCCTGCCAGAATACCACGTGGTGGGTCCAGTCCGAGTAGATGCCAGTGGGCATT  
TTTTGTTCATATGGCTTGCACTATCCCATCACGAGCAGCAGGAGGAAGAGAGATTTGGATGGCT  
CAGAGGACTGGGTGTACTACAGAATTTCTCACGAGGAGAAGGACCTGTTTTTTAACTTGACGG  
TCAATCAAGGATTTCTTTCCAATAGCTACATCATGGAGAAGAGATATGGGAACCTCTCCCATG  
TTAAGATGATGGCTTCCTCTGCCCCCTCTGCCATCTCAGTGGCACGGTTCTACAGCAGGGCA  
CCAGAGTTGGGACGGCAGCCCTCAGTGCCTGCCATGGACTGACTGGATTTTTTCCAACCTACCAC  
ATGGAGACTTTTTTCATTGAACCCGTGAAGAAGCATCCACTGGTTGAGGGAGGGTACCACCCGC  
ACATCGTTTACAGGAGGCAGAAAGTTCCAGAAACCAAGGAGCCAACCTGTGGATTAAAGGGTA  
TTGTGACTCACATGTCCTCCTGGGTTGAAGAATCTGTTTTGTTCTTTTGGTAGTTTTATTAAA  
ACATGACCTATTCTTACTCAAGTCTCTTATCTCCTCTGTATTCTTTTTTTTTTAATATCTTCA  
TGACATTCAAATCTCTTCTGTATTCTCTTGCCAGAAAGTGTACATTCTTTTTTGCTTGTATAAA  
CCCTTTCACCTGTC

178/550

**FIGURE 178**

MPCAQRSWLANLSVVAQLLNFGALCYGRQPQPGPVRFPDRRQEHFIKGLPEYHVVGPPVRVDAS  
GHFLSYGLHYPITSSRRKRDLGSEDWVYYRISHEEKDLFFNLTVNQGLSNSYIMEKRYGNL  
SHVKMMASSAPLCHLSGTVLQQGTRVGTAALSACHGLTGFFQLPHGDDFFIEPVKKHPLVEGGY  
HPHIVYRRQKVPETKEPTCGLKGIVTHMSSWVEESVLFFW

**Signal peptide:**

amino acids 1-27

**N-glycosylation sites.**

amino acids 11-15, 105-109, 125-129

**N-myristoylation site.**

amino acids 149-155

179/550

FIGURE 179

CAGATTTAAAAAGAAAACCTTTACTGAATCAGCTGAGTGTTAATAATACGAATTTTCCTTTTCT  
TGCCAATTCTGATCTGAACAGAAAATCCAAGAACAGGGATATGTGTGGATTACAGTTTTTCTCT  
GCCTTGCCTACGACTGTTTCTGGTTGTTACCTGTTATCTTTTATTATTACTCCACAAAGAAAT  
ACTTGGATGTTTCGTCTGTTTGTCTGAGCTCTGCACTGGGAGACAAATTAAGTCCCGTAACTTAGG  
CCTTTCGAGTATTCCCTAAGAATTTTCCTGAAAGTACAGTTTTTCTGTATCTGACTGGGAATAA  
TATATCTTATATAAATGAAAGTGAATTAACAGGACTTCATTCTCTTGTAGCATTGTATTTGGA  
TAATTCTAACATTCTGTATGTATATCCAAAAGCCTTTGTTCAATTGAGGCATCTATATTTTCT  
ATTTCTAAATAATAATTTTCATCAAACGCTTAGATCCTGGAATATTTAAGGGACTTTTAAATCT  
TCGTAATTTATATTTACAGTATAATCAGGTATCTTTTGTTCGAGAGGAGTATTTAATGATCT  
AGTTTCAGTTCAGTACTTAAATCTACAAAGGAATCGCCTCACTGTCCTTGGGAGTGGTACCTT  
TGTTGGTATGGTTGCTCTTCGGATACTTGATTTATCAAACAATAACATTTTGAGGATATCAGA  
ATCAGGCTTTCAACATCTTGAAAACCTTGCTTGTTTGTATTTAGGAAGTAATAATTTAACAAA  
AGTACCATCAAATGCCTTTGAAGTACTTAAAGTCTTAGAAGACTTTCTTTGTCTCATAATCC  
TATTGAAGCAATACAGCCCTTTGCATTTAAAGGACTTGCCAATCTGGAATACCTCCTCCTGAA  
AAATTCAGAATTAGGAATGTTACTAGGGATGGGTTTAGTGGAAATTAATAATCTTAAACATTT  
GATCTTAAGTCATAATGATTTAGAGAATTTAAATTTCTGACACATTCAGTTTGTAAAGAATTT  
AATTTACCTTAAGTTAGATAGAAACAGAATAATTAGCATTGATAATGATACATTTGAAAATAT  
GGGAGCATCTTTGAAGATCCTTAATCTGTCATTTAATAATCTTACAGCCTTGCATCCAAGGGT  
CCTTAAGCCGTTGTCTTCATTGATTCATCTTCAGGCAAATCTAATCCTTGGGAATGTAAGT  
CAAATTTTGGGCCTTCGAGACTGGCTAGCATCTTCAGCCATTACTCTAAACATCTATTGTCA  
GAATCCCCCATCCATGCGTGGCAGAGCATTACGTTATATTAACATTACAAATTGTGTTACATC  
TTCAATAAATGTATCCAGAGCTTGGGCTGTTGTAAATCTCCTCATATTCATCACAAAGACTAC  
TGCGCTAATGATGGCCTGGCATAAAGTAACCACAAATGGCAGTCCTCTGGAAAATACTGAGAC  
TGAGAACATTACTTTCTGGGAACGAATTCCTACTTCACCTGCTGGTAGATTTTTTCAAGAGAA  
TGCCTTTGGTAATCCATTAGAGACTACAGCAGTGTTACCTGTGCAAATACAACTTACTACTTC  
TGTTACCTTGAAGTTGGAAAAAACAGTGCTCTACCGAATGATGCTGCTTCAATGTCAGGGAA  
AACATCTCTAATTTGTACACAAGAAGTTGAGAAGTTGAATGAGGCTTTTGACATTTTGCTAGC  
TTTTTTCATCTTAGCTTGTGTTTTAATCATTTTTTTTGATCTACAAAGTTGTTTCAGTTTAAACA  
AAAATAAAGGCATCAGAAAATCAAGGGAAAATAGACTTGAATACTACAGCTTTTATCAGTC  
AGCAAGGTATAATGTAAGTGCCTCAATTTGTAACACTTCCCCAAATTTCTCTAGAAAGTCCTGG  
CTTGGAGCAGATTCGACTTCATAAACAAATTGTTTCTGAAAATGAGGCACAGGTCATTCTTTT  
TGAACATTCTGCTTTATAACTCAACTAAATATTGTCTATAAGAACTTCAGTGCCATGGACAT  
GATTTAAACTGAAACCTCCTTATATAATTATATACTTTAGTTGGAAATATAATGAATTATATG  
AGGTTAGCATTATTAAATATGTTTTTTNTTAAAAAAAAAAAAAAAAAAAAAAAAA

180/550

**FIGURE 180**

MCGLQFSLPCLRLFLVVTCYLLLLLHKEILGCSSVCQLCTGRQINCRNLGLSSIPKNFPPESTV  
FLYLTGNNISYINESELTGLHSLVALYLDNSNILYVYPKAFVQLRHLYFLFLNNNFIKRLDPG  
IFKGLLNLRNLYLQYNQVSFVPRGVFNDLVSVQYLNLRNRLTVLGSGTFVGMVALRILDLSN  
NNILRISESGFQHLENLACLYLGSNNLTKVPSNAFEVLKSLRRLSLSHNP IEAIQPF AFKGLA  
NLEYLLLKNSRIRNVTRDGFSGINNLKHLILSHNDLENLNSDTFSLLKNLIYKLDNRNIISI  
DNDTFENMGASLKILNLSFNNLTALHPRVLKPLSSLIHLQANSNPWECNCKLLGLRDWLASSA  
ITLNIYCQNPPSMRGRALRYINITNCVTSSINVSRAWAVVKSPHIHHKTTALMMAWHKVTNG  
SPLENTETENITFWERIPTSPAGRFFQENAFGNPLETTAVLPVQIQLTTSVTLNLEKNSALPN  
DAASMSGKTSLECTQEVEKLNEAFDILLAFFILACVLIIFLIYKVVQFKQKLKASENSRENRL  
EYYSFYQSARYNVTASICNTSPNSLES PGLEQIRLHKQIVPENE AQVILFEHSAL

**Signal peptide:**

amino acids 1-41

**Transmembrane domain:**

amino acids 530-547

**N-glycosylation sites.**amino acids 71-75, 76-80, 215-219, 266-270, 317-321, 331-335,  
336-340, 400-404, 410-414, 451-455, 579-583**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 231-235

**N-myristoylation sites.**

amino acids 3-9, 69-75, 126-132, 174-180

**ATP/GTP-binding site motif A (P-loop).**

amino acids 506-514

181/550

**FIGURE 181**

GGCCTGGCGCGGCGCTCCGGTAAGGCGTGTGTGCGGCAGGGCGGGGACAGAACCGTCCTCTCG  
GGCTCTGGGCGTGTCCGAGACCGCGCTCCCCGCCGAAATCAAGCTCCGAGTCATCCGTGTGGG  
GCATTTCGTCCCCCTGGCACAGTTGGCCTCTTTCCAGAAGCCCGTTTTGTTTGTTTTACGTCT  
AAATTTCGCGTCGGTTCCTATTTCTCTCCCTGGCAAGGTCTGAAGACGGGTAGGAGAATAACCT  
GTGTCAGCGTGTTATGATGCCGTCCCGTACCAACCTGGCTACTGGAATCCCCAGTAGTAAAGT  
GAAATATTCAAGGCTCTCCAGCACAGACGATGGCTACATTGACCTTCAGTTTAAAGAAAACCCC  
TCCTAAGATCCCTTATAAGGCCATCGCACTTGCCACTGTGCTGTTTTTGATTGGCGCCTTTCT  
CATTATTATAGGCTCCCTCCTGCTGTCAGGCTACATCAGCAAAGGGGGGGCAGACCGGGCCGT  
TCCAGTGCTGATCATTGGCATTCTGGTGTTCCTACCCGGATTTTACCACCTGCGCATCGCTTA  
CTATGCATCCAAAGGCTACCGTGGTTACTCCTATGATGACATTCAGACTTTGATGACTAGCA  
CCCACCCCATAGCTGAGGAGGAGTCACAGTGGAAGTGTCCAGCTTTAAGATATCTAGCAGAA  
ACTATAGCTGAGGACTAAGGAATTCTGCAGCTTGCAAGATGTTTAAGAAAATAATGGCCAGATT  
TTTTGGGTCCTTCCCAAAGATGTTAAGTGAACCTACAGTTAGCTAATTAGGACAAGCTCTATT  
TTTCATCCCTGGGCCCTGACAAGTTTTTCCACAGGAATATGTATCATGGAAGAATAGAGGTTA  
TTCTGTAATGAAAAGTGTTGCCTGCCACCACCCTCTGTAGAGCTGAGCATTCTTTTAAATA  
GTCTTCATTGCCAATTTGTTCTTGTAGCAAATGGAACAATGTGGTATGGCTAATTTCTTATTA  
TTAAGTAGTTTATTTTAAAAATATCTGAGTATATTATCCTGTACACTTATCCCTACCTTCATG  
TTCCAGTGGAAGACCTTAGTAAATCAAAGATCAGTGAGTTCATCTGTAATATTTTTTTTACT  
TGCTTTCTTACTGACAGCAACCAGGAATTTTTTTATCCTGCAGAGCAAGTTTTTCAAATGTAA  
ATACTTCCTCTGTTTAAACAGTCCTTGGACCATTCTGATCCAGTTCACCAGTAGGTTGGACAGC  
ATATAATTTGCATCATTTTGTCCCTTGTAATCAAGATGTTCTGCAGATTATTCCTTTAACGG  
CCGGACTTTTGGCTGTTTCCTAATGAAACATGTAGTGGTTATTATTTAGAGTTTATAGCCGTA  
TTGCTAGCACCTTGTAGTATGTCATCATCTGCTCATGATTCOAAGGATCAGCCTGGATGCCT  
AGAGGACTAGATCACCTTAGTTTGATTCTATTTTTTTAGCTTGCAAAAAGTGAAGTTATATTTCCA  
AAGAAATTTAAATGTTGAAATCCAAATCCTAGAAATAAAATGAGTTTNNNTCCAAAAA  
AAA



182/550

## **FIGURE 182**

MMPSRTNLATGIPSSKVKYSRLSSTDDGYIDLQFKKTPPKIPYKAIALATVLFLLIGAFLLIIG  
SLLLSGYISKGGADRAVPVLIIGILVFLPGFYHLRIAYYASKGYRGYSYDDIPDFDD

**Transmembrane domains:**

amino acids 45-66, 79-95

**N-myristoylation sites.**

amino acids 11-17, 75-81

183/550

**FIGURE 183**

CTAAAAAATACAAAAATTAGCTGGGCGTGGTGTCTATGTACCTGTAATCCCAGCTACTCAAGAGGCTGAGGCAGGA  
GAATCGCTTGAACCCAGGAGGCAGAGGTTGCAGTGAGCCAAGATTAAGTCACTGCCTCCAGCCTGGGTGACAGA  
GCAAGACTCTGTATCAAATAAATAAATAAAGTACAACCTCTGGATGGGCATGGTGGCTTATGTCTGTAATCCCAG  
CACTTTGGGAACTTGAGGCGGGTAGATTGCTTGAGTCCGGGAGTTTGAGACCAGTCTGGGTAATATGGTAACCTT  
GTCTACCAAAAAATACAGGTATTAGCCAGTCTCATAACTCGGTCTCAAAATAAATAAATACATACATACATAGATG  
AAAATTTAAAAAATAAAGTCCAACCTCAGCGGTTTTTCAGCATATTTACAGAGTTGTACAATCTTCACCACTATCTA  
ATTTTCAGAACATTTTCATCACCCCCAAAAGAAACCTAACCATTGACTATCTCTCCATTTCTCCCTCTCCCTAG  
CCTCTGGCAACCACTAATCTCTTTTTTGTCTCTATAGATTTGCCTATTTTGGACAGTTTCATATACAAGGAATCAT  
ACCACATGTAGCCTTTTGTGTCCGGCTTCTTTGATTAATAGAATGTTTTCAAGGCTCATCTATGCTGTAGCCTGT  
ATCAGCACTTCATTCTTTCTATGGCTGAATAATAGTCCACTGTAGGGATGTGCCATGTTTTTCCACTAGCTGAT  
GGACATTTGGGTTGTTTCCACCTTCTGGCTATTATAAATATTGCTGCTATAAATATTCACTTACAAGTTTTTGTG  
TGGACATATGTTTTTATTTCTTCTGGTATATCCTTCGGAGTGGAACCTGCTGGATCAGGTGGTAACCTCTAGGTCTA  
ACCTGGCAGTTAAACAGAATCCTATGCATGCTGTAGTCCATGAGTTGAAATAAACACTTGACCCATAGTAAGTGC  
CAGATCATCTTCATTTACAGCAACCAGTAATTTACAGATGAGGAAATGAAGGCTCCCAGAGGTGAAGTGGCTT  
TTCCCATTGAGCAGTTCCAAGTCAGACAGTTAAAAAGTGGCAGGACCTGGAAGAGAAGCTAGTTCTTTACCCCT  
GGCATTACAGGGCTGCCTCCTGGGCTACGGGGCTGGCATTTAGAATAGAGCTAAGGTCTGCTGCCAAGGCAGGTGC  
CCCAGTCTGCCTCCTCTGTGTCTTATTCACCTTCTCTGCAGCCCTCCAGGGGACCCCTCTCTCAGCCACCCCTC  
TCTCTGGTGATGTACAGTGCTGCCGGAAGATCAAAGATACGGTGACAGAACTGGCTTCGGACCATAAGGACATT  
CACAGCAGTGTATCCCGAGTGGGCAAAGCCATTGACAGGAACCTCGACTCTGAGATCTGTGGTGTGTGTGATGAT  
GCGGTGTGGGACGCGCGGGAACAGCAGCAGCAGATCCTGCAGATGGCCATCGTGGAACACCTGTATCAGCAGGGC  
ATGCTCAGCGTGGCCGAGGAGCTGTGCCAGGAATCAACGCTGAATGTGGACTTGGAATTTCAAGCAGCCTTTCTTA  
GAGTTGAATCGAATCCTGGAAGCCCTGCACGAACAAGACCTGGGTCTGCGTTGGAATGGGCGCTCTCCACAGG  
CAGCGCTGCTGGAACCTCAACAGCTCCCTGGAGTTCAAGCTGCACCGACTGCATTCATCCGCTCTTGGCAGGA  
GGCCCCGCGAAGCAGCTGGAGGCCCTCAGCTATGCTCGGCACTTCAGCCCTTTGCTCGGCTGCACCAGCGGGAG  
ATCCAGGTGATGATGGGCAGCCTGGTGTACCTGCGGCTGGGCTTGGAGAAGTCACCCCTACTGCCACCTGCTGGAC  
AGCAGCCACTGGGCAGAGATCTGTGAGACCTTTACCCGGGACGCTGTTCCCTGCTGGGGCTTTCTGTGGAGTCC  
CCCCTTAGCGTCAGCTTTGCCTCTGGCTGTGTGGCGCTGCCTGTGTTGATGAACATCAAGGCTGTGATTGAGCAG  
CGGCAGTGCCTGGGGTCTGGAATCACAAGGACGAGTTACCGATTGAGATTGAAGTGGCATGAAGTGTGGTAC  
GCTCATCTGTGGCCATGTTATCTCCCGAGATGCACTCAATAAGCTCATTAATGGAGGAAACACTCCGTGTTTCGCT  
TGCCCCATCCTCCGCCAGCAGACGTCAGATTCCAACCCTCCCATCAAGCTGAAGTGTCCCTACTGTCCCATGGAG  
CAGAACCCGGCAGATGGGAAACGCATCATATTCTGATTTCCTACCTGGAAGGAATTTTGTGAAAGGGGTTTTTCAC  
CTGTGAGCCTTGGTCTGTCTCGGTAGGGTGGTCAACTTCAGTGGACTGTGGTTGGTTTCAGAGCGCCTGGCTGAG  
GAGTTCCACTGAGGGGAGCACTGGAGCAGCCCTTTGGCAGAGGCTGAGGAGGGAGATGGACCAGCCACGCCTGG  
CACCTGGCTCCATGGCATAAGGAAAGGGAGATGCTGGCCTCTGTGCTCCTGCTGTCTTTTCTGTTTCTGTTTGC  
GTTTGACTTAGTAGCAACCGACAGAGTGGCAAGGGATTTGGTCTTCAGCAGTAGACATCCTTCCACCCCTGCCCT  
CAGCCAAGTCTCTTGCTGCCATGCCAATGCTATGTCCACCCTTGCCCCCGGCCCAAGAGTGTCCAGCGGTGGCC  
CACCTCTTCTCCCACTACAGCCTCAACAGTATGTACCATCTCCCACTGTAAATAGTCCCAGTTAGAACGGAATG  
CCGTTGTTTTATAACTTTGAACAAATGTATTTACTGCCCTTCTCAAAA

184/550

**FIGURE 184**

QCCRKIKDTVQKLASDHKDIHSSVSRVGKAIDRNFSEICGVVSDAVWDAREQQQQILQMAIV  
EHLYQQGMLSVAEELCQESTLNVDLDFKQPFLELNRILEALHEQDLGPALEWAVSHRQRLLLEL  
NSSLEFKLHRLHFIRLLAGGPAKQLEALSYARHFQPFARLHQREIQVMMGSLVYLRLGLEKSP  
YCHLLDSSHWAEICETFTRDACSLGLSVESPLSVSFASGCVALPVLNMIKAVIEQRQCTGVW  
NHKDELPIEIELGMKCWYHSVFACPILRQQTSDSNPPIKLICGHVISRDALNKLINGGKLKCP  
YCPMEQNPADGKRIIF

**Transmembrane domain:**

amino acids 222-241

**N-glycosylation site.**

amino acids 129-133

**Tyrosine kinase phosphorylation site.**

amino acids 151-159, 184-193

**Amidation site.**

amino acids 327-331

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 222-233

185/550

**FIGURE 185**

GAGCGACGCTGTCTCTAGTCGCTGATCCCAAATGCACCGGCTCATCTTTGTCTACACTCTAAT  
CTGCGCAAACCTTTTGCAGCTGTCGGGACACTTCTGCAACCCCGCAGAGCGCATCCATCAAAGC  
TTTGCGCAACGCCAACCTCAGGCGAGATGACTTGTACCGAAGAGATGAGACCATCCAGGTGAA  
AGGAAACGGCTACGTGCAGAGTCCTAGATTCCCGAACAGCTACCCCGAGAACCTGCTCCTGAC  
ATGGCGGCTTCACTCTCAGGAGAATACACGGATACAGCTAGTGTTTGACAATCAGTTTGGATT  
AGAGGAAGCAGAAAATGATATCTGTAGGTATGATTTTGTGGAAGTTGAAGATATATCCGAAAC  
CAGTACCATTATTAGAGGACGATGGTGTGGACACAAGGAAGTTCCTCCAAGGATAAAATCAAG  
AACGAACCAAATTTAAATCACATTCAAGTCCGATGACTACTTTGTGGCTAAACCTGGATTCAA  
GATTTATTATTCTTTGCTGGAAGATTTCCAACCCGCAGCAGCTTCAGAGACCAACTGGGAATC  
TGTCACAAGCTCTATTTTCAGGGGTATCCTATAACTCTCCATCAGTAACGGATCCCACTCTGAT  
TGCGGATGCTCTGGACAAAAAATTGCAGAATTTGATACAGTGGAAGATCTGCTCAAGTACTT  
CAATCCAGAGTCATGGCAAGAAGATCTTGAGAATATGTATCTGGACACCCCTCGGTATCGAGG  
CAGGTCATACCATGACCGGAAGTCAAAAGTTGACCTGGATAGGCTCAATGATGATGCCAAGCG  
TTACAGTTGCACTCCCAGGAATTACTCGGTCAATATAAGAGAAGAGCTGAAGTTGGCCAATGT  
GGTCTTCTTTCCACGTTGCCTCCTCGTGCAGCGCTGTGGAGGAAATTGTGGCTGTGGAAGTGT  
CAACTGGAGGTCCTGCACATGCAATTCAGGGAAAACCGTGAAAAAGTATCATGAGGTATTACA  
GTTTGAGCCTGGCCACATCAAGAGGAGGGGTAGAGCTAAGACCATGGCTCTAGTTGACATCCA  
GTTGGATCACCATGAACGATGCGATTGTATCTGCAGCTCAAGACCACCTCGATTAAGAGAATGT  
GCACATCCTTACATTAAGCCTGAGAGAA

186/550

**FIGURE 186**

MHRLIFVYTLICANFCSCRDTSATPQSASIKALRNANLRRDDLYRRDETIQVKNGYVQSPRF  
PNSYPRNLLLTWRLHSQENTRIQLVFDNQFGLLEEAENDICRYDFVEVEDISETSTIIRGRWCG  
HKEVPPRIKSRTNQIKITFKSDDYFVAKPGFKIYYSLLLEDFQPAAASETNWESVTSSISGVSY  
NSPSVTDPTLIADALDKKIAEFDTVEDLLKYFNPESWQEDLENMYLDTPRYRGRSYHDKRSKV  
DLDRLNDDAKRYSCTPRNYSVNIREELKLANVVFFPRCLLVQRCGGNCGCGTVNWRSCTCNSG  
KTVKKYHEVLQFEPGHIKRRGRAKTMALVDIQLDHHERCDCICSSRPPR

**Signal peptide:**

amino acids 1-18

**N-glycosylation site.**

amino acids 270-274

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 262-266

**Tyrosine kinase phosphorylation site.**

amino acids 256-265

**N-myristoylation sites.**

amino acids 94-100, 186-192, 297-303, 298-304

**TonB-dependent receptor proteins signature 1.**

amino acids 1-56

187/550

FIGURE 187

CATGCCGCTGCCGCCGCTGCTGCTGTTGCTCCTGGCGGCGCCTTGGGGACGGGCAGTTCCCTG  
TGTCTCTGGTGGTTTGCCTAAACCTGCAAACATCACCTTCTTATCCATCAACATGAAGAATGT  
CCTACAATGGACTCCACCAGAGGGTCTTCAAGGAGTTAAAGTTACTTACACTGTGCAGTATTT  
CATATATGGGCAAAGAAATGGCTGAATAAATCAGAATGCAGAAATATCAATAGAACCTACTG  
TGATCTTTCTGCTGAAACTTCTGACTACGAACACCAGTATTATGCCAAAGTTAAGGCCATTTG  
GGGAACAAAGTGTTCCAAATGGGCTGAAAGTGGACGGTTCTATCCTTTTTTAGAAACACAAAT  
TGGCCCACCAGAGGTGGCACTGACTACAGATGAGAAGTCCATTTCTGTTGTCCTGACAGCTCC  
AGAGAAGTGGAAGAGAAATCCAGAAGACCTTCCTGTTTCCATGCAACAAATATACTCCAATCT  
GAAGTATAACGTGTCTGTGTTGAATACTAAATCAAACAGAACGTGGTCCCAGTGTGTGACCAA  
CCACACGCTGGTGCTCACCTGGCTGGAGCCGAACACTCTTTACTGCGTACACGTGGAGTCCTT  
CGTCCCAGGGCCCCCTCGCCGTGCTCAGCCTTCTGAGAAGCAGTGTGCCAGGACTTTGAAAGA  
TCAATCATCAGAGTTCAAGGCTAAAATCATCTTCTGGTATGTTTTGCCCATATCTATTACCGT  
GTTTCTTTTTTCTGTGATGGGCTATTCCATCTACCGATATATCCACGTTGGCAAAGAGAAACA  
CCCAGCAAATTTGATTTTGATTTATGGAAATGAATTTGACAAAAGATTCTTTGTGCCTGCTGA  
AAAAATCGTGATTAACCTTTATCACCTCAATATCTCGGATGATTCTAAAATTTCTCATCAGGA  
TATGAGTTTACTGGGAAAAAGCAGTGATGTATCCAGCCTTAATGATCCTCAGCCCAGCGGGAA  
CCTGAGGCCCCCTCAGGAGGAAGAGGAGGTGAAACATTTAGGGTATGCTTCGCATTTGATGGA  
AATTTTTTGTGACTCTGAAGAAAACACGGAAGGTACTTCTCTCACCCAGCAAGAGTCCCTCAG  
CAGAACAATACCCCCGGATAAAACAGTCATTGAATATGAATATGATGTCAGAACCACTGACAT  
TTGTGCGGGGCCTGAAGAGCAGGAGCTCAGTTTGCAGGAGGAGGTGTCCACACAAGGAACATT  
ATTGGAGTCGCAGGCAGCGTTGGCAGTCTTGGGCCCGCAAACGTTACAGTACTCATACACCCC  
TCAGCTCCAAGACTTAGACCCCCTGGCGCAGGAGCACACAGACTCGGAGGAGGGGGCCGGAGGA  
AGAGCCATCGACGACCCTGGTCGACTGGGATCCCCAACTGGCAGGCTGTGTATTTCCTTCGCT  
GTCCAGCTTCGACCAGGATTCAGAGGGCTGCGAGCCTTCTGAGGGGGATGGGCTCGGAGAGGA  
GGGTCTTCTATCTAGACTCTATGAGGAGCCGGCTCCAGACAGGCCACCAGGAGAAAATGAAAC  
CTATCTCATGCAATTCATGGAGGAATGGGGTTATATGTGCAGATGGAAAACTGATGCCAACA  
CTTCCTTTTGCCTTTTGTTCCTGTGCAAACAAGTGAGTCACCCCTTTGATCCCAGCCATAAA  
GTACCTGGGATGAAAGAAGTTTTTTCCAGTTTGTGTCAGTGTCTGTGAGAA

188/550

FIGURE 188

MPLPPLLLLLLLAAPWGRAVPCVSGGLPKPANITFLSINMKNVLQWTPPEGLQGKVTYTVQYF  
IYGQKKWLNKSECRNINRTYCDLSAETSDYEHQYYAKVKAIWGTKCSKWAESGRFYPFLETQI  
GPPEVALTTDEKSI SVVLTAPEKWKRNPEDLPVSMQQIYSNLKYNVSVLNTKSNRTWSQCVTN  
HTLVLTWLEPNTLYCVHVESFVPGPPRRAQPSEKQCARTLKDQSSEFKAKIIFWYVLPISITV  
FLFSVMGYSIYRYIHVGKEKH PANLILYGNFDRFFVPAEKIVINFITLNI SDDSKISHQD  
MSLLGKSSDVSSLNDPQPSGNLRPPQEEEEVKHLGYASHLMEIFCDSEENTEGTSLTQQESLS  
RTIPPDKTVIEWEYDVRTTDICAGPEEQELSLQEEVSTQGTLLLESQAALAVLGPQTLQYSYTP  
QLQDL DPLAQEHTDSEEGPEEEPSTTLVDWDPQTGRLCIPSLSSFQDSEGCEPSEG DGLGEE  
GLLSRLYE EPAPDRPPGENETYLMQFMEEWGLYVQMEN

**Signal sequence:**

amino acids 1-18

**Transmembrane domain:**

amino acids 240-260

**N-glycosylation sites.**amino acids 31-34, 72-75, 80-83, 171-174, 180-183, 189-192,  
304-307, 523-526**Tyrosine kinase phosphorylation site.**

amino acids 385-392, 518-526

**N-myristoylation sites.**

amino acids 53-58, 106-111, 368-373, 492-497

**Tissue factor**

amino acids 1-278

189/550

**FIGURE 189**

**ATG**TGCTGCTGGCCGCTGCTCCTGCTGTGGGGGCTGCTCCCCGGGACGGCGGGCGGGGGGCTCG  
GGCCGAACCTATCCGCACCGGACCCTCCTGGACTCGGAGGGCAAGTACTGGCTGGGCTGGAGC  
CAGCGGGGCAGCCAGATCGCCTTCCGCCTCCAGGTGCGCACTGCAGGCTACGTGGGCTTCGGC  
TTCTCGCCCCACCGGGGCCATGGCGTCCGCCGACATCGTCTGGGCGGGGTGGCCACGGGGCGG  
CCCTACCTCCAGGATTATTTTACAAATGCAAATAGAGAGTTGAAAAAAGATGCTCAGCAAGAT  
TACCATCTAGAATATGCCATGGAAAATAGCACACACACAATAATTGAATTTACCAGAGAGCTG  
CATACATGTGACATAAATGACAAGAGTATAACGGATAGCACTGTGAGAGTGATCTGGGCCTAC  
CACCATGAAGATGCAGGAGAAGCTGGTCCCAAGTACCATGACTCCAATAGGGGCACCAAGAGT  
TTGCGGTTATTGAATCCTGAGAAAAGTAGTGTGCTATCTACAGCCTTACCATACTTTGATCTG  
GTAAATCAGGACGTCCCCATCCCAAACAAAGATACAACATATTGGTGCCAAATGTTTAAAGATT  
CCTGTGTTCCAAGAAAAGCATCATGTAATAAAGGTTGAGCCAGTGATACAGAGAGGCCATGAG  
AGTCTGGTGCACCACATCCTGCTCTATCAGTGCAGCAACAACCTTTAACGACAGCGTTCTGGAG  
TCCGGCCACGAGTGCTATCACCCCAACATGCCCGATGCATTCCTCACCTGTGAAACTGTGATT  
TTTGCCTGGGCTATTGGTGGAGAGGGCTTTTCTTATCCACCTCATGTTGGATTATCCCTTGGC  
ACTCCATTAGATCCGCATTATGTGCTCCTAGAAGTCCATTATGATAATCCCACTTATGAGGAA  
GGCTTAATAGATAAATCTGGACTGAGGTTATTTTACACAATGGATATAAGGAAATATGATGCT  
GGGGTGATTGAGGCTGGCCTCTGGGTGAGCCTCTTCCATACCATCCCTCCAGGGATGCCTGAG  
TTCCAGTCTGAGGGTCACTGCACTTTGGAGTGCCTGGAAGAGGCTCTGGAAGCCGAAAAGCCA  
AGTGAATTCATGTGTTTGTGTTCTTCTCCATGCTCACCTGGCTGGCAGAGGCATCAGGCTG  
CGTCATTTTCGAAAAGGGAAGGAAATGAAATTACTTGCCTATGATGATGATTTTGACTTCAAT  
TTCCAGGAGTTTCAGTATCTAAAGGAAGAACAACAATCTTACCAGGAGATAACCTAATTACT  
GAGTGTGCTACAACACGAAAGATAGAGCTGAGATGACTTGGGGAGGACTAAGCACCAGGAGT  
GAAATGTGTCTCTCATAACCTTCTTTATTACCCAAGAATTAATCTTACTCGATGTGCAAGTATT  
CCAGACATTATGGAACAACCTCAGTTCATTGGGGTTAAGGAGATCTACAGACCAGTCACGACC  
TGGCCTTTCATTATCAAAAGTCCCAAGCAATATAAAAACCTTCTTTTCATGGATGCTATGAAT  
AAGTTTAAATGGACTAAAAGGAAGGTCTCTCCTTCAACAAGCTGGTCCTCAGCCTGCCAGTG  
AATGTGAGATGTTCCAAGACAGACAATGCTGAGTGGTCGATTCAAGGAATGACAGCATTACCT  
CCAGATATAGAAAGACCCTATAAAGCAGAACCTTTGGTGTGTGGCAGCTCTTCTTCTCTTCC  
CTGCACAGAGATTTCTCCATCAACTTGCTTGTTTGCCTTCTGCTACTCAGCTGCACGCTGAGC  
ACCAAGAGCTT**GTGA**TCAAAATTCTGTTGGACTTGACAATGTTTTCTATGATCTGAACCTGTC  
ATTTGAAGTACAGGTAAAGACTGTGTCCACTTTGGGCATGAAGAGTGTGGAGACTTTTCTTC  
CCCATTTTCCCTCCCTCCTTTTTCTTCCATGTTACATGAGAGACATCAATCAGGTTCTCTT  
CTCTTTCTTAGAAATACCTGATGTTATATATACATGGTCAATAAAATAAACTGGCCTGACTT  
AAGATAACCATTTTAAAAAATTGGGCTGTGATGTGGGAATAAAAGAATTCTTTCTTCTCTAA  
AAAAAAA



190/550

**FIGURE 190**

MCCWPLLLLWGLLPGTAAGGSGRTYPHRTLLDSEGKYWLGWSQRGSQIAFRLQVRTAGYVGFG  
FSPTGAMASADIVVGGVAHGRPYLQDYFTNANRELKKDAQQDYHLEYAMENSTHTIIEFTREL  
HTCDINDKSITDSTVRVIWAYHHEDAGEAGPKYHDSNRGTKSLRLLNPEKTSVLSTALPYFDL  
VNQDVPIPNKDDTTYWCQMFKIPVFQEKHHVIKVEPVIIQRGHESLVHHILLYQCSNNFNDSVLE  
SGHECYHPNMPDAFLTCTVIFAWAIGGEGFSYPPHVGLSLGTPLDPHYVLLEVHYDNPTYEE  
GLIDNSGLRLFYTMDIRKYDAGVIEAGLWVSLFHTIPPGMPEFQSEGHCTLECLEEALEAEKP  
SGIHVFAVLLHAHLAAGRIRLRHFRKGKEMKLLAYDDDFDNFQEFQYLKEEQTILPGDNLIT  
ECRYNTKDRAEMTWGGLSTRSEMCLSYLLYYPRINLTRCASIPDIMEQLQFIGVKEIYRPVTT  
WPFIIKSPKQYKNLSFMDAMNKFVKWKKEGLSFNKLVLVSLPVNVRCSTDNAEWSIQGMTALP  
PDIERPYKAEPLVCGTSSSSSLHRDFSINLLVCLLLLSCTLSTKSL

**Signal peptide:**

amino acids 1-18

**Transmembrane domains:**

amino acids 56-73, 378-393, 583-602

**N-glycosylation sites.**

amino acids 114-118, 247-251, 476-480, 517-521

**N-myristoylation sites.**amino acids 11-17, 15-21, 20-26, 45-51, 68-74, 79-85, 290-296,  
316-322, 337-343, 342-348, 456-462, 534-540, 582-588**Copper type II, ascorbate-dependent monooxygenases proteins.**

amino acids 271-321, 422-474

191/550

**FIGURE 191**

GCTTCAGCTGAAGAAAGAGAGGAATGAAGCGCCTTCTGCTTCTGTTTTTGTTCCTTTATAACAT  
TTTCTTCTGCATTTCCCTTAGTCCGGATGACGGAAAATGAAGAAAATATGCAACTGGCTCAGG  
CATATCTCAACCAGTTCTACTCTCTTGAAATAGAAGGGAATCATCTTGTTCAAAGCAAGAATA  
GGAGTCTCATAGATGACAAAATTCGGGAAATGCAAGCATTTTTTGGATTGACAGTGAAGTGGAA  
AACTGGACTCAAACACCCTTGAGATCATGAAGACACCCAGGTGTGGGGTGCCTGATGTGGGCC  
AGTATGGCTACACCCTCCCTGGGTGGAGAAAATACAACCTCACCTACAGAATAATAAACTATA  
CTCCGGATATGGCACGAGCTGCTGTGGATGAGGCTATCCAAGAAGGTTTAGAAGTGTGGAGCA  
AAGTCACTCCACTAAAATTCACCAAGATTTCAAAGGGGATTGCAGACATCATGATTGCCTTTA  
GGACTCGAGTCCATGGTCCGTGTCCTCGCTATTTTGATGGTCCCTTGGGAGTGGCTGGCCATG  
CCTTTCCTCCTGGTCCGGGTCTGGGTGGTGACACTCATTTTGATGAGGATGAAAACCTGGACCA  
AGGATGGAGCAGGATTCAACTTGTTTCTTGTTGGCTGCTCATGAATTTGGTCATGCACTGGGGC  
TCTCTCACTCCAATGATCAAACAGCCTTGATGTTCCCAAATTATGTCTCCCTGGATCCCAGAA  
AATACCCACTTTCTCAGGATGATATCAATGGAATCCAGTCCATCTATGGAGGTCTGCCTAAGG  
TACCTGCTAAGCCAAAGGAACCCACTATACCCCATGCCTGTGACCCTGACTTGACTTTTGACG  
CTATCACAACTTTCCGCAGAGAAGTAATGTTCTTTAAAGGCAGGCACCTATGGAGGATCTATT  
ATGATATCACGGATGTTGAGTTTGAATTAATTGCTTCATTCTGGCCATCTCTGCCAGCTGATC  
TGCAAGCTGCATACGAGAACCCAGAGATAAGATTCTGGTTTTTAAAGATGAAAACCTTCTGGA  
TGATCAGAGGATATGCTGTCTTGCCAGATTATCCCAAATCCATCCATACATTAGGTTTTCCAG  
GACGTGTGAAGAAAATAGATGCAGCCGTCTGTGATAAGACCACAAGAAAAACCTACTTCTTTG  
TGGGCATTTGGTGCTGGAGGTTTGATGAAATGACCCAAACCATGGACAAAGGATTCCCGCAGA  
GAGTGGTAAACACTTTCCTGGAATCAGTATCCGTGTTGATGCTGCTTTCCAGTACAAAGGAT  
TCTTCTTTTTTTCAGCCGTGGATCAAAGCAATTTGAATACAACATTAAGACAAAGAATATTACCC  
GAATCATGAGAACTAATACTTGGTTTCAATGCAAAGAACCAAGAACTCCTCATTTGGTTTTG  
ATATCAACAAGGAAAAAGCACATTCAGGAGGCATAAAGATATTGTATCATAAGAGTTTAAGCT  
TGTTTATTTTTTGGTATTGTTTCATTTGCTGAAAAACACTTCTATTTATCAATTAAATTCATAGAC  
CTAAAATAAACCTCAACAGGTCTTTTAATATAAATTCTGCTTCAAATAGAATAAAACCATTC  
TTTAACAAC

192/550

**FIGURE 192**

MKRLLLLLFLFFITFSSAFPLVRMTENEENMQLAQAYLNQFYSLEIEGNHLVQSKNRSLIDDKI  
REMQAFFGLTVTGKLDSENTLEIMKTPRCGVPDVGQYGYTLPGWRKYNLTIRIINYTPDMARAA  
VDEAIQEGLEVWSKVTPKFTKISKGIADIMIAFRTRVHGRCPRYFDGPLGVLGHAFFPPGPGL  
GGDTHFDEDENWTKDGAGFNFLVAAHEFGHALGLSHSNDQTALMFPNYVSLDPRKYPLSQDD  
INGIQSIYGGLPKVPAKPKEPTIPHACDPDLTFDAITTFRREVMFFKGRHLWRIYYDITDVEF  
ELIASFWPSLPADLQAAYENPRDKILVFKDENFWMIRGYAVLPDYPKSIHTLGFPGRVKKIDA  
AVCDKTTRKTYFFVGIWCWRFDEMTQTMDKGFPQRVVKHFPGISIRVDAAFAQYKGFFFFSRGS  
KQFEYNIKTKNITRIMRTNTWFQCKEPKNSSFGFDINKEKAHSGGIKILYHKSLSLFIFGIVH  
LLKNTSIYQ

**Signal peptide:**

amino acids 1-17

**N-glycosylation sites.**

amino acids 55-59, 110-114, 200-204, 452-456, 470-474, 508-512

**N-myristoylation site.**

amino acids 71-77, 205-211, 223-229

**Hemopexin domain signature.**

amino acids 171-202, 207-238, 318-334

**Neutral zinc metallopeptidases, zinc-binding region signature.**

amino acids 213-223

**Matrixins cysteine switch.**

amino acids 89-97, 207-238

193/550

**FIGURE 193**

CACAATCAGGTCCCATTCTATAGATGGGGAAACTGAGGCTTGAGGTCACATAGGCGTCGTTCA  
AGGCTGGTATACCTGCACCCTCTCCCATGTGAACAACATGGTTCTGGGTAATGGGGGCTGTCA  
TCCAGTCTCCTCCCTGCCCCTGCTGGTGCACCTCCTGCCTCTGCTGGTGCACCTTCTGCCCCCT  
ACTGGTATATTTGCTGCCTCTGCTGGGGCGCTTCCTGCCTCGGCTGGTGTATCTCCTGCCCCCT  
GCTGGTGCACCTTCTGCCCCCGCTGATGCACTTCCTGCCTCTGCTGGTGCACCTCCTGGCTCT  
GCTGGCACACTTCCTGCCTCTGCTGGTGCACCTCCTGGCTCTGCTGGCGCACTTTCCTGCCCC  
TGCTGGTGTATTTCTGCCCCCTGCTGGTGTACTTCCTTCCCCTGCTGGTGCACCTCCTGCCTC  
TGCTGGCGCACTTCTTGCCTCTCCAGGCCCTACCTTAGCCTCTCCCTCTTATATATGGAAGTCT  
TCCCAGTTCACCTGACACTGGTAACAGGGACTCTGCTCTTGGTGTGCTGTCTGCCCTGGGGAT  
GGGCATCTGTGTCTTCCTTTACTACTGCTGGCTCAGGACCCAGAGCTTTGAAGCATGTCCAGA  
TGCAGGTCCGGGCACCAGAGTCTAAGGAGCCCCCTACACCCACCAGGATTTTCCAATAAAGAGA  
TGTTACCA

194/550

## **FIGURE 194**

MVLGNNGGCHPVSSLPLLVHFLPLLVHFLPLLVYLLPLLGRFLPRLVYLLPLLVHFLPPLMHFL  
PLLVHFLALLAHFLPLLVHFLALLAHFPAPAGVFPAPAGVLPSPAGALPASAGALLASPGPT

**Signal peptide:**

amino acids 1-39

**N-myristoylation sites.**

amino acids 4-10, 109-115, 116-122

**Leucine zipper pattern.**

amino acids 14-36, 16-38, 17-39, 21-43, 24-46, 28-50, 31-53,  
35-57, 38-60, 42-64, 45-67, 49-71, 52-74, 56-78, 59-81, 63-85,  
65-87, 66-88

FIGURE 195

[illegible]

196/550

FIGURE 196

MRRLTRRLVLPVFGVLWITVLLFFWVTKRKLEVPTGPEVQTPKPSDADWDDLWDQFDERRYLN  
AKKWRVGDDPYKLYAFNQRESERISSNRAIPDTRHLRCTLVYCTDLPPTSIIITFHNEARST  
LLRTIRSVLNRTPTHLIREIILVDDFSNDPDDCKQLIKLPKVKCLRNNERQGLVRSRIRGADI  
AQGTTLTFLDSHCEVNRDWLQPLLHRVKEDYTRVVCVIDIINLDTFTYIESASELRGGFDWS  
LHFQWEQLSPEQKARRLDPTPIRTPIIAGGLFVIDKAWFDYLGKYDMDMDIWGGENFEISFR  
VWMC GGSLEIVPCSRVGHVFRKKHPYVFPDGNANTYIKNTKRTAEVWMDEYKQY Y AARP FAL  
ERPFGNVESRLDLRKNLRCQSFKWYLENIYPELSIPKESSIQKGNIRQRQKCLESQRQNNQET  
PNLKLSPCAKVKGEDAKSQVWAFTYTQQILQEELCLSVITLFPGAPVVLVLCKNGDDRQQWTK  
TGSHEHIA SHLC LDTDMFGDGTENGKEIVVNPCESSLMSQHWD MVSS

**Transmembrane domain:**

amino acids 475-493

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 2-6

**Tyrosine kinase phosphorylation sites.**

amino acids 68-75, 401-409

**N-myristoylation sites.**

amino acids 178-184, 186-192, 192-198, 346-352, 383-389, 526-532

197/550

**FIGURE 197**

GCAGCTCACCTTCGCAGCCGCGATGGGGGAAGACGACGCCGCGCTTCGGGCTGGCAGCAGGGGGCTCTCCGACC  
CGTGGGCAGACTCAGTGGGAGTGCAGACCCCGCACCACGGAGCGCCACATCGCCGTACACAAGCGGCTTGTGCTGG  
CCTTCGCTGTGTCCCTCGTGGCATTGCTCGCGGTACAAATGCTCGCTGTGCTGCTCAGCCTGCGCTTCGACGAGT  
GCGGGGCGAGTGCCACGCCAGGCGCGGACGGTGGCCCTCAGGCTTTCGGAGCGCGGCGGCAACGGGAGCCTCC  
CTGGATCGGCCCGCGCAACCACCACGCGAGGCGGGGACTCCTGGCAGCCGAGGCGGGTGGGGTGGCCAGTCCGG  
GGACCACGTGCGCCCGAGCCGCCGTGCGAGGAGGAGCGGGAGCCGTGGGAGCCGTGGACGCAGCTGCGCCTGTCCG  
GCCACCTGAAGCCGCTGCACTACAATCTGATGCTCACCGCCCTCATGGAGAACTTACCTTCTCCGGGGAGGTCA  
ACGTGGAGATCGCGTGCCGGAACGCCACCCGCTACGTAGTGCTGCACGCTTCCCGAGTGGCGGTGGAGAAAGTGC  
AGCTGGCCGAGGACCGGGCGTTCGGGGCTGTCCCTGTAGCCGGTTTTTCTCTACCCGCAAACCCAGGTCTTAG  
TGGTGGTGCTGAATAGGACACTGGACGCGCAGAGGAATTACAATCTGAAGATTATCTACAACGCGCTCATCGAGA  
ATGAGCTCCTGGGCTTCTTCCGCAGCTCCTATGTGCTCCACGGGGAGAGAAGATTCCCTGGTGTACTCAGTTTT  
CGCTACACATGCCAGAAAGGCATTTCTTGTGTTTGTATGAGCCAATCTACAAGGCTACTTTCAAAATCAGCATCA  
AGCATCAAGCAACCTATTTATCTTTATCTAATATGCCAGTGGAACTTCCGTGTTTGAGGAAGATGGATGGGTTA  
CGGATCACTTTTACAGACCCCTCTCATGTCCACATATTATTTAGCCTGGGCAATTTGCAACTTCACATACAGAG  
AACTACCACCAAGAGTGGGGTGTAGTACGATTATATGCAAGACCTGATGCTATCAGAAGAGGATCCGGGGACT  
ATGCTCTCCATATAACAAAGAGATTAATAGAATTTTATGAAGACTACTTTAAAGTGCCCTATTCTTGGCAAAAC  
TAGATCTTTTAGCTGTGCCTAAGCATCCGTATGCTGCTATGGAGAACTGGGGACTAAGTATTTTTGTGGAACAAA  
GAATACTGCTGGATCCAGTGTTCATCTATTTCTTATTTGCTGGATGTCACCATGGTCATTGTTTCATGAGATAT  
GTCACCAAGTGGTTTGGTGACCTTGTGACGCTGTGTGGTGGGAAGACGTGTGGCTGAAGGAAGGGTTTGTCTACT  
ACTTTGAATTTGTTGGTACAGACTACCTCTATCCTGGCTGGAACATGGAAAAGCAGAGGTTTCTGACCGATGTTT  
TGCATGAAGTGATGCTGCTGGACGGTTTGCCAGTTCCCATCCAGTATCACAGGAAGTGCTGCAGGCAACAGATA  
TTGACAGGGTGTGTTGACTGGATCGCATATAAAAAGGGTGCTGCTTTAATAAGAATGCTGGCTAATTTTATGGGCC  
ATTCAGTTTTCCAGAGGGGTTTGCAAGATTATTTAACCATTTCATAAGTATGGTAATGCAGCCAGAAATGATCTCT  
GGAATACATTATCGGAGGCTTTAAAAGAAATGGGAATATGTAAATATACAAGAAGTAATGGATCAGTGGACAC  
TCCAGATGGGTTATCCTGTTATCACCATCTTGGGAACACACAGCAGAAAATAGAATAATAATTACCCAACAGC  
ATTTTATCTATGATATCAGTGCTAAAACCTAAAGCACTTAACTTCAGAATAACAGTTACCTGTGGCAGATTCCAT  
TAATCTTTGTTAGGAAATAGAAGCCATGTGCTTTCAGAAGCAATTATTTGGGTGTCTAACAAATCAGAGCACC  
ACAGAATAACTTATTTGGACAAAGGAAGCTGGCTGCTGGGAACATCAATCAAACCTGGCTATTTTAGAGTCAACT  
ATGACCTAAGGAAGTGGAGATTATTAATTGATCAATTAATCCGGAATCATGAGGTTCTTTCTGTGAGTAACCGAG  
CGGGCTTGATCGATGATGCCTTCAGCCTAGCCAGGGCTGGCTATTTGCCTCAGAATATTCCTCTGGAGATTATCA  
GATACCTGTCTGAGGAGAAGGATTTTCTTCTTGGCATGCTGCCAGCCGAGCTCTTTATCCTCTAGATAAATTAC  
TGGACCGCATGGAAAACCTACAACATTTTCAATGAATATATTTTAAAGCAAGTTGCAACAACATATATCAAGCTTG  
GGTGGCCGAAATAATTTTAAATGGATCTCTTGTTCAGCATCTTACCAACATGAAGAAGTACGTAGAGAAGTTA  
TAATGCTGGCCTGCAGTTTGGCAACAAGCACTGTCCCAACAGGCATCAACACTTATTTAGATTGGATTTCGA  
GCAACAGGAACAGAATACCACTAAATGTTAGAGACATCGTATACTGTACAGGAGTGTCACTACTGGATGAGGATG  
TCTGGGAATTCATATGGATGAAATCCATTCACCACAGCAGTTTCTGAGAAGAAAATATTATTGGAAGCCTTAA  
CTTGACAGTATGACAGGAATTTATTAACAGGCTTCTAAATCTGTCACTGAATTCTGAGGTGGTGTGATCAAG  
ATGCAATTGATGTCATAATCCATGTAGCTCGAAATCCACATGGTCGAGACCTTGCTTGGAGGTTTTCAGGGATA  
AATGGAAGATATTAATACCAGGTATGGAGAAGCATTTGTTTATGATTCCAAACTCATCAGTGGTGTACAGAAT  
TTCTTAATACTGAAGGTGAAGTCAAAGAGCTCAAGAACTTCATGAAAACTATGATGGGGTAGCTGCTGCTTCTT  
TCTCACGAGCTGTGGAACTGTGCAAGCCAATGTGCGCTGGAAAATGCTTTACCAAGACGAGCTTTTCCAATGGT  
TAGGAAAAGCTCTAAGACACTAATATATGATCTTATAAACAAACAATTCAACTCAGAAGTTTATGAGAAGACAC  
GCTTTTTTGTGGAATGAGGAAAATGTACTACCTAGAAAATGGCCAGATTTTCAGTGTAAACGTGTGGGAGGAATTT  
TTTTTTTTAGTTTTTATTTTTTGGTGGGATATTTTTTATTTGTTTTCATTCTGTTCTGTTTCTCTAC  
TGGGTGTTCTCTCTAAAGAACTCTTGCAAGTGAACTAGCCATGATTGCTTCAGCTGATCATTCTGCTGTGTA  
CAGGACCAAAATATGATAGTGATGCATGTTGATGTTACAGTCAATTTGGAAAAACATATTCAGAATATCTGTGCAT  
GGATATATTGTCTGCTGTGTTCCAGCATGCTTATTTCAAACGTCCAGTGTGTGTGTAATATGTGTTACACC  
TAGGATGGGCATTATGCAAAAGCACAAGATTATATATGACAATCAGTATTGCAATGAAAGAAAACTAAAAACA  
GAAATGATATTCTCAATTTTGGGCAATGTGAGAGGTAAAAATAGCCCTTGACATGATGAACATCACTTATTTTCAGC  
ACTTGGATTGTCTGGCAATGATTACTGTGTGCTAACTCATTTTCTTTGAGTTAAAGCTGTGTATACATTTTAA  
AGGCATATAGATAGTGTATGATATGATATGATAGGGAAGCCCATATGATATAGTATGTTGTACACTGC  
ACATGTACAAAGAATGTCTTCAGATCAAAGAAAATTTATCTCTTTTTATAAACTTAAAGGACAGTTGCAAAAGGCT  
TCAAGGAATTTATCTCAACATTATTCTTTCTATGCTCTAACTAAATTTCTCACTGTTATGAATTTTTTCATCTAC  
TTCTTGAACAGTGGTCTATTCTGCTACATGAAGATGAATACAAACAAATTTTTGTATAAACTCCCAAAAAAAA  
AAAAA



198/550

**FIGURE 198**

MGEDDAALRAGSRGLSDPWADSVGVRPRRTTERHIAVHKRLVLAFVSLVALLAVTMLAVLLSL  
RFDECGASATPGADGGPSGFPERGGNGSLPGSARRNHHAGGDSWQPEAGGVASPGTTSAQPPS  
EEEREPPWEPWTQLRLSGHLKPLHYNLMLTAFMENFTFSGEVNVEIACRNATRYVVLHASRVAV  
EKVQLAEDRAFGAVPVAGFFLYPQTQVLVVVLNRTLDAQRNYNLKIIYNALIENELLGFFRSS  
YVLHGERRFLGVTQFSPTHARKAFPCFDEPIYKATFKISIKHQATYLSLSNMPVETSVFEEDG  
WVTDHFSQTPLMSTYYLAWAICNFTYRETTTKSGVVVRLYARPD AIRRGSGDYALHITKR LIE  
FYEDYFKVPYSLPKDLLAVPKHPYAAMENWGLSIFVEQRILLDPSVSSISYLLDVTMVIVHE  
ICHQWFGDLVTPVWWEDVWLKEGFAHYFEFVGTDYLYPGWNMEKQRFLT DVLHEVMLLDGLAS  
SHPVSQEV LQATDIDRVFDWIAYKKGAALIRMLANFMGHSVFQ RGLQDYLT I HKYGN AARNDL  
WNTLSEALKRNGKYVNIQEVMDQWTLQMGYPVITILGN TTAENRI IITQQHFIYDISAKTKAL  
KLQNN SYLWQIPLTIVVGNRSHVSSEAIWVSNKSEHHRITYLDKGSWLLGNINQTGYFRVNY  
DLRNWRL LIDQLIRNHEVLSVSNRAGLIDDAFSLARAGYLPQNI PLEIIRYLSEEKDFLPWHA  
ASRALYPLDKLLDRMENYNIFNEYILKQVATTYIKLGWPKNNFNGLVQASYQHEELRREVIM  
LACSFNGKHCHQQASTLISDWISSNRNRIPLNVRDIVYCTGVSLLEDVWEFIWMKFHSTTAV  
SEKKILLEALTCSDDRNLLNRLNLSLNSEVVLDQDAIDV I IHVARNP HGRDLAWKFFRDKWK  
ILNTRYGEALFMYSKLISGVTEFLNTEGELKELKNFMKNYDGVAAASFSRAVETVEANVRWKM  
LYQDEL FQWL GKALRH

**Transmembrane domain:**

amino acids 44-63

**N-glycosylation sites.**amino acids 89-93, 160-164, 175-179, 222-226, 338-342, 605-609,  
634-638, 649-653, 663-667, 684-688, 800-804, 906-910**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 362-366

**Tyrosine kinase phosphorylation site.**

amino acids 520-528

**N-myristoylation sites.**amino acids 78-84, 87-93, 90-96, 118-124, 501-507, 604-610,  
825-831, 987-993**Neutral zinc metallopeptidases, zinc-binding region signature.**

amino acids 437-447

199/550

**FIGURE 199**

GCGCCCGGCGCAGCTCGGCCAGAGCGACCGCGGGGCTGAGCGCGCGTCCGCCAGGGGGCTCCGGAAGCTGCCCC  
GGCCCGCGGGCTCCTCCCTCGCTCCCGCTTCCCTTTCTCGCTCACCGCCGCCCTCCTTCCCCAGCTCCCTCGCC  
GTCCGCCCCGCCACAGCCAGCGGCTCCGCGCCCCCTGCAGCCACGATGCCCCGCGGCCCGGCCCGCCGCGGG  
ACTCCGCGGGATCTCGCTGTTCTCGCTCTGCTCCTGGGGAGCCCGGCGGCAGCGCTGGAGCGAGATGCTCTTCC  
CGAGGGAGATGCTAGCCCTTTGGGTCTTACCTCCTGCCCTCAGGAGCCCCGGAGAGAGGCAGTCTGGCAAAGA  
GCACCCTGAAGAGAGAGTGGTAACAGCGCCCCCAGTTTCTCACAGTCGGCGGAAGTGTGGGCGAGCTGGTGCT  
GGATGGGACCGCACCTCTGCACATCACGACATCCCAGCCCTGTCACCGCTGCTTCCAGAGGAGGCCCGCCCCAA  
GCACGCTTGCCCCCAAGAAGAACTGCCTTCGCTCAAGCAGGTGAACTCTGCCAGGAAGCAGCTGAGGCCCAA  
GGCCACCTCCGAGCCACTGTCAAAGGGCAGGGTCCCAGCCAGCGTCCCAGGGCCTAGATCTCCTCTCCTCCTC  
CACGGAGAAGCCTGGCCCCACCGGGGACCCCGGACCCCATCGTGGCCTCCGAGGAGGCATCAGAAGTGCCCTTTG  
GCTGGATCGAAAGGAGAGTGCAGTCCCTACAACACCCGACCCCTGCAAATCTCCCCCTTCACTTCGCAGCCCTA  
TGTGGCCACACACTCCCCAGAGGCCAGAACCCGGGGAGCCTGGGCCTGACATGGCCCAGGAGGCCCCCCAGGA  
GGACACCAGCCCCATGGCCCTGATGGACAAAGGTGAGAATGAGCTGACTGGGTGAGCCTCAGAGGAGAGCCAGGA  
GACCACTACCTCCACCATTATCACCACCACGGTCATCACCACCGAGCAAGCACCAGCTCTCTGCAGTGTGAGCTT  
CTCCAATCCTGAGGGGTACATTGACTCCAGCGACTACCACTGCTGCCCTCAACAACCTTTCTGGAGTGCACATA  
CAACGTGACAGTCTACACTGGCTATGGGGTGGAGCTCCAGGTGAAGAGTGTGAACCTGTCCGATGGGGAAGTGT  
CTCCATCCGCGGGGTGGACGGCCCTACCCTGACCGTCTGGCCAACCAGACACTCCTGGTGGAGGGGCAGGTAAT  
CCGAAGCCCCACCAACACCATCTCCGTCTACTTCCGGACCTTCCAGGACGACGGCCTTGGGACCTTCCAGCTTCA  
CTACCAGGCCTTCATGCTGAGCTGCAACTTTCCCCGCCGGCCTGACTCTGGGGATGTACGGTGTGACCTGCA  
CTCAGGTGGGGTGGCCCACTTTCACTGCCACCTGGGCTATGAGCTCCAGGGCGCTAAGATGCTGACATGCATCAA  
TGCTCCCAAGCCGCACTGGAGCAGCCAGGAGCCCATCTGCTCAGCTCCTTGTGGAGGGCAGTGCACAATGCCAC  
CATCGGCCGCTCCTCTCCCCAAGTTACCCTGAAAAACAAATGGGAGCCAATTCTGCATCTGGACGATTGAAGC  
TCCAGAGGGCCAGAAGCTGCACCTGCACTTTGAGAGGCTGTTGCTGCATGACAAGGACAGGATGACGGTTCACAG  
CGGGCAGACCAACAAGTCAGCTCTTCTTACGACTCCCTTCAAACCGAGAGTGTCCCTTTTGAGGGCCTGCTGAG  
CGAAGGCAACACCATCCGCATCGAGTTCAGTCCGACCAGGCCCGGGCGGCCTCCACCTTCAACATCCGATTTGA  
AGCGTTTGAAGAGGCCACTGCTATGAGCCCTACATCCAGAATGGGAACCTTCACTACATCCGACCCGACCTATAA  
CATTGGGACTATAGTGGAGTTCACCTGCGACCCCGGCCACTCCCTGGAGCAGGGCCCCGGCCATCATCGAATGCAT  
CAATGTGCGGGACCCATACTGGAATGACACAGAGCCCCCTGTGCAGAGCCATGTGTGGTGGGGAGCTCTCTGCTGT  
GGCTGGGGTGGTATTGTCCCCAACTGGCCCGAGCCCTACGTGGAAGGTGAAGATTGTATCTGGAAGATCCACGT  
GGGAGAAGAGAAACGGATCTTCTTAGATATCCAGTTCCTGAATCTGAGCAACAGTGACATCTTGACCATCTACGA  
TGGCGACGAGGTGATGCCCCACATCTTGGGGCAGTACCTTGGGAACAGTGGCCCCCAGAACTGTACTCCTCCAC  
GCCAGACTTAACCATCCAGTTCCATTCCGACCCCTGCTGGCCTCATCTTTGGAAGGGCCAGGGATTTATCATGAA  
CTACATAGAGGTATCAAGGAATGACTCCTGCTCGGATTTACCCGAGATCCAGAATGGCTGGAAAACCACTTCTCA  
CACGGAGTTGGTGCAGGGGAGCCAGAATCACCTACCAGTGTGACCCCGGCTATGACATCGTGGGGAGTGACACCCT  
CACCTGCCAGTGGGACCTCAGCTGGAGCAGCGACCCCCATTTTGTGAGAAAATTATGTACTGCACCGACCCCGG  
AGAGGTGGATCACTCGACCCGCTTAATTTCCGATCCTGTGCTGCTGGTGGGGACCACCATCCAATACACCTGCAA  
CCCCGTTTTGTGCTTGAAGGGAGTTCTTCTGACCTGCTACAGCCGTGAAACAGGGACTCCCATCTGGACGTC  
TCGCTGCCCCACTGCGTTTTCGGAGGAGTCCCTGGCATGTGACAACCCAGGGCTGCCTGAAAATGGATACCAAAT  
CCTGTACAAGCGACTCTACCTGCCAGGAGAGTCCCTCACCTTCATGTGCTACGAAGGCTTTGAGCTCATGGGTGA  
AGTGACCATCCGCTGCATCCTGGGACAGCCATCCCACTGGAACGGGCCCCCTGCCGCTGTGTAAAGTTAATCAAGA  
CAGTTTTGAACATGCTTTAGAAGCAGAAGCGGCAGCAGAGACGTCGCTGGAAGGGGGGAACATGGCCCTGGCTAT  
CTTCATCCCGGTCTCATCATCTCCTTACTGCTGGGAGGAGCCTACATTTACATCACAAGATGTGCTACTATTC  
CAACCTCCGCTGCCTCTGATGTACTCCCACCCCTACAGCCAGATCACCCTGGAACCCGAGTTTGACAACCCCAT  
TTACGAGACAGGGGAAACAGAGAGTATGAGGTTTCTATCTAAAGAGAGCTACACTTGAGAAGGGGACTTGTGAA  
CTCAACCACAATCTCCTCGAGACATTCATCCAGAGACCATGTGGCACTTGATTGAAACCCCAAGATGTGCACTGT  
CTTTTGTGTTAGACTCTTTATCAAAGGTTTACTGTTTTCTCCCTGTATTTATTATATTTAAAGTGAAAAA  
AAAAA

200/550

**FIGURE 200**

MPAARPPAAGLRGISLFLALLLGSPAAALERDALPEGDASPLGPYLLPSGAPERGSPGKEHPE  
 ERVVTAPPSSSQSAEVLGELVLDGTAPSAHHDIPALSPLLPEEARPKHALPPKKKLPSLKQVN  
 SARKQLRPKATSAATVQRAGSQPASQGLDLLSSSTEKPGPPGDPDPIVASEEASEVPLWLDK  
 ESAVPTTPAPLQISPFTSQPYVAHTLPQRPEPGEPGDMAQEAPQEDTSPMALMDKGENELTG  
 SASEESQETTTSTIITTTVITTEQAPALCSVSFSNPEGYIDSSDYPLLPLNNFLECTYNVTY  
 TGYGVELQVKS VNLS DGELLSIRGVDGPTLTVLANQTLLEVGQVIRSPTNTISVYFRTFQDDG  
 LGTFQLHYQAFMLSCNFPRRPDSGDVTVM DLHSGGVAHFHCHLGYELQGA KMLTCINASKPHW  
 SSQEPICSA PCGGAVHNATIGRVLSPSY PENTNGSQFCIWTIEAPEGQKLHLHFERLLLHDKD  
 RMTVHSGQTNKSALLYDSLQTESVPFEGLLSEGNTIRIEFTSDQARAASFNIRFEAFEKGHC  
 YEPYIQNGNFTTSDPTYNIGTIVEFTCDPGHSLEQGPAIECINVRDPYWNDTEPLCRAMCGG  
 ELSAVAGVVLSPNWPEPYVEGEDCIWKIHVGE EKRIFLDIQFLNLSNSDILTIYDGDEVMPHI  
 LGQYLGNSGPQKLYSSTPDLTIQFHSDPAGLIFGKGQGFIMNYIEVSRNDSCSDLPEIQNGWK  
 TTSHTELVRGARITYQCDPGYDIVGSDTLTCQWDLSSSDPPFCEKIMYCTDPGEVDHSTRLI  
 SDPVLLVGTTIQYTCNPGFVLEGSSLLTCYSRETGTPIWTSRLPHCVSEESLACDNPGLPENG  
 YQILYKRLYLPGESLTFMCYEGFELMGEVTIRCILGQPSHWNGPLPVCKVNQDSFEHALEAEA  
 AAETSLEGGMALAI FIPVLIISLLLGGAYIYITRCRYYSNLRLPLMYSHPY SQITVETEFDN-  
 PIYETGETREYEVSI

**Signal peptide:**

amino acids 1-28

**Transmembrane domain:**

amino acids 893-915

**N-glycosylation sites.**

amino acids 311-315, 328-332, 350-354, 435-439, 458-462, 474-478,  
 514-518, 576-580, 618-622, 674-678, 742-746

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 188-192

**N-myristoylation sites.**

amino acids 23-29, 87-93, 146-152, 454-460, 475-481, 575-581,  
 629-635, 695-701, 723-729, 766-772, 877-883, 953-959

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 383-394

201/550

**FIGURE 201**

**GATG**GCTACGGCAGGGGGTGGCTCTGGGGCTGACCCGGGAAGTCGGGGTCTCCTTCGCCTTCT  
GTCTTTCTGCGTCCTACTAGCAGGTTTGTGCGAGGGGAAACTCAGTGGAGAGGAAGATATATAT  
CCCCTTAAATAAAACAGCTCCCTGTGTTTCGCCTGCTCAACGCCACTCATCAGATTGGCTGCCA  
GTCTTCAATTAGTGGAGACACAGGGGTTATCCACGTAGTAGAGAAAGAGGAGGACCTACAGTG  
GGTATTGACTGATGGCCCCAACCCCCCTTACATGGTTCTGCTGGAGAGCAAGCATTTTACCAG  
GGATTTAATGGAGAAGCTGAAAGGGAGAACCAGCCGAATTGCTGGTCTTGCAGTGTCTTGAC  
CAAGCCCAGTCCTGCCTCAGGCTTCTCTCCTAGTGTACAGTGCCCAAATGATGGGTTTGGTGT  
TTACTCCAATTCCCTATGGGCCAGAGTTTGTCTACTGCAGAGAAATACAGTGGAAATTCGCTGGG  
CAATGGTTTGGCTTATGAAGACTTTAGTTTCCCCATCTTTCTTCTTGAAGATGAAAATGAAAC  
CAAAGTCATCAAGCAGTGCTATCAAGATCACAACCTGAGTCAGAATGGCTCAGCACCAACCTT  
CCCCTATGTGCCATGCAGCTCTTTTACACATGCATGCTGTCTCATCAGCACTGCCACCTGCAT  
GCGGCGCAGCTCCATCCAAAGCACCTTCAGCATCAACCCAGAAATCGTCTGTGACCCCTGTC  
TGATTACAATGTGTGGAGCATGCTAAAGCCTATAAATACAACTGGGACATTAAAGCCTGACGA  
CAGGGTTGTGGTTGCTGCCACCCGGCTGGATAGTCGTTCTTTTCTGGAATGTGGCCCCAGG  
GGCTGAAAGCGCAGTGGCTTCCTTTGTACCCAGCTGGCTGCTGCTGAAGCTTTGCAAAGGC  
ACCTGATGTGACCACCCTGCCCCGCAATGTCATGTTTGTCTTCTTTCAAGGGGAAACTTTTGA  
CTACATTGGCAGCTCGAGGATGGTCTACGATATGGAGAAGGGCAAGTTTCCCGTGCAGTTAGA  
GAATGTTGACTCATTTGTGGAGCTGGGACAGGTGGCCTTAAGAACTTCATTAGAGCTTTGGAT  
GCACACAGATCCTGTTTCTCAGAAAAATGAGTCTGTACGGAACCAGGTGGAGGATCTCCTGGC  
CACATTGGAGAAGAGTGGTGTGCTGGTGTCCCTGCTGTCATCCTCAGGAGGCCAAATCAGTCCCA  
GCCTCTCCCAACCATCTTCCCTGCAGCGATTTCTTCGAGCTCGAAACATCTCTGGCGTTGTTCT  
GGCTGACCACTCTGGTGCCTTCCATAACAAATATTACCAGAGTATTTACGACACTGCTGAGAA  
CATTAATGTGAGCTATCCCGAATGGCTGAGCCCTGAAGAGGACCTGAACTTTGTAACAGACAC  
TGCCAAGGCCCTGGCAGATGTGGCCACGGTGTGGGACGTGCTCTGTATGAGCTTGCAGGAGG  
AACCAACTTCAGCGACACAGTTTCAGGCTGATCCCCAAACGGTTACCCGCTGCTCTATGGGT  
CCTGATTAAAGCCAACAACCTCATGGTTCCAGTCTATCCTCAGGCAGGACCTAAGGTCCTACTT  
GGGTGACGGGCCTCTTCAACATTACATCGCTGTCTCCAGCCCCACCAACACCACTTATGTTGT  
ACAGTATGCCTTGGCAAATTTGACTGGCACAGTGGTCAACCTCACCCGAGAGCAGTGCCAGGA  
TCCAAGTAAAGTCCCAAGTGAAAACAAGGATCTGTATGAGTACTCATGGGTCCAGGGCCCTTT  
GCATTCTAATGAGACGGACCGACTCCCCCGGTGTGTGCGTTCTACTGCACGATTAGCCAGGGC  
CTTGTCTCCTGCCTTTGAACTGAGTCAGTGGAGCTCTACTGAATACTCTACATGGACTGAGAG  
CCGCTGGAAAGATATCCGTGCCCCGATATTTCTCATCGCCAGCAAAGAGCTTGAGTTGATCAC  
CCTGACAGTGGGCTTCGGCATCCTCATCTTCTCCCTCATCGTCACCTACTGCATCAATGCCAA  
AGCTGATGTCCTTTTTCATTGCTCCCCGGGAGCCAGGAGCTGTGTACATACT**TGAG**GAGGACCCCA  
GCTTTTCTTGCCAGNTCAGCAGTTCACTTCCTAGAGCATCTGTCCCACTGGGACACAACCACT  
AATTTGTCACTGGAACCTCCCTGGGCCTGTCTCAGATTGGGATTAACATAAAAGAGTGGAAC  
ATCCAAAAGAGACAGGGAGAAATAAATAAATTGCCTCCCTTCCCTCCGCTCCCCTTTCCCATCA  
CCCCTTCCCCATTTCTCTTCTTCTCTACTCATGCCAGATTTTGGGATTACAAATAGAAGCT  
TCTTGCTCCTGTTTAACTCCCTAGTTACCCACCCTAATTTGCCCTTCAGGACCCTTCTACTTT  
TTCCTTCTGCCCCTGTACCTCTCTCTGCTCCTCACCCCCACCCCTGTACCCAGCCACCTTCCT  
GACTGGGAAGGACATAAAAGGTTTAAATGTCAGGGTCAAACCTACATTGAGCCCCTGAGGACAGG  
GGCATCTCTGGGCTGAGCCTACTGTCTCCTTCCCACTGTCCTTTCTCCAGGCCCTCAGATGGC  
ACATTAGGGTGGGCGTGCTGCGGGTGGGTATCCACCTCCAGCCCACAGTGCTCAGTTGTACT  
TTTTATTAAGCTGTAATATCTATTTTTGTTTTGTCTTTTTCCTTTATTCTTTTTGTAAATAT  
ATATATAATGAGTTTCATTAAATAGATTATCCC

202/550

**FIGURE 202**

MATAGGGSGADPGSRGLLRLLSFCVLLAGLCRGNSVERKIYIPLNKTAPCVRLLNATHQIGCQ  
SSISGDTGVIHVVEKEEDLQWVLTGPNPPYMVLLSKHFTRDLMEKLGKRTSRIAGLAVSLT  
KPSPASGFSPSVQCPNDGFGVYSNSYGPEFAHCREIQWNSLGNGLAYEDFSFPIFLEDENET  
KVIKQCYQDHNLSQNGSAPTFLCAMQLFSMHMAVISTATCMRRSSIQSTFSINPEIVCDPLS  
DYNVWSMLKPINTTGTLKPDDRNVVAATRLDSRSFFWNVAPGAESAVASFVTQLAAAEALQKA  
PDVTTLPRNVMFVFFQGETFDYIGSSRMVYDMEKGKFPVQLENVDSFVELGQVALRTSLELWM  
HTDPVSQKNESVRNQVEDLLATLEKSGAGVPAVILRRPNQSQPLPPSSLQRFRLARNISGVVL  
ADHSGAFHNKYYQSIYDTAENINVSYPEWLSPEEDLNFVTD TAKALADVATVLGRALYELAGG  
TNFSDTVQADPQTVTRLLYGFLIKANNSWFQSILRQDLRSYLGDGPLQHYIAVSSPTNTTYV  
QYALANLTGTVVNLTREQCQDPSKVPSSENKDLYEYSWVQGPLHSNETDRLPRCVRSTARLARA  
LSPAFELSQWSSTEYSTWTESRWKDIRARIFLIASKELELITLTVGFGILIFSLIVTYCINAK  
ADVLFIAPREPGA VSY

**Signal peptide:**

amino acids 1-33

**Transmembrane domain:**

amino acids 671-692

**N-glycosylation sites.**

amino acids 45-49, 55-59, 187-191, 200-204, 204-208, 264-268,  
387-391, 417-421, 435-439, 464-468, 506-510, 530-534, 562-566,  
573-577, 580-584, 612-616

**Glycosaminoglycan attachment site.**

amino acids 404-408

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 232-236

**N-myristoylation site.**

amino acids 5-11, 6-12, 9-15, 29-35, 61-67, 120-126, 146-152,  
168-174, 205-211, 294-300, 438-444, 446-452, 504-510, 576-582

203/550

**FIGURE 203**

GCTAGACCGAGCCCTGGGAGGCTACGGGCTCCCCCGGAAACCCTGCCAGGGGAGCCGGGTTTT  
GAGCTCAGGCGCCTCTAGCGGCGGCCCCAGAAATCTGACTCGCGAGGCCAGAGTTGCAGGGA  
CTGAATAGCAAACCTGAGGCTGAGTAGGGAACAGACCATGAGGTCAGTGCAGATCTTCCTCTCC  
CAATGCCGTTTGCTCCTTCTACTAGTTCCGACAATGCTCCTTAAGTCTCTTGGCGAAGATGTA  
ATTTTTACCCCTGAAGGGGAGTTTGACTCGTATGAAGTCACCATTCTTGAGAAGCTGAGCTTC  
CGGGGAGAGGTGCAGGGTGTGGTCAGTCCCGTGTCTTACCTACTGCAGTTAAAAGGCAAGAAG  
CACGTCCTCCATTTGTGGCCCAAGAGACTTCTGTTGCCCCGACATCTGCGCGTTTTCTCCTTC  
ACAGAACATGGGGAACCTGCTGGAGGATCATCCTTACATAACCAAGGACTGCAACTACATGGGC  
TCCGTGAAAGAGTCTCTGGACTCTAAAGCTACTATAAGCACATGCATGGGGGGTCTCCGAGGT  
GTATTTAACATTGATGCCAAACATTACCAAATTGAGCCCCCTCAAGGCCTCTCCAGTTTTGAA  
CATGTCGTCTATCTCCTGAAGAAAGAGCAGTTTGGGAATCAGGTTTGTGGCTTAAGTGATGAT  
GAAATAGAATGGCAGATGGCCCCCTTATGAGAATAAGGCGAGGCTAAGGGACTTTCCTGGATCC  
TATAAACACCCAAAGTACTTGAATTGATCCTACTCTTTGATCAAAGTAGGTATAGGTTTGTG  
AACAACAATCTTTCTCAAGTCATACATGATGCCATTCTTTTACTGGGATTATGGACACCTAC  
TTTCAAGATGTTTCGTATGAGGATACACTTAAAGGCTCTTGAAGTATGGACAGATTTTAAACAA  
ATACGCGTTGGATATCCAGAGTTAGCTGAAGTTTTAGGCAGATTTGTAATATATAAAAAAAGT  
GTATTAATGCTCGCCTGTCATCAGATTGGGCACATTTATATCTTCAAAGAAAATATAATGAT  
GCTCTTGATGGTTCGTTTTGGAAAAGTGTGTTCTCTAGAATATGCTGGATCAGTGAGTACTTTA  
CTAGATACAAATATCCTTGCCCCCTGCTACCTGGTCTGCTCATGAGCTGGGTCATGCTGTAGGA  
ATGTCACATGATGAACAATACTGCCAATGTAGGGGTAGGCTTAATTGCATCATGGGCTCAGGA  
CGCACTGGGTTTAGCAATTGCAGTTATATCTCTTTTTTAAACATATCTCTTCGGGAGCAACA  
TGTCTAAATAATATCCCAGGACTAGGTTATGTGCTTAAGAGATGTGGAAACAAAATTGTGGAG  
GACAATGAGGAATGTGACTGTGGTTCACAGAGGAGTGTGAGAAAGATCGGTGTTGCCAATCA  
AATTGTAAGTTGCAACCAGGTGCCAAGTGTAGCATTGGACTTTGCTGTCTATGATTGTTCGGTTT  
CGTCCATCTGGATACGTGTGTAGGCAGGAAGGAAATGAATGTGACCTTGCAGAGTACTGCGAC  
GGGAATTCAAGTTCTTGCCCAATGACGTTTATAAGCAGGATGGAACCCCTTGCAAGTATGAA  
GGCCGTTGTTTCAGGAAGGGGTGCAGATCCAGATATATGCAGTGCCAAAGCATTTTTGGACCT  
GATGCCATGGAGGCTCCTAGTGAGTGCTATGATGCAGTTAACTTAATAGGTGATCAATTTGGT  
AACTGTGAGATTACAGGAATTCGAAATTTAAAAAGTGTGAAAGTGCAATTCAATATGTGGC  
AGGCTACAGTGTATAAATGTTGAAACCATCCCTGATTTGCCAGAGCATACGACTATAATTTCT  
ACTCATTTACAGGCAGAAAATCTCATGTGCTGGGGCACAGGCTATCATCTATCCATGAAACCC  
ATGGGAATACCTGACCTAGGTATGATAAATGATGGCACCTCCTGTGGAGAAGGCCGGGTATGT  
TTTAAAAAAATTGCGTCAATAGCTCAGTCCTGCAGTTTGACTGTTTGCCTGAGAAATGCAAT  
ACCCGGGGTGTGTTGCAACAACAGAAAAAAGTGGCACTGCATGTATGGGTGGGCACCTCCATTC  
TGTGAGGAAGTGGGGTATGGAGGAAGCATTGACAGTGGGCCTCCAGGACTGCTCAGAGGGGCG  
ATTCCCTCGTCAATTTGGGTGTGTCCATCATTAATGTTTCGCCTTATTTTATTAATCCTTTCA  
GTGGTTTTTGTGTTTTTCCGGCAAGTGATAGGAAACCACTTAAACCCAAACAGGAAAAAATG  
CCACTATCCAAAGCAAAAAGTGAACAGGAAGAATCTAAAACAAAAGTGTACAGGAAGAATCT  
AAAACAAAAGTGGACAGGAAGAATCTGAAGCAAAAAGTGGACAGGAAGAATCTAAAGCAAAA  
ACTGGACAGGAAGAATCTAAAGCAAAAGTGAAGTAAACGACCCAAAGCAAGAGTGTCAAG  
AAACAAAAAAGTAAACCGGGCAATCCATACTCATTTCAGTAACACAGGCTCATTTATTTAACCA  
GCTAATCATTTATCCAAAGGCTTTCATTCTTCTCCCAATATTTTTTTACTTTAATTTTTTCCC  
ACAAGTTTTGATCAGCAATAAACAGCATTCTTGTTTTGGAAACAAAAA

204/550

**FIGURE 204**

MRSVQIFLSQCRLLLLLVPTMLLKS LGEDVIFHPEGEFDSYEVTIPEKLSFRGEVQGVVSPVS  
YLLQLKGKKHVLHLWPKRLLLPRHLRVFSFTEHGELLEDPYIPKDCNYMGSVKESLDSKATI  
STCMGGLRGVFNIDAKHYQIEPLKASPSFEHV VYLLKKEQFGNQVCGLSDDEIEWQMAPYENK  
ARLRDFPGSYKHPKYLELILLFDQSR YRFVNNNLSQVIHDAILLTGIMDTYFQDVRMRIHLKA  
LEVWTD FNKIRVGYPELAEVLGRFVIYKKSVLNARLSSDWAHLYLQ RKYNDALAWSFGKVCSL  
EYAGSVSTLLDTNILAPATWSAHELGHAVGMSHDEQYCQCRGRLNCIMGSGRTGFSNCSYISF  
FKHISSGATCLNNIPGLGYVLKRCGNKIVEDNEECDCGSTEECQKDRCCQSNCKLQPGANCSI  
GLCCHDCRFRPSGYVCRQEGNECDLAEYCDGNSSSCPNDVYKQDGT PCKYEGRCFRKGCRSRY  
MQCQSIFGPDAMEAPSECYDAVN LIGDQFGNCEITGIRNFKKCESANSICGR LQCINVETIPD  
LPEHTTIISTHLQAENLMCWGTGYHLSMKPMGIPDLGMINDGTSCGEGRVCFKKNCVNSSVLQ  
FDCLPEKCNTRGVCNNRKNCHCMYGWAPPFCEEVGYGGSIDSGPPGLLRGAIPSSIWVVSIIIM  
FRLILLILSVVFVFFRQVIGNHLKPKQEKMPLSKAKTEQEESKTKTVQEESKTKTGQE ESEAK  
TGQEESKAKTGQEESKANIESKRPKAKSVKKQKK

**Signal peptide:**

amino acids 1-27

**Transmembrane domain:**

amino acids 684-705

**N-glycosylation sites.**

amino acids 222-226, 372-376, 438-442, 473-477, 625-629

**N-myristoylation sites.**amino acids 131-137, 168-174, 235-241, 319-325, 364-370, 436-442,  
472-478, 609-615, 642-648, 668-674, 676-680, 680-686, 749-755,  
758-764, 767-773**Amidation site.**

amino acids 69-73

**Disintegrins proteins**

amino acids 429-479

**EGF-like domain proteins**

amino acids 650-662

**Neutral zinc metallopeptidases, zinc-binding region proteins**

amino acids 335-345

205/550

**FIGURE 205**

CGGACGCGTGGGCGGACGCGTGGGCGGACGCGTGGGGGAAGGTTGAATGGGGTAGAAGGCCTG  
TTGTGGAGGGGAAACCACCCATCCTCCTGCCTCCACCACCACCATCATCCTGGCTGGACGGAG  
AGGGTGACGGGGGCTGGGAAGGGGCAGCTCATGTTCAAGTTTCCAGGAGGGGCTACCTGTTGA  
CTGTCTTTGCAGGAAGAAGAAAACACCTGAGTGACCAGATGTCCCAGCTCCAGGTGCCTTGCC  
AGATGGCCAGAACCACACCTCTTGAAGAGTGACAGTGCTGTGGAGCATGGTTTCTGCACACCT  
GGAATGACTGGAACCCCAAGACTCAAGAAGGAGCTAAAGATCTTGAAGTAGACATGAATAAA  
ACAGAAGGCTGTGGACCACCTGTGAGATGGAGAAGTCCTTCTGAGGCTATCCAAACACGGAC  
CAGGCCATGAGACCCCGATGACCATCCCTGAATTTTTTCGAGAGTCAGTCAACCGATTGGA  
CTTATCCAGCCCTCCCATCCAAGAATGGCAAAAAGTGGGAAATTCTGAATTTCAACCAGTACT  
ATGAGGCTTGTGCGAAGGCTGCAAAATCCTTGATCAAGCTGGGTTTGGAGCGTTTCCACGGAG  
TTGGTATCCTGGGGTTTAACTCTGCAGAGTGTTTATCACTGCTGTTGGTGCCATCCTAGCCG  
GGGGTCTTTGTGTTGGTATTTATGCCACCAACTCTGCCGAGGCTTGTCAATATGTCATCACTC  
ATGCCAAAGTGAACATCTTGCTGGTTGAGAATGATCAACAGTTACAGAAAATCCTTTCGATTC  
CACAGAGCAGCCTAGAGCCCCTAAAAGCGATCATCCAGTACAGACTGCCAATGAAGAAGAACA  
ACAACCTTGACTCTTGGGATGATTTTATGGAACCTGGCAGAAGTATCCCTGACACCCAACTGG  
AGCAGGTCATCGAGAGCCAGAAGGCGAATCAATGCGCAGTGCTCATCTACACTTCAGGGACCA  
CAGGCATACCCAAGGGAGTGATGCTCAGTCATGACAACATCACGTGGATTGCAGGAGCAGTGA  
CAAAGGACTTTAAACTGACAGACAAGCATGAGACGGTGGTTAGCTACCTCCCACTCAGCCATA  
TTGCAGCACAGATGATGGACATCTGGGTACCCATAAAGATTGGGGCGCTCACATACTTTGCTC  
AAGCAGATGCTCTCAAGGGCACCTTGGTAAGTACTCTAAAGGAGGTAACCTACTGTCTTCA  
TTGGAGTGCCTCAAATTTGGGAGAAGATACATGAGATGGTGAAGAAAAATAGTGCCAAGTCCA  
TGGGCTTGAAGAAGAAGGCATTCGTGTGGGCAAGAAACATTGGCTTCAAGGTCAACTCAAAAA  
AGATGTTGGGGAAATATAATACTCCCGTGAGCTACCGCATGGCTAAGACTCTCGTGTTCAGCA  
AAGTCAAGACATCCCTTGGCTTGGATCACTGTCACTCTTTTATCAGTGGGACTGCGCCCCTCA  
ACCAAGAGACTGCCGAGTTCTTTCTAAGCTTGGACATACCTATAGGCGAGTTGTATGGGTTGA  
GTGAGAGCTCGGGACCCACACGATATCCAACCAGAATAACTACAGGCTTCTAAGCTGTGGCA  
AGATCTTGACTGGGTGTAAGAATATGCTGTTCCAGCAGAACAAGGATGGCATTGGGGAGATCT  
GCCTCTGGGGTAGGCACATCTTCATGGGCTATCTGGAAAGTGAGACTGAAACTACAGAGGCCA  
TCGATGATGAAGGCTGGCTACACTCTGGGGATCTGGGCCAGCTGGACGGTCTGGGTTTCTCTCT  
ATGTCACCGGCCACATCAAAGAAATCCTTATCACTGCTGGTGGTGAAAATGTGCCCCCATTC  
CTGTTGAGACCTTGGTTAAGAAGAAGATCCCCATCATCAGTAACGCCATGTTAGTAGGAGATA  
AACTGAAGTTTCTGAGCATGTTGCTGACGCTGAAGTGTGAGATGAATCAGATGAGCGGAGAAC  
CTCTGGACAAGCTGAACTTCGAGGCCATCAACTTCTGTGCGGGTCTGGGCAGCCAGGCATCCA  
CCGTGACTGAGATTGTGAAGCAGCAAGACCCCCTGGTCTACAAGGCCATCCAGCAAGGCATCA  
ATGCTGTGAACCAGGAAGCCATGAACAATGCACAGAGGATTGAAAAGTGGGTCATCTTGGAGA  
AGGACTTTTCCATCTATGGTGGAGAGCTAGGTCCAATGATGAACTTAAGAGACATTTTGTAG  
CCCAGAAATACAAAAACAAATTGATCACATGTACCCTGACTGCTTTGATGGAGCTGCTCTC  
AGCTGTTCTGATGCCTTCAGCAGGAAGACCTCATTGCAATAAGTGAAATGCTGCTCTAGGTAG  
AAGCTCTCCCTGCTGTTTTTAAGAAGCCACATTCCTCATTGGTCAGTTTCTTGATTGTTTCGTC  
TGTTGGAGAGGTGCTCCCTAGAAGAACCTGCCATACGTTTTCAAAGCAATAAAATCACTGTATA  
TCTTTCTAAGGACCTTCAAGTCATGACTCCAGGGAAGCCTATTGGGAAGTCTACTAAAACTG  
CCTGATTTACAAGAAAGACCTGAACTTGTGGGCTCCCATTTGATTTTTTCTCCTCAGGGGAC  
TCAGACATTAGAAAGAAAAAGCCTCACAGATTTGAAGAACTGGACCCCAATCAACTCACCT  
GCCTGGAAGCAACTGGGAAACCCTTCCAATAAGTCCTGATAATAAAGCACTTCAGGGTCCCAA  
AAAAAAAAAA



206/550

**FIGURE 206**

MTIPEFFRESVNRFGTYPALPSKNGKKWEILNFNQYYEACRKAASLIKGLERFHGVGILGF  
NSAEWFITAVGAILAGGLCVGIYATNSAEACQYVITHAKVNILLVENDQQLQKILSIPQSSLE  
PLKAI IQYRLPMKKNNNLYSWDDFMELGRSIPDTQLEQVIESQKANQCAVLIYTS GTTGIPKG  
VMLSHDNITWIAGAVTKDFKLTDKHETVVSYLPLSHIAAQMMDIWVPIKIGALTYFAQADALK  
GTLVSTLKEVKPTVFIGVPQIWEKIHVMVKKNSAKSMGLKKKAFVWARNIGFKVNSKKMLGKY  
NTPVSYRMAKTLVFSKVKTS LGLDHCHSFISGTAPLNQETAEFFLSLDIPIGELYGLSESSGP  
HTISNQNNYRLLSCGKILTGCKNMLFQQNKDGIGEICLWGRHIFMGYLESETETTEAIDDEGW  
LHSGDLGQLDGLGFLYVTGHIKEILITAGGENVPPIPVETLVKKKIPIISNAMLVGDKLKFLS  
MLLTLKCEMNQMSGEPLDKLNFEAINFCRGLGSQASTVTEIVKQQDPLVYKAIQQGINAVNQE  
AMNNAQRIEKWVILEKDFS IYG GELGPMMLKRHFVAQKYKKQIDHMYH

**Signal peptide:**

amino acids 1-22

**Transmembrane domain:**

amino acids 65-86

**N-glycosylation site.**

amino acids 196-200

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 282-286

**Tyrosine kinase phosphorylation sites.**

amino acids 547-555, 608-616

**N-myristoylation sites.**amino acids 15-21, 74-80, 80-86, 84-90, 185-191, 189-195,  
253-259, 337-343, 371-377, 448-454, 536-542**Amidation site.**

amino acids 24-28

**Putative AMP-binding domain signature.**

amino acids 177-189

**Putative AMP-binding domain proteins.**

amino acids 173-190

207/550

FIGURE 207

CCCACGCGTCCGCCCACGCGTCCGCGGACGCGTGGGGCCAGATCGCGGCCGGCGCCAGCGCCA  
CCGTCCGGTCCACCCGCCAGCCCGCACAGCCGCGCCGCGCCGAGCGTTTCGTGAGCGGCGCT  
CCGAGGATCAGGAATGGGGCTTCGGGCGCTGGGCGCGCTCCGAACCCGGCGCACGTAAGAGCC  
TGGGAGCGCCCCGAGCCGCCCGGCTGCCCGGAGCCCCATCGCCTAGGACCGGGAGATGCTGGAA  
ATGCAACCGCCTGTTCCTCCGAGGAGCGCTGCCCCGGGACCCCCCTGGCACTGTGCGCACCCCT  
GGTCAGCAGCCCCCGGAGAAGACGGCGCCCCCAACGCCCCGACCGCGTGGCCGTGGCAGCGCC  
ACGCGAGCCCTCTAGGCGACCGCAGGGCCACAGCAGCTCAGCCGCCGGTGGCCCCCTCGGAAAC  
CATGACCCCCGGCGCGGGGCCCATGGAGCCATGGCCTATAGGGTCTTGGGCCGCGCGGGGCCAC  
CTCAGCCGCGGAGGGCGCGCAGGCTGCTCTTCGCCTTCACGCTCTCGCTCTCCTGCACTTACC  
TGTGTTACAGCTTCCTGTGCTGCTGCGACGACCTGGGTGCGAGCCGCCTCCTCGGCGCGCCTC  
GCTGCCTCCGCGGCCCCAGCGCGGGCGGCCAGAACTTCTCCAGAAGTCCCGCCCCCTGTGATC  
CCTCCGGGCGGACGCCCAGCGAGCCAGCGCTCCAGCGCGCCCCGCGCGCCGTGCCCGCCC  
CTCGCCTCTCCGTTCCAACCACTCCGGCTCACCCAAGCTGGGTACCAAGCGGTTGCCCCAAG  
CCCTCATTTGTGGGCGTGAAGAAGGGGGGCACCCGGGCCGTGCTGGAGTTTATCCGAGTACACC  
CGGACGTGCGGGCCTTGGGCACGGAACCCCACTTCTTTGACAGGAACTACGGCCGCGGGCTGG  
ATTGGTACAGGAGCCTGATGCCCAGGACCCTCGAGAGCCAGATCACGCTGGAGAAGACGCCCA  
GCTACTTTGTCACTCAAGAGGCTCCTCGACGCATCTTCAACATGTCCCGAGACACCAAGCTGA  
TCGTGGTTGTGCGGAACCCTGTGACCCGTGCCATCTCTGATTACACGCAGACACTCTCCAAGA  
AGCCCGACATCCCGACCTTTGAGGGCCTCTCCTTCCGCAACCGCACCCCTGGGCCTGGTGGACG  
TGTCATGGAACGCCATCCGCATCGGCATGTACGTGCTGCACCTGGAGAGCTGGCTGCAGTACT  
TCCCGCTAGCTCAGATTCACTTCGTGAGTGGCGAGCGACTCATCACTGACCCGGCCGGCGAGA  
TGGGGCGAGTCCAGGACTTCCTGGGCATTAAGAGATTTCATCACGGACAAGCACTTCTATTTCA  
ACAAGACCAAAGGATTCCCTTGCTTGAAAAAACAGAATCGAGCCTCCTGCCTCGATGCTTGG  
GCAAATCAAAGGGAGAATCATGTACAGATTGATCCTGAAGTGATAGACCAGCTCCGAGAAT  
TTTATAGACCGTATAATATCAAATTTTATGAAACCGTTGGGCAGGACTTCAGGTGGGAATTAAG  
CCCACGAAAGGAAAGGGCTCTCAAGGGCTCTTCTGCTCATCTCTTCCGTGAGATTTGCTCCCA  
GACCCTCTGATCTCCCTCCAACAAACCCTGGCTCCAGCCCCCTTCCCAACTTGAGTTGCATC  
ATCTTGGAACCAGGAAGCCAGCTAAAGCCAAGAGACCAGAGAGTCCCTGCCACTAGTTTTCA  
TCAGTCTGTTCAAGCAAAGTTGATCTGCTCCTGGCACGTCCAGTAAATTCCAGAATCATTCTC  
CTTTCTGCCCATAAAGGGCCTTGGAGAATTGCTTTAAGAAGAGTGAATGTTCCAATGATGATA  
GATATTATAAGCGATGATGGTTCTGTTGCTATGAACACAGCAGTCGGTCCCTGTCAATTGTCCA  
CCCAGGAGTGGCCTTGTTAATTCAGAGTGGCATGTATCTTCCCTCTGAGCTTCATTTCTTCAA  
GATGCTCTGGGTGGTGGGATGGGAGACCATCCTCAGCCCTCCTCAGACCTTATCAATTCATTG  
AGAGATTGCAAAGCTGAAAGCACCTCCGGCCACTCCTGGGAGACAGACCCTTTGGTGATGAAA  
TAAACCAGTGACTTCAGAGCCTATGGTCTCAACTGTGCTTGAAAAACACTGTCTCTGAAAAACA  
ACTTTGTGATTCTCCCTGCTCCCTGTGGACAAAAGCACATAATTCTGCTGTTACGGGTACTTT  
GCTCATACGAGCTTTCATGTTCAAGCATGCAATGGAATCATGCTTGTCCATGTGAAATAAATAT  
GGCTCTCTCGTGTCTTAATGCTGGGCTTTTCTCTGTAAGCTGGTTCTGCAGCACAATTCATT  
AATTAACCTTCTCCAGTGCAAGAAGGCAGCTGGTGCTGGGGGTGGTCTGGGGGGTCAGGGAG  
GAGGGCAAGGACTACATGGGGCAGAGGCAAGGCGGTGGTGGAGATGAGGAAAGAAGTTCTTCT  
TGGCAGAAGCTGGGGCAGAAAGATCACATGAGATCTGTGGGGACACCCTCTATCTGAAACATA  
AGTCTGTGTTCACTCTCTGCTTAGAAATTTTAGATCTGAAGTGCTACACTGAAGGTCCGAAGG  
TTGATGGGGCATCAGATATCTTTTTGGTTGGCCAGCATGATATTTTGAAATAACTGTCAACAG  
TTAGAAACTGGGAGCATTCATATGTAAAAAATATGGATTTTTCAGCTTCTTCTTAAAAA  
AAA  
AAAAAAAAAA

208/550

**FIGURE 208**

MAYRVLGRAGPPQPRRARRLLFAFTLSLSCTYLCYSFLCCDDLGRSRLLGAPRCLRGPSAGG  
QKLLQKSRPCDPSGPTPSEPSAPSAPAAAVPAPRLSGSNHSGSPKLGTKRLPQALIVGVKKGG  
TRAVLEFIRVHPDVRLGTEPHFFDRNYGRGLDWYRSLMPRTLESQITLEKTPSYFVTQEAPR  
RIFNMSRDTKLIVVVRNPVTRAISDYTQTLSKKPDIPTFEGLSFRNRTLGLVDVSWNAIRIGM  
YVLHLESWLQYFPLAQIHVSGERLITDPAGEMGRVQDFLGIKRFITDKHFYFNKTKGFPCLK  
KTESSLLPRCLGKSKGRTHVQIDPEVIDQLREFYRPYNIKFYETVGQDFRWE

**Signal peptide:**

amino acids 1-33

**N-glycosylation sites.**

amino acids 102-106, 193-197, 235-239, 306-310

**Tyrosine kinase phosphorylation site.**

amino acids 296-305

**N-myristoylation sites.**

amino acids 51-57, 100-106, 121-127, 125-131

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 20-31

209/550

FIGURE 209

CTTTCCTTATCTGTGTGTACTCTTATCTCACTGTTCTATTTTTTCTCCTCATTTATATTA  
CTTTCCTTACCTTTTTTTCTGAACCTTCTAGGCCTTCTCTTCCAGAACTGGTGGAAAGACAAATG  
AAACGGCCAAGATGGTAAGAAACAAGCCGCATTTCTCCTTGGGGAGACTGATAATTTAAAAGG  
TTTGTTGTGTGAGAAACATTCCCAGCTTCATCACCAACCCTTTCCTTCCACCTCTGCCCCACTG  
GAGACCACTTACATCCCGAAGCGGACGCGGCAGCTGAAGTCAGGAAACCATGCATCACATTAG  
CAGGAGCCAACCTGCAGACTTTAAACTCCGTTCAACATGTGGATGCGGCAGAGAAATGACCTGT  
CCAGACAAGCCGGGGCAGCTCATAAACTGGTTCATCTGCTCCCTGTGCGTCCCGCGGGGTGCGT  
AAGCTCTGGAGCAGCCGGCGTCCAAGGACCCGGAGAAACCTTCTGCTGGGCACTGCGTGTGCC  
ATCTACTTGGGCTTCTGCTGGTGGAGCCAGGTGGGGAGGGCCTCTCTCCAGCATGGACAGGCGGCT  
GAGAAGGGGGCCACATCGCAGCCGCGACACCGCCGAGCCATCCTTCCCTGAGATACCCCTGGAT  
GGTACCCTGGCCCCCTCCAGAGTCCCAGGGCAATGGGTCCACTCTGCAGCCCAATGTGGTGTAC  
ATTACCCTACGCTCCAAGCGCAGCAAGCCGGCCAATATCCGTGGCACCGTGAAGCCCAAGCGC  
AGGAAAAAGCATGCAGTGGCATCGGCTGCCCCAGGGCAGGAGGCTTTGGTTCGGACCATCCCTT  
CAGCCGCAGGAAGCGGCAAGGGAAGCTGATGCTGTAGCACCTGGGTACGCTCAGGGAGCAAAC  
CTGGTTAAGATTGGAGAGCGACCCTGGAGGTTGGTGCGGGGTCCGGGAGTGCGAGCCGGGGGC  
CCAGACTTCCCTGCAGCCAGCTCCAGGGAGAGCAACATTAGGATCTACAGCGAGAGCGCCCCC  
TCCTGGCTGAGCAAAGATGACATCCGAAGAATGCGACTCTTGGCGGACAGCGCAGTGGCAGGG  
CTCCGGCCTGTGTCTCTAGGAGCGGAGCCCGTTTGTCTGGTGTGAGGGGGGGCGCACCTGGC  
GCTGTGCTCCGCTGTGGCCCTAGCCCTGTGGGCTTCTCAAGCAGCCCTTGGACATGAGTGAG  
GTGTTTGCCTTCCACCTAGACAGGATCCTGGGGCTCAACAGGACCCTGCCGTCTGTGAGCAGG  
AAAGCAGAGTTCATCCAAGATGGCCGCCCATGCCCCATCATTCTTTGGGATGCATCTTTATCT  
TCAGCAAGTAATGACACCCATTCTTCTGTTAAGCTCACCTGGGGAACCTTATCAGCAGTTGCTG  
AAACAGAAATGCTGGCAGAATGGCCGAGTACCCAAGCCTGAATCAGGTTGTACTGAAATACAT  
CATCATGAGTGGTCCAAGATGGCACTCTTTGATTTTTTGTACAGATTTATAATCGCTTAGAT  
ACAAATTGCTGTGGATTTCAGACCTCGCAAGGAAGATGCCTGTGTACAGAATGGATTGAGGCCA  
AAATGTGATGACCAAGGTTCTGCGGCTCTAGCACACATTATCCAGCGAAAGCATGACCCAAGG  
CATTTGGTTTTTTATAGACAACAAGGGTTTTCTTTGACAGGAGTGAAGATAACTTAACTTCAA  
TTGTTAGAAGGCATCAAAGAGTTTCCAGCTTCTGCAGTTTCTGTTTTGAAGAGCCAGCACTTA  
CGGCAGAAACTTCTTCAGTCTCTGTTTCTTGATAAAGTGTATTGGGAAAGTCAAGGAGGTAGA  
CAAGGAATTGAAAAGCTTATCGATGTAATAGAACACAGAGCCAAAATTCTTATCACCTATATC  
AATGCACACGGGGTCAAAGTATTACCTATGAATGAATGACAAAAGAATCTTCTGGCTAGGGTG  
TTAGATATATTTATGCATTTTTTGGTTTTTGTAAAAATCAAGCACATCAACCTCAAGCCCGTT  
TAGCAATGAGGCAGTGTAGATGAATACGTAAAATAAATGACTTTAACCAAGTAGCTATAAAGG  
GACTTAGCACTGTATGCATACTTAAAAAGGTTTTGAAAAACAACTACTTGAGAAATATTTGT  
TTATATTTTTTCTCTAACATCATGCTATGTGTGAGTCTGAACATCTGACAACAGAAATTTTCACT  
TATTATTCTAGCTAAGTTTTGAAAACATTTGTGCTGCTGTTTAAATAGAAAACCTGCAAACCAGA  
GATACTGACTCCATTAATAAACCATATTTTGTGCCGTTTTGACTGTTCTGACCAAATACTAAT  
GGGAACAATTCTTGACGTTTTTCTGTTGCTGATTGTTAACATAGAGCAGTCTCTACACTACCC  
TGAGGCAACTCTACATTGGAACACTGAGGCTTACAGCCTGCAAGAGCATCAGAGCTGACCATA  
CATTTAAACAGAAATGCTGGTTTTATTTGCAAAATCACCAGTATATTTTCTATTGTGTCTATAA  
AAAATCAGTCATTTAAGTACAAGAATCATATTTTCCATTCCCTTTTTAGAAATTTATTTTGTG  
TCCCTATGGAAATCATTCACATCTGACAATTTATATGTTAAAGAGTTTTACTCTCTCTATTTT  
GGTCCAATTTGTATCTAGTGGCTGAGAAATTAAATAAATTCTAAAGTATGAAGTTACCTATCTG  
AAAATGTACTTACAGAGTATCATTTTAAATGGATGTCTCTTAAAAATTTTGTACTTTTAC  
CAACAATGTAATATAATTTATGTATATTTTATTAATAATAGTGAATTCCTTAAATTTGTTCT  
ATGTACTTATATTTAATTTGATTTAATGGTTACTGCCAGATATTGAGAAATGGTTCAAATAT  
TGAGTGTGTTTCAATAA

210/550

FIGURE 210

MTCPDKPGQLINWFICSLCVPRVRKLWSSRRPRTRRNLLLTACAIYLGFLVSQVGRASLQHG  
QAAEKGPHRSDTAEPSFPEIPLDGTLAPPESQNGSTLQPNVVYITLSKRSKPANIRGTVK  
PKRRKKHAVASAPGQEALVGPSLQPQEAAREADAVAPGYAQGANLVKIGERPWRLVRGPGVR  
AGGPDFLQPSSRESNIRIYSESAPSWLSKDDIRRMRLADS AVAGLRPVSSRSGARLLVLEGG  
APGAVLRCGPSPCGLLKQPLDMSEVFAFHLDRI LGLNRTLPSVSRKAEFIQDGRPCPIILWDA  
SLSSASNDTHSSVKLTWGTYQQLLKQKCWQNGRVKPKESGCTEIHHEWSKMALFDLLQIYN  
RLDTNCCGFRPRKEDACVQNGLRPKCDDQGSAA LAHIIQRKHDPRLV FIDNKGFFDRSEDNL  
NFKLLLEGIKEFPASAVSVLKSQHLRQKLLQSLFLDKVYWESQGG RQGIEKLIDVIEHRAKILI  
TYINAHGVKVLPMNE

**Transmembrane domain:**

amino acids 40-56

**N-glycosylation sites.**

amino acids 98-102, 289-293, 322-326

**N-myristoylation sites.**amino acids 8-14, 41-47, 97-103, 187-193, 251-257, 252-258,  
287-293, 484-490

211/550

**FIGURE 211**

GTGGGGTGGTGAGCGCAGCGCCGAGGATGAGGAGGTGCAACAGCGGCTCCGGGGCCGCGCCGCTCGCTGCTGCTGC  
TGCTGCTGTGGCTGCTCGCGGTTCCCGGCGCTAACGCGGCCCCGCGGTGGGCGCTCTATTGCGCTTCCGACCCGC  
TGACGCTGCTGCAGGCGGACACGGTGCGCGGCGCGGTGCTGGGCTCCCGCAGCGCCTGGGCGGTGGAGTTCTTCG  
CCTCCTGGTGCGGCCACTGCATCGCCTTCGCCCCGACGTGGAAGGCGCTGGCCGAAGACGTCAAAGCCTGGAGGC  
CGGCCCTGTATCTCGCCGCCCTGGACTGTGCTGAGGAGACCAACAGTGCAGTCTGCAGAGACTTCAACATCCCTG  
GCTTCCCGACTGTGAGGTTCTTCAAGGCCTTTACCAAGAACGGCTCGGGAGCAGTATTTCCAGTGGCTGGTGCTG  
ACGTGCAGACGCTGCGGGAGAGGCTCATTGACGCCCTGGAGTCCCATCATGACACGTGGCCCCCAGCCTGTCCCC  
CACTGGAGCCTGCCAAGCTGGAGGAGATTGATGGATTCTTTGCGAGAAATAACGAAGAGTACCTGGCTCTGATCT  
TTGAAAAGGGAGGCTCCTACCTGGGTAGAGAGGTGGCTCTGGACCTGTCCCAGCACAAAGGCGTGGCGGTGCGCA  
GGGTGCTGAACACAGAGGCCAATGTGGTGAGAAAGTTGGTGTACCGACTTCCCCTCTTGCTACCTGCTGTTCC  
GGAATGGCTCTGTCTCCCGAGTCCCCGTGCTCATGGAATCCAGGTCCTTCTATACCGCTTACCTGCAGAGACTCT  
CTGGGCTCACCAGGGAGGCTGCCCAGACCACAGTTGCACCAACCACTGCTAACAAGATAGCTCCCACTGTTTGA  
AATGGCAGATCGCTCCAAGATCTACATGGCTGACCTGGAATCTGCACTGCACTACATCCTGCGGATAGAAGTGG  
GCAGGTTCCCGGCTCCTGGAAGGGCAGCGCCTGGTGGCCCTGAAAAAGTTTGTGGCAGTGCTGGCCAAGTATTTCC  
CTGGCCGGCCCTTAGTCCAGAACTTCTGCACTCCGTGAATGAATGGCTCAAGAGGCAGAAAGAGAAATAAAATTC  
CCTACAGTTTCTTTAAAACTGCCCTGGACGACAGGAAAGAGGGTGCCGTTCTTGCCAAGAAGTGAACCTGGATTG  
GCTGCCAGGGGAGTGAGCCGCATTTCCGGGGCTTCCCTGCTCCCTGTGGGTCTCTTCCACTTCTTGACTGTGC  
AGGCAGCTCGGCAAAATGTAGACCACTCACAGGAAGCAGCCAAGGCCAAGGAGGTCTCCCAGCCATCCGAGGCT  
ACGTGCACTACTTCTTCGGCTGCCGAGACTGCGCTAGCCACTTCGAGCAGATGGCTGCTGCCCTCCATGCACCGGG  
TGGGGAGTCCCAACGCCGCTGTCTCTGGCTCTGGTCTAGCCACAACAGGCTCAATGCTCGCCTTGCAAGTGGCC  
CCAGCGAGGACCCCAAGTTCCCAAGGTGCAGTGGCCACCCCGTGAACCTTGTCTGCTGCCACAATGAACGCC  
TGGATGTGCCGCTGTGGGACGTGGAAGCCACCCCTCAACTTCCTCAAGGCCCACTTCTCCCCAAGCAACATCATCC  
TGGACTTCCCTGCAGCTGGGTGAGCTGCCCCGAGGGATGTGCAGAATGTGGCAGCCGCCCCAGAGCTGGCGATGG  
GAGCCCTGGAGCTGGAAAGCCGGAATTCAACTCTGGACCCTGGGAAGCCTGAGATGATGAAGTCCCCCACAACA  
CCACCCACATGTGCCGGCTGAGGGACCTGAGGCAAGTCGACCCCCGAAGCTGCACCCCTGGCCTCAGAGCTGCAC  
CAGGCCAGGAGCCTCCTGAGCACATGGCAGAGCTTCAGAGGAATGAGCAGGAGCAGCCGCTTGGGCAGTGGCACT  
TGAGCAAGCGAGACACAGGGGCTGCATTGCTGGCTGAGTCCAGGGCTGAGAAGAACCCTCTGGGGCCCTTTGG  
AGGTGAGGCGCTGGGCGCAGCTCCAAGCAGCTGGTCGACATCCCTGAGGGCCAGCTGGAGGCCGAGCTGGAC  
GGGCGCAGGCCAGTGGCTGCAGGTGCTGGGAGGGGGCTTCTCTTACCTGGACATCAGCCTCTGTGTGGGGCTCT  
ATTCCCTGTCTTCATGGGCCTGCTGGCCATGTACACCTACTTCCAGGCCAAGATAAGGGCCCTGAAGGGCCATG  
CTGGCCACCCCTGCAGCCTGAACACCTGGGGAGGAGGCGGGAGAGGGAGCTGCCATCTCTAGGCACCTCAAGCCC  
CCTGACCCCATTCCTCCCCTCCCACCCCTTGCTCCTTGTCTGGCCTAGAAGTGTGGGAAATTCAGGAAAACGAG  
TTGCTCCAGTGAAGCTTCTTGGGGTTGCTAGGACAGAGAGCTCCTTTGACACAAAAGACAGGAGCAGGTCAGG  
TTCCCTGCTGTGCAGGGAGGGCAGCCCCGGGCAGTGGGCATAGGGCAGCTCAGTCCCTGGCCTCTTAGCACCAC  
ATTCCTGTTTTTTCAGCTTATTTGAAGTCTGCCTCATTCTCACTGGAGCCTCAGTCTCTCTGCTTGGTCTTGGC  
CCTCAACTGGGGCAAGTGAAGCCAGAGGAGGTCCTCCAGCTGGGTGGGCTGGAATGGAACCTCTCACTAGCTGC  
TGGGGCTCCGCCCACCTGCTCCCTTCCGGACAATGAAGAAGCCTTTGCACCCTGGGAGGAAGGACCACCCCGGG  
CCCTCTATGCTGGCCAGCCTCCAGCTCCTCAGACCTCCTGGGTGGGGTTTGGCTTCAGGGTGGGGTTTGAAGC  
TTCTGGAAGTCGTGCTGGTCTCCAGGTGAGGCAAGCCATGTTGCTG3GCTGTAGGGTGAGTGGCTTGCTTGGT  
GGGACCTGACGAGTTGGTGGCATGGGAAGGATGTGGGTCTCTAGTGCCTTGGCCTGGCTTAGCTGCAGGAGAAGA  
TGGCTGCTTTCATTCCCCCATTGAGCTCTGCTCCCTCTGAGCCTGGTCTTTTGTCTTTTATTTTGGTCTC  
CAAGATGAATGCTCATCTTTGGAGGGTGCCAGGTAGAAGCTAGGGAAGGGAGTGTCTTCTCTCTCCAGGTTTAC  
CTTCCAGTGTGCAGAAGTTAGAAGGGTCTGGCGGGGCGAGTGCCTTACACATGCTTGATTCCCACGCTACCCCT  
GCCTTGGGAGGTGTGTGAATAAATTATTTTGTAAAGGCA

212/550

**FIGURE 212**

MRRCNSSGSGPPPSLLLLLLWLLAVPGANAAPRSALYSPSDPLTLLQADTVRGAVLGSRSAWAV  
EFFASWCGHCIAFAPTWKALAEDVKAWRPALYLAALDCAEETNSAVCRDFNIPGFPTVRFFKA  
FTKNGSGAVFPVAGADVQTLRERLIDALESHHDTWPPACPPLEPAKLEEIDGFFARNNEEYLA  
LIFEKGGSYLGREVALDLSQHKGVAVRRVLNTEANVVRKFGVTDFPSCYLLFRNGSVSRVPVL  
MESRSFYTAYLQRLSGLTREAAQTTVAPTTANKIAPT VWKLADRSKIYMA DLESALHYILRIE  
VGRFPVLEGQRLVALKKFVAVLAKYFPGRPLVQNFLHSVNEWLKRQKRNKIPYSFFKTALDDR  
KEGAVLAKKVNWIGCQGSEPHFRGFPCSLWVLFHFLT VQAARQNV DHSQEA AKAKEVLPAIRG  
YVHYFFGCRDCASHFEQMAAASMRV GSPNAAVLWLWSSHN RVNARLAGAP SEDPQFPKVQWP  
PRELCSACHNERLDVPVWDVEATL NFLKAHFS PNIILDFPAAGS AARRDVQNVA APELAMG  
ALELESRNSTLDPGKPEMMKSPTNTTPHVPAEGPEASRPPKLHPGLRAAPGQEPPEHMAELQR  
NEQEQLGQWHL SKRDTGAALLAESRAEKNRLWGPLEVRRVGRSSKQLVDIPEGQLEARAGRG  
RGQWLQVLGGGFSYLDISLCVGLYSLSF MGLLAM YTYFQAKIRALKGHAGHPAA

**Signal peptide:**

amino acids 1-29

**Transmembrane domain:**

amino acids 705-728

**N-glycosylation sites.**

amino acids 130-134, 243-247, 575-579

**Glycosaminoglycan attachment site.**

amino acids 6-10

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 644-648

**N-myristoylation sites.**amino acids 52-58, 56-62, 196-202, 381-387, 392-398, 448-454,  
468-474, 684-690, 702-708**Cytochrome c family heme-binding site signature.**

amino acids 509-515

**Thioredoxin family proteins**

amino acids 62-78

213/550

**FIGURE 213**

GCACGAGGCCGACTTCCAGACCATCTACAACCTGCACGGCCTGGAACAGCTTCGGCTCCGACAC  
TGAGATCATCCGGCTCAAGGAGCAAGGTTCCGAAATGAAGTCGGGAGCCGGGCTGGAAGCAGA  
GTCTGTGCCGATGGCCGTCATCATTGGGGTGGCCGTAGGAGCTGGTGTGGCCTTCCTCGTCCT  
TATGGCAACCATCGTGGCGTTCTGCTGTGCCCCGTTCCCAGAGAAATCTCAAAGGTGTTGTGTC  
AGCCAAAAATGATATCCGAGTGGAATTTGTCCACAAGGAACCAGCCTCTGGTCGGGAGGGTGA  
GGAGCACTCCACCATCAAGCAGCTGATGATGGACCGGGGTGAATTCCAGCAAGACTCAGTCCT  
GAAACAGCTGGAGGTCTCAAAGAAGAGGAGAAAGAGTTTCAGAACCTGAAGGACCCCAACAA  
TGGCTACTACAGCGTCAACACCTTCAAAGAGCACCCTCAACCCCGACCATCTCCCTCTCCAG  
CTGCCAGCCCGACCTGCGTCCTGCGGGTAAGCAGCGTGTGCCACAGGCATGTCCTTCACCAA  
CATCTACAGCACCCTGAGCGGCCAGGGCCGCCTCTACGACTACGGGCAGCGGTTTGTGCTGGG  
CATGGGCAGCTCGTCCATCGAGCTTTGTGAGCGGGAGTTCCAGAGAGGCTCCCTCAGCGACAG  
CAGCTCCTTCCTGGACACGCAGTGTGACAGCAGCGTCAGCAGCAGCGGCAAGCAGGATGGCTA  
TGTGCAGTTCGACAAGGCCAGCAAGGCTTCTGCTTCCTCCTCCCACTCCAGTCCTCGTC  
CCAGAACTCTGACCCCACTCGACCCCTGCAGCGCGGATGCAGACTCACGTCTTAAGGATCACA  
CACCGCGGGTGGGGACGGGCCAGGGAAGAGGTCAGGGCACGTTCTGGTTGTCCAGGGACGAGG  
GGTACTTTGCAGAGGACACCAGAATTGGCCACTTCCAGGACAGCCTCCAGCGCCTCTGCCAC  
TGCCTTCCTTCGAAGCTCTGATCAAGCACAAATCTGGGTCCCCAGGTGCTGTGTGCCAGAGGT  
GGGCGGGTGGGGAGACAGACAGAGGCTGCGGCTGAGTGCCTGTGCTTAGTGCTGGACACCCG  
TGTCCCCGGCCCTTTCTGGAGGCCCTCTACCACCTGCTCTGCCACAGGCACAAGTGGCAG  
CTATAACTCTGCTTTCATGAACTGCGGTCCACTCTCTGGTCTCTCTGTGGGCTCTACCCCTC  
ACTGACCACAAGCTCTACCTACCCCTGTGCCTGTGCTCCCATAACAGCCCTGGGGAGAAGGGGA  
TGACGTCTTCCCAGCACTGAGCTGCCCCAGAAACCCCGGCTCCCCACTGCTGCTCATAGCCCA  
TACCCTGGAGGCTGACAAGCCAGAAATGGCCTTGGCTAAAGGAGCCTCTCTCTCACCAGGCTG  
GCCGGGAGCCCAACCCCAATTTGTTTGGTGTGTTTGTGTCCATACTCTTGACAGTTCTGTCTTG  
GACTTGATGCCGCTGAACTCTGCGGTGGGACCGGTCCCGTCAGAGCCTGGTGTACTGGGGGGA  
GGGAGGGAGGAGGGAGCCTGTGCTGACGGAGCACCTCGCCGGGTGTGCCCCCTCCTGGGCTGTG  
TGACCCCAAGCCTCCCCACCCACCTCCTGCTTTGTGTACTCCTCCCCCTCCCCCTCAGCACAATC  
GGAGTTCATATAAGAAGTGCGGGAGCTTCTCTGGTCAGGGTTCTCTGAACACTTATGGAGAGA  
GTGCTTCCTGGGAAGTGTGGCGTTTGAAGGGGCTGGAGGGCAGGTCTTTAAGATGGCGAGACT  
GCCCTTCTCAGCTGATAAACACAAGAACGGCGATCCTGTCTTCAGTAAGGCTCCACGAGAAGA  
GAGGAAGTATATCTACACCTCAACCTCCTAGTCACCACCTGAAATAAATGTTAGGGAAAAAAA



214/550

**FIGURE 214**

MAVIIGVAVGAGVAFLVLMATIVAFCCARSQRNLKGVVSAKNDIRVEIVHKEPASGREGEEHS  
TIKQLMMDRGEFQQDSVLKQLEVLKEEEKEFQNLKDPTNGYYSVNTFKEHHSTPTISLSSCQP  
DLRPAGKQRVPTGMSFTNIYSTLSGQGRLYDYGQRFVLGMGSSSIELCEREFQRGSLSDSSSF  
LDTQCDSSVSSSGKQDGYVQFDKASKASASSSHHSQSSSQNSDPSRPLQRRMQTHV

**Signal peptide:**

amino acids 1-28

**Glycosaminoglycan attachment site.**

amino acids 150-154

**N-myristoylation sites.**

amino acids 6-12, 10-16, 36-42, 139-145, 165-171

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 114-125

215/550

**FIGURE 215**

CAGCCTTCCTCCCCCAGCCTGAGTGACTACTCTATTCCCTTGGTCCCTGCTATTGTCGGGGACG  
ATTGCATGGGCTACGCCAGGAAAGTAGGCTGGGTGACCGCAGGCCTGGTGATTGGGGCTGGCG  
CCTGCTATTGCATTTATAGACTGACTAGGGGAAGAAAACAGAACAAGGAAAAAATGGCTGAGG  
GTGGATCTGGGGATGTGGATGATGCTGGGGACTGTTCTGGGGCCAGGTATAATGACTGGTCTG  
ATGATGATGATGACAGCAATGAGAGCAAGAGTATAGTATGGTACCCACCTTGGGCTCGGATTG  
GGACTGAAGCTGGAACCAGAGCTAGGGCCAGGGCAAGGGCCAGGGCTACCCGGGCACGTCCGG  
CTGTCCAGAAACGGGCTTCCCCCAATTTCAGATGATACCGTTTTTGTCCCCTCAAGAGCTACAAA  
AGGTTCTTTGCTTGGTTGAGATGTCTGAAAAGCCTTATATTCTTGAAGCAGCTTTAATTGCTC  
TGGGTAAACAATGCTGCTTATGCATTTAACAGAGATATTATTCGTGATCTGGGTGGTCTCCCAA  
TTGTGCGCAAAGATTCTCAATACTCGGGATCCCATAGTTAAGGAAAAGGCTTTAATTGTCCTGA  
ATAACTTGAGTGTGAATGCTGAAAATCAGCGCAGGCTTAAAGTATACATGAATCAAGTGTGTG  
ATGACACAATCACTTCTCGCTTGAACCTCATCTGTGCAGCTTGCTGGACTGAGATTGCTTACAA  
ATATGACTGTTACTAATGAGTATCAGCACATGCTTGCTAATTCCATTTCTGACTTTTTTCGTT  
TATTTTCAGCGGGAAATGAAGAAACCAAACCTTCAGGTTCTGAAACTCCTTTTGAATTTGGCTG  
AAAATCCAGCCATGACTAGGGAACCTGCTCAGGGCCCAAGTACCATCTTCACTGGGCTCCCTCT  
TTAATAAGAAGGAGAACAAAGAAGTTATTCTTAAACTTCTGGTCATATTTGAGAACATAAATG  
ATAATTTCAAATGGGAAGAAAATGAACCTACTCAGAATCAATTCGGTGAAGGTTCACTTTTTT  
TCTTTTTTAAAAGAATTTCAAGTGTGTGCTGATAAGGTTCTGGGAATAGAAAGTCACCATGATT  
TTTTTGGTGAAAGTAAAAGTTGGAAAATTCATGGCCAAACTTGCTGAACATATGTTCCCAAAGA  
GCCAGGAATTAACACCTTGATTTTGTAAATTTAGAAGCAACACACATTGTAAACTATTCATTTTC  
TCCACCTTGTTTATATGGTAAAGGAATCCTTTTCAGCTGCCAGTTTTGAATAATGAATATCATA  
TTGTATCATCAATGCTGATATTTAACTGAGTTGGTCTTTAGGTTTAAAGATGGATAAATGAATA  
TCACTACTTGTTCTGAAAACATGTTTGTGCTTTTTATCTCGCTGCCTAGATTGAAATATTTT  
GCTATTTCTTCTGCATAAGTGACAGTGAACCAATTCATCATGAGTAAGCTCCCTTCTGTCATT  
TTCATTGATTTAATTTGTGTATCATCAATAAAATTGTATGTTAATGCTGGAAAGA

216/550

**FIGURE 216**

MGYARKVGVVTAGLVIGAGACYCIYRLTRGRKQNKKEKMAEGGSGDVDDAGDCSGARYNDWSDD  
DDDSNESKSIWYPPWARIGTEAGTRARARARARATRRARRAVQKRASPNSDDTVLSPQELQKV  
LCLVEMSEKPYILEAALIALGNNAAYAFNRDIIRD LGGLPIVAKILNTRDPIVKEKALIVLNN  
LSVNAENQRRLKVYMNQVCDDTITSRLNSSVQLAGLRLLTNMTVTNEYQHMLANSISDFFRLF  
SAGNEETKLQVLKLLLNLAENPAMTRELLRAQVPSSLGSLFNKKENKEVILKLLVIFENINDN  
FKWEENEPTQNQFGECSLFFFLKEFQVCADKVLGIESHHDFLVKVKVGKFMAKLAEHMFPSQE

**Signal peptide:**

amino acids 1-20

**N-glycosylation sites.**

amino acids 68-72, 189-193, 217-221, 230-234

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 107-111

**N-myristoylation sites.**amino acids 13-19, 17-23, 19-25, 54-60, 83-89, 147-153, 255-261,  
290-296**Amidation site.**

amino acids 29-33

217/550

**FIGURE 217**

GAGACACAAAGGCAGGCGGGATGCGGGAGCAGGCAAAGGGAAAGCGAAAGCCGCGCGCCCCGGC  
CGGTGACTGGGTGAAGGCGCCGCGCAGCTTTCCCGACGCCGGCTGTACCCGGACCTCCTGGTC  
GAGCCTGGCGCGCCGCGAGCCATGGCCATCGCTCAACTGGCCACGGAGTACGTGTTCTCGGATT  
TCTTGCTGAAGGAGCCCACGGAGCCCAAGTTCAAGGGGCTGCGACTGGAGCTGGCTGTGGACA  
AGATGGTCACGTGCATTGCGGTGGGGCTGCCCCCTGCTGCTCATCTCGCTGGCCTTCGCGCAGG  
AGATCTCGATTGGTACACAGATAAGCTGTTTCTCTCCAAGTTCTTTCTCCTGGCGTCAGGCTG  
CCTTTGTGGATTTCATATTGCTGGGCGGCTGTTTCAGCAGAAGAACTCACTGCAGAGCGAGTCTG  
GAAACCTCCCCTGTGGCTGCATAAGTTTTTCCCCTACATCCTGCTGCTCTTTGCGATCCTCC  
TGTACCTGCCCCCGCTGTTCTGGCGTTTTCGCAGCTGCTCCTCATATTTGCTCAGACTTGAAGT  
TTATCATGGAAGAACTTGACAAAGTTTACAACCGTGCAATTAAGGCTGCAAAGAGTGCGCGTG  
ACCTTGACATGAGAGATGGAGCCTGCTCAGTTCCAGGTGTTACCGAGAACTTAGGGCAAAGTT  
TGTGGGAGGTATCTGAAAGCCACTTCAAGTACCCAATTGTGGAGCAGTACTTGAAGACAAAGA  
AAAATTCTAATAATTTAATCATCAAGTACATTAGCTGCCGCCTGCTGACACTCATCATTATAC  
TGTTAGCGTGTATCTACCTGGGCTATTACTTCAGCCTCTCCTCACTCTCAGACGAGTTTGTGT  
GCAGCATCAAATCAGGGATCCTGAGAAACGACAGCACCGTGCCCGATCAGTTTCAGTGCAAAC  
TCATTGCCGTGGGCATCTTCCAGTTGCTCAGTGTCATTAACCTTGTGGTTTTATGTCCTGCTGG  
CTCCCGTGTTGTCTACACGCTGTTTGTTCATTCCGACAGAAGACAGATGTTCTCAAAGTGT  
ACGAAATCCTCCCCACTTTTGATGTTCTGCATTTCAAATCTGAAGGGTACAACGATTTGAGCC  
TCTACAATCTCTTCTTGAGGAAAATATAAGTGAGGTCAAGTCATACAAGTGTCTTAAGGTAC  
TGGAGAATATTAAGAGCAGTGGTCAGGGGATCGACCCAATGCTACTCCTGACAAACCTTGGCA  
TGATCAAGATGGATGTTGTTGATGGCAAACTCCCATGTCTGCAGAGATGAGAGAGGAGCAGG  
GGAACCAGACGGCAGAGCTCCAAGGTATGAACATAGACAGTGAACTAAAGCAAATAATGGAG  
AGAAGAATGCCCCGACAGAGACTTCTGGATTCTTCTTGCTTGATGATTTTTTTTTTCCTTGAGCTGT  
AAATCTGTGACTTCTGCGACATGGGATTTAATTTGGCTAAAGCACCCCTGTTGGTTTTACAGC  
TGGTTTGCAATAAATGGTTCTTGGTGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  
AAA

218/550

**FIGURE 218**

MAIAQLATEYVFSDFLLEKEPTEPKFKGLRLELAVDKMVTCTIAVGLPLLLISLAFQEISIGTQ  
ISCFSPSSFSWRQAAAFVDSYCWAAVQQKNSLQSESGNLPLWLHKFFPYILLFFAILLYLPPLF  
WRFAAAPHICSDLKFIMEELDKVYNRAIKAASARDLDMRDGACSVPGVTENLGQSLWEVSES  
HFKYPIVEQYLKTKKNSNNLI IKYISCRLLTLIIILLACIYLGYYFSLSSLSDEFVCSIKSGI  
LRNDSTVPDQFQCKLIAVGIFQLLSVINLVVYVLLAPVVVYTLFVPPFRQKTDVLKVYEILPTF  
DVLHFKSEGYNDLSLYNLFLEENISEVKSYKCLKVLENIKSSGQGIDPMLLLTNLGMKMDVV  
DGKTPMSAEMREEQGNQTAELOGMNIDSETKANNGEKNARQRLDSSC

**Transmembrane domains:**

amino acids 37-55, 108-126, 216-232, 273-290

**N-glycosylation sites.**

amino acids 255-259, 338-342, 394-398

**Glycosaminoglycan attachment site.**

amino acids 357-361

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 203-207

**N-myristoylation sites.**

amino acids 61-67, 174-180, 251-257, 393-399

**Prokaryotic membrane lipoprotein lipid attachment site.**

amino acids 218-229

219/550

**FIGURE 219**

CTGTGAGTGACACACGCTGAGTGGGGTGAAGGGAAATGCTGGTGAATTTTCATTTTGAGGTGTG  
GGTTGCTGTTAGTCACTCTGTCTCTTGCCATTGCCAAGCACAGCAATCTTCCTTCACCAAAA  
GTTGTTACCCAAGGGGAACATTGTCCCAAGCTGTTGACGCTCTCTATATCAAAGCAGCATGGC  
TCAAAGCAACGATTCCAGAAGACCGCATAAAAAATATACGATTATTAAAAAAGAAAACAAAAA  
AGCAGTTTATGAAAACTGTCAATTTCAAGAACAGCTTCTGTCCTTCTTCATGGAAGACGTTT  
TTGGTCAACTGCAATTGCAAGGCTGCAAGAAAATACGCTTTGTGGAGGACTTTCATAGCCTTA  
GGCAGAAATTGAGCCACTGTATTTCTGTGCTTCATCAGCTAGAGAGATGAAATCCATTACCA  
GGATGAAAAGAATATTTTATAGGATTGGAAACAAAGGAATCTACAAAGCCATCAGTGAAGTGG  
ATATTCTTCTTTCTGGATTAAAAAATTATTGGAAAGCAGTCAGTAAACCAAAGCCAAGTACA  
TTGATTTTACAGTTATTTTGAAATACAATAAGAACTGCTAGAAATATGTTTATAACAGTCTAT  
TTCTTTTAAAACTTTTAAACATAATACTGACGGCATGTTAGGTGATTCAGAATAGACAAGAA  
GGATTTAGTAAATTAACGTTTTGGATATAAGTTGTCACTAATTTGCACATTTTCTGTGTTTTT  
AAATAATGTTTCCATTCTGAACATGTTTTGTCAATTCACAAGTACATTGTGTCAACTTAATTTA  
AAGTATGTAACCTGAATTAACCTCGTGTAATATTTGTGTGTGGAGTGGGATGTGGGGGGTGGAG  
GGGGAATGACAGATTTCTGGAATGCAATGTAATGTTACTGAGACTTAAATAGATGTTATGTAT  
ATGATTGTCTGTTTAAAGTGTGTTGAAAATTGTTAATTATGCCCAGTGTGAACTTAGTACTTAAC  
ACATTTTGATTTTAAATTAAATAAATTGGGTTTCTCTCAAAAAAAAAAAAAAAAAAAAAA  
AAAAA

220/550

**FIGURE 220**

MLVNFILRCGLLLVTLSLAIAKHKQSSFTKSCYPRGTLTSAVDALYIKAAWLKATIPEDRIKN  
IRLLKKKTKKQFMKNCQFQEQLLSFFMEDVFGQLQLQGCKKIRFVEDFHSLRQKLSHCISCAS  
SAREMKSITRMKRIFYRIGNKGIYKAISELDILLSWIKKLLESSQ

**Signal sequence:**

amino acids 1-21

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 68-71

**N-myristoylation site.**

amino acids 148-153

**Interleukin-10 proteins.**

amino acids 58-94, 74-102, 128-170

221/550

**FIGURE 221**

GACCACGGCCCTGCGCCCCAGCCAGGCCTGAGGACATGAGGCGGCCGGCGGGCGGTGCCGCTCC  
TGCTGCTGCTGTGTTTTGGGTCTCAGAGGGCCAAGGCAGCAACAGCCTGTGGTCGCCCCAGGA  
TGCTGAACCGAATGGTGGGCGGGCAGGACACGCAGGAGGGCGAGTGGCCCTGGCAAGTCAGCA  
TCCAGCGCAACGGAAGCCACTTCTGCGGGGGCAGCCTCATCGCGGAGCAGTGGGTCCTGACGG  
CTGCGCACTGCTTCCGCAACACCTCTGAGACGTCCCTGTACCAGGTCCTGCTGGGGGCAAGGC  
AGCTAGTGCAGCCGGGACCACACGCTATGTATGCCCCGGGTGAGGCAGGTGGAGAGCAACCCCC  
TGTACCAGGGCACGGCCTCCAGCGCTGACGTGGCCCTGGTGGAGCTGGAGGCACCAAGTGCCCT  
TCACCAATTACATCCTCCCCGTGTGCCTGCCTGACCCCTCGGTGATCTTTGAGACGGGCATGA  
ACTGCTGGGTCACTGGCTGGGGCAGCCCCAGTGAGGAAGACCTCCTGCCCCGAACCGCGGATCC  
TGCAGAAACTCGCTGTGCCCATCATCGACACACCCAAGTGCAACCTGCTCTACAGCAAAGACA  
CCGAGTTTGGCTACCAACCCAAAACCATCAAGAATGACATGCTGTGCGCCGGCTTCGAGGAGG  
GCAAGAAGGATGCCTGCAAGGGCGACTCGGGCGGGCCCCCTGGTGTGCCTCGTGGGTGAGTCGT  
GGCTGCAGGCGGGGGTGATCAGCTGGGGTGAGGGCTGTGCCCCGCCAGAACCGCCCAGGTGTCT  
ACATCCGTGTCACCGCCCCACCACAACCTGGATCCATCGGATCATCCCCAACTGCAGTTCCAGC  
CAGCGAGGTTGGGCGGCCAGAAGTGAGACCCCCGGGGCCAGGAGCCCCTTGAGCAGAGCTCTG  
CACCAGCCTGCCCCGCCACACCATCCTGCTGGTCCTCCCAGCGCTGCTGTTGCACCTGTGAG  
CCCCACCAGACTCATTTGTAAATAGCGCTCCTTCCTCCCCTCTCAAATACCCTTATTTTATTT  
ATGTTTCTCCCAATAAAAACCCAGCCTGTGTGCCAGCTGAAAAAAAAAAAAAAAAAAAAA



222/550

**FIGURE 222**

MRRPAAVPLLLLLCFGSQRAKAATACGRPRMLNRMVGGQDTQEGEWPWQVSIQRNGSHFCGGS  
LIAEQWVLTAAHCFRNTSETSLYQVLLGARQLVQPGPHAMYARVRQVESNPLYQGTASSADVA  
LVELEAPVPFTNYILPVCLPDPSVIFETGMNCWVTGWGSPSEEDLLPEPRILQKLAVPIIDTP  
KCNLLYSKDTEFGYQPKTIKNDMLCAGFEEGKKDACKGDSGGPLVCLVGQSWLQAGVISWGEG  
CARQNRPGVYIRVTAHHNWIHRIIPKLQFQPARLGGQK

**Important features of the protein:****Signal peptide:**

amino acids 1-22

**N-glycosylation sites.**

amino acids 55-58, 79-82

**Casein kinase II phosphorylation sites.**

amino acids 121-124, 165-168, 167-170, 248-251

**Tyrosine kinase phosphorylation sites.**

amino acids 78-86, 197-203

**N-myristoylation sites.**

amino acids 16-21, 37-42, 56-61, 62-67, 118-123

**Amidation site.**

amino acids 219-222

**Serine proteases, trypsin family, histidine active site.**

amino acids 71-76

223/550

**FIGURE 223**

CAAGATGTGGACAGCTCTTGTGCTCATTTGGATTTTCTCCTTGTCTTATCTGAAAGCCATGC  
GGCATCCAACGATCCACGCAACTTTGTCCCTAACAAAATGTGGAAGGGATTAGTCAAGAGGAA  
TGCATCTGTGGAAACAGTTGATAATAAAACGTCTGAGGATGTAACCATGGCAGCAGCTTCTCC  
TGTCACATTGACCAAAGGGACTTCGGCAGCCACCTCAACTCTATGGAAGTCACAACAGAGGA  
CACAAGCAGGACAGATGTGAGTGAACCAGCAACTTCAGGAGTTGCAGCTGATGGTGTGACCTC  
CATTGCTCCACGGCTGTGGCCTCCAGTACGACTGCGGCCTCCATTACGACTGCGGCCTCCAG  
TATGACTGTGGCCTCCAGTGCTCCACGACTGCAGCCTCCAGTACAACGTGTGGCCTCCATTGC  
TCCCACGACTGCAGCCTCCAGTATGACTGCGGCCTCCAGCACTCCCATGACACTTGCACTCCC  
CGCGCCACGTCCACTTCCACAGGGCGGACCCCGTCCACTACCGCCACTGGGCATCCATCTCT  
CAGCACAGCCCTCGCACAAAGTGCCAAAGAGCAGCGGTTGCCAAGAACAGCAACCCTGGCCAC  
ATTGGCCACACGTGCTCAGACTGTAGCGACCACAGCAAACACAAGCAGCCCCATGAGCACTCG  
TCCAAGTCCTTCCAAGCACATGCCCAGTGACACCGCGGCAAGCCCTGTACCCCCTATGCGTCC  
CCAAGCACAAAGTCCCATTAGCCAGGTGTCAGTGGACCAGCCTGTGGTTAACACAACAAATAA  
ATCCACACCCATGCCCTCAAACACAACCCAGAGCCCGCCCCACCCCCACAGTGGTGACCAC  
CACCAAGGCACAAGCCAGGGAGCCAAGTGCAGCCAGTGCAGTACCTCACACCAGCCCAAT  
CCCTGAGATGGAGGCCATGTCCCCACGACACAGCCAAGCCCCATGCCATATACCCAGAGGGC  
CGCTGGGCCAGGCACATCCCAGGCACCGGAGCAGGTAGAGACTGAAGCCACACCAGGTACTGA  
TTCCACTGGGCCAACACCCAGGAGCTCAGGGGGCACTAAGATGCCAGCCACGGACTCGTGCCA  
GCCCAGCACCCAAGGCCAGTACATGGTGGTCAACCTGAGCCCCTCACCCAGGCCGTGGTAGA  
CAAACTCTCCTTCTGGTGGTGTGTTACTCGGGGTGACCCTTTTCATCACAGTCTTGGTTTT  
GTTTGCCCTGCAGGCCTATGAGAGCTACAAGAAGAAGGACTACACCCAGGTGGACTACTTAAT  
CAACGGGATGTATGCGGACTCAGAAATGTGAAGGGGGGCGGGGGCCTGGCGGGAGGCCTGGCCC  
CTTCCTCGTCCTTTTCCTTTTGCCCTTGAGACCAAACCAAGTGCTTCCAAATTCTTTTGGTGCA  
ATTGAGGAGATATGCCAGATGCTTAAACACATTTAATTGCTGTCAGATTAATTCCATGATCAC  
TAAAGAGTTGCTGCTTTTTTCATATTTATTTTGTAAATGATTCTGTGCCAGGAGCAGCTGG  
GGGTTCACCTCAGGGTGGGGCGGGCAGGACCCCGTCTCCCCAGGTGTCGGAGCCTGACCTGA  
ATTAAAGTACTGACTGCTCGCCA

224/550

**FIGURE 224**

MWTALVLIWIFSLSLSESHAASNDPRNFVPNKMWKGLVKRNASVETVDNKTSSEDTVMAAASPV  
TLTKGTSAAHLNSMEVTTEDTSRTDVSEPATSGVAADGVTSIAPTAVASSTTAASITTAASSM  
TVASSAPTTAASSTTVASIAPTTAASSMTAASSTPMTLALPAPTSTSTGRTPSTTATGHPSLS  
TALAQVPKSSALPRTATLATLATRAQTVATTANTSSPMSTRPSPSKHMPSDTAASPVPMPRPQ  
AQQPISQVSVDQPVVNTTNKSTPMPSTNTTPEPAPTPTVVTTTKAQAREPTASVPVPHTSPIP  
EMEAMSPPTQPSMPYTQRAAGPGTSQAPEQVETEATPGTDSTGPTPRSSGGTKMPATDSCQP  
STQGQYMVVTTTEPLTQAVVDKTLVLLVLLGLVTLFITVLVLFALQAYESYKKKDYTQVDYLIN  
GMYADSEM

**Signal peptide:**

amino acids 1-20

**Transmembrane domain:**

amino acids 396-420

**N-glycosylation sites.**

amino acids 41-44, 49-52, 222-225, 268-271, 271-274

**Casein kinase II phosphorylation sites.**

amino acids 14-17, 51-54, 80-83, 85-88, 280-283, 434-437

**N-myristoylation sites.**

amino acids 68-73, 354-359

**Aldo/keto reductase family putative active site signature.**

amino acids 195-210

225/550

**FIGURE 225**

GGAAGGCGCTCAAGGTGCGCGGCCCGGGGCGCGCTACTGGGGGCGCCCTCCGCGGTGGGCAGC  
GCGCCAGGGATCGGCCTGGGCAGCCGCGGGGCGCGCGAAGGCTGCGCTTCCCTACGGCCCCC  
CTCGCTTCCTCCGGCACGGCGGCAACGGAGATTTCTCTCGGGGAACTACGCGGATCCTTTT  
CGGGGATCCTCGCCCCGCCCCAGTTCTCCGCCCCCTCCCCTTTGCTGGGGCGCCTGGGCTGGC  
CCGCGCAGGGGAGGAGGCTCTGGCAGCCTGGGCAGGGAGGCGGGGGGGGCCGCGGAGCCGCT  
GGCCATCGATTCTCCCCGCCATGTGACGCCGTCCTTAGCCCTGCGACCCCCAGCGCGTCCCGG  
GCCTGCGCCTCCGCCCCGCCGCGCAGCGCACG**ATG**CTTCTGCCGGGACGCGCACGCCAACCGC  
CGACGCCCCAGCCCGTGCAGCATCCCGGCCTCCGCCGGCAGGTAGAGCCGCCGGGGCAGCTCC  
TGCGCCTCTTCTACTGCACTGTCTGGTCTGCTCCAAAGAGATCTCAGCGCTCACCGACTTCT  
CTGGTTACCTAACCAAACTCCTGCAAACACACCACCTATGCCTGTGATGGGGACTATTTGA  
ATCTACAGTGCCCTCGGCATTCTACGATAAGTGTCCAATCGGCATTTTATGGGCAAGATTACC  
AAATGTGTAGTTCCCAGAAGCCTGCCTCCCAGAGGGAAGACAGCTTAACCTGTGTGGCAGCCA  
CCACCTTCCAGAAGGTGCTGGACGAATGCCAGAACCAGCGGGCCTGCCACCTCCTGGTCAATA  
GCCGTGTTTTTTGGACCTGACCTTTGTCCAGGAAGCAGTAAATACCTCCTGGTCTCCTTTAAAT  
GCCAACCTAATGAATTAAAAAACAAAACCGTGTGTGAAGACCAGGAGCTGAAACTGCACTGCC  
ATGAATCCAAGTTCCTCAACATCTACTCTGCGACCTACGGCAGGAGGACCCAGGAAAGGGACA  
TCTGCTCCTCCAAGGCAGAGCGGCTCCCCCCTTTTCGATTGCTTGTCTTACTCAGCTTTGCAAG  
TCCTATCCCGAAGGTGCTATGGGAAGCAGAGATGCAAATCATCGTCAACAATCACCATTTTG  
GAAGCCCCTGTTTGGCAGGCGTGAAAAAATACCTCACTGTGACCTACGCATGTGTTCCTCAAGA  
ACATACTCACAGCGATTGATCCAGCCATTGCTAATCTAAAACCTTCTTTGAAGCAGAAAGATG  
GTGAATATGGTATAAACTTCGACCCAAGCGGATCGAAGGTTCTGAGGAAAGATGGAATTCTTG  
TTAGCAACTCTCTGGCAGCCTTTGCTTACATTAGAGCCCACCCAGAGAGAGCTGCCCTGCTGT  
TCGTGTCCAGTGTCTGCATCGGCCTGGCCCTCACACTGTGCGCCCTGGTCATCAGAGAGTCCT  
GTGCCAAGGACTTCCGCGACTTGCAGCTGGGGAGGGAGCAGCTGGTGCCAGGAAGTGACAAGG  
TCGAGGAGGACAGCGAGGATGAAGAAGAGGAGGAGGACCCCTCTGAGTCTGATTTCCCAGGGG  
AACTGTGCGGGGTTCTGTAGGACTTCATATCCTATATACAGTTCCATAGAAGCTGCAGAGCTCG  
CAGAAAGGATTGAGCGCAGGGAGCAAATCATTAGGAAATATGGATGAACAGTGGTTTGGACA  
CCTCGCTCCCAAGAAACATGGGCCAGTTCTACT**TG**AAAACCACATGCATCTTGATGCGATCGCA  
CTTTCTGAAGAAGGAAGGATCCCAAATGCCCTCCAGTTCTGGTTCACCTGTACCTTCTATGA  
AGGAGAATTCGTTCATGTCATTCAACACTCGTGAGGCCAGGAAGCTATTAAAGGGATGTTTCAA  
GCTGTTTCTAGCACATTCCAAAATAAATGAGGAGGGAGGAAAAAAAAAAAAAAAAAAAAA  
AAAAAAAAAAAAAAAAAAAAA

226/550

**FIGURE 226**

MLLPGRARQPPTPQPVQHPLRRQVEPPGQLLRIFYCTVLVCSKEISALTDGSGYLTKLLQNH  
TTYACDGDYLNLCPRHSTISVQSAFYGQDYQMCSSQKPPASQREDSLTCAATTFQKVLDECQ  
NQRACHLLVNSRVFGPDLCPGSSKYLLVSFKCQPNELKNKTVCEDQELKLHCHESKFLNIYSA  
TYGRRTQERDICSSKAERLPPFDCLSYSALQVLSRRCYQKQRCIIIVNNHHFGSPCLPGVKKY  
LTVTYACVPKNILTAIDPAIANLKPSTLQKDGEGYGINFDPSSGSKVLRKDGILVSNLSLAAFAYI  
RAHPERAALLFVSSVCIGLALTLCALVIRESCAKDFRDLQLGREQLVPGSDKVEEDSEDEEEE  
EDPSESDFPGELSGFCRTSYPIYSSIEAAELAERIERREQIIQEIWMNSGLDTS�PRNMGQFY

**Transmembrane domains:**

amino acids 32-49, 322-343

**N-glycosylation sites.**

amino acids 62-66, 165-169

**Tyrosine kinase phosphorylation site.**

amino acids 280-287

**N-myristoylation site.**

amino acids 302-308, 333-339, 428-434

**Amidation site.**

amino acids 191-195

227/550

**FIGURE 227**

GGCACGAGGTGGAAGGGCTTTTACAAACAGATTGCTGGCCCCACCCCCCAGAATTTCTCATCA  
GGAGTGGGCAAGACCAATCATTTGCATTCTGACAAGTTCCCAGGAGCTGCAGCTGCTGGCCC  
TGGAACCACACTTTGAGAACCACTGCTTTAGACCAAACACCAAAGGAAGATGCAGCCACCCTC  
CTTTACATGTCACAACGCTCAGGGTCCATGAGTACCTCAGGCTGTCCAGCTGAGCTCCACCTG  
CAGCAGCCGAGATTCCCGACTCGCTCCACCATTGGGGGCTAGGAGTGAAGCGTGTCACC**ATGG**  
TCAGCTCATGGCCAGCCAGGAAAGCCTCTCTGCTGTGCGTCTGTGCAGTTCTTGTTCTTCCCT  
GGAGGACTCTTGGATCGCCTGTGATCTTGCCAGGAGACCAGGTGCCTGGGTCCCTTCCTGGA  
AGGGGACAAGTTACACACCCCAGCCCCATTTCCACCAACTTCTACATGCCTTGGGAGAACC  
TTCTACATGTTGGCTGCCCCCTTCCCCTATTTTCAGCAGTGCCCAGTCCTGCTTATAAACCTGA  
GGCCTGCTCCCCATACCTTCCCTGTGCAAGTGCCAGCCGTTATTCCAGGCAGCCCAATGTTGT  
TGAGGCCAGATGGATTCCCTGGAAGCAGCTGGCCCATGGATG**TGA**GTGCATCACAGTATTCTAGA  
AACAGAGAAGAGGTCTTAACCTAATGCGCATAGAGAAATTGTTCTCATTGTAAACATACCCCT  
GTCCTTAGCTGATCTAGGTGGAAGCCCAGCTTCATGTGCTAGGGGGCATGATAATGATAATAA  
AGGAATTGTATCTAGGACTAA

228/550

**FIGURE 228**

MVSSWPARKASLLCVC AVLVL PWRTL GSPVILARRPGAWVPSWKGTSYTPQPHFPTNFYMPWE  
NLLHVGCP LPLFQQCPVLLINLRPAPHTFPVQVPAVIPGSPM LLRPDGFLEAAGPWM

**Signal peptide:**

amino acids 1-27

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 8-12

229/550

**FIGURE 229**

GGGAAGGGATGCAAGGAAGCCCTCCGGCGCTGCGCTCCGAGGCGGGAGACAGCGTCCCGCTGA  
AAATGTGTGTCTGACATGCAAGCTCAGTGGGGCAGAGACCCGTGGATTGCTGTGCCCTGCCCT  
CCGGACCTGGATCATGAAGGTGTTGGGAAGAAGCTTCTTCTGGGTGCTGTTTCCCGTCCCTTCC  
CTGGGCGGTGCAGGCTGTGGAGCACGAGGAGGTGGCGCAGCGTGTGATCAAACCTGCACCGCGG  
GCGAGGGGTGGCTGCCATGCAGAGCCGGCAGTGGGTCCGGGACAGCTGCAGGAAGCTCTCAGG  
GCTTCTCCGCCAGAAGAATGCAGTTCTGAACAACTGAAAAGTGAATTTGGAGCAGTGGAGAA  
AGACGTGGGCCTGTCGGATGAAGAGAACTGTTTCAGGTGCACACGTTTGAAATTTTCCAGAA  
AGAGCTGAATGAAAGTGAAATTCGGTTTTTCCAAGCTGTCTACGGACTGCAGAGAGCCCTGCA  
GGGGGATTACAAAGATGTCGTGAACATGAAGGAGAGCAGCCGGCAGCGCCTGGAGGCCCTGAG  
AGAGGCTGCAATAAAGGAAGAAACAGAATATATGGAAGTCTTGGCAGCAGAAAAACATCAAGT  
TGAAGCCCTTAAAAATATGCAACATCAAAACCAAAGTTTATCCATGCTTGACGAGATTCTTGA  
AGATGTAAGAAAGGCAGCGGATCGTCTGGAGGAAGAGATAGAGGAACATGCTTTTGACGACAA  
TAAATCAGTCAAGGGGGTCAATTTTGAGGCAGTTCTGAGGGTGGAGGAAGAAGAGGCCAATTC  
TAAGCAAAATATAACAAAACGAGAAGTGGAGGATGACTTGGGTCTTAGCATGCTGATTGACTC  
CCAGAACAACCAAGTATATTTTGACCAAGCCAGAGATTCAACCATCCCACGTGCAGATCACCA  
CTTTATAAAGGACATTGTTACCATAGGAATGCTGTCCTTGCCTTGTGGCTGGCTATGTACAGC  
CATAGGATTGCCTACAATGTTTGGTTATATTATTTGTGGTGTACTTCTGGGACCTTCAGGACT  
AAATAGTATTAAGTCTATTGTGCAAGTGGAGACATTAGGAGAATTTGGGGTGTTTTTTACTCT  
TTTTCTTGTGGCTTAGAATTTTCTCCAGAAAAGCTAAGAAAGGTGTGGAAGATTTCCCTTACA  
AGGGCCGTGTTACATGACACTGTTAATGATTGCATTTGGCTTGCTGTGGGGGCATCTCTTGCG  
GATCAAACCCACGCAGAGCGTCTTCATTTCCACGTGTCTGTCTTGTCAAGCACACCCCTCGT  
GTCCAGGTTCCTCATGGGCAGTGTCTGGGGTGACAAAGAAGGCGACATTGACTACAGCACCCGT  
GCTCCTCGGCATGCTGGTGACGCAGGACGTGCAGCTCGGGCTCTTCATGGCCGTGTCATGCCGAC  
TCTCATACAGGCGGGCGCCAGTGCATCTTCTAGCATTTGTCGTGGAAGTTCTCCGAATCCTGGT  
TTTGATTGGTTCAGATTCTTTTTTCACTAGCGGCGGTTTTTCTTTTATGTCTTGTTATAAAGAA  
GTATCTCATTTGGACCCTATTATCGGAAGCTGCACATGGAAAGCAAGGGGAACAAAGAAATCCT  
GATCTTGGGAATATCTGCCTTTATCTTCTTAATGTTAACGGTCCACGGAGCTGCTGGACGTCTC  
CATGGAGCTGGGCTGTTTCCCTGGCTGGAGCGCTCGTCTCCTCTCAGGGCCCCGTGGTCACCGA  
GGAGATCGCCACCTCCATCGAACCCATCCGCGACTTCCCTGGCCATCGTTTTCTTCGCCCTCCAT  
AGGGCTCCACGTGTTCCCCACGTTTGTGGCGTACGAGCTCACGGTGTGTTGTTTCTCACCTT  
GTCAGTGGTGGTGATGAAGTTTCTCCTGGCGGCGCTGGTCTGTCTCTCATTCTGCCGAGGAG  
CAGCCAGTACATCAAGTGGATCGTCTCTGCGGGGCTTGCCCAGGTGAGCGAGTTTTCCTTTGT  
CCTGGGGAGCCGGGCGCGAAGAGCGGGCGTCTCTCTCGGGAGGTGTACCTCCTTATACTGAG  
TGTGACCACGCTCAGCCTCTTGCTCGCCCCGGTGTGTGGAGAGCTGCAATCACGAGGTGTGT  
GCCCAGACCGGAGAGACGGTCCAGCCTCTGAAGGCTCGGAGATGATGGACCGTGGAAGGGAAG  
CGTCTGTGGGGAGTGAGCGCTTAGATGGCCAGCAGCTGCTCCTTCTGGGAAGCTCGCACCTTG  
GCAACAGAACAGCCCTCTAGCAGAGCGTCAGTGCAGTGTGTTATCCCGGCTTTTACAGAATA  
TTCTTGTCCTATTTTAGAATTTTCCGGAGTAGTTTATTTGCAGTCTGTTGATTATGTGCAGTA  
GACCCGGGACACTGCGTTTTTACCGATCACCTTGAATGTGGTGCCTGGATGTGCCTTTTTTTTT  
TTTCCCTGAAATTATTATTAATTTTCTATTGTGAGTTCATCAGTTCATAGTTTTTTTTTAGTAAA  
GAAGCAAAATTAAAAGGCTTTTAAAAATGTACAACTTCAGAATTATAATCTGTTAGTCAAATA  
TTTGTTATTAAACATTTCTGTAATATGAAGTTGTAATCCTGGCCGTGAGCTTGGAAGCTTACT  
TTTGATTCTTAAAGCCTATGTTTTCTAAAATGAGACAAATACGGATGTCTATTTGCCTTTTAT  
TGTAACCTTTTAAATGAAATAATTTTCATGTCAATTTCTATTAGATATATCACTTAAAATATTTG  
GTTTTAAATCACAAGAATATGTATTCTTTAATAAAGATAATTTATGATCATGGTAAAAA



230/550

**FIGURE 230**

MKVLGRSFFWVLPVLPWAVQAVEHEEVAQRVIKLRGRGVAAMQSRQWVRDSCRKLSGLLRQ  
KNAVLNKLKTAIGAVEKDVGLSDEEKLQVHTFEIFQKELNESENSVVFQAVYGLQRALQGDYK  
DVVNMKESSRQRLEALREAAIKEETEYMEALLAAEKHQVEALKNMQHQNQSLSMLEILEDVRK  
AADRLEEEIEEHAFDDNKSVMKGVNFEAVLRVEEEEANSKQNITKREVEDDLGLSMLIDSQNNQ  
YILTKPRDSTIPRADHHFIKDIVTIGMLSLPCGWLCTAIGLPTMFGYIICGVLLGPSGLNSIK  
SIVQVETLGEFGVFVFTLFLVGLFESPEKLRKVWKISLQGPCYMTLLMIAFGLLWGHLLRIKPT  
QSVFISTCLSLSSSTPLVSRFLMGSARGDKEGDFDYSTVLLGMLVTQDVQLGLFMAVMPTLIQA  
GASASSIVVEVLRILVLIGQILFSLAAVFLLCLVIKKYLIGPYRKLHMESKGNKEILILGI  
SAFIFLMLTVTELLDVSMELGCFLAGALVSSQGPVVTEEIATSIEPIRDFLAIVFFASIGLHV  
FPTFVAYELTVLVFLTSLSVVVMKFLAALVLSLILPRSSQYIKWIVSAGLAQVSEFSFVLGSR  
ARRAGVISREVYLLILSVTTLSLLLAPVLWRAAITRCVPRPERRSSL

**Signal peptide:**

amino acids 1-22

**Transmembrane domains:**amino acids 282-304, 322-337, 354-370, 379-395, 445-474, 501-520,  
576-598, 641-660**N-glycosylation sites.**

amino acids 104-108, 174-178, 206-210, 230-234

**cAMP- and cGMP-dependent protein kinase phosphorylation site.**

amino acids 55-59, 673-677

**Tyrosine kinase phosphorylation site.**

amino acids 407-414

**N-myristoylation sites.**amino acids 116-122, 327-333, 366-372, 401-407, 419-425, 429-435,  
442-448, 525-531, 530-536**Cell attachment sequence.**

amino acids 404-407

231/550

**FIGURE 231**

GAGAAAAACAACAGGAAGCAGCTTACAAACTCGGTGAACAACTGAGGGAACCAAACCAGAGAC  
GCGCTGAACAGAGAGAATCAGGCTCAAAGCAAGTGGAAGTGGGCAGAGATTCCACCAGGACTG  
GTGCAAGGCGCAGAGCCAGCCAGATTTGAGAAGAAGGCCAAAAAGATGCTGGGGAGCAGAGCTG  
TAATGCTGCTGTTGCTGCTGCCCTGGACAGCTCAGGGCAGAGCTGTGCCTGGGGGCAGCAGCC  
CTGCCTGGACTCAGTGCCAGCAGCTTTCACAGAAGCTCTGCACACTGGCCTGGAGTGCACATC  
CACTAGTGGGACACATGGATCTAAGAGAAGAGGGAGATGAAGAGACTACAAATGATGTTCCCC  
ATATCCAGTGTGGAGATGGCTGTGACCCCCAAGGACTCAGGGACAACAGTCAGTTCTGCTTGC  
AAAGGATCCACCAGGGTCTGATT TTTTATGAGAAGCTGCTAGGATCGGATATTTTCACAGGGG  
AGCCTTCTCTGCTCCCTGATAGCCCTGTGGGCCAGCTTCATGCCTCCCTACTGGGCCTCAGCC  
AACTCCTGCAGCCTGAGGGTCACCACTGGGAGACTCAGCAGATTCCAAGCCTCAGTCCCAGCC  
AGCCATGGCAGCGTCTCCTTCTCCGCTTCAAATCCTTCGCAGCCTCCAGGCCTTTGTGGCTG  
TAGCCGCCCCGGGTCTTTGCCCATGGAGCAGCAACCCTGAGTCCCATAAGGCAGCAGCTCAAGG  
ATGGCACTCAGATCTCCATGGCCCAGCAAGGCCAAGATAAATCTACCACCCCAGGCACCTGTG  
AGCCAACAGGTTAATTAGTCCATTAATTTTAGTGGGACCTGCATATGTTGAAAATTACCAATA  
CTGACTGACATGTGATGCTGACCTATGATAAGGTTGAGTATTTATTAGATGGGAAGGGAAATT  
TGGGGATTATTTATCCTCCTGGGGACAGTTTGGGGAGGATTATTTATTGTATTTATATTGAAT  
TATGTACTTTTTTCAATAAAGTCTTATTTTTGTGGCTAAAAAAAAAAAAA

232/550

FIGURE 232

MLGSRAVMLLLLLPWTAAQGRAVPGGSSPAWTQCQQLSQKLCTLAWSAHPLVGHMDLREEGDEE  
TTNDVPHIQCGDGCDPQGLRDNSQFCLQRIHQGLIFYEKLKGSDIFTGEPSSLPDSPVGQLHA  
SLLGLSQLLQPEGHHWETQQIPSLSPSQPWQRLLLRFKILRSLQAFVAVAAARVFAHGAATLSP

**Important features of the protein:**

**Signal peptide:**

amino acids 1-21

**Casein kinase II phosphorylation site.**

amino acids 64-67

**N-myristoylation sites.**

amino acids 25-30, 81-86, 122-127

233/550

**FIGURE 233**

CCCACGCGTCCGGCCCTGTAACCAAGATACTGACTGAACATGGCTGGCGGACTCAGGCTGGGGTCTGCAGTGCAG  
CATTAAATGGGCGCTGACATGAATATGGAGTAGTTTTCTCTAGCAAAGAGTAATGTGGGCCATGGAGTCAGGCCA  
CCTCCTCTGGGCTCTGCTGTTTCATGCAGTCCTTGTGGCCTCAACTGACTGATGGAGCCACTCGAGTCTACTACCT  
GGGCATCCGGGATGTGCAGTGGAACTATGCTCCCAAGGGAAGAAATGTCATCACGAACCAGCCTCTGGACAGTGA  
CATAGTGGCTTCCAGCTTCTTAAAGTCTGACAAGAACCGGATAGGGGGAACCTACAAGAAGACCATCTATAAAGA  
ATACAAGGATGACTCATACACAGATGAAGTGGCCCAGCCTGCCTGGTTGGGCTTCTGGGGCCAGTGTTCAGGC  
TGAAGTGGGGGATGTCATTCTTATTACCTGAAGAATTTTGGCCACTCGTCCCTATACCATCCACCCTCATGGTGT  
CTTCTACGAGAAGGACTCTGAAGGTTCCCTATACCCAGATGGCTCCTCTGGGCCACTGAAAGCTGATGACTCTGT  
TCCCCCGGGGGGAGCCATATCTACAACCTGGACCATTCCAGAAGGCCATGCACCCACCGATGCTGACCCAGCGTG  
CCTCACCTGGATCTACCATTTCTCATGTAGATGCTCCACGAGACATTGCAACTGGCCTAATTGGGCCTCTCATCAC  
CTGTAAAGAGGAGCCCTGGATGGGAACCTCCCTCCTCAACGCCAGGATGTAGACCATGATTTCTTCTCCTCTT  
CAGTGTGGTAGATGAGAACCTCAGCTGGCATCTCAATGAGAACATTGCCACTTACTGCTCAGATCCTGCTTCAGT  
GGACAAAGAAGATGAGACATTTTCAAGGAGCAATAGGATGCATGCAATCAATGGCTTTGTTTTGGGAATTTACC  
TGAGCTGAACATGTGTGCACAGAAACGTGTGGCCTGGCACTTGTGGCATGGGCAATGAAATTGATGTCCACAC  
AGCATTTTTCCATGGACAGATGCTGACTACCCGTGGACACCACACTGATGTGGCTAACATCTTTCCAGCCACCTT  
TGTGACTGCTGAGATGGTGGCCTGGGAACCTGGTACCTGGTTAATTAGCTGCCAAGTGAACAGTCACTTTCGAGA  
TGGCATGCAGGCACTCTACAAGGTCAAGTCTTGTCCATGGCCCCCTCCTGTGGACCTGCTCACAGGCAAGTTCG  
ACAGTACTTTCATTGAGGCCCATGAGATTCAATGGGACTATGGCCCCGATGGGGCATGATGGGAGTACTGGGAAGAA  
TTTGAGAGAGCCAGGCAGTATCTCAGATAAGTTTTTCCAGAAGAGCTCCAGCCGAATTGGGGGCACTTACTGGAA  
AGTGGCATATGAAGCCTTTCAAGATGAGACATTTCAAGAGAAGATGCATTTGGAGGAAGATAGGCATCTTGGAA  
CCTGGGGCCAGTATCCGGGCTGAGGTGGGTGACACCATTCAGGTGGTCTTCTACAACCGTGCCTCCAGCCATT  
CAGCATGCAGCCCCATGGGGTCTTTTATGAGAAAGACTATGAAGGCACTGTGTACAATGATGGCTCATCTTACCC  
TGGCTTGGTTGCCAAGCCCTTTGAGAAAGTAACATACCGCTGGACAGTCCCCCTCATGCCGTCCCCACTGCTCA  
GGATCCTGCTTGTCTCACTTGGATGTACTTCTCTGCTGCAGATCCCATAGAGACACAAATTCTGGCCTGGTGGG  
CCCGCTGCTGGTGTGCAGGGCTGGTGCCTTGGGTGCAGATGGCAAGCAGAAAGGGGTGGATAAAGAATTCTTTCT  
TCTCTTCACTGTGTTGGATGAGAACAAAGAGCTGGTACAGCAATGCCAATCAAGCAGCTGCTATGTTGGATTTCG  
ACTGCTTTTCAAGGATATTGAGGGCTTCCAAGACTCCAATCGGATGCATGCCATTAATGGGTTTCTGTTCTCTAA  
CCTGCCCCAGGCTGGACATGTGCAAGGGTGACAGTGGCCTGGACCTGCTCGGCCTGGGCACAGAGACTGATGT  
GCATGGAGTCATGTTCCAGGGCAACACTGTGCAGCTTCAGGGCATGAGGAAGGGTGCAGCTATGCTCTTCTCA  
TACCTTTGTCTATGGCCATCATGCAGCCTGACAACCTTGGGACATTTGAGATTTATTGCCAGGCAGGCAGCCATCG  
AGAAGCAGGGATGAGGGCAATCTATAATGTCTCCAGTGTCTGGCCACCAAGCCACCCCTCGCCAACGCTACCA  
AGTGCAAGAATCTACTATATCATGGCAGAAGAAGTAGAGTGGGACTATTGCCCTGACCGGAGCTGGGAACGGGA  
ATGGCACAACCAAGTCTGAGAAGGACAGTTATGGTTACATTTTCTGAGCAACAAGGATGGGCTCCTGGGTTCCAG  
ATACAAGAAAGCTGTATTTCAGGGAATACACTGATGCTACATTTCAGGATCCCTCGGCCAAGGACTGGGCAGAGA  
ACACTTGGGAATCTTGGGTCCACTTATCAAAGGTGAAGTTGGTGATATCCTGACTGTGGTATTCAAGAATAATGC  
CAGCCGCCCTACTCTGTGCATGCTCATGGAGTGCTAGAATCTACTACTGTCTGGCCACTGGCTGCTGAGCCTGG  
TGAGGTGGTCACTTATCAGTGAACATCCCAGAGAGGTCTGGCCCTGGGGCCAATGACTCTGCTTGTGTTTCTCTG  
GATCTATTATTCTGCAGTGGATCCCATCAAGGACATGTATAGTGGCCTGGTGGGGCCTTGGCTATCTGCCAAA  
GGGCATCCTGGAGCCCCATGGAGGACGGAGTGACATGGATCGGCAATTGTCATTGTTGTTCTGATTGTTTATGTA  
AAATAAGTCTTGGTATTTGGAGGAAAATGTGGCAACCCATGGGTCCCAGGATCCAGGCAGTATTAACCTACAGGA  
TGAAACTTTCTTGGAGAGCAATAAAATGCATGCAATCAATGGGAACTCTATGCCAACCTTAGGGGTCTTACCAT  
GTACCAAGGAGAACGAGTGGCCTGGTACATGCTGGCCATGGGCCAAGATGTGGATCTACACACCATCCACTTTCA  
TGCAGAGAGCTTCTCTATCGGAATGGCGGAGAACTACCGGGCAGATGTGGTGGATCTGTTCCCAGGGACTTTTGA  
GGTTGTGGAGATGGTGGCCAGCAACCTGGGACATGGCTGATGCACTGCCATGTGACTGACCATGTCCATGCTGG  
CATGGAGACCCTCTTCACTGTTTTTTCTCGAACAGAACACTTAAGCCCTCTCACCGTCATCACCAAGAGACTGA  
AAAAGTGCCCCCAGAGACATTGAAGAAGGCAATGTGAAGATGCTGGGCATGCAGATCCCCATAAAGAATGTTGA  
GATGCTGGCCTCTGTTTTGGTTGCCATTAGTGTCACCCCTCTGCTCGTTGTTCTGGCTCTTGGTGGAGTGGTTTG  
GTACCAACATCGACAGAGAAAGCTACGACGCAATAGGAGGTCCATCCTGGATGACAGCTTCAAGCTTCTGTCTTT  
CAAACAGTAAATCTGGAGCCTGGAGATATCCTCAGGAAGCACATCTGTAGTGCATCCCAGCAGGCCATGGACT  
AGTCACTAACCCCACTCAAAGGGCATGGGTGGTGGAGAAGCAGAAGGAGCAATCAAGCTTATCTGGATATTT  
CTTCTTTATTTTACATGGAAATAATATGATTTCACTTTTCTTTAGTTTCTTTGCTCTACGTGGGCACCT  
GGCACTAAGGGAGTACCTTATTATCCTACATCGCAAATTTCAACAGCTACATTATATTTCTTCTGACACTTGA  
AGGTATTGAAATTTCTAGAAATGTATCCTTCTCACAAAGTAGAGACCAAGAGAAAACTCATTGATTGGGTTTCT  
ACTTCTTCAAGGACTCAGGAATTTCACTTTGAACTGAGGCCAAGTGAGCTGTTAAGATAACCCCACTTAAAC  
TAAAGGCTAAGAATATAGGCTTGATGGGAAATGAAGGTAGGCTGAGTATTGGGAATCCAAATTGAATTTTGATT  
CTCCTTGGCAGTCACTTTGAAGAAGTGGTCAATGGGTGTTGCTGCCATGAGCATGTACAACCTCTGGAGC  
TAGAAGCTCCTCAGGAAAGCCAGTTCTCCAAGTTCTTAACCTGTGGCACTGAAAGGAATGTTGAGTTACCTCTTC  
ATGTTTTAGACAGCAACCCCTATCCATTAAAGTACTTGTAGACCAAAAAAAAAAAAA

234/550

**FIGURE 234**

MWAMESGHLLWALLFMQSLWPQLTDGATRVYYLGIRDVQWNYAPKGRNVITNQPLDSDIVASS  
FLKSDKNRIGGTYKKTIYKEYKDDSYTDEVAQPAWLGLGPVLQAEVGDVILHLKNFATRPY  
TIHPHGVFYEKDSEGSLYPDGSSGPLKADDSVPPGGSHIYNWTIPEGHAPTADPACLTWIYH  
SHVDAPRDIATGLIGPLITCKRGALDGNSSPPQRQDVDHDFLLFSVVDENLSWHLNENIATYC  
SDPASVDKEDETFQESNRMHAINGFVFGNLPENLMCAQKRVAWHLFGMGNEIDVHTAFFHGM  
LTTRGHHTDVANIFPATFVTAEMVPWEPGTWLI SCQVNSHFRDGMQALYKVKSCSMAPPVDLL  
TGKVRQYFIEAHEIQWDYGPMGHGSGTGKNLREPGSISDKFFQKSSSRIGGTYWKVRYEAFQD  
ETFQEKMHLEEDRHLGILGPVIRAEVGDTIQVVFYNRASQPFSMQPHGVFYEKDYEGTVYNDG  
SSYPGLVAKPFEKVTYRWTVP PHAGPTAQDPACLTWMYFSAADPIRDTNSGLVGPLLVCRA  
LGADGKQKGV DKEFFLLFTVLDENKSWYSNANQAAAMLDFRLLSE DIEGFQDSNRMHAINGFL  
FSNLPRLD MCKGDTVAVHLLGLGTETDVHGV MFQGN TVQLQGM RKGAA MLFPHTFVMAIMQPD  
NLGTFEIYCQAGSHREAGMRAIYNVSQCPGHQATPRQRYQAARIYYIMAEVEWDYCPDRSWE  
REWHNQSEKDSYGYIFLSNKDGLLGSRYKKAVFREYTDGTFRI PRPRTGPEEHLGILGPLIKG  
EVGDILT VVFKNNASRPYSVHAHGVLESTTVWPLAAEPGEVV TYQWNI PERSGPGPNDSACVS  
WIYYSAVDPIKDMYSGLVGLAICQKGILEPHGGRSDMDREFALLFLIFDENKSWYLEENVAT  
HGSQDPGSINLQDET FLESNKMHAINGKLYANLRGLTMYQGERVAWYMLAMGQDVDLHTIHFH  
AESFLYRNGENYRADVVDLFPGTFEVVMVASNPGTWLMHCHVTDH VHAGMETLFTVFSRTEH  
LSPLTVITKETEKVPPRDIEEGNVKMLGMQIPIKNVEMLASVLVAISVTL LLVVLALGGVVWY  
QHRQRKLRRNRRSILDDSFKLLSFKQ

**Signal peptide:**

amino acids 1-21

**Transmembrane domain:**

amino acids 1109-1130

**N-glycosylation sites.**amino acids 167-171, 239-243, 591-595, 717-721, 761-765, 832-836,  
876-880, 934-938**Glycosaminoglycan attachment site.**

amino acids 871-875

**Tyrosine kinase phosphorylation sites.**

amino acids 82-90, 137-145, 494-502, 513-521

**N-myristoylation sites.**amino acids 212-218, 313-319, 498-504, 566-572, 672-678, 778-784,  
843-849**Multicopper oxidases signature 1.**

amino acids 344-365, 696-717, 1043-1064

**Multicopper oxidases signature 2.**

amino acids 1048-1060

235/550

**FIGURE 235**

GGAAAGAGTGCTGGTACTACAACCAGGAAGTGACAGATAATGTGCTTTAAACTACATTAGAAAAAGCTTCTCATAG  
CAAACCTGAGAGATTGAAGCAGTGATTATTTTTACATAGTTGTCTATTAAATATTTGGAGCTCTGCTGTGCATAGA  
GATGGCAACATACTTAGAATACACAGCTTTCTGGGCCAGAAATTGATCTTCTGACTTTTGAGCCTTATCTGATTA  
CTGCTTGGTTCATCTTTATTTTGTAAACTACTCTGTAGGCTGAAAGGGAGAGACTCTCCTTGGTTTGCAGAGCC  
TGACTAGACAGGAATTCTGGCAACTGCTCCAGCAGAACTATGGCACTGAGCTAGGTTTAAATGCTGAGGAGATGG  
AAAACCTGTCACTGTCGATTGAGGATGTGCAGCCAAGAAGTCCAGGAAGAAGCAGCTTGGATGACTCTGGGGAGA  
GAGATGAAAAATTATCCAAGTCAATCAGTTTTACCAGTGAATCAATTAGTCGGGTTTCAGAAACAGAGTCATTTCG  
ATGGAAATTCATCAAAAGGAGGATTAGGCAAGAGGAGTCCCAAATGAGAAACAGACCAAAAAGAGTCTCTTAC  
CACTTTTGGAAAAGAAGTTAACTAGAGTGCCATCAAAGTCACTGGACTTGAATAAAAATGAATATCTTTCTCTGG  
ACAAAAGCAGCACTTCAGATTCTGTTGATGAAGAAAATGTTCTTGAGAAAGATCTTCATGGAAGACTTTTTATCA  
ACCGTATTTTTTCATATCAGTGTCTGACAGAATGTTTGAATTGCTCTTTACCAGTTTCACGCTTTATGCAGAAATTTG  
CCAGTTCTAGAAATATAATAGATGTAGTATCTACCCCTTGGACTGCAGAACTTGGAGGTGATCAGCTGAGAACGA  
TGACCTACACTATAGTCTTAATAGTCCACTTACTGGAAAATGCACTGCTGCCACTGAAAAGCAGACACTGTATA  
AAGAAAGTCGGGAAGCACGATTTTATTTGGTAGATTGAGAAGTACTGACACATGATGTCCCTTACCATGATTACT  
TCTATACCGTGAACAGATACTGTATCATCCGATCTTCAAACAGAAATGCAGGCTAAGAGTTTCCACAGATTTGA  
AATACAGAAAACAGCCATGGGGCCTTGTCAAATCTTTAATTGAAAAGAATTCTGGAGTTCTTTGGAGGACTATT  
TCAAACAGCTTGAATCAGATTTGTTAATTGAAGAATCTGTATTAAATCAGGCCATTGAAGACCTTGGAAAACCTTA  
CTGGCCTACGAAGGAGAAGGCGAACCTTCAACCGAACAGCAGAAACAGTTTCTAACTTTCTCTCAGCATTCTCT  
CTGGAGATGTGGGCTTAGGTGCCAAAGGGGATATTACAGGAAGAAAAAGGAAATGGAAAACATAACGTCACCTC  
TTATTGTGGTAATGAGTATTTTTGTGTTGTTATTAGTTTTGTTGAATGTGACACTGTTTCTGAAGCTGTCAAAGA  
TAGAACATGCTGCTCAGTCTTTTACCGTCTCCGCCTCCAAGAAGAGAAATCTTTAAATTTAGCCTCTGATATGG  
TGTCAAGAGCAGAAACTATTGAGTGGTATGGTCTCATTTCTACAGTGAAGTCTGATGCTTTGTTAGCACAGAATCCG  
TGATGCTTGAACAGCTGAAGAGCTCACTCATTATGCTTCAGAAAACGTTTGATCTACTAAATAAGAATAAGACTG  
GCATGGCTGTTGAAAGCTAGTGATCTGAAGGACTAAAACCGCAGAGATACTTGGAACTTAAAGAAAATACCTGGA  
AGAAAACCAGACGAATGAAGGATTTTGGCATAGAACATTTCTATGTTTTTTCATTATTGAGATTTCTAATATGAA  
CATTTCTTTTCACTAACATTTATTTGATAATTAGTTTCTGCTGGCCTTAATAATCCATCCTTTCACTTCTTATAGA  
TATTTTTAAGCTGTGAATTTCTTCAGTGAACCATGAATATATTATAGAAGTGAATTTCTCTGATACAAAAGAA  
AATGACACACCTGAATTGAGTGGTATGGTCTCATTTCTACAGTGAAGTCTGATGCTTTGTTAGCACAGAATCCG  
TACATGTCCAATAGGTCGCTTTTGTAACTGAGATAAGACCAAGAGGATAAACAGGACAATATAAGAAGAAACCTC  
TATGTCACTTACTGATTTTAAAGGTTCTGTTTTTCCAGGATATAACATTTCCAGGTTTGTGTACTGTAAAGATTATA  
ATGTCTTCATTTATTTAGCATGCAAATTTAATAGTCAAACCTTTTTGAATCTGCATGTTGATGATGATTATCAGAA  
AGGGTCTTCTGCCATGCTGTATCTTTATGAAAGAAATAGTTGTTTTTCTTAAGGTAACATCAGAGGTGGGATT  
ATCTTGCCCTCCTCACTTAGAATACCAACAGTCAAAGGAAGAACCATCCTCTGAGTTTTAAAACAGAAAGGTTA  
TGTTAAATCTGGGCATTTAGTGACAGATCAAATGCATACTTGAAGTAAAGATTGGCTTCAGCTTAGCAGTCTTTC  
ATGGTGGAAGTGACACATCTGGTTGAAAATAATTTGTGTATTTTTCAGTAACCATGTATGGCTTCTTCTTTATGT  
ATGTGTGTGACTTGTTTTAATTGGTAAGTTATAAGCCAGACATAGATTTTAGCTCTTTAATAAAAACCTTCAGGGG  
CACGTATGTCCAGTACAAGTGTACTGACTATCAAGTTTTAACTCAGATGCAAGCTTTGGCTCTTTCATAAAAAG  
TTTTTATGCATATGTGTCTCCATACAAGTGGCTCATTTAAATAAGAAGTGTGTAAGTGAAGTAAATCAGATAT  
TTTTTCAAGAGTTAGGGAAAGTTGAAGTGTTTTACTGTTTTGTCTCTTGAGCCCTTTCTCTGGGGAAAAAATACA  
TATCCATCTATCTATCTATATATAAACTGTGTATACATTCTTACTGTTTGAACAACATATTGCCTTTAATTTAATG  
TTTCATTTTTCTCCAGAGTCCCCAAAGCCACATGGCATTATTATAGTCATTTTTGAGATGCCTGTAGAGAATGAA  
AGTATTGACTCCGTTAGAGGGAAAATGGGTTCTCTGGGTGAATTCACGAAGCATACCTAGGGGTAACAGTGA  
ACCTACCTGGGTTTGTGTTTTGTTTGGTAAGGATTTATGTAGTGTCTGGCTGTAAAGCAAGAATGAGTGGATTATAA  
ACTTGAAGATTTCTCTGTTAAAGTCACAAAATGATCGACAAACAATATTTTTGTGATGTTTATTTAAACGTTGT  
ATTTTATAACATACTTCAAGGAAGAGTATCGAAGTAAAGTTGCTTTATAAATTAAGACTAAATTCGTATGGATGCA  
GAATTCAATTAATAAAAATTTGAGCCTGTTACGTAAATTGAATATTAATAAAAATTGAAAATTTCAAAA

236/550

FIGURE 236

MENLSLSIEDVQPRSPGRSSLDDSGERDEKLSKSI SFTSESISRVS ETE SFDGNSSKGGLGKE  
ESQNEKQTKKSLPTLEKKLTRVPSKSLDLNKNEYLSLDKSSTSDSVDEENVPEKDLHGRLFI  
NRI FHI SADRMFELLFTSSRFMQKFASSRNIIDVVSTPWTAE LGGDQLRTMTYTIVLNSPLTG  
KCTAATEKQTLYKESREARFYLV DSEVLTHDVPYHDYFYTVNRYCIIRSSKQKCRLRVSTD LK  
YRKQPWGLVKSLIEKNSWSSLEDYFKQLES D L LIEESVLNQAIEDPGKLTGLRRRRRTFNRTA  
ETV PKLSSQHSSGDVGLGAKGDITGKKKEMENYNVT LIVVMSIFVLLLVL LNVT LFLKLSKIE  
HAAQSFYRLRLQEEKSLNLASDMVSRAETIQKNKDQAHRLKGVLRDSIVMLEQLKSS LIMLQK  
TFDLLNKNKTGM AVES

**Transmembrane domain:**

amino acids 352-371

**N-glycosylation sites.**

amino acids 3-7, 54-58, 312-316, 349-353, 367-371, 449-453

**cAMP- and cGMP-dependent protein kinase phosphorylation sites.**

amino acids 81-85, 307-311

**Tyrosine kinase phosphorylation sites.**

amino acids 202-211, 246-254, 341-349

**N-myristoylation site.**

amino acids 259-265

**Amidation site.**

amino acids 339-343

237/550

**FIGURE 237**

CAGGGGCTGGAGGGCAGGGGAGGGGATGATGTCATTCTGCTCGGCGCAATCCTGACCCTGCT  
CTGGGCGCCACGGCTCAGGCTGAGGTTCTGCTGCAGCCTGACTTCAATGCTGAAAAGTTCTC  
AGGCCTCTGGTACGTGGTCTCCATGGCATCTGACTGCAGGGTCTTCCTGGGCAAGAAGGACCA  
CCTGTCCATGTCCACCAGGGCCATCAGGCCCACAGAGGAGGGCGGCCTCCACGTCCACATGGA  
GTTCCCGGGGCGGACGGCTGTAACCAGGTGGATGCCGAGTACCTGAAGGTGGGCTCCGAGGG  
ACACTTCAGAGTCCCGGCCTTGGGCTACCTGGACGTGCGCATCGTGGACACAGACTACAGCTC  
CTTCGCCGTCCTTTACATCTACAAGGAGCTGGAGGGGGGCCCTCAGCACCATGGTGCAGCTCTA  
CAGCCGGACCCAGGATGTGAGTCCCCAGGCTCTGAAGTCCTTCCAGGACTTCTACCCGACCCT  
GGGGCTCCCCAAGGACATGATGGTCATGCTGCCCCAGTCAGATGCATGCAACCCTGAGAGCAA  
GGAGGCGCCCTGACACCTCCGGAGCCCCACCCCCGCCCTTCCCAGGTGGAGCCAAAGCAGCAG  
GCGCCTTTGCCCTGGAGTCAAGACCCACAGCCCTCGGGGACCACCTGGAGTCTCTCCATCCT  
CCACCCCCCGCCTGTGGGATGCCTTGTGGGACGTCTCTTTCTATTCAATAAACAGATGCTGCA  
GCCTCA